NCT Number	Title	Acronym	Status	Conditions	Interventions	Outcome Measures	Sponsors	Gender	Age	Enrollment	Funders	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	Last Verified	First Submitted	First Posted	Results First Submitted	Results First Posted	Last Update Submitted	Last Update Posted	URL	Setting	Stage	Sponsor_Type	Controlled	Multi-Arm	Pediatric	Country_PI	Cancer_Group	Cancer_Type	Drug_INN	Primary-EP	Phase	DrugBank	Removed
NCT02969681	Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer	Vitality	Recruiting	Colorectal Neoplasms	Drug: ascorbic acid; Drug: Chemotherapy	Progression Free Survival; Overall Survival; Response Rate	Sun Yat-sen University	All	18 Years to 75 Years   (Adult, Older Adult)	428	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VitC001	01/01/2017	12/01/2019	12/01/2020			21/11/2016				27/02/2019	https://ClinicalTrials.gov/show/NCT02969681	Palliative	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	GI	Colon Cancer	Ascorbic acid	PFS	Phase 3	DB00126	N
NCT02678975	Disulfiram in Recurrent Glioblastoma		Active, not recruiting	Glioma|Glioblastoma	Drug: Disulfiram; Dietary Supplement: Copper; Drug: Alkylating Agents	Survival 6 mo; Progression free survival; Survival 12 and 24 mo; Median overall survival; Health related quality of life; Volumetric tumor assessment; Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Sahlgrenska University Hospital, Sweden; St. Olavs Hospital; Lund University Hospital; Karolinska University Hospital; University Hospital, Linkoeping; Region  rebro County; Ryhov County Hospital; Uppsala University Hospital	All	18 Years and older   (Adult, Older Adult)	88	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	no ID yet	01/01/2017	15/01/2021	15/01/2021			02/10/2016				11/09/2020	https://ClinicalTrials.gov/show/NCT02678975		Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	Sweden	CNS	Glioblastoma	Disulfiram	OS	Phase 2/3	DB00822	N
NCT01844076	Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma		Active, not recruiting	Colorectal Adenocarcinoma	Drug: Phase I (Quinacrine); Drug: Capecitabine	Phase I - Tolerability and Safety; Phase II - Rate of Response	Fox Chase Cancer Center	All	18 Years and older   (Adult, Older Adult)	19	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GI-078	01/01/2016	04/01/2021	04/01/2021			05/01/2013				05/07/2020	https://ClinicalTrials.gov/show/NCT01844076		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	GI	Colon Cancer; Rectal Cancer	Mepacrine	Safety and/or Dose; Response rate	Phase 1/2	DB01103	N
NCT01342692	Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes	AZA-PLUS	Active, not recruiting	MDS	Drug: Azacitidine; Drug: Azacitidine associated with Valproic acid; Drug: Azacitidine associated with Lenalidomide; Drug: Azacitidine associated with Idarubicine	Remission, complete, partial or medullary after 6 cycles; Stable disease with hematological improvement; Duration of response; Progression to acute myeloid leukemia; Overall survival; Number of adverse events	Assistance Publique - H pitaux de Paris	All	18 Years and older   (Adult, Older Adult)	320	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P081225	06/01/2011	07/01/2018	06/01/2019			27/04/2011				19/02/2019	https://ClinicalTrials.gov/show/NCT01342692		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	France	Other Haem-onc	Myelodysplastic Syndromes	Valproic Acid	Safety and/or Dose; Response rate; OS; Other (specify)	Phase 2	DB00313	N
NCT04054362	Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	PINBALL	Recruiting	Pancreatic Cancer	Drug: Paclitaxel protein bound; Drug: Cisplatin; Drug: Gemcitabine; Drug: Paricalcitol	Clinical benefit	Barts   The London NHS Trust	All	18 Years and older   (Adult, Older Adult)	14	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12255	29/11/2018	30/06/2021	30/06/2021			13/08/2019				16/12/2019	https://ClinicalTrials.gov/show/NCT04054362		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United Kingdom	GI	Pancreatic Cancer	Paricalcitol	Other (specify)	Phase 2	DB00910	N
NCT01586260	Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission		Active, not recruiting	Neuroblastoma	Drug: DFMO	To evaluate the preventative activity of DFMO as a single agent in patients that are in remission based on: Event free survival (EFS); To evaluate the preventative activity of DFMO as a single agent in patients with neuroblastoma who are in remission based on: Overall Survival (OS); Number of Participants with Adverse Events as a Measure of Safety and Tolerability; Biology studies	Giselle SaulnierSholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii; University of Vermont; Beat NB Cancer Foundation; Atrium Health	All	up to 21 Years   (Child, Adult)	89	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	NMTRC 003	06/01/2012	26/04/2021	26/04/2021			26/04/2012				18/11/2020	https://ClinicalTrials.gov/show/NCT01586260		Localised/Locoregional	Hospital/University/Research Institute	N	N	Y	United States	Other	Neuroblastoma	Eflornithine	DFS/RFS/EFS	Phase 2	DB06243	N
NCT04096911	Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer		Recruiting	Uterine Cervical Neoplasms|Cervical Cancer|Cervical Neoplasms|Cervix Cancer	Drug: Sintilimab; Drug: quadrivalent HPV vaccine	Objective Response Rate; Progression-free survival; Overall survival; Duration of Response	Buhai Wang; Innovent Biologics (Suzhou) Co. Ltd.; Northern Jiangsu Province People's Hospital	Female	18 Years and older   (Adult, Older Adult)	20	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WBH-7209	31/07/2019	31/03/2021	31/03/2021			20/09/2019				20/09/2019	https://ClinicalTrials.gov/show/NCT04096911		Recurrent/Refractory	Company	N	N	N	China	Gynaecological	Cervical Cancer	HPV vaccine	Response rate; PFS; OS; Other (specify)	Phase 2	Not found in DrugBank	N
NCT03831178	Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting	DHA-WIN	Recruiting	Breast Cancer	Dietary Supplement: Docosahexaenoic acid (DHA); Drug: Placebo oral capsule	Percent change in Ki67 index from baseline to surgical excision.; Percent of DHA in plasma phospholipids between DHA and placebo arms.; Change in immune function (e.g. ability to produce IL-2 after stimulation) following DHA supplementation in combination with chemotherapy.; Age of participants and other factors affecting DHA incorporation; Percent change on markers of apoptosis (e.g. caspase-3) following DHA or placebo supplementation.; Pathological complete response rate; Comparison of rate of chemotherapy associated grade 3 and 4 toxicities between treatment arms.	AHS Cancer Control Alberta; Canadian Institutes of Health Research (CIHR); University of Alberta	Female	18 Years and older   (Adult, Older Adult)	52	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	IIT-0005	28/08/2019	03/01/2021	09/01/2021			02/05/2019				10/02/2019	https://ClinicalTrials.gov/show/NCT03831178		Localised/Locoregional	Collaborative Group	Y	N	N	Canada	Breast	Any Breast Cancer	Omega 3	Biomarker	Phase 2	DB13961	N
2020-000725-27	Intratumoral Influenza Vaccine for Early Colorectal Cancer		Ongoing	Patients with colorectal cancer	Drug: Influenza vaccine	Safety endpoints Safety evaluation will be performed via continuous assessment of safety parameters by reviewing events as they arise. We will conduct the pilot study in order to measure potential safety issues in a small cohort of patients before including patients in the phase 2 study. The investigation will be put on hold if unacceptable safety issues are detected. Primary safety endpoints: 1. Evaluation of serious adverse events 2. Evaluation of any adverse events reported.	Center for Surgical Science, Department of Surgery, Zealand University Hospital	All	Adult 18-64	30	Not applied yet	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000725-27/DK		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Denmark	GI	Colon Cancer; Rectal Cancer	Influenza vaccine	Safety and/or Dose	Phase 2	Not found in DrugBank	N
NCT02607072	Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients: a Multi-center Randomized Trial	APREMEC	Recruiting	Colorectal Cancer	Drug: Acetylsalicylic acid (ASA)/aspirin 200 mg daily; Drug: Acetylsalicylic acid (ASA)/aspirin 100 mg daily; Drug: Placebo	3-year disease free survival	The Fourth Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University; Anhui Provincial Hospital	All	18 Years and older   (Adult, Older Adult)	3000	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	APREMEC-01	10/01/2015	10/01/2020	10/01/2022			17/11/2015				18/11/2015	https://ClinicalTrials.gov/show/NCT02607072	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	China	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	DFS/RFS/EFS	Phase 3	DB00945	N
NCT03491410	Breast Cancer Active Surveillance, Alternative Option, Aspirin Included		Not yet recruiting	Breast Cancer	Drug: Aspirin Low Dose; Drug: Placebo Oral Tablet	Overall Survival; Metastatic Disease Stability; Tumor response till patient decides to exit the active surveillance	Centro Hospitalar Lisboa Ocidental	All	18 Years and older   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CHLOBREASTASP	06/01/2018	31/12/2019	31/05/2023			04/09/2018				04/09/2018	https://ClinicalTrials.gov/show/NCT03491410		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Portugal	Breast	Breast - Other	Acetylsalicylic Acid	Response rate; OS	Phase 2/3	DB00945	N
NCT02945033	Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk	ASPIK French	Recruiting	Colorectal Cancer	Drug: aspirin intake; Drug: placebo intake; Procedure: Surgical resection of colonic adenocarcinoma stage III or II high risk; Biological: Molecular analysis of exon 9 and 20 of PI3K; Biological: blood intake	Number of patient with local or distant recurrence or second colorectal cancer or death from any cause, whichever occurred first; Number of alive patient; Number of pills taken by the patient for compliance evaluation; Number of severe bleeding grade 3-4 events; Number of participants with treatment-related adverse events	University Hospital, Rouen; Federation Francophone de Cancerologie Digestive	All	18 Years and older   (Adult, Older Adult)	264	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2015/222/HP	07/12/2018	07/01/2024	07/01/2024			26/10/2016				24/10/2019	https://ClinicalTrials.gov/show/NCT02945033	Primary/Main Curative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	France	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	Safety and/or Dose; OS; Recurrence rate	Phase 3	DB00945	N
NCT03464305	ASPIRIN Trial Belgium	ASPIRIN	Recruiting	Colon Cancer	Drug: acetylsalicylic acid; Drug: Placebo	5 year overall survival; Disease Free Survival; Time to Treatment Failure	University Hospital, Antwerp; Kom Op Tegen Kanker; Anticancerfund	All	45 Years and older   (Adult, Older Adult)	400	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BE 2017-001397-41	22/02/2018	31/12/2026	31/12/2026			14/03/2018				22/12/2020	https://ClinicalTrials.gov/show/NCT03464305	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Belgium	GI	Colon Cancer	Acetylsalicylic Acid	OS; DFS/RFS/EFS	Phase 3	DB00945	N
NCT01936233	Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery		Recruiting	Hepatocellular Carcinoma|Recurrence	Drug: Aspirin; Drug: Lamivudine	recurrence free survival; overall survival; adverse events	Fudan University	All	18 Years to 75 Years   (Adult, Older Adult)	112	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LC-ASPIRIN	08/01/2013	12/01/2021	12/01/2023			09/06/2013				08/05/2019	https://ClinicalTrials.gov/show/NCT01936233	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Liver Cancer	Acetylsalicylic Acid	OS; DFS/RFS/EFS	Phase 3	DB00945	N
NCT02804815	Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours		Recruiting	Cancer|Breast Cancer|Prostate Cancer|Colorectal Cancer|Gastro-oesophageal Cancer	Drug: Aspirin 100mg; Drug: Aspirin 300mg; Drug: Placebo 100mg; Drug: Placebo 300mg	Overall Survival; Invasive disease-free survival (IDFS); Disease-free survival (DFS); Overall survival; Biochemical recurrence-free survival (bRFS); Adherence; Number of participants with serious haemorrhage (grade 3 or above) as measured by CTCAE V4.0. Data will be collected on case report forms.; Number of participants with treatment-related (active drug and placebo) cardiovascular events as assessed by CTCAE v4.0; Number of participants with second malignancies as assessed by case report form; Number of participants that show a decline in cognition and extent of decline as assessed by the Montreal Cognitive Assessment (MoCA)	University College, London	All	16 Years and older   (Child, Adult, Older Adult)	11000	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other	14/0814; 2013-004398-28; 120104	10/01/2015	10/01/2026	10/01/2026			17/06/2016				21/02/2021	https://ClinicalTrials.gov/show/NCT02804815	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	United Kingdom	Breast; Urological; GI	Any Breast Cancer; Prostate Cancer; Esophageal Cancer; Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	OS; DFS/RFS/EFS; Recurrence rate	Phase 3	DB00945	N
NCT03900871	Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma		Not yet recruiting	Aspirin as an Adjuvant Therapy, to Observe Its Effect on the Disease Free Survival Rate of Patients With Esophageal Squamous Cell Carcinoma	Drug: Acetylsalicylic acid	disease free survival	Hebei Medical University Fourth Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	600	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2018051702	04/10/2019	30/04/2020	30/04/2024			04/03/2019				04/03/2019	https://ClinicalTrials.gov/show/NCT03900871		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Esophageal Cancer	Acetylsalicylic Acid	DFS/RFS/EFS	Phase 1	DB00945	N
NCT03290820	Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients		Not yet recruiting	Nasopharyngeal Carcinoma	Radiation: Radiotherapy; Drug: Concurrent chemotherapy; Drug: Aspirin	Distant-metastasis-free survival; Overall survival; Aspirin-related toxicities	Sun Yat-sen University	All	18 Years to 70 Years   (Adult, Older Adult)	184	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-FXY-067	01/01/2018	30/09/2024	30/09/2024			25/09/2017				26/10/2017	https://ClinicalTrials.gov/show/NCT03290820		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Head and Neck	Nasopharyngeal Cancer	Acetylsalicylic Acid	OS; DFS/RFS/EFS	Phase 2	DB00945	N
NCT04840004	Efficacy and Safety of High Dose Aprepitant Treatment in Patients With Advanced Non-Small Cell Lung Cancer		Recruiting	Non Small Cell Lung Cancer|Advanced Cancer|Refractory Cancer	Drug: Aprepitant	Effect; Progression Free Survival and Overall Survival; High Dose	PlusVitech S.L.; ECONiX Ara t rma Analiz ve Dan  manl k A. .	All	18 Years and older   (Adult, Older Adult)	24	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PLUSV_00	03/10/2021	15/12/2021	15/12/2021			04/09/2021				05/04/2021	https://ClinicalTrials.gov/show/NCT04840004		Advanced/Metastatic; Recurrent/Refractory	Company	N	N	N	Turkey	Lung	Non-Small Cell Lung Cancer	Aprepitant	Response rate	Phase 2	DB00673	N
NCT04801511	Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer	CORT	Recruiting	Rectal Cancer	Drug: Vitamin C	PCR rate; acute toxicity; Resection rate of anus preserving surgery; 2-year survival rate; 2-year disease-free survival rate	Zhou Fuxiang; Zhongnan Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCCSC R02	03/08/2021	30/06/2023	31/12/2024			17/03/2021				17/03/2021	https://ClinicalTrials.gov/show/NCT04801511		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	GI	Rectal Cancer	Ascorbic acid	Response rate	Phase 2	DB00126	N
NCT04463459	Effect of Vitamin C and E in Breast Cancer Patients Undergoing Chemotherapy		Recruiting	Breast Cancer	Drug: Vitamin C, Vitamin E	To measure the serum level of MDA and RBC glutathione in breast cancer patients receiving chemotherapy and following administration of vitamin C and vitamin E concurrent to chemotherapy.	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Female	30 Years to 70 Years   (Adult, Older Adult)	80	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	BSMMU/2019/8874	10/10/2019	20/07/2020	15/09/2020			07/09/2020				07/09/2020	https://ClinicalTrials.gov/show/NCT04463459		Any/All Stages	Hospital/University/Research Institute	Y	N	N	Bangladesh	Breast	Any Breast Cancer	Ascorbic acid	Biomarker	Other	DB00126	N
NCT04035096	The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients		Not yet recruiting	Colon Cancer Stage Iv	Drug: Ascorbic Acid; Other: Control group	Change from baseline by computerized tomography of Chest, abdomen and pelvis; Number of participants with changes of tumor markers	National Taiwan University Hospital	All	20 Years and older   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201901083MINB	01/01/2020	31/12/2021	30/06/2022			29/07/2019				29/07/2019	https://ClinicalTrials.gov/show/NCT04035096		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Taiwan	GI	Colon Cancer	Ascorbic acid	Response rate	Phase 1/2	DB00126	N
NCT04516681	IV Ascorbic Acid in Peritoneal Metastatic Colorectal Cancer		Recruiting	Colorectal Cancer|Vitamin C|GLUT3	Drug: Ascorbic acid; Drug: FOLFOXIRI Protocol	Objective Response Rate; Progression Free Survival; Overall Survival	Fudan University	All	18 Years to 75 Years   (Adult, Older Adult)	400	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Vitamin C-GLUT3-2020	09/01/2020	09/01/2022	09/01/2023			18/08/2020				18/08/2020	https://ClinicalTrials.gov/show/NCT04516681	Palliative	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	GI	Colon Cancer	Ascorbic acid	Response rate	Phase 3	DB00126	N
NCT04488783	Potentiation of Chemotherapy in Brain Tumors by Zinc		Recruiting	Newly Diagnosed Glioblastoma Who Underwent at Least Partial Resection of the Tumor Surgically	Dietary Supplement: zinc and ascorbate	progression free survival (PFS); overall survival (OS); Tcell count; Level of Interleukin 6; Tumor Necrosis Factor quantification	Sheba Medical Center	All	18 Years to 90 Years   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4266-17-SMC	30/07/2020	30/07/2022	30/12/2022			28/07/2020				28/07/2020	https://ClinicalTrials.gov/show/NCT04488783		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Israel	CNS	Glioblastoma	Ascorbic acid	PFS	Other	DB00126	N
NCT03799094	Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations		Recruiting	Carcinoma, Non-Small-Cell Lung	Drug: Vitamin C; Drug: Tyrosine kinase inhibitor	Progression free survival; Overall survival	Clifford Hospital, Guangzhou, China	All	18 Years to 75 Years   (Adult, Older Adult)	150	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2/2018-19	12/05/2018	31/12/2020	31/12/2022			01/10/2019				01/10/2019	https://ClinicalTrials.gov/show/NCT03799094		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	Lung	Non-Small Cell Lung Cancer	Ascorbic acid	PFS	Phase 1/2	DB00126	N
NCT03986268	Vitamin D Can Increase Pathological Response of the Breast Cancer Patients Treated With Neoadjuvant Therapy		Recruiting	Vitamin D Deficiency|Chemotherapy Effect|Pathology	Drug: Vit D	pathological complete response (PCR); pathological complete response (PCR) relations with vitamin D levels; pathological complete response (PCR) ratio regarding molecular sub types	Florence Nightingale Hospital, Istanbul	Female	18 Years to 65 Years   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-40016-06	05/10/2019	12/10/2020	12/10/2020			14/06/2019				22/07/2020	https://ClinicalTrials.gov/show/NCT03986268		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Turkey	Breast	Any Breast Cancer	Cholecalciferol	Response rate	Other	DB00169	N
NCT03389659	XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC		Not yet recruiting	Vitamin D3	Drug: vitamin D3; Drug: Placebo	PFS(progression-free survival); OS(overall survival); DCR; ORR; Incidence of Treatment-Emergent Adverse Events	Tianjin Medical University Cancer Institute and Hospital	All	18 Years and older   (Adult, Older Adult)	750	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	TianjinCIH20171212	02/01/2018	12/01/2021	06/01/2022			01/03/2018				01/03/2018	https://ClinicalTrials.gov/show/NCT03389659	Palliative	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	GI	Colon Cancer; Rectal Cancer	Cholecalciferol	PFS	Phase 3	DB00169	N
NCT03652467	The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma		Recruiting	Hepatocellular Carcinoma Non-resectable	Drug: Conventional TACE; Drug: Deferoxamine and conventional TACE	Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer; Time to Progression; Overall Survival; Percentage of Participants With Complete Response or Partial Response; Duration of Response; Tumor Necrosis; Number of Participants With Iron Reduction of Liver; The Prognostic Value of Reduction of Liver Iron; Number of Participants With Drug-Related Treatment-Emergent Adverse Events	Jinan Military General Hospital	All	18 Years and older   (Adult, Older Adult)	100	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	JNZY20181245	09/01/2018	09/01/2022	31/12/2023			29/08/2018				22/02/2019	https://ClinicalTrials.gov/show/NCT03652467		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	GI	Liver Cancer	Deferoxamine	PFS	Phase 1	DB00746	N
NCT04265274	Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.		Recruiting	Metastatic Breast Cancer	Drug: Disulfiram; Drug: Vinorelbin; Drug: Cisplatin; Drug: Copper	Objective response rates; Progression-free survival; overall survival	National Cancer Institute, Slovakia	Female	18 Years and older   (Adult, Older Adult)	28	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BREAST-SK-001	01/01/2020	01/01/2022	01/01/2023			02/11/2020				03/03/2021	https://ClinicalTrials.gov/show/NCT04265274		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Slovakia	Breast	Breast Cancer - ER/HR+; Breast Cancer - HER2-	Disulfiram	Response rate	Phase 2	DB00822	N
NCT03950830	Disulfiram and Cisplatin in Refractory TGCTs.	DISGCT	Recruiting	Germ Cell Tumor	Drug: Disulfiram	Overall response rate; Progression-free survival; Overall survival	National Cancer Institute, Slovakia	Male	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCT-SK-006	14/05/2019	31/12/2021	31/12/2022			15/05/2019				08/06/2020	https://ClinicalTrials.gov/show/NCT03950830		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Slovakia	Urological	Testicular Cancer	Disulfiram	Response rate	Phase 2	DB00822	N
NCT04226066	Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors		Recruiting	Advanced Malignant Solid Tumors	Biological: T601; Combination Product: T601+5-FC	AEs (adverse events); Assessment of ORR (objective response rate); Assessment of DCR (disease control rate); Assessment of PFS (progression free survival); Quantification of viral genome in patients' blood samples by Quantitative Polymerase Chain Reaction.; Determination of 5-FC, 5-FU and FBAL concentration in plasma by updated LC/MS/MS method; T601 antibody test by ELISA	Tasly Tianjin Biopharmaceutical Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	69	Industry	Interventional Study	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	T60101	20/11/2019	31/05/2021	31/05/2022			13/01/2020				12/07/2020	https://ClinicalTrials.gov/show/NCT04226066		Advanced/Metastatic	Company	N	N	N	China	Multiple cancer types	Any solid tumours	Flucytosine	Safety and/or Dose; Response rate	Phase 1/2	DB01099	N
NCT03848039	Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9	HOPE9	Not yet recruiting	Cervical Intraepithelial Neoplasia	Biological: Gardasil-9; Drug: Placebo	evaluation of disease recurrence reduction (cervical intraepithelial neoplasia up to microinvasive cancer of the cervix); impact of the vaccine on prevalent post-surgery infections; impact of the vaccine in the post-surgical surveillance times, comparison of viral wash-out times (negativity of the HPV test), times of negativization of the pap test and of the colposcopic picture in the post-operative period	Alessandro Ghelardi; Azienda USL Toscana Nord Ovest	Female	18 Years and older   (Adult, Older Adult)	1220	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	HOPE9 STUDY; 2018-003507-19	12/01/2020	12/01/2022	05/01/2028			20/02/2019				11/05/2020	https://ClinicalTrials.gov/show/NCT03848039	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Italy	Gynaecological	Cervical Cancer	HPV vaccine	Recurrence rate	Phase 3	Not found in DrugBank	N
NCT02416739	Anticancer Activity of Nicotinamide on Lung Cancer		Active, not recruiting	Non-Small-Cell Lung Carcinoma	Drug: Nicotinamide	Hazard ratio (PFS) of the nicotinamide arm to the placebo arm; Response rate; Difference in quality of life between the nicotinamide arm and the placebo arm; Overall survival	Il Yeong Park, Ph.D.; Chungbuk National University	All	18 Years and older   (Adult, Older Adult)	110	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Amina-X-002	03/01/2015	03/01/2020	06/01/2020			15/04/2015				27/01/2020	https://ClinicalTrials.gov/show/NCT02416739		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	Lung	Non-Small Cell Lung Cancer	Nicotinamide	Response rate; PFS; OS; QoL	Phase 2/3	DB02701	N
NCT03516253	Fish Oil and EPO in Breast Cancer		Active, not recruiting	Breast Cancer	Dietary Supplement: Fish oil + EPO	Change in disease status; Change in quality of life; Changes in nutritional status; Changes in lipid profiles; Changes in plasma fatty acids profiles; Changes in interleukins; Changes in activity of superoxide dismutase.; Changes in activity of catalase.; Changes in activity of glutathion peroxidase.; Changes in activity of glutathion reductase.	University of Belgrade	Female	45 Years to 65 Years   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	VMA-253-18	20/02/2019	20/12/2022	20/06/2023			05/04/2018				05/04/2021	https://ClinicalTrials.gov/show/NCT03516253		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Serbia	Breast	Any Breast Cancer	Omega 3	Safety and/or Dose; Response rate; QoL; Biomarker	Other	DB13961	N
NCT04664816	Omega-3 Polyunsaturated Fatty Acids and Non-Muscle Invasive Bladder Cancer		Recruiting	Non-Muscle Invasive Bladder Cancer	Drug: n-3PUFAs Treatment; Drug: Placebo Treatment	Time to first recurrence.; Recurrence-free survival	Mansoura University	All	18 Years to 90 Years   (Adult, Older Adult)	110	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention	Omega3-NMIBC	12/01/2020	12/01/2022	12/01/2023			12/11/2020				21/12/2020	https://ClinicalTrials.gov/show/NCT04664816		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Egypt	Urological	Bladder Cancer	Omega 3	DFS/RFS/EFS; Recurrence rate	Other	DB13961	N
NCT04175769	EPA+DHA for Non-small Cell Lung Cancer Patients.		Not yet recruiting	Non-small Cell Lung Cancer	Dietary Supplement: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA); Other: Placebo	Disease control rate; Progression-free survival; 1-year survival; Chemotherapy-induced toxicities; Change in skeletal muscle mass and adipose tissue; Change in Serum CRP; Change in Serum Albumin; Change in Fatty Acid Incorporation and Omega-3 Index; Changes in Quality of Life	AHS Cancer Control Alberta; Cross Cancer Institute	All	18 Years and older   (Adult, Older Adult)	88	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	IIT-0001	01/01/2020	03/01/2022	09/01/2022			25/11/2019				26/11/2019	https://ClinicalTrials.gov/show/NCT04175769		Advanced/Metastatic	Collaborative Group	Y	N	N	Canada	Lung	Non-Small Cell Lung Cancer	Omega 3	Safety and/or Dose; PFS; OS; QoL; Biomarker	Other	DB13961	N
NCT03357757	Avelumab With Valproic Acid in Virus-associated Cancer	LATENT	Recruiting	Cancer That is Associated With a Chronic Viral Infection|p16 Positive SCCHN|Squamous Cell Carcinoma of the Cervix|p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva|p16 Positive Squamous Cell Carcinoma of the Penis|p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal|EBER Positive NPC|EBER Positive Hodgkins and Non-hodgkins Lymphona	Drug: Valproic Acid; Biological: Avelumab	Efficacy of Avelumab and VPA; Proportion of subjects who complete 4 doses of Avelumab in combination with VPA; Overall survival; Progression free survival; Number of participants with adverse events; Identify specific virus-associated cancers as candidates for subsequent study; Measurement of Immuno-score; Measurement of MHC expression; Measurement of cell-free tumoral DNA in blood; Phenotyping of Tumour Infiltrating Lymphocytes; DNA viral load; Expression of lytic viral genes; Cytotoxic T-Lymphocyte immunophenotyping; T-cell receptor sequencing; Hsp90 concentration in serum	AHS Cancer Control Alberta; EMD Serono	All	18 Years and older   (Adult, Older Adult)	39	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LATENT	02/07/2018	30/03/2022	26/02/2027			30/11/2017				07/05/2019	https://ClinicalTrials.gov/show/NCT03357757		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Canada	Multiple cancer types	Other multiple cancer group (specify)	Valproic Acid	Safety and/or Dose; PFS; OS; Other (specify)	Phase 2	DB00313	N
NCT02124174	Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS		Recruiting	Acute Myelogenous Leukemia AML|Myelodysplastic Syndrome MDS	Drug: Vidaza and Valproic Acid	Survival; Disease Relapse	Patrick Stiff; Loyola University	All	2 Years to 89 Years   (Child, Adult, Older Adult)	50	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	203835	01/01/2012	01/01/2022	01/01/2022			28/04/2014				26/04/2021	https://ClinicalTrials.gov/show/NCT02124174		Advanced/Metastatic	Hospital/University/Research Institute	N	N	Y	United States	Leukemia; Other Haem-onc	Acute Myeloid Leukemia, Adult; Acute Myeloid Leukemia, Childhood; Myelodysplastic Syndromes	Valproic Acid	OS; Recurrence rate	Phase 2	DB00313	N
NCT02595138	Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer		Active, not recruiting	Triple Negative Breast Cancer	Drug: Zoledronic acid	disease free survival; overall survival; Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Chinese Academy of Medical Sciences; Beijing Municipal Science   Technology Commission	Female	18 Years and older   (Adult, Older Adult)	430	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CH-BC-039	10/01/2015	10/01/2018	12/01/2023			11/03/2015				11/03/2015	https://ClinicalTrials.gov/show/NCT02595138	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Breast	Breast Cancer - TNBC	Zoledronic Acid	Safety and/or Dose; OS; DFS/RFS/EFS	Phase 3	DB00399	N
NCT03932071	Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma		Recruiting	Lung Metastases|Tumor Necrosis	Drug: Zoledronic Acid	rate of lung metastasis; rate of tumor recurrence; rate of tumor necrosis less than 90 	Second Affiliated Hospital, School of Medicine, Zhejiang University	All	Child, Adult, Older Adult	150	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	ChiCTR-IPR-16008568	01/01/2017	01/01/2020	01/01/2023			30/04/2019				05/06/2019	https://ClinicalTrials.gov/show/NCT03932071		Localised/Locoregional	Hospital/University/Research Institute	Y	N	Y	China	Bone Sarcoma	Osteosarcoma	Zoledronic Acid	Recurrence rate; Other (specify)	Phase 4	DB00399	N
2009-017137-22	Clinical course after substitution of Vitamin-D deficiency in patients with lung cancer or oesophageal carcinoma. Double blind randomised prospective, placebo-controlled study.	Vitamin D3 in thoracic surgery	Ongoing	Patients admitted for treatment on a general thoracic surgery division with the following conditions:  Lung cancer  Esophageal cancer  Cancer of the gastroesophageal junction (GEJ)	Drug: Oleovit D3 Tropfen; Drug: Colecalciferol; Placebo	Determination of the 25(OH)Vitamin D - levels in a patient collective requiring general thoracic surgery.     The main hypothesis of the study is, that high-dose supplementation of vitamin D will reduce perioperative/periinterventional morbidity and mortality and will prolong survival or tumour-free survival in patients treated for lung cancer or oesophageal carcinoma.	Klinische Abteilung f uuml;r Thorax -u. Hyperbare Chirurgie, Medizinische Universit auml;t Graz	All	Adult 18-64	400		-	Contolled|Randomised|Placebo|Double blind												https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017137-22/AT	Perioperative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Austria	Lung; GI	Any lung cancers; Esophageal Cancer	Cholecalciferol	OS; DFS/RFS/EFS; Biomarker	Phase 3	DB00169	N
2017-000695-28	Pilot study of Vitamin D biological effects in patients with resectable urinary tract urothelial carcinoma.		Ongoing	Patients with resectable urinary tract urothelial carcinoma candidates to radical cystectomy o nephroureterectomy.	Drug: Colecalciferol (Vitamin D); Drug: COLECALCIFEROL	Tumor expression of differentiation and Vitamin D response markers (RNA and protein), comparing pre- versus post- intervention with Vitamin D.	Hospital Universitari Germans Trias i Pujol	All	Adult 18-64	50	Fundaci oacute;n Asociaci oacute;n Espa ntilde;ola contra el C aacute;ncer	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000695-28/ES		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Spain	Urological	Bladder Cancer	Cholecalciferol	Biomarker	Phase 4	DB00169	N
2019-002748-25	Repurposing disulfiram as treatment for metastatic colorectal cancer  An investigator initiated clinical phase II trial	Disulfiram colorectal cancer	Ongoing	Metastatic, non-resectable and irinotecan-resistant colorectal cancer	Drug: disulfiram	Primary objective:    Disease-control rate (complete response, partial response and/or stable disease  gt;= 18 weeks   	Department of Oncology, Odense Universitetshospital	All	Adult 18-64	28	Danish Cancer Society	-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002748-25/DK		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Denmark	GI	Colon Cancer; Rectal Cancer	Disulfiram	Other (specify)	Phase 2	DB00822	N
2019-001972-12	A phase 1b/2 open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors and advanced breast cancer  	Disulfiram trial	Ongoing	in phase 1b part: advanced and/or treatment refractory solid malignancies   in phase 2 part : advanced or metastatic HER2-negative breast cancer	Drug: disulfiram; Drug: vinorelbine	Phase 1b:   Safety and tolerability assessments include adverse event (AE), vital signs, physical examination, electrocardiogram (ECG) and clinical laboratory tests.    Phase 2:  clinical benefit rate (CBR=CR+PR+SD ge;18 weeks) per RECIST 1.1.	Department of Oncology, Herlev  amp; Gentofte Hospital	All	Adult 18-64	52	Danish Cancer Society	-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001972-12/DK		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Denmark	Multiple cancer types; Breast	Any solid tumours; Breast Cancer - HER2-	Disulfiram	Safety and/or Dose; Response rate; Other (specify)	Phase 1/2	DB00822	N
2019-000558-68	Phase II study of disulfiram and cisplatin in refractory testicular germ cell cancer.	GCTSK006	Ongoing	platina refractory testicular germ cell cancer	Drug: cisplatina; Drug: DISULFIRAM	Overall response rate (ORR) by RECIST 1.1 (intent-to-treat population)	N aacute;rodn yacute; onkologick yacute;  uacute;stav	Male	Adult 18-64	20	N aacute;rodn yacute; onkologick yacute;  uacute;stav	-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000558-68/SK		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Slovakia	Urological	Testicular Cancer	Disulfiram	Response rate	Phase 2	DB00822	N
2016-000089-45	A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy	STELLAR Study	GB - no longer in EU/EEA	Anaplastic Astrocytoma	Drug: Eflornithine; Drug: Lomustine; Drug: EFLORNITHINE HYDROCHLORIDE	The primary endpoint is the duration of overall survival as measured from the date of randomization. 	Orbus Therapeutics, Inc.	All	Adult 18-64	340	Orbus Therapeutics, Inc.	-	Contolled|Randomised|Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000089-45/GB	Palliative	Recurrent/Refractory	Company	Y	N	N	United States	CNS	Astrocytoma	Eflornithine	OS	Phase 3	DB06243	N
2014-001523-69	Preclinical and clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of head and neck	Valproic acid  ndash; Cisplatin and Cetuximab in Head And Neck CancEr	Ongoing	Recurrent and/or metastatic squamous cell carcinoma of head and neck	Drug: Valproic Acid; Drug: Erbitux; Drug: CETUXIMAB	The overall response rate	Istituto Nazionale Tumori di Napoli - Fondazione  G. Pascale 	All	Adult 18-64	39	Ricerca Corrente - Ministry of Health	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001523-69/IT		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Italy	Head and Neck	Any head and neck squamous cell carcinoma	Valproic Acid	Response rate	Phase 2	DB00313	N
2014-004194-16	A multicenter, single-arm, phase II study to evaluate the activity of pre-operative zoledronate in triple negative breast cancer patients, according to p53 level	TRIPLE NEGATIVE	Ongoing	Newly diagnosed, untreated, operable triple negative breast cancer		The study is primarily aimed at assessing the anti-tumor activity of pre-operative zoledronate (zol), measured through its effect on the Ki67 proliferative surrogate biomarker, in patients with TNBC selected according to the p53 expression (high vs low p53 expression). Primary endpoint of the study is the proportion of responder patients, defined as those with at least 30  reduction in Ki67 at surgery with respect to core-biopsy analysis. Prior to enrolment, the FFPE diagnostic core biopsy specimens will be analyzed by the study pathologist to determine the presence of invasive TNBC and the Ki67/p53 values. The ki67/p53 evaluation will be then repeated after treatment at the time of definitive surgery.	IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI	All	Adult 18-64	40	Associazione Italiana per la Ricerca sul Cancro	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004194-16/IT		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Italy	Breast	Breast Cancer - TNBC	Zoledronic Acid	Biomarker	Phase 2	DB00399	N
2009-016932-11	Phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative breast cancer.	NEO-ZOTAC	Ongoing	Patients with locally advanced or large resectable HER2-negative breast cancer	Drug: Zometa; Drug: pegfilgrastim	The primary endpoint of this study is the pathologic complete response (pCR) rate to neoadjuvant chemotherapy with or without zoledronic acid at surgery.	BOOG Study Center B.V	Female	Adult 18-64	250		-	Contolled|Randomised|Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016932-11/NL	Neo-adjuvant/Window	Localised/Locoregional	Collaborative Group	Y	N	N	Netherlands	Breast	Breast Cancer - HER2-	Zoledronic Acid	Response rate	Phase 3	DB00399	N
2011-003154-12	Circulating Tumor Cells in Patients with Castration Resistant Metastatic Prostate Cancer Undergoing Zoledronate Therapy	Cicero- Z	Ongoing	hormone refractory metastatic prostate cancer    	Drug: ZOLEDRONIC ACID	Proportion of patients with decreased CTCs at 12 weeks after first infusion of zoledronic acid	Privat auml;rztliche urologische Partnerschaft GbR, EuromedClinic	Male	Adult 18-64	60	Novartis	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003154-12/DE		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Germany	Urological	Prostate Cancer	Zoledronic Acid	Other (specify)	Phase 4	DB00399	N
2006-000426-31	STUDIO DI FASE I DELLA COMBINAZIONE FARMACOLOGICA TRA ACIDO ZOLEDRONICO E DOCETAXEL IN PAZIENTI CON CARCINOMA PROSTATICO METASTATICO ORMONO - REFRATTARIO 	ZANTE	Ongoing	carcinoma prostatico metastatico ormono refrattario 	Drug: Docetaxel	 middot; Determinare la dose massima tollerata (MTD) e la tossicita' dose-limitante (DLT) di DTX in due diverse sequenze di somministrazione con ZOL in pazienti affetti da carcinoma prostatico ormono-refrattario con metastasi ossee.	ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE  G. PASCALE 	Male	Adult 18-64; Elderly 65+	36		-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000426-31/IT		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Italy	Urological	Prostate Cancer	Zoledronic Acid	Safety and/or Dose	Phase 1/2	DB00399	N
2013-001188-22	Interleukin 2 and zolendronic acid as maintaining treatment in multiple myeloma patients after autologous bone marrow transplant		Ongoing	Multiple Myeloma patients underwent to autologous bone marrow transplant	Drug: zoledronic acid	Clinical and laboratoristic progression of disease (onset or increase of monoclonal component, increased beta-2 microglobulin in two consecutive quarterly checks, progression of bone lesions, onset or progression of renal insufficiency).	AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA	All	Adult 18-64	43	Regione Toscana e Ministero della Salute	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001188-22/IT		Any/All Stages	Hospital/University/Research Institute	N	N	N	Italy	Other Haem-onc	Multiple Myeloma	Zoledronic Acid	PFS	Phase 2	DB00399	N
2019-004207-13	Tocotrienol and Bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial  	Toco-CoR	Ongoing	Metastatic colorectal cancer	Drug: Fluorouracil; Drug: Calciumfolinate; Drug: Bevacizumab; Drug: CALCIUM FOLINATE; Placebo	The rate of progression free patients at six months	Vejle Hospital	All	Adult 18-64	74	Vejle Hospital	-	Contolled|Randomised|Placebo|Double blind												https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004207-13/DK		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Denmark	GI	Colon Cancer; Rectal Cancer	Acetaminophen	PFS	Phase 2	DB00316	N
2012-002107-17	International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours	Euro Ewing 2012	GB - no longer in EU/EEA	Ewing's Sarcoma Family of Tumours	Drug: Vincristine; Drug: Ifosfamide; Drug: Etoposide; Placebo	Event-free survival (EFS)	University of Birmingham	All	Under 18; Adult 18-64; Elderly 65+	600	CTAAC	-	Contolled|Randomised|Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002107-17/GB		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	Y	United Kingdom	Bone Sarcoma	Ewing Sarcoma	Zoledronic Acid	DFS/RFS/EFS	Phase 3	DB00399	N
2010-022104-50	A randomized phase II study of paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV non-squamous-non-small cell lung cancer: NVALT12	NVALT12	Ongoing	metastatic non-squamous non-small-cell lung cancer	Drug: Nitroglycerin transdermal patch	Progression free survival.	Stichting NVALT Studies	All	Adult 18-64	222		-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022104-50/NL		Advanced/Metastatic	Collaborative Group	Y	N	N	Netherlands	Lung	Non-Small Cell Lung Cancer	Nitroglycerin	PFS	Phase 2	DB00727	N
2011-004062-15	Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma	RIST-rNB-2011	Ongoing	Relapsed or refractory high risk neuroblastoma	Drug: Sprycel; Drug: Temodal; Drug: Irinotecan Kabi; Drug: DASATINIB; Drug: TEMOZOLOMIDE; Drug: IRINOTECAN; Drug: SIROLIMUS	The primary endpoint is progression-free survival (PFS), which is defined as the time interval between randomization and date of progression (first time at which progression can be declared) according to   bull; Imaging criteria  (MRI, MIBG. CT, US)  and/or   bull; Bone marrow morphology or   bull; date of death of any cause  Patients with no progression until end of study or patients lost to follow up will be classified as censored cases at the latest date they will be confirmed to be progression free. 	University Hospital of Regensburg	All	Under 18; Elderly 65+	114	Medac GmbH	-	Contolled|Randomised|Open|Cross over												https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004062-15/AT		Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	Germany	Other	Neuroblastoma	Sirolimus	PFS	Phase 2	DB00877	N
2012-001106-26	PHASE II MULTICENTRIC AND PROSPECTIVE TRIAL WITH GEMCITABINE AND RAPAMYCIN IN SECOND LINE OF METASTATIC OSTEOSARCOMA	OSTEOSARCOMA METASTASICO PREVIOUSLY TREATED	Ongoing	Patients diagnosed with metastatic osteosarcoma cancer types that have been treated with chemotherapy and have active disease that permits to receive this treatment combination.	Drug: GEMCITABINE HYDROCHLORIDE	Analyze progression-free survival (PFS), measured as SLP index at 4 months, in patients with metastatic osteosarcoma who have previously received the more active drugs in this disease (methotrexate, cisplatin, adriamycin and ifosfamide) and are in metastatic progression or cannot be operated.	JAVIER MART Iacute;N BROTO	All	Under 18; Adult 18-64	33	Direcci oacute;n General de Farmacia y Productos Sanitarios del Ministerio de Sanidad, Pol iacute;tica Social e Igualdad	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001106-26/ES		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Spain	Bone Sarcoma	Osteosarcoma	Sirolimus	PFS	Phase 2	DB00877	N
ACTRN12616001350415	the efficacy of histone deacetylase inhibitor valproic acid in the treatment of gliomas		Recruiting	Brain Cancer; <br>Brain Cancer<br>;Cancer - Brain	Addition of oral valproate (dose is epilepsy dose titrated to plasma concentration so changes) or placebo to standard care.<br>start dose is 15-20mg/kg, titrated in 100-200mg amounts depending on clinical status. Once daily until completion of second scan after chemotherapy/radiotherapy scan (3-4 months). VPA commences 4-5 days pre surgery to enable CSF samples at time of surgery. Blood concentrations to monitor adherence.	F-DOPA and F-MISO PET uptake using standard PET measurement tool[After treatment completed. this includes the chemotherapy (Temozolamide and the RT) and is usually 3-4 months. As the original (standard) pre-op scan is not being done (as too much brain shift to interpret PET volumes accurately post op), the second scan, at the completion of chemo and radiotherapy is the primary time point.]	RBWH	All	18 Years: No limit	20	RBWH Foundation	Interventional Study	Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Safety/efficacy;		01/01/2013				27/09/2016					13/01/2020	https://anzctr.org.au/ACTRN12616001350415.aspx		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Australia	CNS	Glioblastoma	Valproic Acid	Other (specify)	Phase 4	DB00313	N
ACTRN12615000778583	Investigating the effects of metformin on growth factors involved in prostate cancer progression in prostate cancer patients		Not yet recruiting	Prostate cancer; <br>Prostate cancer;Cancer - Prostate;Metabolic and Endocrine - Metabolic disorders	Metformin treatment over 6 weeks; oral tablets, dose - 500 mg twice daily for the first week, followed by 1000 mg twice daily from the second week for 5 weeks. Adherence monitored by empty tablet packet return. No washout between metformin and placebo, as study visits will be at baseline and at the end of each treatment.	A composite primary outcome is serum IGF-1, IGF-2, IGFBPs (IGFBP-1 to 3) and bioactive IGF-1[Baseline and at 6 and 12 weeks]	Western Sydney Local Health District	Male	50 Years: 80 Years	26	Department of Endocrinology internal funds, UWS Blacktown Clinical School.	Interventional Study	Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Crossover;Type of endpoint: Efficacy;		03/08/2015				27/07/2015					13/01/2020	https://anzctr.org.au/ACTRN12615000778583.aspx		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Australia	Urological	Prostate Cancer	Metformin	Biomarker	Phase 4	DB00331	N
ACTRN12607000082404	A pilot study to evaluate the feasibility, safety and tolerability of neoadjuvant triple therapy with zoledronic acid, docetaxel, and luteinising hormone-releasing hormone (LH-RH) analogue for men with high-risk prostate cancer to be treated by radical prostatectomy		Not yet recruiting	Prostate cancer; <br>Prostate cancer;Cancer - Prostate	Docetaxel 75mgm/m2 intravenously every 3 weeks for 4 cycles.<br>Zoledronic acid 4mgm intravenously every 3 weeks for 4 cycles.<br>Goserelin acetate 10.5 mgm subcutaneously x 1 dose.<br>All administered prior to radical prostatectomy.	Safety: haematology and biochemistry evaluation.[Weekly whilst receiving therapy, then 3/12 and 24/12 following radical prostatectomy.];Tolerability: assessment of adverse events.[Weekly during therapy, then 3/12 and 24/12 following radical prostatectomy.]	Urology Department The Royal Melbourne Hospital	Male	18 Years: No limit	15	The Royal Melbourne Hospital	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety/efficacy;		01/04/2007				24/01/2007					13/01/2020	https://anzctr.org.au/ACTRN12607000082404.aspx		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Australia	Urological	Prostate Cancer	Zoledronic Acid	Safety and/or Dose	Phase 2	DB00399	N
ACTRN12606000079549	The LoPeZ study		Recruiting	Metastatic non-small cell lung carcinoma with bony metastases; <br>Metastatic non-small cell lung carcinoma with bony metastases;Cancer - Lung - Non small cell;Cancer - Bone	Zoledronic acid, 4 mg intravenously monthly for six months	The primary endpoint is the Visual metabolic response rate in asymptomatic non-osseous lesions[At 1 and 3 months, as determined by changes from baseline on [18F]-FDG PET/CT scans]	Peter MacCallum Cancer Centre	All	18 Years: Not stated	14	Novartis pharmaceuticals	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Efficacy;		06/02/2006				23/02/2006					13/01/2020	https://anzctr.org.au/ACTRN12606000079549.aspx		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Australia	Lung	Non-Small Cell Lung Cancer	Zoledronic Acid	Response rate	Phase 2	DB00399	N
ACTRN12611000301965	Immunomodulatory effect of anaesthetic technique in breast cancer surgery		Not yet recruiting	breast cancer;partial mastectomy with sentinel lymph node dissection; <br>breast cancer <br>partial mastectomy with sentinel lymph node dissection;Cancer - Breast;Anaesthesiology - Anaesthetics	general anaesthesia with propofol 3 microg/ml, remifentanil 2 ng/ml in air (1 L/min) delivered at the same time with  oxygen (1L/min) mixture and continuously maintained with propofol 3 microg/ml, remifentanil 2 ng/ml in air (1 L/min)  delivered at the same time with oxygen  (1L/ min) mixture during operation (approximately 90-120 minutes)	activated T-cell panel (CD4/CD8/CD69/CTLA4) in peripheral blood will be evaluated using flow cytometry after monoclonal antibody staining[before anaesthetic induction, before discharge from the post anaesthesia care unit (PACU), 24 hour after end of operation];regulatory T cell subset(CD4/CD25/FoxP3) in peripheral blood will be evaluated using flow cytometry after monoclonal antibody staining[before anaesthetic induction, before discharge from the post anaesthesia care unit (PACU), 24 hour after end of operation]	Jie Ae Kim	Female	30 Years: 60 Years	60	Samsung Medical Center Clinical Research Development Program grant, CRS110-07-1	Interventional Study	Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;		28/03/2011				22/03/2011					13/01/2020	https://anzctr.org.au/ACTRN12611000301965.aspx		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	Breast	Any Breast Cancer	Propofol	Biomarker	Phase 4	DB00818	N
ChiCTR2000038589	A multicenter, randomized, controlled clinical study of abiraterone combined with dutasteride in the treatment of castration-resistant prostate cancer		Recruiting	prostate cancer	dutasteride+abiraterone:dutasteride+abiraterone;placebo+abiraterone:abiraterone;	progression-free survival;PSA decrease range;overall survival;bone events;liver function;	Shanghai Tongji Hospital	Male	-	dutasteride+abiraterone:128;placebo+abiraterone:64;	Shanghai Shenkang Hospital Development Center	Interventional Study	Parallel		17/09/2020				24/09/2020					30/11/2020	http://www.chictr.org.cn/showproj.aspx?proj=61685		Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	China	Urological	Prostate Cancer	Dutasteride	Response rate; PFS; OS; Biomarker; Other (specify)	Not available/Missing	DB01126	N
ChiCTR2000037943	Metformin combined with FOLFIRI+bevacizumab in the second-line treatment of non-diabetic RAS mutant metastatic colorectal cancer: a multi-center, single-arm phase II clinical study		Recruiting	Colorecal cancer	Single arm:Metformin;	Effect;toxicity;Quality of Life;	Sun Yat-Sen University Cancer Center	All	-	Single arm:116;	Sun Yat-sen University Cancer Center Clinical Research 308 Project	Interventional Study	Single arm		08/01/2020				09/04/2020					16/11/2020	http://www.chictr.org.cn/showproj.aspx?proj=60832		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	GI	Colon Cancer; Rectal Cancer	Metformin	Safety and/or Dose; Response rate; QoL	Phase 2	DB00331	N
ChiCTR2000037740	A prospective study of dextromethorphan and metformin in treating patients with esophageal squamous cell carcinoma sufferering the failure of radiography and chemotherapy		Recruiting	esophageal squamous cell carcinoma	Metformin treatment group:Metformin hydrochloride;Dextromethorphan treatment group:Dextromethorphan hydrobromide;Metformin and dextromethorphan treatment group:Metformin hydrochloride and Dextromethorphan hydrobromide;Placebo group:Placebo;	Disease-free survival;Overall survival;CD44;SOX2;OCT4;a7nAchR;Inflammation marker;Immune cell marker;PD-L1;PD-1;	Jinan University	All	-	Metformin treatment group:150;Dextromethorphan treatment group:150;Metformin and dextromethorphan treatment group:150;Placebo group:150;	Self-funding	Interventional Study	Parallel		15/09/2020				31/08/2020					11/02/2020	http://www.chictr.org.cn/showproj.aspx?proj=53770		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	China	Head and Neck	Any head and neck squamous cell carcinoma	Metformin	OS; DFS/RFS/EFS; Biomarker	Not available/Missing	DB00331	N
ChiCTR2000036618	Precision therapy strategy for osteosarcoma based on molecular typing: a prospective, single-center, one-brachial umbrella phase II exploratory clinical study		Pending	osteosarcoma	A:Everolimus 5mg qd + Anlotinib 8mg-12mg day 1-21,28-day cycle;B:Camrelizumab 3mg/kg + Ipilimumab 1 mg/kg, 21-days cycle;C:Palbociclib 125mg day 1-21 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle;D:Olaparib 300mg bid day 1-14 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle;D:Metformin 2000mg qd + gemcitabine 675mg/m2 day 1,8, docetaxol 900mg/m2 day 8, 21-days cycle;	Objective mitigation rate (ORR);	Shanghai General Hospital	All	-	A:3;B:3;C:4;D:4;D:4;	Project special fund	Interventional Study	Factorial		10/01/2020				24/08/2020					21/09/2020	http://www.chictr.org.cn/showproj.aspx?proj=59675		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	Y	N	China	Bone Sarcoma	Osteosarcoma	Metformin	Response rate	Phase 2	DB00331	N
ChiCTR2000036467	A prospective single center study on the safety and efficacy of TACE + lovastatinib + PD1 monoclonal antibody in trans transplantation of hepatocellular carcinoma beyond Hangzhou standard		Pending	Hepatocellular carcinoma	Experimental group:Combined intervention of PD-1 mAb + lovastatin + TACE;Control group:TACE intervention alone;	disease free survival;CD4+ / CD8+ ratio;	Huashan Hospital Affiliated to Fudan University	All	-	Experimental group:30;Control group:30;	Shanghai Shenkang Hospital Development Center	Interventional Study	Parallel		09/01/2020				23/08/2020					14/09/2020	http://www.chictr.org.cn/showproj.aspx?proj=59555		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Liver Cancer	Lovastatin	DFS/RFS/EFS	Not available/Missing	DB00227	N
ChiCTR2000035935	The effect of local radical treatment on the breast cancer with bone oligometastasis		Pending	Breast cancer	Experimental group:Surgery combined with radiofrequency ablation + Systemic anti-tumor therapy + bone repair therapy for breast cancer (4mg Zoleic acid vgtt q.m. / 6mg ibandronic acid vgtt q.m.);Control group:Systemic anti-tumor therapy + bone repair therapy for breast cancer (4mg Zoleic acid vgtt q.m. / 6mg ibandronic acid vgtt q.m.);	Progression Free Survival;	Shanghai Tenth People's Hospital	Female	-	Experimental group:80;Control group:40;	Hospital Development Center	Interventional Study	Parallel		01/01/2021				20/08/2020					24/08/2020	http://www.chictr.org.cn/showproj.aspx?proj=58950		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	Breast	Any Breast Cancer	Ibandronic Acid	PFS	Not available/Missing	DB00710	N
ChiCTR2000035469	Effect of continuous intravenous infusion of lidocaine on postoperative recovery and long-term outcomes of patients with pancreatic cancer: A prospective, randomized controlled trial		Pending	Pancreatic cancer	Lidocaine Group :Intravenous infusion of lidocaine;Control Group:Intravenous infusion of saline;	Overall survival;	Zhongshan Hospital, Fudan University	All	-	Lidocaine Group :415;Control Group:415;	National Natural Science Foundation of China 81871591	Interventional Study	Parallel		09/01/2020				08/12/2020					17/08/2020	http://www.chictr.org.cn/showproj.aspx?proj=57569		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Pancreatic Cancer	Lidocaine	OS	Not available/Missing	DB00281	N
IRCT20120922010901N7	The effect of metformin in patients with ovarian cancer		Recruiting	Serum CA125 changes. <br>Elevated cancer antigen 125 [CA 125];R97.1	Intervention 1: Intervention group: Metformin starts with a daily dose of 500 mg and during one week the dose will be increased to 1500 mg daily in three divided doses (500 mg every 8 hours). This group will also receive carboplatin  €  paclitaxel periodically (every 21 days). Intervention 2: Control group: Will receive carboplatin  €  paclitaxel periodically (every 21 days).	Response to treatment. Timepoint: Three months after the intervention. Method of measurement: Serum level of cancer antigen 125.	Tabriz University of Medical Sciences	Female	18 years: no limit	90	Tabriz University of Medical Sciences	Interventional Study	Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be divided into intervention and control groups using even and odd numbers, respectively. The number zero is considered as even.		22/07/2020				26/07/2020					17/08/2020	http://en.irct.ir/trial/49801		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Iran	Gynaecological	Ovarian Epithelial Cancer	Metformin	Response rate	Phase 3	DB00331	N
ChiCTR2000034678	Ascorbic acid (vitamin C tablets) enhances the efficacy of targeted drugs in advanced renal cell carcinoma: a multicenter randomized controlled trial		Recruiting	Renal cell carcinoma	experimental group: Vitamin C tablets ;control group :Blank;	Disease progression-free survival ;	Affiliated Hospital of Qingdao University	All	-	experimental group:59;control group :59;	raise independently	Interventional Study	Parallel		07/01/2020				14/07/2020					20/07/2020	http://www.chictr.org.cn/showproj.aspx?proj=56452		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	China	Urological	Renal Cell Carcinoma	Ascorbic acid	DFS/RFS/EFS	Phase 4	DB00126	N
ChiCTR2000034398	Gemcitabine plus nab-paclitaxel, paricalcitol and PD-1 antibody for locally advanced pancreatic cancer: a phase II, single center, single arm study		Pending	Pancreatic cancer	experimental group:gemcitabine plus nab-paclitaxel, paricalcitol and PD-1 antibody;	ORR;	Sun Yat-Sen Cancer Center	All	-	experimental group:21;	Sponsored by the company	Interventional Study	Single arm		08/01/2020				07/04/2020					07/06/2020	http://www.chictr.org.cn/showproj.aspx?proj=56055		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	GI	Pancreatic Cancer	Paricalcitol	Response rate	Phase 2	DB00910	N
ChiCTR2000034397	Gemcitabine, plus nab-paclitaxel, pirfenidone for pancreatic cancer with liver metastasis: a phase II, single center, single arm study		Pending	Pancreatic cancer	experimental group:gemcitabine plus nab-paclitaxel, pirfenidone;	ORR;	Sun Yat-Sen Cancer Center	All	-	experimental group:33;	Sponsered by company	Interventional Study	Single arm		08/01/2020				07/04/2020					07/06/2020	http://www.chictr.org.cn/showproj.aspx?proj=56065		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	GI	Pancreatic Cancer	Pirfenidone	Response rate	Phase 2	DB04951	N
KCT0005192	Identification of anti-tumor effect of propofol using microRNA profile analysis in patients undergoing lung cancer surgery		Not yet recruiting	;Neoplasms	Drug, Procedure/Surgery : Upon arrival at the operating room, patients #39; electrocardiogram, peripheral oxygen saturation (SpO2), non-invasive arterial pressure and  bispectral index(BIS) are monitored. General anesthesia is induced and maintained with propofol and remifentanil in the propofol group. In the sevoflurane group, anesthesia is induced and maintained with sevoflurane inhalation and remifentanil. For maintenance of anesthesia, propofol effect site concentration is targeted  3-5   g/kg in the propofol group, and sevoflurane is administered 1-1.5 MAC in the sevoflurane group for maintaining BIS 40-60. Venous or arterial blood is drawn through intravenous or arterial catheter at the pre-operative time point and immediately before emergence from anesthesia.	microRNA profile	Hallym University Medical Center	All	20(Year): 90(Year)	30	Hallym University Medical Center	Interventional Study	Primary Purpose : Basic Science, Intervention Model : Parallel, Blinding/Masking : Single, Blinding Target : Subject, Allocation : Not Applicable		13/07/2020				07/01/2020					13/07/2020	http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=17071		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	Lung	Non-Small Cell Lung Cancer	Propofol	Biomarker	Not available/Missing	DB00818	N
ChiCTR2000034140	Study on Metformin Plus Temozolomide in Patient With Recurrent Glioblastoma Multiforme		Pending	Glioblastoma Multiforme	Case series:Metformin Plus Temozolomide;	Progression Free Survival;	Sun Yat-sen University Cancer Center	All	-	Case series:67;	Sun Yat-sen University Cancer Center 308 Plan	Interventional Study	Single arm		06/01/2019				26/06/2020					29/06/2020	http://www.chictr.org.cn/showproj.aspx?proj=49143		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	CNS	Glioblastoma	Metformin	PFS	Phase 1/2	DB00331	N
ChiCTR2000034035	Five-year prognosis of postmenopausal patients with hormone receptor-positive early breast cancer treated with different stains and aromatase inhibitors: a prospective, randomized controlled trial		Pending	Breast Cancer	Lipophilic stain simvastatin treatment:Simvastatin;Hydrophilic stain simvastatin treatment:Pravastatin;	5-year relapse-free survival;	The First Hospital of China Medical University	Female	50: 70	Lipophilic stain simvastatin treatment:187;Hydrophilic stain simvastatin treatment:187;	self-raised	Interventional Study	Parallel		15/07/2020				21/06/2020					22/06/2020	http://www.chictr.org.cn/showproj.aspx?proj=55473		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Breast	Breast Cancer - ER/HR+	Pravastatin; Simvastatin	DFS/RFS/EFS	Phase 4	DB00175; DB00641	N
IRCT20200313046756N1	Vitamin D, Probiotics and Breast Cancer		Recruiting	Breast Cancer.	Intervention 1: Intervention group: Patients receiving vitamin D3 at a dose of 1000 IU daily as a single oral capsule, with food, and with a probiotic placebo capsule for 16 consecutive weeks from breast cancer diagnosis until surgery. Intervention 2: Intervention group: Patients who receive single probiotics capsule daily at 1 billion CFU before meals with a single vitamin D3 placebo capsule for at least 16 weeks from cancer diagnosis until surgery. Intervention 3: Intervention group: Patients receiving vitamin D3 at a dose of 1000 IU daily as a capsule, with food and probiotic capsules daily with 1 billion CFU  for 16 consecutive weeks from breast cancer diagnosis until surgery. Intervention 4: Intervention group: Patients who receive one vitamin D3 placebo capsule with food and one probiotic placebo capsule daily before meals for 16 consecutive weeks from breast cancer diagnosis until surgery.	Measurement of Miller-Payne Grade Index on Residual Tumor Tissue. Timepoint: 4 months after intervention. Method of measurement: Microscopic examination.;Residual Cancer Burden Score on residual tumor tissue. Timepoint: 4 months after intervention. Method of measurement: By http://www.mdanderson.org/breastcancer_RCB.;Ki-67 nuclear protein as a biomarker of cell proliferation. Timepoint: ?At the beginning of the intervention, by Core needle biopsy and 4 months later (after surgery) on the residual tumor tissue. Method of measurement: Immunohistochemical staining.	Kerman University of Medical Sciences	Female	18 years: no limit	88	Kerman University of Medical Sciences;Zist Takhmir Pharmaceutical Company	Interventional Study	Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Factorial, Purpose: Treatment, Randomization description: Patients will be divided into four intervention groups by the factorial method.Randomization Method: FactorialRandomization Unit: PersonRandomization Tool: Random Number Table, Blinding description: People will be kept blind.1. Patients: Each patient will receive a label according to the random number table that will appear on the patient's drug box. Medicines do not differ in appearance, taste, odor. The patient consumes two capsules daily.2. Physician: The analyzing team will give the medicine boxes to the physician, and the physician will provide the medication based on the random number table.		04/08/2020				28/03/2020					21/04/2020	http://en.irct.ir/trial/46512	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	Iran	Breast	Any Breast Cancer	Calcipotriol; Calcitriol; Cholecalciferol	Response rate; Biomarker	Phase 3	DB02300; DB00136; DB00169	N
KCT0004846	Efficacy of antiplatelet therapy in reducing risk of recurrence for patients with hepatocellular carcinoma		Not yet recruiting	;Neoplasms	Drug : Patients are administered orally once a day for a total of 96 weeks, depending on the group. Those who are taking antiviral agents for chronic hepatitis B can change their antiviral agents to tefovir tablets at the discretion of the investigator.<br>1) Chronic Hepatitis B Patient<br>-Test group: Tefovir tablet 292mg / day + Hanmi aspirin enteric tablet 100mg / day<br>-Control: Tefovir tablet 292mg / day + Hanmi aspirin enteric tablet placebo 100mg / day<br><br>2) Patients other than chronic hepatitis B<br>-Test group: Hanmi aspirin enteric tablet 100mg / day<br>-Control group: Hanmi aspirin enteric tablet placebo 100mg / day	Cumulative recurrence rate of hepatocellular carcinoma	Seoul National University Hospital	All	19(Year): 85(Year)	288	Hanmi Pharm	Interventional Study	Primary Purpose : Prevention, Intervention Model : Parallel, Blinding/Masking : Double, Blinding Target : Subject, Investigator, Allocation : RCT		17/03/2020				20/03/2020					23/03/2020	http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=15958		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	GI	Liver Cancer	Acetylsalicylic Acid	Recurrence rate	Phase 4	DB00945	N
KCT0004674	Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients		Not yet recruiting	;Neoplasms	Drug : Aspirin arm: Daily oral aspirin 100 mg for 5 years<br>Placebo arm: Daily oral placebo for 5 years	The incidence of gastric cancer between the intervention and placebo groups	National Cancer Center	All	19(Year): 70(Year)	1700	National Cancer Center	Interventional Study	Primary Purpose : Prevention, Intervention Model : Parallel, Blinding/Masking : Double, Blinding Target : Subject, Investigator, Outcome Accessor, Allocation : RCT	NCT04214990	19/02/2020				30/01/2020					24/02/2020	http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=14998	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	GI	Gastric Cancer	Acetylsalicylic Acid	Recurrence rate	Phase 3	DB00945	N
ChiCTR2000029245	The efficacy and safety of the combination of transcatheter arterial chemoembolisation with metronidazole in hepatocellular carcinoma		Pending	Hepatocellular carcinoma	experimental group:TACE combined with Metronidazole;control group:TACE;	Survival rate at 1-year;	Beijing Ditan Hospital, Capital Medical University	All	-	experimental group:116;control group:116;	Beijing Talents Project	Interventional Study	Parallel		03/01/2020				20/01/2020					20/01/2020	http://www.chictr.org.cn/showproj.aspx?proj=47069		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Liver Cancer	Metronidazole	OS	Other	DB00916	N
ChiCTR2000028905	Metformin for chemoradiotherapy prevention in advanced nasopharyngeal carcinoma patients: a double-blind, placebo-controlled, randomized clinical trial		Pending	nasopharyngeal carcinoma	Treatment group:Metformin and chemoradiotherapy;Control group:Placebo and chemoradiotherapy;	Progression free survival;	Hunan Cancer Hospital	All	-	Treatment group:101;Control group:101;	National Natural Science Foundation of China (No.81874329)	Interventional Study	Parallel		03/01/2020				01/06/2020					13/01/2020	http://www.chictr.org.cn/showproj.aspx?proj=48015		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	Head and Neck	Nasopharyngeal Cancer	Metformin	PFS	Phase 4	DB00331	N
KCT0004571	Phase II trial evaluating the efficacy and safety of physician chosen chemotherapy with hormonal therapy in patients with heavily pretreated advanced ovarian cancer: A multicenter pilot study		Recruiting	;Neoplasms	Drug : Receptor status is assessed by immunohistochemistry using recurrent tissues obtained from biopsy as determined by central laboratory. Dominant receptor, which means the receptor that has the highest expression, will be determined and hormonal therapeutic agent for the dominant receptor will be selected. In addition to chemotherapy, ER dominant EOC patients will be treated with tamoxifen 40 mg (20mg, bid, oral), daily and PR dominant patients will be treated with megestrol acetate 160mg (once, oral), daily. Hormonal therapies are performed from day 1 of 1st cycle of chemotherapy until progression of disease or unacceptable toxicity.	objective response rate	Inha University Hospital	Female	19(Year): No Limit	58	Dalim BioTech	Interventional Study	Primary Purpose : Other(To evaluate the efficacy and safety of combination therapy of various types of physician chosen chemotherapy and tailored targeting hormonal therapies in patients with heavily pretreated advanced OC), Intervention Model : Parallel, Blinding/Masking : Open, Allocation : Non-RCT		11/08/2019				20/12/2019					14/01/2020	http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=14535		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	Y	N	Korea, Republic of	Gynaecological	Ovarian Epithelial Cancer; Fallopian Tube Cancer	Megestrol Acetate	Response rate	Phase 2	DB00351	N
IRCT20191203045594N1	The effect of metformin on treatment of squamous cell carcinoma of neck		Pending	Malignant neoplasm of larynx. <br>Malignant neoplasm of larynx, unspecified;C32.9	Intervention group: The patients with proven diagnosis of squamous cell carcinoma of hypopharynx, nasopharynx, and larynx receiving concurrent chemoradiation will take metformin orally twice daily (1000 mg/day) after eating from 7 to 11 days prior chemoradiotherapy until the end of it.	The complete response. Timepoint: 12 weeks after the intervention. Method of measurement: Spiral CT scan.;Toxicity. Timepoint: Weekly. Method of measurement: Common Terminology Criteria for Adverse Events (CTCAE).	Shiraz University of Medical Sciences	All	18 years: 75 years	25	Shiraz University of Medical Sciences	Interventional Study	Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.		18/12/2019				12/12/2019					17/12/2019	http://en.irct.ir/trial/43982		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Iran	Head and Neck	Any head and neck squamous cell carcinoma	Metformin	Response rate	Phase 2	DB00331	N
ChiCTR1900026213	Effect of optimized thoracic paravertebral nerve block on early and rapid recovery and long-term clinical outcome of radical lung cancer patients		Recruiting	Lung Cancer	Sevoflurane:Sevoflurane;Sevoflurane+TPVB:Sevoflurane+TPVB;Sevoflurane+Optimized TPVB:Sevoflurane+Optimized TPVB;Propfol:Propofol;Propofol+TPVB:Propofol+TPVB;Propofol+Optimized TPVB:Propofol+Optimized TPVB;	Stay duration in hospital;	Henan Provincial People's Hospital	All	-	Sevoflurane:55;Sevoflurane+TPVB:55;Sevoflurane+Optimized TPVB:55;Propfol:55;Propofol+TPVB:55;Propofol+Optimized TPVB:55;	Self-raised	Interventional Study	Parallel		10/01/2019				26/09/2019					30/09/2019	http://www.chictr.org.cn/showproj.aspx?proj=43733		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Lung	Non-Small Cell Lung Cancer	Propofol	PFS; OS; Biomarker; Other (specify)	Not available/Missing	DB00818	N
KCT0004236	Effect of adjunctive metformin on recurrence of non-DM colorectal cancer		Recruiting	;Neoplasms	Drug : This study is an open label randomized controlled clinical trial to examine the effect of adjunctive metformin on recurrence of non-DM colorectal cancer stage II high-risk/ III colorectal cancer. The 1g/day of metformin will be given to patients during adjuvant chemotherapy after surgery and continued for 4 years.	recurrence rate	Yonsei University Health System, Severance Hospital	All	20(Year): 80(Year)	593	Yonsei University Health System, Severance Hospital	Interventional Study	Primary Purpose : Prevention, Intervention Model : Parallel, Blinding/Masking : Open, Allocation : RCT		07/08/2016				23/08/2019					12/02/2020	http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=18121		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	GI	Colon Cancer; Rectal Cancer	Metformin	Recurrence rate	Phase 2	DB00331	N
IRCT20190726044335N1	Therapeutic effect of metformin in rectal cancer		Recruiting	Rectal cancer. <br>Malignant neoplasm of rectum	Intervention 1: Intervention group: The patients with rectal cancer in the case group will be taken the metformin 500 mg Po Bid after eating and taking into account the contraindications. Intervention 2: Control group: The patients with rectal cancer in the control group will not be taken the metformin.	Pathologic complete response. Timepoint: Post operation. Method of measurement: Pathologic examination.	Shiraz University of Medical Sciences	All	18 years: 75 years	90	Shiraz University of Medical Sciences	Interventional Study	Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using the random numbers table, Blinding description: The patient will not be unaware of the medication content.		23/08/2019				20/08/2019					10/07/2019	http://en.irct.ir/trial/41127		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Iran	GI	Rectal Cancer	Metformin	Response rate	Phase 2	DB00331	N
KCT0003946	The Identification of the Safety and Efficacy of Tadalafil for the Suppression of Recurrence of Hepatocellular Carcinoma		Recruiting	;Neoplasms	Drug : Subjects will take a dose of 20mg of tadalafil once daily at 10 PM, and the therapy will last for one year.	Toxicities of grade 3 or higher	Seoul National University Hospital	Male	19(Year): No Limit	24	Daewoong Research Development Center	Interventional Study	Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable		22/05/2019				20/05/2019					17/06/2019	http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=14056		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Korea, Republic of	GI	Liver Cancer	Tadalafil	Safety and/or Dose	Phase 1/2	DB00820	N
ChiCTR1900021896	Prospective study for pd-1 inhibitor combined with liquid biopsy ctDNA detection combined with targeted drugs in the treatment of advanced unresectable liver cancer patients		Recruiting	hepatocelluar carcinoma	Opdivo+targeted drug:Once every 2 weeks Opdivo drug therapy, medicine according to the 3 mg/kg body weight calculation Opdivo dose, intravenous drug. Using the technology of liquid biopsy ctDNA for gene mutation to screen suitable targeted drug including sorafenib, Lomatinib, Apatinib and sirolimus.other drugs including COX2 inhibitor aspi;Keytruda+targeted drug:The Keytruda drug treatment group will be given Keytruda drug treatment once every three weeks, with a dose of 200mg, usage and precautions the same as Opdivo drug. intravenous drug.Using the technology of liquid biopsy ctDNA for gene mutation to screen suitable targeted drug including sorafenib, Lomatinib, Apa;	Objective response rate;Duration of response;Progression-free survival;Overall survival;	The Third Affiliated Hospital of Sun Yat-sen University	All	-	Opdivo+targeted drug:25;Keytruda+targeted drug:25;	Researcher afford	Interventional Study	Case-Control study		12/01/2018				15/03/2019					18/03/2019	http://www.chictr.org.cn/showproj.aspx?proj=34506		Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	China	GI	Liver Cancer	Sirolimus	Response rate; PFS; OS; Other (specify)	Phase 4	DB00877	N
ChiCTR1900021641	A randomized controlled trial for the effect of metformin on prognosis in patients with oral cancer		Pending	oral cancer	Experimental group:surgery + postoperative Metformin;Control group:surgury;	Whether recurrence;	Xiangya Hospital, Central South University	All	-	Experimental group:73;Control group:73;	Provincial planning project: B2017003, clinical and basic research on prevention and treatment of oral cancer recurrence of metformin; National Natural Science Foundation of China: 81837317, DEC1	Interventional Study	Parallel		20/03/2019				03/02/2019					03/04/2019	http://www.chictr.org.cn/showproj.aspx?proj=35809		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Head and Neck	Oropharyngeal Cancer	Metformin	Recurrence rate	Not available/Missing	DB00331	N
ChiCTR1900021426	Effects of flurbiprofen on immune function in patients under radical operation for colon carcinoma		Pending	colon cancer	FA+FA group:Flurbiprofen axetil 50mg i.v. before induction;FA+FA group:PCA with Sufentanil 1  g/kg +Flurbiprofen axetil 300mg+Tropisetron 10mg;	Changes in perioperative immune-related cells, including: number of CD4+, CD8+ and NK cells, CD4+/CD8+ ratio;	Affiliated Hospital of Xuzhou Medical University	All	-	FA+FA group:75;FA+FA group:75;	BEIJING TIDE PHRAMACEUTICAL CO.,LTD	Interventional Study	Parallel		03/01/2019				21/02/2019					25/02/2019	http://www.chictr.org.cn/showproj.aspx?proj=36161		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	China	GI	Colon Cancer	Flurbiprofen	Biomarker	Phase 4	DB00712	N
ChiCTR1900020701	A randomized controlled trial for intra-arterial infusion chemotherapy combined with sodium bicarbonate and systemic chemotherapy for unresectable gastric cancer		Recruiting	gastric cancer	Group 1:Systemic chemotherapy plus oral chemotherapy group;Group 2:Arterial catheter infusion chemotherapy plus oral chemotherapy;Group 3:Arterial catheter infusion chemotherapy + oral chemotherapy + sodium bicarbonate;	Successful conversion rate of operation;	The Second affiliated Hospital, Zhejiang University School of Medicine	All	-	Group 1:50;Group 2:50;Group 3:50;	cientific research project of Zhejiang Province	Interventional Study	Randomized parallel controlled trial		01/01/2019				14/01/2019					28/01/2019	http://www.chictr.org.cn/showproj.aspx?proj=34916		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	China	GI	Gastric Cancer	Sodium Bicarbonate	Other (specify)	Not available/Missing	DB01390	N
ChiCTR1800020425	Effects of total intravenous anesthesia and inhalation anesthesia on the prognosis of patients with endoscopic lung cancer		Recruiting	lung canser	Group 1:Propofol intravenous combined general anesthesia;Group 2:Sevoflurane inhalation combined general anesthesia;Group 3:Propofol intravenous + sevoflurane inhalation combined general anesthesia;	Secrete body outside;Micro vesicles;CD151;CD171;microRNA-10b-5p;microRNA-212-3p;microRNA-21-5p;IL-1;IL-6;IL-10;TNF-a;Total T-lymphocyte;Thlymphocyte;Tslymphocyte;NK cell;B lymphocyte;Cancer cells in the blood;Hydrothorax cancer cell;Total anesthesia drugs;Tumor marker;PET-CT;The pathologic types;Clinical staging;Tumor recurrence time;Time of distant metastasis;	Affiliated Cancer Hospital of Guangxi Medical University	All	-	Group 1:30;Group 2:30;Group 3:30;	Affiliated Cancer Hospital of Guangxi Medical University	Interventional Study	Randomized parallel controlled trial		01/01/2019				29/12/2018					14/01/2019	http://www.chictr.org.cn/showproj.aspx?proj=34334		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Lung	Non-Small Cell Lung Cancer	Propofol	PFS; OS; Biomarker	Not available/Missing	DB00818	N
ChiCTR1800016053	Effect of Ultrasound-guided thoracic paravertebral block on perioperative analgesia and tumor immune function in patients of video-assisted lung cancer surgery		Recruiting	lung cancer	Experience group:thoracic paravertebral block + propofol general anesthesia;Control group:opioid + sevoflurane general anesthesia;	pain score;opioid consumption;the number ofCD4+/CD8+ T and PD-1;VEGF;MMP-2;	Third Affiliated Hospital of Army Medical University (Field Surgery Institute)	All	40: 80	Experience group:50;Control group:50;	self-collected	Interventional Study	Randomized parallel controlled trial		05/01/2018				05/08/2018					14/05/2018	http://www.chictr.org.cn/showproj.aspx?proj=21590		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Lung	Non-Small Cell Lung Cancer	Propofol	Biomarker	Not available/Missing	DB00818	N
ChiCTR1800015808	Pilot Clinical Study of Chemo-Cocktail (TTF) for Recurrent Glioblastoma		Recruiting	Recurrent Glioblastoma	TTF:temmozoldmide+tranilast+fasudil;	Survival time;Survival time;Patient condition;Monitoring of blood, cerebrospinal fluid;Neuroimaging examination;	Huashan Hospital, Fudan University	All	-	TTF:10;	No	Treatment Study	Case series		05/01/2018				22/04/2018					30/04/2018	http://www.chictr.org.cn/showproj.aspx?proj=25630		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	CNS	Glioblastoma	Fasudil; Tranilast	OS	Phase 1	DB08162; DB07615	N
ChiCTR1800015510	A single-arm exploratory trail of combination of abiraterone with dutasteride in the treatment of abiraterone resistant CRPC		Temporary halt	prostate cancer	single arm:abiraterone+ dutasteride+ prednisone;	progression-free survival;	Shanghai Tongji Hospital	Male	-	single arm:50;	scientific research grands of Shanghai Tongji Hospital	Interventional Study	Single arm		06/01/2018				04/04/2018					16/02/2021	http://www.chictr.org.cn/showproj.aspx?proj=26413		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Urological	Prostate Cancer	Dutasteride	PFS	Not available/Missing	DB01126	N
IRCT20170314033080N2	Effect of losartan with whole bain radiotherapy in brain metastasis		Recruiting	Brain metastasis. <br>Malignant neoplasm of brain	Intervention 1: Intervention group: whole brain radiation with 30 Gray in 10 fractions and using 25 mg losartan tablet during radition course. Intervention 2: Control group: standard treatment with whole brain radiation with 30 Gray in 10 fractions and using placebo during radiation course.	Radiologic response of brain metastatic lesion. Timepoint: 6 weeks after ending of intervention. Method of measurement: RECIST V1.1criteria for response evaluation in solid tumors.	Ahvaz Jundi Shapour university of Medical Science	All	18 years: 90 years	60	Ahvaz Jundi Shapour university of Medical Science	Interventional Study	Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Individuals randomly divided to two groups based on fourth permutation blocks, so that reasercher do not interfere with the allocation of treatment methods to patients, Blinding description: Participants in study which are patients with brain metastasis, after being informed about attending in a clinical study and obtaining consent, are unaware that they are taking Losartan pill in addition to standard radiotherapy or placebo. The researcher and the evaluator of outcome is also unaware which groups is taking drug and which group taking placebo.		21/03/2018				03/11/2018					26/03/2018	http://en.irct.ir/trial/25613		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Iran	Multiple cancer types	Any solid tumours	Losartan	Response rate	Phase 2	DB00678	N
ChiCTR1800014946	Thalidomide, Clarithromycin and Dexamethasone Regimen for Patients With Newly Diagnosed Multiple Myeloma		Recruiting	Multiple Myeloma	Case series:Thalidomide, Clarithromycin and Dexamethasone;	Percentage of participants with very good partial remission (VGPR) or better;	Bejing Chaoyang Hospital	All	-	Case series:37;	Key Medical Program of Full Sail Plan of Beijing Municipal Administration of Hospitals: Multiple Myeloma	Treatment Study	Cohort study		03/01/2018				24/02/2018					26/02/2018	http://www.chictr.org.cn/showproj.aspx?proj=25260		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	Other Haem-onc	Multiple Myeloma	Clarithromycin	Response rate	Other	DB01211	N
ChiCTR-IPR-17013973	The effect of Metformin combine with FOLFOX + Bevacizumab as the first-line therapy in metastatic colorectal cancer, a randomized, open, prospective  clinical study (BeFoLMe study)		Pending	Colorectal Cancer;C18.9,C20	Study Group:Metformin 250mg per day combine with FOLFOX + Bevacizumab;Control Group:FOLFOX + Bevacizumab;	PFS, Progression-Free-Survival;	Xiangya Hospital, Central South University	All	-	Study Group:20;Control Group:20;	Xiangya Hospital, Central South University	Interventional Study	Randomized parallel controlled trial		01/01/2018				15/12/2017					18/12/2017	http://www.chictr.org.cn/showproj.aspx?proj=23560		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	GI	Colon Cancer; Rectal Cancer	Metformin	PFS	Phase 4	DB00331	N
ChiCTR-IOR-17011859	The Exploration of the Efficacy of Metformin Combined with First-line Chemotherapy for the Treatment of Ovarian Cancer		Recruiting	ovarian cancer	optimal cytoreductive surgery group:TC;optimal cytoreductive surgery group:TC+metformin;non-optimal cytoreductive surgery group:TC;non-optimal cytoreductive surgery group? :TC+metformin;	response rate;progression free survival;	Obstetrics and Gynecology Hospital of Fudan University	Female	-	optimal cytoreductive surgery group:20;optimal cytoreductive surgery group:20;non-optimal cytoreductive surgery group:20;non-optimal cytoreductive surgery group? :20;	Science and Technology Commission of Shanghai Municipality (16411963600)	Interventional Study	Randomized parallel controlled trial		07/01/2016				07/04/2017					07/10/2017	http://www.chictr.org.cn/showproj.aspx?proj=20252		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Gynaecological	Ovarian Epithelial Cancer	Metformin	Response rate; PFS	Other	DB00331	N
ChiCTR-IOR-17010695	The significance of minimal residual disease exmination on the multiple myeloma maintain treatment		Pending	Multiple myeloma	maintain treatment:thalidomide and Clarithromycin;Observation:Observation;	Progression Free Survival;	Shanghai Changzheng Hospital	All	-	maintain treatment:300;Observation:300;	National Natural Science Foundation of China. Project approval number 30828017	Interventional Study	Randomized parallel controlled trial		04/01/2017				21/02/2017					18/04/2017	http://www.chictr.org.cn/showproj.aspx?proj=18048		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Other Haem-onc	Multiple Myeloma	Clarithromycin	PFS	Other	DB01211	N
IRCT2015112725256N1	Effect of Metformin on Glioblastoma Multiform		Recruiting	Glioblastom multiform. <br>Brain, unspecified;Brain, unspecified	Intervention 1: Intervention Group will receive radiotherapy plus Temozolomide and Metformin 1g daily. The patients should take Metformin durng radiotherapy and after that till primay endpoint. Intervention 2: Control Group will receive radiotherapy and Temozolomide as routine adjuvant treatment.;Treatment - Drugs;Treatment - Drugs;Intervention Group will receive radiotherapy plus Temozolomide and Metformin 1g daily. The patients should take Metformin durng radiotherapy and after that till primay endpoint.;Control Group will receive radiotherapy and Temozolomide as routine adjuvant treatment.	Overall survival. Timepoint: monthly. Method of measurement: alive or dead.	Kerman Neuroscience Research Center	All	18 years: no limit	60	Kerman Neuroscience Research Center	Interventional Study	Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.		22/07/2016				08/04/2016					22/02/2018	http://en.irct.ir/trial/21147		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Iran	CNS	Glioblastoma	Metformin	OS	Phase 2	DB00331	N
ChiCTR-IPR-16008553	Clinical study on the anti-cancer effect of metformin in the breast cancer patients with prediabetes during neoadjuvant chemotherapy.		Pending	breast cancer;prediabetes;diabetes	Group 1:placebo;Group 2:metformin,850mg,Bid.;	Pathologic complete response(PCR);	Department of Endocrine and Breast Surgery of the First Affiliated Hospital of Chongqing Medical University	Female	-	Group 1:250;Group 2:250;	The metformin manufacturer provides financial assistance	Interventional Study	Randomized parallel controlled trial		30/06/2016				28/05/2016					18/04/2017	http://www.chictr.org.cn/showproj.aspx?proj=14483		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Breast	Any Breast Cancer	Metformin	Response rate	Phase 4	DB00331	N
ChiCTR-IPR-16008128	Effects of two types of anesthesia maintenance on body immunity and malignant behaviours of patients after cancer surgery		Recruiting	Malignant solid tumors	Sevoflurane groupin in each tumor type:Sevoflurane for inhalation;Propofol groupin in each tumor type:Propofol for injection;	The expression of hypoxia-induced molecules;	Peking University First Hospital	All	-	Sevoflurane groupin in each tumor type:30;Propofol groupin in each tumor type:30;	Self-prepare	Interventional Study	Randomized parallel controlled trial		22/03/2016				22/03/2016					27/11/2017	http://www.chictr.org.cn/showproj.aspx?proj=13760		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Multiple cancer types	Any solid tumours	Propofol	Biomarker	Not available/Missing	DB00818	N
ChiCTR-IPR-16008078	Effect of ulinastatin on clinical outcomes of patients with advanced lung cancer resection via thoracotomy		Recruiting	lung cancer	U:continuously intravenously infusion ulinastatin;C:NS;	postoperative pulmonary complications;hospital mortality;recurrence and metastasis rate;rate of survival;	Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.	All	-	U:120;C:120;	Techpool Fund	Interventional Study	Randomized parallel controlled trial		06/01/2015				03/10/2016					18/04/2017	http://www.chictr.org.cn/showproj.aspx?proj=12894		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	Lung	Any lung cancers	Ulinastatin	Safety and/or Dose; OS; Recurrence rate	Phase 4	DB12038	N
ChiCTR-IIR-16007908	Zoledronate combinate with gefitinib in advanced non-small cell lung cancer with EGFR activation mutation: a multicenter, randomised controlled, phase II trial.		Recruiting	non small lung cancer	Experimental group:Gefitinib and zoledronate. zoledronate 4 mg intravenous (IV) monthly +Gefitinib 250mg orally (PO) daily.Placebo Comparator: Arm B Gefitinib and placebo. Placebo was given to patients in the same way as that of zoledronate in Arm A.;Placebo Comparator:Gefitinib and placebo. Placebo was given to patients in the same way as that of zoledronate;	Progression-free survival (PFS) of the patients.;	Enshi Tujia and Miao Autonomous Prefecture Central Hospital	All	-	Experimental group:25;Placebo Comparator:25;	self-collected	Interventional Study	Randomized parallel controlled trial		02/05/2016				02/06/2016					18/04/2017	http://www.chictr.org.cn/showproj.aspx?proj=13357		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	Lung	Non-Small Cell Lung Cancer	Zoledronic Acid	PFS	Phase 2	DB00399	N
ChiCTR-IIR-16007801	Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer		Recruiting	non small cell lung cancer	treatment group:vitamin C infusion;treatment group:Electro-Hyperthermia;treatment group:Lifestyle counseling ;control group:Lifestyle counseling ;	Safety of vitamin C infusion in combination with oncothermia on NSCLC patients;	CLIFFORD HOSPITAL	All	-	treatment group:35;treatment group:35;treatment group:35;control group:35;	CLIFFORD HOSPITAL	Interventional Study	Randomized parallel controlled trial		20/01/2016				20/01/2016					18/04/2017	http://www.chictr.org.cn/showproj.aspx?proj=13023		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Lung	Non-Small Cell Lung Cancer	Ascorbic acid	Safety and/or Dose; PFS; Biomarker	Phase 1/2	DB00126	N
ChiCTR-IPR-15006066	Clinical research of chemotherapy consisted of temozolomide with concomitant sodium valproate and nicardipine for Glioma		Pending	glioma	Standard Chemoradiotherapy :TMZ;TMZ+Nicardipine+Sodium Valproate:TMZ+Nicardipine+Sodium Valproate;	KPS score;WHO tumor objective curative effect evaluation;survival time;	Department of Neurosurgery, The Second Affiliated Hospital of Suzhou University	All	-	Standard Chemoradiotherapy :20;TMZ+Nicardipine+Sodium Valproate:20;	Chinese Anti Cancer Association Fund	Interventional Study	Randomized parallel controlled trial		03/01/2015				03/11/2015					18/04/2017	http://www.chictr.org.cn/showproj.aspx?proj=10540		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	China	CNS	Glioma	Nicardipine; Valproic Acid	Safety and/or Dose; OS; QoL	Other	DB00622; DB00313	N
CTRI/2012/07/002802	Metformin in Triple Negative Operable or Locally Advanced Breast cancer		Open to Recruitment	Health Condition 1: null- Locally advanced or Large Operable Breast cancer patients with Triple Negative hormone receptor status.	Intervention1: Tab.Metformin 500mg OD: Patient randomised on Tab.Metformin plus taxane based chemotherapy arm will received Tab.metformin 500mg OD 7 days prior to chemotherapy 1st cycle till completion of 8 chemotherapy cycles.<br>Control Intervention1: Taxane/ Platinum  based chemotherapy: Patient randomised on taxane/Platinum based chemotherapy will received 8 cycles of chemotherapy in neo adjuvant setting before surgery<br>Control Intervention2: Taxane and Platinum based chemotherapy: Patient randomized on taxane plus platinum based chemotherapy will receive 8 cycles of taxane plus platinum based chemotherapy in neo adjuvant setting before surgery<br>	To see the effect of platinum based chemotherapy and metformin on disease free and overall survival and response rates in triple negative breast cancer.Timepoint: 5 years after completion of accrual	Tata Memorial Centre	-	-	800	Tata Memorial Centre	Interventional Study	Randomized Factorial Trial<br>  Method of generating randomization sequence:Stratified randomization  Method of allocation concealment:Other  Blinding and masking:Open Label		02/04/2010				16/07/2012					27/01/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4759	Neo-adjuvant/Window	Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	India	Breast	Breast Cancer - TNBC	Metformin	OS; DFS/RFS/EFS	Phase 3	DB00331	N
ACTRN12620000815965	Phase II Trial of Doxycycline with Radiotherapy for Rectal Cancer		Not yet recruiting	Rectal Cancer; <br>Rectal Cancer;Cancer - Bowel - Back passage (rectum) or large bowel (colon)	Doxycycline is a broad-spectrum antibiotic, which prevents the binding of amino-acyltRNA to the messenger RNA-30S ribosomal subunit, preventing polyribosome formation. It is approved in New Zealand for the treatment of chronic prostatitis, sinusitis, syphilis, pelvic inflammatory disease, malaria, recurrent aphthous ulceration, and acne vulgaris. Doxycycline primarily exerts it's antimicrobial action by bacteriostasis. It also has antinflammatory effects. <br><br>Doxycycline will be administered as two 100mg tablets orally each morning, starting two days prior to the first dose of short-course radiotherapy (SCRT), until one day prior to surgery for rectal cancer. Surgery will be performed within three weeks of starting radiotherapy treatment. The duration of doxycycline will be between 12 and 23 days, and will be determined by each participant s individual treatment schedule.  <br><br>Adherence will be assessed through a combination of a patient diary, and count of the number of tablets remaining in the drug container on the patients admission for rectal cancer surgery.	Difference in the mean immunohistochemistry (IHC) H-scores for CD133 in resected tumours between the doxycycline and control groups.[Based on rectal cancers surgically resected within 3 weeks of radiotherapy.]	Dr Natalie Briggs	All	18 Years: No limit	40	Waikato Medical Research Foundation	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Type of endpoint: Safety/efficacy;		17/08/2020				14/08/2020					24/08/2020	https://anzctr.org.au/ACTRN12620000815965.aspx		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	New Zealand	GI	Rectal Cancer	Doxycycline	Biomarker	Phase 2	DB00254	N
ACTRN12612000852853	Preventing Colorectal Cancer Metastases following Surgical Removal of a Primary Tumor		Recruiting	Colorectal cancer; <br>Colorectal cancer;Cancer - Bowel - Back passage (rectum) or large bowel (colon)	In the current study we aim at testing the safety and efficacy of our drug cocktail in patients undergoing excision of colorectal cancer.  Both short-term outcomes (immune and endocrine indices), as well as 3-year recurrence rates will be assessed within patients. Specifically, we propose a double blind clinical trial with two major arms: (I) placebo treatment, and (II) treatment with a cocktail of a B-blocker (propranolol  €  to block catecholamines, oral tablet 40 mg , 3 times daily) and a COX2 inhibitor (etodolac  €  to block prostaglandin receptors, 200 mg oral tablets every 6 hours ). A total of 206 patients will be recruited. The drug treatment will be given for a total of 20-day period, commencing five days before surgery, with no time overlap with adjuvant therapy, and independently of any other routine therapy. The drug treatment is planned for only 15 post-operative days to reduce potential side effects, and because most immunological and endocrine perturbations induced by surgery dissipate during this period. Immune and endocrine baseline levels will be established in a group of thirty healthy matched control subjects.<br>Short-term endocrine and immune measures will include: serum levels of various cytokines; serum cortisol, C-reactive protien, Vascular endothelial growth factor,  leukocyte subpopulations and their functional markers; and Natural killar cells activity. All indices will be assessed repeatedly within subjects, using freshly drawn blood samples that will be collected twice before surgery (days -5 and on the morning of surgery), and on post-operative days 1 and 3. Resected malignant tumors and normal colonic tissue will be tested for catecolamines (CA) and prostaglandines (PG) receptor expression. Clinical outcomes will include perioperative complic	Tumor recurrence by abdominal CT scan and colonoscope[recurrence survey starts 6 months after surgery and then every 6 months for 2 years]	Khaled Madbouly	All	18 Years: 70 Years	200	Khaled Madbouly	Interventional Study	Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;		15/08/2012				14/08/2012					13/01/2020	https://anzctr.org.au/ACTRN12612000852853.aspx		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Egypt	GI	Colon Cancer; Rectal Cancer	Etodolac; Propranolol	Recurrence rate; Biomarker	Phase 2	DB00749; DB00571	N
ACTRN12614000507684	Pre-surgical aromatase inhibitor combined with non-steroidal anti inflammatory drug treatment in breast cancer		Recruiting	post menopausal breast cancer; <br>post menopausal breast cancer;Cancer - Breast	in window of time between diagnosis and surgery, post-menopausal women with ER positive breast cancer will be treated with an aromatase inhibitor alone, letrozole 2.5mg daily oral tablet, or with aspirin 200mg twice daily, oral tablet, in an anti inflammatory dose. Adherence will be monitored by twice weekly nurse review, and blood estradiol levels.	change in biological markers, including inflammation and proliferation,  over 14 days of treatment. Pre- and post treatment tumour samples will be compared, and studied by immunohistochemistry for immune cell subsets, inflammatory cells, and tumour cell Ki67. Gene expression profiling using the same tumour samples will also be studied at a later stage.[14 days, or day of surgery if this is sooner.]	University of otago	Female	50 Years: No limit	100	Health Research Council of New Zealand	Interventional Study	Purpose: Treatment; Allocation: Randomised controlled trial;		04/12/2014				13/05/2014					13/01/2020	https://anzctr.org.au/ACTRN12614000507684.aspx		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	New Zealand	Breast	Breast Cancer - ER/HR+	Acetylsalicylic Acid	Biomarker	Phase 2	DB00945	N
ACTRN12612000416897	Sequential evaluation of tumours undergoing pre-operative therapy with aromatase inhibitors and metformin (setup-aim) a neo-adjuvant pilot study in operable hormone sensitive breast cancer in post menopausal women		Recruiting	hormone positive operable breast cancer; <br>hormone positive operable breast cancer;Cancer - Breast	2 weeks of metformin (oral tablets, 1 gm per day) followed by 2 weeks of metformin (oral tablets, 1gm per day) plus aromatase inhibitor (oral tablets 1 mg Arimidex (trade name) or oral tablets 2.5 mg Femara (trade name)) all prior to surgery	Reduction in tumour tissue Ki67 level (proliferative index)[At surgery to be performed 4 weeks after comencing treatment]	Dr Vinod Ganju	Female	18 Years: No limit	40	Victorian Breast Cancer Research Consortium	Interventional Study	Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Safety/efficacy;		30/07/2014				13/04/2012					13/01/2020	https://anzctr.org.au/ACTRN12612000416897.aspx		Localised/Locoregional	Collaborative Group	Y	N	N	Australia	Breast	Breast Cancer - ER/HR+	Metformin	Biomarker	Other	DB00331	N
ACTRN12613000520730	The effect of adjuvant therapy with aspirin on relapse prevention of hepatocellular carcinoma after curative resection: A prospective randomized controlled trial		Not yet recruiting	recurrence of hepatocellular carcinoma with microvascular tumor thrombus after curative resection; <br>recurrence of hepatocellular carcinoma with microvascular tumor thrombus after curative resection;Cancer - Liver	After 1 month of the curative resection, the adjuvant group received 100mg aspirin tablet one time per one day by oral until tumor recurrence confirmed by Liver contrast-enhanced CT or MRI tumor  with or without elevated AFP or 2 years after operation or the patient death during the study.<br>The monthly review after the blood, liver, kidney function, alpha-fetoprotein (AFP) and liver ultrasound. The three-monthly review of liver-enhanced CT or MRI. If bone pain, line ECT or check<br>The processing schedule of Adverse reactions:<br>a. Grade III adverse reactions: aspirin dose reduced by 50 ;<br>b. Grade III adverse reactions are continued more than 2 weeks or Grade IV adverse reactions: stop taking aspirin<br>c. When WBC <2.5    109 / L and/or PLT <40    109 / L: aspirin dose reduced by 50  and get drugs which can enhance white blood cells and/or platelet count;<br>d. When the dose of aspirin reduced but WBC and/or platelet count continued to decline: stop taking aspirin<br><br>A standardized clinical data management procedure will be carried out to make sure all of the data including the data on the adherences satisfy good clinical practice (GCP) requirements. All of the data will be entered in a verified database while the original paper records will be kept for at least 5 years. To make sure that the data in the database is consistent with the original one, a data validation process will be carried out. Disagreements were adjudicated by answering the query forms after referring to the original records.	Recurrence was confirmed by dynamic contrast-enhanced Computerised Tomography scan or selective hepatic arteriography in subjects with an elevated AFP level or with a newly identified mass[Time from curative resection to the first diagnosis of tumor recurrence];Overall survival: Time from operation to death. Patients alive at the end of follow-up are surveyed via patient census[Every year after operation for 2 years]	Estern hepatobiliary surgery hospital	All	18 Years: 70 Years	120		Interventional Study	Purpose: Treatment; Allocation: Randomised controlled trial;		01/06/2013				10/05/2013					13/01/2020	https://anzctr.org.au/ACTRN12613000520730.aspx		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Liver Cancer	Acetylsalicylic Acid	DFS/RFS/EFS	Not available/Missing	DB00945	N
ACTRN12614000133639	The STRICT pilot study - Simvastatin Therapy for Reducing Inflammation in Colorectal cancer Trial		Not yet recruiting	Colorectal cancer;Systemic Inflammation; <br>Colorectal cancer <br>Systemic Inflammation;Cancer - Bowel - Back passage (rectum) or large bowel (colon);Inflammatory and Immune System - Other inflammatory or immune system disorders	Participants will receive standard first line chemotherapy, as chosen by their treating medical oncologist. In addition, participants will be asked to take a daily 40mg dose of simvastatin orally in the evening from the first day of chemotherapy until tumour progression or patient is withdrawn from treatment due to clinician or patient decision. <br><br>Adherence to medication will be conducted using patient diaries, completion of a monthly Medication Adherence Record Scale-5 questionnaire, and pharmacy records.	Toxicity: Incidence of serious Grade 3 or 4 toxicity graded according to NCI CTCAE version 4.03[until tumour progression (anticipated to be <12 months)]	University of Sydney	All	18 Years: No limit	10	Northern Translational Cancer Research Unit SeedFunding;Bosch Institute (University of Sydney) Translational Grant in Aid	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety/efficacy;		01/04/2014				05/02/2014					13/01/2020	https://anzctr.org.au/ACTRN12614000133639.aspx		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Australia	GI	Colon Cancer; Rectal Cancer	Simvastatin	Safety and/or Dose	Phase 2	DB00641	N
ACTRN12610000936022	Vitamin D supplementation prior to surgery for colorectal cancer: a randomised pilot study.		Not yet recruiting	Colorectal Cancer; <br>Colorectal Cancer;Cancer - Bowel - Back passage (rectum) or large bowel (colon)	Colorectal cancer patients scheduled to undergo routine elective surgery at Dunedin Hospital will be randomised to receive either a single oral 5mg dose of vitamin D3 (cholecalciferol), or identical placebo to be taken 7-21 days prior to surgery. <br><br>A dose of 5mg of vitamin D3 will consistently achieve therapeutic serum levels >80nmol/L, peaking at 1 week and gradually falling thereafter. The dose is safe and designed to rapidly achieve desirable levels without delaying surgery. <br><br>All patients enrolled will recieve all other treatment and care as they would have otherwise done so.	A significant increase in the expression of genes containing the Vitamin D responsive element (VDRE), in tumour tissue, in patients receiving active study medication compared to placebo.<br><br>Previously published data on the effects of vitamin D on gene expression in a colorectal cancer cell line will be used to identify genes that are responsive to vitamin D.  Affymetrix microarray data from these experiments are available from the NCBI GEO database under the accession number GSE444. In addition, genes representing vitamin D targets in normal colon tissues will be identified by searching publically available colon array databases for expressed genes which contain the VDRE.  The VDRE element is present within the promoter region of genes activated by vitamin D and therefore acts as a convenient tag to identify vitamin D responsive genes.<br><br>RNA will be isolated from CRC samples from 50 patients, half of whom will have received vitamin D.  RNA expression profiles of the 50 tumour RNA samples will then be generated in the Otago Genomics Facility using Affymetrix HG-U133+2.0 GeneChips. Evidence of activation of vitamin D pathways in the tumours from treated and untreated patients will be determined using the vitamin D responsive genes identified above.  This will be accomplished by generating a vitamin D meta-gene to represent the coordinated expression of these genes across all tumours, so that tumours exhibiting a molecular response to vitamin D will have high levels of the meta-gene.  This meta-gene will then be tested for association with treatment status, as well as clinicopathological (e.g. tumour stage, histology etc), molecular (e.g. proliferation) and immune reponse  variables.[Tissue samples will be collected on the day of surgery. These will be batched and analysed in the laboratory within 6 months of the final patients surgery.];A significant difference between treatment groups with respect to macrophage activation against tumour tissue and their ability to prime T cells.<br><br>Macrophages isolated from the blood and tumour tissue of CRC patients will be infected with bacterial pathogens in vitro and their ability to destroy these agents measured by quantifying nitric oxide production using the Greiss reaction.  Their ability to prime the adaptive immune response will also be measured by analysing activation of T cells recovered from patient tissues using flow cytometry of surface activation markers. Results will be compared between treatment and placebo groups.[Tissue samples will be collected on the day of surgery. These will be batched and analysed in the laboratory within 6 months of the final patients surgery.]	University of Otago	All	18 Years: No limit	50	University of Otago	Interventional Study	Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Bio-availability;		01/03/2011				03/11/2010					13/01/2020	https://anzctr.org.au/ACTRN12610000936022.aspx		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	New Zealand	GI	Colon Cancer; Rectal Cancer	Calcipotriol; Calcitriol	Other (specify)	Phase 2	DB02300; DB00136	N
ACTRN12612001050842	Valproic acid and Metformin to treat patients with brain tumours		Not yet recruiting	Brain tumours - Glioblastoma multiforme (GBM); <br>Brain tumours - Glioblastoma multiforme (GBM);Cancer - Brain	Valproic acid and metformin added to standard therapy (Temozolomide/radiotherapy)<br>Valproic acid: oral - 200 mg twice daily to a maximum of 60 mg/day; dose adjusted based on plasma levels; maximum of 10 months<br>Metformin: oral titrated upto 2 gm per day; maximum of 10 months	To assess the tolerability and feasibility of adding sodium valproate and metformin to concurrent TMZ+XRT in patients with newly diagnosed GBM.<br>This outcome will be assessed by clinical examination, blood tests and adverse event monitoring[7 weeks from study entry]	Flinders Centre for Innovation in Cancer, Flinders University/Flinders Medical centre	All	18 Years: No limit	12	Flinders Centre for Innovation in Cancer, Flinders University/Flinders Medical centre	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety;		01/01/2013				03/10/2012					13/01/2020	https://anzctr.org.au/ACTRN12612001050842.aspx		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Australia	CNS	Glioblastoma	Metformin; Valproic Acid	Safety and/or Dose	Phase 1	DB00331; DB00313	N
ACTRN12614001054606	Pilot study to evaluate the prognostic and metabolic effects of metformin during treatment of metastatic prostate cancer with androgen deprivation therapy		Recruiting	Metastatic prostate cancer ; <br>Metastatic prostate cancer ;Cancer - Prostate	This is a two-arm study. Both Arm 1 and Arm 2 will be receiving androgen deprivation therapy (ADT). The ADT used is a combined androgen blockade with luteinizing hormone releasing hormone (LHRH) agonist (45mg EligardTrademark) and AR antagonist (50mg Cosudex/bicalutamide) for the first 4 weeks as per standard of care. After that, EligardTrademark will continue as monotherapy 6 monthly unless clinically indicated for complete androgen blockade. At 12 weeks into ADT, participants will receive 1500mg metformin (3x500mg daily, with meals) or placebo depending on the treatment arm allocated after randomization.<br><br>Metformin or Placebo tablets will be dispensed every 12 weeks. Participants will need to return the unused tablets to the research team before or after each dispensing for drug accountability purpose. Moreover, participants will have 6 weekly medical review.<br><br>Arm 1<br>Metformin hydrochloride 500mg tablet <br>Dosage: 1500mg daily<br>Duration: 30 weeks<br>Mode of administration: Oral<br><br>	Time to progression of disease defined as biochemical, radiographic or clinical progression[Prostate specific antigen and 6 weekly clincial review will be used to determine biochemical and clinical progression: every 6 weeks for 42 weeks and at week 54 (end-of-study visit)<br><br>CT scan and bone scan will be used to determine radiographic progression: if clinically indicated. Radiographically, Prostate Cancer Working Group (PCWG) 2 criteria will be used.  ]	Queensland University of Technology	Male	18 Years: No limit	80	2014 Princess Alexandra Hospital Research Support Scheme Grants;Tolmar Australia Pty Ltd	Interventional Study	Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;		08/09/2014				02/10/2014					13/01/2020	https://anzctr.org.au/ACTRN12614001054606.aspx		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Australia	Urological	Prostate Cancer	Metformin	Other (specify)	Phase 2	DB00331	N
ACTRN12616001021460	Sodium Valproate/Metformin Combination therapy for prostate cancer		Not yet recruiting	Prostate cancer; <br>Prostate cancer;Cancer - Prostate	Combination of sodium valproate and metformin will be administered as oral tablets.<br>Three dose levels of the drugs are planned. First level  €  a fixed dose of Met and VPA at 500 mg twice daily will be given to the participants. If no dose limiting toxicity is seen in this cohort I (N=3), after the 4 weeks of drug administration, participants will be next dosed at level 2 dosing where the starting dose is 500 mg twice daily for both drugs. In this cohort II (N=3), Met dose alone will be increased to 1000 mg twice daily from week 2 onwards while VPA dose will be maintained at 500 mg twice daily. If no dose limiting toxicity is seen in this cohort II, subjects will be dosed at next dose level. Subjects in this cohort III (N=6) will have both the drug doses increased from the starting dose of 500 mg twice daily to 1000 mg twice daily sequentially. Dose escalation will not proceed beyond the 1000 mg twice daily schedule. Participants in cohort I will receive 4 weeks on Met and VPA 500mg each twice daily; cohort II week 1 Met and VPA 500mg each twice daily then Met 1000mg and VPA 500mg twice daily from week 2 -4; cohort III week 1 Met and VPA 500mg each twice daily then Met 1000mg and VPA 500mg twice daily from week 2; then Met 1000 mg and VPA 1000 mg twice daily week 3-4. All study drugs will be ceased at least 48 hours but no more than 7 days prior to surgery. Participants will be requested to return any left over tablets.	To evaluate the safety of the combination of Metformin and VPA in men undergoing radical prostatectomy for prostate cancer. <br>Safety will be assessed using the common toxicity critieria (NCI-CTC v1.0) as well as physical examination and blood tests for organ function.[At the end of 4 weeks of commencement of study drug therapy]	Flinders University	Male	18 Years: No limit	12	The Repat Foundation: Road Home Grant	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Type of endpoint: Safety;		01/12/2016				02/08/2016					13/01/2020	https://anzctr.org.au/ACTRN12616001021460.aspx		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Australia	Urological	Prostate Cancer	Metformin; Valproic Acid	Safety and/or Dose; Biomarker	Phase 1	DB00331; DB00313	N
ChiCTR2000038968	A prospective, randomized controlled, multicenter clinical trial of indomethacin in the treatment of abiraterone-resistant castration-resistant prostate cancer		Recruiting	Prostate Cancer	experiment group:indomethacin treatment;control group:Abiraterone treatment;	OS;PFS;PSA response rate;	The Second Hospital of Tianjin Medical University	Male	-	experiment group:60;control group:60;	Special funds for clinical research projects of the Second Hospital of Tianjin Medical University	Interventional Study	Parallel		30/10/2020				10/11/2020					01/11/2021	http://www.chictr.org.cn/showproj.aspx?proj=61151		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	China	Urological	Prostate Cancer	Indomethacin	Response rate; PFS; OS	Phase 4	DB00328	N
ChiCTR2000039296	Effects of intra-venous lidocaine in general anesthesia on postoperative inflammatory response and prognosis in patients with breast cancer		Recruiting	Breast Cancer	Lidocaine Group:Total intravenous anesthesia was used. Lidocaine was used in the induction and maintenance of anesthesia;Opioids Group:Total intravenous anesthesia was used. Opioids was used in the induction and maintenance of anesthesia;	NLR;LMR;IL-6;IL-8;OFS;OS;	Tongji Hospital Affiliated to Tongji University	Female	-	Lidocaine Group:120;Opioids Group:120;	National Natural Science Foundation of China (No. 81974155)	Interventional Study	Parallel		01/01/2021				22/10/2020					25/01/2021	http://www.chictr.org.cn/showproj.aspx?proj=63173		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Breast	Any Breast Cancer	Lidocaine	PFS; OS; Biomarker	Not available/Missing	DB00281	N
ChiCTR2000039651	Effects of sevoflurane inhalation anesthesia on proliferation and apoptosis of colon cancer cells in vitro: a randomized controlled trial.		Recruiting	Colorectal cancer	Sevo:Sevoflurane inhalation anesthesia was performed during the operation;Pro:propofol intravenous anesthesia was performed during the operation;Sevo+Pro:sevoflurane € propofol combined anesthesia during the operation;	Postoperative mortality;	Affiliated Hospital of Zunyi Medical University	All	-	Sevo:10;Pro:10;Sevo+Pro:10;	Doctoral project	Interventional Study	Parallel		11/01/2020				11/04/2020					02/08/2021	http://www.chictr.org.cn/showproj.aspx?proj=63427		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	GI	Colon Cancer; Rectal Cancer	Propofol	OS; Biomarker	Not available/Missing	DB00818	N
ChiCTR2000041072	A Phase II Open-Label Randomized Controlled Clinical Trial of Pembrolizumab Plus Chemotherapy Combined With Cox-2 Inhibitor (Celecoxib) Versus Pembrolizumab Plus Chemotherapy In Advanced Non-small Cell Lung Cancer (NSCLC)		Recruiting	Lung Cancer	Trial group:Pembrolizumab + chemotherapy (squamous cell carcinoma: albumin paclitaxel + carboplatin / adenocarcinoma: pemetrexed + carboplatin) + celecoxib;Control group:Pembrolizumab + chemotherapy (squamous cell carcinoma: albumin paclitaxel + carboplatin / adenocarcinoma: pemetrexed + carboplatin);	ORR;PFS;Side-effect;	West China Hospital, Sichuan University	All	-	Trial group:81;Control group:81;	West China Hospital, Sichuan University	Interventional Study	Parallel		01/01/2021				17/12/2020					03/01/2021	http://www.chictr.org.cn/showproj.aspx?proj=66052		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	Lung	Non-Small Cell Lung Cancer	Celecoxib	Safety and/or Dose; Response rate; PFS	Phase 2	DB00482	N
ChiCTR2000040604	the effect of anaesthetic technique in patients undergoing NSCLC surgery- a multicenter study		Pending	non small cell lung cancer	A:the sedative of induction and anesthesia maintenance is sevofluane;B:the sedative of induction and anesthesia maintenance is propofol;C:no;D:Paravertebral block pre-operation;	NRF2;NLRP3;ROS;GSH;IL-11;	National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital   Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	All	-	A:30;B:30;C:30;D:30;	Sanming Project of Medical and Health in Shenzhen	Interventional Study	Parallel		12/07/2020				12/03/2020					15/03/2021	http://www.chictr.org.cn/showproj.aspx?proj=65257		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Lung	Non-Small Cell Lung Cancer	Propofol	Biomarker	Phase 4	DB00818	N
NCT00565708	Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers	ASCOLT	Active, not recruiting	Colorectal Cancer	Other: placebo; Drug: Acetylsalicylic acid	Disease-free survival; Overall survival	National Cancer Centre, Singapore; University of Oxford; Australasian Gastro-Intestinal Trials Group; INDOX Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	1587	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CDR0000577892; SINGAPORE-ICR-02; SINGAPORE-ASCOLT	12/01/2008	12/01/2025	06/01/2026			30/11/2007				13/09/2021	https://ClinicalTrials.gov/show/NCT00565708	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Singapore	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	OS; DFS/RFS/EFS	Phase 3	DB00945	N
NCT03999723	Combining Active and Passive DNA Hypomethylation	EVI-3	Recruiting	Myelodysplastic Syndromes|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia	Dietary Supplement: Vitamin C; Dietary Supplement: Placebo	Event-free survival; Adverse events and serious adverse events; Overall survival; Overall response rate; Patient-reported outcome (PRO) measures; Variant allele frequency (VAF) of mutated clones; Global 5-hydroxymethylcytosine (5-hmC)/5-methylcytosine (5-mC); Site specific 5-hmC/5-mC; Gene expression; mRNA expression of HERV and HERV specific T-cell responses; Duration of azacitidine (AZA) therapy	Kirsten Gr nb k; Van Andel Research Institute; Karolinska University Hospital; Skane University Hospital; Sahlgrenska University Hospital, Sweden; Oslo University Hospital; Helsinki University Central Hospital; University of Southern California; Imperial College London; University of Copenhagen; Zealand University Hospital; Aalborg University Hospital; Odense University Hospital; Technical University of Denmark; Aarhus University Hospital; Norrland University Hospital; Uppsala University Hospital; Rigshospitalet, Denmark	All	18 Years and older   (Adult, Older Adult)	196	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	H-18040929	09/11/2019	03/01/2024	03/01/2024			27/06/2019				29/09/2021	https://ClinicalTrials.gov/show/NCT03999723		Any/All Stages	Hospital/University/Research Institute	Y	N	N	Denmark	Leukemia	Acute Myeloid Leukemia, Adult	Ascorbic acid	DFS/RFS/EFS	Phase 2	DB00126	N
NCT03596073	Topical Calcipotriene Treatment for Breast Cancer Immunoprevention		Recruiting	Breast Cancer	Drug: Topical Calcipotriene Ointment; Other: Topical Vaseline	The changes in the magnitude of CD3+ T cell infiltration in tumor microenvironment; The comprehensive changes in tumor immune microenvironment; The changes in tumor immune microenvironment in patients with neoplastic tumors versus benign lesions; The changes in tumor immune microenvironment in patients with stage I-II, versus stage 0 tumors; The changes in tumor immune microenvironment in patients with hormone receptor and Her2 positive versus triple negative tumors; Serum Serum Thymic Stromal Lymphopoietin (TSLP) levels (picogram/milliliter) before and after topical calcipotriene treatment compared to Vaseline control group; Disease free survival; Number of Participants with Treatment Related Adverse Events	Massachusetts General Hospital	All	50 Years and older   (Adult, Older Adult)	120	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	18-040	11/07/2018	31/12/2022	31/07/2025			23/07/2018				11/04/2021	https://ClinicalTrials.gov/show/NCT03596073		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Breast	Any Breast Cancer	Calcipotriol	Biomarker	Phase 1	DB02300	N
NCT03363659	Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme		Active, not recruiting	Glioblastoma|Glioblastoma Multiforme	Drug: Disulfiram; Dietary Supplement: Copper gluconate; Drug: Temozolomide	Progression Free Survival (PFS); Overall Survival; Quality of life (QOL)	Aurora Health Care	All	18 Years and older   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17.56	28/03/2018	31/12/2021	31/12/2022			12/06/2017				09/09/2021	https://ClinicalTrials.gov/show/NCT03363659		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Disulfiram	PFS	Phase 2	DB00822	N
NCT02265770	An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma	SIOP-EP-II	Recruiting	Childhood Ependymoma	Drug: 16 weeks of VEC + CDDP; Drug: VEC + HD-MTX; Drug: Chemotherapy + Valproate; Radiation: Conformal radiotherapy; Drug: VEC; Drug: Chemotherapy; Radiation: conformal radiotherapy +/- boost	Gross Total Resection rate; Progression-Free Survival; Number of treatment responders; Number of participants undergoing a second-look surgery; Overall Survival; Quality of Survival; Evaluation of neuropsychological morbidity; Comparison of neuroendocrine morbidity; Number of participants with adverse events as a measure of safety and tolerability; Radiotherapy-free survival rate	Centre Leon Berard	All	up to 22 Years   (Child, Adult)	480	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SIOP Ependymoma II (ET-13-002); 2013-002766-39; VHP358	06/02/2015	06/01/2028	08/01/2031			16/10/2014				13/10/2021	https://ClinicalTrials.gov/show/NCT02265770		Localised/Locoregional	Hospital/University/Research Institute	N	N	Y	France	CNS	Ependymoma	Valproic Acid	Safety and/or Dose; Response rate; PFS; OS; QoL; Other (specify)	Phase 2/3	DB00313	N
2021-001375-16	DIPGEN  ndash; Multicenter, open label study using molecularly determined targeted therapies in children 3-18 years of age with DIPG (diffuse intrinsic pontine glioma- DIPG)	DIPGen	Ongoing	diffuse intrinsic pontine glioma		1. Overall survival (OS) from the time of diagnosis until last visit or death. 2. Safety assessment of sirolimus administered during radiotherapy and in combination with trametinib as adjunctive treatment after irradiation.	The Children's Memorial Health Institute	All	Under 18; Elderly 65+	100	Medical Research Agency	-	Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001375-16/PL		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Poland	CNS	DIPG/DMG	Sirolimus	OS	Phase 2	DB00877	N
NCT04038489	COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer	Breast 51	Withdrawn	Breast Cancer|Estrogen Receptor-positive Breast Cancer	Drug: Aspirin; Drug: Tamoxifen Pill; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Paclitaxel	Pathologic complete response (pCR) rate; Adverse events (AEs)	University of Virginia	All	18 Years and older   (Adult, Older Adult)	0	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	21822	18/10/2019	30/04/2023	30/04/2023			30/07/2019				22/11/2021	https://ClinicalTrials.gov/show/NCT04038489		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - ER/HR+; Breast Cancer - HER2-	Acetylsalicylic Acid	Safety and/or Dose; Response rate	Phase 2	DB00945	N
NCT04617067	Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer		Active, not recruiting	Advanced Pancreatic Cancer	Drug: Paricalcitol; Drug: Gemcitabine (GEM) and Nab-paclitaxel	Progression free survival; Overall survival (OS); Time to treatment failure; Tumour response rate Duration of response	Cancer Trials Ireland	All	18 Years and older   (Adult, Older Adult)	15	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTRIAL-IE 19-33; 2020-000073-24	16/10/2020	04/01/2024	04/01/2024			11/05/2020				18/11/2021	https://ClinicalTrials.gov/show/NCT04617067		Advanced/Metastatic	Collaborative Group	N	N	N	Ireland	GI	Pancreatic Cancer	Paricalcitol	Response rate; PFS; OS; Other (specify)	Phase 2	DB00910	N
NCT04348747	Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer		Not yet recruiting	Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Malignant Neoplasm in the Brain|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8	Biological: Anti-HER2/HER3 Dendritic Cell Vaccine; Drug: Celecoxib; Biological: Pembrolizumab; Biological: Recombinant Interferon Alfa-2b; Drug: Rintatolimod	Central nervous system (CNS) objective response rate (ORR); Volumetric quantification of brain metastases; Non-CNS (i.e. of systemic disease) response rate; Median CNS progression free survival (PFS); Non-CNS PFS; Overall PFS; Proportion of patients who have a CNS PFS; Median overall survival (OS); Incidence of adverse events; Proportion of patients not requiring retreatment for their brain metastasis at 6 months since the first dose of anti-HER2/3 vaccine; Rate of failure of irradiated lesions	Roswell Park Cancer Institute; National Cancer Institute (NCI)	Female	18 Years and older   (Adult, Older Adult)	23	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I-19-04120; NCI-2020-01520; P30CA016056	02/01/2022	02/01/2024	02/01/2025			16/04/2020				01/05/2022	https://ClinicalTrials.gov/show/NCT04348747		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - HER2+; Breast Cancer - TNBC	Celecoxib	Response rate	Phase 2	DB00482	N
NCT05164952	Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole		Recruiting	Use of Zoledronic Acid in Breast Cancer	Drug: Zoledronic Acid 4 MG	The percentage change in lumber spine (L2-L4) BMD at 12 and 24 months for immediate- versus delayed-ZOL patients.; percentage change in total hip BMD at each assessment, fracture incidence in percentage, time to disease recurrence in months (local relapse or distant metastasis), DFS in months, and safety.; Fracture incidence in percentage	Assiut University	Female	45 Years to 80 Years   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Zoledronic Acid In Breast Ca	30/09/2021	30/08/2023	30/09/2023			21/12/2021				21/12/2021	https://ClinicalTrials.gov/show/NCT05164952	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Egypt	Breast	Breast Cancer - ER/HR+	Zoledronic Acid	Recurrence rate; Biomarker	Phase 3	DB00399	N
NCT02796261	Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients	STELLAR	Active, not recruiting	Anaplastic Astrocytoma|Recurrent Anaplastic Astrocytoma	Drug: Eflornithine; Drug: Lomustine	Overall survival; Progression-free survival (PFS); Objective response rate (ORR)	Orbus Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	343	Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OT-15-001	07/01/2016	06/01/2023	06/01/2023			06/10/2016				21/01/2022	https://ClinicalTrials.gov/show/NCT02796261	Palliative	Recurrent/Refractory	Company	Y	N	N	United States	CNS	Astrocytoma	Eflornithine	OS	Phase 3	DB06243	N
NCT02647099	Adjuvant Low Dose Aspirin in Colorectal Cancer	ALASCCA	Recruiting	Colorectal Cancer	Drug: Acetylsalicylic acid; Drug: Placebo	Time To Recurrence (TTR); Disease free survival (DFS); Overall survival (OS); Frequency and severity of adverse events (AE)	Anna Martling; Uppsala University Hospital; Skane University Hospital; Karolinska Institutet	All	18 Years to 80 Years   (Adult, Older Adult)	600	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	921-2014-7074	04/07/2016	08/01/2024	08/01/2026			01/06/2016				14/04/2022	https://ClinicalTrials.gov/show/NCT02647099	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Sweden	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	OS; DFS/RFS/EFS; Recurrence rate	Phase 3	DB00945	N
NCT03326791	Aspirin in Colorectal Cancer Liver Metastases	ASAC	Recruiting	Colorectal Cancer Liver Metastases|Colorectal Cancer|Liver Metastases	Drug: Acetylsalicylic acid; Drug: Placebo Oral Tablet	Disease Free Survival (DFS) after three years treatment; Time to recurrence (TTR) of disease after randomization; Overall survival (OS) three years after treatment start; Health-related Quality of Life with 36-item Short Form Health Survey (SF-36); Health-related Quality of Life with EuroQoL 5 Dimensions (EQ-5D); ASA in CRC and Cost-Effectiveness Analyses I; ASA in CRC and Cost-Effectiveness Analyses II; ASA in CRC and Cost-Effectiveness Analyses III	Oslo University Hospital; Norwegian Cancer Society; The Research Council of Norway; Klinbeforsk	All	18 Years and older   (Adult, Older Adult)	800	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	2014/2217	15/12/2017	02/01/2022	02/01/2026			31/10/2017				22/04/2022	https://ClinicalTrials.gov/show/NCT03326791		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Norway	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	OS; DFS/RFS/EFS; Recurrence rate	Phase 2/3	DB00945	N
NCT04697576	Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma		Recruiting	Clinical Stage I Cutaneous Melanoma AJCC v8|Clinical Stage IA Cutaneous Melanoma AJCC v8|Clinical Stage IB Cutaneous Melanoma AJCC v8|Clinical Stage II Cutaneous Melanoma AJCC v8|Clinical Stage IIA Cutaneous Melanoma AJCC v8|Clinical Stage IIB Cutaneous Melanoma AJCC v8|Clinical Stage IIC Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Melanoma	Biological: Ipilimumab; Biological: Nivolumab; Biological: Pembrolizumab; Biological: Quadrivalent Inactivated Influenza Vaccine; Procedure: Resection	Incidence of adverse events (AEs); Maximum tolerated dose (MTD) in Cohorts #1 and #2; Tumor dimensions of injected (Cohorts #1); Tumor dimensions of non-injected lesions (Cohort #2); Time to disease progression (local or distant); Biomarker analysis; Granzyme B H-score; NanoString Pan Cancer Immune Profiling Panel; Tumor-infiltrating lymphocytes analysis; Degree of tumor regression (percent); Changes in micro ribonucleic acid (RNA) expression; T-cell subset evaluation and changes in circulating microRNA	Carlo Contreras; Ohio State University Comprehensive Cancer Center	All	18 Years to 90 Years   (Adult, Older Adult)	36	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSU-20221; NCI-2020-13282	20/10/2021	31/12/2023	31/12/2024			01/06/2021				29/04/2022	https://ClinicalTrials.gov/show/NCT04697576		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	United States	Skin	Melanoma	Influenza vaccine	Safety and/or Dose; Biomarker; Other (specify)	Phase 1	Not found in DrugBank	N
NCT05116917	Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.	INFLUENCE	Recruiting	Pancreatic Cancer	Drug: Nivolumab; Drug: Ipilimumab; Biological: Influenza vaccine; Radiation: SBRT	Objective response rate (ORR); Duration of response (DoR); Disease control rate (DCR); Progression free survival (PFS); Overall survival (OS); EORTC QLQ-C30; Treatment-related adverse events as assessed by CTCAE v5.0	Herlev Hospital	All	18 Years and older   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GI 2118	11/05/2021	12/01/2023	12/01/2024			11/11/2021				16/03/2022	https://ClinicalTrials.gov/show/NCT05116917		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Denmark	GI	Pancreatic Cancer	Influenza vaccine	Safety and/or Dose; Response rate; PFS; OS; Other (specify)	Phase 2	Not found in DrugBank	N
NCT03753334	Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.	RCT-EPAII-BCR	Recruiting	Prostate Cancer	Combination Product: MAG-EPA; Dietary Supplement: Placebo group	Prostate-specific antigen (PSA) doubling time from baseline to 12 months.; Fatty acid profiles in red blood cells, changes relative to baseline (time 0).	CHU de Quebec-Universite Laval	Male	18 Years to 100 Years   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2017-3407	07/10/2017	06/01/2023	12/01/2023			27/11/2018				31/03/2022	https://ClinicalTrials.gov/show/NCT03753334		Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	Canada	Urological	Prostate Cancer	Omega 3	Biomarker	Phase 2	DB13961	N
NCT05300958	Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer		Recruiting	Triple Negative Breast Cancer	Drug: Deferoxamine Plus Chemotherapy	Objective Response Rate (ORR); clinical benefit rate (CBR); progression-free survival (PFS); overal survival (OS)	Sun Yat-sen University	Female	18 Years to 70 Years   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SYSUCC-017	21/03/2022	30/09/2023	10/01/2024			29/03/2022				29/03/2022	https://ClinicalTrials.gov/show/NCT05300958		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	Breast	Breast Cancer - TNBC	Deferoxamine	Response rate; PFS; OS	Phase 2	DB00746	N
NCT02905578	A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)		Recruiting	Pancreatic Neoplasms|Cancer of Pancreas|Cancer of the Pancreas|Neoplasms, Pancreatic|Pancreas Cancer|Pancreas Neoplasms|Adenocarcinoma	Drug: Gemcitabine; Drug: nab-paclitaxel; Drug: Pharmacological ascorbate	Overall survival; Tumor Response; Progression free survival; Adverse event frequency and categorization	Joseph J. Cullen; National Institutes of Health (NIH); National Cancer Institute (NCI); Holden Comprehensive Cancer Center; McGuff Pharmaceuticals, Inc.; University of Iowa	All	18 Years and older   (Adult, Older Adult)	65	Other; NIH; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	201801759; 3P30CA086862; 5U01CA140206; P01CA217797	28/11/2018	31/12/2025	31/12/2025			19/09/2016				07/08/2022	https://ClinicalTrials.gov/show/NCT02905578		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	United States	GI	Pancreatic Cancer	Ascorbic acid	OS	Phase 2	DB00126	N
NCT02344355	A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme		Active, not recruiting	Glioblastoma Multiforme	Drug: Temozolomide; Radiation: radiation therapy; Drug: Ascorbic Acid	Overall Survival (OS); Progression Free Survival (PFS); Adverse Event Frequency	Bryan Allen; Holden Comprehensive Cancer Center; National Cancer Institute (NCI); University of Iowa	All	18 Years and older   (Adult, Older Adult)	90	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201504786	13/03/2017	07/06/2022	12/01/2024			22/01/2015				07/11/2022	https://ClinicalTrials.gov/show/NCT02344355		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Ascorbic acid	OS	Phase 2	DB00126	N
NCT02786875	Diet, Exercise and Vitamin D in Breast Cancer Recurrence	DEDiCa	Active, not recruiting	Breast Cancer	Other: low Glycemic Index Mediterranean diet; Other: Mediterranean diet; Behavioral: Moderate physical activity; Behavioral: Basic physical activity; Drug: high level Vitamin D; Drug: normal level Vitamin D	Recurrence of disease at study end; Changes in glycemic markers; Changes in hormonal markers; Changes in cardiovascular risk factors; Changes in epigenetic factors	National Cancer Institute, Naples; Unity Health Toronto; University of Catania	Female	30 Years to 74 Years   (Adult, Older Adult)	506	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DEDiCa; 2015-005147-14	11/04/2016	10/10/2020	15/12/2023			06/01/2016				23/05/2022	https://ClinicalTrials.gov/show/NCT02786875	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Italy	Breast	Any Breast Cancer	Cholecalciferol	DFS/RFS/EFS; Recurrence rate; Biomarker	Phase 3	DB00169	N
NCT02671890	Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer		Recruiting	Metastatic Pancreatic Adenocarcinoma|Refractory Malignant Solid Neoplasm|Stage IV Pancreatic Cancer AJCC v8	Drug: Chemotherapy; Drug: Disulfiram; Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis	Maximum tolerated dose (MTD) (Cohort I); Adverse events profile (Cohort I and II); Toxicity profile defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment (Cohorts I and II); Overall survival (OS) (Cohort I and II); Change in muscle area at the L3 level using a computed tomography (CT) scan (Cohort II); Response rate (Cohort II); Change in muscle area at the L3 level using a computed tomography scan (Cohort II); Changes in fist-grip strength as measured by hand dynamometer (Cohort II)	Mayo Clinic; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	74	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1512; NCI-2016-00007; 15-003194; P30CA015083	25/02/2016	05/05/2023	05/05/2023			02/02/2016				06/02/2022	https://ClinicalTrials.gov/show/NCT02671890		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	Y	N	United States	Multiple cancer types; GI	Any solid tumours; Pancreatic Cancer	Disulfiram	Safety and/or Dose	Phase 1	DB00822	N
NCT02679144	Neuroblastoma Maintenance Therapy Trial	NMTT	Recruiting	Neuroblastoma	Drug: Difluoromethylornithine (DFMO)	Number of participants with event free survival (EFS) during study.; Length of time that participants experience Overall Survival (OS); Number of Participants with Adverse Events as a Measure of Safety and Tolerability; Peak Plasma Concentration (Cmax); Area under the plasma concentration versus time curve (AUC); Time to reach Peak Plasma Concentration (Tmax); Number of participants with ODC (Ornithine decarboxylase) single nucleotide polymorphisms.	Wake Forest University Health Sciences; Beat NB Cancer Foundation; Team Parker for Life	All	1 Year to 30 Years   (Child, Adult)	258	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	NMTRC014	02/01/2016	02/01/2026	02/01/2029			02/10/2016				29/06/2022	https://ClinicalTrials.gov/show/NCT02679144		Localised/Locoregional	Hospital/University/Research Institute	N	N	Y	United States	Other	Neuroblastoma	Eflornithine	DFS/RFS/EFS	Phase 2	DB06243	N
NCT04564521	Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma.		Recruiting	Retinoblastoma	Drug: Nitroglycerin; Drug: Normal saline	The incidence of the cardio-respiratory side effects during ophthalmic artery selection and intra-arterial injection of chemotherapy agents. (percent); The duration of the cardio-respiratory side effects during ophthalmic artery selection and intra-arterial injection of chemotherapy agents. (percent); The incidence of using vaso-active drugs (percent); The incidence of the side effect of nitroglycerin infusion (percent); The concentration of inhaled sevoflurane (vol ); The depth of anesthesia; Duration of anesthesia (min); Total procedure time (min); The procedural satisfaction score of radiologist (1-3); Incidence of the newly developed focal ischemia or infarct in retina photography(yes or no)	Seoul National University Hospital	All	up to 7 Years   (Child)	36	Other	Interventional Study	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	2006-108-1134	28/09/2020	30/06/2024	30/12/2024			25/09/2020				06/03/2022	https://ClinicalTrials.gov/show/NCT04564521		Localised/Locoregional	Hospital/University/Research Institute	Y	N	Y	Korea, Republic of	Ocular	Retinoblastoma	Nitroglycerin	Safety and/or Dose	Other	DB00727	N
NCT02333435	Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life	RCT-EPA	Active, not recruiting	Prostate Cancer	Dietary Supplement: EPA; Dietary Supplement: Placebo	Change in Prostate Cancer Proliferative Index; Change in Inflammatory mediators levels- Systemic; Modulation of Inflammatory mediators levels - Prostatic; Modulation of the Quality of life of patients; Modulation of the psychosocial functioning of patients; Impact of inflammation on Quality of life; Impact of inflammation on psychosocial functioning	CHU de Quebec-Universite Laval	Male	18 Years and older   (Adult, Older Adult)	130	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2012-1012	01/01/2015	12/01/2020	12/01/2023			01/07/2015				31/05/2022	https://ClinicalTrials.gov/show/NCT02333435		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Canada	Urological	Prostate Cancer	Omega 3	QoL; Biomarker	Phase 2	DB13961	N
NCT04729543	MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer	MC2TCR	Recruiting	Melanoma|Melanoma, Uveal|Head and Neck Cancer	Biological: Adoptive therapy with autologous MC2 TCR T cells	Maximum Tolerated Dose (MTD) of MC2 TCR T cells; Objective anti-tumor responses of MC2 TCR T cells	Erasmus Medical Center; Ludwig Institute for Cancer Research; Dutch Cancer Society; Stichting Coolsingel Rotterdam grant; Jan Ivo Stichting grant	All	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NL69011.000.19	20/10/2020	20/12/2022	20/10/2027			28/01/2021				06/02/2022	https://ClinicalTrials.gov/show/NCT04729543		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Netherlands	Skin; Head and Neck	Melanoma; Any head and neck squamous cell carcinoma	Valproic Acid	Safety and/or Dose; Biomarker	Phase 1/2	DB00313	N
NCT03243461	International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)	HIT-HGG-2013	Recruiting	Glioblastoma WHO Grade IV|Diffuse Midline Glioma Histone 3 K27M WHO Grade IV|Anaplastic Astrocytoma WHO Grade III|Diffuse Intrinsic Pontine Glioma|Gliomatosis Cerebri	Drug: Temozolomide + Valproic Acid	Comparison of effects of valproine acid with respect to historical control group.	University of G ttingen; Deutsche Kinderkrebsstiftung; Hannover Medical School	All	3 Years to 17 Years   (Child)	167	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	01153; 2013-004187-56	17/07/2018	31/12/2023	31/12/2023			08/09/2017				06/06/2022	https://ClinicalTrials.gov/show/NCT03243461	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	N	N	Y	Germany	CNS	Glioblastoma; DIPG/DMG; Astrocytoma; Other CNS	Valproic Acid	DFS/RFS/EFS	Phase 3	DB00313	N
NCT05080790	Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma	DiTuSarc	Recruiting	Leiomyosarcoma	Drug: Dinutuximab Beta, Zoledronic acid, Interleukin-2	The primary objective of this study is to assess the feasibility of the combined treatment with dinutuximab beta, zoledronic acid and low-dose interleukin 2.; A secondary objective of this study is to assess the safety and tolerability of the combined treatment with dinutuximab beta, zoledronic acid and low-dose interleukin 2.; An additional secondary objective of this study is to assess the efficacy of the combined treatment with dinutuaseximab beta, zoledronic acid and low-dose interleukin 2.	Institut f r Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; EUSA Pharma, Inc.	Female	18 Years and older   (Adult, Older Adult)	10	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DiTuSarc / GISG-20	15/11/2021	26/07/2024	26/07/2024			18/10/2021				06/03/2022	https://ClinicalTrials.gov/show/NCT05080790		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Germany	Soft Tissue Sarcoma	Leiomyosarcoma	Zoledronic Acid	Safety and/or Dose	Phase 1	DB00399	N
NCT00470223	Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma	OS2006	Active, not recruiting	Sarcoma	Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate; Drug: zoledronic acid; Procedure: conventional surgery	Event-free survival; Overall survival; Percentage of good responders; Short term and long term toxicity	UNICANCER; Novartis; Chugai Pharmaceutical; National Cancer Institute, France; SFCE; Ligue contre le cancer, France	All	5 Years to 50 Years   (Child, Adult)	318	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sarcome 09/0603; UNICANCER-SARCOME-09-0603; 2006-003377-27	03/01/2007	12/01/2015	12/01/2025			05/07/2007				27/06/2022	https://ClinicalTrials.gov/show/NCT00470223	Neo-adjuvant/Window; Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	Y	France	Bone Sarcoma	Osteosarcoma	Zoledronic Acid	Safety and/or Dose; Response rate; OS; DFS/RFS/EFS	Phase 3	DB00399	N
NCT04477200	Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma		Recruiting	Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Astrocytoma, Grade IV|Newly Diagnosed Glioblastoma|Newly Diagnosed Gliosarcoma|Newly Diagnosed Astrocytoma, Grade IV	Drug: Mycophenolate Mofetil; Radiation: Radiation Therapy; Procedure: Re-resection (as part of standard of care); Drug: Temozolomide	Concentration of mycophenolic acid (MPA) in tumor tissue in Phase 0 participants; Number of recurrent phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level; Number of newly diagnosed phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level -- DLT1 period; Number of newly diagnosed phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level -- DLT2 period; Concentrations of guanosine triphosphate (GTP) in tumor tissue in Phase 0 participants; Adverse events associated with treatment in all Phase 1 Participants; Adverse events associated with treatment in newly diagnosed phase 1 participants; Overall Response Rate in phase 1 participants with recurrent GBM/GS; Median Progression Free Survival (PFS) in phase 1 participants with recurrent GBM/GS; Median Freedom from Local Progression (FFLP) in phase 1 participants with recurrent GBM/GS; Median Overall Survival (OS) in phase 1 participants with recurrent GBM/GS	University of Michigan Rogel Cancer Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	68	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UMCC 2019.192; HUM00175785; R37CA258346	08/05/2020	10/01/2024	10/01/2027			20/07/2020				07/11/2022	https://ClinicalTrials.gov/show/NCT04477200		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma; Astrocytoma; Other CNS	Mycophenolate	Safety and/or Dose; Biomarker	Phase 1	DB01024	N
NCT01852890	Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I		Active, not recruiting	Pancreatic Neoplasms	Drug: Ascorbate; Drug: Gemcitabine; Radiation: Radiation therapy	Number of grade 3, 4,   5 adverse events during radiation; Time to progression; Overall survival; Number of grade 3, 4,   5 adverse events post-treatment	Joseph J. Cullen; Holden Comprehensive Cancer Center; Gateway for Cancer Research; University of Iowa	All	18 Years and older   (Adult, Older Adult)	16	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201310772	01/01/2014	22/01/2019	01/01/2024			14/05/2013				26/07/2022	https://ClinicalTrials.gov/show/NCT01852890		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Ascorbic acid	Safety and/or Dose	Phase 1	DB00126	N
NCT03146962	High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies		Recruiting	Colorectal Cancer|Pancreatic Cancer|Lung Cancer	Drug: Vitamin C	Change in antitumor activity measured by pathologic response based on tumor regression grading in cohort A patients.; 3-month disease control rate (DCR) will be evaluated using RECIST v 1.1 in cohort B patients.; Maximal tolerated dose of high dose vitamin C in combination with Y90 radioembolization; Progression-free survival (PFS); Objective response rate (ORR); Assessment of pharmacokinetics of high dose vitamin C plasma levels concentrations; Safety of high dose vitamin C administration using CTCAE 4.03.	Weill Medical College of Cornell University; Stand Up To Cancer	All	18 Years and older   (Adult, Older Adult)	78	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1610017688	29/03/2017	06/01/2023	06/01/2023			05/10/2017				10/04/2022	https://ClinicalTrials.gov/show/NCT03146962		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types	Multiple cancer types	Ascorbic acid	Other (specify)	Phase 2	DB00126	N
NCT02420314	Pharmacological Ascorbate for Lung Cancer		Active, not recruiting	Carcinoma, Non-Small-Cell Lung	Drug: Paclitaxel; Drug: Carboplatin; Drug: Ascorbic Acid	Tumor response; Progression free survival (PFS); Overall survival (OS); Adverse Event Frequency	Joseph J. Cullen, MD, FACS; National Cancer Institute (NCI); National Institutes of Health (NIH); Holden Comprehensive Cancer Center; McGuff Pharmaceuticals, Inc.; University of Iowa	All	18 Years and older   (Adult, Older Adult)	55	Other; NIH; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201412760; 3P30CA086862	04/01/2015	12/01/2021	12/01/2024			17/04/2015				18/08/2022	https://ClinicalTrials.gov/show/NCT02420314		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Lung	Non-Small Cell Lung Cancer	Ascorbic acid	Response rate	Phase 2	DB00126	N
NCT02905591	A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC	XACT-LUNG	Recruiting	Carcinoma, Non-Small-Cell Lung|Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|NSCLC	Drug: Radiation Therapy; Drug: Paclitaxel; Drug: Carboplatin; Drug: Ascorbic Acid	Progression rate at completion of radiation and chemotherapy; Tumor response; Progression free survival (PFS); Overall survival (OS); Adverse event frequency and categorization	Joseph J. Cullen, MD, FACS; National Institutes of Health (NIH); National Cancer Institute (NCI); Holden Comprehensive Cancer Center; University of Iowa	All	18 Years and older   (Adult, Older Adult)	46	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201712770; 3P30CA086862; 5U01CA140206; 1P01CA217797-01A1	16/11/2018	12/01/2024	31/12/2026			19/09/2016				15/08/2022	https://ClinicalTrials.gov/show/NCT02905591		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Lung	Non-Small Cell Lung Cancer	Ascorbic acid	Response rate	Phase 2	DB00126	N
NCT01752491	A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme		Active, not recruiting	Glioblastoma|GBM|Glioblastoma Multiforme	Drug: Ascorbate; Drug: Temozolomide; Radiation: Radiation therapy	Number of grade 3, 4,   5 adverse events; Time to progression; Overall survival	Joseph J. Cullen, MD, FACS; National Institutes of Health (NIH); National Cancer Institute (NCI); University of Iowa	All	18 Years and older   (Adult, Older Adult)	13	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201211713; P30CA086862; U01CA140206	04/01/2013	30/11/2015	31/12/2024			19/12/2012				26/07/2022	https://ClinicalTrials.gov/show/NCT01752491		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Ascorbic acid	Safety and/or Dose	Phase 1	DB00126	N
NCT05184816	A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis		Recruiting	Leptomeningeal Metastases	Drug: Deferoxamine (DFO)	Frequency of dose-limiting toxicities (DLTs) during Phase Ia (Primary safety endpoint during dose-finding phase); Frequency of dose-limiting toxicities (DLTs) during Phase Ib (RP2D of IT-DFO in patients with LM from NSCLC); objective response rate (ORR)	Memorial Sloan Kettering Cancer Center; Center for Experimental Therapeutics; F.M. KIRBY FOUNDATION	All	18 Years and older   (Adult, Older Adult)	35	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	21-378	22/12/2021	12/01/2024	12/01/2024			01/11/2022				16/09/2022	https://ClinicalTrials.gov/show/NCT05184816		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types	Any solid tumours	Deferoxamine	Safety and/or Dose	Phase 1	DB00746	N
NCT05077137	A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy	TdVax	Recruiting	Melanoma	Biological: Tetanus Diptheria Vaccine; Biological: Polio Boost Immunization	Number of subjects out of the proposed 25 that successfully receive the vaccine after 4 cycles of IO therapy; Safety, as measured by the change in the number and severity of adverse events deemed related to the vaccine or study procedures (blood draw and biopsies); Preliminary efficacy, as measured by objective response rate	Duke University	All	18 Years and older   (Adult, Older Adult)	25	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00108367	09/07/2021	09/01/2023	09/01/2024			14/10/2021				09/10/2022	https://ClinicalTrials.gov/show/NCT05077137		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Skin	Melanoma	Diphtheria vaccine; Tetanus vaccine	Safety and/or Dose	Phase 1	Not found in DrugBank; Not found in DrugBank	N
NCT04696029	DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma		Recruiting	Medulloblastoma	Drug: Difluoromethylornithine	Number of participants with event free survival (EFS) during study; Length of time that participants experience Overall Survival (OS); Determine the Overall Response Rate (ORR) of Participants using Modified RANO Criteria; Number of Participants with Adverse Events as a Measure of Safety and Tolerability; Determine amount of DFMO in the CSF at 3 hours post dose	Wake Forest University Health Sciences	All	up to 21 Years   (Child, Adult)	118	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BCC016	29/03/2021	03/01/2028	03/01/2029			01/06/2021				08/04/2022	https://ClinicalTrials.gov/show/NCT04696029		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	CNS	Medulloblastoma	Eflornithine	Response rate; OS; DFS/RFS/EFS	Phase 2	DB06243	N
NCT02559778	Pediatric Precision Laboratory Advanced Neuroblastoma Therapy	PEDS-PLAN	Recruiting	Neuroblastoma	Drug: Ceritinib; Drug: dasatinib; Drug: sorafenib; Drug: vorinostat; Drug: DFMO	Number of days from start of therapy to date of first relapse; Number of subjects that have a targeted agent chosen for treatment.; Number of subjects that receive 75  of dosing of medications while on study protocol during cycles 3-6.; Number of days that subjects remain alive; Overall Response Rate (ORR) of Participants by the presence of radiologically assessable disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans.; Number of participants with treatment-related adverse events as assessed by CTCAE v4.0; Amount of pain medicine required by Arm A versus Arm B; Number of subjects required to go off therapy due to treatment-related adverse events as assessed by CTCAE v4.0.	Wake Forest University Health Sciences; Dell, Inc.; Beat NB Cancer Foundation; K C Pharmaceuticals Inc.; Team Parker for Life	All	up to 22 Years   (Child, Adult)	500	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NMTRC012	09/01/2015	09/01/2027	09/01/2032			24/09/2015				27/09/2022	https://ClinicalTrials.gov/show/NCT02559778		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	Y	United States	Other	Neuroblastoma	Eflornithine	DFS/RFS/EFS	Phase 2	DB06243	N
NCT05055323	A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer		Recruiting	Resectable Pancreatic Ductal Adenocarcinoma|Stage 0 Pancreatic Cancer AJCC v8|Stage I Pancreatic Cancer AJCC v8|Stage IA Pancreatic Cancer AJCC v8|Stage IB Pancreatic Cancer AJCC v8|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8	Drug: Pyrvinium Pamoate	Incidence of dose limited toxicity (DLT); Profile of pyrvinium pamoate (PP); Bioavailability of PP; Fatty tissue accumulation of PP	Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	18	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20F.041	29/07/2021	06/01/2023	06/01/2023			24/09/2021				08/03/2022	https://ClinicalTrials.gov/show/NCT05055323		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Pyrvinium Pamoate	Safety and/or Dose; Biomarker	Phase 1	DB06816	N
NCT03919292	Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca		Recruiting	Solid Tumor, Adult	Drug: Neratinib; Drug: Divalproex Sodium	Determination of Recommended Phase 2 Dose (RP2D); Evaluation of Treatment Related Adverse Events of Neratinib combined with Sodium Valproate; Solid Tumor Antitumor Effects; Glioblastoma Antitumor Effects; Progression Free Survival (PFS)	Virginia Commonwealth University; Puma Biotechnology, Inc.	All	18 Years and older   (Adult, Older Adult)	113	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-17-13821	05/01/2019	31/12/2023	31/12/2024			18/04/2019				23/09/2022	https://ClinicalTrials.gov/show/NCT03919292		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types	Any solid tumours	Valproic Acid	Safety and/or Dose; PFS; Other (specify)	Phase 1/2	DB00313	N
NCT05053750	TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer		Recruiting	Epithelial Ovarian|Fallopian Tube|Primary Peritoneal Cancer	Drug: Paclitaxel/Bev (control); Drug: Paclitaxel/Bev + ZA (experimental)	To assess macrophage counts by image cytometry in women with platinum resistant ovarian cancer treated with weekly paclitaxel/bevacizumab and ZA relative to weekly paclitaxel/bevacizumab	M.D. Anderson Cancer Center; Gateway for Cancer Research; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	30	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2021-0694; NCI-2021-04298	14/12/2021	31/03/2023	31/03/2023			22/09/2021				08/11/2022	https://ClinicalTrials.gov/show/NCT05053750		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer	Zoledronic Acid	Biomarker	Phase 1	DB00399	N
NCT03396952	Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma		Completed	Stage III Cutaneous Melanoma|Stage IIIA Cutaneous Melanoma|Stage IIIB Cutaneous Melanoma|Stage IIIC Cutaneous Melanoma|Stage IV Cutaneous Melanoma	Drug: Aspirin; Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab	Objective Response Rate (ORR); Number of Participants With Reported Treatment-related Adverse Events; Proportion of Participants With Progression-free Survival (PFS) at 6 Months; Median Duration of PFS; Median Overall Survival (OS)	University of California, San Francisco; Merck Sharp   Dohme LLC	All	19 Years and older   (Adult, Older Adult)	27	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17854; NCI-2017-02441	19/04/2018	30/04/2020	30/06/2022			01/11/2018		06/10/2021		13/10/2022	https://ClinicalTrials.gov/show/NCT03396952		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Skin	Melanoma	Acetylsalicylic Acid	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00945	N
NCT04046094	Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients		Active, not recruiting	Bladder Cancer	Drug: Ascorbic Acid	Post Treatment Pathological Staging; Overall change in patient-reported quality of life outcomes; Disease free survival rate (DFS) among participants	University of Kansas Medical Center	All	18 Years and older   (Adult, Older Adult)	16	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT-2019-IVC_CarboGem	17/10/2019	09/12/2022	08/01/2024			08/06/2019				26/09/2022	https://ClinicalTrials.gov/show/NCT04046094		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Urological	Bladder Cancer	Ascorbic acid	DFS/RFS/EFS; QoL; Other (specify)	Phase 1/2	DB00126	N
NCT03508726	High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas		Active, not recruiting	Soft Tissue Sarcoma	Drug: Ascorbate	Incidence of dose limiting toxicities (DLTs) using CTCAE, Version 4.0; Tumor response as assessed by pathological complete response rates (pCR); Disease progression as measured by time to disease progression (TTP); Overall response rate as measured by RECIST 1.1; Overall survival estimated using the Kaplan-Meier Method; Skin toxicity; Labile iron; Evaluate diffusion weighted imaging sequences	Varun Monga, MD; University of Iowa	All	18 Years and older   (Adult, Older Adult)	25	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201901810	27/06/2019	06/03/2022	06/01/2024			26/04/2018				10/12/2022	https://ClinicalTrials.gov/show/NCT03508726		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Soft Tissue Sarcoma	Any soft tissue sarcoma	Ascorbic acid	Safety and/or Dose; Response rate	Phase 1/2	DB00126	N
NCT02553447	Cholecalciferol in Treating Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency		Active, not recruiting	Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma|Untreated Chronic Lymphocytic Leukemia|Vitamin D Deficiency	Dietary Supplement: Cholecalciferol; Other: Laboratory Biomarker Analysis	Progression-free survival; Incidence of adverse events and serious events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0; Overall survival	University of Nebraska; National Cancer Institute (NCI)	All	19 Years and older   (Adult, Older Adult)	197	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	556-15; NCI-2015-01502; P30CA036727	19/10/2015	24/03/2025	24/03/2025			17/09/2015				08/08/2022	https://ClinicalTrials.gov/show/NCT02553447		Any/All Stages	Hospital/University/Research Institute	Y	Y	N	United States	Lymphoma; Leukemia	Non-Hodgkin Lymphoma, Adult; Chronic Lymphocytic Leukemia	Cholecalciferol	PFS	Phase 1	DB00169	N
NCT04442412	Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy	FIL_PREVID	Recruiting	Diffuse Large B-Cell Lymphoma|Elderly Patients	Drug: Vitamin D3 (Cholecalciferol); Drug: RCHOP o R-miniCHOP at standard doses	Progression-Free Survival; Overall Survival; Event Free Survival; Response rate; Early death rate; Rate of ECOG changes after prephase; Rate of patients who maintain 25(OH)VitD levels; Rate of 25(OH)VitD correction (VitD supplementation arm); time-to-deterioration physical functioning and fatigue	Fondazione Italiana Linfomi ONLUS; GRADE Onlus	All	65 Years and older   (Older Adult)	430	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FIL_PREVID	23/03/2021	09/01/2025	09/01/2030			22/06/2020				26/08/2022	https://ClinicalTrials.gov/show/NCT04442412	Adjuvant/Maintenance	Any/All Stages	Collaborative Group	Y	N	N	Italy	Lymphoma	Non-Hodgkin Lymphoma, Adult	Cholecalciferol	PFS	Phase 3	DB00169	N
NCT02715609	Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma		Active, not recruiting	Glioblastoma Multiforme	Drug: Disulfiram; Drug: Copper Gluconate; Procedure: Surgery; Radiation: Radiation; Drug: Temozolomide	Maximum tolerated dose (MTD) of the regimen (dose-escalation phase only); Overall survival (dose-expansion phase only); Toxicity associated with DSF when given concurrently with radiation therapy and temozolomide as measured by the grade and frequency of adverse events (dose- escalation phase only); Intratumoral drug uptake of DSF and its metabolites in resected GBM tissue (dose-escalation phase only); Proteasome inhibition of DSF on GBM tissues (dose-escalation phase only); Effect of DSF on DNA breaks on GBM tissues (dose-escalation phase only); Time to tumor progression (TTP) (dose-escalation phase only); Rate of pseudo-progression (PsP) (dose-escalation phase only); Progression-free survival (PFS); Overall survival (OS) (dose-escalation phase only); Active DSF metabolite concentration in plasma and tumor tissues (dose-expansion phase only); Pharmacodynamic studies on glutamate metabolism as measured by measurement of glutamine levels in plasma and tumor tissues (dose-escalation phase only); Pharmacodynamic studies on glutamate metabolism as measured by measurement of glutamate levels in plasma and tumor tissues (dose-escalation phase only); Pharmacodynamic studies on glutamate metabolism as measured by measurement of aspartate levels in plasma and tumor tissues (dose escalation phase only); Pharmacodynamic studies on glutamate metabolism as measured by measurement of glucose levels in plasma and tumor tissues (dose escalation phase only); Pharmacodynamic studies on glutamate metabolism as measured by measurement of lactate levels in plasma and tumor tissues (dose escalation phase only)	Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)	35	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201604115	15/06/2016	28/02/2025	28/02/2025			22/03/2016				25/07/2022	https://ClinicalTrials.gov/show/NCT02715609		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Disulfiram	Safety and/or Dose; OS	Phase 1/2	DB00822	N
NCT01265849	Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity	IT-MATTERS	Completed	Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of the Soft Palate	Biological: LI; Drug: Cyclophosphamide; Drug: Indomethacin; Dietary Supplement: Zinc; Procedure: Surgery; Drug: Cisplatin; Radiation: Radiotherapy	Overall Survival (OS); OS in Low Risk Subjects; Local Regional Control (LRC); LRC in Low Risk Subjects; Progression Free Survival (PFS); PFS in Low Risk Subjects; Quality of Life by EORTC QLQ-C30 Global Health Status [GHS] at Month 2; Quality of Life by EORTC QLQ-C30 Global Health Status [GHS] at Month 36; EORTC Quality of Life Questionnaire (QLQ) - Head   Neck Cancer Module: QLQ-H N35 at Month 2; EORTC Quality of Life Questionnaire (QLQ) - Head   Neck Cancer Module: QLQ-H N35 at Month 36; Statistical Comparisons of Time-to-event Outcomes (OS, LRC, PFS) Were Repeated for Varying Levels of Histopathology (HP) Markers in Low Risk Subjects	CEL-SCI Corporation; Teva Branded Pharmaceutical Products R D, Inc.; Orient Europharma Co., Ltd.	All	18 Years and older   (Adult, Older Adult)	928	Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CS001P3; 2010-019952-35	12/01/2010	15/05/2020	12/04/2020			23/12/2010		19/08/2022		19/08/2022	https://ClinicalTrials.gov/show/NCT01265849	Adjuvant/Maintenance	Localised/Locoregional	Company	Y	Y	N	United States	Head and Neck	Oropharyngeal Cancer	Indomethacin	PFS; OS; QoL	Phase 3	DB00328	N
NCT05236036	Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma		Recruiting	Astrocytoma|Glioblastoma|Glioblastoma, IDH-Wildtype|MGMT-Unmethylated Glioblastoma|Recurrent Glioblastoma	Drug: Mycophenolate Mofetil; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Drug: Temozolomide	Maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) for mycophenolate mofetil (MMF) (Group 1); MTD/RP2D for MMF (Group 2); Frequency of adverse events; Progression Free Survival (PFS); Overall survival (OS); Overall response rate (ORR); Quality of life (QOL)	Northwestern University; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	60	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 21C01; NCI-2021-12424; STU00215766; P30CA060553	08/08/2022	01/03/2025	01/03/2027			02/11/2022				25/08/2022	https://ClinicalTrials.gov/show/NCT05236036		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Mycophenolate	Safety and/or Dose	Phase 1	DB01024	N
NCT03035331	Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma		Active, not recruiting	Aggressive Non-Hodgkin Lymphoma|Indolent Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma	Procedure: Cryosurgery; Biological: Dendritic Cell Therapy; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab; Biological: Pneumococcal 13-valent Conjugate Vaccine; Other: Quality-of-Life Assessment	Maximum tolerated dose (MTD); Proportion of complete responses of combination therapy with pembrolizumab, cryoablation, and intra-tumor injection of autologous dendritic cells (DC) at maximum tolerated dose (MTD) dose; Complete response; Progression free survival; Treatment free survival; Duration of response; Disease free survival rate; Overall survival; Incidence of adverse events; Quality of life	Mayo Clinic; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	11	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1685; NCI-2017-00113; P30CA015083; P50CA097274	27/03/2017	07/01/2023	07/01/2023			30/01/2017				08/11/2022	https://ClinicalTrials.gov/show/NCT03035331		Localised/Locoregional; Recurrent/Refractory	Company	N	N	N	United States	Lymphoma	Non-Hodgkin Lymphoma, Adult	Pneumococcal vaccine	Safety and/or Dose; Response rate; PFS; Biomarker	Phase 1/2	Not found in DrugBank	N
2021-006689-18	An open randomized phase II clinical trial evaluating the safety and efficacy of rapamycin in the treatment of gliomas high-grade malignant gliomas in children as part of the establishment management of rare and ultra rare diseases of the central nervous system associated with mTOR pathway activation: BraimTOR- ONKO 	BraimTOR-ONKO		high grade glioma	Drug: Rapamune 1mg/ml oral solution	The primary safety endpoint of rapamycin will be the assessment of the incidence of 3 and 4 grade adverse reactions (according to the CTCAE classification) during the treatment phase and follow-up.	The Children's Memorial Health Institute	All	Under 18; Elderly 65+	50	Medical Research Agency	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006689-18/PL		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	Y	Poland	CNS	Any CNS cancers	Sirolimus	Safety and/or Dose	Phase 2	DB00877	N
NCT02467582	Adjuvant Aspirin Treatment for Colon Cancer Patients		Active, not recruiting	Colon Cancer	Drug: Aspirin; Drug: Placebo	Disease-free survival (DFS); Time to recurrence (TTR); Overall survival (OS); Cancer-specific survival (CSS); Adverse events (AEs)	Swiss Group for Clinical Cancer Research; European Organisation for Research and Treatment of Cancer - EORTC; Central European Society for Anticancer Drug Research	All	18 Years and older   (Adult, Older Adult)	185	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	SAKK 41/13 - Aspirin; SNCTP000001339; 2015-001482-57	06/09/2016	12/01/2024	12/01/2024			06/10/2015				01/10/2023	https://ClinicalTrials.gov/show/NCT02467582	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Switzerland	GI	Colon Cancer	Acetylsalicylic Acid	OS; DFS/RFS/EFS	Phase 3	DB00945	N
NCT03602235	High Dose Ascorbic Acid for Plasma Cell Disorders		Recruiting	Multiple Myeloma	Other: Ascorbate; Drug: Melphalan	Number of treatment related adverse events as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03; Rate of minimal residual disease (MRD) negativity through bone marrow testing and imaging; Overall response rate based on International Myeloma Working Group (IMWG) criteria; Categorize and quantify adverse events compared to historical control; Oxidative stress parameters in plasma through blood testing	Michael Tomasson; University of Iowa	All	18 Years and older   (Adult, Older Adult)	9	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201804754	03/05/2019	31/08/2023	31/08/2024			26/07/2018				12/08/2022	https://ClinicalTrials.gov/show/NCT03602235		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Other Haem-onc	Multiple Myeloma	Ascorbic acid	Safety and/or Dose	Phase 1	DB00126	N
NCT04677816	Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients		Recruiting	Triple Negative Breast Cancer|Vitamin D Deficiency|Invasive Breast Cancer	Drug: Standard of Care Neoadjuvant Chemotherapy; Dietary Supplement: Vitamin D3; Other: Drug Diary	Number of Pathologic Complete Response (pCR) in Vitamin D Supplementation Group; Number of Participants with Residual Cancer Burden (RCB) Index - Vitamin D Supplementation Group; Number of Participants with Residual Cancer Burden (RCB) Index - Observational Arm; Accrual Rate; Participation Rate; Retention Rate; Adherence Rate; Number of Adverse Events; Change in Vitamin D Receptor (VDR) Expression; Change in Fecal Microbiomes; Change in Mammary Gland Microbiomes	Wake Forest University Health Sciences; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	50	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00074154; WFBCCC 98121; P30CA012197	22/10/2021	07/01/2023	07/01/2024			21/12/2020				02/09/2023	https://ClinicalTrials.gov/show/NCT04677816		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Breast	Breast Cancer - TNBC	Cholecalciferol	Response rate; Biomarker	Phase 2	DB00169	N
NCT04839731	Combination 5-FU / Calcipotriene Cream for SCCIS/SCC		Recruiting	Squamous Cell Carcinoma	Drug: Combination topical 5-fluorouracil 5  / calcipotriene 0.005  cream; Drug: Nourivan Base Cream	Cancer resolution on histopathology; Final scar length; Cosmetic appearance	Carilion Clinic	All	18 Years to 100 Years   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	IRB-19-691	14/04/2021	12/01/2023	12/01/2023			04/09/2021				13/02/2023	https://ClinicalTrials.gov/show/NCT04839731		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Skin	Other skin cancer	Calcipotriol	Response rate	Phase 1	DB02300	N
NCT02139397	Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma		Active, not recruiting	Neuroblastoma Recurrent	Drug: DFMO; Drug: Bortezomib	Number of Participants with Adverse Events as a Measure of Safety and Tolerability; Determine the Overall Response Rate (ORR) of Participants using RECIST criteria; Determine the Progression Free Survival (PFS) of Participants using days until progression; Correlate PET scan changes with Progression Free Survival; Biology studies; Correlate urinary polyamine levels with response and progression of disease in neuroblastoma.	Wake Forest University Health Sciences; Beat NB Cancer Foundation; Because of Ezra; K C Pharmaceuticals Inc.	All	up to 21 Years   (Child, Adult)	16	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NMTRC010	05/01/2014	07/01/2023	12/01/2023			15/05/2014				23/01/2023	https://ClinicalTrials.gov/show/NCT02139397		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	Other	Neuroblastoma	Eflornithine	Safety and/or Dose	Phase 1/2	DB06243	N
NCT02176902	Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer		Active, not recruiting	Adenocarcinoma of the Prostate|Stage I Prostate Cancer|Stage IIA Prostate Cancer|Stage IIB Prostate Cancer	Behavioral: behavioral dietary intervention; Dietary Supplement: omega-3 fatty acid; Other: laboratory biomarker analysis	Decipher score in one year prostate biopsy tissue sample; Composite measure: Prostate biopsy tissue markers of proliferation, cell cycle progression, and prostate biopsy pathologic features (Gleason grade, percent of cores with cancer, and percent of tissue with cancer); Serum PSA; Composite measure: Long-term clinical outcomes (clinical progression, prostate cancer therapies); Composite measure: Potential surrogate biomarkers of proliferation (RBC membrane fatty acid analyses, ex-vivo bioassay); Correlation of GPR120 expression in peripheral blood mononuclear cells (PBMCs) and prostate biopsy tissue with immunostaining of Ki67 and Decipher Score; Compliance, defined as having taken 80  or more of the daily fish oil throughout the trial determined based on pill count; Incidence of adverse events graded according to National Cancer Institute Common Toxicity Criteria version 4.0; Sample storage for future research	Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI); Pharmavite LLC; Seafood Industry Research Fund	Male	50 Years to 80 Years   (Adult, Older Adult)	106	Other; NIH; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	13-000432; NCI-2014-01257; P50CA092131	11/01/2014	11/01/2023	11/01/2024			27/06/2014				02/09/2023	https://ClinicalTrials.gov/show/NCT02176902		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Urological	Prostate Cancer	Omega 3	Biomarker	Other	DB13961	N
NCT03428477	EPA for Metastasis Trial 2	EMT2	Recruiting	Liver Metastasis|Colon Cancer	Drug: Icosapent Ethyl; Other: Placebo	Progression Free Survival (PFS); Overall Survival (OS); Safety and Tolerability of Icosapent Ethyl; Patient reported quality of life 1; Patient reported quality of life 2; Patient reported quality of life 3; New Primary Cancers	Mark A Hull, PhD FRCP; Yorkshire Cancer Research; Amarin Pharma Inc.; University of Leeds	All	18 Years and older   (Adult, Older Adult)	448	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	MO16/053	05/02/2018	30/11/2025	30/04/2026			02/09/2018				11/08/2022	https://ClinicalTrials.gov/show/NCT03428477	Adjuvant/Maintenance	Advanced/Metastatic	Collaborative Group	Y	N	N	United Kingdom	GI	Colon Cancer; Rectal Cancer	Omega 3	Safety and/or Dose; PFS; OS; QoL	Phase 3	DB13961	N
NCT01351896	Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma		Active, not recruiting	Ann Arbor Stage I Small Lymphocytic Lymphoma|Ann Arbor Stage II Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene|Small Lymphocytic Lymphoma|Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia	Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Other: Pharmacological Study; Biological: Pneumococcal Polyvalent Vaccine	Proportion of patients who achieve an antibody response; Seroconversion rates; Antibody titre levels for each of the serotypes; Complete response rate; Time to first treatment; Overall survival; Progression-free survival; Incidence of adverse events; Pharmacokinetic (PK) parameters of lenalidomide; Change in serum immunoglobulin; Change in anti-tumor antibody levels	National Cancer Institute (NCI)	All	18 Years to 79 Years   (Adult, Older Adult)	48	NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2011-02584; CDR0000698438; OSU 10156; 2011C0005; 8834; N01CM00070; N01CM62207; P01CA095426; P30CA016058; P50CA140158	09/08/2011	31/12/2024	31/12/2024			05/11/2011				26/01/2023	https://ClinicalTrials.gov/show/NCT01351896		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	United States	Lymphoma; Leukemia	Lymphoma - Other; Chronic Lymphocytic Leukemia	Pneumococcal vaccine	Safety and/or Dose; PFS; OS; Biomarker	Phase 2	Not found in DrugBank	N
NCT00873275	Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer		Active, not recruiting	Colorectal Cancer	Biological: bevacizumab; Drug: FOLFOX regimen; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: ursodiol; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Genetic: western blotting; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: positron emission tomography (PET)	Maximum-tolerated dose of ursodiol; Toxicities as assessed by NCI CTCAE 3.0; Survival; Time to failure; Pharmacokinetics of ursodiol	City of Hope Medical Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	11	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	08005; P30CA033572; CHNMC-08005; CDR0000637521; NCI-2010-00926	03/11/2009	25/09/2012	13/01/2025			04/01/2009				28/11/2022	https://ClinicalTrials.gov/show/NCT00873275		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Rectal Cancer; Colon Cancer	Ursodeoxycholic Acid	Safety and/or Dose; OS; Biomarker	Phase 1	DB01586	N
NCT03073785	Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer		Recruiting	Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage I Pancreatic Cancer AJCC v6 and v7|Stage IA Pancreatic Cancer AJCC v6 and v7|Stage IB Pancreatic Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage IIA Pancreatic Cancer AJCC v6 and v7|Stage IIB Pancreatic Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7	Drug: Capecitabine; Drug: Fluorouracil; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Radiation: Stereotactic Body Radiation Therapy; Drug: Zoledronic Acid	Local control; Maximum tolerated dose of zoledronic acid determined by dose limiting toxicities evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0; Local failure-free survival will be compared between patients with and without Zometa; Overall survival will be compared between patients with and without Zometa; Surgical complete resection (negative margin) rate will be compared between patients with and without Zometa; Pathologic response for patients who undergo resection will be compared between patients with and without Zometa; The change of tumor size after SBRT will be compared between patients with and without Zometa; The change of max and average SUV after SBRT will be compared between patients with and without Zometa.; Tumor and organ motion	Chi Lin, MD, PhD; National Cancer Institute (NCI); University of Nebraska	All	19 Years and older   (Adult, Older Adult)	44	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	552-16; NCI-2016-01360; P30CA036727	16/09/2016	12/01/2024	12/01/2024			03/08/2017				25/01/2023	https://ClinicalTrials.gov/show/NCT03073785		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	United States	Urological	Prostate Cancer	Zoledronic Acid	Safety and/or Dose; OS; DFS/RFS/EFS; Biomarker; Other (specify)	Phase 2	DB00399	N
NCT04534218	Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer	REPROGRAM-01	Active, not recruiting	Colo-rectal Cancer|Metastatic Cancer	Drug: Regorafenib; Drug: Cyclophosphamide; Drug: Capecitabine; Drug: Aspirin	objective response rate	Centre Hospitalier Universitaire de Besancon; Bayer	All	18 Years and older   (Adult, Older Adult)	49	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020/490	16/10/2020	07/01/2023	01/01/2024			09/01/2020				02/10/2023	https://ClinicalTrials.gov/show/NCT04534218		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	France	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	Response rate	Phase 2	DB00945	N
NCT01787409	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency		Active, not recruiting	Aggressive Non-Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Mediastinal (Thymic) Large B-Cell Lymphoma|Nasal Type Extranodal NK/T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Primary Cutaneous Anaplastic Large Cell Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Small Lymphocytic Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma	Dietary Supplement: Cholecalciferol; Other: Laboratory Biomarker Analysis	Event free survival (EFS) (Study I); Treatment free status (Study II); Bio-R response rate (Study II); EFS time (Study I); OS (Study II); Overall response rate (Study II); Overall survival (OS) time (Study I); Time to first treatment (Study II)	Mayo Clinic; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	315	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LS1293; NCI-2013-00037; P50CA097274	03/06/2013	09/04/2023	09/04/2023			02/08/2013				18/01/2023	https://ClinicalTrials.gov/show/NCT01787409		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	Lymphoma	Any lymphoma	Cholecalciferol	DFS/RFS/EFS	Other	DB00169	N
NCT05381597	5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer		Recruiting	Superficial Basal Cell Carcinoma|Squamous Cell Carcinoma in Situ	Drug: Combination cream of 5-fluorouracil and calcipotriene; Drug: 5-fluorouracil cream	Clearance rate of cancer lesions at 3 months; Clearance rate of cancer lesions at 3 years; Percent of participants that experience pain during treatment; Severity of pain during treatment; Percent of participants that experience redness during treatment; Severity of redness during treatment; Day of worst redness; Percent of participants who experienced scaling/flaking; Percent of participants who experienced skin itching; Percent of participants who experienced skin burning; Participant compliance with treatment; Participant satisfaction with treatment; Recurrence rate of cancer lesions at 1 year; Recurrence rate of cancer lesions at 3 years	Boston University	All	18 Years and older   (Adult, Older Adult)	200	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	H-42421	15/10/2022	06/01/2025	06/01/2025			19/05/2022				14/11/2022	https://ClinicalTrials.gov/show/NCT05381597		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Skin	Basal Cell Carcinoma	Calcipotriol	Response rate	Phase 2/3	DB02300	N
NCT03520790	Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer		Active, not recruiting	Pancreatic Cancer	Drug: Gemcitabine; Drug: Nab-paclitaxel; Drug: Paricalcitol; Other: Placebo	Assess adverse events (per CTCAE v4.0 criteria); Overall survival; Response rate; Progression free survival	Dana-Farber Cancer Institute; Stand Up To Cancer; Lustgarten Foundation; American Association for Cancer Research	All	18 Years and older   (Adult, Older Adult)	112	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	18-021	12/05/2018	30/11/2023	30/11/2025			05/11/2018				01/11/2023	https://ClinicalTrials.gov/show/NCT03520790		Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	United States	GI	Pancreatic Cancer	Paricalcitol	Safety and/or Dose; Response rate; PFS; OS	Phase 1/2	DB00910	N
NCT05210374	Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas		Recruiting	Relapsed Sarcomas	Drug: Disulfiram; Drug: Copper Gluconate; Drug: Liposomal Doxorubicin (Doxil)	Safety as measured by percent of participants experiencing grade 3+ with at least possible attribution to study drug using CTCAE 5.0 guidelines; Recommended phase 2 dose (RP2D) of DSF/Cu in combination with liposomal doxorubicin; Number of participants able to take at least 80  of the drug doses during the first cycle of treatment; Number of dose-limiting toxicities (DLT); Number of participants who experienced drug-attributed grade 3+ Adverse events per CTCAE5.0; Percent of participants with tumor response evaluated using RECIST v1.1; Median Overall Survival (OS); Median Event free survival; Pharmacokinetics of DSF/Cu in combination with liposomal doxorubicin [Peak concentration (Cmax)]; Pharmacokinetics of DSF/Cu in combination with liposomal doxorubicin [area under the concentration-vs-time curve (AUC)]; Pharmacokinetics of DSF/Cu in combination with liposomal doxorubicin [clearance and average steady state concentrations for disulfiram and its active metabolites]	Case Comprehensive Cancer Center	All	1 Year and older   (Child, Adult, Older Adult)	24	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE1720	24/01/2023	10/01/2023	11/01/2023			27/01/2022				26/01/2023	https://ClinicalTrials.gov/show/NCT05210374		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Soft Tissue Sarcoma; Bone Sarcoma	Any Bone Sarcomas	Disulfiram	Safety and/or Dose	Phase 1	DB00822	N
NCT02068586	Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma		Active, not recruiting	Ciliary Body and Choroid Melanoma, Medium/Large Size|Ciliary Body and Choroid Melanoma, Small Size|Iris Melanoma|Stage I Intraocular Melanoma|Stage IIA Intraocular Melanoma|Stage IIB Intraocular Melanoma|Stage IIIA Intraocular Melanoma|Stage IIIB Intraocular Melanoma|Stage IIIC Intraocular Melanoma|Stage I Uveal Melanoma AJCC V7|Stage II Uveal Melanoma AJCC V7|Stage III Uveal Melanoma AJCC V7	Drug: Sunitinib; Drug: Valproic Acid; Drug: Sunitinib Malate; Drug: Sunitinib Malate + Valproic Acid	Overall survival (Cohort 1); Relapse-free survival (RFS) (Cohort 2 and 3); Relapse-free survival (Cohort 1); Overall survival (Cohort 2); Tolerability, defined as the proportion of patients able to complete 6 months of treatment, including those who underwent dose reduction; Incidence of toxicity assessed according to the National Institute of Health Common Terminology Criteria for Adverse Events (NIH CTCAE) version 4.0; Quality of life (QOL) assessed by Functional Assessment of Cancer Therapy-General (FACT-G) questionnaires	Sidney Kimmel Cancer Center at Thomas Jefferson University; Pfizer; National Cancer Institute (NCI); Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	210	Other; Industry; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13P.377; 2013-047; P30CA056036	19/11/2014	30/06/2023	30/06/2023			21/02/2014				02/06/2023	https://ClinicalTrials.gov/show/NCT02068586		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	United States	Skin	Other skin cancer	Valproic Acid	Safety and/or Dose; OS; DFS/RFS/EFS; QoL	Phase 2	DB00313	N
NCT05637567	Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head	ASAP	Not yet recruiting	Pancreatic Cancer Resectable	Drug: Acetylsalicylic acid; Drug: Placebo	Hematogenous metastases-free survival; Overall survival; Cancer-specific survival; Disease-free survival; Intraoperative blood loss; Duration of surgery; Perioperative surgical complications; Perioperative medical complications; R status; Number of resected lymph nodes	German Cancer Research Center	All	18 Years to 80 Years   (Adult, Older Adult)	458	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	DKFZ-2022-006	07/01/2023	06/01/2030	12/01/2030			12/05/2022				12/06/2022	https://ClinicalTrials.gov/show/NCT05637567	Perioperative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Germany	GI	Pancreatic Cancer	Acetylsalicylic Acid	OS; DFS/RFS/EFS; Other (specify)	Phase 3	DB00945	N
NCT05667415	Treatment of Advance Gastric Cancer With Disulfiram		Not yet recruiting	Chemotherapy Advanced Gastric Cancer Cisplatin Disulfiram	Drug: disulfiram and cisplatin; Drug: cisplatin	Complete response (CR); Partial response (PR); Stable disease (SD); Disease progression (PD)	First People's Hospital of Hangzhou; College of Pharmaceutical Sciences at Zhejiang University; The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University	All	18 Years and older   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20221212	06/01/2023	31/12/2025	30/06/2026			28/12/2022				28/12/2022	https://ClinicalTrials.gov/show/NCT05667415		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	GI	Gastric Cancer	Disulfiram	Response rate	Other	DB00822	N
NCT05694936	Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer		Recruiting	Metastatic Colorectal Cancer	Drug: Sodium Valproate; Drug: Panitumumab; Drug: Cetuximab	Progression free survival; Overall Survival; Objective response rates (ORRs); Quantification of the incidence of treatment-emergent adverse events according to CTCAE V5.0	Australasian Gastro-Intestinal Trials Group; Olivia Newton-John Cancer Research Institute	All	18 Years and older   (Adult, Older Adult)	90	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VADER	23/01/2023	09/01/2024	09/01/2024			23/01/2023				25/01/2023	https://ClinicalTrials.gov/show/NCT05694936		Advanced/Metastatic	Collaborative Group	Y	N	N	Australia	GI	Colon Cancer; Rectal Cancer	Valproic Acid	PFS	Phase 2	DB00313	N
NCT05036109	DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease		Recruiting	Colorectal Cancer|Colon Cancer	Drug: Aspirin; Drug: Vitamin D; Dietary Supplement: Diet; Other: Physical Activity; Behavioral: Behavioral Support Counseling Sessions	To estimate the ctDNA clearance rate of colorectal cancer patients with minimal residual disease	M.D. Anderson Cancer Center	All	18 Years and older   (Adult, Older Adult)	17	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2021-0320; NCI-2021-09193	10/12/2021	31/05/2023	31/05/2023			09/05/2021				04/12/2023	https://ClinicalTrials.gov/show/NCT05036109		Other (specify)	Hospital/University/Research Institute	N	N	N	United States	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid; Cholecalciferol	Biomarker	Phase 1	DB00945; DB00169	N
NCT03899987	Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery		Suspended	Prostate Adenocarcinoma|Stage I Prostate Cancer AJCC v8|Stage II Prostate Cancer AJCC v8|Stage IIA Prostate Cancer AJCC v8|Stage IIB Prostate Cancer AJCC v8|Stage IIC Prostate Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8	Drug: Aspirin; Procedure: Radical Prostatectomy; Biological: Recombinant Interferon Alfa-2b; Drug: Rintatolimod	Count of tumor infiltrating CD8+ lymphocytes; Pathologic response; Number of patients with Surgical margin positivity; PSA response; Incidence of treatment-related adverse events	Roswell Park Cancer Institute; AIM ImmunoTech Inc.	Male	18 Years and older   (Adult, Older Adult)	30	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 77318; NCI-2019-01192	29/11/2019	29/11/2023	29/11/2024			04/02/2019				15/05/2023	https://ClinicalTrials.gov/show/NCT03899987		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	United States	Urological	Prostate Cancer	Acetylsalicylic Acid	Safety and/or Dose; Response rate; Biomarker	Phase 2	DB00945	N
NCT05501548	Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer		Not yet recruiting	Prostate Cancer|Castration-resistant Prostate Cancer	Drug: Olaparib; Dietary Supplement: Vitamin C	PSA50 response; Safety and tolerability of olaparib in combination with IV ascorbic acid in patients with mCRPC; PSA doubling time in patients with mCRPC receiving olaparib in combination with IV ascorbic acid; Radiographic progression free survival (rPFS) of patients with mCRPC receiving olaparib in combination with IV ascorbic acid; PSA progression free survival (PSA PFS) of patients with mCRPC receiving olaparib in combination with IV ascorbic acid; Overall survival of patients with mCRPC receiving olaparib in combination with IV ascorbic acid	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; AstraZeneca; McGuff Pharmaceuticals, Inc.; The Marcus Foundation	Male	18 Years and older   (Adult, Older Adult)	15	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J21127; IRB00292465; ESR 19-20448	05/01/2023	03/01/2028	03/01/2028			15/08/2022				04/07/2023	https://ClinicalTrials.gov/show/NCT05501548		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Ascorbic acid	PFS; Biomarker	Phase 2	DB00126	N
NCT03541486	A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients	XACT-PANC-2	Not yet recruiting	Pancreatic Neoplasm	Drug: Ascorbate; Drug: Gemcitabine; Radiation: radiation therapy	Overall survival (OS); Progression free survival (PFS); Toxicity over time (ToxT); Metastasis free survival (MFS); Resection rate; Adverse event frequency and categorization; Patient reported outcome measure: Vaizey Incontinence questionnaire; Quality of life: Modified Inflammatory Bowel Disease questionnaire; Pathologic characteristics	Joseph J. Cullen, MD, FACS; Holden Comprehensive Cancer Center; University of Iowa	All	18 Years and older   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	XACT-PANC-2	31/12/2025	31/12/2029	31/12/2030			30/05/2018				17/02/2023	https://ClinicalTrials.gov/show/NCT03541486		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	United States	GI	Pancreatic Cancer	Ascorbic acid	PFS; OS; Recurrence rate	Phase 2	DB00126	N
NCT04634227	Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)		Recruiting	Sarcoma|Soft Tissue Sarcoma|Unresectable Soft Tissue Sarcoma|Metastatic Bone Tumor|Bone Sarcoma	Drug: Ascorbate	Determine the 12 weeks progression free survival (PFS 12) at 12 weeks post treatment initiation; Assess overall survival of patients with unresectable or metastatic soft tissue and bone sarcoma treated with high dose ascorbate when administered intravenously concurrently with gemcitabine; Determine the tumor response as per RECIST 1.1 criteria; Incidence of Adverse Events (AE) Per CTCAE 4.03	Varun Monga, MD; University of Iowa Adolescent and Young Adult (AYA) Cancer Program; St. Baldrick's Foundation; University of Iowa	All	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201802800 (Pilot)	24/11/2020	31/12/2023	31/12/2023			18/11/2020				16/02/2023	https://ClinicalTrials.gov/show/NCT04634227		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Soft Tissue Sarcoma; Bone Sarcoma	Any soft tissue sarcoma; Any Bone Sarcomas	Ascorbic acid	PFS	Phase 1	DB00126	N
NCT04687176	Frontline Oral Arsenic Trioxide for APL		Recruiting	Acute Promyelocytic Leukemia	Drug: Oral Arsenic Trioxide Formulation	Relapse-free survival (RFS); Event-free survival (EFS); Overall survival; Treatment toxicities	The University of Hong Kong	All	Child, Adult, Older Adult	100	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APL003	01/01/2021	31/12/2025	30/06/2026			29/12/2020				23/05/2023	https://ClinicalTrials.gov/show/NCT04687176		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Hong Kong	Leukemia	Leukemia - Other	Ascorbic acid	DFS/RFS/EFS	Phase 2	DB00126	N
NCT03418038	Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or Clonal Cytopenia of Undetermined Significance		Recruiting	Clonal Cytopenia of Undetermined Significance|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Lymphoma	Dietary Supplement: Ascorbic Acid; Drug: Carboplatin; Drug: Cisplatin; Drug: Cytarabine; Drug: Dexamethasone; Drug: Etoposide; Drug: Gemcitabine Hydrochloride; Drug: Ifosfamide; Other: Laboratory Biomarker Analysis; Drug: Oxaliplatin; Other: Placebo Administration; Other: Questionnaire Administration; Biological: Rituximab	Overall response rate (ORR) (Arms A and B); ORR (Arm C); Hematologic response (HI) rate (Arm D); Clinical benefit rate (Arms A, B, and C); Overall survival; Progression-free survival; Percent of transplant eligible patients proceeding to transplant (Arms A, B and C); Transfusion dependency (Arm D); Incidence of adverse events; Continued salvage therapy beyond cycle 2 (Arm A, B and C)	Mayo Clinic; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	55	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	LS1781; NCI-2018-00057; P30CA015083	23/03/2018	15/03/2024	15/03/2024			02/01/2018				05/03/2023	https://ClinicalTrials.gov/show/NCT03418038		Recurrent/Refractory	Hospital/University/Research Institute	Y	Y	N	United States	Lymphoma	Any lymphoma	Ascorbic acid	Response rate; PFS; OS	Phase 2	DB00126	N
NCT04094688	Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer	SOLARIS	Recruiting	Colorectal Adenocarcinoma	Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Leucovorin Calcium; Drug: Fluorouracil; Drug: Irinotecan Hydrochloride; Drug: Irinotecan; Dietary Supplement: Cholecalciferol; Other: Quality-of-Life Assessment; Other: Questionnaire Administration	Progression-free survival (PFS); Objective response; Overall survival (OS); Incidence of adverse events; Physical activity (PA) and progression-free survival (PFS); Incidence of vitamin D3 deficiency; 25(OH)D levels; Prognostic effect of highest achieved 25(OH)D	Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	400	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	A021703; NCI-2019-01034; U10CA180821	30/09/2019	01/01/2024	07/01/2024			19/09/2019				24/03/2023	https://ClinicalTrials.gov/show/NCT04094688	Palliative	Advanced/Metastatic	Collaborative Group	Y	N	N	United States	GI	Colon Cancer; Rectal Cancer	Cholecalciferol	PFS	Phase 3	DB00169	N
NCT03078855	A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma	ILyAD	Active, not recruiting	Follicular Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma|Mucosal-Associated Lymphoid Tissue Lymphoma	Dietary Supplement: Vitamin D; Biological: Rituximab; Other: Placebo	Time to progression or death; Time from randomization to death; Response to rituximab defined as reduction of lymphoma burden by at least 50 	Jonathan Friedberg; National Institutes of Health (NIH); National Cancer Institute (NCI); University of Rochester	All	18 Years and older   (Adult, Older Adult)	211	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	66593; R01CA214890	09/07/2017	09/01/2023	09/01/2023			13/03/2017				04/07/2023	https://ClinicalTrials.gov/show/NCT03078855	Adjuvant/Maintenance	Any/All Stages	Hospital/University/Research Institute	Y	N	N	United States	Lymphoma	Non-Hodgkin Lymphoma, Adult	Cholecalciferol	PFS	Phase 3	DB00169	N
NCT03467789	Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma		Active, not recruiting	Basal Cell Carcinoma|Basal Cell Nevus Syndrome	Drug: Dietary Vitamin D3 pre-treatment; Radiation: Photodynamic therapy; Drug: Serum Maintenance Vitamin D3	BCC: Rate of tumor clearance; BCC: Level of protoporphyrin IX (PpIX) accumulation in BCC lesions; Serum 25-hydroxy-vitamin D3 (25OH-D3) levels; Number of patients with active form of leukocyte DNA vitamin D Receptor (VDR); Pain scale measurement; Erythema score; Satisfaction with treatment outcome from the technique; Satisfaction with cosmetic outcome from the technique	Case Comprehensive Cancer Center	All	Child, Adult, Older Adult	37	Other	Interventional Study	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CASE5617	10/01/2018	06/01/2023	30/11/2023			16/03/2018				30/03/2023	https://ClinicalTrials.gov/show/NCT03467789		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Skin	Basal Cell Carcinoma	Calcipotriol; Calcitriol; Cholecalciferol; Paricalcitol	Response rate	Other	DB02300; DB00136; DB00169; DB00910	N
NCT02518555	Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma		Active, not recruiting	Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma	Biological: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed; Drug: Ibrutinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Biological: Pneumococcal 13-valent Conjugate Vaccine; Other: Quality-of-Life Assessment; Biological: Trivalent Influenza Vaccine	Proportion of patients who are alive and progression-free; Degree of response (CR MRD-,CR, PR, PR with lymphocytosis, and SD); Incidence of adverse events, evaluated using the NCI CTCAE version 4.0; Proportion of patients who achieve complete response; Time to next treatment; Time to treatment failure	Jennifer Woyach; Pharmacyclics LLC.; Ohio State University Comprehensive Cancer Center	All	18 Years and older   (Adult, Older Adult)	42	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSU-15012; NCI-2015-00932	01/12/2016	31/12/2023	31/12/2023			08/10/2015				04/03/2023	https://ClinicalTrials.gov/show/NCT02518555		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	United States	Leukemia; Lymphoma	Chronic Lymphocytic Leukemia; Lymphoma - Other	Diphtheria vaccine; Pertussis vaccine; Tetanus vaccine	Safety and/or Dose; Response rate; PFS	Phase 2	Not found in DrugBank; DB15274; Not found in DrugBank	N
NCT03323346	Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	DISC	Recruiting	Breast Neoplasm Female|Metastatic Breast Cancer	Drug: Disulfiram	Clinical response rate (RR); Clinical benefit rate (CBR); Time to progression (TTP); Overall survival (OS); The pharmacokinetic (PK) characteristics; The pharmacokinetic (PK) characteristic - Area Under Curve (AUC); The pharmacokinetic (PK) characteristic - T-max; The pharmacokinetic (PK) characteristic - T1/2; The pharmacokinetic (PK) characteristic -  z; Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	The Institute of Molecular and Translational Medicine, Czech Republic; University Hospital Olomouc	Female	18 Years and older   (Adult, Older Adult)	150	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-1-DSF-MBC	29/09/2017	31/12/2023	31/12/2023			27/10/2017				03/08/2023	https://ClinicalTrials.gov/show/NCT03323346		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Czech Republic	Breast	Any Breast Cancer	Disulfiram	Response rate	Phase 2	DB00822	N
NCT04301843	Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma		Recruiting	Neuroblastoma	Drug: Eflornithine	Number of participants with event free survival (EFS) during study; Length of time that participants experience Overall Survival (OS); Determine the Overall Response Rate (ORR) of Participants using INSS Response Evaluation Criteria.; Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Wake Forest University Health Sciences; K C Pharmaceuticals Inc.; Beat NB Cancer Foundation; Team Parker for Life	All	up to 31 Years   (Child, Adult)	131	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BCC015	25/09/2020	10/01/2025	10/01/2030			03/10/2020				05/08/2023	https://ClinicalTrials.gov/show/NCT04301843		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	Other	Neuroblastoma	Eflornithine	DFS/RFS/EFS	Phase 2	DB06243	N
NCT02395666	Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission		Active, not recruiting	Neuroblastoma	Drug: DFMO	Number of Participants With Event Free Survival (EFS) During Study.; Percentage of Participants With Overall Survival (OS); Number of Participants With Adverse Events as a Measure of Safety and Tolerability; Test the Association of Survival With ODC1 Genotype; Circulating Tumor Cell Analysis; Peak Plasma Concentration (Cmax); Area Under the Plasma Concentration Versus Time Curve (AUC); Time to Reach Peak Plasma Concentration (Tmax)	Wake Forest University Health Sciences; Beat NB Cancer Foundation; Because of Ezra; K C Pharmaceuticals Inc.	All	up to 21 Years   (Child, Adult)	140	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	NMTRC003B	03/05/2015	03/01/2018	30/04/2023			23/03/2015		04/03/2020		04/06/2023	https://ClinicalTrials.gov/show/NCT02395666		Localised/Locoregional	Hospital/University/Research Institute	N	N	Y	United States	Other	Neuroblastoma	Eflornithine	DFS/RFS/EFS	Phase 2	DB06243	N
NCT03794349	Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma		Recruiting	High Risk Neuroblastoma|Recurrent Neuroblastoma|Refractory Neuroblastoma	Biological: Dinutuximab; Drug: Eflornithine Hydrochloride; Drug: Irinotecan Hydrochloride; Biological: Sargramostim; Drug: Temozolomide	Response rate; Progression-free survival (PFS); Overall survival (OS); Incidence of adverse events >= Grade 3 (Regimen B)	Children's Oncology Group; National Cancer Institute (NCI)	All	1 Year and older   (Child, Adult, Older Adult)	95	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANBL1821; NCI-2018-03377; U10CA180886	28/05/2019	30/06/2024	30/06/2024			01/07/2019				23/05/2023	https://ClinicalTrials.gov/show/NCT03794349		Recurrent/Refractory	Collaborative Group	Y	N	Y	United States	Other	Neuroblastoma	Eflornithine	Response rate	Phase 2	DB06243	N
NCT05634707	Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)		Not yet recruiting	Primary Brain Tumor|Brain Tumor, Recurrent	Drug: Fluoxetine; Drug: Temozolomide	Change in LAMP1 expression in tumor samples obtained pre-resection via biopsy and during surgery; Proportion of patients with partial or complete response at the time of surgical resection; Serum levels of fluoxetine using LC-MS/MS quantification; Serum levels of norfluoxetine using LC-MS/MS quantification; Intra-tumoral levels of fluoxetine using LC-MS/MS quantification; Intra-tumoral levels of norfluoxetine using LC-MS/MS quantification	Duke University	All	24 Years and older   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00110628	15/05/2023	12/01/2023	06/01/2024			12/02/2022				04/12/2023	https://ClinicalTrials.gov/show/NCT05634707		Any/All Stages	Hospital/University/Research Institute	Y	N	N	United States	CNS	Glioma	Fluoxetine	Biomarker	Phase 1	DB00472	N
NCT02935205	Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer		Recruiting	Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer	Drug: Enzalutamide; Drug: Indomethacin	Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0; PSA response rate defined as >= 50  decrease from the baseline; Overall response determined by PCWG2 criteria; Overall survival; PFS	Mamta Parikh; National Cancer Institute (NCI); University of California, Davis	Male	19 Years and older   (Adult, Older Adult)	38	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	949968; UCDCC#267; P30CA093373; NCI-2016-01479	17/01/2017	07/01/2023	02/01/2024			17/10/2016				26/04/2023	https://ClinicalTrials.gov/show/NCT02935205		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Indomethacin	Safety and/or Dose; Biomarker	Phase 1/2	DB00328	N
NCT02429570	Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary		Active, not recruiting	Recurrent Brain Metastases|Progressive Brain Metastases	Drug: Meclofenamate	Feasible (if at least 50  of patients enrolled are evaluable in brain by MRI at the 2-month timepoint); Adverse events; Progression free survival	Memorial Sloan Kettering Cancer Center	All	18 Years to 80 Years   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-068	22/04/2015	04/01/2024	04/01/2024			29/04/2015				05/03/2023	https://ClinicalTrials.gov/show/NCT02429570		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	CNS	Other CNS	Meclofenamate	Other (specify)	Other	DB00939	N
NCT04844528	Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)		Recruiting	Chronic Lymphocytic Leukemia	Drug: Nicotinamide; Drug: Placebo	Proportion of CLL patients who develop a new NMSC after 1 year of nicotinamide therapy.; Number of new NMSC on skin exam after 1 year of treatment; proportion of CLL patients who develop squamous cell carcinoma (SCC) on skin exam after 1 and 2 years of treatment.; proportion of CLL patients who develop basal cell carcinoma (BCC) on skin exam after 1 and 2 years of treatment.; proportion of CLL patients who develop actinic keratosis (AK) on skin exam after 1 and 2 years of treatment.; number of new NMSC developed during year 1 and year 2 for patients who receive placebo during the first year; objective response rate (the proportion of subjects achieving a complete response [CR] or partial response [PR]) and complete response rate as calculated per International Workshop on CLL (IWCLL) 2018 Criteria at Month 6, 12, 18, and 24; objective response rate (the proportion of subjects achieving a CR or PR) and complete response rate as calculated per International Workshop on CLL (IWCLL) 2018 Criteria at Month 6, 12, 18, and 24; frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0 and iwCLL), seriousness, duration, and relationship to study treatment	University of Utah	All	18 Years and older   (Adult, Older Adult)	86	Other	Interventional Study	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	HCI141430	08/05/2021	08/01/2024	08/01/2026			14/04/2021				03/10/2023	https://ClinicalTrials.gov/show/NCT04844528		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Leukemia	Chronic Lymphocytic Leukemia	Nicotinamide	Recurrence rate	Phase 2	DB02701	N
NCT04677049	Study of Niacin in Glioblastoma		Recruiting	Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype	Drug: Niacin CRT	Determining the Maximum Tolerated Dose; Evaluating if Niacin CRT Improves Glioblastoma Survival Rates; Effect of Niacin CRT in Peripheral Monocytes; Response Rate Associated with Niacin; Overall Survival Rate Associated with Niacin; Quality of Life While on Study using EORTC QLQ-C30 Questionnaires; Quality of Life While on Study using EORTC BN-20 Questionnaires	AHS Cancer Control Alberta; Tom Baker Cancer Centre	All	18 Years to 75 Years   (Adult, Older Adult)	59	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NiacinCNS2020	18/03/2021	01/01/2026	01/01/2026			21/12/2020				23/03/2023	https://ClinicalTrials.gov/show/NCT04677049		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Canada	CNS	Glioblastoma	Nicotinamide	Safety and/or Dose; PFS	Phase 1/2	DB02701	N
NCT02295059	Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention		Active, not recruiting	Breast Cancer	Dietary Supplement: omega 3 fatty acids	Changes in eicosanoids/metabolites including PGE2, PGE3 in breast adipose tissue; Changes in cytomorphology and/or cell proliferation of mammary epithelial cells; Changes in DNA promoter methylation and pro-inflammatory gene expression in mammary epithelial and adipose tissue	City of Hope Medical Center; National Cancer Institute (NCI)	Female	18 Years and older   (Adult, Older Adult)	80	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	16421; 1R01CA164019-01A1	08/09/2017	30/12/2023	30/12/2023			20/11/2014				22/02/2023	https://ClinicalTrials.gov/show/NCT02295059		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	United States	Breast	Breast Cancer - ER/HR-	Omega 3	Biomarker	Other	DB13961	N
NCT03138720	Pre-operative Treatment for Patients With Untreated Pancreatic Cancer		Active, not recruiting	Resectable Pancreatic Cancer|Unresectable Pancreatic Cancer|Pancreatic Adenocarcinoma|Neoadjuvant Pancreatic Cancer	Drug: Paclitaxel Protein Bound (Abraxane)	CA19-9 value; Pathologic Complete Response Rate; Overall Survival	HonorHealth Research Institute	All	18 Years and older   (Adult, Older Adult)	24	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NABPLAGEM-NEO 2017-001	23/05/2017	31/12/2023	07/01/2024			05/03/2017				18/04/2023	https://ClinicalTrials.gov/show/NCT03138720		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Paricalcitol	Response rate; OS; Biomarker	Phase 2	DB00910	N
NCT03415854	Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)	NABPLAGEMD	Active, not recruiting	Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma|Pancreatic Adenocarcinoma|Pancreas Metastases|Adenocarcinoma	Drug: Paricalcitol (Zemplar)	Pathologic Complete Response Rate; Carbohydrate Antigen 19-9 (CA19-9) value; changes in circulating biomarkers induced by paricalcitol; changes in circulating biomarkers induced by chemotherapy; pharmacodynamics effect of Paricalcitol; Parathyroid Hormone (PTH); Vitamin D 25-hydroxy (OH)	HonorHealth Research Institute; Barts Cancer Institute; Abramson Cancer Center at Penn Medicine; Salk Institute for Biological Studies; Mayo Clinic; Princeton University; Imaging Endpoints; Translational Genomics Research Institute; Stand Up To Cancer; Cancer Research UK; Lustgarten Foundation; University of California, San Diego	All	18 Years and older   (Adult, Older Adult)	14	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SU2C HRI NPG-001	31/01/2018	31/12/2023	31/01/2024			30/01/2018				13/04/2023	https://ClinicalTrials.gov/show/NCT03415854		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Paricalcitol	Response rate; Biomarker	Phase 2	DB00910	N
NCT02754726	Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma		Active, not recruiting	Untreated Metastatic Pancreatic Ductal Adenocarcinoma	Drug: Nivolumab; Drug: Albumin-bound paclitaxel; Drug: Paricalcitol; Drug: Cisplatin; Drug: Gemcitabine	Complete response rate; Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	HonorHealth Research Institute; Translational Genomics Research Institute; Bristol-Myers Squibb; Lustgarten Foundation	All	18 Years and older   (Adult, Older Adult)	10	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NAPPCG-EB 2015-001	04/01/2016	30/06/2023	12/01/2023			28/04/2016				13/04/2023	https://ClinicalTrials.gov/show/NCT02754726		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Paricalcitol	Safety and/or Dose; Response rate	Phase 2	DB00910	N
NCT03746080	Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma		Recruiting	Glioblastoma|Glioblastoma With Primitive Neuronal Component|Gliosarcoma|Malignant Glioma|Oligodendroglial Component Present	Drug: Plerixafor; Drug: Temozolomide; Radiation: Whole-Brain Radiotherapy (WBRT); Radiation: Radiation Therapy	Progression-free survival (PFS) at six months; Median Survival; Toxicity associated with Plerixafor/WBRT; Patterns of treatment failure	Lawrence D Recht; Sanofi; Stanford University	All	18 Years to 75 Years   (Adult, Older Adult)	20	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-46410; NCI-2018-02159; BRN0037	12/04/2018	26/01/2024	07/01/2027			19/11/2018				14/04/2023	https://ClinicalTrials.gov/show/NCT03746080		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Plerixafor	Safety and/or Dose; PFS; OS	Phase 2	DB06809	N
NCT04310176	Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer	REVOLUTION	Recruiting	Ras-mutated Metastatic Colorectal Cancer	Drug: Bevacizumab; Drug: mFOLFOX6 regimen; Drug: mOXXEL regimen; Drug: Valproic acid; Drug: Capecitabine; Drug: 5-fluorouracil	progression-free survival (PFS); centrally reviewed PFS (CR-PFS); overall survival (OS); Determination of changes in quality of life; Response rate; Number of participants with treatment-related side effects; metastases resection rate (R0/R1/R2)	National Cancer Institute, Naples	All	18 Years and older   (Adult, Older Adult)	200	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	REVOLUTION; 2018-001414-15	24/05/2019	06/01/2023	11/01/2024			17/03/2020				27/03/2023	https://ClinicalTrials.gov/show/NCT04310176		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Italy	GI	Colon Cancer; Rectal Cancer	Valproic Acid	Safety and/or Dose; Response rate; PFS; OS; QoL	Phase 2	DB00313	N
NCT01898104	Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer	V-shoRT-R3	Recruiting	Colorectal Cancer	Radiation: preoperative radiation therapy; Drug: Valproic Acid; Drug: Capecitabine	maximum tolerated dose of capecitabine, given alone or in combination with valproic acid; number of patients with complete pathological tumor regression; overall survival; number of patients alive with disease progression; number of patients with pathologic complete response; changes in quality of life from baseline	National Cancer Institute, Naples	All	18 Years to 70 Years   (Adult, Older Adult)	152	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	V-shoRT-R3; 2012-002831-28	05/01/2012	11/01/2023	04/01/2024			07/12/2013				24/03/2023	https://ClinicalTrials.gov/show/NCT01898104		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	Italy	GI	Rectal Cancer	Valproic Acid	Safety and/or Dose; Response rate; PFS; OS	Phase 1/2	DB00313	N
NCT01953900	iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma	VEGAS	Active, not recruiting	Osteosarcoma|Neuroblastoma	Genetic: GD2 T cells; Biological: VZV vaccine; Drug: Fludarabine; Drug: Cyclophosphamide	Number of patients with dose limiting toxicity; Amount of T cells in the blood after the infusions; Number of patients with a response to the T cells	Baylor College of Medicine; National Cancer Institute (NCI); Center for Cell and Gene Therapy, Baylor College of Medicine; The Methodist Hospital Research Institute	All	Child, Adult, Older Adult	26	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H-32335 VEGAS; VEGAS; P01CA094237	04/01/2014	31/10/2019	31/10/2034			10/01/2013				30/03/2023	https://ClinicalTrials.gov/show/NCT01953900		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Other; Soft Tissue Sarcoma	Any soft tissue sarcoma	Varicella vaccine	Safety and/or Dose	Phase 1	Not found in DrugBank	N
NCT03664687	Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)	REaCT-ZOL	Active, not recruiting	Early-stage Breast Cancer	Drug: Zoledronate	Multiple Site Activation; Time to Activate Six Sites; Medical Oncologist Active Participation; Patient Enrollment; Bone-Metastasis-Free Survival; Time to first bone metastasis; Fragility fractures rates; Direct Estimation of Health Utility Values; Incremental Cost-Effectiveness Ratio	Ottawa Hospital Research Institute	All	18 Years and older   (Adult, Older Adult)	211	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OTT 18-01	31/10/2018	04/02/2020	12/01/2024			09/10/2018				05/11/2023	https://ClinicalTrials.gov/show/NCT03664687		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Canada	Breast	Any Breast Cancer	Zoledronic Acid	DFS/RFS/EFS; Other (specify)	Phase 4	DB00399	N
NCT03173976	Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial		Recruiting	Chondrosarcoma	Drug: Zoledronic Acid	Phase 1b cohort: Dose Limiting Toxicity - to examine the toxicity related to the therapy by measuring the number of treatment related adverse events in patients; Expansion cohort: Response Rate - Change at evaluations; Recurrence (local or metastatic) free survival; Overall survival	Varun Monga, MD; Rising Tide Foundation; University of Iowa	All	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201610743	18/07/2017	07/01/2023	07/01/2023			06/02/2017				16/02/2023	https://ClinicalTrials.gov/show/NCT03173976		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Bone Sarcoma	Chondrosarcoma	Zoledronic Acid	Safety and/or Dose; OS; DFS/RFS/EFS	Phase 1	DB00399	N
NCT02301286	A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients	ASPIRIN	Active, not recruiting	Colon Cancer|Adjuvant Therapy	Drug: Acetylsalicylic acid; Drug: Placebo Acetylsalicylic acid	5 year overall survival; Disease Free Survival; Time to Treatment Failure	Leiden University; Stichting voor Patienten met Kanker aan het Spijsverteringskanaal (SPKS); Dutch Colorectal Cancer Group; Stichting Geriatrische Oncologie Nederland (GeriOnNe); Fonds NutsOhra; Innovatiefonds Zorgverzekeraars; Leiden University Medical Center	All	45 Years and older   (Adult, Older Adult)	770	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	P14.152	01/01/2015	12/01/2023	12/01/2023			25/11/2014				13/03/2023	https://ClinicalTrials.gov/show/NCT02301286	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Netherlands	GI	Colon Cancer	Acetylsalicylic Acid	OS; DFS/RFS/EFS	Phase 3	DB00945	N
NCT03103152	A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression	PROVENT	Completed	Prostate Cancer	Drug: High dose Aspirin   Vitamin D; Drug: High dose Aspirin, Vitamin D placebo; Drug: Low dose Aspirin , Vitamin D; Drug: Low dose Aspirin, Vitamin D placebo; Drug: Aspirin Placebo, Vitamin D; Drug: Aspirin placebo, Vitamin D placebo	Rate of Patient Recruitment to a Randomised Chemoprevention Study in Men Enrolled on an Active Surveillance Programme for Prostate Cancer. Number Accrued Per Month.; Response to Treatment as Determined by Serial Multi-parametric Magnetic Resonance Imaging (MRI) of the Prostate. New Lesion Present or Existing Lesion + or - in Size.; Number of Participants With Biochemical (PSA) Disease Progression; Number of Participants With Histological Disease Progression; Number of Patients With Adverse With Toxicity, Allergy or Symptoms From Aspirin or Vitamin D	Queen Mary University of London; Barts and the London School of Medicine and Dentistry; Cancer Research UK	Male	16 Years to 100 Years   (Child, Adult, Older Adult)	104	Other	Interventional Study	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	isrctn91422391	12/01/2016	31/03/2020	31/03/2020			04/06/2017		29/03/2023		29/03/2023	https://ClinicalTrials.gov/show/NCT03103152		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United Kingdom	Urological	Prostate Cancer	Acetylsalicylic Acid; Cholecalciferol	Response rate; PFS; Other (specify)	Phase 2/3	DB00945; DB00169	N
NCT05080946	Using Aspirin to Improve Immunological Features of Ovarian Tumors		Recruiting	Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer	Drug: Aspirin 325mg; Drug: Placebo	Change in intratumoral density of immunosuppressive T-regulatory (FOXP3+) cells from diagnostic biopsy to interval debulking surgery; Change in intratumoral density of M2 tumor-associated macrophages (CD163+ cells) from diagnostic biopsy to interval debulking surgery; Change in density of tumor COX1; Change in density of tumor COX2; Change in blood levels of IL-6; Change in blood levels of p-selectin; Change in blood levels of CA 125; Change in tumor burden as defined by RECIST 1.1	H. Lee Moffitt Cancer Center and Research Institute; United States Department of Defense; Sharp Clinical Services, Inc	Female	18 Years and older   (Adult, Older Adult)	100	Other; U.S. Fed	Interventional Study	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	MCC-20870; E01775.1a	11/02/2021	03/01/2025	03/01/2025			18/10/2021				04/12/2023	https://ClinicalTrials.gov/show/NCT05080946		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Gynaecological	Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Ovarian Germ Cell Tumor; Ovarian - Other	Acetylsalicylic Acid	Biomarker	Phase 1	DB00945	N
NCT05462613	Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer	REPROGRAM-02	Recruiting	Metastatic Colorectal Cancer	Other: quality of life questionnaires; Procedure: Blood sample; Drug: Regorafenib; Drug: Metronomic chemotherapies; Drug: Aspirin; Drug: Bevacizumab; Drug: FOLFIRI or FOLFOX	best objective response during treatment period (phase II); overall survival (OS) (phase III)	Centre Hospitalier Universitaire de Besancon	All	18 Years and older   (Adult, Older Adult)	446	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2022/702	05/09/2023	11/01/2029	11/01/2030			18/07/2022				26/05/2023	https://ClinicalTrials.gov/show/NCT05462613		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	France	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	Response rate; OS	Phase 2/3	DB00945	N
NCT04900792	A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma	XACT-Fe-GBM-01	Suspended	Glioblastoma|Glioblastoma Multiforme	Drug: Ferumoxytol injection; Drug: Pharmacological ascorbate; Radiation: External beam radiation therapy; Drug: Temozolomide	Determination of recommended phase 2 ferumoxytol dosing regimen; Estimate progression free survival (PFS); Estimate overall survival (OS); Estimate Objective Response Rate (ORR); Tumor size; Clinical response; Number of Treatment-Related Adverse Events	Bryan Allen; Holden Comprehensive Cancer Center; National Cancer Institute (NCI); University of Iowa	All	18 Years and older   (Adult, Older Adult)	12	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202103125	28/02/2023	30/06/2024	31/12/2025			25/05/2021				20/04/2023	https://ClinicalTrials.gov/show/NCT04900792		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	CNS	DIPG/DMG; Glioblastoma	Ascorbic acid	Safety and/or Dose; PFS; OS	Phase 1	DB00126	N
NCT03299309	PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma	PRiME	Active, not recruiting	Recurrent Medulloblastoma|Recurrent Brain Tumor, Childhood|Malignant Glioma	Drug: PEP-CMV	Proportion of patients with unacceptable toxicity; Mean or median change from baseline at each follow-up assessment in ELISPOT (IFN- ); Mean or median change from baseline at each follow-up assessment in ELISA (gB-KLH)	Daniel Landi; Pediatric Brain Tumor Foundation; Annias Immunotherapeutics, Inc.; Duke University	All	3 Years to 35 Years   (Child, Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00079843	29/06/2018	27/04/2023	04/01/2025			10/03/2017				18/05/2023	https://ClinicalTrials.gov/show/NCT03299309		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	CNS	Medulloblastoma; Glioma	Diphtheria vaccine; Tetanus vaccine	Safety and/or Dose	Phase 1	Not found in DrugBank; Not found in DrugBank	N
NCT05096481	PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma		Not yet recruiting	High Grade Glioma|Diffuse Intrinsic Pontine Glioma|Recurrent Medulloblastoma	Biological: PEP-CMV; Drug: Temozolomide; Biological: Tetanus Diphtheria Vaccine	4-mo PFS in patients with recurrent medulloblastoma; 1-yr OS in patients with newly diagnosed DIPG; 1-yr PFS in patients with newly diagnosed HGG; ORR in patients with recurrent medulloblastoma; PFS in patients with recurrent medulloblastoma; OS in patients with newly diagnosed HGG by PEP-CMV	Nationwide Children's Hospital	All	3 Years to 25 Years   (Child, Adult)	120	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CONNECT1906; R01FD007283	15/05/2023	15/05/2027	15/05/2029			27/10/2021				21/02/2023	https://ClinicalTrials.gov/show/NCT05096481		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	CNS	DIPG/DMG; Medulloblastoma; Glioblastoma	Diphtheria vaccine; Tetanus vaccine	Response rate; PFS; OS	Phase 2	Not found in DrugBank; Not found in DrugBank	N
NCT03688178	DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab	DERIVe	Recruiting	Glioblastoma	Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs; Drug: Temozolomide; Biological: Varlilumab; Biological: Td; Biological: Unpulsed DCs	Median Overall Survival (OS) of Subjects Receiving Td pre-conditioning; Safety of administering Varlilumab to GBM patients receiving temozolomide and dendritic cell vaccines   Td pre-conditioning as measured by the percentage of patients with unacceptable toxicity regardless of attribution; Median percent change between baseline, assessed on day 14, and nadir levels of Treg before the time that the second cycle of adjuvant TMZ would be administered. Treg determined by flow cytometry (CD3+ CD4+ CD25+ Foxp3+).; Median Overall Survival (OS) of Subjects Receiving DC vaccines, varlilumab, and Td pre-conditioning; Median Progression-free Survival (PFS); Median Chemokine (C-C motif) ligand 3 (CCL3) Levels in Serum at 24, 48, and 72 hours after Pre-conditioning	Annick Desjardins, MD; Celldex Therapeutics; Duke University	All	18 Years and older   (Adult, Older Adult)	80	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Pro00082570	26/08/2020	03/01/2025	03/01/2025			28/09/2018				03/02/2023	https://ClinicalTrials.gov/show/NCT03688178		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	United States	CNS	Glioblastoma	Diphtheria vaccine; Tetanus vaccine	Safety and/or Dose; OS	Phase 2	Not found in DrugBank; Not found in DrugBank	N
NCT05500508	Oral AMXT 1501 Dicaprate in Combination With IV DFMO		Recruiting	Cancer|Solid Tumor|Solid Carcinoma|Advanced Cancer|DIPG Brain Tumor|Ovary Cancer|Breast Cancer|Papillary Thyroid Cancer|Head and Neck Cancer|Gastric Cancer|Nsclc|Mesotheliomas Pleural|Mesothelioma Peritoneum|Esophageal Cancer|Diffuse Midline Glioma, H3 K27M-Mutant|Endometrial Cancer|Cervical Cancer|Melanoma|Colorectal Cancer|Glioma, Malignant	Drug: AMXT1501; Drug: DFMO	Determine DLTs and RP2Ds in AMXT 1501 in combination with IV DFMO; Determine safety and tolerability of AMXT1501 in combination with IV DFMO; Determine the PK using AUC of AMXT 1501 and IV DFMO; Determine the PK using Cmax of AMXT 1501 and IV DFMO; Characterize investigator defined response Overall Response Rate (ORR) using RECIST v1.1; Characterize investigator defined Duration of Response (DOR); Characterize AMXT1501 and IV DFMO on the expression of immune related gene signatures	Aminex Therapeutics, Inc.	All	12 Years and older   (Child, Adult, Older Adult)	56	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AMXT1501-102	29/11/2022	30/12/2023	31/03/2024			15/08/2022				25/05/2023	https://ClinicalTrials.gov/show/NCT05500508		Advanced/Metastatic; Recurrent/Refractory	Company	N	N	Y	United States	Multiple cancer types	Any solid tumours	Eflornithine	Safety and/or Dose	Phase 1/2	DB06243	N
NCT05717153	Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma		Recruiting	Diffuse Glioma|Malignant Glioma	Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Eflornithine; Procedure: Magnetic Resonance Imaging; Drug: Polyamine Transport Inhibitor AMXT-1501 Dicaprate; Procedure: Resection; Device: Post-operative Microdialysis	Change in the tumor/brain extracellular guanidinoacetate ratio; Measured extracellular levels of glutamate in tumor and brain microdialysates; Proportion of longitudinal microdialysis aliquots containing > 30 uL of microdialysate; Central nervous system free drug levels from microdialysate; AMXT1501 brain/plasma ratio over time; Incidence of adverse events	Mayo Clinic; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	15	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	22-005690; NCI-2022-10375; P30CA015083	03/01/2023	15/01/2025	15/01/2026			02/08/2023				03/03/2023	https://ClinicalTrials.gov/show/NCT05717153		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	CNS	Glioma; DIPG/DMG	Eflornithine	Safety and/or Dose; Biomarker	Phase 1	DB06243	N
NCT04432597	HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers		Active, not recruiting	HPV Positive Cancer|Vulvar, Vaginal, Penile, Rectal Cancer|Anal Cancer|Oropharyngeal Cancer|Cervical Cancer	Biological: PRGN-2009; Biological: M7824	Safety and recommended phase II dose of PRGN-2009; Level increase in CD3+ tumor infiltrating T cells post-treatment compared to pre-treatment; ratio of participants that are hospitalized because of adverse events attributed to disease progression; 3-year overall and relapse-free survival rate for PRGN-2009 alone; overall survival (OS); progression-free survival time (PFS); duration of response; assess the safety of the recommended phase II dose (RP2D) of PRGN-2009 (HPV vaccine) alone; does the use of PRGN-2009 alone result in significantly prolonged survival; overall response rate (ORR)	National Cancer Institute (NCI); National Institutes of Health Clinical Center (CC)	All	18 Years and older   (Adult, Older Adult)	20	NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	200104; 20-C-0104	08/11/2020	22/11/2022	10/01/2023			16/06/2020				25/04/2023	https://ClinicalTrials.gov/show/NCT04432597		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types	Other multiple cancer group (specify)	HPV vaccine	Safety and/or Dose; PFS; OS; Biomarker	Phase 1/2	Not found in DrugBank	N
NCT03253289	Meclizine for Hepatocellular Carcinoma	OPTIM	Active, not recruiting	Carcinoma, Hepatocellular	Drug: Meclizine Oral Tablet	Change in mRNA levels; Change in Ki-67 proliferation index; change in apoptosis by TUNEL assay; Tumor response; Change in Serum AFP; Change in growth differentiation factor (GDF-15); A panel of CAR downstream target genes	Tannaz Armaghnay; Baylor College of Medicine	All	18 Years and older   (Adult, Older Adult)	13	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H-40370	13/10/2017	12/01/2023	12/01/2026			17/08/2017				04/06/2023	https://ClinicalTrials.gov/show/NCT03253289		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Liver Cancer	Meclizine	Safety and/or Dose	Phase 1	DB00737	N
NCT05607407	Methimazole in Patients With Progressive Glioblastoma		Recruiting	Glioblastoma|Glioma	Drug: Methimazole; Procedure: Recurrent Glioblastoma Surgical Resection; Diagnostic Test: Pharmacodynamic Assays	Progression Free Survival (PFS) Rate	Case Comprehensive Cancer Center	All	18 Years and older   (Adult, Older Adult)	19	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE3322	30/04/2023	01/01/2025	01/01/2026			11/07/2022				04/06/2023	https://ClinicalTrials.gov/show/NCT05607407		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Methimazole	PFS	Phase 2	DB00763	N
NCT03942328	Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer		Recruiting	Stage III Hepatocellular Carcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Unresectable Hepatocellular Carcinoma|Unresectable Intrahepatic Cholangiocarcinoma	Biological: Atezolizumab; Biological: Bevacizumab; Radiation: External Beam Radiation Therapy; Procedure: Pheresis; Biological: Pneumococcal 13-valent Conjugate Vaccine; Biological: Therapeutic Autologous Dendritic Cells	Incidence of significant toxicity (Pilot study); Progression-free survival rate at 2 years (Phase II); Overall response rate; Number of patients who received at least one dose of intratumoral DC injection; Clinical benefit rate; Time to response; Duration of response; Overall survival; Progression-free survival	Mayo Clinic; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	54	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1641; NCI-2019-02452; P30CA015083; R01CA274985	06/11/2019	31/12/2026	31/12/2026			05/08/2019				19/05/2023	https://ClinicalTrials.gov/show/NCT03942328		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Liver Cancer	Pneumococcal vaccine	Safety and/or Dose; Response rate; PFS; OS	Phase 1	Not found in DrugBank	N
NCT05400603	Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma	Aflac-NBL-2002	Recruiting	Neuroblastoma|Refractory Neuroblastoma|Relapsed Neuroblastoma	Combination Product: Ex Vivo Expanded Allogeneic    T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate	Maximum Tolerated Dose/Recommended Phase 2 Dose of gamma delta T cells; Describe Non-Hematological Toxicities; Describe Hematological Toxicities; Overall Response	Emory University	All	12 Months to 16 Years   (Child)	24	Other	Interventional Study	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00003123	05/01/2023	12/01/2025	12/01/2025			06/01/2022				27/04/2023	https://ClinicalTrials.gov/show/NCT05400603		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Other	Neuroblastoma	Zoledronic Acid	Safety and/or Dose	Phase 1	DB00399	N
NCT05865548	Addition of Aspirin to Standard of Care in Oral Cancer		Recruiting	Oral Cancer	Drug: Aspirin 150 mg; Procedure: Standard of care	Adverse events; Disease free survival; Overall survival	Banaras Hindu University	All	18 Years to 99 Years   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HNC02	17/05/2023	30/09/2024	30/09/2024			19/05/2023				24/05/2023	https://ClinicalTrials.gov/show/NCT05865548		Any/All Stages	Hospital/University/Research Institute	Y	N	N	India	Head and Neck	Any head and neck cancer	Acetylsalicylic Acid	Safety and/or Dose	Phase 2/3	DB00945	N
NCT05849129	Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer	AIVAA	Not yet recruiting	Lung Cancer	Drug: Ascorbic acid; Other: Normal Saline	Change in Quality of Life; Chemotherapy-Related Toxicities; Frequency of Discontinuation of Chemotherapy; Change in General Symptom Burden; Change in C-Reactive Protein Levels; Tumour Progression; Survival; Safety; Cytotoxicity	The Canadian College of Naturopathic Medicine; Ottawa Hospital Research Institiute	All	18 Years and older   (Adult, Older Adult)	90	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	20220721-01H	07/01/2023	07/01/2029	07/01/2030			05/08/2023				05/10/2023	https://ClinicalTrials.gov/show/NCT05849129		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Canada	Lung	Non-Small Cell Lung Cancer	Ascorbic acid	QoL	Phase 2	DB00126	N
NCT05846880	VitD3 Supplementation in Patients With Multiple Myeloma		Not yet recruiting	Multiple Myeloma	Drug: Lenalidomide; Drug: Vitamin D - Intensified; Drug: Vitamin D - Therapeutic	To describe the lymphocyte subset analysis for the two treatment arms at 120 days post autologous stem cell transplant [120 days]; To report the 3-year progression-free survival for both treatment arms - intensified vs. therapeutic Vitamin D supplementation; To report the overall response rate for both treatment arms 120 days after ASCT for adult patients with multiple myeloma.; To report the overall response rate for both treatment arms 2 years after transplantation; To report the 3-year overall survival for the two treatment arms after transplantation.; To report the minimal residual disease status for the two treatment arms at randomization, and within 120 days after transplantation and 2 years after transplantation.; To report the vitamin D levels between the two treatments arms before autologous stem cell transplant, within 120 days, and 3-years post-transplantation; To describe the adverse events for the two treatment arms; To report time to neutrophil and platelet engraftment as well as transfusion independence after transplantation in both treatment arms	Amany Keruakous, MD, MS.; Augusta University	All	18 Years and older   (Adult, Older Adult)	100	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCC-22-044	05/01/2023	05/01/2028	05/01/2028			05/06/2023				05/06/2023	https://ClinicalTrials.gov/show/NCT05846880		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Other Haem-onc	Multiple Myeloma	Cholecalciferol	Other (specify)	Phase 1	DB00169	N
NCT05879367	Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma		Recruiting	Glioblastoma, IDH-wildtype|Glioblastoma|Glioblastoma Multiforme|Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype|GBM	Drug: Eflornithine (Dose Level 1); Drug: Eflornithine (Dose Level 2); Drug: Eflornithine (Dose Level -1); Drug: Temozolomide	Assessment of Dose Limiting Toxicities; Incidence of TEAEs; Vital Signs (Heart and Respiratory Rate); Vital Signs (Blood Pressure); Incidence of Treatment-Emergent Abnormalities in Clinical Laboratory Tests; Progression Free Survival; Overall Response Rate; Pharmacokinetics Cmax; Pharmacokinetics Cmin; Pharmacokinetics Tmax; Pharmacokinetics AUCt; Pharmacokinetics lambdaz; Pharmacokinetics t 1/2	Orbus Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	60	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OT-21-101	26/05/2023	15/12/2024	15/12/2024			29/05/2023				29/05/2023	https://ClinicalTrials.gov/show/NCT05879367		Localised/Locoregional	Company	N	Y	N	United States	CNS	Glioblastoma	Eflornithine	Safety and/or Dose	Phase 1	DB06243	N
NCT05799144	pBI-11   TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS 1, hrHPV+ Oropharyngeal Cancer		Recruiting	Metastatic Oropharyngeal Carcinoma|Recurrent Oropharyngeal Carcinoma	Biological: DNA Vaccine; Biological: Human Papillomavirus Tumor Antigen Vaccine; Biological: Pembrolizumab; Procedure: Computed Tomography (CT); Procedure: Magnetic Resonance Imaging (MRI); Procedure: Magnetic Resonance Imaging; Procedure: Biopsy	Objective response rate (ORR); Disease control rate (DCR); Progression-free survival (PFS); Overall survival (OS)	Michael K. Gibson; Vanderbilt-Ingram Cancer Center	All	18 Years and older   (Adult, Older Adult)	54	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VICCHN2208; NCI-2023-02083	31/05/2023	30/04/2027	30/04/2028			04/05/2023				05/10/2023	https://ClinicalTrials.gov/show/NCT05799144		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Head and Neck	Oropharyngeal Cancer	HPV vaccine	Response rate	Phase 2	Not found in DrugBank	N
NCT05866172	HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC		Recruiting	Hepatocellular Carcinoma	Procedure: HAIC; Drug: Zoledronic acid	overall survival; Progression Free Survival (PFS); Objective Response Rate (ORR); Adverse Events	Sun Yat-sen University	All	18 Years to 75 Years   (Adult, Older Adult)	264	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	S-069	05/10/2023	12/01/2024	06/01/2025			19/05/2023				19/05/2023	https://ClinicalTrials.gov/show/NCT05866172	Adjuvant/Maintenance	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	GI	Liver Cancer	Zoledronic Acid	OS	Phase 3	DB00399	N
NCT00885326	N2007-02:Bevacizumab,Cyclophosphamide,  Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma		Completed	Neuroblastoma	Drug: Bevacizumab; Drug: cyclophosphamide; Drug: zoledronic acid	Determination of toxicities and feasibility of the combination of bolus plus metronomic cyclophosphamide and zoledronic acid with and without bevacizumab when given to children with refractory or recurrent high risk neuroblastoma.; Evaluation of response within the confines of a phase I study.; Analysis of Circulating Endothelial Cells, Circulating Factors, Gene expression and Bone Metabolism Studies.	New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)	All	up to 30 Years   (Child, Adult)	29	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000638257; P01CA081403	12/01/2009	04/01/2014	12/01/2019			21/04/2009				04/10/2023	https://ClinicalTrials.gov/show/NCT00885326		Recurrent/Refractory	Collaborative Group	N	N	N	United States	Other	Neuroblastoma	Zoledronic Acid	Safety and/or Dose	Phase 1	DB00399	N
NCT05833594	Whole-course Immunonutrition Combined With Chemoradiotherapy ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma		Not yet recruiting	Esophageal Squamous Cell Carcinoma|Chemoradiotherapy|Immunonutrition|Inoperable	Dietary Supplement: Whole-course Immunonutrition Combined With Chemoradiotherapy ICIs	Rate of adverse events; Disease Control Rate; 1-, 2-, 3-year Progression-free survival rate (PFS).	Anhui Provincial Hospital	All	18 Years to 85 Years   (Adult, Older Adult)	70	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2023WCIN001	07/01/2023	01/01/2026	12/01/2026			27/04/2023				27/04/2023	https://ClinicalTrials.gov/show/NCT05833594		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Head and Neck	Throat Cancer	L-Glutamine; Omega 3	Safety and/or Dose; Other (specify)	Phase 2	DB00130; DB13961	N
NCT05487859	Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)		Not yet recruiting	Kidney Cancer	Drug: Acarbose Tablets	To assess the safety profile of acarbose in addition to standard of care (SOC) treatment in RCC; To assess the effect of acarbose on the gut microbiome in patients receiving as standard of care therapy.; To assess the efficacy of Acarbose in combination with SOC treatment in RCC	University of Alabama at Birmingham	All	18 Years and older   (Adult, Older Adult)	24	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UAB22115	11/01/2023	07/01/2025	12/01/2026			08/04/2022				24/04/2023	https://ClinicalTrials.gov/show/NCT05487859		Advanced/Metastatic	Other	N	N	N	United States	Urological	Renal Cell Carcinoma	Acarbose	Safety and/or Dose; Biomarker	Phase 2	DB00284	N
NCT03467360	Inhibition of CArbonic Anhydrase in Combination With Platinum and Etoposide-based Radiochemotherapy in Patients With Localized Small Cell Lung Cancer	ICAR	Recruiting	Small Cell Lung Cancer	Drug: acetazolamide in combination with platinum and etoposide-based radiochemotherapy	To identify the Tolerated Maximum Dose (DMT) and Recommended Dose (DR) of acetazolamide in combination with radiotherapy combined with platinum and etoposide chemotherapy; To determine the overall tolerance of the association acetazolamide and radiochemotherapy; To evaluate the effectiveness of the treatment; To identify predictive factors for response to acetazolamide; To evaluate progression-free survival at 24 months; To evaluate overall survival at 24 months; To determine the compliance of acetazolamide; To evaluate the quality of life	Centre Antoine Lacassagne	All	18 Years and older   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017/14	08/02/2019	30/11/2023	30/11/2024			16/03/2018				20/01/2023	https://ClinicalTrials.gov/show/NCT03467360		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	France	Lung	Small Cell Lung Cancer	Acetazolamide	Safety and/or Dose	Phase 1	DB00819	N
NCT05470283	Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma		Recruiting	Tumor|Metastatic Melanoma|Melanoma	Drug: OBX-115; Drug: Acetazolamide; Drug: Cyclophosphamide; Drug: Furosemide; Drug: Mesna; Drug: Fludarabine Phosphate	Incidence and nature of dose-limiting toxicities (DLTs) during the first 28 days after OBX-115 + acetazolamide administration as assessed by CTCAE version 5.0. Incidence and severity of AEs and SAEs after OBX-115 + acetazolamide administration.	M.D. Anderson Cancer Center	All	18 Years and older   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2022-0356; NCI-2022-06873	09/07/2022	04/01/2027	04/01/2027			22/07/2022				16/10/2023	https://ClinicalTrials.gov/show/NCT05470283		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Skin	Melanoma	Acetazolamide	Safety and/or Dose	Phase 1	DB00819	N
NCT03011671	Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma		Recruiting	Malignant Glioma of Brain	Drug: Acetazolamide; Drug: Temozolomide	Number of participants with adverse events; Measure objective response rate (ORR); change in tumor size; Time until progression free survival (PFS); Time until overall survival (OS); Analysis of formalin fixed paraffin embedded surgical specimens.; To determine feasibility of cooperative interaction between multiple sites	University of Chicago	All	18 Years and older   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB16-0767	10/03/2018	10/01/2026	10/01/2026			01/05/2017				03/06/2023	https://ClinicalTrials.gov/show/NCT03011671		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioma	Acetazolamide	Safety and/or Dose; Response rate; PFS; OS	Phase 1	DB00819	N
NCT02366884	Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)		Recruiting	Neoplasms	Drug: Anti-Bacterial Agents; Drug: Anti-Fungal Agents; Drug: Anti-Protozoal Agents	Clinical efficacy as measured by the number of participants with an objective clinical tumor regression response; Clinical safety as measured by the incidence of adverse events in each intervention group	Dr. Frank Arguello Cancer Clinic; Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia.com	All	1 Year to 75 Years   (Child, Adult, Older Adult)	250	Industry; Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	ACI/2015	26/07/2011	31/12/2022	31/12/2023			19/02/2015				04/06/2022	https://ClinicalTrials.gov/show/NCT02366884		Any/All Stages	Other	N	N	N	Mexico	Multiple cancer types	Multiple cancer types	Albendazole; Chloroquine; Clarithromycin; Clotrimazole; Dapsone; Doxycycline; Itraconazole; Ivermectin; Levamisole; Mebendazole; Metronidazole; Miconazole; Miltefosine; Nitazoxanide; Terbinafine	Safety and/or Dose; Response rate	Phase 2	DB00518; DB00608; DB01211; DB00257; DB00250; DB00254; DB01167; DB00602; DB00848; DB00643; DB00916; DB01110; DB09031; DB00507; DB00857	N
NCT05049863	Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)		Recruiting	Small-cell Lung Cancer|Small Cell Lung Carcinoma	Drug: Mycophenolate Mofetil; Drug: Allopurinol; Drug: Irinotecan	Number of study treatment related adverse events as measured by NCI-CTCAE v 5.0 (Phase I only); Overall response rate (ORR) (Phase II and phase I patients who receive the MTD); Recommended phase II dose (RP2D) (Phase I only); Number of discontinuations due to treatment related adverse events (Phase I only); Number of DLTs in Phase I patients; Progression-free survival (PFS) (Phase II and phase I patients who receive the MTD); Overall survival (OS) (Phase II and phase I patients who receive the MTD)	Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)	36	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202301066	27/02/2023	30/04/2025	31/10/2025			20/09/2021				22/11/2023	https://ClinicalTrials.gov/show/NCT05049863		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Lung	Small Cell Lung Cancer	Allopurinol; Mycophenolate	Safety and/or Dose; Response rate; PFS; OS	Phase 1/2	DB00437; DB01024	N
NCT04942626	Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients	ACO/ARO/AIO-21	Active, not recruiting	Rectal Cancer	Drug: Kineret 100 MG in 0.67 ML Prefilled Syringe; Drug: Capecitabine; Radiation: Radiotherapy; Procedure: Watch and Wait (cCR) or TME surgery (non-cCR)	Analysis of safety for capecitabine administered concomitantly with standard radiotherapy in combination with Anakinra at a fixed dose of 100 mg s.c.; Identification of the maximum tolerated dose for capecitabine administered concomitantly with standard radiotherapy in combination with Anakinra at a fixed dose of 100 mg s.c; Postoperative complications of (salvage) surgery; Late toxicity assessment according to NCI CTCAE V.5.0; Rate of W W with or without local regrowth; Cumulative incidence of locoregional regrowth after cCR; Rate of salvage surgery (LE/TME with or without APR/stoma) after locoregional regrowth; Cumulative incidence of local recurrence after (salvage) surgery; Cumulative incidence of distant recurrences; Disease-free survival; Overall survival; Pathological TNM-staging; R0 resection rate;; negative circumferential resection rate; Tumor regression grading according to Dworak; Quality of TME according to MERCURY; Quality of life based on treatment arm and surgical procedures/organ preservation; functional outcome based on treatment arm and surgical procedures/organ preservation	Goethe University	All	18 Years to 99 Years   (Adult, Older Adult)	12	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACO/ARO/AIO-21	20/08/2021	31/12/2024	31/12/2025			28/06/2021				12/04/2023	https://ClinicalTrials.gov/show/NCT04942626		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Germany	GI	Rectal Cancer	Anakinra	Safety and/or Dose; Response rate; PFS; DFS/RFS/EFS	Phase 1	DB00026	N
NCT04926467	Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)		Not yet recruiting	Pancreatic Adenocarcinoma	Drug: Anakinra	To determine the percentage of patients that have a normalization of CA19-9 after pre-op treatment with the combination of nab-paclitaxel (abraxane), gemcitabine, cisplatin and anakinra.; To determine the effect of anakinra in combination with perioperative chemotherapy on overall survival (OS) of PDAC patients. A benchmark of 24 months OS will be used to determine how many patients meet or exceed this goal.; To determine the effect of anakinra in combination with perioperative chemotherapy on the median disease free survival (DFS). A benchmark of 12 months DFS will be used to determine how many patients meet or exceed this goal.; To determine the effect of anakinra in combination with perioperative chemotherapy on response rate; To determine the R0 resection rates (complete tumor removal with negative resection margins) obtained with anakinra + pre-operative chemotherapy.; To describe the effect of anakinra in combination with perioperative chemotherapy on the prevalence and severity of pain by monitoring patients' pain level using memorial pain assessment card (MPAC).; To determine the effect of anakinra in combination with perioperative chemotherapy on patients' health-related quality of life by monitoring patients using EORTC quality of life survey questionnaire (EORTC QLQ-C30).; To determine the effect of anakinra in combination with perioperative chemotherapy on the inflammasomes ( IL6, CRP, IL1  and IL1 ) in blood and in the resected pathology specimens.	Baylor Research Institute	All	18 Years and older   (Adult, Older Adult)	24	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	020-476	06/01/2021	06/01/2025	06/01/2026			15/06/2021				15/06/2021	https://ClinicalTrials.gov/show/NCT04926467		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Anakinra	PFS; OS; DFS/RFS/EFS	Phase 2	DB00026	N
NCT04691765	Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients	Anakinra	Unknown status	Chronic Lymphocytic Leukemia	Drug: Kineret	Safety and dose limiting toxicities of anakinra in CLL patients; Efficacy of anakinra in CLL patients	Dr. David Spaner; Swedish Orphan Biovitrum; Sunnybrook Health Sciences Centre	All	18 Years and older   (Adult, Older Adult)	12	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Anakinra	05/01/2021	12/01/2021	12/01/2022			31/12/2020				19/03/2021	https://ClinicalTrials.gov/show/NCT04691765		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Sweden	Leukemia	Chronic Lymphocytic Leukemia	Anakinra	Safety and/or Dose	Phase 1	DB00026	N
NCT02633098	A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer	NeoART	Recruiting	Colorectal Cancer|Bowel Cancer	Drug: Artesunate 200mg; Drug: Placebo	Recurrence free survival at 2 years; Recurrence free survival at 5 years; Overall survival at 2 and 5 years; Colon cancer specific death at 2 and 5 years; Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0; Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0; Pathological assessment of tumour regression (involvement of lymph nodes; serosa; resection margin); Patient quality of life; Surgical complications; Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy; Immunohistochemical analyses of paraffin-embedded tumour sections to assess Kirsten rat sarcoma viral oncogene homolog (Kras) mutation status; Immunohistochemical analyses of paraffin-embedded tumour sections to assess Mismatch Repair (MMR) status; Immunohistochemical analyses of paraffin-embedded tumour for v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation status; Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor (PDGF) expression; Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor receptor (PDGFR) expression; Immunohistochemical analyses of paraffin-embedded tumour for Vascular endothelial Growth Factor (VEGF) expression; Immunohistochemical analyses of paraffin-embedded tumour on Vascular endothelial Growth Factor Receptor (VEGFR) expression; Determination of proliferative activity (Ki-67 staining, Cluster of Differentiation 31 protein (CD31) staining); Determination of activation of the Deoxyribonucleic acid damage response (DDR) pathway; Wnt/ -catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins)	St George's, University of London	All	18 Years and older   (Adult, Older Adult)	200	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	15.0154	26/04/2017	31/12/2022	31/10/2025			17/12/2015				10/12/2022	https://ClinicalTrials.gov/show/NCT02633098		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United Kingdom	GI	Colon Cancer; Rectal Cancer	Artesunate	Safety and/or Dose; OS; DFS/RFS/EFS	Phase 2	DB09274	N
NCT03093129	Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART-V)	NeoART-V	Unknown status	Colorectal Cancer	Drug: artesunate; Other: placebo	recurrence free survival 2 years after surgery; Recurrence free survival at 5 years; Overall survival at 2 and 5 years; Colon cancer specific death at 2 and 5 years; Artesunate drug related toxicity; Pathological assessment of tumour regression (involvement of lymph nodes ; serosa ; resection margin); Surgical morbidity/mortality; Predictive value of tumour biomarkers in terms of predicting response to artesunate therapy	The 108 Military Central Hospital; Institute of Tropical Medicine, University of Tuebingen	All	18 Years to 70 Years   (Adult, Older Adult)	200	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NeoArt-V	01/08/2018	12/01/2021	12/01/2022			28/03/2017				01/09/2018	https://ClinicalTrials.gov/show/NCT03093129		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Viet Nam	GI	Colon Cancer; Rectal Cancer	Artesunate	Safety and/or Dose; OS; DFS/RFS/EFS	Phase 2	DB09274	N
NCT04026230	Impact of Atorvastatin on Prostate Cancer Progression During ADT	ESTO2	Recruiting	Metastatic Prostate Cancer|Recurrent Prostate Cancer	Drug: Atorvastatin 80mg; Drug: Placebo oral capsule	Castration resistance; Lipid levels; Prostate cancer mortality; Overall survival; Circulating cell-free DNA; Fasting blood glucose; Occurrence of cardiovascular events during ADT; General quality of life (QOL); Prostate cancer-specific quality of life (QOL)	Tampere University Hospital; Turku University Hospital; Central Finland Hospital District; Tartu University Hospital; University of Aarhus; Fimlab laboratories; Helsinki University Central Hospital; Kuopio University Hospital; Oulu University Hospital; Seinajoki Central Hospital; The Hospital of Vestfold; Telemark Hospital Trust	Male	18 Years and older   (Adult, Older Adult)	400	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	2016-004774-17	15/08/2019	31/12/2025	31/12/2025			19/07/2019				21/10/2022	https://ClinicalTrials.gov/show/NCT04026230	Palliative	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Finland	Urological	Prostate Cancer	Atorvastatin	PFS	Phase 3	DB01076	N
NCT01980823	Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer		Completed	Breast Cancer|Breast Tumors|Cancer of Breast	Drug: Metformin; Drug: Atorvastatin; Procedure: Breast surgery	Change in tissue levels of the proliferation marker Ki-67	Columbia University	Female	21 Years and older   (Adult, Older Adult)	23	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AAAM2306	10/01/2013	24/05/2018	12/01/2022			11/11/2013				30/08/2023	https://ClinicalTrials.gov/show/NCT01980823		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Breast	Any Breast Cancer	Atorvastatin; Metformin	Biomarker	Phase 1	DB01076; DB00331	N
NCT05507398	The Anti-tumor Effect of Metformin And Atorvastatin in Breast Cancer		Not yet recruiting	Breast Cancer Female	Drug: Placebo, metformin and atorvastatin	Improvement in the overall response rate; Improvement in the pathological response	Tanta University	Female	18 Years and older   (Adult, Older Adult)	100	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Breast cancer treatment	10/01/2022	07/01/2023	09/01/2023			19/08/2022				31/10/2022	https://ClinicalTrials.gov/show/NCT05507398		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	Egypt	Breast	Any Breast Cancer	Atorvastatin; Metformin	Response rate	Phase 4	DB01076; DB00331	N
NCT04601116	The MASTER Study (MAmmary Cancer STatin ER Positive Study)		Recruiting	Breast Cancer Female|Estrogen Receptor Positive Tumor	Drug: Atorvastatin 80 Mg Oral Tablet; Drug: Placebo oral tablet	Invasive disease-free survival; Distant-recurrence free interval; Recurrence-free interval; Overall survival.; Incidence of Treatment-Emergent Adverse Events as assessed by CTC-AE, 5.0; Cardiac death-free interval; Co-morbidity	Aarhus University Hospital; Rigshospitalet, Denmark; Hospital of Southern Jutland; University of Copenhagen; Bornholms Hospital; Naestved Hospital; Vejle Hospital; Odense University Hospital; Nordsjaellands Hospital; Aalborg University Hospital; Herning Hospital	Female	18 Years and older   (Adult, Older Adult)	3360	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SBMASTER; 2019-002508-42	01/04/2021	01/01/2025	01/01/2035			23/10/2020				14/01/2021	https://ClinicalTrials.gov/show/NCT04601116	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Denmark	Breast	Breast Cancer - ER/HR+	Atorvastatin	DFS/RFS/EFS	Phase 3	DB01076	N
NCT02958852	A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer	ABC-SE	Recruiting	Breast Cancer	Drug: Letrozole; Drug: Letrozole and atorvastatin; Drug: Fulvestrant	Clinical benefit rate.; Progression free survival.; Objective response rate.; Time to progression.; Duration of Clinical benefit.; Overall survival.; Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.	Lund University Hospital; South Sweden Breast Cancer Group	Female	18 Years and older   (Adult, Older Adult)	126	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OKFE 15-ABC-SE	11/01/2016	04/01/2024	04/01/2024			11/08/2016				09/02/2020	https://ClinicalTrials.gov/show/NCT02958852		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Sweden	Breast	Breast Cancer - ER/HR+	Atorvastatin	Safety and/or Dose; Response rate; PFS; OS; Other (specify)	Phase 2	DB01076	N
NCT05103644	Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients 		Recruiting	Breast Cancer	Drug: Atorvastatin 80mg; Other: placebo	Ki-67 molecular; TAZ (WWTR1) TAZ expression; cardiac markers; Overall survival OS; Overall response rate	Beni-Suef University	Female	18 Years to 80 Years   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	FMBSUREC/10102021/Rabie	30/10/2021	30/12/2023	30/12/2024			11/02/2021				11/02/2022	https://ClinicalTrials.gov/show/NCT05103644		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Egypt	Breast	Breast Cancer - HER2-	Atorvastatin	Response rate; OS; Biomarker	Phase 2/3	DB01076	N
NCT03358017	Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	YAPPETIZER	Completed	Triple Negative Breast Cancer	Drug: Zoledronate; Drug: Atorvastatin 80mg; Drug: Standard neoadjuvant cht	Proof of concept primary activity endpoint - Efficacy endpoint; The proportion of responded patients; In relation to high/low p53 levels, relative reductions of YAP and TAZ IHC-expression at surgery with respect to core-biopsy analysis. Efficacy endpoint; Proportion of responder patients according to high/low p53 levels - Efficacy endpoint; Disease Free Survival (DFS) - Efficacy endpoint; Overall survival - Efficacy endpoint; Regulation of YAP and TAZ gene expression by RNA-Seq in tumor tissue - Efficacy endpoint; Relative reduction of Ki67 in tumor samples - Efficacy endpoint; Study treatment safety - Safety endpoint - AE; Study treatment safety - Safety endpoint - Maximum grade; Study treatment safety - Safety endpoint - Percentage	Mario Negri Institute for Pharmacological Research; Associazione Italiana per la Ricerca sul Cancro	Female	18 Years and older   (Adult, Older Adult)	54	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRFMN-BRC-7103; 2016-005112-17	03/05/2018	17/06/2021	25/07/2023			30/11/2017				19/10/2023	https://ClinicalTrials.gov/show/NCT03358017		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Italy	Breast	Breast Cancer - TNBC	Atorvastatin; Zoledronic Acid	Response rate	Phase 2	DB01076; DB00399	N
NCT03819101	Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer	PEACE-4	Recruiting	Prostate Cancer	Drug: Acetylsalicylic acid; Drug: Atorvastatin	Overall Survival (OS)	Gustave Roussy, Cancer Campus, Grand Paris; National Cancer Institute, France	Male	18 Years and older   (Adult, Older Adult)	1210	Other	Interventional Study	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-004639-35; 2017/2601	06/06/2019	03/01/2034	03/01/2038			28/01/2019				14/02/2023	https://ClinicalTrials.gov/show/NCT03819101	Palliative	Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	Y	N	France	Urological	Prostate Cancer	Acetylsalicylic Acid; Atorvastatin	OS	Phase 3	DB00945; DB01076	N
NCT03560882	A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies		Recruiting	Malignant Disease|Solid Tumor|Acute Myeloid Leukemia|Myelodysplastic Syndromes|Cancer|Relapsed Hematologic Malignancy	Drug: Atorvastatin	Change in conformational mutant tumor protein 53 (p53); Change in Ki-67 (protein); Change in caspase-3	Joaquina Baranda; University of Kansas Medical Center	All	18 Years and older   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT-2018-p53Atorva	19/07/2018	08/01/2024	08/01/2025			18/06/2018				19/05/2022	https://ClinicalTrials.gov/show/NCT03560882		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types; Leukemia	Any solid tumours; Any leukemias	Atorvastatin	Biomarker	Phase 1	DB01076	N
NCT03872388	Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy		Completed	Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Negative|HER2/Neu Negative|Inflammatory Breast Carcinoma|Progesterone Receptor Negative|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma	Drug: Atorvastatin; Drug: Capecitabine	Proportions of patients with undetectable circulating tumor cells (CTC); Baseline fasting lipid profile level (low density lipoprotein cholesterol [LDL-C]) and/or change in serum lipid levels; Biomarkers on atorvastatin treatment response; Baseline C-reactive protein (CRP) and/or change in serum lipid levels; Baseline absolute number of circulating tumor cells (CTCs) and/or CTC change; Recurrence-free survival (RFS); Incidence of adverse events	M.D. Anderson Cancer Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	6	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018-0550; NCI-2019-00004	14/01/2019	19/10/2023	19/10/2023			13/03/2019				23/10/2023	https://ClinicalTrials.gov/show/NCT03872388		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - TNBC	Atorvastatin	Biomarker	Phase 2	DB01076	N
NCT02497638	LIpitor and biGuanide to Androgen Delay Trial	LIGAND	Withdrawn	Prostate Cancer	Drug: Metformin; Drug: Atorvastatin; Drug: Placebo (corresponding to metformin); Drug: Placebo (corresponding to atorvastatin)	Time to disease progression (defined as PSA rise to 10 ng/mL or greater, development of clinically overt metastases) or patient/physician desire for androgen deprivation therapy.; Time to androgen deprivation therapy; Time to PSA progression; Time to disease progression; Body mass index; Circulating glycated hemoglobin levels; C-peptide levels; Adipokine levels; LDL/HDL cholesterol levels; Triglyceride levels; Incidence of adverse events during administration of metformin and atorvastatin to men with prostate cancer.	University Health Network, Toronto	Male	18 Years to 80 Years   (Adult, Older Adult)	0	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	15-053	12/01/2021	12/01/2021	12/01/2022			14/07/2015				19/04/2021	https://ClinicalTrials.gov/show/NCT02497638		Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	Canada	Urological	Prostate Cancer	Atorvastatin; Metformin	PFS	Phase 2	DB01076; DB00331	N
NCT03971019	Survival Benefits of Statins in Breast Cancer Patients	SBSBC	Recruiting	Breast Cancer Female	Drug: statins; Behavioral: Dietary intervention group (control group)	DFS; OS	Peking Union Medical College Hospital	Female	18 Years to 75 Years   (Adult, Older Adult)	314	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PUMCH-SBSBC	28/03/2019	28/05/2024	28/06/2024			06/03/2019				14/08/2019	https://ClinicalTrials.gov/show/NCT03971019	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Breast	Any Breast Cancer	Atorvastatin; Simvastatin	DFS/RFS/EFS	Phase 3	DB01076; DB00641	N
NCT04862260	Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma		Recruiting	Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer|Pancreas Cancer|Metastatic Cancer	Drug: Cholesterol metabolism disruption	Safety as measured by the rate of adverse events; Characterization of dose-limiting toxicities; LDLR (low-density lipoprotein receptor) tumoral and hepatic changes in response to the multipathway cholesterol embargo.; LRP1 (Low-density lipoprotein Receptor-Related Protein 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo.; NPC1L1 (Niemann-Pick C1-Like 1 protein) tumoral and hepatic changes in response to the multipathway cholesterol embargo.; SRB1 (Scavenger Receptor class B type 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo.; MHC-1 (Major Histocompatibility Complex class 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo.; PD-L1 (Programmed Death-Ligand-1) changes in response to the multipathway cholesterol embargo.; Change in tumoral and hepatic levels of TILs (Tumor-Infiltrating Lymphocytes); CD36 (Cluster of Differentiation 36) changes in response to the multipathway cholesterol embargo	CHU de Quebec-Universite Laval; Canadian Institutes of Health Research (CIHR); Biovalorem	All	18 Years to 99 Years   (Adult, Older Adult)	12	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CHLOE pancreas	10/04/2021	31/01/2025	31/12/2026			27/04/2021				23/08/2023	https://ClinicalTrials.gov/show/NCT04862260		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Canada	GI	Pancreatic Cancer	Atorvastatin	Safety and/or Dose; Biomarker	Phase 1	DB01076	N
NCT03275376	Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma		Terminated	Overall Survival|Tumor Responses	Drug: Atorvastatin 10mg; Drug: Placebo Oral Tablet	Overall survival; Best tumor response; Progression free survival	Taichung Veterans General Hospital	All	40 Years and older   (Adult, Older Adult)	34	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CF16263B	21/12/2017	21/12/2020	13/03/2021			09/07/2017				16/03/2021	https://ClinicalTrials.gov/show/NCT03275376		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Taiwan	GI	Liver Cancer	Atorvastatin	OS	Phase 2	DB01076	N
NCT05796973	Measuring Oncological Value of Exercise and Statin	MOVES	Recruiting	Prostate Cancer|Breast Cancer|Kidney Cancer|Ovarian Cancer|Metastatic Breast Cancer|Metastatic Kidney Cancer|Metastatic Renal Cell Carcinoma|Metastatic Renal Cancer|Metastatic Prostate Cancer|Metastatic Prostate Adenocarcinoma|Metastatic Ovarian Cancer|Metastatic Ovary Cancer	Behavioral: Guided physical exercise; Drug: Atorvastatin; Other: Independent exercise	Time to cancer progression; Mortality; Hypoxia markers in serum (VEGF, HIF1-alpha, carboanhydrase IX, LADH); Tolerability of treatment; Fat/muscle ratio as measured with impedance test; Physical performance with standardized muscle strength tests; Changes in tissue hypoxia; Changes in quality of life; Depressive symptoms; Severity of pain; Nutritional status; Relationship satisfaction	Tampere University Hospital; Tampere University; Aalto University; University of Helsinki; University of Turku	All	18 Years to 99 Years   (Adult, Older Adult)	240	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-001982-34	31/03/2023	31/12/2025	31/12/2027			04/04/2023				24/05/2023	https://ClinicalTrials.gov/show/NCT05796973	Primary/Main Curative; Palliative	Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	Finland	Gynaecological; Breast; Urological	Ovarian Epithelial Cancer; Prostate Cancer; Any Breast Cancer; Renal Cell Carcinoma	Atorvastatin	PFS; OS	Phase 3	DB01076	N
NCT05675787	Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia		Recruiting	Atypical Endometrial Hyperplasia|Endometrial Carcinoma Stage I	Drug: Medroxyprogesterone acetate + Atorvastatin	Pathological cumulative complete response rate;; The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion tissue; Overall complete response rate; Pathological response rate classified by different blood lipid level; Relapse rate; Pregnancy rate; Toxic Side Effect	Peking University People's Hospital	Female	17 Years to 45 Years   (Child, Adult)	82	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2022PHB416	01/06/2023	31/08/2025	31/10/2025			01/09/2023				16/05/2023	https://ClinicalTrials.gov/show/NCT05675787		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Gynaecological	Endometrial Cancer	Atorvastatin	Safety and/or Dose; Response rate; Biomarker; Other (specify)	Phase 2	DB01076	N
NCT03024684	Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment	SHOT	Recruiting	HepatoCellular Carcinoma	Drug: Atorvastatin; Drug: Placebo Oral Tablet	3-year cumulative incidence of recurrent HCC between the intervention group and control counterpart; occurrence of clinical complications related to hepatic decompensation	Chiayi Christian Hospital; E-DA Hospital; National Taiwan University Hospital; Taichung Veterans General Hospital; Mackay Memorial Hospital; Tainan Municipal Hospital; National Cheng-Kung University Hospital; Chi Mei Medical Hospital	All	20 Years to 75 Years   (Adult, Older Adult)	240	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	105005	01/03/2017	01/01/2025	01/01/2027			19/01/2017				28/04/2022	https://ClinicalTrials.gov/show/NCT03024684	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Taiwan	GI	Liver Cancer	Atorvastatin	Recurrence rate	Phase 3	DB01076	N
NCT05483010	Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)		Not yet recruiting	Clonal Cytopenia of Undetermined Significance|Myelodysplastic Syndromes	Drug: Atorvastatin; Drug: Rosuvastatin	Change in hs-CTRP levels in peripheral blood during statin therapy; Change in allele burden (VAF) of somatic mutation	Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)	16	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202211020	01/03/2024	30/04/2027	30/04/2027			08/01/2022				19/12/2023	https://ClinicalTrials.gov/show/NCT05483010		Other (specify)	Hospital/University/Research Institute	N	N	N	United States	Other Haem-onc	Myelodysplastic Syndromes	Atorvastatin; Rosuvastatin	DFS/RFS/EFS; Biomarker	Phase 2	DB01076; DB01098	N
NCT04648033	Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC	ARCADIAN	Completed	Locally Advanced Non-Small Cell Lung Cancer	Drug: Atovaquone Oral Suspension; Drug: Standard of care chemotherapy; Radiation: Standard of care radiotherapy	The dose of atovaquone associated with no more than 48  dose limiting toxicity (DLT) rate (target toxicity level); Number of adverse events graded per Common Terminology Criteria for Adverse Events (CTCAE) v4.03; Hypoxia metagene signature from diagnostic tissue using 3'RNA-Seq; Correlation between tumour hypoxic volume and plasma miR-210 level; Correlation between tumour hypoxic volume and tumour hypoxia gene expression; Correlation between changes in tumour hypoxic volume and plasma miR-210 level; Response to treatment assessed per Response Evaluation Criteria in Solid Tumours (RECIST) V1.1	University of Oxford; Cancer Research UK; National Institute for Health Research, United Kingdom; NHS Lothian; Oxford University Hospitals NHS Trust; NHS Research Scotland; Guy's and St Thomas' NHS Foundation Trust	All	18 Years and older   (Adult, Older Adult)	21	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OCTO_088	12/07/2020	10/02/2023	10/02/2023			12/01/2020				10/12/2023	https://ClinicalTrials.gov/show/NCT04648033		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United Kingdom	Lung	Non-Small Cell Lung Cancer	Atovaquone	Safety and/or Dose	Phase 1	DB01117	N
NCT05998135	Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer		Not yet recruiting	Ovarian High Grade Serous Adenocarcinoma|Platinum-Resistant Ovarian Carcinoma	Drug: Atovaquone; Procedure: Biopsy; Procedure: Computed Tomography; Procedure: Paracentesis	Progression free survival (PFS); Clinical benefit rate; Overall survival (OS); Incidence of adverse events	Emory University; National Cancer Institute (NCI)	Female	18 Years and older   (Adult, Older Adult)	28	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00005363; NCI-2023-03479; WINSHIP5782-22; P30CA138292	09/01/2023	30/06/2024	30/06/2025			18/08/2023				18/08/2023	https://ClinicalTrials.gov/show/NCT05998135		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Ovarian Epithelial Cancer	Atovaquone	Safety and/or Dose; PFS; OS; Other (specify)	Phase 2	DB01117	N
NCT03568994	Atovaquone (Mepron ) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)	ATACC AML	Active, not recruiting	Acute Myeloid Leukemia	Drug: Atovaquone; Drug: Cytarabine; Drug: Daunorubicin; Drug: Etoposide; Drug: Gemtuzumab Ozogamicin	Plasma Concentrations; Dose Omission Frequency; Time to Achieve Steady State	Baylor College of Medicine; William Marsh Rice University	All	1 Month to 20 Years   (Child, Adult)	26	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H-42691	07/10/2018	29/09/2020	31/10/2025			26/06/2018				18/11/2023	https://ClinicalTrials.gov/show/NCT03568994		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	Leukemia	Acute Myeloid Leukemia, Adult	Atovaquone	Safety and/or Dose	Phase 1	DB01117	N
NCT03456700	Auranofin and Sirolimus in Treating Participants With Ovarian Cancer		Active, not recruiting	Ovarian Serous Tumor|Recurrent Ovarian Carcinoma	Drug: Auranofin; Other: Laboratory Biomarker Analysis; Drug: Sirolimus	Number of Participants With a Confirmed Tumor Response (Partial Response [PR] or Complete Response [CR] at Least 4 Weeks Apart); Number of Participants With a Confirmed Tumor Response (PR or CR at Least 4 Weeks Apart) in the Subset of Participants That Have Over-expression of Protein Kinase C (PKC) Iota; Progression-free Survival (PFS); Overall Survival (OS); Number of Participants Experiencing at Least One Grade 3 or Worse Adverse Event (AE)	Mayo Clinic; National Cancer Institute (NCI)	Female	18 Years and older   (Adult, Older Adult)	22	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1761; NCI-2018-00321; P30CA015083	30/03/2018	31/07/2019	15/12/2023			03/07/2018		07/02/2020		14/07/2023	https://ClinicalTrials.gov/show/NCT03456700		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Ovarian Epithelial Cancer	Auranofin; Sirolimus	Response rate	Phase 2	DB00995; DB00877	N
NCT01737502	Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer		Completed	Extensive Stage Small Cell Lung Carcinoma|Lung Adenocarcinoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer	Drug: Auranofin; Drug: Sirolimus; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study	MTD of auranofin (Phase I); Number and severity of all adverse events (Phase I); Progression-free survival rate (Phase II); Survival time; Progression-free survival time; Overall response rate, defined to be either a complete response (CR) or partial response (PR) noted as the objective status; Duration of response	Mayo Clinic; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	29	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1125; NCI-2012-00518; 11-001987; P30CA015083	14/05/2014	24/04/2023	24/04/2023			29/11/2012				07/10/2023	https://ClinicalTrials.gov/show/NCT01737502		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	Lung	Non-Small Cell Lung Cancer	Auranofin; Sirolimus	Safety and/or Dose; PFS	Phase 1/2	DB00995; DB00877	N
NCT04812808	Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma	BAZE	Recruiting	Pancreas Cancer	Drug: Bazedoxifene 20 mg	Change in IL-6/GP-130/STAT3 pathway expression ( ); Carbohydrate-Antigen 19-9 (CA 19-9) in U/ml; Change in Quality of life measured by EORTC QLQ-C30; Heart rate (bpm); Blood pressure (mmHg); Oxygen saturation ( ); weight (kg); body temperature ( Celcius); liver enzymes (GOT/ASAT in U/l); liver enzymes (GPT/ALAT in U/l); liver enzymes (GGT in U/l); liver enzymes (alkaline phosphatase in U/l); liver enzymes (bilirubine in umol/l); renal parameters (creatinine in umol/l); electrolytes (sodium in mmol/l); electrolytes (potassium in mmol/l); electrolytes (phosphate in mmol/l); electrolytes (calcium in mmol/l); Number of patients with adverse events	H pital Fribourgeois	All	18 Years to 85 Years   (Adult, Older Adult)	10	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Grant-2104	02/01/2022	31/01/2024	31/05/2024			24/03/2021				25/02/2022	https://ClinicalTrials.gov/show/NCT04812808		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Switzerland	GI	Pancreatic Cancer	Bazedoxifene	Biomarker	Other	DB06401	N
NCT04997811	Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes	REPAIR-MDS	Recruiting	Myelodysplastic Syndromes (MDS)	Drug: Sodium Valproate, Bezafibrate, Medroxyprogesterone; Drug: Danazol	Haematological improvement (HI) in each arm and in the trial overall, with 25  or more of the participants having HI in each arm and overall.; Reduced burden of red cell and/or platelet transfusion in each arm and in the trial overall, as per the IWG 2018 response criteria.; Duration of haematological response; Reported improved Health Related Quality of Life scores in each arm and in the trial overall.; Overall survival	Prof. Janet Dunn; Blood Cancer UK; Dudley Group NHS Foundation Trust; University of Birmingham; University of Manchester; King's College Hospital NHS Trust; University of Warwick	All	18 Years and older   (Adult, Older Adult)	120	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SOC.11/20-21; 2020-005446-42	21/12/2021	31/01/2025	30/06/2025			08/10/2021				10/03/2023	https://ClinicalTrials.gov/show/NCT04997811		Any/All Stages	Hospital/University/Research Institute	N	Y	N	United Kingdom	Other Haem-onc	Myelodysplastic Syndromes	Bezafibrate; Danazol; Valproic Acid	OS; QoL; Other (specify)	Phase 2	DB01393; DB01406; DB00313	N
NCT04158635	Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer		Recruiting	Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Pancreatic Carcinoma	Drug: Bosentan; Drug: Gemcitabine; Drug: Nab-paclitaxel; Other: Quality-of-Life Assessment; Other: Questionnaire Administration	Incidence of adverse events; Dose limiting toxicities (DLTs); Compliance; Progression-free survival (PFS); Overall survival (OS); Time to treatment failure (TTF)	City of Hope Medical Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	21	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	21314; NCI-2021-06609; 19312	09/01/2021	27/01/2026	27/01/2026			11/12/2019				19/10/2023	https://ClinicalTrials.gov/show/NCT04158635		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Bosentan	Safety and/or Dose	Phase 1	DB00559	N
NCT03107416	Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells		Active, not recruiting	Unresectable Hepatocellular Carcinoma	Procedure: Hepatic artery embolization (HAE); Drug: Bumetanide	Maximum tolerated dose (MTD) (phase I); estimate the local tumor progression (LTP) rates (phase II)	Memorial Sloan Kettering Cancer Center	All	18 Years and older   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-141	04/05/2017	04/05/2024	04/05/2024			04/11/2017				02/08/2023	https://ClinicalTrials.gov/show/NCT03107416		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Liver Cancer	Bumetanide	Safety and/or Dose; Other (specify)	Phase 1/2	DB00887	N
NCT02840227	The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections		Active, not recruiting	Non-small Cell Lung Cancer	Procedure: General anesthesia with opioid analgesia; Procedure: Combined general/epidural anesthesia	Cancer-free survival; Pain intensity; SF-12 Health Survey; McGill Pain Questionnaire; Neuropathic Pain Questionnaire; Opioid use	The Cleveland Clinic; Shanghai Chest Hospital	All	18 Years to 85 Years   (Adult, Older Adult)	2000	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	91051	12/01/2013	06/01/2024	12/01/2024			21/07/2016				18/06/2023	https://ClinicalTrials.gov/show/NCT02840227		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Lung	Non-Small Cell Lung Cancer	Propofol	Safety and/or Dose; DFS/RFS/EFS; Other (specify)	Other	DB00818	N
NCT04657237	Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer		Unknown status	Programmed Cell Death 1	Procedure: Thoracic Paravertebral block	change in level of PD1 and PD1 ligand postoperatively; total request of analgesia	Assiut University	Female	18 Years to 65 Years   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other	359	01/01/2017	09/01/2021	11/01/2021			12/08/2020				12/08/2020	https://ClinicalTrials.gov/show/NCT04657237		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Egypt	Breast	Any Breast Cancer	Acetaminophen	Biomarker	Other	DB00316	N
NCT05903703	Canagliflozin With Gemcitabine in Pancreatic Carcinoma		Not yet recruiting	Pancreatic Cancer	Drug: Canagliflozin and Gemcitabine; Drug: Gemcitabine	Evaluation the clinical complete response (CR) at 6 weeks intervals; Evaluation the clinical partial response (PR) at 6 weeks intervals; Evaluation the clinical stable disease (SD) at 6 weeks intervals; Evaluation the clinical disease progression (PD) at 6 weeks intervals	Zhang Xiaofeng,MD; College of Pharmaceutical Sciences at Zhejiang University; The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University; First People's Hospital of Hangzhou	All	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20230519	10/01/2023	30/09/2026	31/03/2027			15/06/2023				15/06/2023	https://ClinicalTrials.gov/show/NCT05903703		Advanced/Metastatic; Other (specify)	Hospital/University/Research Institute	Y	N	N	China	GI	Pancreatic Cancer	Canagliflozin	Response rate	Other	DB08907	N
NCT04073680	A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors		Unknown status	Breast Cancer|Endometrial Cancer|Lung Cancer|Colo-rectal Cancer|Head and Neck Cancer	Drug: Serabelisib; Drug: Canagliflozin 300mg	Rate of Adverse Events; Rate of Laboratory Abnormalities; Dose confirmation; Tumor Assessments by RESIST; Cmax Pharmacokinetic assessment; Tmax Pharmacokinetic assessment; AUC Pharmacokinetic assessment	Petra Pharma	All	18 Years and older   (Adult, Older Adult)	60	Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PT06-01	09/01/2020	15/07/2021	30/12/2021			29/08/2019				21/05/2020	https://ClinicalTrials.gov/show/NCT04073680		Advanced/Metastatic	Company	N	N	N	United States	Multiple cancer types	Any solid tumours	Canagliflozin	Safety and/or Dose; Response rate	Phase 1/2	DB08907	N
NCT05016349	Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.		Unknown status	Breast Cancer Female	Drug: All trans-retinoic acid; Drug: 13-Cis Retinoic Acid plus Tocopherol; Drug: Mifepristone; Drug: Cannabidiol; Drug: 9 cis retinoic acid; Drug: Tamoxifen; Drug: Standard therapy	Cytokeratin 5 (CK5)-expression; To evaluate and compare the pathological complete response (pCR) rates; To evaluate the overall clinical response rate; Estradiol and progesterone levels in breast tissue and plasma assessed by liquid chromatography/tandem mass spectrometry; Retinoic acid, TAM and their metabolites levels in breast tissue and plasma; Effect on level of serum tumor markers compared to baseline	Mahmoud Ramadan mohamed Elkazzaz; Ministry of Health, Saudi Arabia; Kafrelsheikh University	Female	18 Years to 70 Years   (Adult, Older Adult)	160	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	New theory(Tamoxifen retinoic)	08/01/2021	10/01/2021	12/01/2021			23/08/2021				23/08/2021	https://ClinicalTrials.gov/show/NCT05016349	Primary/Main Curative	Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	Saudi Arabia	Breast	Any Breast Cancer	Mifepristone	Response rate; Biomarker	Phase 3	DB00834	N
NCT02944201	Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate		Unknown status	Prostate Cancer	Drug: Carvedilol	Change in Biomarkers in Prostate Biopsy Compared to Prostatectomy Tissues; Change in Serum PSA	Montefiore Medical Center; Albert Einstein College of Medicine	Male	18 Years and older   (Adult, Older Adult)	22	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-6632	04/01/2017	31/12/2020	31/12/2021			25/10/2016				21/02/2021	https://ClinicalTrials.gov/show/NCT02944201		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Carvedilol	Biomarker	Phase 2	DB01136	N
NCT03980249	Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells		Withdrawn	Glioblastoma|Glioblastoma Multiforme	Drug: Carvedilol	Survival curve of overall survival; Survival curve of progression free survival; Quantify Circulating Tumor Cells (CTCs)	West Virginia University; NovoCure Ltd.; West Virginia Clinical and Translational Science Institute	All	18 Years and older   (Adult, Older Adult)	0	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WVU020318	09/01/2020	12/01/2021	06/01/2022			06/10/2019				04/12/2021	https://ClinicalTrials.gov/show/NCT03980249		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Carvedilol	OS	Phase 1	DB01136	N
NCT05281276	Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)		Recruiting	Metastatic Colorectal Cancer	Drug: chidamide; Drug: celecoxib	Maximum Feasible Dose (MFD); Pharmacokinetics profiles-(AUC0-t); Pharmacokinetics profiles-(AUC0- ); Pharmacokinetics profiles-(Cmax); Pharmacokinetics profiles-(Tmax); Pharmacokinetics profiles-(T1/2); Pharmacokinetics profiles-(Kel); Pharmacokinetics profiles-(AUC0- ,ss); Pharmacokinetics profiles-(Cave,ss); Pharmacokinetics profiles-(Cmin,ss); Pharmacokinetics profiles-(Cmax,ss); Pharmacokinetics profiles-(Tmax,ss); Pharmacokinetics profiles-(DF); Progression-free survival; Objective response	Taipei Medical University Shuang Ho Hospital	All	20 Years and older   (Adult, Older Adult)	12	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N202007026	20/09/2022	31/12/2024	31/12/2024			16/03/2022				14/12/2023	https://ClinicalTrials.gov/show/NCT05281276		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Taiwan	GI	Colon Cancer; Rectal Cancer	Celecoxib	Safety and/or Dose; PFS	Phase 1	DB00482	N
NCT02885974	Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer	BLAST	Recruiting	Bladder Cancer	Drug: Celecoxib; Drug: Gemcitabine; Drug: Cisplatin	mRNA expression in pre- and post-chemotherapy tissues; Number and severity of adverse events; Pathological disease stage at cystectomy, including the rate of pT0 and the rate of < pT2.; Two-year progression free survival; Two-year overall survival	Baylor College of Medicine	All	18 Years and older   (Adult, Older Adult)	15	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H-36486	12/01/2016	12/01/2023	12/01/2023			09/01/2016				13/07/2023	https://ClinicalTrials.gov/show/NCT02885974		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Urological	Bladder Cancer	Celecoxib	Biomarker	Phase 1	DB00482	N
NCT03645187	Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer		Recruiting	Colon Cancer Stage	Drug: FOLFERI; Drug: Folferi and celecoxib	number of patients with improved radiology	Sherief Abd-Elsalam; Tanta University	All	18 Years to 70 Years   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	celecoxib	08/01/2018	08/01/2025	12/01/2025			24/08/2018				20/04/2021	https://ClinicalTrials.gov/show/NCT03645187		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Egypt	GI	Colon Cancer; Rectal Cancer	Celecoxib	Response rate	Phase 4	DB00482	N
NCT03498326	Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer	GCRP	Recruiting	Pancreatic Cancer|Chemotherapy Effect	Drug: Gemcitabine	disease free survival; overall survival; Carbohydrate antigen 19-9; Quality of Life; Common Toxicity Criteria for Adverse Effects	Second Affiliated Hospital, School of Medicine, Zhejiang University	All	18 Years to 90 Years   (Adult, Older Adult)	480	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SAHZhejiangU-GCRP	04/02/2018	31/03/2023	31/03/2030			13/04/2018				30/05/2018	https://ClinicalTrials.gov/show/NCT03498326		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Pancreatic Cancer	Celecoxib	DFS/RFS/EFS	Phase 2	DB00482	N
NCT03864575	An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced   Cold   Solid Tumors	NICE-COMBO	Unknown status	Metastatic Cancer	Drug: Celecoxib 400 mg	objective response rate; Number of participants with treatment-related adverse events as assessed by CTCAE v4.0; Efficacy - Duration of response (DOR); Efficacy - Time to response (TTR); Disease control rate (DCR); Progression-free survival (PFS); Overall survival (OS)	Cliniques universitaires Saint-Luc- Universit  Catholique de Louvain	All	18 Years and older   (Adult, Older Adult)	68	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LUC-19-002	15/08/2019	15/06/2021	15/06/2021			03/06/2019				07/12/2019	https://ClinicalTrials.gov/show/NCT03864575		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Belgium	Multiple cancer types	Multiple cancer types	Celecoxib	Response rate	Phase 2	DB00482	N
NCT05578287	RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer	DETECT	Recruiting	Colorectal Cancer	Drug: Anti-HER2 ADC	Safety; Feasibility; Objective response rate; disease control rate,DCR; Progression-free survival (PFS); Overall Survival (OS)	Sun Yat-sen University	All	18 Years to 75 Years   (Adult, Older Adult)	29	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GIHSYSU-26	18/07/2023	15/12/2024	25/12/2025			13/10/2022				12/07/2023	https://ClinicalTrials.gov/show/NCT05578287		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	GI	Colon Cancer; Rectal Cancer	Celecoxib	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00482	N
NCT01150045	Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery		Active, not recruiting	Colorectal Cancer	Drug: celecoxib; Drug: 5-fluorouracil; Other: placebo; Drug: oxaliplatin; Drug: leucovorin	Disease-free Survival; Overall Survival	Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	2527	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CALGB-80702; U10CA031946; CDR0000675693	06/01/2010	28/02/2020				24/06/2010		08/06/2021		22/03/2022	https://ClinicalTrials.gov/show/NCT01150045	Adjuvant/Maintenance	Localised/Locoregional	Collaborative Group	Y	N	N	United States	GI	Colon Cancer	Celecoxib	DFS/RFS/EFS	Phase 3	DB00482	N
NCT03896113	Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma	CELEBRIDO	Unknown status	Endometrium Cancer	Drug: Celecoxib 200mg capsule	Reduction of tumoural cells expression IDO after celecoxib treatment. If more than 10  of all the tumoural cells have a staining for IDO, the tumour is considered as IDO (+), if less than 10 .; Modification of tumoural T Cells infiltration after the treatment with celecoxib. The number of Cluster of Differenciation (CD) 4 and CD8 T cells will be counted before and after the treatment.; Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Event Version 4.0 (CTCAE v4.0).	Cliniques universitaires Saint-Luc- Universit  Catholique de Louvain	Female	18 Years to 99 Years   (Adult, Older Adult)	48	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LUC19-001	13/11/2019	30/06/2022	30/06/2022			29/03/2019				01/10/2020	https://ClinicalTrials.gov/show/NCT03896113		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Belgium	Gynaecological	Endometrial Cancer	Celecoxib	Biomarker	Phase 2	DB00482	N
NCT00538031	Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer		Completed	Fallopian Tube Cancer|Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer	Drug: cyclophosphamide; Drug: celecoxib	Overall Response; Time to Treatment Failure; Overall Survival	City of Hope Medical Center	Female	18 Years and older   (Adult, Older Adult)	52	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	03092; NCI-2009-01597; CDR0000567043	22/12/2003	21/04/2011	13/09/2019			10/02/2007		21/04/2023		21/04/2023	https://ClinicalTrials.gov/show/NCT00538031		Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	United States	Gynaecological	Ovarian Epithelial Cancer	Celecoxib	Response rate; OS	Phase 2	DB00482	N
NCT05933980	Sintilimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer	SINCERE	Not yet recruiting	Colorectal Cancer|Liver Metastases|MSS	Drug: Sinti+Rego+Cele	ORR; OS; PFS; DCR; DoR	Sun Yat-sen University	All	18 Years to 100 Years   (Adult, Older Adult)	33	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GIHSYSU26	20/08/2023	20/08/2024	20/08/2025			07/06/2023				07/06/2023	https://ClinicalTrials.gov/show/NCT05933980		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	GI	Colon Cancer; Rectal Cancer	Celecoxib	Response rate; PFS; OS	Phase 2	DB00482	N
NCT03926338	Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer	PICC	Recruiting	Colorectal Cancer|Mismatch Repair-deficient (dMMR)|Microsatellite Instability-high (MSI-H)|Neoadjuvant Therapy	Drug: Neoadjuvant therapy with PD-1 inhibitor plus COX inhibitor; Drug: Neoadjuvant therapy with PD-1 inhibitor	Disease-free survival (DFS); Pathological complete response (pCR) rates; Overall survival (OS); R0 resection rates; Surgical and perioperative treatment safety; Surgery feasibility	Sun Yat-sen University	All	18 Years to 75 Years   (Adult, Older Adult)	69	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GIHSYSU-14	05/10/2019	05/01/2023	05/01/2026			24/04/2019				28/02/2023	https://ClinicalTrials.gov/show/NCT03926338		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Colon Cancer; Rectal Cancer	Celecoxib	Safety and/or Dose; Response rate; OS; DFS/RFS/EFS	Phase 1/2	DB00482	N
NCT02574728	Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors	AflacST1502	Recruiting	Cancer	Drug: Sirolimus; Drug: Celecoxib; Drug: Etoposide; Drug: Cyclophosphamide	Change in radiographic response to treatment for solid tumors; Change in radiographic response to treatment for central nervous system (CNS) tumors; Number of adverse events	Emory University; Cannonball Kids' Cancer Foundation; Hyundai Hope On Wheels	All	12 Months to 30 Years   (Child, Adult)	60	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00082488	06/01/2015	01/01/2024	01/01/2024			14/10/2015				20/12/2022	https://ClinicalTrials.gov/show/NCT02574728		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	Multiple cancer types	Multiple cancer types	Celecoxib; Sirolimus	Response rate	Phase 2	DB00482; DB00877	N
NCT05731726	Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer		Recruiting	pMMR|MSS|MSI-L|Locally Advanced Rectal Carcinoma	Drug: Serplilumab; Drug: Capecitabine; Drug: Oxaliplatin; Drug: Celecoxib	Pathological complete response rates; Major pathological response rates; Rate of clinical complete response rate (cCR); R0 resection rates; Treatment-related adverse events.; Detection of MRD; single cell sequence	Zhejiang University	All	18 Years to 75 Years   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ASTRUM-REC01	22/02/2023	20/02/2024	20/02/2025			16/02/2023				13/03/2023	https://ClinicalTrials.gov/show/NCT05731726		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	GI	Rectal Cancer	Celecoxib	Response rate	Phase 2	DB00482	N
NCT02432378	Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines		Suspended	Cancer of Ovary|Cancer of the Ovary|Neoplasms, Ovarian|Ovarian Cancer|Ovary Cancer|Ovary Neoplasms	Biological: Cisplatin + celecoxib + DC vaccine; Biological: Cisplatin + CKM + Celecoxib + DC Vaccine	Change in the number of CD8+ tumor infiltrating T cells in the peritoneal fluid.; Number of adverse events for the different combinations; Change in the number of CD3+CD8+ T cells in the peritoneal fluid.; Change in the number of effector CD8+ T cells in the peritoneal fluid.; Change in the number of CD4+ T cells in the peritoneal fluid.; Change in the number of Tregs in the peritoneal fluid.; Change in the number of myeloid-derived suppressor cells in the peritoneal fluid.	Roswell Park Cancer Institute; AIM ImmunoTech Inc.; National Cancer Institute (NCI); University of Pittsburgh	Female	18 Years and older   (Adult, Older Adult)	25	Other; Industry; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-128; 5P01CA132714	09/04/2015	31/12/2025	06/01/2026			05/04/2015				19/10/2022	https://ClinicalTrials.gov/show/NCT02432378		Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	United States	Gynaecological	Primary Peritoneal Cancer; Ovarian Epithelial Cancer; Fallopian Tube Cancer	Celecoxib	Biomarker	Phase 1/2	DB00482	N
NCT03728179	RACIN in Patients With Advanced TIL-negative Solid Tumors	RACIN	Unknown status	Solid Tumor, Adult	Combination Product: Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib	Phases Ia and Ib: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]; Maximum Tolerated dose (MTD) or recommended phase Ib dose of low-dose irradiation for radio-immunotherapy combination (RP1bD).; Objective response rate (ORR); Disease Control Rate (DCR); Progression free survival (PFS) rate; Time to Progression (TTP):; Overall survival (OS)	Centre Hospitalier Universitaire Vaudois	All	18 Years and older   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CHUV-DO-0003-RACIN_2017	16/01/2019	30/03/2022	30/03/2022			11/01/2018				14/01/2022	https://ClinicalTrials.gov/show/NCT03728179		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	Y	N	Switzerland	Multiple cancer types	Any solid tumours	Acetylsalicylic Acid; Celecoxib	Safety and/or Dose; Response rate	Phase 1	DB00945; DB00482	N
NCT04162873	Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer		Recruiting	Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Nasal Cavity and Paranasal Sinus Carcinoma|Oral Cavity Carcinoma|Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Recurrent Hypopharyngeal Carcinoma|Recurrent Laryngeal Carcinoma|Recurrent Nasal Cavity and Paranasal Sinus Carcinoma|Recurrent Oral Cavity Carcinoma|Recurrent Oropharyngeal Carcinoma|Stage III Hypopharyngeal Carcinoma AJCC v8|Stage III Laryngeal Cancer AJCC v8|Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IV Hypopharyngeal Carcinoma AJCC v8|Stage IV Laryngeal Cancer AJCC v8|Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IVA Hypopharyngeal Carcinoma AJCC v8|Stage IVA Laryngeal Cancer AJCC v8|Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IVB Hypopharyngeal Carcinoma AJCC v8|Stage IVB Laryngeal Cancer AJCC v8|Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IVC Hypopharyngeal Carcinoma AJCC v8|Stage IVC Laryngeal Cancer AJCC v8|Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8	Drug: Celecoxib; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration	The number of days from surgery to the initiation of radiation and adjuvant therapy; Assessment of overall pain control and management for patients on celecoxib compared to placebo.; Assessment of functional outcomes for patients on celecoxib compared to placebo; To assess the effect of celecoxib therapy on Quality of Life (QoL) compared to placebo.; Assessment of the average number of treatment days missed during adjuvant radiation for patients on celecoxib compared to placebo.	University of Utah; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	60	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	HCI124211; NCI-2019-07104; P30CA042014	27/11/2019	10/12/2024	10/12/2025			14/11/2019				26/06/2023	https://ClinicalTrials.gov/show/NCT04162873		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	United States	Head and Neck	Any head and neck cancer	Celecoxib	Other (specify)	Phase 2	DB00482	N
NCT01881048	Window of Opportunity Study Targeting the Inflammatory Milieu		Active, not recruiting	Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer	Dietary Supplement: Omega-3 fatty acid; Drug: Celecoxib	Change in mean Ki-67 index in patients receiving either omega-3 fatty acid or celecoxib for 1 or more weeks as compared to controls	University of Colorado, Denver	Female	18 Years to 50 Years   (Adult)	42	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	08-0104.cc; NCI-2011-02967	12/08/2009	14/01/2014	12/01/2023			19/06/2013				31/01/2023	https://ClinicalTrials.gov/show/NCT01881048		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	United States	Breast	Any Breast Cancer	Celecoxib; Omega 3	Biomarker	Phase 1	DB00482; DB13961	N
NCT05756166	Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer		Not yet recruiting	Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma	Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Celecoxib; Procedure: Computed Tomography; Biological: Interferon Alpha-2; Procedure: Magnetic Resonance Imaging; Biological: Pembrolizumab; Drug: Rintatolimod	Incidence of adverse events; Progression-free survival; Overall response rate; Overall survival; Disease control rate	Roswell Park Cancer Institute; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	12	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I-3010822; NCI-2023-01262; P01CA234212	30/12/2023	30/12/2025	30/12/2025			03/06/2023				31/10/2023	https://ClinicalTrials.gov/show/NCT05756166		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - TNBC	Celecoxib	Safety and/or Dose	Phase 1/2	DB00482	N
NCT04469530	Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors	AflacST1903	Recruiting	Solid Tumor	Drug: Sirolimus; Drug: Cyclophosphamide; Drug: Etoposide; Drug: Celecoxib	Two-year progression-free survival in patients with high-risk solid tumors; Median progression-free survival of children with high-risk solid tumors; Two-year progression-free survival for all prospectively enrolled participants; Two-year overall survival for all prospectively enrolled participants; Number of cases of severe toxicities; Number of patients who come off protocol therapy due to toxicity or non-compliance; Median progression-free survival of children with recurrent solid tumors in second complete remission	Emory University; PeachBowl LegACy Fund	All	1 Year to 30 Years   (Child, Adult)	50	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00000113	16/09/2020	09/01/2025	09/01/2025			14/07/2020				25/10/2023	https://ClinicalTrials.gov/show/NCT04469530		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	Y	United States	Multiple cancer types	Multiple cancer types	Celecoxib; Sirolimus	DFS/RFS/EFS	Phase 2	DB00482; DB00877	N
NCT03184493	Celebrex and Metformin for Postoperative Hepatocellular Carcinoma	XBD	Unknown status	Liver Cancer	Drug: Celebrex plus Metformin; Drug: Celebrex; Drug: Metformin	Number of participants with tumor recurrence	Guangxi Medical University	All	18 Years to 75 Years   (Adult, Older Adult)	200	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	Celebrex for HCC	06/02/2017	12/01/2020	06/01/2021			06/12/2017				31/05/2019	https://ClinicalTrials.gov/show/NCT03184493	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	China	GI	Liver Cancer	Celecoxib; Metformin	DFS/RFS/EFS	Phase 3	DB00482; DB00331	N
NCT03599453	Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer		Completed	Triple -Negative Breast Cancer|Estrogen Receptor Negative|HER2/Neu Negative|Anatomic Stage IV Breast Cancer AJCC|Progesterone Receptor Negative	Procedure: Biopsy; Procedure: Chemokine Modulation Therapy; Drug: Celecoxib; Biological: Recombinant Interferon Alfa-2b; Drug: Rintatolimod; Biological: Pembrolizumab	Overall response rate (ORR) as measured by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) criteria 1.1; Progression-free survival (PFS) as measured by irRECIST 1.1 criteria; Overall survival (OS) as measured by irRECIST 1.1 criteria; Disease control rate (DCR) as measured by irRECIST 1.1 criteria; Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	Roswell Park Cancer Institute; AIM ImmunoTech Inc.	Female	18 Years and older   (Adult, Older Adult)	8	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 62218	01/09/2019	09/02/2020	21/03/2023			26/07/2018				18/07/2023	https://ClinicalTrials.gov/show/NCT03599453		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - TNBC	Celecoxib	Response rate	Phase 1	DB00482	N
NCT00268476	Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy	STAMPEDE	Active, not recruiting	Prostate Cancer	Drug: Celecoxib; Drug: Docetaxel; Drug: Prednisolone; Drug: ADT; Drug: Zoledronic Acid; Drug: Abiraterone; Radiation: Radiotherapy to the prostate; Drug: Enzalutamide; Drug: Metformin; Drug: Transdermal Oestradiol	Overall survival; Failure-free survival; Cost effectiveness by EuroQol; Quality of life (QOL) by EORTC QOL Questionnaire C30 and prostate specific 25-item; Number of participants with treatment-related side effects as assessed by CTCAE v4.0; Skeletal related events; Biochemical failure; Progression-free survival; Lymph node progression; Distant metastases; Treatment for progression; Disease-specific survival; Non-prostate cancer death; Metabolic effects	Medical Research Council	Male	up to 120 Years   (Child, Adult, Older Adult)	11992	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000455008; MRC-STAMPEDE; EU-205102; PR08; ISRCTN78818544; 2004-000193-31	07/08/2005	03/01/2026	12/01/2030			22/12/2005				18/04/2023	https://ClinicalTrials.gov/show/NCT00268476		Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	United Kingdom	Urological	Prostate Cancer	Celecoxib; Metformin; Zoledronic Acid	OS	Phase 2/3	DB00482; DB00331; DB00399	N
NCT03026140	Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer	NICHE	Recruiting	Colon Carcinoma	Drug: Nivolumab; Drug: Ipilimumab; Drug: Celecoxib 200mg; Drug: BMS-986253; Drug: BMS-986016	Incidence of adverse events during the treatment and follow-up (safety); Disease free survival; Immune activating capacity of short-term pre-operative immunotherapy; Relapse free survival	The Netherlands Cancer Institute; Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	268	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N16NCI	29/03/2017	12/01/2024	12/01/2024			20/01/2017				26/01/2023	https://ClinicalTrials.gov/show/NCT03026140		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Netherlands	GI	Colon Cancer	Celecoxib	Safety and/or Dose; DFS/RFS/EFS	Phase 2	DB00482	N
NCT03638297	PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer	PCOX	Recruiting	Colorectal Cancer	Drug: PD-1 antibody + cox inhibitor	Response rate; Progression free survival; Overall survival time; disease control rate; Toxicity assessed using the NCI common toxicity criteria, version 4.0.; duration of response	Sun Yat-sen University	All	18 Years to 80 Years   (Adult, Older Adult)	29	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GIHSYSU13	23/08/2018	20/08/2022	31/08/2025			20/08/2018				17/10/2023	https://ClinicalTrials.gov/show/NCT03638297		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	Response rate; PFS	Phase 2	DB00945	N
NCT04081389	Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer		Completed	Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma	Drug: Celecoxib; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Paclitaxel; Biological: Recombinant Interferon Alfa-2b; Drug: Rintatolimod	Number of Patients With Dose Limiting Toxicities; Number of Patients With Pathological Complete Response (pCR); Residual Cancer Burden Index; Recurrence-free Survival (RFS); Overall Survival (OS)	Roswell Park Cancer Institute; National Center for Advancing Translational Sciences (NCATS)	All	18 Years and older   (Adult, Older Adult)	9	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 73718; NCI-2019-05299; UL1TR001412	12/06/2019	24/05/2022	27/02/2023			09/09/2019		09/11/2023		09/11/2023	https://ClinicalTrials.gov/show/NCT04081389		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - TNBC	Celecoxib	Safety and/or Dose	Phase 1	DB00482	N
NCT02748707	Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study	ERLO-XIB	Active, not recruiting	Oral Squamous Cell Carcinoma|Carcinoma of Buccal Mucosa|Tongue Cancers|Head and Neck Cancers	Drug: Arm1; Drug: Arm 2; Drug: Arm 3; Other: Arm 4	Change in expression of selected biomarkers in tissue samples, assessed by immunohistochemistry (IHC) and PCR; Clinical and radiological Change in tumor size and appearance	Tata Memorial Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	64	Other	Interventional Study	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	830	18/08/2015	02/12/2018	04/01/2023			22/04/2016				28/04/2022	https://ClinicalTrials.gov/show/NCT02748707		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	India	Head and Neck	Oropharyngeal Cancer	Celecoxib	Biomarker	Phase 2	DB00482	N
NCT04093323	Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma		Suspended	HLA-A2 Positive Cells Present|Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells; Drug: Celecoxib; Drug: PD-1 Ligand Inhibitor; Drug: PD1 Inhibitor; Biological: Recombinant Interferon Alfa-2b; Drug: Rintatolimod	Objective response rate (ORR); ORR; Durable objective response rate (>= 6 months)	Roswell Park Cancer Institute; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	24	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 82419; NCI-2019-05911; P01CA234212	31/12/2023	22/10/2025	22/12/2025			18/09/2019				30/11/2023	https://ClinicalTrials.gov/show/NCT04093323		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Skin	Melanoma	Celecoxib	Response rate	Phase 2	DB00482	N
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial		Active, not recruiting	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma	Drug: Abemaciclib; Drug: Abiraterone; Drug: Afatinib; Biological: Bevacizumab; Drug: Bicalutamide; Procedure: Biospecimen Collection; Drug: Bortezomib; Drug: Cabazitaxel; Drug: Cabozantinib; Drug: Capecitabine; Drug: Carboplatin; Drug: Celecoxib; Drug: Cobimetinib; Drug: Copanlisib; Drug: Dabrafenib; Drug: Dacomitinib; Drug: Darolutamide; Drug: Dasatinib; Drug: Doxorubicin; Biological: Durvalumab; Drug: Enasidenib; Drug: Entrectinib; Drug: Enzalutamide; Drug: Erlotinib; Drug: Everolimus; Drug: Fluorouracil; Drug: Idelalisib; Drug: Imatinib; Biological: Ipilimumab; Drug: Lenvatinib; Drug: Leucovorin; Drug: Lorlatinib; Drug: Losartan; Drug: Nab-paclitaxel; Drug: Neratinib; Biological: Nivolumab; Drug: Olaparib; Drug: Oxaliplatin; Drug: Palbociclib; Drug: Panobinostat; Biological: Pembrolizumab; Biological: Pertuzumab; Drug: Ponatinib; Other: Quality-of-Life Assessment; Drug: Regorafenib; Drug: Ruxolitinib; Drug: Sirolimus; Drug: Sorafenib; Drug: Sunitinib; Drug: Trametinib; Biological: Trastuzumab Emtansine; Drug: Tretinoin; Drug: Vemurafenib; Drug: Venetoclax; Drug: Vismodegib; Drug: Vorinostat	Feasibility of implementing an individualized treatment strategy (number of participants to receive first dose); Incidence of grade 3+ toxicities attributable to assigned study drug(s); Time to treatment discontinuation; Overall survival (OS); Time to decline (TTD)	OHSU Knight Cancer Institute; Oregon Health and Science University	All	21 Years and older   (Adult, Older Adult)	2	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00015588; NCI-2020-02743	04/01/2020	30/06/2025	30/06/2027			18/03/2019				29/11/2023	https://ClinicalTrials.gov/show/NCT03878524		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types	Multiple cancer types	Celecoxib; Clotrimazole; Losartan; Mebendazole; Miconazole; Sirolimus	Other (specify)	Phase 1	DB00482; DB00257; DB00678; DB00643; DB01110; DB00877	N
NCT02030964	N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan	DFMO	Active, not recruiting	Neuroblastoma	Drug: DFMO; Drug: Celecoxib; Drug: Cyclophosphamide; Drug: Topotecan	Number of participants with adverse events as a measure of safety and tolerability.	New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)	All	2 Years to 30 Years   (Child, Adult)	30	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N2012-01; P01CA081403	12/01/2013	12/01/2023	12/01/2023			01/09/2014				31/01/2023	https://ClinicalTrials.gov/show/NCT02030964		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	Other	Neuroblastoma	Celecoxib; Eflornithine	Safety and/or Dose	Phase 1	DB00482; DB06243	N
NCT03710876	Efficacy   Safety of rAd-IFN Administered With Celecoxib   Gemcitabine in Patients With Malignant Pleural Mesothelioma	INFINITE	Active, not recruiting	Malignant Pleural Mesothelioma	Biological: rAd-IFN; Drug: Celecoxib Oral Product; Drug: Gemcitabine	Overall Survival; Survival rate; Progression Free Survival; Best response	Trizell Ltd; University of Pennsylvania	All	18 Years and older   (Adult, Older Adult)	53	Industry; Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	rAd-IFN-MM-301; 2017-003169-82	21/01/2019	11/01/2023	11/01/2024			18/10/2018				26/10/2021	https://ClinicalTrials.gov/show/NCT03710876	Palliative	Recurrent/Refractory	Company	Y	N	N	United States	Lung	Malignant Mesothelioma	Celecoxib	OS	Phase 3	DB00482	N
NCT02641314	Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma	METRO-NB2012	Recruiting	Recurrent Neuroblastoma	Drug: metronomic therapy	non-inferiority of EFS compared to historical control group; disease control rate at 6 months; Overall survival; hospitalization days; number of transfusion days; drop-out rate; disease control rate at 12 months	University of Cologne	All	2 Years to 20 Years   (Child, Adult)	26	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Uni-Koeln-1495; 2011-004593-29	22/12/2016	12/01/2023	12/01/2023			29/12/2015				11/04/2022	https://ClinicalTrials.gov/show/NCT02641314		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	Germany	Other	Neuroblastoma	Celecoxib; Propranolol	DFS/RFS/EFS	Phase 2	DB00482; DB00571	N
NCT01356290	Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT	MEMMAT	Recruiting	Medulloblastoma Recurrent|Ependymoma Recurrent|ATRT Recurrent	Drug: Bevacizumab; Drug: Thalidomide; Drug: Celecoxib; Drug: Fenofibric acid; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Etoposide phosphate; Drug: Cytarabine	Efficacy; Overall survival rate; Progression free survival rate; Toxicity; Feasibility; Quality of life; Prognostic factors; Angiogenic factors	Medical University of Vienna	All	up to 19 Years   (Child, Adult)	100	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MUV-MEMMAT-01	04/01/2014	04/01/2026	04/01/2026			19/05/2011				21/04/2023	https://ClinicalTrials.gov/show/NCT01356290		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	Austria	CNS	Ependymoma; Central Nervous System Atypical Teratoid/Rhabdoid Tumor; Medulloblastoma	Celecoxib; Fenofibrate	Response rate	Phase 2	DB00482; DB01039	N
NCT05647330	Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer		Not yet recruiting	Hydroxychloroquine|Gemcitabine|Lung Neoplasms	Drug: Hydroxychloroquine Combined With Gemcitabine	Objective response rate(ORR); Disease control rate(DCR); Progression-free survival(PFS); Overall survival(OS)	Henan Cancer Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	55	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2022213	15/12/2022	10/01/2024	10/01/2025			12/12/2022				12/12/2022	https://ClinicalTrials.gov/show/NCT05647330		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	Lung	Non-Small Cell Lung Cancer	Hydroxychloroquine	Response rate; PFS; OS	Phase 2	DB01611	N
NCT04397679	Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma		Recruiting	Glioblastoma|Gliosarcoma	Radiation: 3-Dimensional Conformal Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy (IMRT); Drug: Temozolomide; Drug: Chloroquine; Procedure: Tumor Treating Fields Therapy (TTF)	Proportion of patients who develop a specific acute toxicity (dermatitis); Incidence of adverse events	Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	10	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018-148; P30CA022453	08/12/2021	27/04/2024	27/04/2025			21/05/2020				24/05/2023	https://ClinicalTrials.gov/show/NCT04397679		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Chloroquine	Safety and/or Dose	Phase 1	DB00608	N
NCT02432417	The Addition of Chloroquine to Chemoradiation for Glioblastoma,		Withdrawn	Glioblastoma|Astrocytoma, Grade IV	Drug: Chloroquine	Six-month progression-free survival; Overall survival; Adverse Events (AE) and serious AEs; Gene mutation, deletion or amplification; Tumor hypoxia	Maastricht Radiation Oncology	All	18 Years to 70 Years   (Adult, Older Adult)	0	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CHLOROBRAINII	11/10/2023	11/10/2023	11/10/2023			05/04/2015				18/11/2023	https://ClinicalTrials.gov/show/NCT02432417		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Netherlands	CNS	Astrocytoma; Glioblastoma	Chloroquine	Safety and/or Dose; PFS; OS; Biomarker	Phase 2	DB00608	N
NCT04772846	Chloroquine for Glioblastoma.		Unknown status	Glioblastoma	Drug: Oral tablet; Drug: Placebo	Survival duration after surgery; End-point evaluation, survival at three years	Egyptian Medical Syndicate	All	18 Years to 70 Years   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment	CQGBM	03/01/2018	12/01/2020	03/01/2021			26/02/2021				26/02/2021	https://ClinicalTrials.gov/show/NCT04772846		Localised/Locoregional	Collaborative Group	Y	N	N	Egypt	CNS	Glioblastoma	Chloroquine	OS	Phase 1/2	DB00608	N
NCT05433402	Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer		Withdrawn	Colon Cancer Stage III	Drug: ChlorproMAZINE 50 MG; Drug: Control	Disease-free survival; Overall survival; Time occurrence of new primary colon cancer and new polyps	Sadat City University	All	18 Years to 60 Years   (Adult)	0	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Onco-2022-7	20/07/2022	30/09/2022	30/09/2022			27/06/2022				27/10/2022	https://ClinicalTrials.gov/show/NCT05433402		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Egypt	GI	Colon Cancer	Chlorpromazine	DFS/RFS/EFS	Phase 1/2	DB00477	N
NCT04224441	Repurposing Chlorpromazine in the Treatment of Glioblastoma	RACTAC	Unknown status	Glioblastoma Multiforme|MGMT-Unmethylated Glioblastoma	Drug: Chlorpromazine Pill	Evaluation of toxicity; Progression-free survival (PFS); Evaluation of tumor response; Overall survival (OS)	Marco G Paggi, MD, PhD; Regina Elena Cancer Institute; Carlo Besta Neurological Institute; Istituto Oncologico Veneto IRCCS	All	18 Years to 70 Years   (Adult, Older Adult)	41	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-001988-75	15/12/2019	15/06/2022	15/12/2022			13/01/2020				13/01/2020	https://ClinicalTrials.gov/show/NCT04224441		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Italy	CNS	Glioblastoma	Chlorpromazine	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00477	N
NCT05190315	Chlorpromazine and Standard of Care in Glioblastoma		Active, not recruiting	Glioblastoma Multiforme	Drug: Chlorpromazine; Drug: Temozolomide; Radiation: Radiation Therapy	Safety and acute toxicity of chlorpromazine (CPZ) when administered throughout the standard treatment for glioblastoma multiforme (GBM) will be graded per NCI's Common Terminology Criteria for Adverse Events v 5.0 (CTCAE v5.0); Recommended phase II dose of chlorpromazine in combination with the standard treatment protocol for glioblastoma; Progression free survival of patients with newly diagnosed GBM treated with CPZ and standard chemoradiation 6 months from the date of surgery; 2-year overall survival of patients with newly diagnosed GBM treated with CPZ and standard chemoradiation 6 months from the date of surgery	Mohammed Milhem; University of Iowa	All	18 Years and older   (Adult, Older Adult)	10	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202109340	28/01/2022	07/01/2024	07/01/2024			13/01/2022				29/08/2023	https://ClinicalTrials.gov/show/NCT05190315		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma; Glioma; DIPG/DMG	Chlorpromazine	Safety and/or Dose	Phase 1	DB00477	N
NCT05462496	Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer		Recruiting	Pancreatic Cancer	Procedure: Biopsy; Drug: FOLFIRINOX; Drug: Ciprofloxacin; Drug: Metronidazole; Drug: Pembrolizumab; Procedure: Surgical Resection	Achievement of overall immune response; Adverse event incidence rate; R0 resection rate; Proportion of participants with histologic regression score 0, 1, or 2; Overall response rate (ORR); Overall survival rate (OS)	Icahn School of Medicine at Mount Sinai	All	19 Years and older   (Adult, Older Adult)	3	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY-21-01814	13/03/2023	12/01/2024	07/01/2025			18/07/2022				18/11/2023	https://ClinicalTrials.gov/show/NCT05462496		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Ciprofloxacin; Metronidazole	Other (specify)	Phase 2	DB00537; DB00916	N
NCT04523987	A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.		Recruiting	Metastatic Pancreatic Ductal Adenocarcinoma	Drug: Ciprofloxacin	Antitumor Effect - Solid Tumors	National University Hospital, Singapore	All	21 Years to 99 Years   (Adult, Older Adult)	10	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PA02/07/18	22/02/2019	02/01/2023	02/01/2024			24/08/2020				24/08/2020	https://ClinicalTrials.gov/show/NCT04523987		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Singapore	GI	Pancreatic Cancer	Ciprofloxacin	Response rate	Phase 1	DB00537	N
NCT02387203	Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin		Active, not recruiting	Pseudomyxoma Peritonei|Appendiceal Neoplasms	Drug: PrevPac (Prevacid, Amoxicillin, Clarithromycin)	Overall survival; Progression-free survival measured by no evidence of disease progression, i.e. tumor markers within normal limits, no radiographical evidence of disease	Mercy Medical Center	All	21 Years and older   (Adult, Older Adult)	80	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MMC-2014-53	01/01/2015	12/01/2024	12/01/2024			03/12/2015				14/03/2023	https://ClinicalTrials.gov/show/NCT02387203		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Other GI	Clarithromycin; Lansoprazole	PFS; OS	Phase 2	DB01211; DB00448	N
NCT04063189	Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma		Unknown status	Multiple Myeloma in Relapse	Drug: Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen	Objective response rate (ORR); Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v4.03; Progression-Free Survival (PFS); Overall Survival (OS); Duration of Response (DOR)	The First Hospital of Jilin University	All	18 Years and older   (Adult, Older Adult)	100	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BiRd 2017-288-1	21/03/2017	02/01/2020	02/01/2020			21/08/2019				21/08/2019	https://ClinicalTrials.gov/show/NCT04063189		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Other Haem-onc	Multiple Myeloma	Clarithromycin	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB01211	N
NCT01745588	Autologous Stem Cell Transplant With Pomalidomide (CC-4047 ) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma		Active, not recruiting	Multiple Myeloma	Drug: Pomalidomide; Procedure: stem cell; Drug: Dexamethasone; Drug: Clarithromycin	overall response rate; safety analyses; overall survival; progression free survival; Determine the rates of   Grade 3 toxicities	Memorial Sloan Kettering Cancer Center; Celgene Corporation; Weill Medical College of Cornell University; North Shore University Hospital; Rutgers Cancer Institute of New Jersey; State University of New York - Upstate Medical University	All	18 Years and older   (Adult, Older Adult)	23	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12-138	12/01/2012	12/01/2024	12/01/2024			12/10/2012				07/03/2023	https://ClinicalTrials.gov/show/NCT01745588		Recurrent/Refractory	Hospital/University/Research Institute	N	Y	N	United States	Other Haem-onc	Multiple Myeloma	Clarithromycin	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB01211	N
NCT04302324	A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab		Recruiting	Multiple Myeloma|Refractory Multiple Myeloma|Relapse Multiple Myeloma	Drug: Daratumumab SC; Drug: Clarithromycin; Drug: Pomalidomide; Drug: Dexamethasone	Very Good Partial Response Rate or better within 8 cycles of induction therapy; Progression-Free Survival; Overall Survival; Complete Response Rate or Better; Time to Progression; Time to Next Therapy; Duration of Response; Rate of minimal residual disease (MRD) negativity; Rate of improvement in response during maintenance therapy; Time to Best Response; Overall Response Rate; Very Good Partial Response (VGPR) Rate or better	Weill Medical College of Cornell University; Janssen Scientific Affairs, LLC	All	18 Years to 75 Years   (Adult, Older Adult)	40	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-12021155	28/10/2021	09/01/2024	01/01/2034			03/10/2020				07/05/2023	https://ClinicalTrials.gov/show/NCT04302324		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Other Haem-onc	Multiple Myeloma	Clarithromycin	Response rate	Phase 2	DB01211	N
NCT02542657	Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma		Active, not recruiting	Myeloma	Drug: Clarithromycin; Drug: Dexamethasone; Drug: Ixazomib Citrate; Drug: Pomalidomide	MTD of clarithromycin when given in combination with ixazomib citrate, pomalidomide, and dexamethasone assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I); Clinical best response	Joseph Tuscano; Takeda; Celgene; University of California, Davis	All	18 Years and older   (Adult, Older Adult)	30	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	728937; UCDCC#253; X16043; PO-TR-MM-PI-004614	10/01/2015	08/01/2024	12/01/2024			09/07/2015				09/01/2023	https://ClinicalTrials.gov/show/NCT02542657		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Other Haem-onc	Multiple Myeloma	Clarithromycin	Safety and/or Dose; Response rate	Phase 1/2	DB01211	N
NCT04287660	Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients		Recruiting	Multiple Myeloma	Drug: clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells	Overall response rate (ORR); Overall survival (OS); Event-free survival (EFS); Cumulative incidence of relapse(CIR); Number of adverse events	The First Affiliated Hospital of Soochow University; Changshu Frist People's Hospital; The Second People's Hospital of Huai'an; Affiliated Hospital of Jiangnan University; Jiangsu Province Hospital of Traditional Chinese Medicine; Jiangyin People's Hospital; Jingjiang People's Hospital; The Third People's Hospital of Kunshan; Lianyungang Hospital Affiliated Bengbu Medical College; Suzhou Municipal Hospital; Zhangjiagang First People's Hospital; Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; The First Affiliated Hospital with Nanjing Medical University; The first Affiliated Hospital of Nanjing University Medical School	All	18 Years to 75 Years   (Adult, Older Adult)	20	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BiRd-01	19/10/2017	31/01/2023	31/01/2025			27/02/2020				25/10/2021	https://ClinicalTrials.gov/show/NCT04287660	Primary/Main Curative	Any/All Stages	Hospital/University/Research Institute	N	N	N	China	Other Haem-onc	Multiple Myeloma	Clarithromycin	Response rate	Phase 3	DB01211	N
NCT01559935	Carfilzomib, Clarithromycin (Biaxin ), Lenalidomide (Revlimid ), and Dexamethasone (Decadron ) [Car-BiRD] Therapy for Subjects With Multiple Myeloma	CarBiRD	Active, not recruiting	Multiple Myeloma	Drug: carfilzomib; Drug: Dexamethasone; Drug: Clarithromycin; Drug: Lenalidomide	Response to Car-BiRD Treatment.; Event Free Survival; MRD Negativity Following CarBiRD Regimen; Progression Free Survival; Stem Cells Collection	Weill Medical College of Cornell University; Onyx Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	74	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1108011903	03/01/2012	06/07/2016	03/01/2024			21/03/2012		22/03/2017		14/04/2023	https://ClinicalTrials.gov/show/NCT01559935		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	Other Haem-onc	Multiple Myeloma	Clarithromycin	Response rate	Phase 2	DB01211	N
NCT02575144	GEM-CLARIDEX: Ld vs BiRd	GEM-CLARIDEX	Active, not recruiting	Multiple Myeloma	Drug: Clarithromycin; Drug: Lenalidomide; Drug: Dexamethasone	Progression free survival	PETHEMA Foundation; Cabyc, S.L.	All	18 Years and older   (Adult, Older Adult)	286	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEM-CLARIDEX	09/01/2015	10/01/2024	10/01/2024			14/10/2015				02/01/2022	https://ClinicalTrials.gov/show/NCT02575144	Primary/Main Curative	Any/All Stages	Collaborative Group	Y	N	N	Spain	Other Haem-onc	Multiple Myeloma	Clarithromycin	PFS	Phase 3	DB01211	N
NCT02343042	Selinexor and Backbone Treatments of Multiple Myeloma Patients	STOMP	Active, not recruiting	Multiple Myeloma	Drug: Selinexor; Drug: Dexamethasone; Drug: Lenalidomide; Drug: Pomalidomide; Drug: Bortezomib; Drug: Daratumumab; Drug: Carfilzomib; Drug: Ixazomib; Drug: Elotuzumab; Drug: Clarithromycin; Drug: Belantamab Mafodotin	Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD); Phase 1 (Dose-escalation): Recommended Phase-2 dose (RP2D); Phase 1 (Dose-escalation): Maximum Plasma Concentration (Cmax) of Selinexor; Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor; Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) (AUC0-inf); Phase 2 (Expansion): Overall response rate (ORR); Phase 2 (Expansion): Duration of response (DOR); Phase 2 (Expansion): Clinical Benefit Rate (CBR)	Karyopharm Therapeutics Inc	All	18 Years and older   (Adult, Older Adult)	518	Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KCP-330-017	10/01/2015	01/01/2025	01/01/2025			21/01/2015				31/08/2023	https://ClinicalTrials.gov/show/NCT02343042		Recurrent/Refractory	Company	N	Y	N	United States	Other Haem-onc	Multiple Myeloma	Clarithromycin	Safety and/or Dose; Response rate	Phase 1/2	DB01211	N
NCT02188368	Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients		Terminated	Multiple Myeloma	Drug: POM; Drug: Steroids; Drug: PLD; Drug: CFZ; Drug: BTZ; Drug: CLA; Drug: CY	Maximum Tolerated Dose (MTD); Number of subjects with adverse events; Overall Response Rate; Clinical Benefit Rate (CBR); Time to Progression; Progression-free survival (PFS); Time to first response (TTP); Duration of response (DOR); Overall survival (OS)	Oncotherapeutics; Celgene Corporation	All	18 Years and older   (Adult, Older Adult)	45	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PO-CL-MM-PI-003854	07/07/2014	23/10/2020	23/10/2020			07/11/2014				11/03/2023	https://ClinicalTrials.gov/show/NCT02188368		Recurrent/Refractory	Company	N	Y	N	United States	Other Haem-onc	Multiple Myeloma	Clarithromycin	Safety and/or Dose; Response rate	Phase 2	DB01211	N
NCT03031483	Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma		Active, not recruiting	Mucosa Associated Lymphoid Tissue (MALT) Lymphoma	Drug: clarithromycin and lenalidomide	Tumor response assessment; Adverse Events assessments	International Extranodal Lymphoma Study Group (IELSG)	All	18 Years to 80 Years   (Adult, Older Adult)	44	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IELSG40	04/03/2017	13/11/2019	11/01/2029			25/01/2017				11/07/2022	https://ClinicalTrials.gov/show/NCT03031483		Recurrent/Refractory	Collaborative Group	N	N	N	Italy	Lymphoma	Lymphoma - Other	Clarithromycin	Response rate	Phase 2	DB01211	N
NCT03245489	Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck		Recruiting	Head and Neck Cancer	Drug: Pembrolizumab; Drug: Clopidogrel; Drug: acetylsalicylic acid	Effect of Pembro + antiplatelet on major cellular parameters; Effect of Pembro + antiplatelets on immunologic markers; Frequency of adverse events reported; Tumor response rate	Medical University of South Carolina	All	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	102727	20/10/2017	31/12/2023	31/03/2024			08/10/2017				14/08/2023	https://ClinicalTrials.gov/show/NCT03245489		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Head and Neck	Any head and neck squamous cell carcinoma	Acetylsalicylic Acid; Clopidogrel	Biomarker	Phase 1	DB00945; DB00758	N
NCT03664115	Itraconazole in Non Small Cell Lung Cancer		Unknown status	Lung Cancer	Drug: Itraconazole 200 mg; Drug: Chemotherapy	one year progression free survival; one year overall survival; Radiological response; quality of life; Adverse effects of Itraconazole.	Ain Shams University	All	18 Years and older   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17585	07/02/2018	12/02/2019	12/02/2020			09/10/2018				09/10/2018	https://ClinicalTrials.gov/show/NCT03664115		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Egypt	Lung	Non-Small Cell Lung Cancer	Itraconazole	PFS	Phase 2	DB01167	N
NCT04194034	Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer		Terminated	Colorectal Neoplasms	Biological: TG6002; Drug: Flucytosine (5-FC)	Dose-limiting toxicities (Phase I part); Disease Control Rate (Phase II part)	Transgene	All	18 Years and older   (Adult, Older Adult)	15	Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TG6002.03	17/01/2020	23/02/2023	23/02/2023			12/11/2019				23/06/2023	https://ClinicalTrials.gov/show/NCT04194034		Advanced/Metastatic	Company	N	N	N	United Kingdom	GI	Colon Cancer; Rectal Cancer	Flucytosine	Safety and/or Dose; Response rate	Phase 1/2	DB01099	N
NCT03724071	Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.		Terminated	Colorectal Neoplasm|Digestive System Neoplasm	Biological: TG6002; Drug: Flucytosine (5-FC, Ancotil)	Phase I part - Dose-limiting toxicities; Phase II part - Overall response rate	Transgene	All	18 Years and older   (Adult, Older Adult)	51	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TG6002.02	16/10/2018	23/02/2023	23/02/2023			30/10/2018				23/06/2023	https://ClinicalTrials.gov/show/NCT03724071		Advanced/Metastatic	Company	N	N	N	France	GI	Any GI cancer	Flucytosine	Safety and/or Dose; Response rate	Phase 1/2	DB01099	N
NCT01562626	Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors		Suspended	Tumors|Neoplasms|Cancer	Drug: APS001F; Drug: Flucytosine (5-FC); Drug: 10  maltose	Number of participants with adverse events as a measure of safety and tolerability of APS001F treatment plus 5-FC and maltose	Anaeropharma Science, Inc.	All	18 Years and older   (Adult, Older Adult)	75	Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APS001F-001	09/01/2012	05/01/2021	05/01/2021			26/03/2012				05/12/2021	https://ClinicalTrials.gov/show/NCT01562626		Advanced/Metastatic	Company	N	N	N	United States	Multiple cancer types	Any solid tumours	Flucytosine	Safety and/or Dose	Phase 1/2	DB01099	N
NCT03294486	Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients	ONCOVIRAC	Unknown status	Glioblastoma|Brain Cancer	Drug: Combination of TG6002 and 5-flucytosine (5-FC, Ancotil )	Number of Participant with Dose Limiting Toxicities defined as Any of the following treatment-related adverse events (AEs) is evaluated and reported from Day 1 through Day 26; as assessed by NCI-CTCAE, version 4.03; Number of patients without documented tumor progression at 6 months from date of first TG6002 infusion according to Response Assessment Neuro-Oncology Criteria (Wen et al., 2010, JCO, PMID:20231676); TG6002 recommended dose prior to the Phase 2a part of the study (RP2D) in combination with 5-FC (Maximum Plasma Concentration [Cmax]); Overall Survival (OS); Relative quantification of circulating viral DNA; Blood pharmacokinetics of 5-FC; Blood pharmacokinetics of 5-Fluorouraril (5-FU); Blood pharmacokinetics of final metabolite a-fluoro-B-alanine(FBAL); Viral shedding in saliva, urine and feces; Humoral response; Isolation of peripheral blood mononuclear cells (PBMC);; Metabolic Response; Safety and tolerability : Incidence of Treatment; evaluation of treatement-releated adverse events	Assistance Publique - H pitaux de Paris; Transgene	All	18 Years and older   (Adult, Older Adult)	78	Other; Industry	Interventional Study	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P150936; 2015-004452-21	10/12/2017	05/01/2019	09/01/2021			27/09/2017				11/06/2017	https://ClinicalTrials.gov/show/NCT03294486		Recurrent/Refractory	Company	N	N	N	France	CNS	Glioblastoma	Flucytosine	Safety and/or Dose; PFS	Phase 1/2	DB01099	N
NCT03513211	Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer	HITMAN-PC	Completed	Prostate Cancer	Drug: SUBA-itraconazole; Drug: Hydroxychloroquine	Determination of Recommended Phase II Dose of Hydroxychloroquine in combination with Suba-itraconazole; PSA response rate; Composite safety; Time to ADT commencement; Metastasis-free survival	St Vincent's Hospital, Sydney	Male	18 Years and older   (Adult, Older Adult)	12	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HITMAN	23/08/2018	30/08/2023	30/10/2023			05/01/2018				22/11/2023	https://ClinicalTrials.gov/show/NCT03513211		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Australia	Urological	Prostate Cancer	Hydroxychloroquine; Itraconazole	Safety and/or Dose	Phase 1/2	DB01611; DB01167	N
NCT04736589	Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway		Not yet recruiting	Breast Cancer	Drug: Inetetamab; Drug: Rapamycin; Drug: Pyrotinib; Drug: Chemotherapy	Progressive-free Survival (PFS); Overall Response Rate (ORR); Overall Survival  OS ; Clinical Benefit Rate (CBR); Safety(AEs and SAEs)	Peking Union Medical College	Female	18 Years to 85 Years   (Adult, Older Adult)	270	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IR-1.1	02/02/2021	02/02/2024	02/02/2027			02/03/2021				02/03/2021	https://ClinicalTrials.gov/show/NCT04736589	Palliative	Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	China	Breast	Breast Cancer - HER2+	Sirolimus	PFS	Phase 3	DB00877	N
NCT02749513	Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients		Unknown status	Esophageal Cancer	Drug: Itraconazole	Inhibition of Hedgehog pathway signaling as measured by real-time PCR.; Inhibition of VEGFR2 pathway signaling as measured by Western blot	Dallas VA Medical Center	All	18 Years and older   (Adult, Older Adult)	18	U.S. Fed	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	15-084	01/01/2016	09/01/2019	10/01/2022			25/04/2016				11/04/2021	https://ClinicalTrials.gov/show/NCT02749513		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Esophageal Cancer	Itraconazole	Biomarker	Phase 1	DB01167	N
NCT05679388	A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients		Recruiting	Prostate Cancer|Prostate Cancer Metastatic|Prostate Adenocarcinoma	Drug: Relugolix Pill; Drug: Ritonavir; Drug: Itraconazole	Testosterone Suppression of Participants as Assessed by Testosterone Levels; Decrease in Relugolix Levels; Reduction in Prostate-Specific Antigens Levels of Participants After Study Treatment; Rate of Reported Adverse Events Among Participants	University of Chicago	Male	18 Years and older   (Adult, Older Adult)	100	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	IRB22-1150	13/02/2023	04/01/2025	04/01/2025			01/11/2023				10/06/2023	https://ClinicalTrials.gov/show/NCT05679388		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	United States	Urological	Prostate Cancer	Itraconazole; Ritonavir	Biomarker	Phase 1	DB01167; DB00503	N
NCT00859781	177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer		Active, not recruiting	Prostate Cancer	Drug: 177Lu-J591; Drug: Ketoconazole; Drug: Hydrocortisone; Drug: 111In-J591	Proportion of Participants Free of Radiographically Evident Metastases From Baseline to 18 Months After Study Drug Administration; Change in PSA Response Rate	Weill Medical College of Cornell University; United States Department of Defense	Male	18 Years and older   (Adult, Older Adult)	55	Other; U.S. Fed	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	0810010067; J591+Ketoconazole	06/01/2009	02/10/2022	12/01/2025			03/11/2009		19/07/2023		19/07/2023	https://ClinicalTrials.gov/show/NCT00859781		Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	United States	Urological	Prostate Cancer	Ketoconazole	DFS/RFS/EFS	Phase 2	DB01026	N
NCT03662412	Study of Sirolimus in Patients With Advanced Pancreatic Cancer		Unknown status	Pancreatic Cancer	Drug: Sirolimus	overall survival; Response rate	Second Affiliated Hospital, School of Medicine, Zhejiang University	All	18 Years to 80 Years   (Adult, Older Adult)	36	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SAHZU-2018-064	06/01/2018	30/06/2023	30/06/2023			09/07/2018				09/07/2018	https://ClinicalTrials.gov/show/NCT03662412		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	GI	Pancreatic Cancer	Sirolimus	OS	Phase 1/2	DB00877	N
NCT01529593	Temsirolimus in Combination With Metformin in Patients With Advanced Cancers		Active, not recruiting	Advanced Cancers	Drug: Temsirolimus; Drug: Metformin	Maximum Tolerated Dose (MTD) of Temsirolimus and Metformin; Clinical Tumor Response	M.D. Anderson Cancer Center	All	14 Years and older   (Child, Adult, Older Adult)	87	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2011-0923; NCI-2012-00216	26/03/2012	06/01/2024	06/01/2024			02/09/2012				10/06/2023	https://ClinicalTrials.gov/show/NCT01529593		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types	Any solid tumours	Metformin	Safety and/or Dose	Phase 1	DB00331	N
NCT05036226	COAST Therapy in Advanced Solid Tumors and Prostate Cancer	COAST	Recruiting	Prostate Cancer Recurrent|Solid Tumor, Adult	Combination Product: Hydroxychloroquine, Metformin, Sirolimus; Combination Product: Hydroxychloroquine, Metformin, Sirolimus, Dasatanib; Combination Product: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir; Combination Product: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib	Maximum Tolerated Dose (MTD) - Phase I; Measure of proportion of patients with disease control - Phase II; Change in Quality of Life (QOL) score	Medical University of South Carolina	All	18 Years and older   (Adult, Older Adult)	76	Other	Interventional Study	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	103352	03/03/2022	15/10/2024	15/10/2025			09/05/2021				18/04/2023	https://ClinicalTrials.gov/show/NCT05036226		Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	United States	Urological; Multiple cancer types	Prostate Cancer; Any solid tumours	Hydroxychloroquine; Metformin; Nelfinavir; Sirolimus	Safety and/or Dose; QoL; Other (specify)	Phase 1/2	DB01611; DB00331; DB00220; DB00877	N
NCT03099356	Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer		Recruiting	Metastatic Thyroid Cancer	Drug: Cyclophosphamide; Drug: Sirolimus	Percentage of patients that respond to treatment; The number of patients that experience toxicity; Median overall survival time; Median progression free survival time	University of Michigan Rogel Cancer Center	All	18 Years and older   (Adult, Older Adult)	19	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UMCC 2017.013; HUM00126559	27/04/2017	12/01/2023	12/01/2024			04/04/2017				31/08/2023	https://ClinicalTrials.gov/show/NCT03099356		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Endocrine	Thyroid Cancer	Sirolimus	Response rate	Phase 2	DB00877	N
NCT01266057	Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer		Completed	Advanced Cancers	Drug: Hydroxychloroquine; Drug: Sirolimus; Drug: Vorinostat	Maximum Tolerated Dose (MTD) of Sirolimus or Vorinostat in Combination with Hydroxychloroquine in Participants with Advanced Cancers; Antitumor Efficacy of Sirolimus or Vorinostat in Combination with Hydroxychloroquine in Participants with Advanced Cancers	M.D. Anderson Cancer Center	All	18 Years and older   (Adult, Older Adult)	143	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2010-0588; NCI-2011-00303	28/04/2011	02/11/2021	02/11/2021			24/12/2010				03/04/2021	https://ClinicalTrials.gov/show/NCT01266057		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types	Any solid tumours	Hydroxychloroquine; Sirolimus	Safety and/or Dose	Phase 1	DB01611; DB00877	N
NCT03458221	Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	STAPOVER	Recruiting	Recurrent Ovarian Cancer|Signal Transduction Pathway Deregulation|Therapy-Associated Cancer	Drug: Letrozole Oral Product; Drug: Bicalutamide Oral Product; Drug: Everolimus Oral Product; Drug: Itraconazole Oral Product	Progression free survival on matched targeted therapy determined by STP-activity (PFS2) in comparison to the PFS recorded on the therapy administered immediately prior to enrolment (PFS1).; Proportion of patients with an actionable active pathway for which targeted therapy is recommended in relation to the number of patients who underwent a biopsy.; Proportion of patients who receive matched targeted therapy in relation to the number of patients included in each study arm.; Best overall response defined by RECIST 1.1 criteria based on radiological imaging.; One-year survival; Overall survival; Predictive value of STA-analysis results on matched targeted therapy response.; Side effects; Health Related Quality of Life; Cost-effectiveness; Change in pathway activity score after disease progression compared to pathway activity score before start of matched therapy.	Gynaecologisch Oncologisch Centrum Zuid; Radboud University Medical Center; Erasmus Medical Center; Maastricht University Medical Center; InnoSIGN; Eurofins	Female	18 Years and older   (Adult, Older Adult)	148	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STAPOVER; 2020-005091-36	31/01/2023	10/01/2026	10/01/2026			03/08/2018				18/04/2023	https://ClinicalTrials.gov/show/NCT03458221	Palliative	Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Netherlands	Gynaecological	Ovarian Epithelial Cancer	Itraconazole	PFS; OS; QoL; Biomarker	Phase 3	DB01167	N
NCT03081702	A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer		Completed	Platinum-resistant Epithelial Ovarian Cancer	Drug: Hydroxychloroquine; Drug: Itraconazole	Maximum tolerated dose of hydroxychloroquine; Median progression-free survival; Overall response rate	University Health Network, Toronto	Female	18 Years and older   (Adult, Older Adult)	13	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HYDRA-1	25/07/2017	27/08/2019	27/08/2019			16/03/2017				04/02/2021	https://ClinicalTrials.gov/show/NCT03081702		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Canada	Gynaecological	Ovarian Epithelial Cancer	Hydroxychloroquine; Itraconazole	Safety and/or Dose	Phase 1/2	DB01611; DB01167	N
NCT04393454	Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy		Terminated	Metastatic dMMR Solid Cancer|Solid Tumor|Cancer|Metastatic Solid Tumor	Drug: Sirolimus 2Mg Tab	Overall Response Rate; Progression Free Survival (PFS) - median months; Response Duration (months); Overall Survival (OS) - median months	Albert Einstein College of Medicine	All	18 Years to 65 Years   (Adult, Older Adult)	6	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-10724	06/03/2020	16/05/2023	16/05/2023			19/05/2020				10/05/2023	https://ClinicalTrials.gov/show/NCT04393454		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types	Any solid tumours	Sirolimus	Response rate; PFS; OS	Phase 2	DB00877	N
NCT04481100	CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer		Unknown status	Esophageal Neoplasm|Esophageal Diseases|Esophageal Squamous Cell Carcinoma	Drug: itraconazole	Objective response rate (ORR); Treatment-emergent adverse events; Local-regional free survival (LRFS); Overall survival (OS)	Hangzhou Cancer Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	38	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20200707	10/01/2020	31/07/2021	31/07/2023			22/07/2020				14/10/2020	https://ClinicalTrials.gov/show/NCT04481100		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	GI	Esophageal Cancer	Itraconazole	Safety and/or Dose; Response rate; OS; DFS/RFS/EFS	Phase 2	DB01167	N
NCT03217669	Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy		Active, not recruiting	Advanced Solid Tumor|Non-small Cell Lung Cancer (NSCLC)	Drug: Epacadostat; Drug: sirolimus	Incidence of treatment-emergent adverse events.; Overall response response in subjects with NSCLC (dose expansion cohort); Disease control rate (DCR) >40  in subjects with NSCLC (dose expansion cohort); Median progression free survival (mPFS) >3 months in subjects with NSCLC (dose expansion cohort); Median Overall Survival (mOS) > 6 months in subjects with NSCLC (dose expansion cohort)	Chao Huang; University of Kansas Medical Center	All	18 Years and older   (Adult, Older Adult)	15	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT-2016-Epacadostat+SIRO	22/02/2018	04/01/2024	08/01/2025			14/07/2017				05/03/2023	https://ClinicalTrials.gov/show/NCT03217669		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types; Lung	Any solid tumours; Non-Small Cell Lung Cancer	Sirolimus	Safety and/or Dose	Phase 1	DB00877	N
NCT02875223	A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas		Active, not recruiting	Lymphoma, Non-Hodgkin|Neoplasms	Drug: CC-90011; Drug: Rifampicin; Drug: Itraconazole	Dose-Limiting Toxicity (DLT); Maximum tolerated dose (MTD) evaluated using the NCI CTCAE criteria; Maximum observed plasma concentration (Cmax); Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity (AUC0- ); AUC from time zero to the last quantifiable concentration (AUC0-t); Clinical Benefit Rate (CBR) determined by response and stable disease rates by disease appropriate response criteria; Objective Response Rate (ORR); Progression-Free Survival (PFS); Overall Survival (OS); Duration of Response (DOR)	Celgene	All	18 Years and older   (Adult, Older Adult)	91	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC-90011-ST-001	31/08/2016	18/09/2025	18/09/2025			23/08/2016				12/08/2023	https://ClinicalTrials.gov/show/NCT02875223		Recurrent/Refractory	Company	N	Y	N	France	Multiple cancer types; Lymphoma; Leukemia	Any solid tumours; Any lymphoma; Any leukemias	Itraconazole; Rifampicin	Safety and/or Dose	Phase 1	DB01167; DB01045	N
NCT02584647	PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors	PLX3397	Recruiting	Sarcoma|Malignant Peripheral Nerve Sheath Tumors	Drug: PLX3397; Drug: Sirolimus	Maximum tolerated dose (MTD) - Phase 1; Progression free survival (PFS) rate - Phase 2; Overall survival rate	Gulam Manji; Daiichi Sankyo, Inc.; Columbia University	All	18 Years and older   (Adult, Older Adult)	43	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AAAO6059; R01FD005745	11/04/2015	07/01/2023	03/01/2024			22/10/2015				21/02/2023	https://ClinicalTrials.gov/show/NCT02584647		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Soft Tissue Sarcoma	Other Soft Tissue Sarcoma; Any soft tissue sarcoma	Sirolimus	Safety and/or Dose; PFS	Phase 1/2	DB00877	N
NCT03796273	Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases		Recruiting	Anatomic Stage IV Breast Cancer AJCC v8|Astrocytoma|Breast Carcinoma Metastatic in the Brain|Glioma|Invasive Breast Carcinoma|Oligodendroglioma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Glioma	Other: Best Practice; Drug: Ketoconazole	tGLI1 activation signature 8 (t-GAS 8); tGLI1 pathway activation; Incidence of adverse events (AEs); Blood brain penetrance of ketoconazole in serum relative to enhancing brain tissue	Wake Forest University Health Sciences; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	19	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00054587; NCI-2018-03087; CCCWFU 91118; P30CA012197	13/03/2019	05/01/2024	07/01/2024			01/08/2019				11/03/2023	https://ClinicalTrials.gov/show/NCT03796273		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	United States	Breast; CNS	Any Breast Cancer; Glioma	Ketoconazole	Biomarker	Phase 1	DB01026	N
NCT02446431	Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence	Metronomic	Recruiting	Solid Tumor	Drug: Bevacizumab; Drug: Cyclophosphamide; Drug: Valproic Acid; Drug: Temsirolimus	5 year Event Free Survival; Number of Participants with Adverse Events as a Measure of Safety and Tolerability; Site(s) of relapse; Composite Cost of Treatment; Fatigue scores on the PedsQL Fatigue Scale; Pain scores on the Present Functioning Scale; Quality of Life scores on the PedsQL Quality of Life Scale	Miller Children's   Women's Hospital Long Beach; Children's Hospital of Orange County	All	12 Months to 31 Years   (Child, Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	1	07/01/2014	07/01/2024	07/01/2029			18/05/2015				18/05/2015	https://ClinicalTrials.gov/show/NCT02446431		Localised/Locoregional	Hospital/University/Research Institute	N	N	Y	United States	Bone Sarcoma; Soft Tissue Sarcoma	Osteosarcoma; Ewing Sarcoma; Other Soft Tissue Sarcoma; Rhabdomyosarcoma	Valproic Acid	DFS/RFS/EFS	Phase 1	DB00313	N
NCT03433183	SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors		Completed	Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1	Drug: Selumetinib; Drug: Sirolimus	Clinical benefit rate of selumetinib in combination with sirolimus in patients with unresectable or metastatic NF1 associated or sporadic MPNST.; Progression free and overall survival; Define and describe the toxicities of selumetinib in combination with sirolimus in patients with unresectable or metastatic NF1 associated or sporadic MPNST.; Assess the impact on pain interference; Assess the impact on pain severity	Sarcoma Alliance for Research through Collaboration; United States Department of Defense; AstraZeneca	All	12 Years and older   (Child, Adult, Older Adult)	21	Other; U.S. Fed; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SARC031; CDMRP-NF150092	10/02/2019	22/06/2022	10/01/2023			14/02/2018				26/12/2023	https://ClinicalTrials.gov/show/NCT03433183		Advanced/Metastatic	Collaborative Group	N	N	Y	United States	Soft Tissue Sarcoma	Other Soft Tissue Sarcoma	Selumetinib; Sirolimus	Response rate	Phase 2	DB11689; DB00877	N
NCT05563766	A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer		Not yet recruiting	Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Gastroesophageal Junction Carcinoma	Drug: Itraconazole	Rate of pathological complete response with itraconazole; Comparison of Hedgehog, AKT, and angiogenesis pathway status before and after intervention; Correlation of peripheral blood and esophageal tissue levels of itraconazole and hydroxyitraconazole with pathologic response; Develop a predictive genomic profile of treatment response; Determine the utility of ctDNA and exosome characterization as a prognostic marker	VA Office of Research and Development; Durham VA Health Care System; VA Palo Alto Health Care System; Portland VA Medical Center; VA Puget Sound Health Care System; Michael E. DeBakey VA Medical Center; VA Boston Healthcare System	All	18 Years and older   (Adult, Older Adult)	78	U.S. Fed	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ONCB-016-21F; I01CX002349	15/01/2024	14/01/2029	28/02/2029			10/03/2022				12/06/2023	https://ClinicalTrials.gov/show/NCT05563766		Localised/Locoregional	Local/National government	N	N	N	United States	GI	Esophageal Cancer	Itraconazole	Response rate; Biomarker	Phase 2	DB01167	N
NCT04018872	Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer		Recruiting	Esophagus Adenocarcinoma|Esophagus Squamous Cell Carcinoma|Gastroesophageal Junction Adenocarcinoma	Drug: Itraconazole	Percentage of pathological complete response with itraconazole; Comparison of hedgehog biomarkers before and after intervention; Comparison of phosphorylated VEGFR2 and AKT before and after intervention; Levels of itraconazole and metabolites in esophageal tissue	Dallas VA Medical Center	All	18 Years and older   (Adult, Older Adult)	78	U.S. Fed	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-017	24/06/2019	24/06/2026	29/09/2026			15/07/2019				11/04/2021	https://ClinicalTrials.gov/show/NCT04018872		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Esophageal Cancer	Itraconazole	Response rate	Phase 2	DB01167	N
NCT01552434	Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease		Active, not recruiting	Advanced Malignant Neoplasm|Castleman Disease|Digestive System Carcinoma|Erdheim-Chester Disease|Lip and Oral Cavity Carcinoma|Lymphangioleiomyomatosis|Malignant Endocrine Neoplasm|Malignant Female Reproductive System Neoplasm|Malignant Male Reproductive System Neoplasm|Malignant Neoplasm|Malignant Respiratory Tract Neoplasm|Malignant Thoracic Neoplasm|Malignant Urinary System Neoplasm|Mesothelial Neoplasm|Metastatic Malignant Neoplasm|Metastatic Urothelial Carcinoma|Neurofibromatosis Type 2|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Digestive System Carcinoma|Recurrent Female Reproductive System Carcinoma|Recurrent Male Reproductive System Carcinoma|Recurrent Malignant Neoplasm|Recurrent Pharyngeal Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Neoplasm|Soft Tissue Neoplasm|Stage III Breast Cancer AJCC v7|Stage III Pharyngeal Cancer|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Pharyngeal Cancer|Stage IVA Pharyngeal Cancer|Stage IVB Pharyngeal Cancer|Stage IVC Pharyngeal Cancer|Thyroid Gland Neoplasm	Biological: Bevacizumab; Biological: Cetuximab; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Temsirolimus; Drug: Valproic Acid	Maximum tolerated dose (MTD) of bevacizumab, defined as the dose level below the dose at which 2 of 6 patients experience drug-related dose limiting toxicity (DLT); MTD of temsirolimus, defined as the dose level below the dose at which 2 of 6 patients experience DLT; Anti-tumor efficacy of each combination (objective response); Levels of surrogate anti-angiogenesis markers	M.D. Anderson Cancer Center; National Cancer Institute (NCI)	All	Child, Adult, Older Adult	155	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2012-0061; NCI-2012-00347	16/03/2012	31/03/2024	31/03/2024			13/03/2012				09/07/2023	https://ClinicalTrials.gov/show/NCT01552434		Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	United States	Multiple cancer types	Any solid tumours	Valproic Acid	Safety and/or Dose	Phase 1	DB00313	N
NCT05896839	Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer		Recruiting	Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8|Metastatic Basal Cell Carcinoma|Metastatic Carcinoma in the Skin|Metastatic Melanoma|Metastatic Merkel Cell Carcinoma|Metastatic Skin Squamous Cell Carcinoma|Unresectable Basal Cell Carcinoma|Unresectable Melanoma|Unresectable Merkel Cell Carcinoma|Unresectable Skin Squamous Cell Carcinoma	Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Ipilimumab; Procedure: Kidney Biopsy; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab; Drug: Prednisone; Drug: Sirolimus	Disease control without allograft loss; Objective response rate (ORR); Rate of allograft loss and rejection; Duration of response (DOR) among patients who experience CR or PR; Progression-free survival (PFS); Overall survival	National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	16	NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2023-04306; 10614; UM1CA186691	08/11/2024	31/01/2027	31/01/2027			06/09/2023				01/03/2024	https://ClinicalTrials.gov/show/NCT05896839		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Skin	Basal Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Other skin cancer	Sirolimus	Response rate; PFS; OS; Other (specify)	Phase 1/2	DB00877	N
NCT04771130	A Study of BGB-11417 in Participants With Myeloid Malignancies		Recruiting	Acute Myeloid Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasm	Drug: BGB-11417; Drug: Azacitidine; Drug: Posaconazole	Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs); Part 1 And 2: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing Treatment-emergent Adverse Events (TEAEs); Part 3 AML Cohort: Complete Remission (CR) Plus CR With Partial Hematologic Recovery (CRh) Rate; Part 3 MDS Cohort: Modified Overall Response (mOR) Rate; Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to the last quantifiable (AUC0-t) Of BGB-11417 When Co-administered With Posaconazole; Part 3 AML Cohort (DDI Sub-cohort): Maximum Observed Plasma Concentration (Cmax) Of BGB-11417 When Coadministered With Posaconazole; Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to infinity (AUC0-infinity) Of BGB-11417 When Co-administered With Posaconazole; Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number Of Participants Experiencing DLTs; Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number of Participants Experiencing TEAEs; Parts 1 And 2 AML Cohort: CR Plus CRh Rate; Parts 1 And 2 MDS Cohort: mOR Rate; Parts 1 And 2: Cmax Of Azacitidine When Coadministered With BGB-11417; Parts 1 And 2: t1/2 Of Azacitidine When Coadministered With BGB-11417; Parts 1 And 2: AUC From Time Zero To Time t (AUC0-t) Of Azacitidine When Coadministered With BGB-11417; Parts 1 And 2: AUC From Time Zero To Infinity (AUC0-inf) Of Azacitidine When Coadministered With BGB-11417; Parts 1 And 2: Apparent Total Clearance Of Drug From Plasma After Oral Administration (CL/F) Of Azacitidine When Coadministered With BGB-11417; Parts 1 And 2: Apparent Volume Of Distribution (Vz/F) Of Azacitidine When Coadministered With BGB-11417; Parts 1 And 2: Steady-state AUC From Time Zero To Time Of Last Measurable Concentration (AUClast,ss) Of BGB-11417 When Coadministered With Azacitidine; Parts 1 And 2: Steady-state Cmax (Cmax,ss) Of BGB-11417 When Coadministered With Azacitidine; Parts 1 And 2: Steady-state Trough Plasma Concentration (Ctrough,ss) Of BGB-11417 When Coadministered With Azacitidine; Parts 1 And 2: Steady-state Time To Maximum Observed Plasma Concentration (tmax,ss) Of BGB-11417 When Coadministered With Azacitidine; Part 3: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing TEAEs; Part 3: Complete Response; Part 3 AML Cohort: CR With Incomplete Hematologic Recovery (CRi) Rate; Part 3 AML Cohort: Overall Response Rate (ORR); Part 3 AML Cohort: Duration Of Response (DOR); Part 3 AML Cohort: Time To Response (TTR); Part 3 AML Cohort: Event-free Survival (EFS); Part 3 AML Cohort: Overall Survival (OS); Part 3 AML Cohort: Number Of Participants Receiving BGB-11417 In Combination With Posaconazole Experiencing TEAEs; Part 3 AML Cohort: Number of Participants with Transfusion Independence; Part 3 MDS Cohort: Number Of Participants With Hematological Improvement-erythroid (HI-E); Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-platelet (HI-P); Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-neutrophil (HI-N); Part 3 MDS Cohort: Number of participants with Transfusion Independence; Part 3: Ctrough,ss Of BGB-11417 When Coadministered With Azacitidine; Part 3 MDS cohort: Partial Hematologic Recovery CRh; Part 3 AML (Treated with Monotherapy): Complete Response + Morphologic complete Remission with Partial Hematologic Recovery; Part 3 AML (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417; Part 3 MDS (Treated with Monotherapy): Modified Overall Response; Part 3 MDS (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417	BeiGene	All	18 Years and older   (Adult, Older Adult)	260	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BGB-11417-103; 2021-003285-12	24/05/2021	12/01/2023	08/01/2025			25/02/2021				19/10/2023	https://ClinicalTrials.gov/show/NCT04771130		Localised/Locoregional; Recurrent/Refractory	Company	Y	N	N	Australia	Leukemia; Other Haem-onc	Acute Lymphoblastic Leukemia, Adult; Myelodysplastic Syndromes	Posaconazole	Safety and/or Dose; Response rate	Phase 1/2	DB01263	N
NCT05591560	Itraconazole in Advanced Ovarian Cancer		Not yet recruiting	Ovarian Carcinoma	Drug: Itraconazole capsule; Drug: Placebo	The change between 2 groups in overall response rate and disease control rate; The change in the serum concentrations of the biological markers (CA-125, VEGFR-2, P-glycoprotein).	Tanta University	Female	18 Years to 65 Years   (Adult, Older Adult)	66	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	35929/10/22	10/01/2022	10/01/2024	10/01/2024			24/10/2022				24/10/2022	https://ClinicalTrials.gov/show/NCT05591560		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	Egypt	Gynaecological	Ovarian Epithelial Cancer	Itraconazole	Response rate; Biomarker; Other (specify)	Other	DB01167	N
NCT03763396	Azoles Targeting Recurrent High Grade Gliomas		Unknown status	Brain Tumor, Recurrent|Cancer, Advanced|Glioma of Brain	Drug: Ketoconazole (KCZ); Drug: Posaconazole (PCZ)	Intratumoral concentrations of KCZ or PCZ; Plasma concentrations of KCZ or PCZ; Assess Hexokinase 2 activity; Assess the biological effects of KCZ or PCZ on metabolites within the glycolytic pathway; assess the biological effects of KCZ or PCZ on tumor proliferation; assess biological effects of KCZ or PCZ on tumor cell death; assess biological effects of KCZ or PCZ on tumor angiogenesis	University Health Network, Toronto	All	18 Years and older   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	18-5097	08/01/2019	08/01/2022	08/01/2022			12/04/2018				04/01/2021	https://ClinicalTrials.gov/show/NCT03763396		Recurrent/Refractory	Hospital/University/Research Institute	N	Y	N	Canada	CNS	Glioma	Ketoconazole; Posaconazole	Other (specify)	Phase 1	DB01026; DB01263	N
NCT04813653	Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells		Recruiting	Multiple Myeloma in Relapse|Multiple Myeloma, Refractory	Drug: cyclosporine in combination with carfilzomib and dexamethasone	Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.; Overall response rate ORR; Progression free survival PFS; Duration of Response DOR; Time to Response TTR; Depth of Best Response (DpR); Time to progression (TTP); Overall Survival (OS); Extramedullary progression; Percentage of cyclosporine trough levels tests in acceptable range; Mean   of levels in acceptable range will be calculated for the efficacy population.	Tel-Aviv Sourasky Medical Center; Weizmann Institute of Science	All	18 Years and older   (Adult, Older Adult)	10	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1007-20-TLV	18/04/2021	04/01/2024	05/01/2024			24/03/2021				21/04/2023	https://ClinicalTrials.gov/show/NCT04813653		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Israel	Other Haem-onc	Multiple Myeloma	Cyclosporine	Safety and/or Dose	Phase 1	DB00091	N
NCT03778996	SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma	HopES	Active, not recruiting	Sarcoma, Ewing|Sarcoma	Drug: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)	Overall Response Rate; Stable Disease for at Least 3 Months; Progression Free Survival on Study of at Least 1.5 Times the Duration of PFS for the Last Prior Treatment; Duration of Response; Overall Survival; Clinical Benefit Rate; Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5	Sarcoma Oncology Research Center, LLC; Tyme, Inc	All	12 Years and older   (Child, Adult, Older Adult)	31	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SM-88-JAF-16	01/03/2020	19/01/2023	31/10/2023			19/12/2018				23/01/2023	https://ClinicalTrials.gov/show/NCT03778996		Advanced/Metastatic; Recurrent/Refractory	Collaborative Group	N	N	N	United States	Bone Sarcoma; Soft Tissue Sarcoma	Ewing Sarcoma; Any Bone Sarcomas; Any soft tissue sarcoma	Phenytoin; Sirolimus	Response rate	Phase 2	DB00252; DB00877	N
NCT02583893	Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia		Completed	Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia	Drug: Sirolimus; Drug: Mitoxantrone; Drug: Etoposide; Drug: Cytarabine	Biochemical response; Clinical response; Incidence of adverse events; Overall response rate (ORR) (complete response [CR], CR with incomplete platelet recovery [CRp], or partial response); Relapse free survival (RFS); Overall survival (OS)	Sidney Kimmel Cancer Center at Thomas Jefferson University; Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	39	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	15D.377; 2013-087; NCI-2015-01507	10/07/2015	17/04/2023	17/05/2023			22/10/2015				10/10/2023	https://ClinicalTrials.gov/show/NCT02583893		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	Leukemia	Acute Myeloid Leukemia, Adult	Sirolimus	Biomarker	Phase 2	DB00877	N
NCT02675452	AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia		Active, not recruiting	Relapsed or Refractory Multiple Myeloma|Relapsed or Refractory Acute Myeloid Leukemia	Drug: AMG 176; Drug: Azacitidine; Drug: Itraconazole	Multiple Myeloma (MM) Part 1a Incidence of dose-limiting toxicities (DLTs); MM Part 1a Incidence of treatment-related adverse events; MM Part 1a Incidence of treatment-emergent adverse events; MM Part 1a Incidence of clinically significant changes in vital signs; MM Part 1a Incidence of clinically significant changes in electrocardiograms (ECGs); MM Part 1a Incidence of clinically significant changes in clinical laboratory tests; MM Part 1a Pharmacokinetic (PK) parameters for AMG 176: maximum observed concentration (Cmax); MM Part 1a Pharmacokinetic parameters for AMG 176: area under the concentration-time curve (AUC); MM Part 1a Pharmacokinetic parameters for AMG 176: clearance (CL); MM Part 1a Pharmacokinetic parameters for AMG 176: half-life (t1/2); MM Part 1b Incidence of DLTs; MM Part 1b Incidence of treatment-related adverse events; MM Part 1b Incidence of treatment-emergent adverse events; MM Part 1b Incidence of clinically significant changes in vital signs; MM Part 1b Incidence of clinically significant changes in ECGs; MM Part 1b Incidence of clinically significant changes in clinical laboratory tests; MM Part 1b Pharmacokinetic parameters for AMG 176: Cmax; MM Part 1b Pharmacokinetic parameters for AMG 176: AUC; MM Part 1b Pharmacokinetic parameters for AMG 176: CL; MM Part 1b Pharmacokinetic parameters for AMG 176: t1/2; Acute Myeloid Leukemia (AML) Part 3a Incidence of DLTs; AML Part 3a Incidence of treatment-related adverse events; AML Part 3a Incidence of treatment-emergent adverse events; AML Part 3a Incidence of clinically significant changes in vital signs; AML Part 3a Incidence of clinically significant changes in ECGs; AML Part 3a Incidence of clinically significant changes in clinical laboratory tests; AML Part 3a Pharmacokinetic parameters for AMG 176: Cmax; AML Part 3a Pharmacokinetic parameters for AMG 176: AUC; AML Part 3a Pharmacokinetic parameters for AMG 176: CL; AML Part 3a Pharmacokinetic parameters for AMG 176: t1/2; AML Part 3b Incidence of DLTs; AML Part 3b Incidence of treatment-related adverse events; AML Part 3b Incidence of treatment-emergent adverse events; AML Part 3b Incidence of clinically significant changes in vital signs; AML Part 3b Incidence of clinically significant changes in ECGs; AML Part 3b Incidence of clinically significant changes in clinical laboratory tests; AML Part 3b Pharmacokinetic parameters for AMG 176: Cmax; AML Part 3b Pharmacokinetic parameters for AMG 176: AUC; AML Part 3b Pharmacokinetic parameters for AMG 176: CL; AML Part 3b Pharmacokinetic parameters for AMG 176: t1/2; AML Part 3c Incidence of DLTs; AML Part 3c Incidence of treatment-related adverse events; AML Part 3c Incidence of treatment-emergent adverse events; AML Part 3c Incidence of clinically significant changes in vital signs; AML Part 3c Incidence of clinically significant changes in ECGs; AML Part 3c Incidence of clinically significant changes in clinical laboratory tests; AML Part 3c Pharmacokinetic parameters for AMG 176: Cmax; AML Part 3c Pharmacokinetic parameters for AMG 176: AUC; AML Part 3c Pharmacokinetic parameters for AMG 176: CL; AML Part 3c Pharmacokinetic parameters for AMG 176: t1/2; AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: Cmax; AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: AUC; AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: CL; AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: t1/2; AML Part 4 Incidence of DLTs; AML Part 4 Incidence of treatment-related adverse events; AML Part 4 Incidence of treatment-emergent adverse events; AML Part 4 Incidence of clinically significant changes in vital signs; AML Part 4 Incidence of clinically significant changes in ECGs; AML Part 4 Incidence of clinically significant changes in clinical laboratory tests; AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: Cmax; AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: AUC; AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: CL; AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: t1/2; AML Part 5 Incidence of treatment-related adverse events; AML Part 5 Incidence of treatment-emergent adverse events; AML Part 5 Incidence of clinically significant changes in vital signs; AML Part 5 Incidence of clinically significant changes in ECGs; AML Part 5 Incidence of clinically significant changes in clinical laboratory tests; AML Part 5 Pharmacokinetic parameters for AMG 176 and azacitidine: Cmax; AML Part 5 Pharmacokinetic parameters for AMG 176 and azacitidine: AUC; AML Part 5 Pharmacokinetic parameters for AMG 176 and azacitidine: CL; AML Part 5 Pharmacokinetic parameters for AMG 176 and azacitidine: t1/2; MM Part 1a Overall response (OR) according to International Myeloma Working Group uniform response criteria (IMWG-URC) for MM subjects; MM Part 1a Progression-free survival (PFS); MM Part 1a Time to response; MM Part 1a Duration of response (DOR); MM Part 1a BAX and caspase 3 expression in circulating monocytes	Amgen	All	18 Years to 85 Years   (Adult, Older Adult)	142	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20150161; 2015-004777-32	13/06/2016	29/01/2024	25/07/2024			02/05/2016				15/12/2023	https://ClinicalTrials.gov/show/NCT02675452		Recurrent/Refractory	Company	N	Y	N	United States	Leukemia; Other Haem-onc	Acute Myeloid Leukemia, Adult; Multiple Myeloma	Itraconazole	Safety and/or Dose	Phase 1	DB01167	N
NCT03972748	Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.		Unknown status	Basal Cell Carcinoma|Hedgehog Pathway	Drug: Itraconazole 200 mg	clinical response; hedgehog pathway activity	Hospital de Clinicas de Porto Alegre	All	18 Years and older   (Adult, Older Adult)	28	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	47011715.0.0000.5327	01/05/2018	12/01/2020	06/01/2021			06/04/2019				06/04/2019	https://ClinicalTrials.gov/show/NCT03972748		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Brazil	Skin	Basal Cell Carcinoma	Itraconazole	Response rate	Other	DB01167	N
NCT03013933	Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma		Active, not recruiting	Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma	Drug: Brentuximab Vedotin; Drug: Cyclosporine; Other: Pharmacokinetic Study; Drug: Verapamil; Drug: Verapamil Hydrochloride	Dose-limiting toxicity; Overall response rate (complete response + partial response); Complete response rate assessed by Cheson 2014 criteria; Duration of overall response; Duration of complete response; Overall survival; Progression-free survival; Incidence of adverse events assessed	City of Hope Medical Center; National Cancer Institute (NCI)	All	15 Years and older   (Child, Adult, Older Adult)	29	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16414; NCI-2016-02062	05/03/2017	26/12/2023	26/12/2023			01/09/2017				21/02/2023	https://ClinicalTrials.gov/show/NCT03013933		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	Lymphoma	Hodgkin Lymphoma, Adult; Hodgkin Lymphoma, Childhood	Verapamil	Safety and/or Dose	Phase 1	DB00661	N
NCT05324384	Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma		Recruiting	Hemangioendothelioma	Drug: Sirolimus	The changes in KHE volume; Quality of life (QOL) in patients; Frequency of adverse events; The changes in the patient's musculoskeletal complication.; The changes of platelet counts.; The changes of fibrinogen levels.; The changes of D-dimer levels.	West China Hospital	All	up to 14 Years   (Child)	30	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2022-405	04/05/2022	30/04/2025	30/11/2025			04/12/2022				05/06/2022	https://ClinicalTrials.gov/show/NCT05324384		Localised/Locoregional	Hospital/University/Research Institute	N	N	Y	China	Other	Other	Sirolimus	Safety and/or Dose; QoL; Biomarker	Phase 2	DB00877	N
NCT04775173	Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.		Completed	Kaposiform Hemangioendothelioma	Drug: Sirolimus	The proportion of patients achieving an objective response at month 12; lesion responses; Quality of life (QOL) in patients; Disease sequelae; Frequency of adverse events; The changes of fibrinogen and D-dimer levels	West China Hospital	All	1 Day to 14 Years   (Child)	79	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2021-217	17/02/2021	08/10/2023	08/10/2023			03/01/2021				21/12/2023	https://ClinicalTrials.gov/show/NCT04775173	Primary/Main Curative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	Y	China	Soft Tissue Sarcoma	Kaposi Sarcoma (non-AIDS related)	Sirolimus	Response rate	Phase 3	DB00877	N
NCT01869114	Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy		Active, not recruiting	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Myelodysplastic Syndrome With Isolated Del(5q)|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia	Drug: Sirolimus; Drug: Azacitidine	Rate of response; Toxicity referring to toxic events during the full course of treatment that are attributed as possibly, probably or definitely due to treatment, graded according to the National Institutes of Health (NIH) Common Toxicity Criteria (CTC) v. 4.0; Pharmacokinetic assessment to assess levels of the drug in vivo; Inhibition of mTOR signaling by sirolimus measured by intracellular flow cytometry for phosphorylation of the downstream signaling target S6 ribosomal protein as a surrogate for mTOR activity; Quality of life (QOL) assessed by the European Organization for Research and Treatment of Cancer (EORTC) QOL and the Mental Health Inventory (MHI)	Sidney Kimmel Cancer Center at Thomas Jefferson University; Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	57	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12D.587; 2012-50	07/08/2013	12/01/2023	12/01/2023			06/05/2013				06/07/2023	https://ClinicalTrials.gov/show/NCT01869114		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	Leukemia	Acute Myeloid Leukemia, Adult	Sirolimus	Response rate	Phase 2	DB00877	N
NCT05279690	Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors		Recruiting	Urothelial Cancer|Metastatic Solid Tumor	Drug: Colchicine	Percent Change in Peripheral blood CRP level	Icahn School of Medicine at Mount Sinai	All	18 Years and older   (Adult, Older Adult)	45	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY-21-01175	14/02/2022	14/02/2025	14/02/2025			15/03/2022				21/03/2023	https://ClinicalTrials.gov/show/NCT05279690		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Urological; Multiple cancer types	Bladder Cancer; Any solid tumours	Colchicine	Biomarker	Phase 1	DB01394	N
NCT04264260	Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment		Recruiting	Hepatocellular Carcinoma Stage IIIB|Cholangiocarcinoma, Intrahepatic|Cholangiocarcinoma; With Hepatocellular Carcinoma|Hepatocellular Carcinoma Stage IV	Drug: Colchicine Tablets	survival; serious adverse effect	Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Medical University	All	20 Years to 85 Years   (Adult, Older Adult)	80	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KMUHIRB-F(II)-20190152	24/12/2019	31/07/2025	31/07/2025			02/11/2020				10/06/2023	https://ClinicalTrials.gov/show/NCT04264260		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Taiwan	GI	Liver Cancer; Cholangiocaricnoma	Colchicine	OS	Phase 2	DB01394	N
NCT05802992	The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients		Recruiting	Multiple Myeloma	Drug: Colchicine; Drug: Lenalidomide	Serum M protein; Proportion of bone marrow plasma cells; Serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP ; Serum free light chain (FLC); Imaging X ray/CT/MRI ; Complete blood count (CBC); Blood biochemistries; Eastern Cooperative Oncology Group (ECOG) Score	Affiliated Hospital of Nantong University	All	18 Years to 80 Years   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2022-K043-01	30/03/2022	31/12/2024	31/12/2024			04/07/2023				04/07/2023	https://ClinicalTrials.gov/show/NCT05802992	Primary/Main Curative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Other Haem-onc	Multiple Myeloma	Colchicine	Biomarker	Phase 3	DB01394	N
NCT05284552	Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer		Recruiting	Epithelial Ovarian Cancer	Drug: Tinzaparin Injectable Solution	Changes in serum levels of CA-125; Changes in blood levels of hemoglobin; Changes in blood levels of platelets; Changes in blood levels of leucocytes; Changes in plasma levels of CRP; Changes in plasma levels of albumin; Changes in plasma levels of interleukin 6; Changes in plasma levels of vascular endothelial growth factor; Self reported compliance to tinzaparin injections; Number of participants with treatment-related adverse events as assessed by CTCAE v4.0; Proportion of participants with treatment-related adverse events as assessed by CTCAE v4.0; Objectively confirmed venous thromboembolism (VTE), i.e. pulmonary embolism, lower-limb deep vein thrombosis or upper extremity deep vein thrombosis. Death due to VTE.	University Hospital, Linkoeping; Region J nk ping County; V stervik Hospital	Female	18 Years and older   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	The TABANETOC-trial; 2021-000135-31	07/12/2022	31/12/2024	31/12/2024			17/03/2022				28/04/2023	https://ClinicalTrials.gov/show/NCT05284552		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Sweden	Gynaecological	Ovarian Epithelial Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancer	Tinzaparin	Safety and/or Dose; Biomarker	Phase 2	DB06822	N
NCT05178628	The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer	imPaCT-PRO	Recruiting	Pancreatic Cancer|Thromboembolism	Drug: Innohep; Drug: Chemotherapy: Gemcitabine + Nab-Paclitaxel	PFS of patients; The number of VTE events during the trial;   of patients experiencing at least one major bleeding event;   of patients experiencing any bleeding event; VTE events; Patients with complete or partial response; Change from baseline in QoL	Michalis Karamouzis; Institute of Molecular Medicine and Biomedical Research	All	18 Years and older   (Adult, Older Adult)	450	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	imPaCT-PRO-01	02/10/2022	31/12/2024	31/12/2024			01/05/2022				29/03/2022	https://ClinicalTrials.gov/show/NCT05178628	Primary/Main Curative	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Greece	GI	Pancreatic Cancer	Tinzaparin	PFS; Other (specify)	Phase 3	DB06822	N
NCT01455831	Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer	PERIOP-01	Completed	Adenocarcinoma of the Colon	Drug: Tinzaparin	Disease Free Survival; Overall Survival; Venous Thromboembolism events; Major surgical site bleeding events; Major bleeding events (not including the surgical site);   Clinically relevant bleeding events prior to surgery and during the   Clinically relevant bleeding events; Transfusion requirements; Correlative endpoints; Other post-operative (day 0 - day 28) complications	Ottawa Hospital Research Institute	All	18 Years and older   (Adult, Older Adult)	616	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	221097	09/01/2011	31/12/2020	02/01/2021			20/10/2011				17/05/2021	https://ClinicalTrials.gov/show/NCT01455831	Perioperative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Canada	GI	Colon Cancer; Rectal Cancer	Tinzaparin	DFS/RFS/EFS	Phase 3	DB06822	N
NCT05025735	Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer		Unknown status	Metastatic Breast Cancer|HER2-negative Breast Cancer	Drug: Dapagliflozin 10Mg Tab	Incidence of all grade hyperglycemia as assessed by CTCAE v5.0; Incidence of Grade 3/4 hyperglycemia as assessed by CTCAE v5.0; Overall response rate (ORR) as assed by RECIST 1.1 in patients with measurable disease; Progression free survival	Saint Luke's Health System; Novartis Pharmaceuticals	All	18 Years to 65 Years   (Adult, Older Adult)	25	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CBYL719A0US03T	25/08/2021	12/01/2022	07/01/2023			27/08/2021				19/10/2021	https://ClinicalTrials.gov/show/NCT05025735		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - HER2-; Breast Cancer - ER/HR+	Dapagliflozin	Response rate; PFS; Biomarker	Phase 2	DB06292	N
NCT04887935	Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer		Not yet recruiting	Prostate Cancer|Cancer of Prostate	Drug: Dapagliflozin; Device: BIOSENSE Meter	Frequency and severity of toxicities related to dapagliflozin as measured by CTCAE v 5.0; Number of patients enrolled in 24 months; Percent reduction in prostate tumor size as determined by pre-operative prostate MRI; Percentage of prostate tumor necrosis; Change in plasma glucose; Change in ketones; Change in HbA1C	Washington University School of Medicine	Male	18 Years and older   (Adult, Older Adult)	24	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202107070	31/12/2023	28/02/2027	28/02/2027			14/05/2021				18/08/2023	https://ClinicalTrials.gov/show/NCT04887935		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Dapagliflozin	Safety and/or Dose; Other (specify)	Phase 1	DB06292	N
NCT04899349	Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant	EPIK-B4	Terminated	Breast Cancer	Drug: Alpelisib; Drug: Fulvestrant; Drug: Metformin XR; Drug: Dapagliflozin + metformin XR; Drug: Dapagliflozin	Number of Participants With Hyperglycemia Grade   3 Over the First Eight Weeks of Alpelisib Plus Fulvestrant Treatment; Progression-free Survival (PFS) Based on Local Investigator Assessment; Overall Response Rate (ORR) With Confirmed Response Based on Local Investigator Assessment as Per RECIST 1.1.; Clinical Benefit Rate (CBR) With Confirmed Response Based on Local Investigator Assessment as Per RECIST 1.1; Number of Participants With Dose Modifications	Novartis Pharmaceuticals; Novartis	All	18 Years and older   (Adult, Older Adult)	2	Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CBYL719C2202	04/06/2022	05/10/2023	05/10/2023			24/05/2021		12/12/2023		12/12/2023	https://ClinicalTrials.gov/show/NCT04899349		Advanced/Metastatic	Company	N	Y	N	United States	Breast	Breast Cancer - ER/HR+; Breast Cancer - HER2+	Metformin	Response rate; PFS; Biomarker; Other (specify)	Phase 2	DB00331	N
NCT05521984	Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)		Recruiting	Pediatric Brain Tumor	Drug: Dapagliflozin; Drug: Carmustine	Number and type of adverse events experienced by participants; Change in blood glucose; Change in ketones; Change in HbA1c; Tumor response rate; Feasibility of regimen; Changes in fructosamine; Changes in c-peptide; Changes in glucagon	Washington University School of Medicine; Children's Discovery Institute	All	6 Years to 21 Years   (Child, Adult)	20	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202210013	04/03/2023	31/08/2026	30/11/2026			30/08/2022				04/06/2023	https://ClinicalTrials.gov/show/NCT05521984		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	CNS	Any CNS cancers	Dapagliflozin	Safety and/or Dose; Response rate; Biomarker	Phase 1	DB06292	N
NCT04113005	Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer		Unknown status	Castrate Resistance Prostate Cancer	Drug: Desmopressin	Number of subjects presenting with AEs within a 21-day period of time post Desmopressin/Docetaxel treatment; nature and severity of AEs (as per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, Appendix B).	Sunnybrook Health Sciences Centre; Sunnybrook Research Institute	Male	Child, Adult, Older Adult	10	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Desmopressin Trial	10/01/2019	30/04/2020	10/01/2020			10/02/2019				10/02/2019	https://ClinicalTrials.gov/show/NCT04113005		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Canada	Urological	Prostate Cancer	Desmopressin	Safety and/or Dose	Phase 1	DB00035	N
NCT03889795	Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors		Recruiting	Advanced Pancreatic Cancer|Advanced Solid Tumor	Drug: Metformin; Drug: Simvastatin; Drug: Digoxin	Maximum Tolerated Dose and/or Recommended Dose within the tested C3 dose range; Safety and Tolerability: Occurrence of treatment - emergent adverse events (TEAEs) and other abnormalities; Efficacy (Disease Response); Assess BIRC5 levels of expression in tumor tissue; Assess molecular changes induced by C3 administration in the blood for biomarker sensitivity/resistance assessment	Danae Hamouda, MD; University of Toledo	All	18 Years and older   (Adult, Older Adult)	15	Other	Interventional Study	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C3	06/05/2019	30/12/2024	30/12/2025			26/03/2019				09/01/2023	https://ClinicalTrials.gov/show/NCT03889795		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types	Any solid tumours	Digoxin; Metformin; Simvastatin	Safety and/or Dose	Phase 1	DB00390; DB00331; DB00641	N
NCT04141995	FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer		Recruiting	Pancreas Cancer|Adenocarcinoma of the Pancreas	Drug: Digoxin; Drug: 5Fluorouracil; Drug: Calcium Leucovorin; Drug: Irinotecan; Drug: Oxaliplatin	Number of patients able to undergo resection surgery; Percentage of subjects with grade 4 thrombocytopenia and grade 3-4 diarrhea	University of Nebraska; National Cancer Institute (NCI)	All	19 Years and older   (Adult, Older Adult)	20	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0668-19-FB; 1P50CA127297-01A2	02/12/2021	02/01/2025	02/01/2025			28/10/2019				10/03/2023	https://ClinicalTrials.gov/show/NCT04141995		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Digoxin	Other (specify)	Phase 2	DB00390	N
NCT05507775	Digoxin for the Reinduction of Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma	DIGUP-TC	Active, not recruiting	Non-Medullary Thyroid Carcinoma	Drug: Digoxin tablet	Reinduction of radioiodine uptake in target lesion; Beneficial effects of high-dose radioactive iodine treatment after reinduction; Safety of digoxin treatment	Radboud University Medical Center	All	18 Years and older   (Adult, Older Adult)	10	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2022-500477-14-00	12/06/2022	21/06/2023	01/01/2024			19/08/2022				08/04/2023	https://ClinicalTrials.gov/show/NCT05507775		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Netherlands	Endocrine	Thyroid Cancer	Digoxin	Safety and/or Dose; Biomarker	Other	DB00390	N
NCT02874430	Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer		Active, not recruiting	Breast Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Uterine Corpus Cancer|Uterine Corpus Carcinosarcoma	Drug: Metformin Hydrochloride; Drug: Doxycycline	Change in the percent of stromal cells expressing Caveolin-1 (CAV1) at an intensity of 1+ or greater assessed by immunohistochemistry; Incidence of adverse events evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0; Change in the percent of stromal cells expressing express Monocarboxylate Transporter 4 (MCT4) in the cancer cells; Change in the percent of tumor cells that express Monocarboxylate Transporter 1 (MCT1) and Transporter of Outer Mitochondrial Membrane 20 (TOMM20) in the cancer cells; Percentage of stromal cells expressing Caveolin-1 (CAV1) or Monocarboxylate Transporter 4 (MCT4); Percentage of tumor cells that express Monocarboxylate Transporter 1 (MCT1) and Transporter of Outer Mitochondrial Membrane 20 (TOMM20); Progress-free survival; Overall survival; Objective response rate	Sidney Kimmel Cancer Center at Thomas Jefferson University; Thomas Jefferson University	Female	18 Years and older   (Adult, Older Adult)	27	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16D.317	06/08/2016	12/02/2020	06/01/2023			22/08/2016				15/12/2022	https://ClinicalTrials.gov/show/NCT02874430		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Breast; Gynaecological	Any Breast Cancer; Endometrial Cancer	Doxycycline; Metformin	Safety and/or Dose; PFS; OS; Biomarker	Phase 2	DB00254; DB00331	N
NCT03076281	Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery		Active, not recruiting	Larynx|LIP|Oral Cavity|Pharynx	Drug: Metformin Hydrochloride; Drug: Doxycycline; Drug: Metformin +Doxycycline	Change in percent of CFS expressing CAV-1 at an intensity of 1+ or greater assessed in tumor-associated stroma cells by immunohistochemistry (IHC); Incidence of adverse events as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0; Change in percent of tumor cells expressing MCT4, that are TUNEL positive and that express BGAL; Change in percent of tumor cells expressing MCT4, that are TUNEL positive and that express MCT1; Change in percent of tumor cells expressing MCT4, that are TUNEL positive and that express MCT4; Change in percent of tumor cells expressing MCT4, that are TUNEL positive and that express TOMM20	Sidney Kimmel Cancer Center at Thomas Jefferson University; Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	7	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	16D.703	04/03/2017	12/03/2018	08/01/2020			03/10/2017				24/12/2018	https://ClinicalTrials.gov/show/NCT03076281		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	United States	Head and Neck	Any head and neck squamous cell carcinoma	Doxycycline; Metformin	Safety and/or Dose; Biomarker	Phase 2	DB00254; DB00331	N
NCT02341209	Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma	CTCL	Terminated	Cutaneous T-cell Lymphoma|Mycosis Fungoides|Sezary Syndrome	Drug: Doxycycline monohydrate	Efficacy of Doxycycline in relapsed CTCL; Duration of Response	Rochester General Hospital	All	18 Years and older   (Adult, Older Adult)	1	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	53677	02/06/2018	02/06/2021	02/06/2021			19/01/2015				27/04/2021	https://ClinicalTrials.gov/show/NCT02341209		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Lymphoma	Cutaneous T-Cell Lymphoma	Doxycycline	Response rate; Other (specify)	Phase 2	DB00254	N
NCT01820910	Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment		Active, not recruiting	Marginal Zone Lymphoma of Ocular Adnexal	Drug: Doxycycline	progression-free survival (PFS)	International Extranodal Lymphoma Study Group (IELSG)	All	18 Years and older   (Adult, Older Adult)	34	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IELSG39	03/01/2013	05/01/2016	09/01/2023			29/03/2013				18/05/2023	https://ClinicalTrials.gov/show/NCT01820910		Localised/Locoregional	Collaborative Group	N	N	N	United States	Lymphoma	Lymphoma - Other	Doxycycline	PFS	Phase 2	DB00254	N
NCT03116659	CTCL Directed Therapy		Unknown status	Lymphoma, T-Cell, Cutaneous	Drug: Doxycycline; Drug: Imiquimod	Pilot assessment of response.	James J. Peters Veterans Affairs Medical Center	All	30 Years to 89 Years   (Adult, Older Adult)	8	U.S. Fed	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DAN-15-028	02/01/2018	30/12/2020	30/12/2020			17/04/2017				13/08/2019	https://ClinicalTrials.gov/show/NCT03116659		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Lymphoma	Cutaneous T-Cell Lymphoma	Doxycycline	Response rate	Phase 1	DB00254	N
NCT01653925	Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression		Active, not recruiting	Prostatic Neoplasms|Low Grade Prostate Cancer	Other: Dietary intervention first; Drug: Drug (Dutasteride) intervention first	Effects of the Interventions on Lipid Metabolism From Blood and Prostatic Microenvironment; Effect of Interventions on Gene Expression Profile; Effects of Interventions on Hormonal Metabolism; Determine the Clinical Utility of Urine-Based Cancer Markers in the Context of Interventions to Reduce Cancer Progression	CHU de Quebec-Universite Laval; Prostate Cancer Canada	Male	35 Years to 75 Years   (Adult, Older Adult)	120	Other	Interventional Study	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	INAF-2010-H09-10-114	11/01/2010	12/01/2023	12/01/2023			31/07/2012				14/02/2023	https://ClinicalTrials.gov/show/NCT01653925		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Canada	Urological	Prostate Cancer	Dutasteride	Biomarker	Other	DB01126	N
NCT02213107	Enzalutamide   Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.		Completed	Prostate Cancer	Drug: Enzalutamide and Dutasteride or finasteride	PSA Progression Free Survival; Change in lowest PSA level compared to baseline PSA level (Absolute PSA response); Time to PSA Nadir; Number of participants who experience a treatment-related adverse events.	University of Rochester	All	65 Years to 85 Years   (Older Adult)	43	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	53018	09/01/2014	31/10/2023	31/10/2023			08/11/2014				01/03/2024	https://ClinicalTrials.gov/show/NCT02213107		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Dutasteride; Finasteride	Biomarker	Phase 2	DB01126; DB01216	N
NCT01342367	Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer		Active, not recruiting	Prostate Cancer	Drug: Bicalutamide; Drug: Dutasteride; Drug: Finasteride; Radiation: Radiation	Quality of Life Was Measured by the Expanded Prostate Cancer Index Composite (EPIC) Hormonal Health-related Quality of Life Questionnaire; Percentage of Participants Free From Biochemical Failure	University of Chicago	Male	18 Years and older   (Adult, Older Adult)	74	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-625-A	17/12/2010	05/01/2020	02/01/2024			27/04/2011		28/10/2021		05/11/2023	https://ClinicalTrials.gov/show/NCT01342367		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Dutasteride; Finasteride	QoL	Other	DB01126; DB01216	N
NCT05513365	Phase II Dutasteride in Combination With CAB vs CAB in SDC	DUCT	Recruiting	Salivary Duct Carcinoma	Drug: Goserelin 10.8 mg; Drug: Bicalutamide 50 mg; Drug: Dutasteride 0.5 mg	Overall Response Rate (ORR); Duration of Response (DoR); Progression Free Survival (PFS); Clinical benefit rate (CBR); Overall survival (OS); Quality of Life (QoL) based on the EORTC QLQ-C30 questionnaire; Quality of Life (QoL) based on the EORTC QLQ-H N43 questionnaire; Quality of Life (QoL) based on the EORTC QLQ-SHQ22 questionnaire; Pain level assessed by the VAS (visual analog scale) questionnaire; Adverse Events according to CTCAE v5.0; Circulating tumor DNA (ctDNA) levels; mRNA expression levels of AR and AR splice variants; mRNA expression levels of SRD5A1/SRD5A2	Radboud University Medical Center; ZonMw: The Netherlands Organisation for Health Research and Development	All	18 Years and older   (Adult, Older Adult)	98	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MOHN22; 1140022110057	27/09/2022	09/01/2025	09/01/2027			24/08/2022				30/03/2023	https://ClinicalTrials.gov/show/NCT05513365		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	Netherlands	Head and Neck	Salivary Gland Cancer	Dutasteride	Response rate; PFS; OS; QoL; Biomarker	Phase 2	DB01126	N
NCT05076682	Reverse Triple Negative Immune Resistant Breast Cancer	Renaissance	Recruiting	Triple-negative Breast Cancer	Drug: Choline; Drug: anti-PD-1 antibody and chemotherapy; Drug: Sodium Cromoglicate; Drug: Efavirenz	Objective Response Rate (ORR); Immune changes in peripheral blood; Disease Control Rate (DCR); Progression Free Survival (PFS); Safety and treatment-related AEs; Biomarker analysis1; Biomarker analysis2; Biomarker analysis3	Fudan University	Female	18 Years to 70 Years   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2107239-9	30/06/2022	12/01/2022	03/01/2023			13/10/2021				10/03/2022	https://ClinicalTrials.gov/show/NCT05076682		Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	China	Breast	Breast Cancer - TNBC	Cromoglicic Acid	Response rate; PFS; OS; Other (specify)	Phase 2	DB01003	N
NCT03603795	Study Impact on Outcome of Eltrombopag in Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy	EPAG2015	Active, not recruiting	Acute Myeloid Leukemia	Drug: Eltrombopag; Drug: Placebo	Overal survival rate; Response rate (CR and CRi) at day 45; Leukemia Free Survival at month 12 (one year); Long-term survival; Percentage of patients with platelets count > 100 Giga/L at day 45; Time to platelet transfusion independence	French Innovative Leukemia Organisation; Novartis Pharmaceuticals	All	60 Years and older   (Adult, Older Adult)	110	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	EPAG 2015	10/11/2018	15/06/2022	09/01/2024			27/07/2018				26/09/2022	https://ClinicalTrials.gov/show/NCT03603795		Localised/Locoregional	Collaborative Group	Y	N	N	France	Leukemia	Acute Myeloid Leukemia, Adult	Eltrombopag	Response rate; OS	Phase 2	DB06210	N
NCT03244358	Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer		Terminated	Triple Negative Breast Cancer	Drug: Epalrestat	Progression-free survival (PFS); Number of participants with treatment-related adverse events as assessed by CTCAE v4.0; Overall Survival	Sun Yat-sen University	Female	18 Years to 70 Years   (Adult, Older Adult)	12	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SYSUCC-010	03/01/2017	12/01/2020	12/01/2020			08/09/2017				29/01/2021	https://ClinicalTrials.gov/show/NCT03244358		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	Breast	Breast Cancer - TNBC	Epalrestat	PFS	Phase 2	DB15293	N
NCT03838029	Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery	BC-PC	Recruiting	Pancreatic Neoplasms	Drug: Propranolol and etodolac; Other: Placebo	Rate of cancer recurrence; Biomarkers in extracted tumor tissue samples; Biomarkers in blood samples; Number of patients with treatment related adverse events; Depression, Anxiety, Global distress; Fatigue	Assaf-Harofeh Medical Center; Sheba Medical Center	All	20 Years to 80 Years   (Adult, Older Adult)	210	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	0308-17-ASF; MOH_2018-03-12_002226	20/11/2019	01/01/2026	01/01/2026			02/12/2019				20/11/2019	https://ClinicalTrials.gov/show/NCT03838029		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Israel	GI	Pancreatic Cancer	Etodolac; Propranolol	Recurrence rate	Phase 2	DB00749; DB00571	N
NCT03919461	Colorectal Metastasis Prevention International Trial 2	COMPIT-2	Recruiting	Colorectal Neoplasms	Drug: Propranolol and etodolac; Other: Placebo	5-year disease-free-survival; Biomarkers in extracted tumor tissue samples assessing pro- and anti-metastatic processes; Biomarkers in blood samples assessing pro- and anti-metastatic processes; Number of patients with treatment related adverse events; Depression, Anxiety, Global distress; Fatigue	Assaf-Harofeh Medical Center; Sheba Medical Center; Rabin Medical Center; Tel-Aviv Sourasky Medical Center; Rambam Health Care Campus; HaEmek Medical Center, Israel	All	20 Years to 80 Years   (Adult, Older Adult)	200	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	0196-17-ASF	28/02/2019	28/02/2027	28/02/2027			18/04/2019				18/04/2019	https://ClinicalTrials.gov/show/NCT03919461		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Israel	GI	Colon Cancer; Rectal Cancer	Etodolac; Propranolol	DFS/RFS/EFS	Phase 2	DB00749; DB00571	N
NCT03647072	PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy		Recruiting	Lymphoma	Drug: CHOP; Drug: CHOP Plus Lanzoprazole; Drug: CHOP Plus Famotidine	Number of patients eith radiological and clinical improvement	Sherief Abd-Elsalam; Tanta University	All	18 Years and older   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	eman elberry	08/01/2018	10/01/2027	12/01/2027			27/08/2018				27/08/2018	https://ClinicalTrials.gov/show/NCT03647072	Primary/Main Curative	Any/All Stages	Hospital/University/Research Institute	Y	Y	N	Egypt	Lymphoma	Lymphoma - Other	Famotidine; Lansoprazole	Response rate	Phase 3	DB00927; DB00448	N
NCT04049747	Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer	IP4-CHRONOS	Recruiting	Prostate Cancer|Non-metastatic Prostate Cancer|Prostate Adenocarcinoma	Procedure: Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]; Procedure: Focal therapy; Procedure: Focal therapy after Finasteride 5Mg tablets for 12 weeks; Procedure: Focal therapy after Bicalutamide 50Mg tablets for 12 weeks	Pilot: Acceptance of randomisation to allocated arm within CHRONOS A   CHRONOS B; Pilot: Estimate recruitment rate to allocated arm within CHRONOS A   CHRONOS B; CHRONOS-A Primary Outcome Measures - progression-free survival (PFS) rates of focal therapy alone compared to radical therapy.; CHRONOS-B Primary Outcome Measures - Failure-Free-Survival (FFS) rates of focal therapy alone compared to focal therapy combined with other therapies.; Progression (Biochemical / Radiological / Clinical); Frequency of adverse events as determined by Common Terminology Criteria for Adverse Events.; Health-related quality-of-life; Urinary side effects, IPSS questionnaire; Urinary side effects, EPIC-Urinary domain questionnaire; Sexual side effects; Effect on quality of life; Impact of participants' overall health-related quality assessed by validated patient reported outcomes measures; Comparison of predictive value of different MRI scoring systems against histological outcomes.	Imperial College London; Prostate Cancer UK; Imperial Clinical Trials Unit (ICTU)	Male	18 Years and older   (Adult, Older Adult)	2450	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19CX5006	12/11/2019	10/01/2021	05/01/2027			08/08/2019				19/04/2021	https://ClinicalTrials.gov/show/NCT04049747		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United Kingdom	Urological	Prostate Cancer	Finasteride	PFS; OS	Phase 2/3	DB01216	N
NCT05450055	Intraperitoneal Lidocaine in Ovarian Cancer Surgery		Not yet recruiting	Ovarian Cancer|Post Operative Pain	Procedure: intraperitoneal lidocaine analgesic or normal saline as control	Postoperative analgesic use; Survival time (months); Disease free survival time (months); Recurrence (yes/no, if yes ,record recurrence date); Postoperitive chronic pain duration (months)	Peking University Third Hospital	Female	18 Years to 75 Years   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	M2021589	18/07/2022	30/07/2024	30/07/2029			07/08/2022				13/07/2022	https://ClinicalTrials.gov/show/NCT05450055		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Gynaecological	Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian - Other	Lidocaine	Other (specify)	Other	DB00281	N
NCT03246074	Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer		Active, not recruiting	Ovarian Cancer	Drug: Fostamatinib and Paclitaxel	Incidence of Treatment-Emergent Adverse Events; Response rate of treatment with combination therapy; Survival determination based on progression-free survival; Drug metabolism determination	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Rigel Pharmaceuticals; Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	Female	18 Years to 100 Years   (Adult, Older Adult)	27	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1708; IRB00110406	04/03/2018	08/09/2022	10/01/2024			08/11/2017				21/08/2023	https://ClinicalTrials.gov/show/NCT03246074		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Ovarian Epithelial Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer	Fostamatinib	Safety and/or Dose; Response rate; PFS; Biomarker	Phase 1	DB12010	N
NCT05030675	Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents		Recruiting	Refractory Chronic Myelomonocytic Leukemia|Refractory Myelodysplastic Syndrome	Drug: Fostamatinib	The PI doesnt wish to add any Outcome Measures this will be add at the time of results	M.D. Anderson Cancer Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	20	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-1117; NCI-2021-08494	13/08/2021	30/04/2025	30/04/2025			09/01/2021				10/10/2023	https://ClinicalTrials.gov/show/NCT05030675		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Other Haem-onc; Leukemia	Myelodysplastic Syndromes; Chronic Myelogenous Leukemia	Fostamatinib	Other (specify)	Phase 1	DB12010	N
NCT04011410	Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer		Active, not recruiting	Prostate Cancer Recurrent	Drug: Hydroxychloroquine Sulfate 200Mg Tab	Change in Prostate Apoptosis Response-4 (PAR-4) Levels; Change in Serum Prostate Specific Antigen (PSA) Levels; Progression-Free Survival; Androgen Deprivation Therapy (ADT)-Free Survival	Patrick Hensley; University of Kentucky	Male	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	50146 - MCC-19-GU-72	12/03/2019	03/01/2024	18/11/2026			07/08/2019				12/11/2023	https://ClinicalTrials.gov/show/NCT04011410		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Hydroxychloroquine	Biomarker	Phase 2	DB01611	N
NCT01494155	Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer		Unknown status	Pancreatic Cancer	Drug: Capecitabine; Drug: Hydroxychloroquine; Radiation: Proton or Photon Radiation Therapy	Progression-free survival; Pathologic response rate; Overall survival; Toxicity/Adverse events; Surgical morbidity; Post-operative Mortality; Biomarkers; Pathologic down-staging; Local control; Describe QoL; Measure utilization of health services	Massachusetts General Hospital	All	18 Years and older   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-073	12/01/2011	01/01/2022	01/01/2023			16/12/2011				02/02/2021	https://ClinicalTrials.gov/show/NCT01494155		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Hydroxychloroquine	PFS	Phase 2	DB01611	N
NCT03037437	Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer		Recruiting	Hepatocellular Cancer	Drug: Sorafenib (SOR); Drug: Hydroxychloroquine (HCQ)	Time to tumor progression evaluated via tumor imaging	The University of Texas Health Science Center at San Antonio	All	18 Years to 100 Years   (Adult, Older Adult)	68	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTMS 16-0076; HSC20160515H	16/02/2017	03/01/2024	03/01/2025			31/01/2017				07/03/2023	https://ClinicalTrials.gov/show/NCT03037437		Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	United States	GI	Liver Cancer	Hydroxychloroquine	PFS	Phase 2	DB01611	N
NCT05083780	Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer		Active, not recruiting	Pancreatic Cancer	Drug: Chlorphenesin Carbamate, Hydroxychloroquine	Number of participants with treatment-related adverse events assessed by CTCAE v5.0; Rate of Progression-Free Survival; Rate of Distant Metastasis-Free Survival; Overall Survival; Objective Response Rate	Changhoon Yoo; Oncocross Co. Ltd.; CytoGen, Inc.; Asan Medical Center	All	19 Years to 79 Years   (Adult, Older Adult)	40	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OC-201/202-001	30/11/2021	30/04/2024	12/01/2024			19/10/2021				19/07/2023	https://ClinicalTrials.gov/show/NCT05083780		Advanced/Metastatic	Company	N	N	N	Korea, Republic of	GI	Pancreatic Cancer	Hydroxychloroquine	Safety and/or Dose; Response rate; PFS; OS	Phase 1	DB01611	N
NCT04523857	ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer	ABBY	Recruiting	Breast Cancer	Drug: Abemaciclib; Drug: Hydroxychloroquine	Incidence of treatment-emergent adverse events during cycle 1 of the safety cohort (safety of combination HCQ + Abema); Change in bone marrow DTC number evaluated by DTC-IHC assay after 6 cycles of therapy compared to baseline (Efficacy of Abema +/- HCQ in eliminating bone marrow DTCs)	Abramson Cancer Center at Penn Medicine	All	18 Years and older   (Adult, Older Adult)	66	Other	Interventional Study	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UPCC 10119	11/01/2021	12/01/2027	12/01/2028			24/08/2020				01/10/2023	https://ClinicalTrials.gov/show/NCT04523857		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	United States	Breast	Any Breast Cancer	Hydroxychloroquine	Biomarker	Phase 2	DB01611	N
NCT05518110	PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer	PaTcH	Recruiting	Pancreatic Cancer	Drug: Trametinib; Drug: Hydroxychloroquine	Patients free of disease progression; Tumour Response Rate; Duration of Response; Overall Survival; Safety and tolerability	Cancer Trials Ireland; Novartis	All	18 Years and older   (Adult, Older Adult)	22	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTRIAL-IE 20-27; 2021-006276-16	31/05/2023	15/07/2024	15/04/2025			26/08/2022				18/06/2023	https://ClinicalTrials.gov/show/NCT05518110		Advanced/Metastatic; Recurrent/Refractory	Collaborative Group	N	N	N	Ireland	GI	Pancreatic Cancer	Hydroxychloroquine	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB01611	N
NCT04735068	Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer		Active, not recruiting	Non-Small Cell Lung Cancer|KRAS Mutation-Related Tumors	Drug: Binimetinib Pill; Drug: Hydroxychloroquine Pill	Objective Response Rate; Number of Patients with Adverse Events as assessed by CTCAE v5.0; progression-free survival (PFS); Number of changes in ctDNA KRAS allelic frequency (blood); Overall survival (OS)	Abramson Cancer Center at Penn Medicine; Pfizer	All	18 Years and older   (Adult, Older Adult)	11	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UPCC 21520; 844511	04/09/2021	21/08/2022	12/01/2023			02/02/2021				29/06/2023	https://ClinicalTrials.gov/show/NCT04735068		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Lung	Non-Small Cell Lung Cancer	Hydroxychloroquine	Safety and/or Dose; Response rate; PFS; OS; Biomarker	Phase 2	DB01611	N
NCT05576896	Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory		Recruiting	Stage IV Colorectal Cancer Positive for BRAF V600E Mutation|Colorectal Cancer|Colorectal Cancer Stage IV	Drug: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab	Objective Response Rate (ORR); Progression-Free Survival (PFS); Overall Survival (OS); Duration of Response (DoR); Duration of Stable Disease (DoSD); Adverse Events	Northwestern University; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	43	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 22I05; Northwestern University; IRB#; P30CA060553; NCI-2022-08532	10/10/2022	07/01/2024	07/01/2025			13/10/2022				18/11/2022	https://ClinicalTrials.gov/show/NCT05576896		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Colon Cancer; Rectal Cancer	Hydroxychloroquine	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB01611	N
NCT04132505	Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer		Recruiting	Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8	Drug: Binimetinib; Drug: Hydroxychloroquine	Maximum tolerated dose (MTD); Response rate; Incidence of adverse events; Progression free survival; Overall survival	M.D. Anderson Cancer Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	39	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-0191; NCI-2019-04991	22/10/2019	31/12/2023	31/12/2023			18/10/2019				22/11/2023	https://ClinicalTrials.gov/show/NCT04132505		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Hydroxychloroquine	Safety and/or Dose	Phase 1	DB01611	N
NCT05221320	Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies		Recruiting	Tumor, Solid|Gastrointestinal Cancer	Drug: Ulixertinib; Drug: Hydroxychloroquine	Overall response rate as defined by the proportion of patients achieving a confirmed partial response (PR) and complete response (CR) (defined by response evaluation criteria in solid tumors (RECIST 1.1) as evaluated by the local treating investigator.; The incidence and frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NCI CTCAE, version 5.0), seriousness, duration, and relationship to study treatment.; Progression-free survival (PFS) as defined as the time from study drug initiation to the time of documented disease progression (as assessed by RECIST 1.1) or death from any cause.	BioMed Valley Discoveries, Inc	All	18 Years and older   (Adult, Older Adult)	215	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BVD-523-HCQ	26/05/2022	03/06/2024	19/06/2024			02/02/2022				16/05/2023	https://ClinicalTrials.gov/show/NCT05221320		Advanced/Metastatic	Company	N	Y	N	United States	GI	Any GI cancer	Hydroxychloroquine	Response rate	Phase 2	DB01611	N
NCT04386057	LY3214996 +/- HCQ in Pancreatic Cancer		Active, not recruiting	Pancreatic Cancer|Advanced Cancer	Drug: Hydroxychloroquine Sulfate; Drug: LY3214996	Disease control rate (DCR); Dose Limiting Toxicity-Lead In; Objective response rate (ORR); Progression-free survival (PFS); Overall survival (OS)	Kimberly Perez, MD; Eli Lilly and Company; Dana-Farber Cancer Institute	All	18 Years and older   (Adult, Older Adult)	52	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-529	27/05/2020	08/09/2023	02/09/2024			13/05/2020				11/08/2023	https://ClinicalTrials.gov/show/NCT04386057		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	United States	GI	Pancreatic Cancer	Hydroxychloroquine	Response rate	Phase 2	DB01611	N
NCT04841148	Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer	PALAVY	Recruiting	Breast Cancer	Drug: HCQ; Drug: Avelumab; Drug: Palbociclib	Determine the efficacy of HCQ or Avelumab, alone or in combination with Palbociclib, in eradicating DTCs; Determine the safety and tolerability of HCQ or Avelumab, alone or in combination with Palbociclib, in this Phase II study: adverse events; Estimate the risk of recurrence after treatment with Palbociclib, Avelumab and HCQ, alone or in combination	Abramson Cancer Center at Penn Medicine; Johns Hopkins University; Translational Breast Cancer Research Consortium; Pfizer; Breast Cancer Research Foundation	All	18 Years and older   (Adult, Older Adult)	96	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UPCC 01121; IRB# 848471; TBCRC 046	06/01/2021	11/01/2024	05/01/2028			04/12/2021				30/10/2023	https://ClinicalTrials.gov/show/NCT04841148		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	United States	Breast	Breast Cancer - ER/HR+	Hydroxychloroquine	Safety and/or Dose; Recurrence rate; Biomarker	Phase 2	DB01611	N
NCT04214418	Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies	MEKiAUTO	Active, not recruiting	Gastrointestinal Cancer	Drug: Cobimetinib; Drug: Hydroxychloroquine; Drug: Atezolizumab	Phase 1: Estimated maximum tolerated dose (MTD); Phase 1: Incidence of Treatment-Emergent Adverse Events with drug combination (Safety and Tolerability)	Columbia University; Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	175	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AAAS4165; ML41472	02/12/2020	06/01/2024	09/01/2024			01/02/2020				12/01/2022	https://ClinicalTrials.gov/show/NCT04214418		Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	United States	Multiple cancer types; GI	Multiple cancer types; Pancreatic Cancer; Colon Cancer; Rectal Cancer	Hydroxychloroquine	Safety and/or Dose	Phase 1/2	DB01611	N
NCT03774472	Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer		Active, not recruiting	Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8	Drug: Hydroxychloroquine; Drug: Letrozole; Drug: Palbociclib	Incidence of adverse events (Phase I); Change in breast tumor proliferation index (Ki67) (Phase II, Part I); Change in autophagy (Phase II, Part I); Change in senescence (Phase II, Part I); Change in cell cycle control (Phase II, Part I); Change in proportion of patients achieving tumoral complete cell cycle arrest (Phase II, Part II); Longer term clinical tumor responsiveness (tumor volume) (Phase II Part I); Tumor biomarker indices (for patients who have extended pre-operative therapy, maximum 24 weeks) (Phase II Part I and II); Blood-based tumor protein, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) biomarkers (Phase II Part I and II); Breast tumor indices of proliferation, autophagy, senescence, cell cycle control and other intersecting pathways (Phase II Part II); Dose responsiveness hydroxychloroquine (400 mg versus recommended phase 2 dose) (Phase II Part II)	M.D. Anderson Cancer Center	Female	18 Years and older   (Adult, Older Adult)	15	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0071; NCI-2018-01050	20/08/2018	31/12/2025	31/12/2025			13/12/2018				18/11/2023	https://ClinicalTrials.gov/show/NCT03774472		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - ER/HR+; Breast Cancer - HER2-	Hydroxychloroquine	Safety and/or Dose; Biomarker	Phase 1/2	DB01611	N
NCT04524702	Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer		Active, not recruiting	Advanced Pancreatic Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8	Drug: Gemcitabine; Drug: Hydroxychloroquine; Drug: Nab-paclitaxel; Drug: Paricalcitol	Change from baseline tumor size as measured by cross sectional imaging at 8 weeks.(every 8 weeks); Incidence of adverse events; Progression-free survival; Overall survival	Emory University; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	12	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00000996; NCI-2020-05417; Winship5079-20; P30CA138292	14/09/2020	14/08/2024	14/08/2024			24/08/2020				01/11/2024	https://ClinicalTrials.gov/show/NCT04524702		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Hydroxychloroquine; Paricalcitol	Response rate	Phase 2	DB01611; DB00910	N
NCT03825289	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer	THREAD	Recruiting	Metastatic Pancreatic Carcinoma|Stage II Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma	Drug: Hydroxychloroquine; Drug: Trametinib	Rate of dose-limiting toxicities during the DLT assessment window.; Incidence of adverse events (AEs) for the duration of study treatment; Response Rate	University of Utah; Novartis Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	39	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCI116898	18/01/2019	18/01/2024	18/01/2025			31/01/2019				07/05/2023	https://ClinicalTrials.gov/show/NCT03825289		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Hydroxychloroquine	Safety and/or Dose	Phase 1	DB01611	N
NCT05843188	Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer		Recruiting	Metastatic Colorectal Cancer	Drug: Hydroxychloroquine; Drug: Irinotecan; Drug: Leucovorin; Drug: Fluorouracil; Drug: Bevacizumab	Overall response rate; Progression-free survival; Overall survival; Incidences and severity of adverse events	University Health Network, Toronto	All	18 Years and older   (Adult, Older Adult)	155	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Targeting DTP in mCRC	08/09/2023	24/04/2026	24/10/2026			05/06/2023				21/08/2023	https://ClinicalTrials.gov/show/NCT05843188		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Canada	GI	Colon Cancer; Rectal Cancer	Hydroxychloroquine	Response rate	Phase 2	DB01611	N
NCT02722369	STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)		Terminated	Small Cell Lung Cancer	Drug: Gemcitabine; Drug: Carboplatin; Drug: Etoposide; Drug: Hydroxychloroquine	Progression free survival; Overall survival; Objective response as measured by Response Evaluation Criteria in Solid Tumours (RECIST) v.1.1; Adverse events; Quality of life as measured by EQ-5D; Quality of life as measured by QLQC-30; Quality of life as measured by QLQ-LC-13; Compliance measured by dose intensity; Compliance measured by dose exposure	University College, London	All	18 Years and older   (Adult, Older Adult)	72	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCL/12/0515	14/03/2017	03/12/2021	03/12/2021			30/03/2016				18/03/2021	https://ClinicalTrials.gov/show/NCT02722369		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	United Kingdom	Lung	Small Cell Lung Cancer	Hydroxychloroquine	PFS	Phase 2	DB01611	N
NCT01480154	Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer		Active, not recruiting	Advanced Malignant Solid Neoplasm|Stage III Cutaneous Melanoma AJCC v7|Stage III Prostate Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7	Drug: Akt Inhibitor MK2206; Drug: Hydroxychloroquine	Maximum tolerated dose of Akt inhibitor MK-2206; Dose-limiting toxicity rate; Changes in expression pattern of markers Beclin1, LC3, and p62; Change in autophagy activity induced by hydroxychloroquine; Validation of Beclin1, LC3, and p62 as markers for autophagy	National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	62	NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-00084; 051105; CDR0000717546; CINJ-051105; 8983; P30CA072720; U01CA132194; UM1CA186716	23/11/2011	14/02/2020				28/11/2011				25/10/2023	https://ClinicalTrials.gov/show/NCT01480154		Advanced/Metastatic	Local/National government	N	N	N	United States	Multiple cancer types; Urological; Skin	Multiple cancer types; Renal Cell Carcinoma; Prostate Cancer; Melanoma	Hydroxychloroquine	Safety and/or Dose	Phase 1	DB01611	N
NCT04873895	TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)	TACE-Ax-HCQ	Recruiting	Colorectal Neoplasms Malignant	Drug: Axitinib 5 MG; Drug: Hydroxychloroquine Pill; Procedure: trans arterial chemoembolization	Serious adverse event (SAE) rate; objective response rate in the liver; Hepatic progression-free survival; Progression-free survival; Overall survival; axitinib treatment intensity	Abramson Cancer Center at Penn Medicine; Pfizer	All	18 Years and older   (Adult, Older Adult)	25	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UPCC03221	24/01/2022	07/01/2024	12/01/2024			05/05/2021				26/09/2023	https://ClinicalTrials.gov/show/NCT04873895		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Colon Cancer; Rectal Cancer	Hydroxychloroquine	Safety and/or Dose; Response rate; PFS; OS	Phase 1	DB01611	N
NCT00813423	Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy		Completed	Adult Solid Neoplasm	Drug: Hydroxychloroquine; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Sunitinib Malate	MTD of sunitinib malate, as assessed by the NCI CTCAE version 4.0 (v4.0); Response rate using the international criteria RECIST; Survival; Percent changes of the marker expressions, beclin1, LC3, p62 and GRp170, as indicators of autophagy potential in tissue; Mean number of autophagic vesicles per cell (mAV/cell) by electron microscopy (EM) as indication of flux through the autophagy pathway for non-apoptotic cells; Steady-state plasma concentration of hydroxychloroquine (HCQ); Autophagy inhibition and PK interaction; Percent changes of the vascular marker levels of CD31, VEGF, thrombospondin-1, and CD105 for detection of decreased vascular proliferation	National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	40	NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03112; CTEP #8342; 050909; 8342; P30CA072720; U01CA132194	19/02/2010	18/07/2023	18/07/2023			23/12/2008				08/02/2023	https://ClinicalTrials.gov/show/NCT00813423		Advanced/Metastatic; Recurrent/Refractory	Local/National government	N	N	N	United States	Multiple cancer types	Any solid tumours	Hydroxychloroquine	Safety and/or Dose; Response rate	Phase 1	DB01611	N
NCT05365893	PHL Treatment in Pancreatic Cancer		Recruiting	Pancreatic Ductal Adenocarcinoma	Combination Product: Paricalcitol, Hydroxychloroquine, Losartan; Other: Neoadjuvant therapy and surgery only (Control)	Number of participants who experience grade 3 or greater treatment-related adverse events assessed by CTCAE v5.0	Fox Chase Cancer Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	20	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20-1085; GI-174; 1R21CA252535-01A1	20/10/2021	31/03/2024	31/12/2024			05/09/2022				26/06/2023	https://ClinicalTrials.gov/show/NCT05365893		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Hydroxychloroquine; Losartan; Paricalcitol	Safety and/or Dose	Phase 1	DB01611; DB00678; DB00910	N
NCT04145297	Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas	UTAH	Active, not recruiting	Gastrointestinal Neoplasms	Drug: Ulixertinib; Drug: Hydroxychloroquine	Recommended phase 2 dose of ulixertinib in combination with a fixed dose of hydroxychloroquine in subjects with advanced, RAS, non-V600 BRAF, ERK or MEK mutated gastrointestinal malignancies; Safety and tolerability of ulixertinib and hydroxychloroquine in the study population: adverse events (AEs) and serious adverse events (SAEs); Efficacy of ulixertinib and hydroxychloroquine in the study population: Objective response rate (PR and CR)	University of Utah; BioMed Valley Discoveries, Inc	All	18 Years and older   (Adult, Older Adult)	17	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCI127114	17/03/2020	03/07/2023	30/03/2025			30/10/2019				23/06/2023	https://ClinicalTrials.gov/show/NCT04145297		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Any GI cancer	Hydroxychloroquine	Safety and/or Dose	Phase 1	DB01611	N
NCT00977470	Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations		Unknown status	Non-small Cell Lung Cancer	Drug: Erlotinib; Drug: Hydroxychloroquine	Median Progression Free Survival; Nine-month Progression-free Survival Rate; Treatment Related Toxicity, > 10  Frequency, Any Grade; Objective Tumor Response Rate Following Treatment With Erlotinib and With Erlotinib/HCQ.; Overall Survival of Patients Treated With Erlotinib and With Erlotinib/HCQ	Massachusetts General Hospital; Stanford University; Yale University; University of Maryland, College Park; Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	76	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	09-097; OSI4620s	10/01/2009	05/01/2015	06/01/2021			15/09/2009		06/06/2017		14/07/2020	https://ClinicalTrials.gov/show/NCT00977470		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	United States	Lung	Non-Small Cell Lung Cancer	Hydroxychloroquine	PFS	Phase 2	DB01611	N
NCT05733000	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors		Recruiting	Advanced Biliary Tract Carcinoma|Advanced Colorectal Carcinoma|Advanced Gastroesophageal Junction Adenocarcinoma|Advanced Lung Adenocarcinoma|Advanced Malignant Solid Neoplasm|Advanced Ovarian Carcinoma|Advanced Pancreatic Carcinoma|Advanced Urothelial Carcinoma|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Metastatic Biliary Tract Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Lung Adenocarcinoma|Metastatic Ovarian Carcinoma|Metastatic Pancreatic Carcinoma|Metastatic Urothelial Carcinoma|Refractory Biliary Tract Carcinoma|Refractory Colorectal Carcinoma|Refractory Gastroesophageal Junction Adenocarcinoma|Refractory Lung Adenocarcinoma|Refractory Ovarian Carcinoma|Refractory Pancreatic Carcinoma|Refractory Urothelial Carcinoma|Stage II Pancreatic Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8	Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Devimistat; Drug: Fluorouracil; Drug: Gemcitabine Hydrochloride; Drug: Hydroxychloroquine; Procedure: Magnetic Resonance Imaging	Overall response rate (ORR); Progression free survival (PFS); Overall survival (OS); Duration of response (DOR); Incidence of adverse events	Northwestern University; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	94	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 22MH03; NCI-2023-00070; STU00218203; P30CA060553	03/08/2023	01/04/2028	03/04/2030			17/02/2023				03/10/2023	https://ClinicalTrials.gov/show/NCT05733000		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types	Any solid tumours	Hydroxychloroquine	Response rate	Phase 2	DB01611	N
NCT04527549	Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma		Active, not recruiting	Clinical Stage IV Cutaneous Melanoma AJCC v8|Locally Advanced Melanoma|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Unresectable Melanoma	Drug: Dabrafenib Mesylate; Drug: Hydroxychloroquine Sulfate; Drug: Placebo Administration; Drug: Trametinib Dimethyl Sulfoxide	Progression-free survival (PFS) rate; PFS distribution; Overall response rate; Complete response rate; Overall survival; Incidence of adverse events; Treatment duration	ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group	All	18 Years and older   (Adult, Older Adult)	84	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	EA6191; NCI-2020-04552; U10CA180820	06/01/2021	30/11/2025	30/11/2025			26/08/2020				22/06/2023	https://ClinicalTrials.gov/show/NCT04527549		Advanced/Metastatic	Collaborative Group	Y	N	N	United States	Skin	Melanoma	Hydroxychloroquine	PFS	Phase 2	DB01611	N
NCT04669197	Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer		Active, not recruiting	Untreated Resectable Pancreatic Adenocarcinoma|Borderline Resectable Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Adenocarcinoma	Drug: Paclitaxel protein bound; Drug: Gemcitabine; Drug: Cisplatin; Drug: Hydroxychloroquine	Normalization Rate of CA 19-9; Resectability Rate; Survival Rate; Response Rate; Incidence of Treatment-Emergent Adverse Events	HonorHealth Research Institute	All	18 Years and older   (Adult, Older Adult)	19	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCQ NABPLAGEM-NEO 2020	12/01/2020	23/05/2023	30/09/2024			16/12/2020				15/08/2023	https://ClinicalTrials.gov/show/NCT04669197		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Hydroxychloroquine	Safety and/or Dose; Response rate; Biomarker; Other (specify)	Phase 2	DB01611	N
NCT04911816	Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma		Recruiting	Adenocarcinoma of the Pancreas	Drug: Hydroxychloroquine sulfate	Phase I - Establishing Maximum tolerated dose (MTD); Phase II - Rate of grade IIb or better histopathological response; Phase II - To establish the potential biological activity of FHQ by biochemical tumor response, as assessed by Ca 19-9.	West Virginia University	All	18 Years and older   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2103260669	16/07/2021	06/01/2025	06/01/2028			06/03/2021				01/12/2024	https://ClinicalTrials.gov/show/NCT04911816		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Hydroxychloroquine	Safety and/or Dose; Response rate; Biomarker	Phase 1/2	DB01611	N
NCT04787991	Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	REVOLUTION	Active, not recruiting	Metastatic Pancreatic Adenocarcinoma	Drug: Nivolumab (Cohort A); Drug: Ipilimumab (Cohort A, B and C); Drug: Hydroxychloroquine (HCQ) (Cohort B); Drug: Nab-paclitaxel (nP) (Cohort A, B and C); Drug: Gemcitabine (gem) (Cohort A, B and C); Drug: NG350A (Cohort C)	Incidence and severity of adverse events; Objective response rate (ORR); Disease control rate (DCR); Duration of response (DOR); Progression-free survival (PFS); Overall survival (OS); Overall survival (OS) at 12 months	Parker Institute for Cancer Immunotherapy; Bristol-Myers Squibb; Cancer Research Institute, New York City; Akamis Bio	All	18 Years and older   (Adult, Older Adult)	45	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PICI0044	08/09/2021	31/10/2024	01/11/2025			03/09/2021				27/10/2023	https://ClinicalTrials.gov/show/NCT04787991		Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	United States	GI	Pancreatic Cancer	Hydroxychloroquine	Safety and/or Dose; Response rate; PFS; OS; Other (specify)	Phase 1	DB01611	N
NCT04464759	A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma	LIMIT	Recruiting	Melanoma	Drug: Nivolumab; Drug: Hydroxychloroquine; Drug: Ipilimumab	Phase 1: Maximum tolerated dose (MTD) - Number of Subjects with Dose-limiting Toxicities; Phase 2: Objective Response Rate (ORR); Progression-free survival; 1 year survival rate	Ravi Amaravadi, MD; Bristol-Myers Squibb; Abramson Cancer Center at Penn Medicine	All	18 Years and older   (Adult, Older Adult)	94	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UPCC 01620; IRB#835033	21/10/2020	30/10/2025	30/10/2025			07/09/2020				10/10/2023	https://ClinicalTrials.gov/show/NCT04464759		Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	United States	Skin	Melanoma	Hydroxychloroquine	Safety and/or Dose; Response rate	Phase 1/2	DB01611	N
NCT03754179	Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma	COMBI-R2	Unknown status	Melanoma	Drug: Dabrafenib; Drug: Trametinib; Drug: Hydroxychloroquine	Ph. 1: incidence of adverse events of DAB, TRA and HCQ; Ph. 2 Arm A: objective response rate (ORR) of DAB, TRA and HCQ; Ph. 1: objective response rate (ORR) of DAB, TRA and HCQ; Ph. 1: progression-free survival (PFS) on DAB, TRA and HCQ; Ph. 1: overall survival (OS) on DAB, TRA and HCQ; Ph. 1: value of BRAF V600 mutant circulating tumor DNA (ctDNA) as a predictive and/or prognostic marker during treatment DAB, TRA and HCQ; Ph. 2 Arm B: objective response rate 1 (ORR 1) of DAB and TRA prior to the addition of HCQ at progression of disease; Ph. 2 Arm B: objective response rate 2 (ORR 2) of DAB and TRA following the addition of HCQ at progression of disease; Ph. 2 Arm A: progression-free survival (PFS) on DAB, TRA and HCQ; Ph. 2 Arm A: overall survival (OS) on DAB, TRA and HCQ; Ph. 2 Arm B: progression-free survival 1 (PFS 1) on DAB and TRA prior to the addition of HCQ; Ph. 2 Arm B: progression-free survival 2 (PFS 2) on DAB and TRA following the addition of HCQ; Ph. 2 Arm B: overall survival 1 (OS 1) on DAB and TRA prior to the addition of HCQ; Ph. 2 Arm B: overall survival 2 (OS 2) on DAB and TRA following the addition of HCQ; Ph. 2 Arm B: overall survival 3 (OS 3) on DAB and TRA following the addition of HCQ; Ph. 2 Arm A and B: incidence of adverse events of DAB, TRA and HCQ; Ph. 2 Arm A and B: value of BRAF V600 mutant circulating tumor DNA (ctDNA) as a predictive and/or prognostic marker during treatment with DAB, TRA and HCQ	Universitair Ziekenhuis Brussel; University Hospital, Ghent	All	18 Years and older   (Adult, Older Adult)	63	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-BN-004	23/01/2018	12/01/2021	07/01/2022			27/11/2018				28/04/2021	https://ClinicalTrials.gov/show/NCT03754179		Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	Belgium	Skin	Melanoma	Hydroxychloroquine	Safety and/or Dose; Response rate	Phase 1/2	DB01611	N
NCT03598595	Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma		Active, not recruiting	Recurrent Osteosarcoma|Refractory Osteosarcoma	Drug: Docetaxel; Drug: Gemcitabine; Drug: Hydroxychloroquine	Maximum tolerated dose of hydroxychloroquine (Phase I); Disease control rate (Phase II); Event free survival; Overall response (complete response [CR] or partial response [PR] versus not CR or PR)	M.D. Anderson Cancer Center; National Cancer Institute (NCI)	All	12 Years and older   (Child, Adult, Older Adult)	31	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018-0224; NCI-2018-01414	28/01/2019	13/09/2024	13/09/2024			26/07/2018				18/11/2023	https://ClinicalTrials.gov/show/NCT03598595		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	Bone Sarcoma	Osteosarcoma	Hydroxychloroquine	Safety and/or Dose; Response rate	Phase 1/2	DB01611	N
NCT04201457	A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration		Recruiting	Low Grade Glioma (LGG) of Brain With BRAF Aberration|High Grade Glioma (HGG) of the Brain With BRAF Aberration|Low Grade Glioma of Brain With Neurofibromatosis Type 1	Drug: Dabrafenib; Drug: Trametinib; Drug: Hydroxychloroquine	Maximum Tolerated Dose (MTD)/ Recommended Phase 2 Dose (RP2D); Maximum Plasma Concentration; Area under the curve (AUC); Phase II: Sustained objective response rate.; Phase I: Dose limiting toxicities of D + T HCQ or T + HCQ; Phase I: Response Rate; Phase II: Progression-free survival; Phase II: Visual outcome based on Teller Grating Acuity at 55 cm in the left eye in children with tumor involving the visual pathway; Phase I and II: Autophagy inhibition as assessed by the accumulation of LC3II in peripheral blood mononuclear cells; Phase I and II: Autophagy inhibition as assessed by the accumulation of p62 in peripheral blood mononuclear cells; Phase I and II: Presence of MAPK pathway aberrations (other than BRAF) as assessed by whole exome sequencing; Phase I and II: biomarker of resistance to RAF or MEK inhibitor therapy by evaluating matched primary and recurrent/progressive in tumor in plasma (and CSF if clinically indicated)	Pediatric Brain Tumor Consortium	All	1 Year to 30 Years   (Child, Adult)	75	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PBTC-055	17/01/2020	30/08/2025	30/06/2027			17/12/2019				01/11/2023	https://ClinicalTrials.gov/show/NCT04201457		Recurrent/Refractory	Collaborative Group	N	N	Y	United States	CNS	Glioma	Hydroxychloroquine	Safety and/or Dose; Response rate	Phase 1/2	DB01611	N
NCT03979651	MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma	CHLOROTRAMMEL	Unknown status	Metastatic NRAS Melanoma	Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1); Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2); Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)	Incidence of Dose-Limiting Toxicities (DLTs); Percentage of patients with a partial or complete response to treatment; Change in Median progression Free survival; Change in Overall Survival; Safety of the drug combination Trametinib and Hydroxychloroquine; Quantification of the autophagic substrate p62; Quantification of Microtubule-associated protein Light Chain 3 (LC3); Quantification of p-ERK; Quantification of the autophagic substrate p62 (cutaneous metastasis); Quantification of Microtubule-associated protein Light Chain 3 (LC3) (cutaneous metastasis); Quantification of p-ERK (cutaneous metastasis); Serum trametinib and hydroxychloroquine concentrations (AUC); Changes in treatment induced immune modifications in patient blood serum	Hospices Civils de Lyon	All	18 Years and older   (Adult, Older Adult)	29	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	69HCL19_0115; 2019-001399-13	15/10/2019	31/03/2022	31/03/2022			06/07/2019				05/08/2020	https://ClinicalTrials.gov/show/NCT03979651		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	France	Skin	Melanoma	Hydroxychloroquine	Safety and/or Dose; Response rate	Phase 1/2	DB01611	N
NCT05842174	Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma	TAQE	Not yet recruiting	Hepatocellular Carcinoma	Drug: Hydroxychloroquine; Drug: Lipiodol; Drug: Placebo	Local Progression Free Survival	VA Office of Research and Development	All	18 Years and older   (Adult, Older Adult)	93	U.S. Fed	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	ONCC-008-22S; IO1CX002542	09/01/2023	31/08/2027	31/08/2028			05/03/2023				05/03/2023	https://ClinicalTrials.gov/show/NCT05842174		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	GI	Liver Cancer	Hydroxychloroquine	PFS	Phase 1/2	DB01611	N
NCT03929211	CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome		Withdrawn	Myelodysplastic Syndromes|Progressive Disease	Drug: CPI-613; Drug: Hydroxychloroquine	Number of Dose Limiting Toxicities; Overall Response Rate; Proportion of Patients with Toxicities; Progression-free-survival; Overall Survival; Changes in the Frequency of Blood Transfusions	Wake Forest University Health Sciences; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	0	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00057945; WFBCCC 99119; P30CA012197; NCI-2019-02787	05/01/2021	09/01/2022	07/01/2027			26/04/2019				14/04/2021	https://ClinicalTrials.gov/show/NCT03929211		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	Leukemia	Leukemia - Other	Hydroxychloroquine	Safety and/or Dose; Response rate	Phase 1/2	DB01611	N
NCT03782415	Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma		Active, not recruiting	Glioblastoma|Recurrent Glioblastoma|GBM|Newly Diagnosed Glioblastoma	Drug: MN-166; Drug: Temozolomide	Evaluate safety and tolerability of ibudilast and temozolomide combination treatment; Evaluate efficacy of ibudilast and TMZ combination treatment; Evaluate Tmax; Cmax; AUC; Terminal rate constant; Terminal half-life; Maximum tolerated dose determination; Evaluate the safety of fixed-dose ibudilast in combination with TMZ; Evaluate overall survival, response rate, and median 6-month progression-free survival (PFS6)	MediciNova	All	18 Years and older   (Adult, Older Adult)	50	Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MN-166-GBM-1201	29/12/2018	31/12/2023	30/06/2024			20/12/2018				13/09/2023	https://ClinicalTrials.gov/show/NCT03782415		Localised/Locoregional; Recurrent/Refractory	Company	N	N	N	United States	CNS	Glioblastoma	Ibudilast	Safety and/or Dose; PFS	Phase 1/2	DB05266	N
NCT03122444	Imipramine on ER+ve and Triple Negative Breast Cancer		Completed	Breast Cancer	Drug: Imipramine	Decrease in the proliferation rate of triple negative breast cancer	The University of Texas Health Science Center at San Antonio	All	18 Years to 71 Years   (Adult, Older Adult)	17	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTMS 17-0037	07/05/2019	03/01/2022	05/01/2022			20/04/2017				28/06/2023	https://ClinicalTrials.gov/show/NCT03122444		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - TNBC; Breast Cancer - ER/HR+	Imipramine	Biomarker	Phase 1	DB00458	N
NCT04863950	Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma		Recruiting	Glioblastoma	Drug: Lomustine; Drug: Imipramine Hydrochloride	Progression Free Survival	The University of Texas Health Science Center at San Antonio	All	Child, Adult, Older Adult	25	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTMS# 20-0148	25/05/2022	09/01/2024	09/01/2025			28/04/2021				08/03/2023	https://ClinicalTrials.gov/show/NCT04863950		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Imipramine	PFS	Phase 2	DB00458	N
NCT05318469	Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer		Recruiting	Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma	Drug: Ivermectin; Drug: Balstilmab	Incidence of adverse events; Objective response rate; Progression free survival; Overall survival; Duration of response; Clinical benefit rate; Patients' quality of life	Yuan Yuan; Agenus Inc.; Gateway for Cancer Research; Cedars-Sinai Medical Center	All	18 Years and older   (Adult, Older Adult)	41	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT2022-07-YUAN-IB-TNBC	13/10/2023	10/01/2026	10/01/2026			04/08/2022				11/02/2023	https://ClinicalTrials.gov/show/NCT05318469		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - TNBC	Ivermectin	Safety and/or Dose; Response rate; PFS; OS; QoL	Phase 2	DB00602	N
NCT03273231	The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection		Unknown status	Colorectal Cancer	Drug: Ketamine; Drug: Saline	natural killer cell cytotoxicity; proinflammatory cytokine; recurrence; metastasis	Yonsei University	All	20 Years to 80 Years   (Adult, Older Adult)	100	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Other	4-2017-0475	09/01/2017	07/01/2020	07/01/2020			09/06/2017				16/01/2019	https://ClinicalTrials.gov/show/NCT03273231		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	GI	Colon Cancer; Rectal Cancer	Ketamine	Biomarker	Other	DB01221	N
NCT02470299	Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients		Active, not recruiting	Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer	Drug: Ketorolac; Other: Placebo	Ketorolac inhibition of GTPase activity; Intraperitoneal and serum pharmacokinetics of ketorolac; Time to CA-125 normalization; Toxicity assessment	New Mexico Cancer Care Alliance	Female	18 Years and older   (Adult, Older Adult)	21	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science	INST 1420	29/10/2015	10/08/2018	10/08/2025			06/12/2015				01/11/2024	https://ClinicalTrials.gov/show/NCT02470299		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Gynaecological	Fallopian Tube Cancer; Primary Peritoneal Cancer; Ovarian Epithelial Cancer	Ketorolac	Safety and/or Dose; Biomarker	Other	DB00465	N
NCT04495894	Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma		Recruiting	Non-small Cell Lung Cancer|Renal Cell Carcinoma	Drug: Preoperative Ketorolac	Incidence of Blood Transfusion Among Ketorolac Group; Incidence of Clinically Significant Hematoma Development Among Ketorolac Group; Incidence of Return to the Operating Room for Bleeding Among Ketorolac Group; Incidence of Postoperative Renal Failure Among Ketorolac Group; Incidence of Postoperative Morbidity Rate Among Ketorolac Group; Change in Interleukin-1 alpha (IL-1alpha) Levels; Change in Interleukin-1beta (IL-1 ) Levels; Change in Interleukin-2 (IL-2) Levels; Change in Interleukin-6 (IL-6) Levels; Change in Interleukin-8 (IL-8) Levels; Change in Interleukin-10 (IL-10) Levels; Change in Interleukin-12p70 (IL-12p70) Levels; Change in Tumor Necrosis Factor-alpha (TNF-alpha) Levels; Change in Interferon (INF)-gamma Levels; Change in Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Levels; Change in Monocyte Chemotactic and Activating Factor (MCAF) Levels	Emory University	All	18 Years to 80 Years   (Adult, Older Adult)	76	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	STUDY00000205	24/08/2020	10/01/2024	10/01/2024			08/03/2020				24/10/2023	https://ClinicalTrials.gov/show/NCT04495894		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Urological; Lung	Renal Cell Carcinoma; Non-Small Cell Lung Cancer	Ketorolac	Safety and/or Dose	Phase 1	DB00465	N
NCT04188119	A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer	IMpALA	Not yet recruiting	Breast Cancer	Drug: Avelumab; Drug: Aspirin; Drug: Lansoprazole	1. Mean combined gene expression of COX-2 tumour-promoting genes; Post treatment tumour infiltrating lymphocytes (TIL); Mean combined gene expression of the cancer-inhibitory elements of the COX-2 inflammatory signature; The post treatment COX-2 inflammatory signature; Safety and tolerability assessed by grade 3-4 AEs and SAEs	The Christie NHS Foundation Trust	Female	18 Years and older   (Adult, Older Adult)	42	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CFT / sp123; 2018-004121-80; 017NovCC107	12/01/2023	30/09/2024	31/05/2025			12/05/2019				17/05/2023	https://ClinicalTrials.gov/show/NCT04188119		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United Kingdom	Breast	Breast Cancer - TNBC	Acetylsalicylic Acid	Biomarker	Phase 2	DB00945	N
NCT00578721	Trial of Aspirin and Arginine Restriction in Colorectal Cancer		Completed	Colorectal Cancer	Drug: Aspirin	Rectal Tissue Putrescine Reduction; Safety/Toxicity	University of California, Irvine	All	18 Years to 80 Years   (Adult, Older Adult)	24	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	UCI 07-47 HS# 2007-5892	24/09/2008	26/11/2013	26/11/2013			21/12/2007		26/06/2023		07/07/2023	https://ClinicalTrials.gov/show/NCT00578721		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	Biomarker	Phase 2	DB00945	N
NCT04549662	The HepatoPancreaticoBiliary Resection Arginine Immunomodulation (PRIMe) Trial	PRIMe	Recruiting	Hepatopancreaticobiliary (HPB) Malignancy|Surgery	Dietary Supplement: Active A; Dietary Supplement: Active B; Dietary Supplement: Lipid bolus; Dietary Supplement: Placebo oil	Natural killer (NK) cell killing; Secondary immune function outcomes: Immune cell subsets; Secondary immune function outcomes: NK cell activating and inhibitory receptors; Secondary immune function outcomes: amino acid levels; Incidence of pancreatic fistula; Postoperative wound complication and surgical site infection; Length of stay; 90-day postoperative complications (Clavien-Dindo 3-5); 90-day postoperative mortality; Incidence of liver insufficiency	Sunnybrook Health Sciences Centre; Enhanced Medical Nutrition; Sunnybrook Health Sciences Centre Clinical Research Grant Competition; Sunnybrook Health Sciences Centre AFP Innovation Fund	All	18 Years and older   (Adult, Older Adult)	45	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	076-2017	16/06/2021	30/12/2023	30/12/2025			16/09/2020				13/10/2023	https://ClinicalTrials.gov/show/NCT04549662		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	United States	GI	Pancreatic Cancer	L-Arginine; Omega 3	Biomarker	Other	DB17289; DB13961	N
NCT03709446	Leflunomide in Previously Treated Metastatic Triple Negative Cancers		Recruiting	Breast Neoplasms|Breast Diseases|Metastatic Triple Negative Breast Cancer	Drug: Leflunomide	Maximum Tolerated Dose (MTD); Clinical Benefit Rate (CBR); Number of side effects; Objective Response Rate; Progression-free survival (PFS)	Joseph Sparano; Icahn School of Medicine at Mount Sinai	Female	18 Years and older   (Adult, Older Adult)	54	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCO 18-1832	16/04/2019	10/01/2025	10/01/2026			17/10/2018				22/06/2023	https://ClinicalTrials.gov/show/NCT03709446		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - TNBC	Leflunomide	Safety and/or Dose; Response rate; PFS	Phase 1/2	DB01097	N
NCT04997993	Leflunomide in Patients With PTEN-null Advanced Solid Malignancies		Recruiting	PTEN-null Advanced Solid Tumors	Drug: Leflunomide	Number of participants with Dose-limiting toxicities; Number of Dose-limiting toxicities; Maximum tolerated dose; Overall Response Rate	Deborah Doroshow; Icahn School of Medicine at Mount Sinai	All	18 Years and older   (Adult, Older Adult)	24	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCO 20-2528	13/12/2023	09/01/2026	09/01/2026			08/10/2021				29/12/2023	https://ClinicalTrials.gov/show/NCT04997993		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Multiple cancer types	Any solid tumours	Leflunomide	Safety and/or Dose; Response rate	Phase 1	DB01097	N
NCT02509052	Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma		Completed	Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma	Other: Laboratory Biomarker Analysis; Drug: Leflunomide; Other: Pharmacological Study	MTD, Defined as the Highest Dose in Which =< 1/6 Patients Experience a Dose-limiting Toxicity, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03; Best Overall Response Rate: Proportion of Patients Reaching CR by IMWG Criteria; Clinical Benefit Response Rate (sCR/CR/VGPR/Partial Response [PR]/Minimal Response [MR] or Stable Disease [SD]), Assessed by IMWG Criteria; Response Duration	City of Hope Medical Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	12	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15140; NCI-2015-01181	12/02/2015	18/09/2018	06/09/2022			27/07/2015		10/10/2023		10/10/2023	https://ClinicalTrials.gov/show/NCT02509052		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Other Haem-onc	Multiple Myeloma	Leflunomide	Safety and/or Dose; Response rate; PFS	Phase 1/2	DB01097	N
NCT04508790	Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma		Recruiting	Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma	Drug: Dexamethasone; Drug: Leflunomide; Drug: Pomalidomide	Overall response; Incidence of adverse events; Response duration; Depth of response; Clinical benefit response; Overall survival; Minimal residual disease (MRD) status	City of Hope Medical Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	29	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19418; NCI-2020-01962	27/11/2020	30/06/2024	30/06/2024			08/11/2020				08/04/2023	https://ClinicalTrials.gov/show/NCT04508790		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Other Haem-onc	Multiple Myeloma	Leflunomide	Safety and/or Dose; Response rate; OS	Phase 2	DB01097	N
NCT03940378	Treatment of Advanced Intrahepatic Cholangiocarcinoma	TAICC	Unknown status	ICC	Drug: Levamisole Hydrochloride; Drug: Anlotinib Hydrochloride Capsules	Progression-free Survival; Overall Survival	The First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Xinjiang Medical University; Luoyang Central Hospital; Nanyang Central Hospital; Anyang Tumor Hospital; Third People's Hospital of Jiaozuo; Sanmenxia Central Hospital; pinmei Group General Hospital	All	18 Years to 65 Years   (Adult, Older Adult)	152	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LEVICC-001	02/01/2019	02/01/2023	02/01/2023			05/07/2019				05/07/2019	https://ClinicalTrials.gov/show/NCT03940378	Adjuvant/Maintenance	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	GI	Cholangiocaricnoma	Levamisole	PFS; OS	Phase 3	DB00848	N
NCT02815410	Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients		Unknown status	Glioblastoma Multiforme	Drug: levetiracetam	6 months Progression free survival; Overall survival	Seoul National University Hospital	All	20 Years to 76 Years   (Adult, Older Adult)	73	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	cykim	07/01/2016	06/01/2019	06/01/2022			28/06/2016				28/06/2016	https://ClinicalTrials.gov/show/NCT02815410		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Korea, Republic of	CNS	Glioblastoma	Levetiracetam	PFS; OS	Phase 2	DB01202	N
NCT02035787	Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients		Active, not recruiting	Complex Atypical Hyperplasia|Endometrial Cancer	Drug: Metformin	Response rate; adverse event measurement	UNC Lineberger Comprehensive Cancer Center; Golfers Against Cancer Grant	Female	18 Years and older   (Adult, Older Adult)	21	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LCCC1326; 12-0886	27/02/2014	04/12/2024	10/01/2024			14/01/2014				30/11/2023	https://ClinicalTrials.gov/show/NCT02035787		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Endometrial Cancer	Metformin	Safety and/or Dose; Response rate	Other	DB00331	N
NCT01686126	Improving the Treatment for Women With Early Stage Cancer of the Uterus	feMMe	Active, not recruiting	Complex Endometrial Hyperplasia With Atypia|Grade 1 Endometrial Endometrioid Adenocarcinoma	Drug: Levonorgestrel; Drug: Metformin	Pathological complete response; Predict the response to treatment	Queensland Centre for Gynaecological Cancer; The University of Queensland; Queensland University of Technology	Female	18 Years and older   (Adult, Older Adult)	165	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	feMMe	12/01/2012	10/03/2022	12/01/2023			17/09/2012				18/04/2023	https://ClinicalTrials.gov/show/NCT01686126		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	Australia	Gynaecological	Endometrial Cancer	Levonorgestrel; Metformin	Response rate	Phase 2	DB00367; DB00331	N
NCT04634539	Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer		Active, not recruiting	Advanced Pancreatic Adenocarcinoma|Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma	Drug: Gemcitabine; Drug: Nab-paclitaxel; Drug: L-glutamine	Recommended phase II dose (RP2D) of combination gemcitabine, nab-paclitaxel, and L-glutamine in treatment-naive metastatic pancreatic cancer.; Describe the safety of gemcitabine, nab-paclitaxel and L-glutamine across all investigated dose levels in subjects with untreated advanced pancreatic cancer; Describe any preliminary evidence of antitumor activity of the combination by assessment of objective response rate as determined by RECIST 1.1 criteria in patients with measurable disease.; Describe any preliminary evidence of antitumor activity of the combination by assessment of progression-free survival as determined by RECIST 1.1 criteria in patients with measurable disease.; Describe any preliminary evidence of antitumor activity of the combination by assessment of overall survival as determined by RECIST 1.1 criteria in patients with measurable disease.	Jun Gong, MD; Emmaus Medical, Inc.; Cedars-Sinai Medical Center	All	18 Years and older   (Adult, Older Adult)	18	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT2020-02-Gong-GLUTAPANC	13/05/2021	07/06/2023	07/06/2025			18/11/2020				12/04/2023	https://ClinicalTrials.gov/show/NCT04634539		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	L-Glutamine	Safety and/or Dose	Phase 1	DB00130	N
NCT04710290	A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers		Unknown status	Metastatic Cancer|Chemotherapy	Dietary Supplement: Beta-Glucan; Dietary Supplement: Glutamine; Dietary Supplement: Immunoglobuin; Dietary Supplement: Corn starch	the change of total white blood cells, neutrophils, and lymphocytes at day 14 of 2nd cycle, from day 7 of 2nd cycle of chemotherapy; the change of total white blood cells, neutrophils, and lymphocytes at day 1 of 3rd cycle, from day 14 of 2nd cycle of chemotherapy; the change of total white blood cells, neutrophils, and lymphocytes at day 7 of 3rd cycle, from day 1 of 3rd cycle of chemotherapy; the change of total white blood cells, neutrophils, and lymphocytes at day 7 of 4th cycle, from day 7 of 3rd cycle of chemotherapy; the change of total white blood cells, neutrophils, and lymphocytes at day 1 of 5th cycle, from day 7 of 4th cycle of chemotherapy; the change of total white blood cells, neutrophils, and lymphocytes at day 7 of 5th cycle, from day 1 of 5th cycle of chemotherapy; the change of total white blood cells, neutrophils, and lymphocytes at day 1 of 6th cycle, from day 7 of 5th cycle of chemotherapy; the change of total white blood cells, neutrophils, and lymphocytes at day 7 of 6th cycle, from day 1 of 6th cycle of chemotherapy; the change of total white blood cells, neutrophils, and lymphocytes at day 22 of 6th cycle, from day 7 of 6th cycle of chemotherapy; the change of total white blood cells, neutrophils, and lymphocytes at 2nd month after chemotherapy, from day 22 of 6th cycle of chemotherapy; change of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) and EORTC-quality-of-life questionnaire cervical cancer module (EORTC-QLQ-CX24 [Taiwan version]) score at C4D7 from C2D7; change of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) and EORTC-quality-of-life questionnaire cervical cancer module (EORTC-QLQ-CX24 [Taiwan version]) score at C6D22 from C4D7; change of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) and EORTC-quality-of-life questionnaire cervical cancer module (EORTC-QLQ-CX24 [Taiwan version]) score at 2 month from C6D22; the change of lymphocyte surface markers percentage at day 7 of 2nd chemotherapy, from baseline.; the change of lymphocyte surface markers percentage at day 14 of 2nd chemotherapy, from day 7 of 2nd chemotherapy; the change of lymphocyte surface markers percentage at day 7 of 4th cycle of chemotherapy, from day 14 of 2nd chemotherapy; the change of lymphocyte surface markers percentage at day 22 of 6th cycle of chemotherapy, from day 7 of 4th cycle of chemotherapy; the change of lymphocyte surface markers percentage at 2 month after 6th cycle of chemotherapy, from day 22 of 6th cycle of chemotherapy; analysis overall survival	E-DA Hospital	All	20 Years and older   (Adult, Older Adult)	90	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	EMRP50106N	01/04/2018	31/12/2021	31/12/2021			14/01/2021				25/01/2021	https://ClinicalTrials.gov/show/NCT04710290		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	Y	N	Taiwan	Multiple cancer types	Any solid tumours	L-Glutamine	QoL; Biomarker	Phase 2/3	DB00130	N
NCT05250791	Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome	FLICOR	Recruiting	Colorectal Cancer|Quality of Life|Recurrent Cancer	Drug: Lidocaine hydrochloride 2  for injection; Drug: 0.9  sterile Sodium Chloride solution for injection	Feasibility of recruitment; Trial retention; The completion of data collection instruments; Participant's feedback of study experiences; Clinical staff feedback of study experiences; Patients' reasons to refuse consent.; Clinicians' reasons for not recruiting patients.; Disease-free survival; Completion of EQ-5D-5L; Completion of the cancer-specific quality of life questionnaires; Completion of healthcare and social care resource use questionnaires; Total hospital stays including readmission	Imperial College London	All	18 Years and older   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	21CX7298; 2021-006185-20; NIHR301741; 1004491	02/02/2023	15/09/2024	15/09/2024			22/02/2022				06/09/2023	https://ClinicalTrials.gov/show/NCT05250791		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United Kingdom	GI	Colon Cancer; Rectal Cancer	Lidocaine	DFS/RFS/EFS; QoL; Other (specify)	Other	DB00281	N
NCT05560035	The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery		Not yet recruiting	Cervical Cancer|Metastatic Cancer	Drug: Lidocaine; Other: Normal saline (NS)	Changes from Baseline THBS2 before anaesthetic induction and 48 hours after surgery; Changes from Baseline MMP-2 before anaesthetic induction and 48 hours after surgery; Changes from Baseline MMP-9 before anaesthetic induction and 48 hours after surgery; Changes from Baseline VEGF-C before anaesthetic induction and 48 hours after surgery; Monitoring the severity of postoperative pain with verbalre sponse pain score during the first 48hours postoperatively; Resumption of bowel function	General Hospital of Ningxia Medical University	Female	18 Years to 65 Years   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention	maling20220922	12/01/2022	07/01/2024	12/01/2024			29/09/2022				29/09/2022	https://ClinicalTrials.gov/show/NCT05560035		Any/All Stages	Hospital/University/Research Institute	Y	N	N	China	Gynaecological	Cervical Cancer	Lidocaine	Biomarker	Other	DB00281	N
NCT04449289	Influence of Local Anesthetic Administration on the Cancer Recurrence Rate After Pancreatic Oncologic Surgery		Not yet recruiting	Pancreatic Cancer	Drug: Intravenous lidocaine; Drug: Epidural ropivacaine	1- and 3-years recurrence rate after surgery; 1- and 3-years survival after surgery; Lidocaine and ropivacaine concentration; Complication rate after surgery	Institutul Regional de Gastroenterologie   Hepatologie Prof. dr. Octavian Fodor	All	18 Years to 80 Years   (Adult, Older Adult)	100	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	43/3.02.2020	07/01/2020	31/12/2021	31/12/2024			26/06/2020				26/06/2020	https://ClinicalTrials.gov/show/NCT04449289		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Romania	GI	Pancreatic Cancer	Lidocaine	Recurrence rate	Phase 2	DB00281	N
NCT05484687	Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors		Completed	Colorectal Tumors|Lidocaine	Drug: Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation	the concentration of tumor micrometastasis markers were determined by ELISA; the concentration of stress hormones were determined by ELISA; the concentration of inflammatory factor were determined by ELISA; the concentration of angiogenesis factors were determined by ELISA; the concentration of immune indexes were determined by ELISA	Affiliated Hospital of Nantong University	All	30 Years to 85 Years   (Adult, Older Adult)	100	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	MA2021008	24/03/2020	30/12/2021	30/01/2023			08/02/2022				08/02/2023	https://ClinicalTrials.gov/show/NCT05484687		Any/All Stages	Hospital/University/Research Institute	N	N	N	China	GI	Colon Cancer; Rectal Cancer	Lidocaine	Biomarker	Other	DB00281	N
NCT04316013	Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial		Recruiting	Colonic Cancer|Rectal Cancer|Non Small Cell Lung Cancer	Drug: Sevoflurane; Drug: Propofol; Drug: Lidocaine IV	Comparison of disease free survival (DFS) with propofol-TIVA versus sevoflurane; Comparison of disease free survival (DFS) with lidocaine compared with no lidocaine; Comparison of overall survival (OS) with propofol-TIVA versus sevoflurane; Days alive and at home with propofol-TIVA versus sevoflurane; Overall survival with intravenous lidocaine versus no lidocaine; Days alive and at home with intravenous lidocaine versus no lidocaine; Comparison of post-operative complications with propofol-TIVA versus sevoflurane; Comparison of post-operative complications with intravenous lidocaine versus no lidocaine; Comparison of chronic post surgical pain with propofol-TIVA versus sevoflurane; Comparison of chronic post surgical pain with intravenous lidocaine versus no lidocaine; Safety profile of propofol-TIVA versus sevoflurane; Safety Profile intravenous lidocaine versus no lidocaine; Concomitant medication use with propofol-TIVA versus sevoflurane; Concomitant medications use with intravenous lidocaine versus no lidocaine; Health utility with propofol-TIVA versus sevoflurane; Health utility with intravenous lidocaine versus no lidocaine	Peter MacCallum Cancer Centre, Australia; National Health and Medical Research Council, Australia; Australian and New Zealand College of Anaesthetists; Victorian Comprehensive Cancer Centre	All	18 Years and older   (Adult, Older Adult)	3500	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other	18/044	31/07/2020	12/01/2027	06/01/2028			20/03/2020				23/03/2023	https://ClinicalTrials.gov/show/NCT04316013	Perioperative	Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	Australia	GI; Lung	Colon Cancer; Rectal Cancer; Non-Small Cell Lung Cancer	Lidocaine	DFS/RFS/EFS	Phase 3	DB00281	N
NCT04162535	Elucidation of the Mechanisms and Effects of Certain Anesthetic Interventions on Digestive Cancer Patients Subjected to Surgery		Unknown status	Colorectal Cancer	Drug: Lidocaine 1  Injectable Solution; Biological: Blood extraction; Drug: Sevoflurane; Drug: Propofol	Evaluation of the antiproliferative and apoptotic effects of anesthetic agents; Evaluation of patients serum on cell culture; Lidocaine concentration; Survival Comparison	Iuliu Hatieganu University of Medicine and Pharmacy; Institutul Regional de Gastroenterologie   Hepatologie Prof. dr. Octavian Fodor; Prof. Dr. I. Chiricuta Institute of Oncology	All	18 Years to 80 Years   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science	418/14.11.2018	26/11/2018	31/12/2023	31/12/2023			14/11/2019				02/10/2021	https://ClinicalTrials.gov/show/NCT04162535		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	Romania	GI	Colon Cancer; Rectal Cancer	Lidocaine	Biomarker	Phase 1	DB00281	N
NCT03134430	Effects of Regional Nerve Block on Cancer Recurrence		Unknown status	Cancer Patient	Other: Normal saline; Other: peripheral Nerve block	the effect of nerve block on the cancer recurrence rate and survival rate postoperation; dosage of intraoperative anesthetic; the effect of nerve block on the percentage and classification of immunocyte and content of cytokines; VAS after operation; activity after operation; Hospital stay	Luo Foquan; The First Affiliated Hospital of Nanchang University	All	18 Years to 80 Years   (Adult, Older Adult)	400	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	LFoquan	07/10/2017	25/03/2018	05/01/2023			05/01/2017				25/05/2018	https://ClinicalTrials.gov/show/NCT03134430		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Multiple cancer types	Any solid tumours	Lidocaine	Recurrence rate	Other	DB00281	N
NCT03281369	A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)		Active, not recruiting	Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma	Drug: 5-Fluorouracil (5-FU); Drug: Leucovorin; Drug: Oxaliplatin; Drug: Atezolizumab; Drug: Cobimetinib; Biological: Ramucirumab; Drug: Paclitaxel; Biological: PEGylated recombinant human hyaluronidase (PEGPH20); Drug: BL-8040; Drug: Linagliptin; Drug: Cisplatin; Drug: Tiragolumab	Percentage of Participants With Objective Response, as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1); Percentage of Participants with Adverse Events (AEs); For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs; Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1; Overall Survival (OS); Percentage of Participants Who Are Alive at Month 6 and at Month 12; Duration of Response, as Determined by Investigator According to RECIST v1.1; Percentage of Participants With Disease Control, as Determined by the Investigator per RECIST v1.1; Serum Concentration of Atezolizumab; Plasma Concentration of Cobimetinib; Plasma Concentration of PEGPH20; Plasma Concentration of BL-8040; Plasma Concentration of Linagliptin; Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab; Percentage of Participants With ADA to PEGPH20; Percentage of Participants With ADA to BL-8040	Hoffmann-La Roche; Halozyme Therapeutics; BioLineRx, Ltd.	All	18 Years and older   (Adult, Older Adult)	410	Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	YO39609; 2016-004529-17	13/10/2017	24/08/2024	02/08/2025			13/09/2017				27/10/2023	https://ClinicalTrials.gov/show/NCT03281369		Advanced/Metastatic	Company	N	Y	N	United States	GI	Gastric Cancer	Linagliptin	Safety and/or Dose; Response rate	Phase 1/2	DB08882	N
NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	I-SPY	Recruiting	Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer	Drug: Standard Therapy; Drug: AMG 386 with or without Trastuzumab; Drug: AMG 479 (Ganitumab) plus Metformin; Drug: MK-2206 with or without Trastuzumab; Drug: AMG 386 and Trastuzumab; Drug: T-DM1 and Pertuzumab; Drug: Pertuzumab and Trastuzumab; Drug: Ganetespib; Drug: ABT-888; Drug: Neratinib; Drug: PLX3397; Drug: Pembrolizumab - 4 cycle; Drug: Talazoparib plus Irinotecan; Drug: Patritumab and Trastuzumab; Drug: Pembrolizumab - 8 cycle; Drug: SGN-LIV1A; Drug: Durvalumab plus Olaparib; Drug: SD-101 + Pembrolizumab; Drug: Tucatinib plus trastuzumab and pertuzumab; Drug: Cemiplimab; Drug: Cemiplimab plus REGN3767; Drug: Trilaciclib with or without trastuzumab + pertuzumab; Drug: SYD985 ([vic-]trastuzumab duocarmazine); Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab; Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab; Drug: Amcenestrant; Drug: Amcenestrant + Abemaciclib; Drug: Amcenestrant + Letrozole; Drug: ARX788; Drug: ARX788 + Cemiplimab; Drug: VV1 + Cemiplimab; Drug: Datopotamab deruxtecan; Drug: Datopotamab deruxtecan + Durvalumab; Drug: Zanidatamab; Drug: Lasofoxifene; Drug: Z-endoxifen; Drug: ARV-471; Drug: ARV-471 + Letrozole	Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry.; Establishing predictive and prognostic indices based on qualification and exploratory markers to predict pCR and residual cancer burden (RCB).; To determine three- and five-year relapse-free survival (RFS) and OS among the treatment arms.; To determine incidence of adverse events (AEs), serious adverse events (SAEs), and laboratory abnormalities of each investigational agent tested.; MRI Volume	QuantumLeap Healthcare Collaborative	All	18 Years and older   (Adult, Older Adult)	5000	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	97517	03/01/2010	12/01/2030	12/01/2031			01/05/2010				27/07/2023	https://ClinicalTrials.gov/show/NCT01042379		Localised/Locoregional	Other	N	Y	N	United States	Breast	Any Breast Cancer	Metformin	Response rate	Phase 1	DB00331	N
NCT03153280	Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer	Lithium	Active, not recruiting	Colorectal Neoplasms|Stomach Neoplasm|Esophageal Neoplasms	Drug: Lithium; Drug: Oxaliplatin; Drug: Capecitabine	Incidence of dose limiting toxicity (DLT) within the two first cycles at each dose level.; Progression Free Survival (PFS) as defined by RECIST Criteria Version 1.1.; Objective Response Rate (ORR) as defined by RECIST Criteria Version 1.1.; Incidence of adverse events reported as per the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. (Safety and Tolerability).	Cancer Trials Ireland; University College Cork	All	18 Years and older   (Adult, Older Adult)	2	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTRIAL-IE (ICORG) 11-32; 2014-000186-47	13/01/2022	12/01/2024	12/01/2026			15/05/2017				13/10/2023	https://ClinicalTrials.gov/show/NCT03153280		Advanced/Metastatic	Collaborative Group	N	N	N	Ireland	GI	Colon Cancer; Rectal Cancer; Gastric Cancer; Esophageal Cancer	Lithium	Safety and/or Dose	Phase 1	Not found in DrugBank	N
NCT01669369	Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma	Li2CO3	Unknown status	Osteosarcoma	Drug: Lithium Carbonate; Drug: Placebo	progression-free survival,incidence of chemotherapy-induced myelosuppression; over-all survival,metastasis-free survival	Sun Yat-sen University; Qilu Hospital of Shandong University; Nanfang Hospital, Southern Medical University; Shenzhen Second People's Hospital; Guangdong Provincial Hospital of Traditional Chinese Medicine; Shanghai 6th People's Hospital	All	8 Years to 70 Years   (Child, Adult, Older Adult)	400	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Lithium-5010	01/01/2013	12/01/2023	12/01/2023			21/08/2012				11/01/2016	https://ClinicalTrials.gov/show/NCT01669369		Localised/Locoregional	Hospital/University/Research Institute	Y	N	Y	China	Bone Sarcoma	Osteosarcoma	Lithium	PFS	Phase 4	Not found in DrugBank	N
NCT03563248	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer		Active, not recruiting	Pancreatic Cancer	Drug: FOLFIRINOX; Drug: Losartan; Drug: Nivolumab; Radiation: SBRT; Procedure: Surgery	Proportion of participants with R0 resection; Progression-free survival; Overall survival; Pathologic complete response; Number of participants with treatment related serious adverse events	Massachusetts General Hospital; Bristol-Myers Squibb; Stand Up To Cancer; Lustgarten Foundation	All	18 Years and older   (Adult, Older Adult)	168	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-179	08/10/2018	07/12/2022	06/01/2027			20/06/2018				09/08/2022	https://ClinicalTrials.gov/show/NCT03563248		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	United States	GI	Pancreatic Cancer	Losartan	Other (specify)	Phase 2	DB00678	N
NCT05861336	GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer	OVERPASS	Recruiting	Pancreatic Cancer	Drug: Losartan; Drug: Gemcitabine; Drug: Nab paclitaxel; Radiation: Stereotactic Body Radiation Therapy	Number of participants discontinuing study treatment due to treatment related grade 3 non-hematological adverse event [Toxicity]; Number of participants discontinuing study treatment due to treatment related grade 3 adverse event [Toxicity]; Resectability rate; margin-negative resection rate (R0); progression-free survival (PFS); overall survival (OS); biomarker blood response; Incidence of Treatment-Emergent Adverse Events [Toxicity]; Quality of life questionnaire (QLQ)	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori	All	18 Years to 75 Years   (Adult, Older Adult)	34	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRST157.04	14/06/2023	08/01/2026	08/01/2029			16/05/2023				01/05/2024	https://ClinicalTrials.gov/show/NCT05861336		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Italy	GI	Pancreatic Cancer	Losartan	Safety and/or Dose; Other (specify)	Phase 2	DB00678	N
NCT01821729	Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer		Unknown status	Pancreatic Cancer	Drug: FOLFIRINOX; Drug: Losartan; Radiation: Proton Beam Radiation	Number of Participants With R0 Resection; Progression-Free Survival; Overall Survival for FOLFIRINOX + Proton Beam Radiation; Overall Survival for FOLFIRINOX Without Proton Radiation; Determine Toxicity FOLFIRINOX-Losartan; Determine Toxicity of FOLFIRINOX-Losartan and Proton Beam Radiation; Rate of Downstaging; Determine Correlation of Somatic Gene Mutations and Outcome; Determine Correlation Between Circulating Biomarkers and Outcome; Describe Quality of Life, Symptom Burden and Mood; To Measure Utilization of Health Services	Massachusetts General Hospital; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	50	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13-051	07/01/2013	07/01/2018	09/01/2021			04/01/2013		17/09/2019		25/09/2020	https://ClinicalTrials.gov/show/NCT01821729		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Losartan	Other (specify)	Phase 2	DB00678	N
NCT05097248	Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received   1 Line of Chemotherapy		Not yet recruiting	Breast Cancer	Drug: Camrelizumab; Drug: Liposomal Doxorubicin; Drug: Losartan	Objective Response Rate (ORR); Progression-Free Survival (PFS); Overall Survival (OS); Duration of Response (DoR); Clinical Benefit rate (CBR); Adverse events (AEs)	Wuhan Union Hospital, China; Jiangsu HengRui Medicine Co., Ltd.; CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Female	18 Years to 70 Years   (Adult, Older Adult)	52	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WHUH-BC-001	10/01/2021	10/01/2024	10/01/2024			28/10/2021				28/10/2021	https://ClinicalTrials.gov/show/NCT05097248		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Breast	Breast Cancer - TNBC	Losartan	Response rate	Phase 2	DB00678	N
NCT04106856	Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)	SHAPER	Recruiting	Borderline Resectable Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Ductal Adenocarcinoma|Locally Advanced Unresectable Pancreatic Adenocarcinoma|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8	Radiation: Hypofractionated Radiation Therapy; Drug: Losartan; Drug: Losartan Potassium; Other: Quality-of-Life Assessment; Other: Questionnaire Administration	Grade 3 or higher gastrointestinal toxicity rate; Frequency of adverse events; Response rate (clinical and/or pathologic partial response [PR] and complete response [CR]); Progressive free survival (PFS); Overall survival (OS); Number patients that require a medical intervention or hospitalization due to hypotension	University of Utah; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	20	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCI121104; NCI-2019-05882; P30CA042014	08/08/2019	08/08/2025	08/08/2026			27/09/2019				07/03/2023	https://ClinicalTrials.gov/show/NCT04106856		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Losartan	Safety and/or Dose	Phase 1	DB00678	N
NCT05077800	FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer		Recruiting	Pancreatic Adenocarcinoma|Pancreatic Adenocarcinoma Metastatic	Drug: FOLFIRNINOX; Drug: Losartan; Drug: 9-ING-41	Progression-free survival (PFS); Overall survival (OS); Median time of maintenance therapy (mMT):; Objective Response Rate	Colin D. Weekes, M.D.; Actuate Therapeutics Inc.; Lustgarten Foundation; Massachusetts General Hospital	All	18 Years and older   (Adult, Older Adult)	70	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	21-350	21/03/2022	31/12/2023	31/07/2024			14/10/2021				06/09/2022	https://ClinicalTrials.gov/show/NCT05077800		Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	United States	GI	Pancreatic Cancer	Losartan	PFS	Phase 2	DB00678	N
NCT03900793	Losartan + Sunitinib in Treatment of Osteosarcoma		Recruiting	Osteosarcoma	Drug: Losartan; Drug: Sunitinib	Assessment of Dose-Limiting Toxicities of Losartan and Sunitinib Combination; Maximally Tolerated Dose of Losartan and Sunitinib; Recommended Phase 2 Dose of Losartan and Sunitinib; Pharmacokinetics of Losartan and Sunitinib in Pediatric and Adult Patients: Maximum Peak Concentration; Pharmacokinetics of Losartan and Sunitinib in Pediatric and Adult Patients: Time to Peak Concentration; Pharmacodynamics of Losartan and Sunitinib in Pediatric and Adult Patients: CCL2-Mediated Chemotactic Index; Pharmacodynamics of Losartan and Sunitinib in Pediatric and Adult Patients: Plasma CCL2 Levels; Pharmacodynamics of Losartan and Sunitinib in Pediatric and Adult Patients: CCR2+ Monocyte Population; Preliminary Antitumor Activity of Losartan and Sunitinib in Pediatric and Adult Patients: Disease Control Rate (DCR); Preliminary: Progression Free Survival (PFS)	University of Colorado, Denver	All	10 Years to 40 Years   (Child, Adult)	41	Other	Interventional Study	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-2740.cc; NCI-2019-06119	26/08/2019	02/01/2024	02/01/2025			04/03/2019				30/11/2023	https://ClinicalTrials.gov/show/NCT03900793		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Bone Sarcoma	Osteosarcoma	Losartan	Safety and/or Dose	Phase 1	DB00678	N
NCT04721301	Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial		Completed	Colorectal Cancer Metastatic|Pancreatic Cancer Metastatic	Combination Product: Nivolumab plus Ipilimumab plus Maraviroc	Number of participants and severity of treatment-related adverse Events as assessed by CTCAE v4.0; Progression Free Survival; Overall Survival; Tissue Response	University Hospital Heidelberg; German Cancer Research Center	All	18 Years and older   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-003297-13	15/01/2017	15/03/2023	15/03/2023			22/01/2021				17/10/2023	https://ClinicalTrials.gov/show/NCT04721301		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Germany	GI	Colon Cancer; Rectal Cancer; Pancreatic Cancer	Maraviroc	Safety and/or Dose	Phase 1	DB04835	N
NCT03925662	Mebendazole as Adjuvant Treatment for Colon Cancer		Recruiting	Colorectal Cancer	Drug: Folfox with avastin; Drug: Mebendazole	number of patients with tumour response	Sherief Abd-Elsalam; Tanta University	All	18 Years and older   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	colon cancer	04/01/2019	12/01/2028	12/01/2028			24/04/2019				24/04/2019	https://ClinicalTrials.gov/show/NCT03925662	Palliative	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Egypt	GI	Colon Cancer; Rectal Cancer	Mebendazole	Response rate	Phase 3	DB00643	N
NCT04443049	To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.		Unknown status	Hepatocellular Carcinoma|Liver Cirrhosis	Drug: Lenvatinib; Drug: Mebendazole; Other: Placebo	Overall survival in both groups; Death; Progressive disease requiring change of therapy in both groups; Progressive disease requiring quitting therapy in both groups; Therapy related adverse effects in both groups; Worsening of performance status in both groups; Decompensation of underlying cirrhosis in both groups	Institute of Liver and Biliary Sciences, India	All	18 Years to 70 Years   (Adult, Older Adult)	170	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ILBS-Cirrhosis-32	07/10/2020	19/06/2022	19/06/2022			23/06/2020				10/05/2021	https://ClinicalTrials.gov/show/NCT04443049		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	India	GI	Liver Cancer	Mebendazole	OS	Other	DB00643	N
NCT01837862	A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas		Recruiting	Pilomyxoid Astrocytoma|Pilocytic Astrocytoma|Glioma, Astrocytic|Optic Nerve Glioma|Pleomorphic Xanthoastrocytoma|Glioblastoma Multiforme|Anaplastic Astrocytoma|Gliosarcoma|Diffuse Intrinsic Pontine Glioma|DIPG|Low-grade Glioma|Brainstem Glioma	Drug: Mebendazole; Drug: Vincristine; Drug: Carboplatin; Drug: Temozolomide; Drug: Bevacizumab; Drug: Irinotecan	Maximally tolerated dose of mebendazole in combination with vincristine, carboplatin, and temozolomide; Maximally tolerated dose of mebendazole in combination with bevacizumab and irinotecan.; Survival of patients with low-grade gliomas; Survival of patients with high-grade gliomas; Frequency of cerebrospinal fluid (CSF) dissemination in pilomyxoid astrocytoma; Partial or complete response rate on MRI of patients with high-grade gliomas/pontine gliomas; Partial or complete response rate on MRI of patients with low-grade gliomas	Julie Krystal; Janssen Pharmaceuticals; Northwell Health	All	1 Year to 21 Years   (Child, Adult)	36	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCMC1411	22/10/2013	04/01/2024	04/01/2025			23/04/2013				13/04/2023	https://ClinicalTrials.gov/show/NCT01837862		Any/All Stages	Hospital/University/Research Institute	N	N	Y	United States	CNS	Any CNS cancers	Mebendazole	Safety and/or Dose	Phase 1/2	DB00643	N
NCT01430351	Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy		Active, not recruiting	Glioblastoma|Gliosarcoma|Supratentorial Glioblastoma	Drug: Mefloquine; Drug: Memantine Hydrochloride; Drug: Metformin Hydrochloride; Drug: Temozolomide	Incidence of toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0; Median progression free survival (PFS); PFS; Median overall survival (OS)	M.D. Anderson Cancer Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	144	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2011-0374; NCI-2011-03038; P30CA016672	14/09/2011	30/09/2023	30/09/2023			09/08/2011				14/08/2023	https://ClinicalTrials.gov/show/NCT01430351		Any/All Stages	Hospital/University/Research Institute	Y	Y	N	United States	CNS	Glioblastoma	Mefloquine; Memantine; Metformin	Safety and/or Dose	Phase 1	DB00358; DB01043; DB00331	N
NCT05332483	Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer	MA-EEC	Terminated	Endometrial Cancer	Drug: Megestrol Acetate	Overall response rate of patients with biopsy grade 2 endometrioid endometrial cancer treated preoperatively with Megestrol acetate for a minimum of 21 days.; Correlations between response to progestin and clinical, histological and transcriptomic pre-operative biomarkers that may impact therapy planning.	Sunnybrook Health Sciences Centre; Ontario Institute for Cancer Research	Female	18 Years and older   (Adult, Older Adult)	5	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4858	07/05/2022	10/12/2023	10/12/2023			18/04/2022				11/03/2023	https://ClinicalTrials.gov/show/NCT05332483		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Canada	Gynaecological	Endometrial Cancer	Megestrol Acetate	Safety and/or Dose; Response rate	Phase 1	DB00351	N
NCT03306472	A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer	PIONEER	Unknown status	Breast Cancer	Drug: Megestrol Acetate 40 MG; Drug: Megestrol Acetate 160 MG; Drug: Letrozole	Determination of change in tumour proliferation measured by Ki67 immunohistochemical (IHC) assessment ( ) at baseline compared to Day 15 (+  4 days).; Change in tumour apoptosis, measured by Caspase 3 (IHC); Change in expression of Androgen receptor and Progesterone receptor by IHC; Change in expression of Epithelial-Mesenchymal Transition (EMT) markers by IHC; Change in proliferation by Aurora Kinase A labeling by IHC; Absolute value of Ki67 at day 15 (+ 4 Days); Incidence and Severity of Adverse Events	Cambridge University Hospitals NHS Foundation Trust; Anticancer Fund, Belgium	Female	18 Years and older   (Adult, Older Adult)	189	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PIONEER; 2016-003752-79	20/07/2017	31/10/2021	30/11/2022			10/11/2017				13/01/2021	https://ClinicalTrials.gov/show/NCT03306472		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	United Kingdom	Breast	Breast Cancer - ER/HR+	Megestrol Acetate	Biomarker	Phase 2	DB00351	N
NCT03777930	The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol		Unknown status	Cancer, Therapy-Related	Drug: Chemotherapy drugs; Drug: thalidomide and megestrol acetate; Other: optimal support treatment	Imaging efficacy evaluation; Observing the expression of lymphocyte subsets; Observing the expression of inflammatory factors; Nutritional assessment	Shenzhen Fifth People's Hospital	All	18 Years and older   (Adult, Older Adult)	200	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	shenzhenfifth 201807	12/10/2018	10/10/2020	06/10/2021			19/12/2018				19/12/2018	https://ClinicalTrials.gov/show/NCT03777930		Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	China	Multiple cancer types	Any solid tumours	Megestrol Acetate	Response rate	Phase 4	DB00351	N
NCT03024580	A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	MEGA	Unknown status	Breast Neoplasm	Drug: Megestrol Acetate 160Mg Tablet; Drug: Anastrozole 1Mg Tablet; Drug: Letrozole 2.5Mg Tablet; Drug: Exemestane 25 MG; Drug: Tamoxifen 20Mg Tablet; Drug: Fulvestrant 50Mg Solution for Injection	Progression free survival; Overall survival; Clinical benefit	Instituto Nacional de Cancer, Brazil; Cancer Research UK Cambridge Institute	Female	Child, Adult, Older Adult	20	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	64/16	03/06/2017	03/01/2020	09/01/2020			19/01/2017				15/08/2019	https://ClinicalTrials.gov/show/NCT03024580		Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	Brazil	Breast	Breast Cancer - ER/HR+	Megestrol Acetate	PFS	Phase 2	DB00351	N
NCT05247268	Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer		Recruiting	Endometrial Neoplasm Malignant Stage I	Drug: Megestrol Acetate 160 MG Oral Tablet; Drug: Medroxyprogesterone Acetate 500 MG; Drug: Triprorelin Acetate; Drug: Letrozole 2.5mg	Complete response rates within 16 weeks of treatment; Complete response rates within 28 weeks of treatment; Time to achieve complete response; Adverse events; Quality of life during the treatment accessed by WHOQOL-BREF; Relapse rates; Change of AMH (anti-mullerian hormone ) serum level; The rates of fertility outcomes	Fudan University; Peking Union Medical College Hospital	Female	18 Years to 45 Years   (Adult)	104	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	53211032	03/11/2022	03/10/2024	03/10/2025			18/02/2022				28/03/2023	https://ClinicalTrials.gov/show/NCT05247268		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Gynaecological	Endometrial Cancer	Megestrol Acetate	Response rate	Phase 2	DB00351	N
NCT02644408	Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy		Completed	Stage III Esophageal Squamous Cell Carcinoma|Stage II Esophageal Squamous Cell Carcinoma	Drug: Megestrol Yining ; Radiation: radiotherapy; Other: chemotherapy	Quality of Life (QoF); pathological response; adverse events	The First Affiliated Hospital of Henan University of Science and Technology	All	45 Years to 75 Years   (Adult, Older Adult)	184	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MAIQF	10/01/2014	12/01/2019	12/01/2020			31/12/2015				17/02/2021	https://ClinicalTrials.gov/show/NCT02644408	Primary/Main Curative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Esophageal Cancer	Megestrol Acetate	QoL	Phase 3	DB00351	N
NCT05538897	Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers		Suspended	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma|FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma|Metastatic Endometrial Endometrioid Adenocarcinoma|Recurrent Endometrial Endometrioid Adenocarcinoma|Stage IV Uterine Corpus Cancer AJCC v8	Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Ipatasertib; Procedure: Magnetic Resonance Imaging; Drug: Megestrol Acetate	Incidence of adverse events (AEs) (Phase Ib); Maximum tolerated dose for phase II (Phase Ib); Progression free survival (PFS) (Phase II); Incidence of AEs (Phase II); Pharmacokinetics of ipatasertib + megestrol acetate (Phase Ib); Objective response rate (ORR) (Phase II); Biomarkers (Phase II)	National Cancer Institute (NCI); NRG Oncology	Female	18 Years and older   (Adult, Older Adult)	96	NIH; Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2022-07505; NRG-GY028; U10CA180868	31/03/2023	31/01/2027	31/01/2027			14/09/2022				12/06/2023	https://ClinicalTrials.gov/show/NCT05538897		Advanced/Metastatic; Recurrent/Refractory	Local/National government	N	Y	N	United States	Gynaecological	Endometrial Cancer	Megestrol Acetate	Safety and/or Dose; Response rate; PFS	Phase 1/2	DB00351	N
NCT03671811	Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy		Active, not recruiting	Atypical Endometrial Hyperplasia|Endometrial Carcinoma	Drug: Megestrol Acetate; Biological: Pterostilbene	Tumor Ki-67 proliferation index; Histologic response of gland cellularity; Histologic response of mitotic index; Histologic response of metaplasia; Histologic response of eosinophilic cytoplasm; Immunohistochemical expression of Bcl-2 to assess tumor growth and apoptosis; Immunohistochemical expression of Casp3 to assess tumor growth and apoptosis	City of Hope Medical Center; National Cancer Institute (NCI)	Female	18 Years and older   (Adult, Older Adult)	44	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17327; NCI-2018-01555; P30CA033572	21/01/2019	11/07/2024	11/07/2024			14/09/2018				01/05/2024	https://ClinicalTrials.gov/show/NCT03671811		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Gynaecological	Endometrial Cancer	Megestrol Acetate	Biomarker	Phase 2	DB00351	N
NCT05255653	Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features	RAINBO	Recruiting	Endometrial Cancer	Drug: Olaparib; Radiation: Pelvic external beam radiotherapy; Drug: Chemotherapy; Drug: Durvalumab; Drug: Medroxyprogesterone Acetate; Drug: Megestrol Acetate; Radiation: Vaginal brachytherapy; Other: Observation	p53abn-RED trial; MMRd-GREEN trial; NSMP-ORANGE trial; POLEmut-BLUE trial; Recurrence-free survival; Pelvic recurrence-free survival; Vaginal recurrence-free survival; Endometrial cancer-specific survival; Overall survival; Treatment-related toxicity - according to CTCAE v5.0; Health-related quality of life - Assessed using the EORTC QLQ-C30 questionnaire; Health-related quality of life - Assessed using the EORTC QLQ-EN24 questionnaire	Leiden University Medical Center; Institute Gustave Roussy (sponsor p53abn-RED trial); Leiden University Medical center (sponsor MMRd-GREEN trial); University College London (sponsor NSMP-ORANGE trial); Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial); Dutch Gynaecological Oncology Group; Comprehensive Cancer Centre The Netherlands; Cancer Research UK   UCL Cancer Trials Centre; Dutch Cancer Society; AstraZeneca; National Cancer Institute, France; Canadian Institutes of Health Research (CIHR)	Female	18 Years and older   (Adult, Older Adult)	1615	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RAINBO; ENGOT-en14-1,2,3,4; CCTG EN.10 TAPER arm A POLE	11/11/2021	01/01/2030	01/01/2031			24/02/2022				13/07/2023	https://ClinicalTrials.gov/show/NCT05255653		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Netherlands	Gynaecological	Endometrial Cancer	Megestrol Acetate	DFS/RFS/EFS	Phase 2/3	DB00351	N
NCT04046185	Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer	ECCT	Unknown status	Endometrial Cancer Stage I	Drug: PD-1 inhibitor combined progesterone; Drug: progesterone	Pathologic complete remission rate of endometrial curettage tissues; Pathologic partial remission rate of endometrial curettage tissues; adverse effects; pregnancy rate	Shanghai First Maternity and Infant Hospital	Female	18 Years to 45 Years   (Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	ECCT001	10/01/2019	10/01/2021	10/01/2022			08/06/2019				08/06/2019	https://ClinicalTrials.gov/show/NCT04046185		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Gynaecological	Endometrial Cancer	Megestrol Acetate	Response rate	Phase 1	DB00351	N
NCT04491643	Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma		Recruiting	Endometrial Carcinoma Stage I	Drug: Megestrol Acetate; Drug: Rosuvastatin	Pathological response rate; Pathological response duration; Pathological response rate classified by different blood lipid level; Toxicity evaluation; Relapse rate; Pregnancy rate	Fudan University	Female	18 Years to 45 Years   (Adult)	48	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	53211029-02	09/01/2020	31/08/2023	31/08/2023			29/07/2020				17/02/2023	https://ClinicalTrials.gov/show/NCT04491643		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	Gynaecological	Endometrial Cancer	Megestrol Acetate; Rosuvastatin	Response rate	Phase 2	DB00351; DB01098	N
NCT05316467	Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma		Recruiting	Endometrial Carcinoma|Obese|Overweight|Fertility Issues	Behavioral: Intensive Lifestyle Intervention (ILI); Drug: Megestrol Acetate 160 MG Oral Tablet	Pathological complete response (CR) rates; Pregnancy outcomes; Weight change; Change of body composition; Change of heart rates; Change of blood pressures; Blood glucose change; Blood lipids change; Insulin resistance change; Ovarian reserve function change; Quality of life change; Physical activities change; Chronic inflammatory indexes change; Time of pathological complete response (CR); Incidence of adverse events; Relapse rates	Xiaojun Chen; Fudan University	Female	18 Years to 45 Years   (Adult)	89	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	53211036-01	05/01/2022	28/02/2024	28/02/2026			04/07/2022				31/05/2023	https://ClinicalTrials.gov/show/NCT05316467		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	Gynaecological	Endometrial Cancer	Megestrol Acetate	Response rate; QoL; Biomarker; Other (specify)	Phase 2/3	DB00351	N
NCT05913427	Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)	PESETA	Recruiting	Adrenocortical Carcinoma	Drug: Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG; Drug: Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo	Evaluation of the activity of the combination regimen (EDP-M plus progesterone (EDP-MP) versus EDP-M plus placebo) in advanced/ metastatic patients with ACC.; Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	All	18 Years and older   (Adult, Older Adult)	80	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	ASSTBS-FARONCO- PESETA-20	06/08/2022	06/08/2027	06/08/2027			22/06/2023				22/06/2023	https://ClinicalTrials.gov/show/NCT05913427		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Italy	Endocrine	Adrenocortical Carcinoma	Megestrol Acetate	Response rate; Biomarker	Phase 2	DB00351	N
NCT02506777	Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.	MBC1	Unknown status	Breast Cancer	Drug: metformin; Drug: Fluoruracil; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: melatonin	Response rate; Pathomorphological response; Adverse events incidence	N.N. Petrov National Medical Research Center of Oncology	Female	18 Years and older   (Adult, Older Adult)	96	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MBC1	07/01/2015	08/01/2020	08/01/2020			23/07/2015				09/04/2019	https://ClinicalTrials.gov/show/NCT02506777		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	Russian Federation	Breast	Any Breast Cancer	Melatonin; Metformin	Response rate	Phase 2	DB01065; DB00331	N
NCT02506790	Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer		Unknown status	Breast Cancer	Drug: metformin; Drug: Melatonin; Drug: Toremifene	Response rate; Pathomorphological response; Adverse events incidence	N.N. Petrov National Medical Research Center of Oncology	Female	18 Years and older   (Adult, Older Adult)	96	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MBC 2	07/01/2015	08/01/2020	08/01/2022			23/07/2015				09/04/2019	https://ClinicalTrials.gov/show/NCT02506790		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Russian Federation	Breast	Any Breast Cancer	Melatonin; Metformin	Response rate	Phase 2	DB01065; DB00331	N
NCT05502900	Adjuvant Melatonin for Uveal Melanoma	AMUM	Recruiting	Uveal Melanoma|Uveal Melanoma, Posterior, Medium/Large Size|Eye Cancer, Intraocular Melanoma	Drug: Melatonin	Number of patients that develop metastases in Melatonin vs. Control arm, evaluated as relative risk (RR).; Number of patients that develop metastases in Melatonin vs. Control arm, evaluated as Cox regression hazard ratio (HR).; Overall survival (OS) time from randomization in Melatonin vs. Control arm, evaluated with the Log-rank test.; Overall survival (OS) time from the detection of metastasis in Melatonin vs. Control arm, evaluated with the Log-rank test.; Number of patients that develop other cancers (i.e., cancer diagnoses other than uveal melanoma) in Melatonin vs. Control arm, evaluated as relative risk (RR).; Number of patients that develop other cancers (i.e., cancer diagnoses other than uveal melanoma) in Melatonin vs. Control arm, evaluated as Cox regression hazard ratio (HR).; Number of participants with treatment-related adverse events (AEs) and serious adverse events (SAEs) in Melatonin vs. Control arm, as assessed by CTCAE v5.0.	Gustav Stalhammar; Karolinska Trial Alliance; Swedish Cancer Society; The Swedish Eye Foundation ( gonfonden); The Swedish Society of Medicine; St. Erik Eye Hospital	All	18 Years and older   (Adult, Older Adult)	100	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	AMUM v 2.0; 2022-500307-49	10/02/2022	01/01/2031	01/01/2031			16/08/2022				22/11/2023	https://ClinicalTrials.gov/show/NCT05502900	Adjuvant/Maintenance	Localised/Locoregional	Collaborative Group	N	N	N	Sweden	Ocular	Melanoma - Intraocular	Melatonin	OS; Recurrence rate	Phase 3	DB01065	N
NCT04530097	Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC		Unknown status	NSCLC and Theropy	Procedure: RFA	overall survival rate OS; DFS	Shanghai 10th People's Hospital	All	18 Years to 85 Years   (Adult, Older Adult)	260	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020KT128	01/01/2021	30/09/2022	30/09/2022			28/08/2020				28/08/2020	https://ClinicalTrials.gov/show/NCT04530097		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Lung	Non-Small Cell Lung Cancer	Melatonin	OS	Other	DB01065	N
NCT02078102	A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma		Completed	Multiple Myeloma|Non-Hodgkin's Lymphoma	Drug: Meloxicam; Drug: Filgrastim	Percent of Patients Who Mobilize and Collect at Least Half of the Total Target CD34+ Cell Dose in the First Apheresis; Number of Patients With Treatment Related Adverse Events Grade 3 or Higher for Nonhematological Toxicity; Summary Statistics for Graft Composition of Peripheral Blood Stem Cell Collection at Each Time Point; Time to Neutrophil Engraftment; Time to Platelet Engraftment	Sherif S. Farag; National Cancer Institute (NCI); Indiana University	All	18 Years and older   (Adult, Older Adult)	38	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IUCRO-0419; CA182947; 1312925163	03/11/2014	11/06/2018	21/02/2019			03/05/2014		21/02/2021		21/02/2021	https://ClinicalTrials.gov/show/NCT02078102		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	Lymphoma; Other Haem-onc	Non-Hodgkin Lymphoma, Adult; Multiple Myeloma	Meloxicam	Other (specify)	Phase 2	DB00814	N
NCT06007846	A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer		Recruiting	Hepatocellular Carcinoma|Cirrhosis	Drug: Namenda	Patients Progression Free Survival at 6 months	Inova Health Care Services	All	18 Years and older   (Adult, Older Adult)	12	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	U23-01-4957	31/07/2023	31/08/2024	31/08/2025			23/08/2023				21/09/2023	https://ClinicalTrials.gov/show/NCT06007846		Advanced/Metastatic	Company	N	N	N	United States	GI	Liver Cancer	Memantine	PFS	Phase 2/3	DB01043	N
NCT05664464	Glutamate Inhibitors in Glioblastoma	GLUGLIO	Recruiting	Glioblastoma	Drug: Gabapentin; Drug: Sulfasalazine; Drug: Memantine; Drug: Temozolomide; Radiation: Radiotherapy	PFS-6; PFS; OS; OS-12; SFS; SFS-6; QoL; Symptom burden; Quality of life of an informal caregiver; Cognitive Functioning	University of Zurich; Swiss National Science Foundation	All	18 Years and older   (Adult, Older Adult)	120	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2022-01877	01/01/2023	06/01/2026	12/01/2026			23/12/2022				24/03/2023	https://ClinicalTrials.gov/show/NCT05664464		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Switzerland	CNS	Glioblastoma	Memantine; Sulfasalazine	PFS	Phase 1/2	DB01043; DB00795	N
NCT04387630	Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.		Unknown status	Breast Cancer	Drug: Metformin; Drug: Placebo oral tablet	Clinical Response rate	Mansoura University	Female	18 Years to 65 Years   (Adult, Older Adult)	120	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	R.20.05.834	06/05/2020	06/05/2022	05/01/2023			14/05/2020				06/11/2020	https://ClinicalTrials.gov/show/NCT04387630		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Egypt	Breast	Any Breast Cancer	Metformin	Response rate	Phase 2/3	DB00331	N
NCT04559308	The Effect of Metformin on Breast Cancer Patients		Unknown status	Breast Cancer	Drug: Metformin; Drug: Chemotherapy	Clinical benefit rate (Tumor size); Pathological complete response; Number of participants with metformin-related adverse events; The effect of metformin on the quality of life of breast cancer patients	Beni-Suef University; Ahram Canadian University	Female	18 Years to 65 Years   (Adult, Older Adult)	80	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BSU	06/01/2019	15/09/2020	10/01/2020			22/09/2020				22/09/2020	https://ClinicalTrials.gov/show/NCT04559308		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Egypt	Breast	Any Breast Cancer	Metformin	Response rate	Phase 2	DB00331	N
NCT04926155	The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer		Not yet recruiting	Metastatic Prostate Cancer	Drug: Metformin	Progression-free survival defined from randomization to time till biochemical progression or radiographic progression; Overall survival defined from randomization until death due to any reason; Radiographic progression-free survival defined from randomization until radiographic progression; Adverse events which will be assessed according to NCI-CTC AE 5.0	Sun Yat-sen University	Male	18 Years and older   (Adult, Older Adult)	234	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2021-FXY-072	23/06/2021	30/04/2024	31/08/2024			14/06/2021				14/06/2021	https://ClinicalTrials.gov/show/NCT04926155		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	China	Urological	Prostate Cancer	Metformin	PFS; OS	Phase 2	DB00331	N
NCT05921942	The Impact of Metformin Administration on the Clinical Outcome of Stage IV Colon Cancer		Recruiting	Colorectal Cancer	Drug: Metformin	Disease Control Rate according to Response evaluation criteria in solid tumors ( RECIST) 1.1; Progression free survival; IL-6 Levels; Overall Survival; Common terminology criteria adverse events (CTCAE 4.0)	Ain Shams University	All	18 Years to 65 Years   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	262	15/04/2020	21/07/2023	09/06/2023			27/06/2023				27/06/2023	https://ClinicalTrials.gov/show/NCT05921942	Adjuvant/Maintenance	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Egypt	GI	Colon Cancer	Metformin	PFS; OS; Other (specify)	Phase 3	DB00331	N
NCT04170465	Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)	METNEO	Completed	Breast Cancer Female	Drug: Metformin Hydrochloride 850 mg Tablets; Drug: AC-T chemotherapy regimen	Evaluation of the effect on tumor apoptosis; Chemotherapy toxicities; Pathologic complete response rate (pCR)	Damanhour University; Alexandria University	Female	18 Years to 65 Years   (Adult, Older Adult)	70	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	919PP18	29/10/2019	04/02/2022	28/06/2022			20/11/2019				09/10/2022	https://ClinicalTrials.gov/show/NCT04170465		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Egypt	Breast	Any Breast Cancer	Metformin	Safety and/or Dose; Response rate; Biomarker	Phase 2	DB00331	N
NCT03379909	Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer	TROJAN	Recruiting	Superficial Bladder Cancer|Bladder Cancer	Drug: Metformin	Overall response; Time to recurrence; Toxicity of metformin treatment; Partial response	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Radboud University Medical Center	All	18 Years and older   (Adult, Older Adult)	49	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Medonc-17-11	09/01/2019	31/07/2024	10/01/2029			20/12/2017				21/09/2023	https://ClinicalTrials.gov/show/NCT03379909		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Netherlands	Urological	Bladder Cancer	Metformin	Response rate	Phase 2	DB00331	N
NCT02339168	Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer		Active, not recruiting	Prostate Cancer	Drug: Enzalutamide; Drug: Metformin Hydrochloride	DLT graded accorded to the National Cancer institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; Incidence of adverse events graded according to NCI CTCAE version 4.0; PSA response rate as determined by percent of patients achieving >= 50  PSA decline following initiation of treatment; PSA progression by Prostate Cancer Working Group (PCWG) 2, defined as the date that a 25  or greater increase and an absolute increase of 2 ng/mL or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later; Radiographic disease progression, determined by Response Evaluation Criteria in Solid Tumors version 1.1; Progression-free survival; Time to treatment failure which includes discontinuing therapy because of disease progression, toxicity, or patient withdrawal	University of California, Davis; National Cancer Institute (NCI); Medivation, Inc.; Astellas Pharma Inc	Male	18 Years and older   (Adult, Older Adult)	24	Other; NIH; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	680462; UCDCC#243; P30CA093373; NCI-2014-02668	22/06/2016	04/01/2024	12/01/2024			15/01/2015				31/08/2023	https://ClinicalTrials.gov/show/NCT02339168		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Metformin	Safety and/or Dose	Phase 1	DB00331	N
NCT03238495	Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer	HERMET	Unknown status	HER2-positive Breast Cancer	Drug: Taxotere, Carboplatin, Herceptin + Pertuzumab; Drug: Metformin	Pathologic complete response (pCR)	Qamar Khan; University of Kansas Medical Center	Female	18 Years and older   (Adult, Older Adult)	100	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00140673	15/08/2017	06/01/2022	06/01/2023			08/03/2017				12/07/2021	https://ClinicalTrials.gov/show/NCT03238495		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Breast	Breast Cancer - HER2+	Metformin	Response rate	Phase 2	DB00331	N
NCT02640534	Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone		Terminated	Cancer of the Prostate|Prostate Cancer	Drug: Enzalutamide; Drug: Metformin	Disease control (DC); Overall response (OR); Event-free survival (EFS); Adverse events (AEs); Overall survival (OS)	Swiss Group for Clinical Cancer Research	Male	18 Years and older   (Adult, Older Adult)	169	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SAKK 08/14 - IMPROVE	06/10/2016	07/01/2022	16/03/2023			29/12/2015				27/06/2023	https://ClinicalTrials.gov/show/NCT02640534		Recurrent/Refractory	Collaborative Group	Y	N	N	Switzerland	Urological	Prostate Cancer	Metformin	Safety and/or Dose; Response rate; OS; DFS/RFS/EFS	Phase 2	DB00331	N
NCT04925063	The Effect of Metformin in Patients With Newly Diagnosed mHSPC		Not yet recruiting	Metastatic Prostate Cancer	Drug: Metformin	Castration-resistant prostate cancer free survival; Overall Survival; Radiographic progression-free survival; Safety	Sun Yat-sen University	Male	18 Years and older   (Adult, Older Adult)	266	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2021-FXY-078	16/06/2021	30/04/2027	31/08/2027			14/06/2021				14/06/2021	https://ClinicalTrials.gov/show/NCT04925063		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	Urological	Prostate Cancer	Metformin	PFS; OS	Phase 2	DB00331	N
NCT05680662	The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism		Not yet recruiting	Breast Cancer Female|Triple Negative Breast Cancer	Combination Product: quercetin, EGCG, metformin , zinc	invasive Disease Free Survival at 3 Years from the time of randomization until the occurrence of the first of the following events: invasive local/regional recurrence, Contralateral invasive breast cancer, Distant recurrence, Death from any cause; Invasive Disease Free Survival at 10 Years; Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0 [; Total patient chair time of drug administration; Breast cancer-specific survival (BCSS) at 10 Years	Ministry of Health, Saudi Arabia	Female	18 Years to 70 Years   (Adult, Older Adult)	200	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Amr Ahmed	01/01/2023	31/12/2023	31/01/2024			01/11/2023				01/11/2023	https://ClinicalTrials.gov/show/NCT05680662		Localised/Locoregional; Advanced/Metastatic	Local/National government	Y	N	N	Saudi Arabia	Breast	Any Breast Cancer	Metformin	DFS/RFS/EFS	Phase 1	DB00331	N
NCT04248998	Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer	BREAKFAST	Active, not recruiting	Triple-negative Breast Cancer	Dietary Supplement: Fasting-mimicking diet; Drug: Metformin; Drug: Preoperative chemotherapy	pCR rate; Severe adverse events; Safety of the experimental treatments; Compliance with the experimental treatment; RFS; DMFS; OS; Short-term modifications of plasma glycemia (mg/dl); Long-term modifications of plasma glycemia (mg/dl); Short-term modifications of serum insulin concentration ( U/ml); Long-term modifications of serum insulin concentration ( U/ml); Short-term modifications of serum IGF-1 concentration (ng/ml); Long-term modifications ofserum IGF-1 concentration (ng/ml); Short-term modifications of blood lipid profile by UPLC-MS and HPLC-ELDS; Long-term modifications of blood lipid profile by UPLC-MS and HPLC-ELDS; Clinical tumor response; Gene expression profiles; Mutational analyses; Short-term modifications of plasma amino acid profile by UPLC-QDa Mass detector system (Waters); Long-term modifications of plasma amino acid profile by UPLC-QDa Mass detector system (Waters)	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; IFOM ETS - The AIRC Institute of Molecular Oncology; European Institute of Oncology; University of Milan	Female	18 Years to 75 Years   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	INT 192/19; 2019-003093-13	05/05/2020	05/01/2024	05/01/2024			30/01/2020				18/01/2023	https://ClinicalTrials.gov/show/NCT04248998		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Italy	Breast	Breast Cancer - TNBC	Metformin	Safety and/or Dose; Response rate; OS; DFS/RFS/EFS; Biomarker	Phase 2	DB00331	N
NCT04275713	Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC	METOXY-LACC	Recruiting	Cervical Cancer	Drug: Metformin; Drug: Cisplatin	Metformin dependent changes in hypoxia-related gene expression.; Metformin dependent changes in MRI-parameters.; Metformin dependent change in acute toxicity; Metformin dependent change in tumor volume during treatment	Oslo University Hospital	Female	18 Years and older   (Adult, Older Adult)	90	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	METOXY-LACC	22/05/2020	05/01/2025	09/01/2025			19/02/2020				05/03/2022	https://ClinicalTrials.gov/show/NCT04275713		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Norway	Gynaecological	Cervical Cancer	Metformin	Biomarker	Phase 2	DB00331	N
NCT05445791	Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations	METLUNG	Recruiting	Non Small Cell Lung Cancer	Drug: Metformin Hydrochloride; Other: Placebo	Progression-free survival; Overall survival; Overall Response Rate	Instituto Nacional de Cancerologia de Mexico	All	18 Years and older   (Adult, Older Adult)	312	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	(020/023/ICI) (CEI/1421/19)	15/07/2021	14/07/2024	14/07/2025			07/06/2022				27/06/2023	https://ClinicalTrials.gov/show/NCT05445791		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Mexico	Lung	Non-Small Cell Lung Cancer	Metformin	PFS	Phase 3	DB00331	N
NCT01101438	A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer		Completed	Breast Cancer	Drug: metformin hydrochloride; Other: placebo	Invasive Disease-free Survival in Hormone Receptor (ER and PgR) Positive Sub-groups; Invasive Disease-free Survival; Overall Survival; Distant Relapse-free Survival; Breast Cancer-specific Mortality	Canadian Cancer Trials Group; National Cancer Institute (NCI); ETOP IBCSG Partners Foundation; ICR-CTSU	All	18 Years to 74 Years   (Adult, Older Adult)	3649	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MA32; U10CA077202; CAN-NCIC-MA.32; CDR0000669788	13/08/2010	21/09/2021	18/08/2023			04/12/2010		18/10/2022		13/09/2023	https://ClinicalTrials.gov/show/NCT01101438	Adjuvant/Maintenance	Localised/Locoregional	Collaborative Group	Y	N	N	Canada	Breast	Any Breast Cancer	Metformin	OS; DFS/RFS/EFS	Phase 3	DB00331	N
NCT03047837	A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients.	ASAMET	Unknown status	Tertiary Prevention in Colon Cancer	Drug: Aspirin (ASA) + Metformin (MET); Drug: ASA; Drug: MET; Drug: Placebos	NF B; pS6K, p53, beta-catenin, PI3K; IL-6, CRP, VEGF and HOMA index; Gene expression levels; Metformin concentration	Ente Ospedaliero Ospedali Galliera	All	18 Years to 80 Years   (Adult, Older Adult)	160	Other	Interventional Study	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	27UCS2015; 2015-004824-77	15/03/2017	15/09/2019	15/03/2020			02/09/2017				15/02/2019	https://ClinicalTrials.gov/show/NCT03047837		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Italy	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid; Metformin	Biomarker	Phase 2	DB00945; DB00331	N
NCT02614339	Effect of Adjunctive Metformin on Recurrence of Non-DM Colorectal Cancer Stage II High-risk/ III Colorectal Cancer		Unknown status	Non-DM Stage II High-risk Colorectal Cancer|Non-DM Stage III Colorectal Cancer	Drug: metformin; Drug: control	Disease free survival; 5-year overall survival; recurrence rate of polyps after polypectomy	Yonsei University	All	20 Years to 80 Years   (Adult, Older Adult)	593	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	4-2015-0533	12/01/2015	07/01/2021	07/01/2021			25/11/2015				18/09/2019	https://ClinicalTrials.gov/show/NCT02614339	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	GI	Colon Cancer; Rectal Cancer	Metformin	OS; DFS/RFS/EFS; Recurrence rate	Phase 3	DB00331	N
NCT03675893	Abemaciclib + Letrozole +/- Metformin in Recurrent or Persistent Endometrial Cancer		Recruiting	Endometrial Cancer	Drug: Letrozole; Drug: Abemaciclib; Drug: LY3023414; Drug: Metformin	Progression Free Survival Rate; Objective Tumor Response Rate; Overall Survival Rate; Treatment-related toxicities	Dana-Farber Cancer Institute; Eli Lilly and Company	Female	18 Years and older   (Adult, Older Adult)	60	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-301	24/12/2018	05/01/2024	05/01/2026			18/09/2018				13/06/2023	https://ClinicalTrials.gov/show/NCT03675893		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Endometrial Cancer	Metformin	Response rate; PFS	Phase 2	DB00331	N
NCT01930864	Metformin Plus Irinotecan for Refractory Colorectal Cancer		Unknown status	Colorectal Neoplasms|Adenocarcinoma	Drug: metformin; Drug: irinotecan	Non-Progression at week 12th of treatment; Progression-free survival; Overall Survival; Quality of life; Safety	Barretos Cancer Hospital; University of Campinas, Brazil; AC Camargo Cancer Center	All	18 Years and older   (Adult, Older Adult)	41	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MetIri	09/01/2015	12/01/2020	12/01/2020			29/08/2013				22/06/2017	https://ClinicalTrials.gov/show/NCT01930864		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Brazil	GI	Colon Cancer; Rectal Cancer	Metformin	Safety and/or Dose; PFS; OS; QoL	Phase 2	DB00331	N
NCT01864096	The Metformin Active Surveillance Trial (MAST) Study	MAST	Recruiting	Prostate Cancer	Drug: Metformin; Drug: Placebo	Time to progression; Time to primary therapy for prostate cancer; Time to pathological progression; Change from baseline in disease-related patient anxiety; Change from baseline in decisional satisfaction and decisional conflict; Change from baseline in prostate cancer diagnosis at repeat biopsy; Change in Gleason Score at repeat biopsy; Change in clinical stage of prostate cancer based on digital rectal examination; Assess the prognostic and predictive value of prostate cancer biomarkers; To determine the safety and incidence of (serious) adverse events from the administration of 36 months of metformin to men with early stage prostate cancer	University Health Network, Toronto	Male	18 Years to 79 Years   (Adult, Older Adult)	408	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	MAST 01	10/01/2013	08/01/2023	08/01/2024			29/05/2013				19/04/2021	https://ClinicalTrials.gov/show/NCT01864096	Adjuvant/Maintenance	Localised/Locoregional	Collaborative Group	Y	N	N	Canada	Urological	Prostate Cancer	Metformin	Other (specify)	Phase 3	DB00331	N
NCT03874000	Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients	SMART	Unknown status	Non Small Cell Lung Cancer	Biological: Sintilimab; Drug: Metformin Hydrochloride	Objective Response Rate (ORR); Overall Survival (OS); Progress free survival (PFS ; Disease Control Rate (DCR ; Duration of Response (DOR)	Tianjin Medical University Cancer Institute and Hospital; Innovent Biologics (Suzhou) Co. Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	43	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SMART	03/08/2019	28/02/2022	06/05/2022			14/03/2019				19/03/2019	https://ClinicalTrials.gov/show/NCT03874000		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Lung	Non-Small Cell Lung Cancer	Metformin	Response rate; PFS; OS	Phase 2	DB00331	N
NCT03800602	Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer		Active, not recruiting	Colorectal Adenocarcinoma|Metastatic Microsatellite Stable Colorectal Carcinoma|Refractory Colorectal Carcinoma|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer|Stage IVC Colorectal Cancer|Colorectal Cancer Metastatic	Drug: Metformin; Biological: Nivolumab	Overall response rate (ORR); Progression free survival (PFS); Overall survival (OS); Biological response: carcinoembryonic antigen (CEA)	Emory University; Bristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of Health (NIH)	All	18 Years and older   (Adult, Older Adult)	24	Other; Industry; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00106678; NCI-2018-02201; Winship4494-18; P30CA138292	15/01/2019	31/01/2024	31/01/2025			01/11/2019				07/05/2023	https://ClinicalTrials.gov/show/NCT03800602		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	GI	Colon Cancer; Rectal Cancer	Metformin	Response rate; PFS; OS; Biomarker	Phase 2	DB00331	N
NCT04033107	High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors		Recruiting	Hepatocellular Cancer|Pancreatic Cancer|Gastric Cancer|Colorectal Cancer	Drug: Vitamin C; Drug: Metformin	Progression-free survival; Overall survival; Objective response rate; Disease control rate; Changes of quality of life; Number of participants with treatment-related adverse events as assessed by CTCAE v3.0	Zhongnan Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ZNCM	07/01/2020	12/01/2024	12/01/2024			25/07/2019				28/09/2023	https://ClinicalTrials.gov/show/NCT04033107		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	GI	Colon Cancer; Gastric Cancer; Pancreatic Cancer; Liver Cancer	Ascorbic acid; Metformin	PFS	Phase 2	DB00126; DB00331	N
NCT03048500	Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery		Unknown status	Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer	Other: Laboratory Biomarker Analysis; Drug: Metformin Hydrochloride; Biological: Nivolumab	Objective Response Rate (ORR) of Patients With Non-small Cell Lung Cancer Treated With Nivolumab and Metformin Combination Using RECIST 1.1; Depth of Response; Duration of Response; Persistence of Response; Disease Control Rate (DCR); Progression-Free Survival (PFS); Overall Survival (OS); Objective Response Rate (ORR) of Patients With Non-small Cell Lung Cancer Treated With Nivolumab and Metformin Combination Using irRECIST.; Incidence of Adverse Events	Northwestern University; Bristol-Myers Squibb; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	17	Other; Industry; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 16L04; STU00204354; P30CA060553; NCI-2017-00060	07/12/2017	19/09/2019	09/01/2021			02/09/2017		14/10/2020		14/10/2020	https://ClinicalTrials.gov/show/NCT03048500		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Lung	Non-Small Cell Lung Cancer	Metformin	Response rate; PFS	Phase 2	DB00331	N
NCT02336087	Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery		Active, not recruiting	Pancreatic Adenocarcinoma|Unresectable Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7	Drug: Gemcitabine Hydrochloride; Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Drug: Metformin Hydrochloride; Dietary Supplement: Therapeutic Dietary Intervention; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment	Feasibility of the combination of gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a dietary supplement; Compliance of the combination of gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a dietary supplement (percent of patients who are fully compliant); Toxicity of the combination of gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a dietary supplement (National Cancer Institute Common Terminology for Adverse Events criteria version 4); Progression-free survival; Overall survival; Time to treatment failure	City of Hope Medical Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	21	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14122; NCI-2014-02612	14/01/2016	10/04/2020	31/12/2023			01/12/2015				21/03/2023	https://ClinicalTrials.gov/show/NCT02336087		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Metformin	Other (specify)	Phase 1	DB00331	N
NCT02294006	Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs	MetNET1	Unknown status	Well Differentiated Pancreatic Endocrine Tumor	Drug: Everolimus plus Octreotide LAR plus Metformin	to determine the progression free survival rate (PFS) at 12 months from the first drug administration in patients with advanced pancreatic neuroendocrine tumors; to determine the safety and tolerability of the combination of Everolimus, Octreotide LAR and Metformin as measured according to the National cancer Institute-Common Toxicity Criteria v. 3.0 guidelines; to determine the overall survival of the combination of Everolimus, Octreotide LAR and Metformin.; to determine the response rate of the combination of Everolimus, Octreotide LAR and Metformin.; to determine the biochemical response of the combination of Everolimus, Octreotide LAR and Metformin.	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	All	18 Years and older   (Adult, Older Adult)	26	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Ist Nazionale Tumori Milano	06/01/2014	06/01/2021	10/01/2021			19/11/2014				09/09/2021	https://ClinicalTrials.gov/show/NCT02294006		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Italy	Endocrine	Neuroendocrine Tumours	Metformin	Safety and/or Dose; PFS	Phase 2	DB00331	N
NCT02394652	The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial		Completed	Uterine Cervical Neoplasms|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma, Adenosquamous	Drug: Metformin; Drug: Cisplatin; Drug: FAZA	  Change in fractional hypoxic volume of the tumor on FAZA-PET scan before and after 1 week of metformin.; Disease-free survival; Acute and late gastrointestinal and genitourinary toxicities following metformin and chemoradiation.; Effect of metformin on endogenous hypoxia and other markers.; Biomarkers of response to metformin.	University Health Network, Toronto	Female	18 Years and older   (Adult, Older Adult)	16	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CXMET1	21/05/2015	01/12/2021	01/12/2021			20/03/2015				21/04/2021	https://ClinicalTrials.gov/show/NCT02394652		Localised/Locoregional; Advanced/Metastatic	Collaborative Group	Y	N	N	Canada	Gynaecological	Cervical Cancer	Metformin	Safety and/or Dose; DFS/RFS/EFS; Biomarker	Phase 2	DB00331	N
NCT04536805	Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin	REPAIRGETUGP16	Recruiting	Prostate Cancer	Drug: Metformin; Radiation: Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy); Radiation: Stereotactic Body Radiation Therapy (SBRT) 36 Gy; Radiation: Stereotactic Body Radiation Therapy (SBRT) 25 Gy	For phase 1:. Select the recommended dose for SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy), in combination with Metformin; For phase 2: estimate the efficacy of re-irradiation SBRT in combination with Metformin in terms of biochemical relapse-free survival rate.; Estimate the efficacy of re-irradiation SBRT in combination with Metformin in terms of biochemical relapse-free survival and biochemical response; Estimation of the efficacy of SBRT re-irradiation in combination with Metformin in terms of progression-free survival and overall survival; Evaluation of acute and late genitourinary and gastrointestinal toxicities of the SBRT re-irradiation; Evaluation of Quality of life after SBRT re-irradiation in combination with Metformin; Evaluation of urinary symptoms; Evaluation of erectile function	Institut Cancerologie de l'Ouest	Male	18 Years and older   (Adult, Older Adult)	44	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICO-2020-01	17/11/2020	11/01/2026	11/01/2028			09/03/2020				30/08/2022	https://ClinicalTrials.gov/show/NCT04536805		Advanced/Metastatic; Recurrent/Refractory	Collaborative Group	N	Y	N	France	Urological	Prostate Cancer	Metformin	Safety and/or Dose; DFS/RFS/EFS	Phase 1/2	DB00331	N
NCT03994744	Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC		Unknown status	Small-cell Lung Cancer|Small Cell Lung Carcinoma|Small Cell Lung Cancer Recurrent|Small Cell Lung Cancer Extensive Stage	Drug: PD-1 inhibitor; Drug: Metformin	Objective response rate of Sintilimab and Metformin(ORR); Safety of the combination therapy of Sintilimab and Metformin: CTCAE4.03 grading; Median overall survival (OS) time of Sintilimab and Metformin; Median progression free survival(PFS) of Sintilimab and Metformin; Median duration of response (DoR) of Sintilimab and Metformin	Hunan Cancer Hospital; Xiangya Hospital of Central South University; Innovent Biologics (Suzhou) Co. Ltd.	All	18 Years to 65 Years   (Adult, Older Adult)	68	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HNCH-SCLC-2019260	20/08/2019	08/01/2021	07/01/2022			21/06/2019				28/08/2019	https://ClinicalTrials.gov/show/NCT03994744		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Lung	Small Cell Lung Cancer	Metformin	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00331	N
NCT05023967	Metformin and Nightly Fasting in Women With Early Breast Cancer		Recruiting	Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Breast Ductal Carcinoma In Situ|Invasive Breast Carcinoma	Procedure: Biospecimen Collection; Drug: Extended Release Metformin Hydrochloride; Other: Monitoring; Other: Nutritional Assessment; Other: Short-Term Fasting	Frequency of occurrence of dose limiting toxicity; Change in pre-post treatment Ki67 labeling index in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS) (in the absence of IBC); Difference in post-treatment adjacent DCIS (in the presence of IBC), if present, or intraepithelial neoplasia Ki67 between arms; Change in circulating biomarkers; Change of CIP2A-PP2A-GSK3beta-MCL-1 axis in cancer tissue; Change of Ki67 in cancer tissue; Difference of M30; Difference of phosphorylated S6; Physiological distress; Eating habits; Tobacco; Alcohol consumption; Incidence of adverse events; Difference of the area under the curve of glucose levels	M.D. Anderson Cancer Center; National Cancer Institute (NCI)	Female	18 Years and older   (Adult, Older Adult)	120	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2021-0901; NCI-2021-08921; B115UCS2019; 2021-000134-34; 2021-09-01; Pending3; MDA20-02-01; UG1CA242609	04/04/2023	20/11/2025	20/11/2025			27/08/2021				23/06/2023	https://ClinicalTrials.gov/show/NCT05023967		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Breast	Any Breast Cancer	Metformin	Safety and/or Dose; Biomarker	Phase 2	DB00331	N
NCT04414540	Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients		Recruiting	Head and Neck Squamous Cell Carcinoma	Drug: Metformin Extended Release Oral Tablet; Drug: Pembrolizumab	Overall Response by RECIST 1.1 and iRECIST; Number of patients with adverse events measured by CTCAE v5.0; Progression Free Survival (PFS); Overall Survival (OS)	Trisha Wise-Draper; American Cancer Society, Inc.; University of Cincinnati	All	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCCC-HN-19-01	31/08/2020	07/01/2023	07/01/2024			06/04/2020				10/04/2022	https://ClinicalTrials.gov/show/NCT04414540		Advanced/Metastatic	Collaborative Group	N	Y	N	United States	Head and Neck	Any head and neck squamous cell carcinoma	Metformin	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00331	N
NCT02122185	Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer		Suspended	Brenner Tumor|Malignant Ascites|Malignant Pleural Effusion|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Primary Peritoneal Cavity Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Epithelial Cancer|Stage IIIA Ovarian Germ Cell Tumor|Stage IIIA Primary Peritoneal Cavity Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Epithelial Cancer|Stage IIIB Ovarian Germ Cell Tumor|Stage IIIB Primary Peritoneal Cavity Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Epithelial Cancer|Stage IIIC Ovarian Germ Cell Tumor|Stage IIIC Primary Peritoneal Cavity Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Primary Peritoneal Cavity Cancer	Drug: metformin hydrochloride; Drug: placebo; Drug: Chemotherapy	Progression free survival (PFS) evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and Gynecological Cancer Intergroup (GCIG) criteria; Time to biochemical (CA-125) progression using GCIG criteria; Overall survival; Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0	University of Chicago	Female	18 Years and older   (Adult, Older Adult)	160	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	IRB13-1235; NCI-2014-00860	25/02/2015	25/02/2025	25/02/2025			24/04/2014				28/08/2023	https://ClinicalTrials.gov/show/NCT02122185		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Gynaecological	Ovarian Epithelial Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer	Metformin	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00331	N
NCT02946996	Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy		Recruiting	Prostate Cancer	Drug: Metformin; Other: OPC	AGE level reduction; Correlation between changes to AGE level and changes to PSA; Correlation between changes to AGE level and changes to BMI; Correlation between changes to AGE level and changes to insulin resistance (HOMA-IR); Correlation between changes to AGE level and changes to A1C.; Correlations between changes to AGE level and changes to testosterone.; Correlation between changes to AGE level and changes to lipids.; Correlation between changes to AGE level and changes to diet.; Correlation between changes to AGE level and changes to quality of life; Frequency of adverse events as assessed by CTCAE v. 4; Correlation between AGE levels and plasma IL6; Correlation between AGE levels and leptin; Correlation between AGE levels and c-reactive protein (CRP); Correlation between AGE levels and malondialdehyde (MDA); Correlation between AGE levels and oxLDLs (low density lipoprotein); Correlation between AGE levels and sRAGE (soluble receptor for AGE)	Medical University of South Carolina	Male	18 Years and older   (Adult, Older Adult)	45	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	102508	28/12/2016	31/12/2023	30/03/2024			27/10/2016				11/01/2023	https://ClinicalTrials.gov/show/NCT02946996		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Metformin	Biomarker	Phase 2	DB00331	N
NCT01797523	A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma		Active, not recruiting	Endometrial Cancer	Drug: Metformin; Drug: Letrozole; Drug: Everolimus	Clinical Benefit Rate (CBR); Progression-Free Survival (PFS)	M.D. Anderson Cancer Center; Novartis; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	62	Other; Industry; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2012-0543; NCI-2013-00960	10/07/2013	31/10/2025	31/10/2025			22/02/2013				22/09/2023	https://ClinicalTrials.gov/show/NCT01797523		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Endometrial Cancer	Metformin	PFS; Other (specify)	Phase 2	DB00331	N
NCT02365597	An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer		Active, not recruiting	Urothelial Cancer	Drug: Erdafitinib; Drug: Midazolam; Drug: Metformin	Main Study: Percentage of Participants With Best (Overall) Objective Response; Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone or in Combination With Erdafitinib; Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib; Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Metformin Alone or in Combination With Erdafitinib; Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Midazolam Alone or in Combination With Erdafitinib; Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib; Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Metformin Alone or in Combination With Erdafitinib; Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Midazolam Alone or in Combination With Erdafitinib; Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib; Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Metformin Alone or in Combination With Erdafitinib; Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Midazolam Alone or in Combination With Erdafitinib; Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib; Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Metformin Alone or in Combination With Erdafitinib; Main Study: Progression-free Survival (PFS); Main Study: Duration of Response (DoR); Main Study: Overall Survival; Main Study: Percentage of Participants With Treatment-emergent Adverse Event (TEAEs); Main Study: Plasma Concentration of Erdafitinib at 2 Hours (C2h); Main Study: Plasma Concentration of Erdafitinib at 4 Hours (C4h)	Janssen Research   Development, LLC	All	18 Years and older   (Adult, Older Adult)	239	Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR105065; 42756493BLC2001; 2014-002408-26	22/04/2015	15/09/2022	29/12/2023			19/02/2015		10/10/2023		10/10/2023	https://ClinicalTrials.gov/show/NCT02365597		Advanced/Metastatic	Company	N	Y	N	United States	Urological	Bladder Cancer	Metformin; Midazolam	Safety and/or Dose; Response rate; PFS; OS; Biomarker	Phase 2	DB00331; DB00683	N
NCT02823691	The MetNET-2 Trial	MetNET-2	Unknown status	Neuroendocrine Tumors	Drug: Lanreotide and Metformin	incidence of SAEs and AEs; time to progression (TTP) to Lanreotide ATG 120 mg in combination with Metformin; symptomatic responses to Lanreotide ATG 120 mg in combination with Metformin in symptomatic patients; biochemical responses to Lanreotide ATG 120 mg in combination with Metformin	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	All	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NationalCIMilan	04/01/2016	12/01/2021	12/01/2021			07/06/2016				06/07/2021	https://ClinicalTrials.gov/show/NCT02823691		Advanced/Metastatic	Collaborative Group	N	N	N	Italy	Endocrine	Neuroendocrine Tumours	Metformin	Safety and/or Dose; Response rate; Biomarker; Other (specify)	Phase 1	DB00331	N
NCT02065687	Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer		Unknown status	Endometrial Adenocarcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Undifferentiated Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7	Drug: Carboplatin; Other: Laboratory Biomarker Analysis; Drug: Metformin Hydrochloride; Drug: Paclitaxel; Other: Placebo Administration; Other: Quality-of-Life Assessment; Other: Questionnaire Administration	Progression-free Survival (PFS) (Phase II); Overall Survival (OS) (Phase II and III); Proportion of Patients Responding to Therapy; Duration of Response by Treatment; Overall Survival (OS) (Phase II); Progression Free Survival (PFS) (Phase III); Number of Participants With Grade 3 or Higher Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4; Level of Obesity	Gynecologic Oncology Group; National Cancer Institute (NCI); GOG Foundation	Female	18 Years and older   (Adult, Older Adult)	469	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	GOG-0286B; NCI-2013-02284; s14-01068; U10CA180830; U10CA180868; U10CA027469	17/03/2014	17/04/2019	13/09/2023			19/02/2014		01/12/2021		30/09/2021	https://ClinicalTrials.gov/show/NCT02065687		Advanced/Metastatic; Recurrent/Refractory	Collaborative Group	Y	N	N	United States	Gynaecological	Endometrial Cancer	Metformin	Safety and/or Dose; PFS; OS	Phase 2/3	DB00331	N
NCT02978547	The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma	Metformin 001	Unknown status	Resectable Pancreatic Ductal Adenocarcinoma	Drug: Metformin Hydrochloride 500Mg Tablet	The effect of neoadjuvant metformin treatment on tumour cell proliferation in PDAC tumours; R0 resection rates in patients undergoing curative PDAC resection; The effect of metformin on glucose and insulin metabolism as assessed by serum marker, fasting GGT (mmol/L); The effect of metformin on glucose and insulin metabolism as assessed by serum marker, fasting glucose (mmol/L); The effect of metformin on glucose and insulin metabolism as assessed by serum marker, fasting insulin (mU/L); The effect of metformin on glucose and insulin metabolism as assessed by serum marker, HOMA index; The effect of metformin on glucose and insulin metabolism as assessed by clinical marker, weight (kg); The effect of metformin on metabolomic profile of pre- and post-metformin samples; Transcriptome sequencing (RNAseq) of pre- and post-treatment tumour samples.; Plasma ctDNA, measured as percentage of mutant to total DNA fragments in plasma; Correlation between imaging and pathologic parameters	British Columbia Cancer Agency; Pancreatic Cancer Canada; BC Cancer Foundation	All	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H16-02566	01/01/2019	06/01/2020	01/01/2021			12/01/2016				18/01/2018	https://ClinicalTrials.gov/show/NCT02978547		Localised/Locoregional	Collaborative Group	N	N	N	Canada	GI	Pancreatic Cancer	Metformin	Biomarker; Other (specify)	Phase 2	DB00331	N
NCT02186847	Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer		Active, not recruiting	Adenosquamous Lung Carcinoma|Bronchioloalveolar Carcinoma|Large Cell Lung Carcinoma|Lung Adenocarcinoma|Non-Small Cell Lung Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer	Radiation: Radiation Therapy; Drug: Carboplatin; Drug: Metformin; Drug: Paclitaxel	Percentage of Participants Alive Without Progression (Progression-free Survival); Percentage of Participants Alive (Overall Survival); Percentage of Participants With Local-regional Progression; Percentage of Participants With Distant Metastases; Percentage of Participants With Treatment-related Grade 3 or Higher Adverse Events	NRG Oncology; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	170	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NRG-LU001; NCI-2014-01071; PNRG-LU001_A01PAMDREVW01; U10CA180868	08/01/2014	16/04/2019	16/04/2024			07/10/2014		23/06/2020		22/06/2023	https://ClinicalTrials.gov/show/NCT02186847		Localised/Locoregional	Collaborative Group	Y	N	N	United States	Lung	Non-Small Cell Lung Cancer	Metformin	Safety and/or Dose; PFS; OS; Recurrence rate	Phase 2	DB00331	N
NCT04114136	Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies		Recruiting	Melanoma|NSCLC|Hepatocellular Carcinoma|Urothelial Cancer|Gastric Adenocarcinoma|HNSCC|Esophageal Adenocarcinoma|Microsatellite Instability-High Solid Malignant Tumor	Drug: Nivolumab or Pembrolizumab (dependent upon approved indication); Drug: Metformin; Drug: Rosiglitazone	Best overall response; Progression-free survival (PFS); Overall Survival (OS); Number of Participants Experiencing Adverse Events Attributed to Treatment	Dan Zandberg; University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)	72	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCC 18-190	14/09/2020	30/04/2032	30/04/2032			10/03/2019				17/07/2023	https://ClinicalTrials.gov/show/NCT04114136		Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	United States	Multiple cancer types	Multiple cancer types	Metformin	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00331	N
NCT05929495	Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma		Not yet recruiting	Glioblastoma, IDH-wildtype|Metformin|Malignancies	Drug: Metformin	Value of PFS at 6 months after the start of treatment; EORTC QLQ-C30 questionnaire at 6 months after the start of treatment; MMSE questionnaire at 6 months after the start of treatment; Safety and tolerability assessment of treatment; Plasma measurement of circulating metabolites; Plasma measurement of adiponectin; Proteomic analysis; Correlations between in vivo clinical response and effect of association measured in vitro on cell lines obtained from the same patient undergoing surgery; Gene expression analysis	University of Milano Bicocca	All	18 Years and older   (Adult, Older Adult)	25	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GBM MET	12/01/2023	01/01/2026	01/01/2026			07/03/2023				11/09/2023	https://ClinicalTrials.gov/show/NCT05929495		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Italy	CNS	Glioblastoma	Metformin	Safety and/or Dose; PFS; QoL; Biomarker	Phase 2	DB00331	N
NCT03311308	A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma		Recruiting	Advanced Melanoma	Drug: Pembrolizumab Injection [Keytruda]; Drug: Metformin	Ki-67 proliferation index in T cell; Number of participants experiencing adverse events; Hypoxia in the primary tumor by IHC Staining; Mitochondrial functional restoration in Tumor Infiltrating Lymphocytes by mitochondrial mass; Cell cycle status of peripheral blood T lymphocytes by Flow Cytometry; overall tumor response rate; Mitochondrial functional restoration in Tumor Infiltrating Lymphocytes by Seahorse metabolic profiling	Yana Najjar; Merck Sharp   Dohme LLC; University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)	30	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-196	02/07/2018	01/01/2026	12/01/2027			17/10/2017				14/04/2023	https://ClinicalTrials.gov/show/NCT03311308		Localised/Locoregional; Advanced/Metastatic	Company	Y	N	N	China	Skin	Melanoma	Metformin	Safety and/or Dose; Biomarker	Phase 1	DB00331	N
NCT03829020	Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma		Active, not recruiting	Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma	Drug: Bortezomib; Drug: Metformin Hydrochloride; Drug: Nelfinavir Mesylate	Maximum tolerated dose of the combination of metformin, nelfinavir, and bortezomib; Incidence of adverse events; Hematologic response rate	Mayo Clinic; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	9	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1811; NCI-2019-00466	17/04/2019	21/09/2022	08/01/2024			02/04/2019				09/07/2023	https://ClinicalTrials.gov/show/NCT03829020		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Other Haem-onc	Multiple Myeloma	Metformin; Nelfinavir	Safety and/or Dose	Phase 1	DB00331; DB00220	N
NCT02437812	Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma		Unknown status	Epithelial Ovarian Carcinoma	Drug: Metformin; Drug: Paclitaxel; Drug: Carboplatin	Progression free survival; Metabolic biomarker evaluation	Gynecologic Oncology Associates; University of North Carolina, Chapel Hill	Female	18 Years and older   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GOA-TCOM1	01/01/2014	10/01/2017	04/01/2021			05/08/2015				28/02/2017	https://ClinicalTrials.gov/show/NCT02437812		Advanced/Metastatic	Collaborative Group	N	N	N	United States	Gynaecological	Ovarian Epithelial Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer	Metformin	PFS; Biomarker	Phase 2	DB00331	N
NCT05316935	GnRHa + Letrozole in Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients		Recruiting	Endometrial Neoplasms|Atypical Endometrial Hyperplasia|Progesterone Resistance	Drug: GnRHa; Drug: Letrozole 2.5mg; Drug: Diane-35; Drug: MET	Complete response rates within 28 weeks of treatment; Adverse events; Time to achieve complete response; Relapse rates; Rates of fertility outcomes; Compliance	Xiaojun Chen; Fudan University	Female	18 Years to 45 Years   (Adult)	118	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	53211030	13/07/2022	30/03/2025	30/03/2025			04/07/2022				21/02/2023	https://ClinicalTrials.gov/show/NCT05316935		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	China	Gynaecological	Endometrial Cancer	Metformin	Safety and/or Dose; Response rate; Other (specify)	Phase 2/3	DB00331	N
NCT05854966	CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)		Not yet recruiting	Acute Myeloid Leukemia, in Relapse|Acute Myeloid Leukemia Refractory|Granulocytic Sarcoma	Drug: CPI 613; Drug: Metformin; Biological: Blood draws; Procedure: Bone marrow biopsy	Number of Participants to Receive at Least One Cycle of Maintenance Therapy - Feasibility; Response Rate - Efficacy (Acute Myeloid Leukemia European LeukemiaNet 2022); Overall Survival; Number of Reported Adverse Events - Safety	Wake Forest University Health Sciences; National Cancer Institute (NCI); Cornerstone Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	17	Other; NIH; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WFBCCC 22323; P30CA012197	02/01/2024	10/01/2024	09/01/2025			05/11/2023				29/11/2023	https://ClinicalTrials.gov/show/NCT05854966		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Leukemia	Acute Myeloid Leukemia, Adult	Metformin	Other (specify)	Phase 2	DB00331	N
NCT05759312	Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma		Not yet recruiting	Ovarian Clear Cell Carcinoma	Drug: Zimberelimab; Drug: Metformin Hydrochloride	Objective response rate; Progression-free survival; Overall survival; Disease control rate; Duration of response; Number of participants with treatment-related adverse events as assessed by CTCAE v5.0; Patterns of subsequent recurrence	Fudan University	Female	18 Years to 75 Years   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	zsfud-OC-001	03/01/2023	02/01/2025	02/01/2025			03/08/2023				03/08/2023	https://ClinicalTrials.gov/show/NCT05759312		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Gynaecological	Ovarian - Other	Metformin	Response rate	Phase 1/2	DB00331	N
NCT03618654	Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma		Active, not recruiting	Head and Neck Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma	Drug: Metformin; Biological: Durvalumab	Immune cell polarization (Th1/Th2; M1/M2); Alterations in immunohistochemical (IHC) markers; Alterations in intratumoral immune cell populations; Changes of the intratumoral immunophenotype and metabolism after exposure to durvalumab and metformin; Tumor size as measured by immune-related response criteria (irRC)	Sidney Kimmel Cancer Center at Thomas Jefferson University; Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	38	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18P.389	11/01/2018	20/11/2021	10/01/2023			08/07/2018				16/08/2022	https://ClinicalTrials.gov/show/NCT03618654		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Head and Neck	Any head and neck squamous cell carcinoma	Metformin	Biomarker	Phase 1	DB00331	N
NCT05326984	Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia		Recruiting	Acute Lymphoblastic Leukemia	Drug: Metformin	Decrease of ABCB1 gene expression; Increase of AMPK gene expression; Overall survival; Event free survival	Hospital General de Mexico	All	10 Years to 21 Years   (Child, Adult)	20	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	DI/21/505/03/10	02/09/2021	12/01/2023	12/01/2023			14/04/2022				14/04/2022	https://ClinicalTrials.gov/show/NCT05326984		Localised/Locoregional	Hospital/University/Research Institute	Y	N	Y	Mexico	Leukemia	Acute Lymphoblastic Leukemia, Childhood; Acute Lymphoblastic Leukemia, Adult	Metformin	OS; DFS/RFS/EFS; Biomarker	Other	DB00331	N
NCT04758000	Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse	Metform-Bone	Recruiting	Osteosarcoma|Ewing Sarcoma	Drug: Metformin Hydrochloride	Event Free Survival; Metformin toxicity	Istituto Ortopedico Rizzoli	All	14 Years and older   (Child, Adult, Older Adult)	67	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	794/2020/Farm/IOR; 2020-002579-37	03/01/2021	07/01/2027	07/01/2027			17/02/2021				08/04/2023	https://ClinicalTrials.gov/show/NCT04758000		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Italy	Bone Sarcoma	Ewing Sarcoma; Osteosarcoma	Metformin	DFS/RFS/EFS	Phase 2	DB00331	N
NCT02780024	Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM		Active, not recruiting	Glioblastoma Multiforme	Drug: Metformin	Number of patients completing the study treatment; To assess toxicity of the regimen	McGill University Health Centre/Research Institute of the McGill University Health Centre	All	18 Years and older   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MUHC ID: 4315	03/01/2015	20/10/2021	28/02/2026			23/05/2016				24/10/2023	https://ClinicalTrials.gov/show/NCT02780024		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Canada	CNS	Glioblastoma	Metformin	Safety and/or Dose; Other (specify)	Phase 2	DB00331	N
NCT03833466	Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)	ECMTPneo	Unknown status	Esophageal Squamous Cell Carcinoma	Drug: metformin and chemotherapy	Tumor metabolic pathway; Tumor microenvironment; Rate of pathologic complete response pCR 	Peking University	All	18 Years to 70 Years   (Adult, Older Adult)	15	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ESCC-MTPneo	02/05/2019	20/03/2020	20/06/2020			02/07/2019				15/02/2019	https://ClinicalTrials.gov/show/NCT03833466		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	GI	Esophageal Cancer	Metformin	Response rate; Biomarker	Phase 2	DB00331	N
NCT01638676	A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients		Recruiting	Melanoma	Drug: Vemurafenib; Drug: Metformin	Observation of CTCAE grade 4 or higher adverse events in six patients; Overall Survival Follow up; Number of adverse events; type of adverse events; Objective response rate (ORR)as measure of efficacy	University of Louisville; James Graham Brown Cancer Center	All	18 Years and older   (Adult, Older Adult)	55	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BCC-MEL-11-03	07/01/2012	06/01/2025	06/01/2027			07/12/2012				29/10/2021	https://ClinicalTrials.gov/show/NCT01638676		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Skin	Melanoma	Metformin	Safety and/or Dose	Phase 1/2	DB00331	N
NCT04945148	Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide	OPTIMUM	Not yet recruiting	Glioblastoma, IDH-wildtype	Drug: Metformin; Radiation: Radiation IMRT; Drug: Temozolomide	Assessement of Progression Free Survival (PFS) of patients with newly-diagnosed IDH wild-type OXPHOS + GBM (either with or without FGFR3-TACC3 gene fusion) treated with RT plus TMZ combined with metformin; Assessement of the Overall survival (OS) of treated patients; Assessement of the Overall Response rate (ORR); Assessement of the the safety of metformin in association with concomitant RT-TMZ; Assessement of the the tolerability of metformin in association with concomitant RT-TMZ	Hopital Foch; National Cancer Institute, France	All	18 Years and older   (Adult, Older Adult)	640	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019_0007	05/01/2023	10/01/2026	10/01/2026			30/06/2021				28/02/2023	https://ClinicalTrials.gov/show/NCT04945148		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	France	CNS	Glioblastoma	Metformin	PFS; OS	Phase 2	DB00331	N
NCT02143050	Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients		Withdrawn	Melanoma	Drug: Dabrafenib; Drug: Trametinib; Drug: Metformin	Observation of two CTCAE drug related grade 4 toxicities in six patients.; Clinical Response Rate; To estimate the overall survival rates.; To explore the effect of other covariates on overall survival	University of Louisville; James Graham Brown Cancer Center	All	18 Years to 100 Years   (Adult, Older Adult)	0	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BCC-MEL-14-01	09/01/2014	17/11/2017	17/11/2017			20/05/2014				18/11/2023	https://ClinicalTrials.gov/show/NCT02143050		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Skin	Melanoma	Metformin	Safety and/or Dose; Response rate	Phase 1/2	DB00331	N
NCT04691960	A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging		Recruiting	Glioblastoma	Other: Ketogenic Diet; Drug: Metformin	Ability to achieve and maintain ketosis; Tolerability of metformin	Weill Medical College of Cornell University	All	18 Years and older   (Adult, Older Adult)	36	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1604017166	08/01/2016	12/01/2024	12/01/2024			31/12/2020				14/09/2023	https://ClinicalTrials.gov/show/NCT04691960		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Belgium	CNS	Medulloblastoma; Glioblastoma; Astrocytoma; Glioma	Metformin	Safety and/or Dose; Biomarker	Phase 2	DB00331	N
NCT01750567	A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL		Active, not recruiting	Relapsed Chronic Lymphocytic Leukemia	Drug: Metformin	Time to treatment failure; Time to first therapy (TTFT) in previously untreated 11q CLL subsets only.; Changes in the rate of increase of absolute lymphocyte count while on metformin therapy; Change in size of clinically appreciated lymphadenopathy in cm and splenomegaly while on metformin therapy; Change in number of clinically appreciated lymphadenopathy and splenomegaly while on metformin therapy	University of Michigan Rogel Cancer Center	All	18 Years to 80 Years   (Adult, Older Adult)	37	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UMCC 2012.025	11/01/2012	05/01/2024	05/01/2024			17/12/2012				31/08/2023	https://ClinicalTrials.gov/show/NCT01750567		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Leukemia	Chronic Lymphocytic Leukemia	Metformin	Biomarker; Other (specify)	Phase 2	DB00331	N
NCT05183204	Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma		Recruiting	Glioblastoma	Drug: Paxalisib; Drug: Metformin; Other: Ketogenic Diet	Progression-free survival, defined as the survival rate at 6 months; Overall survival, defined as the time of first study treatment to death from any cause; Change in insulin levels; Change in tumor glucose uptake values	Weill Medical College of Cornell University; Kazia Therapeutics Limited	All	18 Years and older   (Adult, Older Adult)	33	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	21-05023537	14/02/2022	12/01/2024	12/01/2025			01/10/2022				26/09/2023	https://ClinicalTrials.gov/show/NCT05183204		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Metformin	PFS; OS; Biomarker	Phase 2	DB00331	N
NCT03600363	A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients		Unknown status	Lymphoma, Large B-Cell, Diffuse|Stage III Follicular Lymphoma	Drug: Metformin; Drug: Placebos	Overall Survival; Progress Free Survival	Ruijin Hospital	All	14 Years and older   (Child, Adult, Older Adult)	250	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	RJ-NHL-1805	09/01/2018	01/01/2021	12/01/2021			26/07/2018				03/11/2020	https://ClinicalTrials.gov/show/NCT03600363		Localised/Locoregional	Hospital/University/Research Institute	N	N	Y	China	Lymphoma	Non-Hodgkin Lymphoma, Adult; Non-Hodgkin Lymphoma, Childhood	Metformin	PFS; OS	Phase 2	DB00331	N
NCT04083651	A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer		Withdrawn	Pancreatic Cancer	Drug: Methylnaltrexone bromide; Drug: Placebo	Overall Survival	Bausch Health Americas, Inc.	All	18 Years and older   (Adult, Older Adult)	0	Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	SAL-REL-2042	01/06/2020	15/10/2023	15/10/2023			09/10/2019				05/07/2021	https://ClinicalTrials.gov/show/NCT04083651		Advanced/Metastatic	Company	Y	N	N	United States	GI	Pancreatic Cancer	Methylnaltrexone	OS	Phase 2/3	DB06800	N
NCT04151719	An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer		Withdrawn	Pancreatic Cancer	Drug: Methylnaltrexone bromide (MNTX)	Overall Survival	Bausch Health Americas, Inc.	All	18 Years and older   (Adult, Older Adult)	0	Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SAL-REL-2043	02/03/2020	02/03/2024	02/03/2024			11/05/2019				05/07/2021	https://ClinicalTrials.gov/show/NCT04151719	Adjuvant/Maintenance	Advanced/Metastatic	Company	N	N	N	United States	GI	Pancreatic Cancer	Methylnaltrexone	OS	Phase 3	DB06800	N
NCT04264676	Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal Cancer		Recruiting	Colorectal Cancer Stage II|Colorectal Cancer Stage III	Drug: Metronidazole Oral Tablet; Drug: Placebo oral tablet	Disease Free Survival, DFS; Overall Survival, OS; Recurrence Rate, RR	Shanghai Jiao Tong University School of Medicine; Shanghai Municipal Commission of Health and Family Planning; Ruijin Hospital; Fudan University; Shanghai Zhongshan Hospital; Shanghai Shenkang Hospital Development Center	All	18 Years to 75 Years   (Adult, Older Adult)	294	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	KY2019-066	31/03/2020	03/01/2023	03/01/2025			02/11/2020				25/11/2020	https://ClinicalTrials.gov/show/NCT04264676		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Colon Cancer; Rectal Cancer	Metronidazole	OS; DFS/RFS/EFS; Recurrence rate	Phase 1	DB00916	N
NCT04312360	Preoperative Endoscopic Treatment With Fosfomycin and Metronidazole in Patients With Right-sided Colon Cancer and Colon Adenoma (MEFO-trial)	MEFO	Completed	Right-sided Colon Cancer|Right-sided Colon Adenoma	Drug: therapeutic endoscopy with metronidazole and fosfomycin disodium	Change in the bacterial biofilm depth adherent to the colonic epithelium; quantitative change in bacterial biomass adherent to the colonic epithelium; Change in gene expression (Exploratory primary outcome 1); Change in bacterial composition (Exploratory primary outcome 2); Differences in the presence of known bacterial drivers for right-sided colon og adenoma cancer in track1; Differences in gene expression in the normal mucosa from preoperative in biopsies and the resected colon in track1; Differences in gene expression in the preoperative and operative blood samples in track1; The immunological assessment of tumor in track1; The pathological assessment of tumor in track1; Occurence of biofilm present on the colon cancer tumor; The pathological assessment of the normal mucosa of the right semicolon in in track1; Assessment of the side effects and adverse events regarding to the spraying of the right hemicolon with fosfomycin/metronidazole gel in track1; Differences in gene expression in the normal mucosa from preoperative biopsies and the operative biopsies in track 2; Differences in gene expression in the tumor tissue from the mucosal resection compared with archived FFPE tumor tissue from patients with colon adenoma in track 2; Differences in gene expression in the preoperative blood samples and the blood samples taken from patients in track 2 on the operation day; The pathological assessment of polyp: Occurence of tumor types using the Paris Classification and the Lateral Spreading Tumor Classification.; The pathological assessment of polyp: size; The immunological assessment of the immunological response; Occurence of biofilm present on the polyp.; The pathological assessment of the normal mucosa of the right hemicolon in track 2; Assessment of any adverse events or side effects regarding the spraying of the right hemicolon with fosfomycin/metronidazole gel in track 2.	Zealand University Hospital; Costerton Biofilm Center; Reponex Pharmaceuticals A/S; Region Zealand	All	18 Years and older   (Adult, Older Adult)	28	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	REG-010-2019; 2019-000131-51	16/01/2020	13/04/2022	07/01/2023			18/03/2020				09/07/2023	https://ClinicalTrials.gov/show/NCT04312360		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	Denmark	GI	Colon Cancer	Metronidazole	Biomarker	Phase 2	DB00916	N
NCT05720559	Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection		Not yet recruiting	Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer	Drug: Oxaliplatin; Drug: S1; Drug: Cetuximab; Drug: Metronidazole; Drug: Vitamin A; Drug: Folic acid; Drug: Capecitabine	Metachronous liver metastasis rate; Overall Survival (OS)	Liaoning Tumor Hospital   Institute	All	18 Years to 80 Years   (Adult, Older Adult)	100	Other	Interventional Study	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20230201zzg	03/01/2023	03/01/2026	09/01/2026			02/09/2023				02/09/2023	https://ClinicalTrials.gov/show/NCT05720559		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Colon Cancer; Rectal Cancer	Metronidazole	OS; Other (specify)	Phase 2	DB00916	N
NCT05774964	Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases		Not yet recruiting	For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method	Drug: Oxaliplatin; Drug: S1; Drug: Cetuximab; Drug: Metronidazole; Drug: Vitamin A; Drug: Folic acid	Overall Response Rate (ORR); Overall Survival (OS); Progression Free Survival (PFS)	Liaoning Tumor Hospital   Institute	All	18 Years to 80 Years   (Adult, Older Adult)	100	Other	Interventional Study	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20230303zzg	15/03/2023	15/03/2025	15/03/2025			20/03/2023				20/03/2023	https://ClinicalTrials.gov/show/NCT05774964		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	China	GI	Colon Cancer; Rectal Cancer	Metronidazole	Response rate; PFS; OS	Phase 2	DB00916	N
NCT05343260	Impact of Anesthesia Maintenance Methods on 5-year Survival After Surgery		Active, not recruiting	Aged|Neoplasms|Surgical Procedure, Operative|Anesthesia, Inhalation|Anesthesia, Intravenous|Survival	Drug: Sevoflurane; Drug: Propofol	Over survival after surgery.; Recurrence-free survival after surgery; Event-free survival after surgery	Peking University First Hospital	All	65 Years to 90 Years   (Older Adult)	1228	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention	2015[869]-3; ChiCTR-IPR-15006209	04/01/2015	29/09/2017	30/09/2022			25/04/2022				05/02/2022	https://ClinicalTrials.gov/show/NCT05343260		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Multiple cancer types	Any solid tumours	Propofol	OS; DFS/RFS/EFS; Recurrence rate	Other	DB00818	N
NCT03225547	Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer		Active, not recruiting	Triple Negative Breast Neoplasms|Breast Cancer	Drug: Pembrolizumab; Drug: Mifepristone	Rate of overall response based on RECIST 1.1; Number of patients with adverse events; Rate of overall response based on irRECIST	University of Chicago	All	18 Years and older   (Adult, Older Adult)	74	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB17-0721	02/12/2018	09/01/2025	09/01/2025			21/07/2017				28/04/2023	https://ClinicalTrials.gov/show/NCT03225547		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - HER2-	Mifepristone	Safety and/or Dose; Response rate	Phase 2	DB00834	N
NCT02788981	Abraxane  With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer		Active, not recruiting	Breast Cancer	Drug: Mifepristone; Other: Placebo; Drug: Nab-Paclitaxel	Progression-free survival (PFS); Response rate in glucocorticoid receptor (GR) positivity; Response Rate; Overall survival	University of Chicago	All	18 Years and older   (Adult, Older Adult)	64	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	IRB16-0403	28/03/2017	21/12/2022	08/01/2024			06/02/2016				02/02/2023	https://ClinicalTrials.gov/show/NCT02788981		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	United States	Breast	Breast Cancer - TNBC	Miltefosine	Response rate; PFS; OS; Biomarker	Phase 2	DB09031	N
NCT05272462	Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer		Recruiting	Ovarian Cancer	Drug: Minoxidil	Overall response rate (ORR); Progression-free survival (PFS)	Loyola University; Cures Within Reach; Medical University of South Carolina	Female	18 Years to 90 Years   (Adult, Older Adult)	34	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	214787	13/12/2021	31/12/2024	31/12/2024			03/09/2022				10/05/2023	https://ClinicalTrials.gov/show/NCT05272462		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Ovarian Epithelial Cancer	Minoxidil	OS	Phase 2	DB00350	N
NCT05968690	Naltrexone and Propranolol Combined With Immunotherapy		Recruiting	Advanced Melanoma	Drug: Propranolol; Drug: Naltrexone	Safety as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0; Dose-limiting toxicity of naltrexone in combination with propranolol and ipilimumab plus nivolumab; Recommended phase 2 dose of naltrexone in combination with propranolol and ipilimumab plus nivolumab; Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Progression-Free Survival (PFS); Overall Survival (OS)	Ryan Stephenson; Rutgers, The State University of New Jersey	All	18 Years and older   (Adult, Older Adult)	12	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	092302; Pro2023001214; NCI-2023-06872	09/11/2023	30/09/2025	30/09/2025			08/01/2023				15/11/2023	https://ClinicalTrials.gov/show/NCT05968690		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Skin	Melanoma	Naltrexone; Propranolol	Safety and/or Dose; PFS; OS	Phase 1	DB00704; DB00571	N
NCT04169763	Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery		Recruiting	Stage II Vulvar Cancer AJCC v8|Stage III Vulvar Cancer AJCC v8|Stage IIIA Vulvar Cancer AJCC v8|Stage IIIB Vulvar Cancer AJCC v8|Stage IIIC Vulvar Cancer AJCC v8|Stage IVA Vulvar Cancer AJCC v8	Drug: Cisplatin; Radiation: External Beam Radiation Therapy; Drug: Nelfinavir	Recommended phase II dose (RP2D) of nelfinavir; Incidence of adverse events; Progression-free survival; Overall survival	M.D. Anderson Cancer Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	18	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-0629; NCI-2019-07570	08/07/2020	31/12/2023	31/12/2023			20/11/2019				24/08/2023	https://ClinicalTrials.gov/show/NCT04169763		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Vulvar Cancer	Nelfinavir	Safety and/or Dose; PFS; OS	Phase 1	DB00220	N
NCT03256916	Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix	NELCER	Recruiting	Carcinoma Cervix,Stage III	Drug: Nelfinavir; Drug: Cisplatin; Radiation: Pelvic EBRT and Brachytherapy	Improvement in 3 year disease free survival; Change in locoregional control rates at 3 years; Overall survival at 5 years; Incidence of grade 3/4 adverse events; Changes in Akt levels in the tumor; Change in tumour hypoxia using multifunctional PET/ MRI.; Interindividual variability of Volume of distribution; Interindividual variability of Clearance of nelfinavir.; Interindividual variability of Clearence of Nelfinavir	Tata Memorial Hospital	Female	18 Years to 65 Years   (Adult, Older Adult)	348	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TMH Project 1543	16/01/2018	30/09/2025	30/09/2025			22/08/2017				21/02/2022	https://ClinicalTrials.gov/show/NCT03256916	Primary/Main Curative	Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	India	Gynaecological	Cervical Cancer	Nelfinavir	Safety and/or Dose; OS; DFS/RFS/EFS; Biomarker	Phase 3	DB00220	N
NCT02807805	Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer		Active, not recruiting	Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer	Drug: Abiraterone Acetate; Drug: Niclosamide; Drug: Prednisone	PSA response rate; Incidence of dose limiting toxicity defined as any grade III non-hematologic toxicity not reversible to grade II or less within 96 hours, or any grade IV toxicity; Overall response as determined by PCWG2 criteria; Overall survival; PFS	Mamta Parikh; National Cancer Institute (NCI); University of California, Davis	Male	19 Years and older   (Adult, Older Adult)	37	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	871875; UCDCC#260; P30CA093373; NCI-2016-00779	10/01/2016	01/01/2024	07/01/2024			21/06/2016				29/11/2023	https://ClinicalTrials.gov/show/NCT02807805		Localised/Locoregional; Recurrent/Refractory	Company	N	N	N	United States	Urological	Prostate Cancer	Niclosamide	Safety and/or Dose; PFS; OS; Biomarker	Phase 2	DB06803	N
NCT05188170	Niclosamide in Pediatric Patients With Relapsed and Refractory AML		Recruiting	Acute Myeloid Leukemia (AML)	Drug: Niclosamide	Dose-limiting toxicity; Efficacy of niclosamide treatment clinical response	Stanford University	All	2 Years to 25 Years   (Child, Adult)	16	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-61916; PEDSHEMAML0007; 641095; 6587-20	21/11/2022	07/01/2025	12/01/2026			01/12/2022				01/11/2024	https://ClinicalTrials.gov/show/NCT05188170		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	Leukemia	Acute Lymphoblastic Leukemia, Childhood	Niclosamide	Safety and/or Dose; Response rate	Phase 1	DB06803	N
NCT04930991	High Dose Omeprazole in Patients With Pancreatic Cancer	OU202005AJ	Recruiting	Exocrine Pancreatic Cancer	Drug: Omeprazole	Proportion; Safety and Tolerability; v-ATPase LC3-I and LC3-II expression; pH; Correlation	University of Oklahoma	All	18 Years to 99 Years   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12368	09/07/2021	06/01/2024	06/01/2025			18/06/2021				10/06/2023	https://ClinicalTrials.gov/show/NCT04930991		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	GI	Pancreatic Cancer	Omeprazole	Biomarker	Phase 1	DB00338	N
NCT04337580	Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer	FASN	Recruiting	Prostate Cancer|Refractory Cancer|Castration Resistant Prostatic Cancer	Drug: Omeprazole 80 mg twice daily	Change Radiographic Response - RECIST 1.1; Change in Bone Metastasis Response - Prostate Cancer Clinical Trials Working Group 3 (PCWG3); Fatty Acid Synthase Activity - Pre Omeprazole Use; Fatty Acid Synthase Activity - Post Omeprazole Use; Prostate Specific Antigen (PSA) Progression; Prostate Specific Antigen (PSA) Response; Patient Reported Outcome - Pain	Wake Forest University Health Sciences; National Cancer Institute (NCI)	Male	18 Years and older   (Adult, Older Adult)	20	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00068039; P30CA012197; WFBCC 85220	03/05/2021	08/01/2024	09/01/2024			04/07/2020				26/10/2023	https://ClinicalTrials.gov/show/NCT04337580		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Omeprazole	QoL; Biomarker	Phase 2	DB00338	N
NCT02950259	Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)		Unknown status	Breast Neoplasm|Breast Neoplasm, Male|Triple Negative Breast Cancer	Drug: Cyclophosphamide; Drug: Indomethacin; Drug: Omeprazole; Dietary Supplement: Multivitamin	Surgical Delays; Tumor Infiltrating Lymphocytes	Providence Health   Services; Brooklyn ImmunoTherapeutics, LLC	All	Child, Adult, Older Adult	16	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-126B; IRX-2 2016-B	02/09/2017	10/01/2022	01/01/2023			11/01/2016				02/02/2022	https://ClinicalTrials.gov/show/NCT02950259		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - TNBC	Indomethacin; Omeprazole	Safety and/or Dose	Phase 1	DB00328; DB00338	N
NCT01748500	Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer		Completed	Prostate Cancer	Drug: Pantoprazole	Confirmed PSA response	University Health Network, Toronto	Male	18 Years and older   (Adult, Older Adult)	21	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PANDORA; 12-0388-C	01/01/2013	03/01/2021	03/01/2021			12/12/2012				23/03/2021	https://ClinicalTrials.gov/show/NCT01748500		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Canada	Urological	Prostate Cancer	Pantoprazole	Biomarker	Phase 2	DB00213	N
NCT01871454	Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers		Recruiting	Non-small Cell Lung Cancers	Radiation: stereotactic ablative radiotherapy (SABR); Drug: Pentoxifylline	primary endpoint is to estimate overall treatment-related toxicity; Estimate progression free survival; Estimate tumor failure; estimate overall survival	University of Louisville; James Graham Brown Cancer Center	All	18 Years and older   (Adult, Older Adult)	59	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BCC-RAD-13-Pentoxifylline	10/01/2013	12/01/2022	12/01/2025			06/06/2013				22/06/2021	https://ClinicalTrials.gov/show/NCT01871454		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Lung	Non-Small Cell Lung Cancer	Pentoxifylline	Safety and/or Dose; PFS; OS	Phase 2	DB00806	N
NCT05490953	Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma		Recruiting	Hodgkin Lymphoma	Drug: Pentoxifylline; Drug: Placebo	Peripheral apoptosis (Fortilin); Peripheral apoptosis (Cytochrome c); Assessment of the clinical response by positron emission tomography (PET); Assessment of the clinical response by Computerized Axial Tomography; Assessment of the clinical response; Determination of event-free survival; Assessment of the severity of adverse effects; Correlation of adverse effects with pentoxifylline	University of Guadalajara; Hospital Civil de Guadalajara	All	6 Years to 35 Years   (Child, Adult)	30	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CI-03122	07/11/2022	31/12/2023	07/01/2024			08/08/2022				18/04/2023	https://ClinicalTrials.gov/show/NCT05490953		Any/All Stages	Hospital/University/Research Institute	Y	N	Y	Mexico	Lymphoma	Hodgkin Lymphoma, Adult; Hodgkin Lymphoma, Childhood	Pentoxifylline	Safety and/or Dose; DFS/RFS/EFS; Biomarker	Phase 4	DB00806	N
NCT02451774	Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction	PTX-II	Unknown status	Acute Lymphoblastic Leukemia	Drug: Pentoxifylline Plus Chemotherapy; Drug: Placebo Plus Chemotherapy	Apoptosis measure by Flow Cytometry; Senescence measure by Flow Cytometry; Safety measure by Common Terminology Criteria for Adverse Events version 4.0	Ram n  scar Gonz lez-Ramella, Ph.D; Instituto de Investigacion en Cancer de la Infancia y la Adolescencia; Hospital Civil Juan I. Menchaca; Centro de Investigacion Biomedica de Occidente; University of Guadalajara	All	1 Year to 18 Years   (Child, Adult)	44	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IICIA -PTX02	01/01/2015	12/01/2019	12/01/2020			22/05/2015				05/09/2018	https://ClinicalTrials.gov/show/NCT02451774		Localised/Locoregional	Hospital/University/Research Institute	Y	N	Y	Mexico	Leukemia	Acute Lymphoblastic Leukemia, Childhood	Pentoxifylline	Safety and/or Dose; Biomarker	Phase 2/3	DB00806	N
NCT04794127	Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.	TRABEPIO	Recruiting	Liposarcoma, Myxoid|Liposarcoma, Dedifferentiated|Liposarcoma, Round Cell	Drug: Trabectedin; Drug: Pioglitazone Oral Product	Objective response (OR) in patients with myxoid liposarcomas according to RECIST criteria or CHOI criteria; Number and severity of Adverse Events; Maximum Plasma Concentration [Cmax]	Mario Negri Institute for Pharmacological Research; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Humanitas Hospital, Italy	All	18 Years and older   (Adult, Older Adult)	10	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRFMN-SARCO-7953	02/02/2022	02/02/2024	02/02/2024			03/11/2021				26/10/2023	https://ClinicalTrials.gov/show/NCT04794127		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Italy	Soft Tissue Sarcoma	Liposarcoma	Pioglitazone	Response rate	Phase 2	DB01132	N
NCT02889003	Second STOP After Pioglitazone Priming in CML Patients	PIO2STOP	Unknown status	Chronic Myeloid Leukemia (CML)	Drug: Pioglitazone + TKI	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0; Treatment free survival after pioglitazone and tyrosine kinase inhibitor discontinuation.	Versailles Hospital; Pr Philippe ROUSSELOT	All	18 Years and older   (Adult, Older Adult)	26	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P16/05_PIO2STOP	12/01/2016	12/01/2021	12/01/2021			09/05/2016				22/03/2018	https://ClinicalTrials.gov/show/NCT02889003		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	France	Leukemia	Chronic Myelogenous Leukemia	Pioglitazone	Safety and/or Dose; Other (specify)	Phase 2	DB01132	N
NCT03177291	Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC		Active, not recruiting	Lung Cancer|Non Small Cell Lung Cancer|Advanced Cancer|Metastatic Lung Cancer|Squamous Cell Lung Cancer|Non-Squamous Non-Small Cell Neoplasm of Lung	Drug: Pirfenidone; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed	Phase 1: Recommended Phase 1b Dose; Phase 1b: Overall Response Rate (ORR); Progression Free Survival (PFS); Overall Survival (OS)	H. Lee Moffitt Cancer Center and Research Institute	All	18 Years and older   (Adult, Older Adult)	48	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-19082	26/09/2017	05/09/2021	06/01/2024			06/06/2017				22/09/2023	https://ClinicalTrials.gov/show/NCT03177291		Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	United States	Lung	Non-Small Cell Lung Cancer	Pirfenidone	Safety and/or Dose; Response rate; PFS; OS	Phase 1	DB04951	N
NCT04467723	Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC		Recruiting	NSCLC Stage IV|NSCLC, Recurrent	Drug: Atezolizumab	Occurrence of Grade 3 toxicity; Occurrence of Grade 4 toxicity; Overall response rate (ORR) of participants; Progression Free Survival (PFS); 1-year overall survival (OS) rate: Proportion of participants alive at 1 year from Cycle 1 day 1	University of Kansas Medical Center; parkview cancer institute	All	18 Years and older   (Adult, Older Adult)	25	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT-2020-CAFs	18/05/2022	08/01/2024	08/01/2025			13/07/2020				09/11/2023	https://ClinicalTrials.gov/show/NCT04467723		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Lung	Non-Small Cell Lung Cancer	Pirfenidone	Safety and/or Dose; Response rate; PFS; OS	Phase 1/2	DB04951	N
NCT05544019	Study of SGR-1505 in Mature B-Cell Neoplasms		Recruiting	Mature B-Cell Neoplasm|Non Hodgkin Lymphoma|DLBCL|Waldenstrom Macroglobulinemia|MALT Lymphoma|Follicular Lymphoma|Pediatric-Type Follicular Lymphoma|IRF4 Gene Rearrangement|EBV-Positive DLBCL, Nos|Burkitt Lymphoma|Plasmablastic Lymphoma|High-grade B-cell Lymphoma|Primary Cutaneous Follicle Center Lymphoma|Primary Effusion Lymphoma|Mantle Cell Lymphoma|DLBCL Germinal Center B-Cell Type|Primary Mediastinal Large B Cell Lymphoma|T-Cell/Histiocyte Rich Lymphoma|ALK-Positive Large B-Cell Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma|Splenic Marginal Zone Lymphoma|Chronic Lymphocytic Leukemia|Nodal Marginal Zone Lymphoma|HHV8-Positive DLBCL, Nos|Lymphoplasmacytic Lymphoma|Duodenal-Type Follicular Lymphoma	Drug: SGR-1505	Nature, severity, and number of incidences of adverse events (AEs), serious AEs (SAEs), and AEs leading to treatment discontinuation.; Nature and number of incidences of dose limiting toxicity (DLT).; SGR-1505 Maximal Plasma Concentration (Cmax); SGR-1505 Time to Maximal Plasma Concentration (tmax); SGR-1505 Area Under the Concentration Versus Time Curve (AUC); Effect of Food on the Cmax of SGR-1505; Effect of Food on the tmax of SGR-1505; Effect of Food on the AUC of SGR-1505; Effect of Posaconazole on the Cmax of SGR-1505; Effect of Posaconazole on the tmax of SGR-1505; Effect of Posaconazole on the AUC of SGR-1505; Objective Response Rate (ORR); Duration of Response (DOR); Disease Control Rate	Schr dinger, Inc.	All	18 Years and older   (Adult, Older Adult)	52	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SGR-1505-101	04/10/2023	03/01/2025	03/01/2025			16/09/2022				01/12/2024	https://ClinicalTrials.gov/show/NCT05544019		Recurrent/Refractory	Company	N	N	N	United States	Leukemia	Leukemia - Other	Posaconazole	Safety and/or Dose	Phase 1	DB01263	N
NCT05606692	Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)	anesthetics	Recruiting	Ovarian Cancer	Drug: Propofol 1 ; Drug: Sevoflurane/Ultane	progression-free survival; 6-month overall survival; 1-year overall survival; 3-year overall survival; 5-year overall survival; Karnofsky performance score; postoperative complications	Kaohsiung Medical University Chung-Ho Memorial Hospital; Tri-Service General Hospital	Female	20 Years to 80 Years   (Adult, Older Adult)	416	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	KMUHIRB-F(II)-20220157	23/11/2022	30/09/2026	30/09/2027			11/07/2022				30/05/2023	https://ClinicalTrials.gov/show/NCT05606692		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Taiwan	Gynaecological	Ovarian Epithelial Cancer	Propofol	PFS	Phase 4	DB00818	N
NCT05141877	Influences of Propofol and Sevoflurane Anesthesia in Brain Tumor	anesthetics	Recruiting	Brain Tumor	Drug: Propofol; Drug: Sevoflurane	Overall survival; The presence of disease progression; Karnofsky performance status score; Postoperative complications within 30 days	Kaohsiung Medical University Chung-Ho Memorial Hospital; Tri-Service General Hospital	All	20 Years to 80 Years   (Adult, Older Adult)	706	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	KMUHIRB-F(II)-20210167	18/02/2022	30/11/2024	30/11/2025			12/02/2021				31/10/2023	https://ClinicalTrials.gov/show/NCT05141877		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Multiple cancer types	Other multiple cancer group (specify)	Propofol	PFS; OS	Phase 4	DB00818	N
NCT04475705	Propofol vs Sevo for Paediatric Tumor Surgery		Recruiting	Solid Tumor|Carcinoma|Malignancy|Cancer	Drug: propofol; Drug: sevoflurane	difference in Hypoxia Inducible Factor-1 gene expression; difference in levels of Interleukin-6; difference in levels of Tumor Necrosis Factor-alpha; difference in levels of high sensitivity C reaction protein; difference in levels of DNA damage (Comet Assay); difference in levels of Glutathione Peroxidase; difference in levels of Superoxide dismutase; difference in levels of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG); difference in levels of 8-oxo-7,8-dihydroguanosine (8-oxoGuo); difference in the quantity of circulating tumor cells (CTC); cancer free survival at 1 and 3 years	Hong Kong Children's Hospital; The University of Hong Kong	All	6 Months to 18 Years   (Child, Adult)	100	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	HKCH-REC-2020-013	01/11/2021	07/01/2028	07/01/2028			17/07/2020				16/03/2022	https://ClinicalTrials.gov/show/NCT04475705		Localised/Locoregional	Hospital/University/Research Institute	Y	N	Y	Hong Kong	Multiple cancer types	Any solid tumours	Propofol	Biomarker	Phase 4	DB00818	N
NCT03447691	Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery		Unknown status	Pancreatic Cancer or Distal CBD Cancer	Drug: Des (volatile anesthetic-desflurane); Drug: TIVA (Total intravenous anesthesia with propofol and remifentanil)	score of QoR40 (Quality of Recovery 40)	Yonsei University	All	20 Years and older   (Adult, Older Adult)	132	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other	4-2017-0662	27/08/2017	28/08/2022	28/08/2022			27/02/2018				01/11/2019	https://ClinicalTrials.gov/show/NCT03447691		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	GI	Pancreatic Cancer; Cholangiocaricnoma	Propofol	Other (specify)	Other	DB00818	N
NCT04259398	Anesthesia and Cancer Study: Colon Cancer		Active, not recruiting	Cancer of Colon|Anesthesia	Drug: Propofol; Drug: Sevoflurane	five year survival; five year recurrence free survival; 1 year recurrence free survival; 3 year recurrence free survival; 1 year survival; 3 year survival	Seoul National University Hospital; Korean Society of Anesthesiologists; Bundang Seoul National University Hospital; Chung-Ang University Hosptial, Chung-Ang University College of Medicine; Seoul St. Mary's Hospital; Seoul National University Boramae Hospital	All	19 Years to 80 Years   (Adult, Older Adult)	797	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	Ane-Can colon (1912-133-109)	18/02/2020	05/03/2028	05/03/2028			02/06/2020				22/11/2023	https://ClinicalTrials.gov/show/NCT04259398		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	GI	Colon Cancer	Propofol	DFS/RFS/EFS	Other	DB00818	N
NCT03034096	General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial	GA-CARES	Active, not recruiting	Anesthesia, General|Surgical Oncology	Drug: Propofol; Drug: Volatile Agent	All-cause mortality; Recurrence free survival; All-cause mortality as a binary outcome	Stony Brook University	All	18 Years and older   (Adult, Older Adult)	1804	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	967670-3	31/01/2017	09/01/2024	12/01/2024			27/01/2017				17/10/2022	https://ClinicalTrials.gov/show/NCT03034096		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Multiple cancer types	Multiple cancer types	Propofol	DFS/RFS/EFS	Phase 4	DB00818	N
NCT05926336	The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action		Recruiting	Lung Cancer|Brain Tumor|Liver Cancer|Ovarian Cancer	Drug: Propofol; Drug: Sevoflurane	Overall survival; The presence of disease progression; Postoperative complications; Karnofsky performance status score; Length of hospital stays	Kaohsiung Medical University Chung-Ho Memorial Hospital	All	20 Years to 80 Years   (Adult, Older Adult)	1316	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	KMUHIRB-F(I)-20230075	23/05/2023	07/01/2026	07/01/2026			07/03/2023				28/09/2023	https://ClinicalTrials.gov/show/NCT05926336		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Taiwan	Multiple cancer types	Multiple cancer types	Propofol	OS; Other (specify)	Phase 4	DB00818	N
NCT04513808	Total Intravenous Anesthesia and Recurrence Free Survival		Recruiting	Esophageal Cancer	Drug: Propofol-based total intravenous anesthesia; Drug: Sevoflurane intravenous anesthesia	Recurrence-free survival; ICU duration; Hospital duration; QoR-15	The Cleveland Clinic	All	18 Years to 90 Years   (Adult, Older Adult)	1614	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	VICTORY	15/08/2020	12/01/2025	12/01/2027			14/08/2020				15/11/2023	https://ClinicalTrials.gov/show/NCT04513808		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Multiple cancer types	Any solid tumours	Propofol	DFS/RFS/EFS	Phase 3	DB00818	N
NCT04962672	Anesthesia Induced Brain Cancer Survival (ABC Survival): A Feasibility Study		Recruiting	Anesthesia|Brain Cancer|Survival	Drug: Propofol group; Drug: Sevoflurane group	Rate of recruitment; retention rate; rate of protocol adherence; Overall survival; Progression free survival	University Health Network, Toronto	All	18 Years and older   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care	21-5527.0	01/01/2022	06/01/2024	30/12/2024			15/07/2021				22/08/2023	https://ClinicalTrials.gov/show/NCT04962672		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Canada	CNS	Glioblastoma	Propofol	PFS; OS; Other (specify)	Other	DB00818	N
NCT04800393	The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.	TeMP	Recruiting	Anesthesia|Breast Cancer	Drug: Sevoflurane; Drug: Propofol	Neutrophil-lymphocyte ratio; Matrix metallopeptidase 9; C-reactive protein; Natural killer cells of blood (CD3-CD16 +); Immunoregulatory index of T helpers (CD3 + CD4 +) / cytotoxic T cells (CD3 + CD8 +); IL-6	Moscow Clinical Scientific Center; Negovsky Reanimatology Research Institute	Female	45 Years to 74 Years   (Adult, Older Adult)	130	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	TeMP 2021	29/03/2022	07/01/2023	04/01/2028			16/03/2021				26/04/2023	https://ClinicalTrials.gov/show/NCT04800393		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Russian Federation	Breast	Any Breast Cancer	Propofol	Biomarker	Other	DB00818	N
NCT05663242	The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action		Recruiting	Lung Cancer|Progression, Disease|Anesthesia	Drug: Propofol; Drug: Sevoflurane	Overall survival; The presence of disease progression; Postoperative complications; Karnofsky performance status score; Length of hospital stays	Kaohsiung Medical University Chung-Ho Memorial Hospital	All	20 Years to 80 Years   (Adult, Older Adult)	300	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	KMUHIRB-F(I)-20210218.	27/12/2022	30/11/2026	30/11/2026			23/12/2022				30/05/2023	https://ClinicalTrials.gov/show/NCT05663242		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Taiwan	Lung	Any lung cancers	Propofol	PFS; OS	Phase 4	DB00818	N
NCT04601961	Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients		Recruiting	Circulating Tumor Cell|Hepatocellular Carcinoma	Drug: Propofol; Drug: Sevoflurane	HIF-1 gene expression; Change in number of recurrence; Level of Gene expression; Level of DNA damage; Level of C-reactive protein; Level of Glutathione Peroxidase; Level of Superoxide dismutase; Level of Oxidative damage DNA; Level of tumor necrosis factor; Number of Circulating tumour cells	The University of Hong Kong	All	18 Years to 80 Years   (Adult, Older Adult)	220	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research	UW 20-022	03/04/2020	31/01/2024	31/03/2024			26/10/2020				31/03/2023	https://ClinicalTrials.gov/show/NCT04601961		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Liver Cancer	Propofol	Recurrence rate; Biomarker	Other	DB00818	N
NCT06017141	Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study		Recruiting	Colon Adenocarcinoma	Procedure: Biospecimen Collection; Other: Electronic Health Record Review; Drug: Fentanyl Citrate; Drug: Propofol; Other: Questionnaire Administration; Drug: Sevoflurane; Procedure: Surgical Procedure	Neutrophil extracellular traps (NET) formation; Early post-operative recovery; Global and post-operative recovery; Post-operative nausea scores; Number and cumulative amount of doses of anti-emetics; Total hospital opioid use; Patient-reported pain scores; Number of times a pro re nata (PRN) medication administered; First post-op day when participant tolerates a regular diet (at the discretion of the surgical team); Time from study entry and from surgery to disease recurrence, death, or loss to follow up; Post-operative complications; Post-operative immune suppression; Circulating tumor deoxyribonucleic acid (ctDNA); Changes in gene expression	University of Kansas Medical Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	80	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	STUDY00149314; NCI-2023-05587; IIT-2022-VIVA; P30CA168524	22/05/2023	22/05/2025	22/05/2026			30/08/2023				30/08/2023	https://ClinicalTrials.gov/show/NCT06017141		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	GI	Colon Cancer	Propofol	OS; Recurrence rate; Biomarker	Phase 2	DB00818	N
NCT04503148	Anesthesia and Cancer Study: Renal Cell Carcinoma		Active, not recruiting	Renal Cell Carcinoma	Drug: Propofol; Drug: Inhaled General Anesthetics	one year metastasis-free survival; three year metastasis-free survival; one year survival; three year survival	Seoul National University Hospital	All	18 Years and older   (Adult, Older Adult)	562	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	Ane-Can Nx	22/09/2020	22/12/2022	22/12/2025			08/07/2020				14/04/2023	https://ClinicalTrials.gov/show/NCT04503148		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	Urological	Renal Cell Carcinoma	Propofol	OS; Other (specify)	Other	DB00818	N
NCT05331911	Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors		Recruiting	Hepatocellular Carcinoma	Drug: Propofol; Drug: Sevoflurane	Overall survival; The presence of disease progression; Postoperative complications; Karnofsky performance status score; Length of hospital stays	Kaohsiung Medical University Chung-Ho Memorial Hospital; Tri-Service General Hospital	All	20 Years to 80 Years   (Adult, Older Adult)	500	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	KMUHIRB-F(I)-20220034	26/04/2022	31/12/2026	31/03/2027			18/04/2022				30/11/2022	https://ClinicalTrials.gov/show/NCT05331911		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Taiwan	GI	Liver Cancer	Propofol	PFS; OS; Other (specify)	Phase 4	DB00818	N
NCT04005365	Clinical Study of Propranolol Combined With Neoadjuvant Chemotherapy in Gastric Cancer		Unknown status	Gastric Cancer	Drug: Propranolol	ORR	Yijing He; Xiangya Hospital of Central South University; Central South University	All	18 Years to 75 Years   (Adult, Older Adult)	78	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019/prop/GC/CSU	20/11/2019	06/01/2020	06/01/2020			07/02/2019				26/11/2019	https://ClinicalTrials.gov/show/NCT04005365		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	GI	Gastric Cancer	Propranolol	Response rate	Phase 2	DB00571	N
NCT05679193	Perioperative Propranolol During Prostatectomy to Decrease Cancer Recurrence	PeP-RALP	Recruiting	Prostate Cancer	Drug: Propranolol	The feasibility of conducting a formal larger RCT to compare the efficacy of propranolol vs placebo to decrease PCa recurrence following RALP.; Safety and tolerability of PeP-RALP intervention; Determine the effect of RALP on catecholamine levels; Determine the bioavailability of propranolol; Determine the effect of preoperative propranolol treatment on the serum level of PSA; To determine the effect of propranolol on post-operative biochemical failure; Intraoperative anesthesiological and surgical challenges Surgical complications in PeP RALP patients; Surgical complications	Oslo University Hospital	Male	40 Years to 80 Years   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	488466	01/02/2023	10/01/2023	10/01/2023			01/10/2023				02/09/2023	https://ClinicalTrials.gov/show/NCT05679193		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Norway	Urological	Prostate Cancer	Propranolol	Other (specify)	Phase 2	DB00571	N
NCT04493489	Propranolol Adjuvant Treatment of Bladder Cancer		Not yet recruiting	Bladder Cancer	Drug: Propranolol Hydrochloride; Drug: BCG	two-year recurrence-free survival	Central South University	All	18 Years to 75 Years   (Adult, Older Adult)	242	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2020/prop/bladder/CSU	09/06/2020	09/06/2023	09/06/2024			30/07/2020				30/07/2020	https://ClinicalTrials.gov/show/NCT04493489		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Urological	Bladder Cancer	Propranolol	DFS/RFS/EFS	Phase 2	DB00571	N
NCT05979818	Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer	BRIO	Not yet recruiting	Non Small Cell Lung Cancer|Propranolol	Drug: Propranolol hydrochloride; Drug: Sintilimab; Drug: Chemotherapy	Objective Response Rate (ORR); Disease Control Rate (DCR); Adverse events (AEs); Progression-free survival (PFS); Overall survival (OS); Quality of life (QoL)	Second Xiangya Hospital of Central South University; Innovent Biologics (Suzhou) Co. Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	6	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XYEYY20230705	31/12/2023	31/08/2025	31/12/2026			08/07/2023				21/11/2023	https://ClinicalTrials.gov/show/NCT05979818		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	Lung	Non-Small Cell Lung Cancer	Propranolol	Safety and/or Dose; Response rate; PFS; OS; QoL	Phase 1	DB00571	N
NCT05741164	Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer		Not yet recruiting	Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Refractory Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma	Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Pembrolizumab; Drug: Propranolol; Other: Questionnaire Administration	Objective response; Progression free survival; Overall survival; Incidence of adverse events of propranolol when given in combination with pembrolizumab	Roswell Park Cancer Institute	All	18 Years and older   (Adult, Older Adult)	25	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 2612022; NCI-2023-00641	15/02/2024	15/12/2026	15/12/2027			23/02/2023				01/05/2024	https://ClinicalTrials.gov/show/NCT05741164		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - TNBC	Propranolol	Response rate	Phase 2	DB00571	N
NCT02897986	Study of a Propranolol (HEMANGIOL ) and Oral Metronomic Vinorelbine (NAVELBINE ) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors	PROVIN	Unknown status	Pediatric Cancer	Drug: administration of a propranolol (HEMANGIOL ) and oral metronomic vinorelbine (NAVELBINE ) combination	number of patients with grade 3 toxicity	Assistance Publique Hopitaux De Marseille	All	4 Years to 21 Years   (Child, Adult)	54	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-06	01/01/2017	01/01/2020	01/01/2021			13/09/2016				13/09/2016	https://ClinicalTrials.gov/show/NCT02897986		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	France	Multiple cancer types	Any solid tumours	Propranolol	Safety and/or Dose	Phase 1	DB00571	N
NCT05451043	Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)		Not yet recruiting	Pancreatic Cancer|Hepatocellular Cancer|Biliary Tract Cancer|Cholangiocarcinoma	Biological: Durvalumab; Drug: Gemcitabine; Drug: Nab paclitaxel; Biological: Tremelimumab; Drug: Propranolol; Drug: Cisplatin	Investigating and establishing the efficacy of propranolol in boosting the effects of immunotherapy in pancreatic adenocarcinoma; Investigating and establishing the efficacy of propranolol in boosting the effects of immunotherapy in hepatocellular carcinoma; Investigating and establishing the efficacy of propranolol in boosting the effects of immunotherapy in biliary tract tumors; Feasibility of study therapy; Safety/tolerability; Progression-free survival; Overall Survival	AHS Cancer Control Alberta	All	18 Years and older   (Adult, Older Adult)	62	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT-0027	03/01/2023	10/01/2025	10/01/2028			07/11/2022				02/02/2023	https://ClinicalTrials.gov/show/NCT05451043		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Canada	GI	Cholangiocaricnoma; Pancreatic Cancer; Liver Cancer	Propranolol	Other (specify)	Phase 2	DB00571	N
NCT03152786	Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery		Terminated	Prostate Carcinoma	Other: Laboratory Biomarker Analysis; Drug: Propranolol Hydrochloride; Other: Questionnaire Administration; Other: Survey Administration	CREB phosphorylation; BAD phosphorylation; Distress score; Levels of transcripts that reflect ADRB2/PKA activation; Plasma catecholamine levels (including epinephrine); Plasma propranolol levels; Self-perceived stress	Wake Forest University Health Sciences; National Cancer Institute (NCI)	Male	19 Years and older   (Adult, Older Adult)	46	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00043227; NCI-2017-00788; CCCWFU 85716; P30CA012197	15/01/2019	15/06/2021	28/02/2023			15/05/2017				17/07/2023	https://ClinicalTrials.gov/show/NCT03152786		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Urological	Prostate Cancer	Propranolol	Biomarker	Phase 2	DB00571	N
NCT04848519	Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma		Recruiting	Locally Advanced Bladder Urothelial Carcinoma|Locally Advanced Renal Pelvis Urothelial Carcinoma|Locally Advanced Ureter Urothelial Carcinoma|Locally Advanced Urethral Urothelial Carcinoma|Locally Advanced Urothelial Carcinoma|Metastatic Bladder Urothelial Carcinoma|Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Ureter Urothelial Carcinoma|Metastatic Urethral Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Stage IV Bladder Cancer AJCC v8|Stage IV Renal Pelvis Cancer AJCC v8|Stage IV Ureter Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8	Drug: Pembrolizumab; Drug: Propranolol Hydrochloride; Drug: Nivolumab; Drug: Avelumab	Incidence of adverse events; Progression free survival (PFS); Overall survival (OS); Objective Response Rate (ORR)	Emory University; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	24	Other; NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00002186; NCI-2021-00437; WINSHIP5200-20; P30CA138292	20/05/2021	01/01/2024	01/01/2025			19/04/2021				27/07/2023	https://ClinicalTrials.gov/show/NCT04848519		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Urological	Bladder Cancer	Propranolol	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00571	N
NCT01988831	Efficacy of Propranolol Treatment to Prevent Melanoma Progression		Suspended	Stages III Skin Melanoma|Stages II Skin Melanoma|Stage IB Skin Melanoma	Drug: Propranolol hydrochloride; Drug: Placebo pill	Efficacy of propranolol on progression free survival for patients suffering from a primary melanoma with a high risk of recurrence; Use of serum microRNA profile as a predictor for recurrence; Overall survival	University Hospital, Geneva	All	18 Years and older   (Adult, Older Adult)	450	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	HUG-MEL-BB	06/01/2016	01/01/2022	03/01/2022			20/11/2013				05/10/2019	https://ClinicalTrials.gov/show/NCT01988831		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Switzerland	Skin	Melanoma	Propranolol	PFS; OS; Biomarker	Phase 2	DB00571	N
NCT03384836	Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery		Recruiting	Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7	Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab; Drug: Propranolol Hydrochloride	Dose limiting toxicities (DLT) defined as any grade 3 or higher hematological or non-hematological toxicity that is probably or definitely related to treatment according to Common Terminology Criteria for Adverse Events version 4.03 (Phase Ib); Overall response rate (ORR) per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) version 1.1 (Phase II); Overall survival (OS) (Phase II); PFS (Phase II); Progression free survival (PFS) (Phase II)	Roswell Park Cancer Institute	All	18 Years and older   (Adult, Older Adult)	47	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 53217; NCI-2017-02210	31/01/2018	31/01/2025	31/01/2025			27/12/2017				11/09/2023	https://ClinicalTrials.gov/show/NCT03384836		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Skin	Melanoma	Propranolol	Safety and/or Dose; Response rate; PFS; OS	Phase 1/2	DB00571	N
NCT04682158	Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma		Recruiting	Esophageal Adenocarcinoma	Drug: Carboplatin; Radiation: 3 Dimensional Conformal Radiation Therapy; Drug: Propranolol; Radiation: Intensity Modulated Radiation Therapy; Drug: Paclitaxel	Occurrence of Adverse Events; Progression Free Survival; Overall Survival	Roswell Park Cancer Institute	All	18 Years and older   (Adult, Older Adult)	106	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	I 630420	04/01/2021	04/01/2027	04/01/2027			23/12/2020				22/11/2023	https://ClinicalTrials.gov/show/NCT04682158		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	United States	GI	Esophageal Cancer	Propranolol	Safety and/or Dose; PFS; OS	Phase 2	DB00571	N
NCT05651594	Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma		Recruiting	Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Esophageal Adenocarcinoma AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Locally Advanced Esophageal Adenocarcinoma|Locally Advanced Gastroesophageal Junction Adenocarcinoma|Metastatic Esophageal Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Unresectable Esophageal Adenocarcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma	Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin; Biological: Pembrolizumab; Drug: Propranolol Hydrochloride; Other: Questionnaire Administration	Overall response rate (ORR); Incidence of toxicities and adverse events; Progression-free survival; Overall survival; ORR	Roswell Park Cancer Institute; United States Department of Defense	All	18 Years and older   (Adult, Older Adult)	40	Other; U.S. Fed	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 2734222; NCI-2022-09209; W81XWH2210916	03/07/2023	30/03/2026	30/03/2026			15/12/2022				22/12/2023	https://ClinicalTrials.gov/show/NCT05651594		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Esophageal Cancer	Propranolol	Response rate	Phase 2	DB00571	N
NCT03108300	Use of Propranolol Hydrochloride in the Treatment of Metastatic STS		Unknown status	Malignant Soft Tissue Sarcoma	Drug: Propranolol Hydrochloride; Drug: Doxorubicin	Progression Free Survival; Overall Survival	Ain Shams University	All	19 Years and older   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CURE002	30/08/2019	30/08/2020	30/08/2021			04/11/2017				23/02/2018	https://ClinicalTrials.gov/show/NCT03108300		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Egypt	Soft Tissue Sarcoma	Any soft tissue sarcoma	Propranolol	PFS; OS	Phase 2	DB00571	N
NCT04518124	Propranolol in Angiosarcoma		Completed	Angiosarcoma	Drug: Propranolol	Clinical response; Histological response on propranolol treatment	The Netherlands Cancer Institute; Anticancer Fund, Belgium	All	18 Years and older   (Adult, Older Adult)	14	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N19PCA	27/12/2019	30/10/2023	30/10/2023			19/08/2020				22/11/2023	https://ClinicalTrials.gov/show/NCT04518124		Any/All Stages	Hospital/University/Research Institute	N	N	N	Netherlands	Soft Tissue Sarcoma	Angiosarcoma	Propranolol	Response rate	Phase 2	DB00571	N
NCT05797662	A Study of Propranolol to Treat Kaposi Sarcoma		Not yet recruiting	Kaposi Sarcoma	Drug: Propranolol	Objective Response Rate; Number of dose-limiting toxicities; Number of treatment-emergent adverse events; Complete and Partial Response rates in children and adults; Time to recurrence among children; Time to recurrence among adults; Time to progression among children; Time to progression among adults	AIDS Malignancy Consortium; National Cancer Institute (NCI)	All	Child, Adult, Older Adult	25	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AMC-116; UM1CA121947	07/01/2024	08/01/2026	08/01/2028			04/04/2023				18/04/2023	https://ClinicalTrials.gov/show/NCT05797662		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Soft Tissue Sarcoma	Kaposi Sarcoma (non-AIDS related)	Propranolol	Response rate	Phase 2	DB00571	N
NCT05961761	Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients	PROPANE	Recruiting	Soft Tissue Sarcoma Adult|Angiosarcoma|Undifferentiated Pleomorphic Sarcoma	Drug: Propranolol; Drug: Pembrolizumab	Progression-free survival rate; Objective response rate; Duration of Response; Progression Free Survival; Overall Survival; Safety of the treatment; Quality of Life assessment	Niels Junker; Aarhus University Hospital; Oslo University Hospital; Karolinska University Hospital; Herlev and Gentofte Hospital	All	18 Years and older   (Adult, Older Adult)	80	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SA2115	17/08/2021	01/01/2028	12/01/2028			27/07/2023				27/07/2023	https://ClinicalTrials.gov/show/NCT05961761		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Denmark	Soft Tissue Sarcoma	Angiosarcoma; Other Soft Tissue Sarcoma	Propranolol	Safety and/or Dose; Response rate; PFS; OS; QoL	Phase 2	DB00571	N
NCT02962947	MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients		Unknown status	Melanoma	Drug: Propranolol; Drug: Placebo	Effect of Propranolol on overall survival for melanoma patients in stage II/IIIA (T2, N0 or N1, M0); Effect of Propranolol on disease free survival for melanoma patients in stage II/IIIA; Effect of propranolol on specific mortality for melanoma patients in stage II/IIIA; Effect of propranolol treatment on the long-term safety on melanoma patients in stage II/IIIA	Azienda Sanitaria di Firenze	All	18 Years to 75 Years   (Adult, Older Adult)	546	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	EudraCT 2014---003970---18	06/01/2017	06/01/2019	06/01/2022			15/11/2016				15/11/2016	https://ClinicalTrials.gov/show/NCT02962947		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Italy	Skin	Melanoma	Propranolol	OS; DFS/RFS/EFS	Phase 2/3	DB00571	N
NCT05678348	Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma		Recruiting	Head and Neck Cancer|Cancer of the Head and Neck	Drug: Pyrimethamine	Change in Log2 of tumor DHFR expression as measured by western blot analysis; Safety and tolerability of pyrimethamine as measured by number of adverse events; Change in Log2 of NRF2 activity score as measured using the NRF2 SureQuant proteomic assay; Number of grade 3 or higher adverse events due to pyrimethamine; Number of participants with a delay in surgery by   10 days due to pyrimethamine	Washington University School of Medicine; Vyera Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202302068	08/03/2023	15/04/2026	15/04/2026			01/10/2023				01/10/2024	https://ClinicalTrials.gov/show/NCT05678348		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Head and Neck	Any head and neck squamous cell carcinoma	Pyrimethamine	Safety and/or Dose; Biomarker; Other (specify)	Phase 1	DB00205	N
NCT05291390	Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)		Recruiting	Acute Myeloid Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)	Drug: Pyronaridine Tetraphosphate	Change in survival lengths to 1 year	Armaceutica, Inc.; Uganda Cancer Institute; African Center for Cancer Research and End of Life Care (ACREOL), Rwanda; Ifakara Health Research and Development Centre; Dalal Jamm Hospital, Dakar, Senegal	All	18 Years and older   (Adult, Older Adult)	200	Industry; Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PND7351	21/11/2022	02/01/2024	03/01/2024			22/03/2022				29/11/2022	https://ClinicalTrials.gov/show/NCT05291390		Localised/Locoregional	Company	Y	N	N	United States	Leukemia	Acute Lymphoblastic Leukemia, Adult; Acute Myeloid Leukemia, Adult	Pyronaridine	OS	Phase 2	DB12975	N
NCT01268579	Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma		Completed	HEAD   NECK Cancer	Drug: ribavirin	To Explore if Ribavirin Therapy for 2 Weeks Decreases Tumor Expression; to Explore the Pharmacodynamic Effects of Ribavirin; To Explore if Ribavirin Reduces the Expression of HPV-16 Oncoproteins E6 and E7	Memorial Sloan Kettering Cancer Center	All	18 Years to 65 Years   (Adult, Older Adult)	9	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-218	28/12/2010	31/10/2022	31/10/2022			31/12/2010		10/02/2023		10/02/2023	https://ClinicalTrials.gov/show/NCT01268579		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Head and Neck	Other Head and Neck	Ribavirin	Biomarker	Other	DB00811	N
NCT04761614	Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer		Active, not recruiting	Metastatic Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8	Biological: Bevacizumab; Drug: Fluorouracil; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Drug: Riluzole	Dose limiting toxicities (DLTs); Pharmacokinetic (PK) profile of riluzole (Cmax); Pharmacokinetic (PK) profile of riluzole (AUC)	Ning Jin; Ohio State University Comprehensive Cancer Center	All	18 Years and older   (Adult, Older Adult)	13	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSU-20096; NCI-2021-00018	04/02/2021	31/12/2023	31/12/2024			21/02/2021				05/06/2023	https://ClinicalTrials.gov/show/NCT04761614		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Colon Cancer; Rectal Cancer	Riluzole	Safety and/or Dose; Other (specify)	Phase 1	DB00740	N
NCT01303341	Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma		Active, not recruiting	Advanced Malignant Solid Neoplasm|Recurrent Melanoma|Refractory Malignant Solid Neoplasm|Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7	Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Riluzole; Drug: Sorafenib Tosylate	Maximum-tolerated dose of sorafenib tosylate and riluzole in patients with all types of solid tumors; Suppression of MAPK and PI3K/AKT pathways; Change in BCL-2 expression; Change in MCL-1 expression; Change in BIM expression; Pharmacokinetic parameters of the combination of riluzole with sorafenib tosylate; Change in microvesicle quantification	National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	35	NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2011-02597; CDR0000695355; 090906; 8850; P30CA072720; R01CA149627; U01CA132194; UM1CA186716	18/02/2011	05/01/2012	09/09/2024			24/02/2011				25/09/2023	https://ClinicalTrials.gov/show/NCT01303341		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Skin; Multiple cancer types	Melanoma; Any solid tumours	Riluzole	Safety and/or Dose; Biomarker	Phase 1	DB00740	N
NCT00866840	Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery		Completed	Melanoma (Skin)	Drug: riluzole	Tumor Response as Measured by RECIST Criteria	Rutgers, The State University of New Jersey; National Cancer Institute (NCI)	All	18 Years to 120 Years   (Adult, Older Adult)	13	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0220080280; P30CA072720; CINJ-090802; CDR0000637646	04/01/2009	07/01/2013	07/01/2013			23/03/2009		28/09/2022		28/09/2022	https://ClinicalTrials.gov/show/NCT00866840		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Skin	Melanoma	Riluzole	Response rate	Phase 2	DB00740	N
NCT05796271	Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy		Not yet recruiting	Lymphoma, B-Cell	Drug: R-Chop and Roflumilast	Anti-tumor efficacy: progression-free survival (PFS)	The University of Texas Health Science Center at San Antonio	All	18 Years to 99 Years   (Adult, Older Adult)	90	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTMS# 22-0016	01/01/2024	01/01/2027	01/01/2028			04/03/2023				04/03/2023	https://ClinicalTrials.gov/show/NCT05796271		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Lymphoma	Lymphoma - Other	Roflumilast	PFS	Phase 1	DB01656	N
NCT03392246	A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor na ve Advanced EGFR Mutant Lung Cancer		Active, not recruiting	Non-small Cell Lung Cancer	Drug: Osimertinib; Drug: Selumetinib	Best Objective Response; Progression Free Survival; Overall Survival; Tolerability Proportion; Toxicity Grading	Dana-Farber Cancer Institute; National Comprehensive Cancer Network	All	18 Years and older   (Adult, Older Adult)	25	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-540	31/01/2018	30/06/2024	30/06/2026			01/05/2018				01/10/2024	https://ClinicalTrials.gov/show/NCT03392246		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Lung	Non-Small Cell Lung Cancer	Selumetinib	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB11689	N
NCT00463814	AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies		Active, not recruiting	Tumor|Cancer	Drug: AZD6244	To assess the pharmacokinetics of the solid dose form of AZD6244; To assess safety and tolerability of solid dose form of AZD6244	AstraZeneca	All	18 Years to 99 Years   (Adult, Older Adult)	58	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D1532C00005; 2006-004497-26	03/08/2007	17/06/2008	29/12/2023			20/04/2007				17/10/2023	https://ClinicalTrials.gov/show/NCT00463814		Advanced/Metastatic	Company	N	N	N	United Kingdom	Multiple cancer types	Any solid tumours	Selumetinib	Safety and/or Dose	Phase 1	DB11689	N
NCT01933932	Assess Efficacy   Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC	SELECT-1	Active, not recruiting	Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV	Drug: Selumetinib; Drug: Docetaxel; Drug: Placebo; Drug: Pegylated G-CSF	Progression-Free Survival (PFS); Overall Survival (OS); Objective Response Rate (ORR); Duration of Response (DoR); Symptom Improvement Rate Using Average Symptom Burden Index (ASBI) of the Lung Cancer Symptom Scale (LCSS); Time to Symptom Progression Using Average Symptom Burden Index (ASBI) of the Lung Cancer Symptom Scale (LCSS)	AstraZeneca	All	18 Years to 130 Years   (Adult, Older Adult)	510	Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	D1532C00079; 2013-001676-38	25/09/2013	06/07/2016	29/12/2023			09/02/2013		29/08/2017		17/10/2023	https://ClinicalTrials.gov/show/NCT01933932	Palliative	Advanced/Metastatic; Recurrent/Refractory	Company	Y	N	N	United Kingdom	Lung	Non-Small Cell Lung Cancer	Selumetinib	Response rate; PFS; OS	Phase 3	DB11689	N
NCT02450656	Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer	M14AFS	Unknown status	Colorectal Neoplasms|Gastrointestinal Neoplasms|Pancreatic Neoplasms|Carcinoma, Non-Small-Cell Lung	Drug: Afatinib; Drug: Selumetinib; Drug: Docetaxel	Dose Limiting Toxicities (Phase I); Progression Free Survival (Phase II); Tolerability (Incidence and severity of adverse events per CTCAE v4.03); Plasma concentrations of afatanib and selumetinib; Efficacy (Phase II) (Overall response rate (ORR), duration of response (DOR) , time to response (TTR) and overall survival (OS) per RECIST v1.1)	The Netherlands Cancer Institute; AstraZeneca; Boehringer Ingelheim	All	18 Years and older   (Adult, Older Adult)	320	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M14AFS	06/01/2015	05/01/2019	12/01/2019			21/05/2015				27/08/2018	https://ClinicalTrials.gov/show/NCT02450656		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Netherlands	Lung	Non-Small Cell Lung Cancer	Selumetinib	Safety and/or Dose; Response rate; PFS	Phase 1/2	DB11689	N
NCT03801369	Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer		Recruiting	Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma	Procedure: Biopsy; Drug: Capivasertib; Drug: Ceralasertib; Biological: Durvalumab; Drug: Olaparib; Other: Quality-of-Life Assessment; Drug: Selumetinib	Objective response rate (ORR); Clinical benefit rate (CBR); Duration of response (DOR); Progression-free survival (PFS); Overall survival (OS); Incidence of grade 3+ acute toxicity	OHSU Knight Cancer Institute; AstraZeneca; Oregon Health and Science University	All	18 Years and older   (Adult, Older Adult)	132	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00018504; NCI-2019-00388	12/12/2018	31/12/2024	31/12/2027			01/11/2019				21/08/2023	https://ClinicalTrials.gov/show/NCT03801369		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	Y	N	United States	Breast	Breast Cancer - TNBC	Selumetinib	Response rate	Phase 2	DB11689	N
NCT03162627	Selumetinib and Olaparib in Solid Tumors		Active, not recruiting	Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands	Drug: Selumetinib; Drug: Olaparib	Maximum Tolerated Dose (MTD) for Combination of Selumetinib and Olaparib in Participants with Advanced or Recurrent Solid Tumors; Determination of Drug Concentration in Selumetinib and Olaparib; Comparison of Baseline Expression Values with Differing Treatment Responses of Selumetinib and Olaparib; Anti-Tumor Activity Evaluation by RECIST v1.1	M.D. Anderson Cancer Center; AstraZeneca	All	18 Years and older   (Adult, Older Adult)	90	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-1129; NCI-2018-01205	08/04/2017	30/08/2026	30/08/2026			22/05/2017				10/04/2023	https://ClinicalTrials.gov/show/NCT03162627		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	Y	N	United States	Multiple cancer types	Any solid tumours	Selumetinib	Safety and/or Dose	Phase 1	DB11689	N
NCT03581487	Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer		Recruiting	Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8	Biological: Durvalumab; Drug: Selumetinib; Biological: Tremelimumab	Maximum tolerated dose (MTD) (dose-escalation phase); Progression free survival time (PFS) (dose expansion phase); Response rate by Response Evaluation Criteria in Solid Tumors 1.1; Disease control rate (complete response + partial response + stable disease); Overall survival (OS); Incidence of adverse events	M.D. Anderson Cancer Center; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	40	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0888; NCI-2018-01098	04/01/2019	31/12/2024	31/12/2024			07/10/2018				18/11/2023	https://ClinicalTrials.gov/show/NCT03581487		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	Y	N	United States	Lung	Non-Small Cell Lung Cancer	Selumetinib	Response rate; PFS; OS	Phase 1/2	DB11689	N
NCT01364051	Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies		Active, not recruiting	Metastatic Melanoma|Refractory Malignant Solid Neoplasm|Stage IV Cutaneous Melanoma AJCC v6 and v7|Unresectable Malignant Solid Neoplasm	Drug: Cediranib; Drug: Cediranib Maleate; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Selumetinib; Drug: Selumetinib Sulfate	Maximum tolerated dose (MTD); Incidence of adverse events, classified as either possibly, probably, or definitely related to study treatment; Incidence of hematologic toxicities; Incidence of non-hematologic toxicities; Overall toxicity incidence; Best response	National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	19	NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02906; CDR0000700596; MC1012; NCI-2011-01083; 8810; P30CA015083; U01CA069912; UM1CA186686	25/05/2011	06/06/2019				06/02/2011				11/08/2023	https://ClinicalTrials.gov/show/NCT01364051		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Skin; Multiple cancer types	Melanoma; Any solid tumours	Selumetinib	Safety and/or Dose; Response rate	Phase 1	DB11689	N
NCT02393690	Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer		Active, not recruiting	Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7	Radiation: Iodine I-131; Other: Placebo Administration; Drug: Selumetinib	Response at 6 Months; Best Overall Response; Progression Free Survival (PFS); Changes in Serum Thyroglobulin Levels; Incidence of Adverse Events	Academic and Community Cancer Research United; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	60	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	RU241306I; NCI-2015-00277; 14-008494; P30CA015083	05/04/2015	17/07/2020	31/12/2023			19/03/2015		08/03/2021		02/02/2023	https://ClinicalTrials.gov/show/NCT02393690		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	United States	Endocrine	Thyroid Cancer	Selumetinib	Safety and/or Dose; Response rate; PFS; Biomarker	Phase 2	DB11689	N
NCT03213691	Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)		Active, not recruiting	Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma|Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Central Nervous System Neoplasm	Other: Laboratory Biomarker Analysis; Drug: Selumetinib; Drug: Selumetinib Sulfate	Response Rate; Percentage of Participants With Treatment-related Adverse Events as Accessed by Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.0; Progression Free Survival (PFS)	National Cancer Institute (NCI)	All	12 Months to 21 Years   (Child, Adult)	21	NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2017-01250; APEC1621E; U10CA180886	30/10/2017	30/06/2021	22/09/2024			07/11/2017		13/12/2022		12/04/2023	https://ClinicalTrials.gov/show/NCT03213691		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Lymphoma; Multiple cancer types	Non-Hodgkin Lymphoma, Childhood; Non-Hodgkin Lymphoma, Adult; Any solid tumours	Selumetinib	Safety and/or Dose; Response rate; PFS	Phase 2	DB11689	N
NCT05554328	Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial		Recruiting	Recurrent Endometrial Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma	Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration and Biopsy; Procedure: Computed Tomography; Procedure: Echocardiography; Procedure: Multigated Acquisition Scan; Drug: Olaparib; Drug: Selumetinib Sulfate	Progression-free survival (PFS); Incidence of adverse events (AE); Objective response rate (ORR) between two arms; ORR in crossover patients; Duration of response of both arms	National Cancer Institute (NCI); NRG Oncology	Female	18 Years and older   (Adult, Older Adult)	165	NIH; Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2022-06841; EAY191-N4; U10CA180868	25/04/2023	30/09/2024	30/09/2024			26/09/2022				01/02/2024	https://ClinicalTrials.gov/show/NCT05554328		Recurrent/Refractory	Collaborative Group	N	Y	N	United States	Gynaecological	Endometrial Cancer; Ovarian Epithelial Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer	Selumetinib	PFS	Phase 2	DB11689	N
NCT02151084	A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer		Active, not recruiting	Biliary Tract Carcinoma|Gallbladder Carcinoma	Drug: Selumetinib; Drug: Cisplatin; Drug: Gemcitabine	Change in tumor size in millimetres; Number of participants with objective response and/or stable disease; Percentage of patients without progressive disease; Progression-free survival in months; Overall survival in months; Total incidence of adverse events; Total rate of grade 3 and 4 toxicities	University Health Network, Toronto	All	18 Years and older   (Adult, Older Adult)	57	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BIL-MEK	11/01/2014	12/01/2023	02/01/2024			30/05/2014				18/06/2023	https://ClinicalTrials.gov/show/NCT02151084		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	Y	N	Canada	Urological; GI	Bladder Cancer; Cholangiocaricnoma	Selumetinib	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB11689	N
NCT03326310	Selumetinib and Azacitidine in High Risk Chronic Blood Cancers		Recruiting	Chronic Myeloid Leukemia|Myelofibroses	Drug: Azacitidine; Drug: Selumetinib	Number of patients with adverse events; Time to completion of next generation sequencing panel.; Rate of overall response.; Rate of symptom response.; Rate of overall survival.; Rate of progression free survival.	University of Chicago	All	18 Years and older   (Adult, Older Adult)	18	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB17-0774	09/04/2018	09/04/2023	09/04/2025			31/10/2017				29/08/2023	https://ClinicalTrials.gov/show/NCT03326310		Other (specify)	Hospital/University/Research Institute	N	N	N	United States	Leukemia; Other Haem-onc	Chronic Myelogenous Leukemia; Myelodysplastic Syndromes	Selumetinib	Safety and/or Dose; Response rate; PFS; OS	Phase 1	DB11689	N
NCT02143466	AZD9291 in Combination With Ascending Doses of Novel Therapeutics		Active, not recruiting	Advanced Non Small Cell Lung Cancer	Drug: Part A - AZD9291 in combination with AZD6094; Drug: Part A - AZD9291 in combination with continuous selumetinib (Asian subjects); Drug: Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects); Drug: Part A - AZD9291 in combination with intermittent selumetinib; Drug: Part A - AZD9291 in combination with MEDI4736; Drug: Part B - AZD9291 in combination with AZD6094; Drug: Part B - AZD9291 in combination with selumetinib; Drug: Part B - AZD9291 in combination with MEDI4736; Drug: Part C - AZD6094 monotherapy (Japan only); Drug: Part C - AZD9291 in combination with AZD6094 (Japan only); Drug: Part D - AZD9291 in combination with AZD6094	Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and Tolerability of AZD9291 when given in combination with AZD6094 or selumetinib; Number of participants with Adverse Events as a measure of Safety and Tolerability of AZD9291 when given in combination with AZD6094 or selumetinib; Cmax after single dosing; Tmax after single dosing; AUC after single dosing; AUC0-t after single dosing; AUC0-24 after single dosing; Terminal half life after single dosing; CL/f after single dosing; Volume of distribution after single dosing; Cssmax after multiple dosing; Tssmax after multiple dosing; Cssmin after multiple dosing; AUCss after multiple dosing; CLss/f after multiple dosing; Rac after multiple dosing; Time dependency of PK after multiple dosing; Objective response rate; Disease control rate; Duration of response; Percentage change in tumour size; Progression free survival; Overall survival	AstraZeneca	All	18 Years to 130 Years   (Adult, Older Adult)	344	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D5160C00006; 2016-004752-29	08/05/2014	03/04/2020	29/12/2023			21/05/2014				12/05/2023	https://ClinicalTrials.gov/show/NCT02143466		Advanced/Metastatic; Recurrent/Refractory	Company	N	Y	N	United States	Lung	Non-Small Cell Lung Cancer	Selumetinib	Safety and/or Dose	Phase 1	DB11689	N
NCT03944772	Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)	ORCHARD	Active, not recruiting	Non-Small Cell Lung Cancer	Drug: Osimertinib; Drug: Savolitinib; Drug: Gefitinib; Drug: Necitumumab; Drug: Durvalumab; Drug: Carboplatin; Drug: Pemetrexed; Drug: Alectinib; Drug: Selpercatinib; Drug: Selumetinib; Drug: Etoposide; Drug: Cisplatin; Drug: Datopotamab deruxtecan	Objective response rate (ORR); Progression-free survival (PFS); Duration of response (DoR); Overall survival (OS); Plasma concentrations of therapeutic agents; Incidence of Treatment-emergent adverse events (AEs) and serious adverse events (SAEs) as characterized and graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v5	AstraZeneca	All	18 Years to 130 Years   (Adult, Older Adult)	250	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D6186C00001; 2018-003974-29	25/06/2019	28/11/2025	28/11/2025			05/10/2019				01/08/2024	https://ClinicalTrials.gov/show/NCT03944772		Recurrent/Refractory	Company	Y	Y	N	United States	Lung	Non-Small Cell Lung Cancer	Selumetinib	Safety and/or Dose; Response rate; PFS; OS; Biomarker	Phase 2	DB11689	N
NCT05253131	Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas		Not yet recruiting	MPNST|NF1|Sarcoma	Drug: Selumetinib	Safety and Tolerability Selumetinib with BI; Safety and Tolerability of Durvalumab with Selumetinib and BI; Determine the Clinical Benefit of Selumetinib, BI and Durvalumab	University of Alabama at Birmingham; United States Department of Defense	All	18 Years to 99 Years   (Adult, Older Adult)	41	Other; U.S. Fed	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	300006373	15/06/2024	15/06/2029	15/06/2030			23/02/2022				01/09/2024	https://ClinicalTrials.gov/show/NCT05253131		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	Bone Sarcoma; Soft Tissue Sarcoma	Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma	Selumetinib	Safety and/or Dose; Other (specify)	Phase 1/2	DB11689	N
NCT02546661	Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer	BISCAY	Active, not recruiting	Muscle Invasive Bladder Cancer	Drug: AZD4547; Drug: MEDI4736; Drug: Olaparib; Drug: AZD1775; Drug: Vistusertib; Drug: AZD9150; Drug: Selumetinib	Module A: The frequency and nature of adverse events related to AZD4547 monotherapy.; Module A: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and oral AZD4547.; Module B: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and oral olaparib.; Module C: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral AZD1775.; Module D: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) monotherapy.; Module E: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral vistusertib.; Module F: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and intravenous AZD9150.; Module G: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral selumetinib.; All Modules: Change from baseline in clinical chemistry parameters.; All Modules: Change from baseline in haematology parameters.; All Modules: Change from baseline in urinalysis results.; All Modules: Change from baseline in vital signs.; All Modules: Change from baseline in physical examination findings.; All Modules: Change from baseline in ECG findings.; All Modules: Change from baseline in ejection fraction determined by assessing ECHO/MUGA scans.; All Modules: Change from baseline in coagulation parameters; All Modules: Change from baseline in lipid profile; Objective response rate (ORR); Disease control rate (DCR); Progression free survival (PFS); Duration of response (DoR); Overall survival (OS) rate at 1 year; Plasma concentration of AZD4547 (Module A); Plasma concentration of MEDI4736 (durvalumab) (Module A); Plasma concentration of olaparib (Module B); Plasma concentration of AZD1775 (Module C); Plasma concentration of MEDI4736 (durvalumab) (Module C); Plasma concentration of MEDI4736 (durvalumab) (Module D); Plasma concentration of vistusertib (Module E); Plasma concentration of Medi4736 (durvalumab) (Module E).; Plasma concentration of AZD9150 (Module F); Plasma concentration of MEDI4736 (durvalumab) (Module F).; The presence of Anti-Drug Antibodies (ADA) and ADA neutralising antibodies to MEDI4736 will be assessed in patients receiving MEDI4736 in any sub-study module.	AstraZeneca	All	18 Years to 130 Years   (Adult, Older Adult)	156	Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D2615C00001; GU 118; BISCAY; 2015-002228-25	10/03/2016	18/03/2020	28/06/2024			09/11/2015				12/11/2023	https://ClinicalTrials.gov/show/NCT02546661		Advanced/Metastatic	Company	N	Y	N	United States	Urological	Bladder Cancer	Selumetinib	Safety and/or Dose	Phase 1	DB11689	N
NCT02664935	National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer		Active, not recruiting	Non-Small Cell Lung Cancer|Carcinoma, Squamous Cell|Adenocarcinoma	Drug: AZD4547; Drug: Vistusertib; Drug: Palbociclib; Drug: Crizotinib; Drug: Selumetinib; Drug: Docetaxel; Drug: AZD5363; Drug: Osimertinib; Drug: Durvalumab; Drug: Sitravatinib; Drug: AZD6738	Objective response (OR); Progression-free survival time (PFS); Durable clinical benefit (DCB); Best percentage change in sum of target lesion diameters (PCSD); Time to Progression (TTP); Overall survival time (OS); Adverse Events (AE)	University of Birmingham; Cancer Research UK; AstraZeneca; Pfizer; Experimental Cancer Medicine Centres; Mirati Therapeutics Inc.	All	18 Years and older   (Adult, Older Adult)	423	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RG_14-072; 2014-000814-73; ISRCTN38344105	05/01/2015	09/01/2023	09/01/2023			27/01/2016				05/11/2023	https://ClinicalTrials.gov/show/NCT02664935		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	Y	N	United Kingdom	Lung	Non-Small Cell Lung Cancer	Selumetinib	Safety and/or Dose; Response rate; PFS; OS; Biomarker	Phase 2	DB11689	N
NCT01306045	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies		Active, not recruiting	Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic	Drug: AZD6244; Drug: MK-2206; Drug: Lapatinib; Drug: Erlotinib; Drug: Sunitinib; Procedure: Molecular Profiling	Percentage of Enrolled Participants Testing Positive for Genomic Abnormality; Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies; Percentage of Evaluable Participants Overall Response Rate (ORR) Based on the Drug Selected for Their Particular Profile; Frequency of Epidermal Growth Factor Receptor (EGFR) Germline Mutations in Families With High Susceptibility to Lung Cancer	National Cancer Institute (NCI); National Institutes of Health Clinical Center (CC)	All	18 Years and older   (Adult, Older Adult)	647	NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	110096; 11-C-0096	02/08/2011	02/12/2014	31/12/2024			03/01/2011		04/11/2023		04/11/2023	https://ClinicalTrials.gov/show/NCT01306045		Advanced/Metastatic	Hospital/University/Research Institute	N	Y	N	United States	Lung; Endocrine	Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Thymoma and Thymic Carcinoma	Selumetinib	Response rate; Other (specify)	Phase 2	DB11689	N
NCT02299999	SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer	SAFIR02_Breast	Active, not recruiting	Metastatic Breast Cancer	Drug: AZD2014; Drug: AZD4547; Drug: AZD5363; Drug: AZD8931; Drug: Selumetinib; Drug: Vandetanib; Drug: Bicalutamide; Drug: Olaparib; Drug: Anthracyclines; Drug: Taxanes; Drug: cyclophosphamide; Drug: DNA intercalators; Drug: Methotrexate; Drug: vinca alkaloids; Drug: Platinum based chemotherapies; Drug: Bevacizumab; Drug: Mitomycin C; Drug: Eribulin; Drug: MEDI4736	Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm; progression-free survival in patients treated with anti-PDL1 antibody (MEDI4736) compared to standard maintenance therapy arm; overall survival in each substudy; overall response rates and changes in tumor size in each substudy; evaluate safety, in each substudy; efficacy (response rate, change in tumor size, progression-free survival, overall survival) and safety of each individual targeted agent (substudy 1); correlate molecular characteristics in patients with the efficacy endpoints (response rate, progression-free and overall survival) in each substudy	UNICANCER; Fondation ARC; AstraZeneca	All	18 Years and older   (Adult, Older Adult)	1460	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UC-0105/1304; 2013-001652-36	04/07/2014	12/01/2022	12/01/2024			24/11/2014				01/10/2024	https://ClinicalTrials.gov/show/NCT02299999		Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	France	Breast	Any Breast Cancer	Selumetinib	Response rate; PFS; OS	Phase 2	DB11689	N
NCT02117167	SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients	SAFIR02_Lung	Completed	Non-small Cell Lung Cancer Metastatic	Drug: AZD2014; Drug: AZD4547; Drug: AZD5363; Drug: AZD8931; Drug: Selumetinib; Drug: Vandetanib; Drug: Standard maintenance for squamous NSCLC; Drug: Pemetrexed; Drug: Durvalumab; Drug: savolitinib; Drug: Olaparib	progression-free survival in the targeted drug arm compared to standard maintenance therapy arm; progression-free survival in patients treated with anti-PDL1 antibody (MEDI4736) compared to standard maintenance therapy arm; overall survival in each substudy; overall response rates and changes in tumor size in each substudy; evaluate safety, in each substudy; efficacy (response rate, change in tumor size, progression-free survival, overall survival) and safety of each individual targeted agent (substudy 1); correlate molecular characteristics in patients with the efficacy endpoints (response rate, progression-free and overall survival) in each substudy	UNICANCER; Intergroupe Francophone de Cancerologie Thoracique; Fondation ARC; AstraZeneca	All	18 Years and older   (Adult, Older Adult)	999	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UC-0105/1305 / IFCT 1301; 2013-001653-27	23/04/2014	22/12/2018	12/01/2023			17/04/2014				01/10/2024	https://ClinicalTrials.gov/show/NCT02117167		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	Y	N	France	Lung	Non-Small Cell Lung Cancer	Selumetinib	Response rate; PFS; OS	Phase 2	DB11689	N
NCT04348045	Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.	MAZEPPA	Active, not recruiting	Metastatic Pancreatic Adenocarcinoma	Drug: Arm A - Olaparib; Drug: ARM B - durvalumab plus selumetinib; Drug: ARM C FOLFIRI	ARM A - Progression free survival (PFS); ARM B/ C - PFS; Disease control rate (DCR); Overall response rate (ORR); Overall survival (OS); Number of participants with treatment-related adverse events; Time to HRQoL score definitive deterioration (TUDD)	GERCOR - Multidisciplinary Oncology Cooperative Group; AstraZeneca	All	18 Years and older   (Adult, Older Adult)	307	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MAZEPPA D19-02 PRODIGE-72	12/07/2020	07/12/2023	12/01/2024			15/04/2020				01/05/2024	https://ClinicalTrials.gov/show/NCT04348045		Advanced/Metastatic	Collaborative Group	Y	Y	N	France	GI	Pancreatic Cancer	Selumetinib	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB11689	N
NCT01089101	Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma		Active, not recruiting	Low Grade Glioma|Recurrent Childhood Pilocytic Astrocytoma|Recurrent Neurofibromatosis Type 1|Recurrent Visual Pathway Glioma|Refractory Neurofibromatosis Type 1|Refractory Visual Pathway Glioma	Procedure: Biospecimen Collection; Drug: Selumetinib	Maximum tolerated dose and recommended phase 2 dose of selumetinib determined by dose-limiting toxicities (phase I); Stratum-specific objective response (complete response + partial response) rate sustained for 8 weeks (phase II); Objective response (objective response = complete response + partial response) (re-treatment study); Disease stabilization rates (re-treatment study); Plasma drug concentrations and pharmacokinetic parameters (Phase I); Stratum-specific progression-free survival distribution (PFS) (phase II); Presence or absence of BRAF V600E mutations or BRAF KIAA1549 fusion (phase II); Progression-free survival (retreatment study)	National Cancer Institute (NCI)	All	3 Years to 21 Years   (Child, Adult)	220	NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03173; PBTC-029B; CDR667932; PBTC-029; U01CA081457; UM1CA081457	19/04/2010	12/01/2025	12/01/2025			18/03/2010				11/08/2023	https://ClinicalTrials.gov/show/NCT01089101		Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	United States	CNS	Glioma	Selumetinib	Safety and/or Dose; Response rate; Biomarker	Phase 1/2	DB11689	N
NCT04576117	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma		Suspended	Recurrent Low Grade Astrocytoma|Recurrent WHO Grade 2 Glioma|Refractory Low Grade Astrocytoma|Refractory Low Grade Glioma|Refractory WHO Grade 1 Glioma	Procedure: Biospecimen Collection; Procedure: Magnetic Resonance Imaging; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Selumetinib Sulfate; Drug: Vinblastine Sulfate	Maximum tolerated dose/recommended phase II dose (MTD/RP2D) of selumetinib and vinblastine combination (feasibility); Event-free survival (efficacy); Radiographic tumor response rate (efficacy); Overall survival (OS) (efficacy); EFS by BRAF Status; Incidence of adverse events (feasibility); Incidence of adverse events (efficacy); Quality of life (QOL); Visual outcome comparison	National Cancer Institute (NCI)	All	2 Years to 25 Years   (Child, Adult)	300	NIH	Interventional Study	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2020-07549; ACNS1931; U10CA180886	16/02/2021	30/12/2026	30/12/2026			10/06/2020				18/12/2023	https://ClinicalTrials.gov/show/NCT04576117	Palliative	Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioma	Selumetinib	Safety and/or Dose; OS; DFS/RFS/EFS	Phase 3	DB11689	N
NCT04166409	A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma		Recruiting	Low Grade Astrocytoma|Low Grade Glioma|Metastatic Low Grade Astrocytoma|Metastatic Low Grade Glioma	Procedure: Biospecimen Collection; Drug: Carboplatin; Procedure: Magnetic Resonance Imaging; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Selumetinib Sulfate; Drug: Vincristine Sulfate	Event-free survival (EFS); Radiographic tumor response rate; Overall survival (OS); Number of patients who experience an improvement in visual acuity (VA); Change in motor function; Change in quality of life (QOL); Processing speed function; Change in executive function	National Cancer Institute (NCI)	All	2 Years to 21 Years   (Child, Adult)	220	NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2019-07600; ACNS1833; U10CA180886	31/01/2020	31/12/2026	31/12/2026			18/11/2019				01/10/2024	https://ClinicalTrials.gov/show/NCT04166409	Primary/Main Curative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	CNS	Glioma	Selumetinib	Response rate; OS; DFS/RFS/EFS; QoL	Phase 3	DB11689	N
NCT01817751	Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma		Active, not recruiting	Glioblastoma|Recurrent Adult Brain Neoplasm|Malignant Glioma|WHO Grade III Glioma	Drug: sorafenib tosylate; Drug: valproic acid; Drug: sildenafil citrate	Number of Participants With 6-Month Progression Free Survival (PFS); Number of Participants Whose Tumors Express PDGFRa With and Without 6-Month PFS.; Number of Participants With Best Response of CR Plus Number of Participants With Best Response of PR.; Number of Participants Whose Tumors Express PDGFRa With Best Response of CR Plus Number of Participants Whose Tumor Expresses PDGFRa With Best Response of PR.; Number of Participants With 12-Month Progression Free Survival (PFS).; Number of Participants Whose Tumors Express PDGFRa With and Without 12-Month PFS.; Evaluation of Safety and Toxicity of Sorafenib, Valproic Acid, and Sildenafil	Virginia Commonwealth University; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	47	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-14816; HM14816; NCI-2013-00705; P30CA016059	04/11/2013	27/08/2020	30/10/2027			25/03/2013		28/10/2021		04/06/2023	https://ClinicalTrials.gov/show/NCT01817751		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Sildenafil; Valproic Acid	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00203; DB00313	N
NCT03324425	Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer	SIMPHONY	Recruiting	Breast Cancer Stage IV	Drug: Simvastatin 80mg	Objective Response; Clinical benefit; Duration of Response; Time to Progression; Number of treatment-related adverse events, as assessed by the National Cancer Institute Common Terminology Criteria v. 4.0 (CTCAE v. 4.0).; HMG-CoA Reductase and HMG-CoA Synthase 1 protein levels in baseline and post-treatment tumor biopsies	Baylor Breast Care Center	Female	18 Years and older   (Adult, Older Adult)	34	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H-41818	03/04/2020	12/01/2028	12/01/2030			27/10/2017				15/06/2023	https://ClinicalTrials.gov/show/NCT03324425		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Breast	Breast Cancer - HER2+	Simvastatin	Safety and/or Dose; Response rate; Biomarker	Phase 2	DB00641	N
NCT03086291	A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy		Unknown status	Stomach Cancer	Drug: Simvastatin	maximum tolerated dose	Samsung Medical Center	All	20 Years and older   (Adult, Older Adult)	9	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-02-138	01/04/2018	09/01/2020	12/01/2020			22/03/2017				30/12/2019	https://ClinicalTrials.gov/show/NCT03086291		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Korea, Republic of	GI	Gastric Cancer; Colon Cancer; Rectal Cancer	Simvastatin	Safety and/or Dose	Phase 1	DB00641	N
NCT05586360	T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer		Recruiting	Prostate Cancer	Drug: Simvastatin 40mg	Intra-prostatic YAP-mediated T-reg dysfunction in total tissue area; Intra-prostatic YAP-mediated T-reg dysfunction, limited to tumor infiltrating Tregs; Intra-prostatic YAP-mediated T-reg dysfunction, limited to T-regs in adjacent normal and stromal tissue; Intra-prostatic anti-tumor immune response	Medical University of South Carolina	Male	18 Years and older   (Adult, Older Adult)	36	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	103472	30/03/2024	02/01/2025	08/01/2025			19/10/2022				12/01/2023	https://ClinicalTrials.gov/show/NCT05586360		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Urological	Prostate Cancer	Simvastatin	Other (specify)	Phase 2	DB00641	N
NCT04457089	Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer		Recruiting	Recurrent Ovarian Cancer|Platinum-sensitive Ovarian Cancer	Drug: Simvastatin 40mg	Completion of the simvastatin intervention with at least 85  compliance; Response by CA125; Progression-free survival	Bobbie Jo Rimel, MD; Cedars-Sinai Medical Center	Female	18 Years and older   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT2020-03-Rimel-STOV	25/01/2021	01/01/2024	01/01/2025			07/07/2020				10/04/2023	https://ClinicalTrials.gov/show/NCT04457089		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian - Other	Simvastatin	PFS; Biomarker; Other (specify)	Phase 1	DB00641	N
NCT05550415	The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer		Recruiting	Triple Negative Breast Cancer|Chemotherapy Effect|Simvastatin Adverse Reaction	Drug: Simvastatin 40mg; Drug: Placebo	Vimentin Expression; Pathological Response; Clinical Response	Indonesia University	Female	18 Years and older   (Adult, Older Adult)	26	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IndonesiaU2022	19/08/2022	08/01/2024	02/01/2025			22/09/2022				26/09/2022	https://ClinicalTrials.gov/show/NCT05550415		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Indonesia	Breast	Breast Cancer - TNBC	Simvastatin	Biomarker	Phase 2	DB00641	N
NCT02161822	Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients		Unknown status	Adenocarcinoma of Rectum	Drug: simvastatin	pathologic complete response rate; rate of sphincter-sparing surgical procedure; rate of R0 resection; disease-free survival; overall survival; pattern of failure; safety and toxicity; lipid lowering effect of simvastatin	Samsung Medical Center	All	20 Years and older   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014-03-056	10/01/2014	12/01/2020	12/01/2020			06/12/2014				25/03/2020	https://ClinicalTrials.gov/show/NCT02161822		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Korea, Republic of	GI	Rectal Cancer	Simvastatin	Safety and/or Dose; Response rate; OS; Biomarker; Other (specify)	Phase 2	DB00641	N
NCT04985201	Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy		Unknown status	Small Cell Lung Cancer	Drug: Irinotecan; Drug: Simvastatin	Progression-free survival (PFS); Disease control rate (DCR); Overall response rate (ORR); Overall survival (OS); Number of participants with treatment-related adverse events (AE) as assessed by CTCAE v4.0	Shanghai Pulmonary Hospital, Shanghai, China; Chinese Academy of Sciences	All	18 Years to 75 Years   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020LY025	11/01/2021	12/01/2022	08/01/2023			08/02/2021				08/09/2021	https://ClinicalTrials.gov/show/NCT04985201		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	Lung	Small Cell Lung Cancer	Simvastatin	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00641	N
NCT04698941	Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy		Unknown status	Small Cell Lung Cancer	Drug: Albumin Paclitaxel; Drug: Simvastatin	Disease control rate (DCR); Overall response rate (ORR); Progression-free survival (PFS); Overall survival (OS); Number of participants with treatment-related adverse events (AE) as assessed by CTCAE v4.0	Shanghai Pulmonary Hospital, Shanghai, China; Chinese Academy of Sciences	All	18 Years to 75 Years   (Adult, Older Adult)	40	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020LY021	25/07/2021	30/12/2021	30/12/2022			01/07/2021				29/07/2021	https://ClinicalTrials.gov/show/NCT04698941		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Lung	Small Cell Lung Cancer	Simvastatin	Safety and/or Dose; Response rate; PFS; OS; Other (specify)	Phase 2	DB00641	N
NCT03454529	The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer		Completed	Invasive Breast Carcinoma|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7	Other: Laboratory Biomarker Analysis; Drug: Simvastatin	Change in Ki-67 Expression Assessed in Tumor Tissue by Immunohistochemistry	Michael Simon; National Cancer Institute (NCI); Barbara Ann Karmanos Cancer Institute	Female	19 Years and older   (Adult, Older Adult)	24	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-073; NCI-2018-00044; P30CA022453	03/09/2018	10/06/2021	10/06/2021			03/06/2018		08/01/2023		08/01/2023	https://ClinicalTrials.gov/show/NCT03454529		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Breast	Any Breast Cancer	Simvastatin	Biomarker	Phase 2	DB00641	N
NCT05464810	Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer		Recruiting	Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma|Invasive Breast Carcinoma	Drug: Letrozole; Drug: Simvastatin	Mean percentage change in Ki-67; Response per Ki-67; Change in the level of the following immune biomarkers: Percentage of CD8+ T cells, percentage of FOXp3 Treg cells, ratio of CD8+/Treg ratio; Patient-Reported Outcomes Measurement Information System (PROMIS) for pain; Incidence of adverse events	Emory University; National Cancer Institute (NCI)	Female	18 Years and older   (Adult, Older Adult)	40	Other; NIH	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	STUDY00004257; NCI-2022-02545; WINSHIP5524-22; P30CA138292	09/02/2022	15/04/2025	15/04/2025			19/07/2022				12/05/2023	https://ClinicalTrials.gov/show/NCT05464810		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Breast	Breast Cancer - ER/HR+	Simvastatin	Biomarker	Phase 1	DB00641	N
NCT02534376	Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal		Completed	Prostate Cancer	Drug: ezetimibe 10mg-simvastatin 40mg	Growth of Gleason grade 3 prostate cancer; Growth of benign prostate glands; Growth of high grade prostate cancer (e.g. Gleason grade 4/5)	Cedars-Sinai Medical Center; Roswell Park Cancer Institute	Male	18 Years and older   (Adult, Older Adult)	63	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Pro00040945	09/01/2015	28/02/2019	28/02/2019			27/08/2015				22/02/2023	https://ClinicalTrials.gov/show/NCT02534376		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Simvastatin	Response rate	Phase 1	DB00641	N
NCT01441349	Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer		Active, not recruiting	Small Cell Lung Carcinoma	Drug: IP chemotherapy; Drug: IP chemotherapy plus simvastatin	1-year survival rate; Tumor Response rate; Progression free survival; Toxicity profile	National Cancer Center, Korea	All	18 Years and older   (Adult, Older Adult)	192	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCCCTS-11-527	08/01/2011	31/10/2022	31/12/2022			27/09/2011				04/06/2022	https://ClinicalTrials.gov/show/NCT01441349		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	Lung	Small Cell Lung Cancer	Simvastatin	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00641	N
NCT05821556	Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients		Recruiting	Adenocarcinoma of the Pancreas	Drug: Valproic acid; Drug: Simvastatin 20mg; Drug: Gemcitabine 1000 mg; Drug: Nab paclitaxel; Drug: Cisplatin; Drug: Capecitabine	Progression Free Survival (PFS); Objective Tumor Response Rate (ORR); Duration of Objective response (DOR); Disease Control Rate (DCR); Overall Survival (OS); Overall toxicity rate; Quality of Life (QoL)	National Cancer Institute, Naples	All	18 Years and older   (Adult, Older Adult)	240	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VESPA; 1/23	06/12/2023	08/01/2025	06/01/2026			20/04/2023				15/06/2023	https://ClinicalTrials.gov/show/NCT05821556		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Italy	GI	Pancreatic Cancer	Simvastatin; Valproic Acid	PFS	Phase 2	DB00641; DB00313	N
NCT05947825	Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients		Not yet recruiting	PDAC - Pancreatic Ductal Adenocarcinoma	Drug: Combination of sitagliptin+ gemcitabine + nab-paclitaxel	Progression-free survival time; Objective Response Rate; Frequency of adverse events in the safety evaluable population; Median Overall Survival (mOS) of the treated population; Disease control rate (DCR)	Tianjin Medical University Cancer Institute and Hospital	All	18 Years and older   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sitagliptin plus AG-Tianjin	30/07/2023	08/01/2024	08/01/2024			17/07/2023				17/07/2023	https://ClinicalTrials.gov/show/NCT05947825		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	GI	Pancreatic Cancer	Sitagliptin	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB01261	N
NCT04410874	Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer	MUSIC-01	Unknown status	Non-melanoma Skin Cancer|Basal Cell Carcinoma|Squamous Cell Carcinoma	Biological: Imvamune	Maximum Tolerated Dose (MTD); Objective Tumor Response Rate (ORR); Viral load in NMSC tumours; Number of T cells/concentration of antigen specific antibodies	Ivan Litvinov; McGill University Health Centre/Research Institute of the McGill University Health Centre	All	18 Years and older   (Adult, Older Adult)	45	Other	Interventional Study	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-4599	16/11/2020	11/01/2022	07/01/2023			06/01/2020				12/01/2020	https://ClinicalTrials.gov/show/NCT04410874		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Canada	Multiple cancer types; Skin	Other multiple cancer group (specify); Basal Cell Carcinoma	Smallpox vaccine	Safety and/or Dose; Response rate; Biomarker	Phase 1/2	Not found in DrugBank	N
NCT03433781	A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations		Active, not recruiting	Myelodysplastic Syndromes	Drug: 50 gm CIVI/24 hours x 5 days every 4 week	Measure of serum bioavailability of Vitamin C in Myelodysplastic syndrome (MDS) patients with TET2 mutations	NYU Langone Health; Perlmutter Cancer Center	All	18 Years and older   (Adult, Older Adult)	4	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-00978	05/01/2018	07/01/2025	07/01/2026			15/02/2018				21/03/2023	https://ClinicalTrials.gov/show/NCT03433781		Other (specify)	Hospital/University/Research Institute	N	N	N	United States	Other Haem-onc	Myelodysplastic Syndromes	Ascorbic acid	Biomarker	Phase 1/2	DB00126	N
NCT05754684	Quadruple Immunotherapy for Neuroblastoma		Recruiting	Neuroblastoma Recurrent	Biological: Natural killer cell; Drug: Dinutuximab beta; Drug: Interleukin-2; Drug: Granulocyte-Macrophage Colony-Stimulating Factor; Drug: Spironolactone	Proportion of patients who have objective response in the tumor; Overall survival at 1 year; Progression-free survival; Proportion of patients who have tumor relapse; Number of patients who experience adverse events; Percentage of donor NK cells	Hong Kong Children's Hospital; The University of Hong Kong	All	up to 18 Years   (Child, Adult)	29	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HKCH-REC-2021-007	01/01/2022	31/12/2024	31/12/2025			03/06/2023				03/06/2023	https://ClinicalTrials.gov/show/NCT05754684		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Hong Kong	Other	Neuroblastoma	Spironolactone	Response rate	Phase 2	DB00421	N
NCT05580861	Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment	SALMA	Recruiting	Acute Myeloid Leukemia	Drug: Sulfasalazine	Dose Limiting Toxicity (for phase I part of the trial); Minimal Residual Disease (MRD)-negative Complete Response (for phase II part of the trial); Adverse events; Peak plasma concentration (Cmax) of Sulfazalazine; Time of peak plasma concentration (Tmax) of Sulfazalazine; Area under the plasma concentration versus time curve (AUC) for Sulfazalazine; Clearance (Cl) of Sulfazalazine; Mean residence time (MRT) of Sulfazalazine; Distribution volume (Vd/F) of Sulfazalazine; Plasma levels of malondialdehyde; Plasma levels of glutathione; Reactive Oxygen Species (ROS) levels of peripheral blood mononuclear cells; Response; Nucleophosmin (NPM1)-transcript based Minimal Residual Disease (MRD); Next-generation sequencing (NGS)-based Minimal Residual Disease (MRD); Event-free survival; Duration of response (DOR); Relapse-free survival; Overall survival; Incidence of subsequent allogeneic hematopoietic stem cell transplant; Targeted gene sequencing; SLC7A11 expression; Genotyping of ABCG2 rs2231142 polymorphisms; NAT2 genotype; RNA-based antioxidogram; Antioxidant score; Expression of NRF2 target genes	Assistance Publique - H pitaux de Paris	All	60 Years and older   (Adult, Older Adult)	64	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP211176	17/05/2023	11/01/2025	12/01/2026			14/10/2022				30/10/2023	https://ClinicalTrials.gov/show/NCT05580861		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	France	Leukemia	Acute Myeloid Leukemia, Adult	Sulfasalazine	Safety and/or Dose	Phase 1/2	DB00795	N
NCT02998736	Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy	PERIOP-04	Completed	Abdominal Cancer	Drug: Cialis; Biological: Influenza vaccine	Determine the change in the number of regimen limiting toxicities (RLT) in the experimental cohort; Document the change in the number and severity of CTCAE adverse events that are probably or definitely related to study treatment (tadalafil or influenza) in the experimental cohort.; Compare the reduction in Natural Killer cell killing as measured on PBMC collected on SD1 as compared to baseline between the control and experimental cohorts, using a standard Natural Killer cell killing assay (51Chromium release assay).	Ottawa Hospital Research Institute	All	18 Years and older   (Adult, Older Adult)	28	Other	Interventional Study	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	20160855-01H	21/11/2017	09/01/2022	10/01/2022			20/12/2016				28/12/2022	https://ClinicalTrials.gov/show/NCT02998736		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Canada	Multiple cancer types	Other multiple cancer group (specify)	Tadalafil	Safety and/or Dose; Biomarker	Phase 1	DB00820	N
NCT05014776	Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer		Recruiting	Pancreatic Cancer	Drug: Tadalafil; Drug: Pembrolizumab; Drug: Ipilimumab; Drug: CRS-207	Objective response rate (irORR) using immune Response Evaluation Criteria for Solid Tumors (iRECIST); Number of participants experiencing grade 3 or above drug-related toxicities	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Lustgarten Foundation; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	20	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J2180; IRB00291762; 5P01CA247886	22/08/2022	12/01/2024	12/01/2024			20/08/2021				09/05/2023	https://ClinicalTrials.gov/show/NCT05014776		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Tadalafil	Response rate	Phase 2	DB00820	N
NCT03993353	Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer		Active, not recruiting	Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Head and Neck Carcinoma|Head and Neck Cancer Stage III|Head and Neck Cancer Stage IV|Head and Neck Cancer Metastatic|Cancer|Cancer of Esophagus|Cancer, Metastatic|Cancer of Head and Neck|Cancer of Mouth|Cancer of Neck	Drug: Pembrolizumab; Drug: Tadalafil	Rate of Dose Limiting Toxicity (DLT); Overall Survival (OS); Response measured by RECIST 1.1; Progression free survival; Adverse event rates	University of California, San Diego	All	18 Years and older   (Adult, Older Adult)	6	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	190098	04/07/2020	12/01/2023	06/01/2024			20/06/2019				24/08/2023	https://ClinicalTrials.gov/show/NCT03993353		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Head and Neck	Any head and neck squamous cell carcinoma	Tadalafil	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB00820	N
NCT05709574	Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer		Recruiting	Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma	Drug: Tadalafil 20 MG	Evaluating the safety and tolerability of tadalafil treatment with FLOT chemotherapy by assessing the number of participants with treatment related adverse events usting CTCAE v. 5.0.; Pathological response after PDE5 inhibition and treatment using Becker's Criteria; Radiographic response after PDE5 inhibition and treatment based on RECIST1.1	University of Arizona	All	18 Years and older   (Adult, Older Adult)	10	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00001728	03/03/2023	03/01/2024	05/01/2025			02/02/2023				17/03/2023	https://ClinicalTrials.gov/show/NCT05709574		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	GI	Gastric Cancer	Tadalafil	Safety and/or Dose	Phase 2	DB00820	N
NCT04757662	Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma		Completed	Grade III Astrocytoma|Grade IV Astrocytoma|Astrocytoma, Grade IV|Astrocytoma, Grade III	Drug: Tadalafil	Relative change of MDSCs in peripheral blood; Frequency of adverse events as measured by CTCAE v5.0; Rate of severe lymphopenia; Progression-free survival (PFS); Overall survival (OS); Number of imaging changes on heterogeneity diffusion imaging (HDI)	Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)	18	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202103257	14/05/2021	06/07/2023	06/07/2023			17/02/2021				13/06/2023	https://ClinicalTrials.gov/show/NCT04757662		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	CNS	Astrocytoma	Tadalafil	Safety and/or Dose; PFS; OS; Biomarker; Other (specify)	Phase 1	DB00820	N
NCT03962920	Personalized Treatment of Urogenital Cancers Depends on the Microbiome		Recruiting	Microbial Disease	Drug: Tigecycline 50 MG; Other: Placebo	recurrence rate after surgical treatment of tumour	Zealand University Hospital	All	40 Years to 70 Years   (Adult, Older Adult)	28	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	ZUHURO	05/01/2020	05/01/2025	05/01/2027			24/05/2019				24/09/2021	https://ClinicalTrials.gov/show/NCT03962920		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Denmark	Multiple cancer types	Other multiple cancer group (specify)	Tigecycline	Recurrence rate	Other	DB00560	N
NCT04691817	Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy		Recruiting	Lung Cancer, Nonsmall Cell	Drug: Atezolizumab; Drug: Tocilizumab	Overall response rate (ORR); Overall survival (OS); Dose Limiting Toxicities of the combination; Progression free survival (PFS).	Abramson Cancer Center at Penn Medicine; Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	28	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UPCC 16520	25/07/2023	12/01/2025	09/01/2026			31/12/2020				28/07/2023	https://ClinicalTrials.gov/show/NCT04691817		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Lung	Non-Small Cell Lung Cancer	Tocilizumab	Safety and/or Dose; Response rate; PFS; OS	Phase 1/2	DB06273	N
NCT05846789	Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers		Recruiting	Metastatic Breast Cancer|Triple Negative Breast Cancer|Estrogen-receptor-low Breast Cancer	Drug: Carboplatin; Drug: Tocilizumab	Overall response rate; Efficacy of tocilizumab in Black and non-Black patients; Progression-free survival; Safety of carboplatin monotherapy compared to carboplatin combined with tocilizumab using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 5.0; Evaluate the differences in inflammatory pathways between Black and non-Black patients; Evaluate the impact of Duffy genotype on efficacy in Black patients	Kathy Miller; Genentech, Inc.; Indiana University	All	18 Years and older   (Adult, Older Adult)	168	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTO-IUSCCC-0817	01/01/2024	12/01/2026	12/01/2027			05/06/2023				19/12/2023	https://ClinicalTrials.gov/show/NCT05846789		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	United States	Breast	Breast Cancer - TNBC	Tocilizumab	Response rate	Phase 2	DB06273	N
NCT02767557	Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients	PACTO	Completed	Unresectable Pancreatic Carcinoma	Drug: Tocilizumab; Drug: Gemcitabine; Drug: nab-Paclitaxel	Overall survival at 6 months; Performance status at 3 and 6 months assessed by investigator; Performance status at 3 and 6 months, assessed by patient; Progression free survival (PFS), defined as the time from the date of randomization until the earliest date of disease progression; Overall survival (OS), defined as the time from the date of randomization until death due to any cause.; Overall response rate (ORR) (ORR = CR + PR), according to RECIST 1.1.RECIST 1.1; Disease control rate (DCR), (DCR = CR + PR + SD), according to RECIST 1.1.; Safety (Data on safety parameters) Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments.; Quality of Life (Quality of Life Questionnaire C30 (QLQ-C30) Version 3.0).	Herlev Hospital; Celgene	All	18 Years and older   (Adult, Older Adult)	147	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GI1612	26/01/2017	08/12/2021	01/01/2023			05/10/2016				22/09/2023	https://ClinicalTrials.gov/show/NCT02767557		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Denmark	GI	Pancreatic Cancer	Tocilizumab	Safety and/or Dose; Response rate; PFS; OS; QoL; Other (specify)	Phase 2	DB06273	N
NCT03821246	Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy		Recruiting	Prostate Adenocarcinoma|Prostate Cancer|Localized Prostate Cancer	Drug: Atezolizumab; Drug: Tocilizumab; Drug: Etrumadenant	Proportion of subjects who demonstrate a positive response to neoadjuvant atezolizumab and atezolizumab-based combination therapy for each Cohort of the study; Number of treatment-related of adverse events; Sum of Pathologic complete response (pCR) and Minimal residual disease (MRD) rate; Rate of Pathologic complete response (pCR) rate; Rate of Minimal residual disease (MRD); Prostate specific antigen (PSA) response	Lawrence Fong; Genentech, Inc.; University of California, San Francisco	Male	18 Years and older   (Adult, Older Adult)	68	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18702; NCI-2018-02805	30/10/2019	31/10/2024	31/10/2024			29/01/2019				10/12/2023	https://ClinicalTrials.gov/show/NCT03821246		Localised/Locoregional	Company	N	Y	N	United States	Urological	Prostate Cancer	Tocilizumab	Safety and/or Dose; Response rate; Biomarker	Phase 2	DB06273	N
NCT04940299	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma		Active, not recruiting	Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Locally Advanced Bladder Carcinoma|Locally Advanced Bladder Urothelial Carcinoma|Locally Advanced Lung Non-Small Cell Carcinoma|Locally Advanced Renal Pelvis Carcinoma|Locally Advanced Renal Pelvis Urothelial Carcinoma|Locally Advanced Ureter Urothelial Carcinoma|Locally Advanced Urethral Urothelial Carcinoma|Malignant Solid Neoplasm|Metastatic Bladder Carcinoma|Metastatic Bladder Urothelial Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Melanoma|Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Ureter Urothelial Carcinoma|Metastatic Urethral Carcinoma|Metastatic Urethral Urothelial Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Stage III Bladder Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Renal Pelvis Cancer AJCC v8|Stage III Ureter Cancer AJCC v8|Stage III Urethral Cancer AJCC v8|Stage IIIA Bladder Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Bladder Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IV Lung Cancer AJCC v6|Stage IV Renal Pelvis Cancer AJCC v8|Stage IV Ureter Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Unresectable Melanoma	Biological: Ipilimumab; Biological: Nivolumab; Biological: Tocilizumab	Incidence of dose limiting toxicity; Occurrence of one or more grade 3 or higher adverse event in a given patient (Cohort 1); Best overall response; Progression-free survival (PFS); Overall survival (OS)	M.D. Anderson Cancer Center	All	18 Years and older   (Adult, Older Adult)	35	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-1166; NCI-2021-04325	23/09/2021	31/12/2024	31/12/2024			25/06/2021				12/06/2023	https://ClinicalTrials.gov/show/NCT04940299		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Lung; Skin; Urological	Urethral Cancer; Non-Small Cell Lung Cancer; Melanoma; Bladder Cancer	Tocilizumab	Safety and/or Dose	Phase 2	DB06273	N
NCT04524871	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)		Recruiting	Advanced Liver Cancers	Drug: Atezolizumab; Drug: Bevacizumab; Drug: Tiragolumab; Drug: Tocilizumab; Drug: TPST-1120; Drug: RO7247669 2100 mg; Drug: RO7247669 600 mg; Drug: RO7247669 1200 mg dose; Drug: ADG126	Objective Response Rate (ORR); Progression Free Survival (PFS); Overall Survival (OS); OS at Specific Timepoints; Duration of Response (DOR); Disease Control; Percentage of Participants With Adverse Events During Stage 1; Percentage of Participants With Adverse Events During Stage 2	Hoffmann-La Roche; Adagene Inc; Tempest Therapeutics	All	18 Years and older   (Adult, Older Adult)	400	Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GO42216	11/02/2020	27/12/2025	27/12/2025			24/08/2020				01/09/2024	https://ClinicalTrials.gov/show/NCT04524871		Advanced/Metastatic	Company	N	Y	N	United States	GI	Liver Cancer	Tocilizumab	Safety and/or Dose; Response rate; PFS; OS; Other (specify)	Phase 1/2	DB06273	N
NCT03708224	Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck		Recruiting	Cancer|Carcinoma|Squamous Cell Carcinoma|Head and Neck Cancer	Biological: Atezolizumab; Biological: Tocilizumab; Biological: Tiragolumab	Proportion of subjects with a >= 40  increase in the cluster of differentiation 3 (CD3) counts; R0 resection rate; Changes in immune parameters using mass cytometry (CyTOF), histology and gene expression; Changes in peripheral immune responses using CyTOF; Number of participants with treatment-related adverse events	Alain Algazi; Genentech, Inc.; University of California, San Francisco	All	18 Years and older   (Adult, Older Adult)	55	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	177018; NCI-2018-01992; ML40180	03/08/2019	30/06/2027	30/06/2027			17/10/2018				17/01/2023	https://ClinicalTrials.gov/show/NCT03708224		Advanced/Metastatic	Company	N	Y	N	United States	Multiple cancer types	Other multiple cancer group (specify)	Tocilizumab	Safety and/or Dose; Response rate; Biomarker; Other (specify)	Phase 2	DB06273	N
NCT05207670	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies	MorningSun	Recruiting	Non-Hodgkin Lymphoma	Drug: Mosunetuzumab (Cohorts A-C); Drug: Mosunetuzumab (Cohorts D-E); Drug: Tocilizumab	Progression-free survival (PFS) rate at 24 months after the first study treatment (Cohorts A1, A2, and B); Objective response rate (ORR), defined as the proportion of participants with a complete metabolic response (CMR) or partial response (PR), as determined by the investigator according to the Lugano Criteria 2014 (Cohorts C, D, and E); Overall survival (OS) (all cohorts); ORR, defined as the proportion pf participants with a CMR or PR, as determined by the investigator according to the Lugano Criteria 2014 (Cohorts A1, A2, and B); Time to response (TTR) (all cohorts); Duration of response (DOR) (all cohorts); DOR for participants with best response of CMR (all cohorts); Duration of complete response (DoCR) (all cohorts); Time to next treatment (TTNT) (all cohorts); PFS (all cohorts); Percentage of participants with adverse events (AEs) (all cohorts); Serum concentration of mosunetuzumab (all cohorts)	Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	345	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML43389	02/01/2022	31/07/2028	31/07/2028			26/01/2022				01/05/2024	https://ClinicalTrials.gov/show/NCT05207670		Any/All Stages	Company	N	N	N	United States	Lymphoma	Follicular Lymphoma; Lymphoma - Other	Tocilizumab	Response rate; PFS; OS	Phase 2	DB06273	N
NCT05391750	Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma		Recruiting	Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma	Biological: Tocilizumab; Drug: Venetoclax	Maximum tolerated dose (MTD); Incidence of adverse events (AEs); Overall response rate (ORR); Complete response rate; Time to response (TTR); Time to disease progression (TTP); Duration of response (DOR); Progression-free survival (PFS); Overall survival (OS)	Emory University; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	72	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00002448; NCI-2021-02510; WINSHIP5273-21; P30CA138292	19/10/2022	02/12/2026	02/12/2026			26/05/2022				26/01/2023	https://ClinicalTrials.gov/show/NCT05391750		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Other Haem-onc	Multiple Myeloma	Tocilizumab	Safety and/or Dose	Phase 1	DB06273	N
NCT04729959	Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma		Suspended	Diffuse Astrocytoma, IDH-Wildtype|Recurrent Glioblastoma	Biological: Atezolizumab; Procedure: Biospecimen Collection; Procedure: Conventional Surgery; Radiation: Fractionated Stereotactic Radiation Therapy; Procedure: Magnetic Resonance Imaging; Biological: Tocilizumab	Dose-limiting toxicities (Safety Run-In); Maximum-tolerated dose (Safety Run-In); Objective radiographic response rate (Phase II, Non-Surgical Cohort); Progression-free survival (PFS) (Phase II, Non-Surgical Cohort); Overall survival (Phase II, Non-Surgical Cohort); Progression-free survival (Phase II, Non-Surgical Cohort); Overall survival (Phase II, Surgical Cohort); Incidence of adverse events (Surgical Cohort and Non-Surgical Cohort)	National Cancer Institute (NCI); NRG Oncology	All	18 Years and older   (Adult, Older Adult)	53	NIH; Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2021-00410; NRG-BN010; U10CA180868	03/11/2022	06/01/2025	06/01/2025			29/01/2021				01/11/2024	https://ClinicalTrials.gov/show/NCT04729959		Recurrent/Refractory	Hospital/University/Research Institute	N	Y	N	United States	CNS	Astrocytoma; Glioblastoma	Tocilizumab	Safety and/or Dose; PFS; OS; Other (specify)	Phase 2	DB06273	N
NCT04554771	Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy	BASALT	Active, not recruiting	Esophageal Adenocarcinoma|Oesophageal Adenocarcinoma|Resectable Carcinoma	Drug: Tocilizumab 20 Mg/mL Intravenous Solution; Drug: Paclitaxel; Drug: Carboplatin; Radiation: External beam radiotherapy	Efficacy defined as pathological response to chemoradiotherapy according to the Mandard criteria; R0 resection rate; Progression free survival; Overall survival; Interleukin 6- Signal Transducer and Activator of Transcription 3 (IL6-STAT3) pathway inhibition measured by gene expression analysis; IL6-STAT3 pathway inhibition measured by immunohistochemistry; Levels of ADAM12 in tumor biopsies and serum; Incidence and severity of toxicity; Incidence and severity of radiation toxicity; Incidence and severity of post-operative complications; Feasibility completion; Feasibility withdrawal rate; Feasibility delay	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Noordwest Ziekenhuisgroep	All	18 Years and older   (Adult, Older Adult)	41	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NL74310.018.20; 2020-002909-25	27/01/2021	05/01/2023	01/01/2024			18/09/2020				19/12/2022	https://ClinicalTrials.gov/show/NCT04554771		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	Netherlands	GI	Esophageal Cancer	Tocilizumab	Response rate; PFS; Biomarker; Other (specify)	Phase 2	DB06273	N
NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)		Active, not recruiting	Pancreatic Adenocarcinoma	Drug: Nab-Paclitaxel; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Leucovorin; Drug: Fluorouracil; Drug: Atezolizumab; Drug: Cobimetinib; Drug: PEGPH20; Drug: BL-8040; Drug: Selicrelumab; Drug: Bevacizumab; Drug: RO6874281; Drug: AB928; Drug: Tiragolumab; Drug: Tocilizumab	Percentage of Participants With Objective Response, as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1); Percentage of Participants With Adverse Events (AEs); Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1; Overall Survival; Percentage of Participants who are Alive at Month 6; Duration of Response, as Determined by Investigator According to RECIST v1.1; Percentage of Participants With Disease Control, as Determined by Investigator According to RECIST v1.1	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	340	Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WO39608; 2016-004126-42	07/05/2017	31/10/2025	31/10/2026			20/06/2017				24/11/2023	https://ClinicalTrials.gov/show/NCT03193190		Advanced/Metastatic	Company	Y	Y	N	United States	GI	Pancreatic Cancer	Tocilizumab	Safety and/or Dose; Response rate; PFS	Phase 1/2	DB06273	N
NCT03869190	Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)		Recruiting	Urothelial Carcinoma|Bladder Cancer	Drug: Atezolizumab; Drug: Enfortumab Vedotin; Drug: Niraparib; Drug: Magrolimab (Hu5F9-G4); Drug: Tiragolumab; Drug: Sacituzumab Govitecan; Drug: Tocilizumab; Drug: Cisplatin; Drug: Gemcitabine	Objective Response Rate (ORR) for mUC Cohort Stage 1; pCR for Muscle Invasive Bladder Cancer (MIBC) Cohorts; Progression Free Survival (PFS) for mUC Cohort Stage 1; Overall Survival (OS) for mUC Cohort Stage 1; Overall Survival (at specific time-points) for mUC Cohort Stage 1; Duration of Response (DOR) for mUC Cohort Stage 1; Disease Control Rate (DCR) for mUC Cohort Stage 1; Percentage of Participants with Adverse Events for mUC Cohort Stage 1; Serum Concentration of Atezolizumab for mUC Cohort Stage 2; Serum Concentration of Enfortumab Vedotin for mUC Cohort Stage 2; Serum Concentration of Sacituzumab Govitecan for mUC Cohort Stage 2; Presence of ADAs to Atezolizumab for mUC Cohort Stage 2; Percentage of Participants with Adverse Events for mUC Cohort Stage 2; Landmark Recurrence-Free Survival (RFS) for MIBC Cohorts; Landmark Event-Free Survival (EFS) for MIBC Cohorts; Landmark Overall Survival (OS) for MIBC Cohorts; Percentage of Participants with Adverse Events for MIBC Cohorts	Hoffmann-La Roche; Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas	All	18 Years and older   (Adult, Older Adult)	645	Industry; Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WO39613	06/01/2019	12/06/2024	27/11/2027			03/11/2019				01/08/2024	https://ClinicalTrials.gov/show/NCT03869190		Advanced/Metastatic	Company	Y	Y	N	United States	Urological	Bladder Cancer	Tocilizumab	Safety and/or Dose; Response rate; PFS; OS; Other (specify)	Phase 1/2	DB06273	N
NCT03999749	A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma		Active, not recruiting	Melanoma	Drug: Ipilimumab; Drug: Nivolumab; Drug: Tocilizumab	Antitumor activity of tocilizumab administered in combination with ipilimumab and nivolumab	NYU Langone Health	All	18 Years and older   (Adult, Older Adult)	75	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-00008	06/11/2019	07/01/2023	11/01/2024			27/06/2019				14/11/2023	https://ClinicalTrials.gov/show/NCT03999749		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Skin	Melanoma	Tocilizumab	Other (specify)	Phase 2	DB06273	N
NCT04034238	Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors		Completed	Neoplasms With Mesothelin Expression|Epithelioid Mesothelioma|Cholangiocarcinoma, Extrahepatic|Adenocarcinoma, Pancreatic	Drug: LMB-100; Drug: Tofacitinib; Device: Mesothelin Expression	Maximum Tolerated Dose (MTD) of LMB-100 With Tofacitinib; Percentage of Participants With Pancreatobiliary Cancer and LMB-100 Plasma Drug Levels Above Threshold 600ng/mL During Cycle 2 Who Received LMB-100 at Maximum Tolerated Dose; Number of Participants With Serious Adverse Events Possibly, Probably, and/or Definitely Related to LMB-100 Treated in the Dose Escalation Group; Percentage of Participants With LMB-100 Plasma Drug Levels Above Threshold 600ng/mL During Cycle 2 in Dose Escalation; Maximum Observed (Peak) Plasma Concentration (Cmax) of LMB-100; Percentage of Participants Without Delayed Formation of Neutralizing Anti-LMB-100 Anti-drug Antibodies (ADAs); Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUC(INF)) of LMB-100; Plasma Half-Life (T1/2) of LMB-100; Number of Participants With Serious Adverse Events Possibly, Probably, and/or Definitely Related to LMB-100 Who Have Pancreatobiliary Cancer	National Cancer Institute (NCI); National Institutes of Health Clinical Center (CC)	All	18 Years and older   (Adult, Older Adult)	19	NIH	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	190128; 19-C-0128	29/08/2019	12/01/2020	19/11/2021			26/07/2019		02/08/2022		08/01/2023	https://ClinicalTrials.gov/show/NCT04034238		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer; Cholangiocaricnoma	Tofacitinib	Safety and/or Dose	Phase 1	DB08895	N
NCT05326464	Tofacitinib in Recurrent GBM Patients		Recruiting	Glioblastoma	Drug: Tofacitinib 10mg	Progression-free survival (PFS) of the study cohort as defined by RANO criteria.; Overall survival (OS) of the study cohort.; Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].; Tumor response by RANO criteria.	University of Texas Southwestern Medical Center; Pfizer	All	18 Years and older   (Adult, Older Adult)	20	Other; Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STU-2021-1029	10/07/2022	06/01/2024	06/01/2026			13/04/2022				01/09/2024	https://ClinicalTrials.gov/show/NCT05326464	Palliative	Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Tofacitinib	Safety and/or Dose; Response rate; PFS; OS	Phase 3	DB08895	N
NCT03598959	Tofacitinib Combined With Chidamide in R/R ENKTCL		Unknown status	Extranodal NK/T-cell Lymphoma	Drug: tofacitinib; Drug: chidamide	2-year progression free survival; complete remission; adverse events (AEs); 2-year overall survival	Sichuan University	All	14 Years and older   (Child, Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HXNKT 2.0	01/01/2019	31/12/2019	31/12/2021			26/07/2018				26/07/2018	https://ClinicalTrials.gov/show/NCT03598959		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Lymphoma	Lymphoma - Other	Tofacitinib	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB08895	N
NCT05348213	Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma	R-ICE+X	Recruiting	Diffuse Large B Cell Lymphoma	Drug: Zanubrutinib plus R-ICE; Drug: Decitabine plus R-ICE; Drug: Chidamide plus R-ICE; Drug: Tofacitinib plus R-ICE; Drug: Pomalidomide plus R-ICE	Complete response rate after 3 cycle chemotherapy; 2 year overall survival; 2 year progression free survival; Objective remission rate after 3 cycle chemotherapy; Chemotherapy-related adverse reactions	Ruijin Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	76	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	R-ICE+X	16/05/2022	06/01/2024	06/01/2025			27/04/2022				23/12/2022	https://ClinicalTrials.gov/show/NCT05348213		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Lymphoma	Lymphoma - Other	Tofacitinib	Safety and/or Dose; Response rate; PFS; OS	Phase 2	DB08895	N
NCT05899465	Perioperative Treatment With Tranexamic Acid in Melanoma	PRIME	Recruiting	Melanoma	Drug: Tranexamic acid; Drug: Saline	Difference in rate of relapse within two years when comparing treatment arms; Incidence of treatment-related adverse events; Assessment of incidens of postoperative complications; Melanoma-specific survival; Overall survival; Relapse free survival	University of Aarhus; Aarhus University Hospital; Central Denmark Region	All	18 Years to 80 Years   (Adult, Older Adult)	1204	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	PRIME	25/08/2023	09/01/2026	09/01/2028			06/12/2023				13/11/2023	https://ClinicalTrials.gov/show/NCT05899465	Perioperative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Denmark	Skin	Melanoma	Tranexamic Acid	Safety and/or Dose; OS; DFS/RFS/EFS; Recurrence rate	Phase 3	DB00302	N
NCT05626829	Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma		Recruiting	Nasopharyngeal Carcinoma|Recurrent Cancer	Drug: Tranilast	the Effectiveness of Tranilast in reradiation of recurrent nasopharyngeal carcinoma; the Safety of Tranilast in reradiation of recurrent nasopharyngeal	Jian Guan; Nanfang Hospital, Southern Medical University	All	18 Years and older   (Adult, Older Adult)	18	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NFEC-2022-270	20/07/2022	20/07/2024	30/11/2024			25/11/2022				10/06/2023	https://ClinicalTrials.gov/show/NCT05626829		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Head and Neck	Nasopharyngeal Cancer	Tranilast	Response rate	Phase 2	DB07615	N
NCT02717884	Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)	TRANSATRA	Unknown status	Acute Myeloid Leukemia|Myelodysplastic Syndrome	Drug: tranylcypromine; Drug: all-trans retinoic acid; Drug: cytarabine	MTD determination of TCP in combination with fixed-dose of ATRA and with fixed-dose Cytarabine;; Objective best response; Overall survival (OS)	Michael Luebbert; University Hospital Freiburg	All	18 Years and older   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	00806 UKF	05/01/2015	12/01/2020	12/01/2021			24/03/2016				18/10/2018	https://ClinicalTrials.gov/show/NCT02717884		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Germany	Leukemia; Other Haem-onc	Acute Myeloid Leukemia, Adult; Myelodysplastic Syndromes	Tranylcypromine	Safety and/or Dose; Response rate; OS	Phase 1/2	DB00752	N
NCT03397706	Dose Escalation   Expansion Study of Oral VRx-3996   Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies		Completed	Epstein-Barr Virus Associated Lymphoma|Lymphoproliferative Disorders	Drug: VRx-3996; Drug: Valganciclovir	Incidence of adverse events and changes in clinical safety laboratory values in Dose Escalation and Cohort Expansion; Incidence of Dose Limiting Toxicities in Dose Escalation and Cohort Expansion; ORR as measured by stable disease (SD), partial response (PR), and complete response (CR) by radiographic assessment; Single-dose and steady-state Cmax of VRx-3996 and valganciclovir; Single-dose and steady-state AUC of VRx-3996 and valganciclovir; Steady-state elimination half-life of VRx-3996 and valganciclovir; Time to response; Duration of response; Progression-free survival	Viracta Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	67	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VT3996-201	29/03/2018	06/01/2023	06/01/2023			01/12/2018				06/05/2023	https://ClinicalTrials.gov/show/NCT03397706		Recurrent/Refractory	Company	N	N	N	United States	Multiple cancer types	Other multiple cancer group (specify)	Valganciclovir	Safety and/or Dose; Response rate	Phase 1/2	DB01610	N
NCT05431244	Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC)		Withdrawn	Gastric Cancer	Drug: Antiviral treatment in combination with low-dose gemcitabine	Objective Response Rate (ORR); Best Overall Response Rate (BOR)	Samsung Medical Center	All	20 Years and older   (Adult, Older Adult)	0	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2022-03-110	07/01/2022	07/01/2024	07/01/2024			24/06/2022				11/01/2022	https://ClinicalTrials.gov/show/NCT05431244		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Korea, Republic of	GI	Gastric Cancer	Valganciclovir	Response rate	Other	DB01610	N
NCT04116411	A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients	VIGAS2	Recruiting	Glioblastoma Multiforme	Drug: Valganciclovir Tablets; Drug: Temozolomide 120 mg; Radiation: Radiotherapy 60 Gy; Drug: Placebo oral tablet	Impact of valganciclovir on median overall survival of glioblastoma patients; Baseline and demographic data; Progression free survival at 12 and 24 months; Incidence of valganciclovir treatment related adverse events; Health related Quality of Life using EORTC QLQ30 module; Cognitive functions; Health related Quality of Life using the EORTC BN20 module	Cecilia Soderberg-Naucler; Karolinska University Hospital; Karolinska Institutet	All	18 Years and older   (Adult, Older Adult)	220	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Eudra CT: 2019-001083-30	09/04/2019	31/08/2024	31/08/2024			10/04/2019				13/09/2021	https://ClinicalTrials.gov/show/NCT04116411		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Sweden	CNS	Glioblastoma	Valganciclovir	Safety and/or Dose; PFS; OS; QoL	Phase 2	DB01610	N
NCT05011058	An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas	NAVAL-1	Recruiting	Epstein-Barr Virus Associated Lymphoproliferative Disorder|EBV-Related PTLD|EBV Related Non-Hodgkin's Lymphoma|EBV-Positive DLBCL, NOS|EBV Associated Lymphoma|EBV Related PTCL, NOS	Drug: Nanatinostat in combination with valganciclovir	Objective response rate (ORR); Duration of response (DOR); Time to next anti-lymphoma treatment (TTNLT); Progression-free survival (PFS); Time to progression (TTP); Overall survival; Incidence and severity of treatment-emergent adverse events; Pharmacokinetic parameter - time to maximum plasma concentration [tmax],; Pharmacokinetic parameter - maximum plasma concentration [Cmax]; Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC]	Viracta Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	140	Industry	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VT3996-202	28/05/2021	07/01/2025	12/01/2026			18/08/2021				01/08/2024	https://ClinicalTrials.gov/show/NCT05011058		Recurrent/Refractory	Company	N	N	N	United States	Lymphoma	Any lymphoma	Valganciclovir	Response rate	Phase 2	DB01610	N
NCT05595473	A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Hepatocellular Carcinoma		Recruiting	Hepatocellular Carcinoma	Drug: RZ-001 Dose 1; Drug: RZ-001 Dose 2; Drug: RZ-001 Dose 3; Drug: RZ-001 Dose 4	Number of participants with Dose limiting toxicities (DLT) in Part 1 as graded by NCI-CTCAE; To determine safety and efficacy of RZ-001 by changes in overall response rate (ORR) for participants in part 2 as graded by RECIST v1.1 and mRECIST; To determine safety and efficacy of RZ-001 by changes in duration of response (DOR) in part 2 as graded by RECIST v1.1 and mRECIST; To determine safety and efficacy of RZ-001 by changes in Progression free survial (PFS) of participants in part 2 as graded by RECIST v1.1 and mRECIST; To determine safety and efficacy of RZ-001 by changes in overall survival (OS) of participants in part 2 as graded by RECIST v1.1 and mRECIST; Number of participants with adverse events (AEs) in part 1 and 2 as graded by NCI-CTCAE; To determine safety and efficacy of RZ-001 by changes in overall response rate (ORR) of the partipants in Part 1 as graded by RECIST v1.1 and mRECIST; To determine safety and efficacy of RZ-001 by changes in duration of response (DOR) of the partipants in Part 1 as graded by RECIST v1.1 and mRECIST; To determine safety and efficacy of RZ-001 by changes in Progression free survial (PFS) of the partipants in Part 1 as graded by RECIST v1.1 and mRECIST; To determine safety and efficacy of RZ-001 by changes in overall survival (OS) of the partipants in Part 1 as graded by RECIST v1.1 and mRECIST	Rznomics, Inc.	All	18 Years and older   (Adult, Older Adult)	42	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RZ-001	29/07/2022	03/01/2029	05/01/2029			27/10/2022				27/10/2022	https://ClinicalTrials.gov/show/NCT05595473		Localised/Locoregional	Company	N	N	N	Korea, Republic of	GI	Liver Cancer	Valganciclovir	Safety and/or Dose; Response rate	Phase 1/2	DB01610	N
NCT03033225	Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study		Completed	Advanced Pancreatic Carcinoma|Locally Advanced Pancreatic Carcinoma|Metastatic Pancreatic Carcinoma|Pancreatic Neoplasm|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Pancreatic Carcinoma	Procedure: Endoscopic Ultrasound; Procedure: Fluorescence Imaging; Drug: Photodynamic Therapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Verteporfin	Tumor response	Mayo Clinic; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	13	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-001243; NCI-2019-07003; P30CA015083; P01CA084203	12/06/2016	20/09/2023	20/09/2023			26/01/2017				01/03/2024	https://ClinicalTrials.gov/show/NCT03033225		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Verteporfin	Response rate	Phase 2	DB00460	N
NCT04590664	Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma		Recruiting	Glioblastoma|Recurrent Glioblastoma	Drug: Verteporfin	Incidence of adverse events (Phase I); Progression free survival (PFS) (Phase II); Response rate (RR) (Phase II); Overall survival (Phase II); PFS (Phase I); RR (Phase I); Overall survival (Phase I); Visudyne blood levels (Phase I); Incidence of adverse events (Phase II)	Emory University; National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	24	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00000974; NCI-2020-05187; WINSHIP5070-20; P30CA138292	15/01/2021	15/08/2024	15/08/2025			19/10/2020				22/02/2023	https://ClinicalTrials.gov/show/NCT04590664		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	CNS	Glioblastoma	Verteporfin	Safety and/or Dose; Response rate; PFS; OS	Phase 1/2	DB00460	N
NCT03536208	Biological Effect of Warfarin on Pancreatic Cancer		Withdrawn	Pancreatic Cancer	Drug: Warfarin	Determine change in AXL pathway; Assess adverse events; Effect of warfarin on tissue markers; Antitumor effect	University of Texas Southwestern Medical Center	All	18 Years and older   (Adult, Older Adult)	0	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STU 022018-090	15/05/2019	06/01/2021	06/01/2022			24/05/2018				25/03/2021	https://ClinicalTrials.gov/show/NCT03536208		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Warfarin	Safety and/or Dose; Biomarker	Phase 1	DB00682	N
NCT04339140	Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer		Recruiting	Ovarian Cancer	Drug: Zafirlukast	CA-125 Response Rate; Plasma D-Dimer Response Rate	Beth Israel Deaconess Medical Center; National Institutes of Health (NIH); National Cancer Institute (NCI); Dana-Farber Cancer Institute	Female	18 Years and older   (Adult, Older Adult)	30	Other; NIH	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-814; 1R21CA231000-01A1	24/06/2020	31/12/2023	31/12/2024			04/09/2020				15/06/2023	https://ClinicalTrials.gov/show/NCT04339140		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Fallopian Tube Cancer; Primary Peritoneal Cancer; Ovarian Epithelial Cancer	Zafirlukast	Biomarker	Phase 2	DB00549	N
2008-001078-34	Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomide		Completed	Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomide	Drug: Viracept 250	Primary endpoints phase I: To determine the MTD of nelfinavir as an adjuvant in the radiochemotherapy treatment in primary glioblastoma patients by assessing the incidence of any grade 3 or higher non-haematological or grade 4 or higher haematological acute toxicity (according to CTCAE v3.0), excluding toxicities that can be expected from the standard treatment of concomitant radiotherapy with temozolomide.  Primary endpoints phase II: Progression free survival at 6 months	Maastro Clinic	All	Adult 18-64; Elderly 65+	57		-	Contolled|Randomised|Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001078-34/NL		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Netherlands	CNS	Glioblastoma	Nelfinavir	PFS	Phase 1/2	DB00220	N
2017-003028-59	Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study	ATC-Anakinra1	Ongoing	Anaplastic Thyroid Carcinoma	Drug: Kineret	Health Related Quality of Life (HR-QoL): defined as outcome of the QoL life questionnaire specifically designed for anaplastic thyroid cancer patients  Tumor dimensions/tumor progression: TNM classification and tumor size etc. This will be assessed using radiological examinations using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria .   Overall survival (OS): defined as time interval from date of official inclusion to death due to any cause.	Radboud University Medical Centre	All	Adult 18-64	10	Radboud University Medical Centre	-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003028-59/NL		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Netherlands	Endocrine	Thyroid Cancer	Anakinra	QoL; Other (specify)	Phase 4	DB00026	N
2014-005508-62	A phase II, randomized, non-comparative, pre-surgical study of atorvastatin or observation in Ki-67 positive, TAZ-expressing early breast cancer patients	TRINACRIA TRIAL	Ongoing	Early breast cancer	Drug: ATORVASTATINA	the rate of Ki-67 reduction below the 15 	ISTITUTI FISIOTERAPICI OSPITALIERI	Female	Adult 18-64	78	Istituto Regina Elena	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005508-62/IT		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Italy	Breast	Any Breast Cancer	Atorvastatin	Biomarker	Phase 2	DB01076	N
2016-001521-13	A PHASE II TRIAL OF LONG-TERM TREATMENT WITH AZITHROMYCIN IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA	MALT-A 1	Completed	MALT Lymphoma		Endpoint: Rate of objective responses (as judged by best response during the study period)  rarr; Clinical response measured according to standard criteria (RECIST 1.1, GELA)	Med. Univ. Wien	All	Adult 18-64	46		-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001521-13/AT		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Austria	Lymphoma	Lymphoma - Other	Azithromycin	Response rate	Phase 2	DB00207	N
2020-003152-33	A phase II trial of long-term intravenous treatment with bi-weekly Azithromycin in patients with gastric lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma)		Ongoing	gastric MALT Lymphoma	Drug: AZITHROMYCIN DIHYDRATE	Primary endpoint: rate of objective responses (as judged by best response during the study period)  rarr; Clinical response measured according to standard criteria (RECIST 1.1, GELA	Med. Univ. Wien	All	Adult 18-64	46		-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003152-33/AT		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Austria	Lymphoma	Lymphoma - Other	Azithromycin	Response rate	Phase 2	DB00207	N
2019-004074-25	A Phase II Open-Label Randomized COntrolled Pre-Surgical Feasibility Study of Antibiotic COmbinations in Early Breast Cancer	ABC2	Ongoing	We investigated, in a population of patients with breast cancer, the combined effect of azithrocyn, docyciclin and vitamin C on biomarkers associated with cell proliferation	Drug: Azitromicina; Drug: vitamina C; Drug: DOXICICLINA ICLATO	Reduction in Ki67 expression in post-treatment tumor samples compared to pre-treatment tumor core biopsies (from the same patient). Post-treatment samples will also be compared with untreated samples	AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA	Female	Adult 18-64; Elderly 65+	90	Lunella Biotech	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004074-25/IT		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Italy	Breast	Any Breast Cancer	Ascorbic acid; Azithromycin	Biomarker	Phase 2	DB00126; DB00207	N
2018-004505-34	A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10  / CBD 5 ) in patients with advanced untreatable hepatocellular carcinoma	Medicinal cannabisoil for untreatable HCC patients	Ongoing	The anti-tumoral effect of cannabis oil will be investigated in patients with untreatable HCC	Drug: Transvamix ; Drug: Cannabidiol	to study the anti-tumor effect of cannabis oil (THC10  / CBD5 ) in untreatable HCC patients by assessing tumor size at 6 months after starting treatment based on RECIST and mRECIST criteria	University Medical Center Groningen	All	Adult 18-64	20	Hubregste stichting	-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004505-34/NL		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Netherlands	GI	Liver Cancer	Cannabidiol	Response rate	Phase 2	DB09061	N
2019-001071-37	Open label, phase II, Proof of Concept study of neoadjuvant celecoxib in newly diagnosed patients with endometrial carcinoma Acronym: Celebrido	CELEBRIDO	Ongoing	Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery	Drug: Celecoxib	Decrease in the proportion of IDO1+ tumour cells by  ge;50 , and increase in the proportion of CD3+ T-cells infiltrating the tumor bed by  ge;50  following celecoxib treatment, as measured by immunostaining and computerized analysis of digitized histological images	Cliniques Universitaires Saint-Luc	Female	Adult 18-64	48		-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001071-37/BE		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Belgium	Gynaecological	Endometrial Cancer	Celecoxib	Biomarker	Phase 2	DB00482	N
2019-000572-41	An open label phase II study combining anti-PD-1 or PD-L1 and Celecoxib in patients with advanced  laquo; cold  raquo; solid tumors	NICE-COMBO	Ongoing	Indication of treatment with anti-PD1 antibodies such as  bull; Melanoma non BRAF mutated in first line of treatment  bull; Melanoma BRAF mutated in first or second line of treatment  bull; Lung cancer (NSCLC) in second line of treatment  bull; Renal cell Cancer (RCC) in second line of treatment  bull; Head and Neck squamous carcinoma (HNSC) after platinum salt based chemotherapy  bull; Bladder cancer after platinum salt based chemotherapy  bull; Endometrial carcinoma  bull; Squamous cell skin carcinoma  bull;Merkel cell carcinoma	Drug: CElecoxib	Overall response rate (ORR), defined as the percentage of subjects having a complete response (CR) or partial response (PR), as determined by investigator assessment of radiographic disease as per RECIST v1.1.	Cliniques Universitaires Saint-Luc	All	Adult 18-64	68		-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000572-41/BE		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Belgium	Skin; Lung; Urological; Head and Neck	Melanoma; Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Bladder Cancer; Any head and neck squamous cell carcinoma	Celecoxib	Response rate	Phase 2	DB00482	N
2006-004465-33	Oral Celecoxib combined with BCG instillation therapy in treatment of carcinoma in situ (CIS), TaG3 and T1 disease of urinary bladder		Ongoing	invasive bladder cancer	Drug: CELECOXIB; Placebo		Eero Kaasinen	All	Adult 18-64	300		-	Contolled|Randomised|Placebo|Double blind|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004465-33/FI		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Finland	Urological	Bladder Cancer	Celecoxib	Other (specify)	Phase 2/3	DB00482	N
2005-000717-35	COX-2-h auml;mmare och kemoterapi vid avancerad icke sm aring;cellig lungcancer.  En prospektiv randomiserad dubbel-blind studie.  Key elements: CYclooxygenase-2 inhibitor, Chemotherapy, LUng cancer, Survival (CYCLUS-studien)	CYCLUS-studien	Ongoing	Histologiskt eller cytologiskt veriferad icke sm aring;cellig lungcancer, stadium IIIB-IV, som inte kan behandlas med operation eller kurativt syftande str aring;lbehandling. WHO performance status 0-2. 	Drug: celecoxib; Placebo	Prim auml;r  auml;ndpunkt:  Ouml;verlevnad	Lungmedicinska kliniken	All	Adult 18-64	760		-	Contolled|Randomised|Placebo|Double blind												https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000717-35/SE	Adjuvant/Maintenance	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Sweden	Lung	Non-Small Cell Lung Cancer	Celecoxib	OS	Phase 3	DB00482	N
2006-004478-29	DOCETAXEL AND PREDNISON IN ASSOCIATION WITH METRONOMIC THERAPY WITH CICLOPHOSPHAMIDE AND CELECOXIN IN HORMONE-REFRACTORY PROSTATIC CANCER PATIENTS : PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC AND PHARMACOGENETIC EVALUATIONS	PROMET 2	Ongoing	PATIENTS WITH PROSTATIC HORMONE-REFRACTORY CANCER	Drug: Docetaxel; Drug: Prednisone	EVALUATION PFS	G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST	Male	Adult 18-64	45		-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004478-29/IT		Recurrent/Refractory	Collaborative Group	N	N	N	Italy	Urological	Prostate Cancer	Celecoxib	PFS	Phase 2	DB00482	N
2009-014772-22	Chloroquine as an anti-autophagy drug in small cell lung cancer (SCLC) patients: A phase I trial to be followed by a phase II trial.	chloroquine in SCLC	Ongoing	To determine the toxicity of adding chloroquine in escalating doses in SCLC patients  - to standard dose cisplatin-etoposide in extensive disease SCLC = STEP 1 - to standard dose concurrent radiotherapy and cisplatin-etoposide in limited disease SCLC = STEP2 	Drug: Chloroquine	Fase I, step 1 and 2: Toxicity (CTCAE 4.0) Fase II, step 1 : progression free survival Fase II, step 2: overall survival at 2 years	MAASTRO Clinic	All	Adult 18-64	225		-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014772-22/NL		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Netherlands	Lung	Small Cell Lung Cancer	Chloroquine	Safety and/or Dose; PFS; OS	Phase 1/2	DB00608	N
2013-004705-59	Monocentric phase III clinical trial using citalopram (antidepressive compound fequently used in clinic) added to the standard of care (radio- combined with temozolomide chemotherapy and followed by temozolomide) for newly diagnosed glioblastoma patients compared to the standard of care published in the literature	Phase III clinical trial using citalopram for glioblastoma patients	Ongoing	Newly diagnosed glioblastoma (primary highly malignant brain cancer) patients Under treatment	Drug: citalopram	could citalopram added to the standard of care increase quality of live and survival of glioblastoma patients	H ocirc;pital Erasme, ULB	All	Adult 18-64	50	Teva	-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004705-59/BE	Primary/Main Curative	Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Belgium	CNS	Glioblastoma	Citalopram	OS; QoL	Phase 3	DB00215	N
2006-005493-52	A pilot phase II study of digitoxin for Androgen-Independent Prostate Cancer (AIPC) 		Ongoing	Androgen-Independent Prostate Cancer	Drug: Digitoxin	The primary endpoint is the proportion of complete or partial responders as determined by repeated S-PSA assessments.	Division K K auml;rnsjukhuset	Male	Adult 18-64	30		-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005493-52/SE		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Sweden	Urological	Prostate Cancer	Digitoxin	Biomarker	Phase 2	DB01396	N
2016-000871-26	Studio di Fase II, randomizzato, in aperto, controllato di fattibilit iquest; dell iquest;impiego di doxiciclina nel tumore mammario in stadio precoce	NA	Ongoing	Breast cancer - Stage 1-2 to or Stage 3 that is candidate for primary surgery	Drug: BASSADO; Drug: DOXICICLINA ICLATO	Ki67 evaluation	AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA	Female	Adult 18-64	130	Fondazione Pisana per la Scienza	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000871-26/IT		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Italy	Breast	Any Breast Cancer	Doxycycline	Biomarker	Phase 2	DB00254	N
2019-004259-35	Ebastine in combination with docetaxel as a treatment for castration-resistant metastatic prostate cancer		Ongoing	Male patients with metastatic castration resistant prostate cancer	Drug: Kestine; Drug: Ebastin	Change in urine biomarkers; Bis(monoacylglycero)phosphate (BMP)	Rigshospitalet	Male	Adult 18-64; Elderly 65+	30	Danish Cancer Society	-	Contolled|Randomised|Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004259-35/DK		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	Denmark	Urological	Prostate Cancer	Ebastine	Biomarker	Phase 2	DB11742	N
2016-004004-60	Prospective study of anti-inflammatory therapy post interventional radiological treatment of HCC in the cirrhotic patient.	Rad-HCC	Ongoing	patients with HCC in the setting of cirrhosis	Drug: Arcoxia; Drug: Brufen; Drug: ETORICOXIB; Drug: IBUPROFENE	Serum levels of inflammatory cytokines  ndash; IL-6 and HGF at baseline and day 7 (pre-op and day 7 blood draws).	IRCCS ISTITUTO CLINICO HUMANITAS	All	Adult 18-64	48	IRCCS Istituto Clinico Humanitas	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004004-60/IT		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Italy	GI	Liver Cancer	Etoricoxib	Biomarker	Phase 2	DB01628	N
2018-004091-35	Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients	IMPROVE-NET trial	Ongoing	Neuroendocrine tumors	Drug: Hydralazine; Drug: Valproate	The percentage of patients that will have an uptake of 68Ga-DOTATATE in the tumor equal to or above that of the liver.	Erasmus University Medical Center	All	Adult 18-64	10	Erasmus Foundation	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004091-35/NL		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Netherlands	Endocrine	Neuroendocrine Tumours	Hydralazine; Valproic Acid	Biomarker	Phase 2	DB01275; DB00313	N
2011-004903-20	Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial	Hydroxychloroquine and erlotinib in NSCLC	Ongoing	Patients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC)   bull; with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy.   OR   bull; who failed after at least one line of platinum based doublet chemotherapy and who are EGFR TKI na iuml;ve.		The difference in metabolic activity of the tumor after one week of treatment as compared to the baseline value, measured with 18F-FDG PET using predefined PET response criteria.		All	Adult 18-64	136		-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004903-20/NL		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Netherlands	Lung	Non-Small Cell Lung Cancer	Hydroxychloroquine	Biomarker	Phase 2	DB01611	N
2011-006350-87	HydrOxychloRoqUine and Sorafenib in locally advanced or Metastatic Hepatocellular Carcinoma as First line therapy: a multi-center phase II trial	HORUS	Ongoing	ADVANCED HEPATOCELLULAR CARCINOMA	Drug: NA	 bull; Evaluation of clinical benefit	UNIVERSITA' CAMPUS BIOMEDICO	All	Adult 18-64	46	universita' campus bio-medico di roma	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006350-87/IT		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Italy	GI	Liver Cancer	Hydroxychloroquine	Other (specify)	Phase 2	DB01611	N
2010-022842-26	Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study 	HCQ TRIAL	Completed	proven invasive adenocarcinoma of the breast	Drug: Hydroxychloroquine	The primary objective is to assess differences in endogenous hypoxia markers (CA9, PAI-1, VEGF [Rademakers et al. 2008]) and autophagy (LC3b [Rouschop et al. 2010]) before and after treatment with HCQ. These parameters will be quantified by immunohistochemistry on formalin fixed paraffin embedded tissue from both pretreatment biopsy, and posttreatment surgically obtained material	University Medical Centre Nijmegen	All	Adult 18-64	20		-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022842-26/NL		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Netherlands	Breast	Any Breast Cancer	Hydroxychloroquine	Biomarker	Phase 2	DB01611	N
2021-004189-37	Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer	HCQHNLcancer	Ongoing	Patients affected by Resectable Head and Neck (HN) cancer (only Squamous Cell Carcinoma of the oral cavity or larynx), or Resectable Non-small cell lung cancer (NSCLC, only Lung Squamous Cell Carcinoma or Adenocarcinoma).	Drug: Idrossiclorochina Solfato	Immunohistochemical studies will be performed for known autophagic and immunological markers (CD3, CD8, CD163, p53, p62, LC3) with quantification of positivity / total cells, intensity, expression pattern.	OSPEDALE SAN RAFFAELE	All	Adult 18-64	20	Fondo di ricerca Oncologia medica OSR	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-004189-37/IT		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Italy	Head and Neck; Lung	Any head and neck squamous cell carcinoma; Non-Small Cell Lung Cancer	Hydroxychloroquine	Biomarker	Phase 2	DB01611	N
2021-001328-17	Histological and clinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1.	HITCLIF	Ongoing	Colorectal cancer and triple negative breast cancer patients (TNBC) who shown overexpression of fascin1 in the diagnostic biopsy tissue.	Drug: Imipramine; Placebo	Comparison of the histological traits of invasive tumour front of the surgical tumour resection specimen between the intervention group and the placebo group: 1. Fascin1 expression in tumour tissue: It will be analysed by immunohistochemistry and the application of Immunoscore. 2. Histological manifestations of the epithelial-mesenchymal transition (EMT): Tumour budding, cytoplasmic pseudo-fragments, infiltrating growth pattern and poorly differentiated nests. It will be evaluated by histological analysis. 3. Invasive histological manifestations: discontinuous extramural extension, lymphatic, venous and perineural infiltration. It will be evaluated by histological analysis. 4. Histological manifestation of the immune response: Peritumoral and intratumour lymphocyte infiltration. It will be evaluated by histological analysis. 5. EMT molecular manifestations: FSCN1, SNAIL and SLUG gene expression. It will be evaluated by NGS analysis of the primary tumour.	Fundaci oacute;n para la formaci oacute;n e investigaci oacute;n sanitarias de la Regi oacute;n de Murcia	All	Adult 18-64	180	ISCarlos III	-	Contolled|Randomised|Placebo|Double blind												https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001328-17/ES		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Spain	Breast; GI	Breast Cancer - TNBC; Colon Cancer; Rectal Cancer	Imipramine	Biomarker; Other (specify)	Phase 2	DB00458	N
2010-021962-31	KEES- A single arm phase II trial of the peroral regimen KEES (Ketokonazole, Etoposide, Estramustine, Sendoxan) in patients with Castration Resistant Prostate Cancer (CRPC) 	KEES- a phase II study in patients with CRPC	Ongoing	Men with castration resistant prostate cancer	Drug: ketoconazole; Drug: Estramustine; Drug: Cyclophosphamide; Drug: ETOPOSIDE	PSA response The proportion of patients with a PSA decline by  gt; 50 , compared to baseline value, within 12 weeks after 1st day of chemotherapy.	Bo Lennern auml;s	Male	Adult 18-64	40		-	Contolled|Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021962-31/SE		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Sweden	Urological	Prostate Cancer	Ketoconazole	Biomarker	Phase 2	DB01026	N
2012-003774-76	Perioperative ketorolac in high risk breast cancer patients with and without inflammation. A prospective randomized placebo-controlled trial.	KBC-trial	Completed	Breast cancer	Drug: KETOROLAC; Placebo	Consequently, our primary endpoint for this analysis was the metastasis-free survival time.	CUSL	Female	Adult 18-64	200	CUSL	-	Contolled|Randomised|Placebo|Double blind|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003774-76/BE	Perioperative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Belgium	Breast	Any Breast Cancer	Ketorolac	DFS/RFS/EFS	Phase 3	DB00465	N
2017-004634-28	A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY (MORPHEUS-mUC)		GB - no longer in EU/EEA	Urothelial carcinoma (UC)	Drug: isatuximab; Drug: niraparib; Drug: atezolizumab; Drug: tocilizumab; Drug: TIRAGOLUMAB	1. Objective response rate	F. Hoffmann-La Roche Ltd	All	Adult 18-64	385	F. Hoffmann-La Roche Ltd	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004634-28/GB		Advanced/Metastatic; Recurrent/Refractory	Company	Y	N	N	United States	Urological	Urethral Cancer	Tocilizumab	Response rate	Phase 2	DB06273	N
2018-004119-36	Altered tumor oxygenation by Metformin, a potential step in overcoming radiotherapy resistance in locally advanced cervical cancer.		Ongoing	Locally advanced cervical cancer	Drug: Glucophage	To determine if one week of metformin treatment can change tumor hypoxia-related gene expression signature	Oslo University Hospital	Female	Adult 18-64	90	Oslo University Hospital	-	Contolled|Randomised|Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004119-36/NO		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Norway	Gynaecological	Cervical Cancer	Metformin	Biomarker	Phase 2	DB00331	N
2014-000349-59	METAL (METformin in Advanced Lung cancer) study: PHASE II STUDY OF METFORMIN PLUS ERLOTINIB IN SECOND LINE THERAPY OF STAGE IV NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS		Ongoing	Patients with metastatic non small cell lung cancer in second line therapy	Drug: erlotinib	The study is a two-part trial, where a safety Run-in part of metformin combined with erlotinib will be followed by a Phase II part of metformin plus erlotinib. Primary objective of the safety run in part is to determine the MTD and the recommended Phase II dose of metformin combined with erlotinib as second-line treatmentin subjects with NSCLC harboringwild-type EGFR gene. Primaryobjective of the phase II part are:  bull; To assess the percentage of patientswithoutdiseaseprogressionat 10 weeks.  bull; To assess the median progression free survival of the second-line combination metformin and erlotinib in subjects with NSCLCharboring wild-type EGFR gene.	department of experimental and clinical medicine  F. Magrassi 	All	Adult 18-64; Elderly 65+	60	department of experimental and clinical medicine  F. Magrassi 	-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000349-59/IT		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Italy	Lung	Non-Small Cell Lung Cancer	Metformin	Safety and/or Dose	Phase 2	DB00331	N
2012-005050-35	Phase Ib/II study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced ovarian cancer		Ongoing	advanced ovarian cancer	Drug: carboplatin; Drug: Paclitaxel	Phase I: Recommended phase II dose based on dose-limiting toxicities and maximum tolerated dose of metformin in combination with carboplatin/paclitaxel.    Phase II: The primary end-point is objective response rate in patients with measureable disease and CA-125 response as defined by the Gynaecologic Cancer Intergroup (GCIG) for non-measurable disease. 	University Medical Center Groningen	Female	Adult 18-64	124	University Medical Center Groningen	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005050-35/NL		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Netherlands	Gynaecological	Ovarian Epithelial Cancer	Metformin	Safety and/or Dose; Response rate	Phase 1/2	DB00331	N
2014-005193-11	METformin And Longevity (METAL): A window of opportunity study investigating biological effects of metformin in localised prostate cancer	METAL	GB - no longer in EU/EEA	Prostate cancer	Drug: Metformin hydrocholride; Placebo	Assessment of the difference in expression levels of markers of the FASN/AMPK pathway pre and post treatment between the placebo and metformin arms.	King's College London	Male	Adult 18-64	105	JP Moulton Charitable Foundation	-	Contolled|Randomised|Placebo|Double blind												https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005193-11/GB		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United Kingdom	Urological	Prostate Cancer	Metformin	Biomarker	Phase 4	DB00331	N
2017-000722-35	Perioperative metformin treatment for colon cancer - a randomized trial	MECORA	Completed	Colon cancer	Drug: METFORMIN HYDROCHLORIDE; Placebo	The primary outcome is determination of the difference of the level of proliferation (Ki67 expression) after the intervention (time of surgery) adjusted for the level seen at baseline (time of colonoscopy). Another primary outcome is the difference in tumor infiltration CD3 and CD8 positive lymphocytes after the intervention adjusted for the level seen at baseline	Ismail G ouml;genur	All	Adult 18-64	48	Department of surgery, Slagelse Hospital	-	Contolled|Randomised|Placebo|Double blind												https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000722-35/DK		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Denmark	GI	Colon Cancer	Metformin	Biomarker	Phase 2	DB00331	N
2015-001001-14	 iquest;A randomized placebo controlled phase II study with metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence (MetBreCS) iquest;	MetBreCS	Ongoing	Metabolic-unbalanced breast cancer survivors at higher risk for recurrence (triple negative breast cancer, luminal B Her2 positive, non luminal HER2 positive)	Placebo	change of Ki-67 in contralateral unaffected breast	ISTITUTO EUROPEO DI ONCOLOGIA	Female	Adult 18-64	236	Ministero della salute - Ricerca corrente 2014	-	Contolled|Randomised|Placebo|Double blind|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001001-14/IT		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Italy	Breast	Breast Cancer - HER2+; Breast Cancer - TNBC	Metformin	Biomarker	Phase 2	DB00331	N
2006-006236-22	Use of Metformin to reduce serum level of Testosterone and improve the metabolic picture in women treated for breast cancer	Metformin and serum Testosterone in women with breast cancer	Ongoing	Menopausal women on treatment for BC, with higher risk of recurrence due to augmented level of T	Drug: Metformin	To define the smallest dose of Metformin able to reduce augmented serum level of Testosterone in women on treatment for breast cancer	AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA	Female	Adult 18-64	250		-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006236-22/IT		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Italy	Breast	Any Breast Cancer	Metformin	Safety and/or Dose	Phase 2	DB00331	N
2019-004916-76	A phase II study of nivolumab combined with metformin in pre-treated metastatic renal cell carcinoma (mRCC) patients.	NivoMet	Ongoing	Patients with advanced renal cell carcinoma pre-treated with VEGFR inhibitors.	Drug: Nivolumab	To evaluate the Progression-Free Survival (PFS) rate at 9 months of the combination of nivolumab plus metformin in mRCC patients previously treated with at least one anti-angiogenic therapy.	FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE	All	Adult 18-64	21		-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004916-76/IT		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Italy	Urological	Renal Cell Carcinoma	Metformin	PFS	Phase 2	DB00331	N
2009-017716-32	A phase II, randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib and metformin in patients with locally advanced and metastastatic pancreatic cancer	metformin and pancreatic cancer	Ongoing	locally advanced and metastatic pancreatic cancer	Drug: erlotinib; Drug: gemcitabine; Placebo	survival after 6 months	Academic Medical Center	All	Adult 18-64	120		-	Contolled|Randomised|Placebo|Double blind												https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017716-32/NL		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	Netherlands	GI	Pancreatic Cancer	Metformin	OS	Phase 2	DB00331	N
2015-004364-11	ENDOLA  A PHASE I/II TRIAL TO ASSESS THE SAFETY AND EFFICACY OF METRONOMIC CYCLOPHOSPHAMIDE, METFORMIN AND OLAPARIB IN RECURRENT ADVANCED/METASTATIC ENDOMETRIAL CANCER PATIENTS 	ENDOLA	Completed	- Patients with histologically and/or cytologically documented endometrial carcinoma (type I or type II), recurrent after platinum-based chemotherapy	Drug: Metformine; Drug: olaparib; Drug: CYCLOPHOSPHAMIDE	Safety including nature, number and grade of adverse events according to NCI-CTAE v.4 criteria in order to determine the phase 2 trial recommended dose (RP2D). RP2D is defined as the highest dose level at which less than 20  of patients experienced dose limiting toxicities during the first 6 week treatment.	Hospices Civils de Lyon	Female	Adult 18-64	36	Institut National du Cancer	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004364-11/FR		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	France	Gynaecological	Endometrial Cancer	Metformin	Safety and/or Dose	Phase 1/2	DB00331	N
2011-004683-30	A phase II study of sorafenib and metformin in patients with locally advanced and/or metastatic non-smal cell lung cancer (NSCLC) with a K-Ras mutation	Phase II study of combined treatment of sorafenib and metformin in NSCLC	Ongoing	Patients with advanced non small cell lung cancer that harbours a K-Ras mutation	Drug: nexavar; Drug: SORAFENIB	The main endpoint of the study is the rate of no progression at 6 weeks (NPR). This NPR is defined as the rate of subjects without progression (based on RECIST criteria) at 6 weeks after start of treatment	VU University Medical	All	Adult 18-64	64	Bayer Healthcare AG	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004683-30/NL		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Netherlands	Lung	Non-Small Cell Lung Cancer	Metformin	Other (specify)	Phase 2	DB00331	N
2009-014662-26	Phase II comparative study of Myocet plus Cyclophosphamide plus metformin versus Myocet plus Cyclophosphamide in first line treatment of HER2 negative metastatic breast cancer patients.	MYME	Ongoing	HER2 negative metastatic breast cancer patients	Drug: Doxorubicin; Drug: Cyclophosphamide	progression free survival	ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI	Female	Adult 18-64; Elderly 65+	112		-	Contolled|Randomised|Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014662-26/IT		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Italy	Breast	Breast Cancer - HER2-	Metformin	PFS	Phase 2	DB00331	N
2014-002602-20	CLINICAL AND TRASLATIONAL PHASE II STUDY OF LIPOSOMAL DOXORUBICIN PLUS DOCETAXEL AND TRASTUZUMAB WITH METFORMIN AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER.	met-HEReMYTA	Ongoing	OPERABLE AND LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER.	Drug: 3'-desosssi-3'-[F-18] fluorotimidina (FLT); Drug: NA; Drug: ND	Pathologic complete response rate (pCR).	ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI IRST - IRCCS	All	Adult 18-64	46	IRST-IRCCS	-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002602-20/IT		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Italy	Breast	Breast Cancer - HER2+	Metformin	Response rate	Phase 2	DB00331	N
2020-002468-30	Study of Metformin activity in patients with differentiated thyroid cancer metastasis with minimally progressive development	Metformin in patients with DTC	Ongoing	patients with differentiated thyroid cancer metastasis with minimally progressive development	Drug: Glucophage unidie 1000 MG	1) Progression-free survival (PFS); 2) Tg levels have been trending over time.	ENTE OSPEDALIERO OSPEDALI GALLIERA	All	Adult 18-64	20		-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002468-30/IT		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Italy	Endocrine	Thyroid Cancer	Metformin	PFS	Phase 2	DB00331	N
2011-000490-30	Phase II randomised, open-label, multicentric clinical trial of neoadjuvant treatment comprising chemotherapy and trastuzumab with or without metformin, in women with HER2/ErbB2 positive primary breast cancer.		Ongoing	Women with stage II-III, HER2/ErbB2-positive primary breast cancer elegible for neoadjuvant treatment.	Drug: METFORMINA HIDROCLORURO; Drug: TRASTUZUMAB	-Pathological Complete Response Rate (pCR) . Percentage of patients who present pathological complete response, defined as the absence of infiltrating carcinoma in resected materials and the axilla or the exclusive presence of in situ non-invasive cancer in resected material (number of patients with pCR)/(total patient numbers according to per protocol population) x 100	Institut Catal agrave; d'Oncologia	Female	Adult 18-64	178	Ministerio de Sanidad, Politica Social e Igualdad	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000490-30/ES		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Spain	Breast	Breast Cancer - HER2+	Metformin	Response rate	Phase 2	DB00331	N
2018-004385-34	Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced rectal cancer. A multi-arm, multi-stage, intergroup (STAR-04/SICO-CR01/GISCAD) randomised clinical trial.	NeoAspMet	Ongoing	LOCALLY ADVANCED RECTAL CANCER PATIENTS IN STAGE II/III	Drug: METFORMINA; Drug: XELODA	Primary endpoint is Good Pathological Response (GPR) defined as Tumour downstaging (ypT0 or ypT1) irrespective of the pathological N stage	ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE	All	Adult 18-64	340	Istituto Nazionale Tumori - Fondazione G.Pascale, IRCCS Napoli	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004385-34/IT		Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	Italy	GI	Rectal Cancer	Acetylsalicylic Acid; Metformin	Response rate	Phase 2	DB00945; DB00331	N
2018-000788-95	Exploiting metformin plus/minus cyclic FAsting Mimicking diet (FMD) to improve the Efficacy of platinum-pemetrexed chemotherapy in advanced LKB1-mutated lung adenocarcinoma: the FAME trial	FAME trial	Ongoing	Patients with LKB1-mutated advanced lung adenocarcinomas	Drug: METFORMINA	Progression-free survival (PFS)	FONDAZIONE IRCCS  ISTITUTO NAZIONALE DEI TUMORI 	All	Adult 18-64	88	AIRC 5x1000	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000788-95/IT		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Italy	Lung	Non-Small Cell Lung Cancer	Metformin	PFS	Phase 2	DB00331	N
2007-002608-16	A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in patients with high risk for recurrence and completely resected non-small-cell lung cancer: NVALT-8B	NVALT-8B	Ongoing	This is a randomized multicenter phase III study. Patient with a high SUVof the primary tumor prior to surgery will be randomised to four cycles of pemetrexed and cisplatin with or without nadroparin for 16 weeks in order to improve the recurrence-free survival rate in these patients.	Drug: Alimta	The main endpoint is recurrence-free survival	UMCG	All	Adult 18-64	600		-	Contolled|Randomised|Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002608-16/NL	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Netherlands	Lung	Non-Small Cell Lung Cancer	Nadroparin	DFS/RFS/EFS	Phase 3	DB08813	N
2009-009114-40	Impact de la technique anesth eacute;sique et analg eacute;sique sur le risque de r eacute;cidive biologique de cancer de la prostate	P eacute;ri-Prostate	Ongoing	prostate cancer	Drug: Naropeine; Drug: Propofol; Drug: Morphine	The primary endpoint is the biological recurrence (PSA) of prostate cancer.	Hopital Foch	Male	Adult 18-64	320		-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009114-40/FR	Perioperative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	France	Urological	Prostate Cancer	Propofol	Recurrence rate	Phase 3	DB00818	N
2022-001184-28	Perioperative Propranolol in Robotic Assisted Laparoscopic Prostatectomy - A Pilot Study  A parallel-group, phase 2, double-blind, 2-arm study to assess the feasibility of conducting a formal larger randomized controlled trial that compare perioperative treatment with propranolol capsules compared with placebo capsules to target perioperative stress induced cancer progression after robotic assisted laparoscopic prostatectomy in participants with European Association of Urology intermediate- and high-risk prostate cancer, aged 40 to 80 years. 	PeP-RALP	Ongoing	Prostate Cancer	Placebo	Numbers needed to screen  Compliance before RALP  gt;80  Compliance after RALP  gt; 80 	Oslo University Hospital	Male	Adult 18-64; Elderly 65+	40	Fondstiftelsen ved Oslo Universitetssykehus	-	Contolled|Randomised|Placebo|Double blind|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-001184-28/NO		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Norway	Urological	Prostate Cancer	Propranolol	Other (specify)	Phase 2	DB00571	N
2013-001096-20	ASSOCIATION BETWEEN PROTON-PUMP INHIBITORS (PPI) and METRONOMIC CAPECITABINE (mCAP) AS SALVAGE TREATMENT FOR PATIENTS WITH ADVANCED GASTRO-INTESTINAL TUMOURS: A RANDOMIZED PHASE II STUDY	metroCAP+PPI	Ongoing	Patients with gastrointestinal malignancies ineligible for conventional chemotherapy	Drug: Pariet; Drug: RABEPRAZOLE	1. 3-months progression-free survival (PFS).PFS is defined as the interval from the first dose of study drug to the date of the first documented disease progression or death for any reason, with censoring at the date of last contact for alive patients. 2. Safety (CTCAE v.4.03)	Department of Molecular and Clinical Medicine;  Sapienza  University of Rome	All	Adult 18-64	66	Department of Molecular and Clinical Medicine;  Sapienza  University of Rome	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001096-20/IT		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	Italy	GI	Any GI cancer	Rabeprazole	Safety and/or Dose; PFS	Phase 2	DB01129	N
2022-001989-36	Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy: a prospective phase II trial 	SIGN	Ongoing	gastroesophageal cancer	Drug: SERTRALINE HYDROCHLORIDE	The primary endpoint of this study is the rate of best responses per any timepoint during study period after administration of at least one cycle of immunochemotherapy defined as CR and PR according to RECIST 1.1 criteria	Med. Univ. Wien, Klinik f. Innere Med I, Onkologie	All	Adult 18-64	35		-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-001989-36/AT		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Austria	GI	Esophageal Cancer; Gastric Cancer	Sertraline	Response rate	Phase 2	DB01104	N
2007-001179-13	Neo-adjuvant Simvastatin therapy in colorectal cancer		Ongoing	Colorectal cancer	Drug: Simvastatin	Levels of BMP2 and 4 and phospho-Smad1 in surgical resection specimens. levels of apoptosis and proliferation in surgical resection specimens levels of angiogenesis in surgical resection specimens	Dutch Cancer Society	All	Adult 18-64	30		-	Contolled|Randomised|Single blind												https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001179-13/NL		Localised/Locoregional	Collaborative Group	Y	N	N	Netherlands	GI	Colon Cancer; Rectal Cancer	Simvastatin	Biomarker	Phase 2	DB00641	N
2009-014452-30	Safety and efficacy of the addition of simvastatin to panitumumab in k-ras mutant advanced or metastatic colorectal cancer patients. A single-arm, multicenter, phase II study using a Simon two stage design.  	RASTAT-P	Ongoing	k-ras mutant advanced or metastatic colorectal cancer failing prior 5FU, oxaliplatin and irinotecan containing regimens	Drug: vectibix	To investigate the percentage of patients with k-ras mutant advanced or metastatic colorectal cancer free from progression (according to RECIST 1.1) and alive after 11 weeks after the first dose of panitumumab (i.e., 12.5 weeks after the scan at baseline at start of simvastatin) in the presence of simvastatin.	Academisch ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum	All	Adult 18-64	46		-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014452-30/NL		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Netherlands	GI	Colon Cancer; Rectal Cancer	Simvastatin	PFS	Phase 2	DB00641	N
2010-018491-24	Effect of aminobisphosphonates and statins on circulating Vy9Vd2-T cells		Ongoing	patients with malignant bone metastases	Drug: simvastatin	1. Phenotypic (APC markers: CD1d, CD40, CD80, CD83, CD86, HLA-DR; activation/memory markers: CD25, CD27, CD45RA, CD45RO, CCR7)and functional (IFN- , TNF- , granzyme B) changes in the circulating pool of Vy9Vd2-T cells. 2. Occurrence of a febrile response.	Vrije Universiteit Medical Center	All	Adult 18-64	40		-	Contolled|Randomised|Placebo|Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018491-24/NL		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Netherlands	Multiple cancer types	Any solid tumours	Simvastatin	Biomarker	Phase 4	DB00641	N
2018-004826-27	A Single Center, Randomized, Phase II Study of the combination of Cisplatin and Gemcitabine with or without Tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic biliary tract cancer.	BILTRACTO	Ongoing	First-line treatment in patients with locally advanced or metastatic biliary tract cancer, inoperable due to extension of the disease. 	Drug: Cisplatin; Drug: TOCILIZUMAB	Overall survival rate at 12 months, the Kaplan-Meier estimate of proportion of patients that survived from the date of randomization by 12 months	Department of Oncology, Herlev  amp; Gentofte Hospital	All	Adult 18-64	166	Department of Oncology, Herlev  amp; Gentofte Hospital	-	Contolled|Randomised|Open|Parallel group												https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004826-27/DK		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Denmark	GI	Cholangiocaricnoma	Tocilizumab	OS	Phase 2	DB06273	N
2019-004438-40	Phase 2 study in pretreated patients with advanced pancreatic cancer to assess efficacy of ipilimumab, nivolumab and tocilizumab in combination with radiation.	TRIPPLE-R	Prematurely Ended	Pretreated patients with advanced pancreatic cancer.	Drug: Nivolumab; Drug: IPILIMUMAB	For PART A : ORR in all patients using Investigator assessments according to RECIST 1.1	Department of Oncology, Herlev  amp; Gentofte Hospital	All	Adult 18-64	30	Department of Oncology, Herlev  amp; Gentofte Hospital	-													https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004438-40/DK		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Denmark	GI	Pancreatic Cancer	Tocilizumab	Response rate	Phase 2	DB06273	N
CTRI/2021/09/037015	Evaluating the Efficacy of Pioglitazone in combination with Neoadjuvant Chemotherapy in Patients with Extremity Skeletal High-Grade Osteosarcoma Treated with Curative Intent: A Multi-centre, Randomized Phase II Clinical Trial		Not Yet Recruiting	Health Condition 1: C408- Malignant neoplasm of overlappingsites of bone and articular cartilage of limb	Intervention1: Pioglitazone will be combined with IAP chemotherapy: Tablet Pioglitazone (p.o) will be administered from day minus 5 of cycle 1 neoadjuvant chemotherapy to day plus 21 of cycle 3 neoadjuvant chemotherapy. Post-surgery, D-5 of cycle 4 up to D+21 of cycle 6 adjuvant chemotherapy<br>Control Intervention1: IAP chemotherapy regimen: Intravenous Ifosfamide 1.3g/m2 D1-3 <br>Intravenous Doxorubicin 50mg/m2 D1 <br>Intravenous Cisplatin 33mg/m2 D1-3 <br>q3weekly <br>3# IAP followed by surgery followed by 3# IAP <br>Duration of therapy- Around 22 weeks<br>	Rate of good responders (tumour necrosis greater than or equal to 90 Timepoint: Week 14	Cancer Institute WIA	-	-	50	Cancer Institute (WIA) funds	Interventional Study	Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Outcome Assessor Blinded		15/10/2021				30/09/2021					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=60852		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Bone Sarcoma	Osteosarcoma	Pioglitazone	Response rate	Phase 2	DB01132	N
CTRI/2021/06/034467	Effect of Ketorolac of VEGF and TGF-B release in breast cancer resection surgery.		Not Yet Recruiting	Health Condition 1: C509- Malignant neoplasm of breast of unspecified site	Intervention1: IV ketorolac: Group 1   ?? will receive intravenous (I.V.) ketorolac Dose - 30 mg, single dose just before incision.  <br><br>Control Intervention1: Group 2 - saline placebo: will receive 1 ml saline as placebo/comparator. Dose - 1 ml, single dose, both drug and saline will be provided in identical 2 ml syringe in opaque sealed envelope.<br>	1) Evaluate the effect of single dose of perioperative ketorolac 30 mg (given before incision) on levels of marker predictive of tumour spread and metastasis   ?? VEFF. <br/ ><br>2) To evaluate the effect of Ketorolac on other markers of tumour spread i.e. TGF-    , NLR and PLR (platelet lymphocyte ratio) in patients undergoing curative breast cancer resection.  <br/ ><br>Timepoint: baseline - before incision <br/ ><br>intaroperative - after tumour resection <br/ ><br>post-operative - 24 hours after surgery <br/ ><br>	All India Institute of Medical Sciences	-	-	100	All  India Institute of Medical Sciences, New Delhi	Interventional Study	Randomized, Parallel Group, Placebo Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant and Investigator Blinded		09/07/2021				30/06/2021					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48513		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Breast	Any Breast Cancer	Ketorolac	Biomarker	Not available/Missing	DB00465	N
CTRI/2020/06/026240	Effects of Mebendazole to Lenvatinib (drug) in liver cancer		Open to Recruitment	Health Condition 1: K769- Liver disease, unspecified	Intervention1: Lenvatinib and Mebendazole: Lenvatinib<br>Dose:8 mg if body weight is less than 60 kg and 12 mg if body weight is more than 60 kg<br>frequency:once a day <br>route of administration: oral  <br>duration of therapy:15 months<br><br>Mebendazole<br>Dose:100 mg<br>frequency: twice a day <br>route of administration: oral  <br>duration of therapy:15 months<br>Intervention2: Lenvatinib and Mebendazole: Lenvatinib will be given orally once a day (OD) at dose of 8 mg if body weight is  60 kg and 12 mg if body weight is  60 kg) and mebendazole will be given at dose of 100 mg orally twice a day (BD) daily<br>Control Intervention1: Lenvatinib with Placebo: Lenvatinib<br>Dose:8 mg if body weight is less than 60 kg and 12 mg if body weight is more than 60 kg<br>frequency:once a day <br>route of administration: oral  <br>Duration of therapy: 15 months<br><br>Placebo (Tab Mecovit) <br>Dose:Placebo <br>Frequency: twice daily<br>route of administration: Oral  <br>Duration of therapy:15 months<br><br>	1) Overall survival in both groups <br/ ><br>2) Death <br/ ><br>3) Progressive disease requiring change of therapy in both groups.Timepoint: 15 months	Institute of Liver and Biliary Sciences	-	-	170	Institute of Liver   Biliary Sciences,D-1, Vasant KunjNew Delhi-110070	Interventional Study	Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Permuted block randomization, variable  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Open Label		06/07/2020				30/06/2020					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44747		Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	India	GI	Liver Cancer	Mebendazole	Response rate; OS	Not available/Missing	DB00643	N
JPRN-jRCT2031190065	Investigator initiated registrational trial of Metformin for atypical endometrial hyperplasia and endometrial carcinoma		Not Recruiting	atypical endometrial hyperplasia and endometrial carcinoma <br>endometrial carcinoma;endometrial carcinoma	Randomization to 3 group and administration of study drug (Metformin);Metformin	The three-year disease-free survival rate	Mitsuhashi Akira	Female	>= 18age old - <= 42age old	138	Japan Agency for Medical Research and Development	Interventional Study	randomized controlled trial, open(masking not used), dose comparison control, parallel assignment, treatment purpose		25/09/2019				30/07/2019					17/10/2023	https://jrct.niph.go.jp/latest-detail/jRCT2031190065		Localised/Locoregional	Hospital/University/Research Institute	Y	Y	N	Japan	Gynaecological	Endometrial Cancer	Metformin	DFS/RFS/EFS	Not available/Missing	DB00331	N
CTRI/2021/09/036956	Pioglitazone in Patients with Recurrent/ Refractory Inoperable High-Grade Osteosarcoma		Not Yet Recruiting	Health Condition 1: C408- Malignant neoplasm of overlappingsites of bone and articular cartilage of limb	Intervention1: Pioglitazone: Dose of tablet Pioglitazone (per oral): <br>Age: 14-17 years- 15 mg twice daily <br>18 years and above- 15 mg thrice a day <br>If there is a response, pioglitazone can be continued at the same dose until disease progression, treatment toxicities or patient refusal.    <br><br>Control Intervention1: Not applicable: Not applicable<br>	Clinical and radiological response assessmentTimepoint:   ?  For every patient recruited in the study, response will be assessed at 3-months (Thereafter, at 3-monthly intervals until disease progression/ treatment discontinuation or death.)	Cancer Institute WIA	-	-	10	None	Interventional Study	Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable		15/10/2021				29/09/2021					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=60703		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	India	Bone Sarcoma	Osteosarcoma	Pioglitazone	PFS	Not available/Missing	DB01132	N
JPRN-jRCTs051190076	Neo-adjuvant combination  chemotherapy of Tranilast in esophageal carcinoma		Recruiting	advanced esophageal squamous cell carcinoma <br>Esophageal Squamous Cell Carcinoma;Esophageal Squamous Cell Carcinoma;Esophageal Squamous Cell Carcinoma	The additional use of tranilast to conventional neoadjuvant chemotherapy (5-FU/CDDP) for advanced esophageal squamous cell carcinoma patients	Pathological therapeutic effect	Shiozaki Atsushi	All	>= 20age old - <= 74age old	59		Interventional Study	single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose		14/11/2019				29/11/2019					17/10/2023	https://jrct.niph.go.jp/latest-detail/jRCTs051190076		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Japan	GI	Esophageal Cancer	Tranilast	Response rate	Phase 1/2	DB07615	N
DRKS00014054	Pancreatic resection with perioperative off-Label study of Propranolol and Etodolac - A Phase II randomized Trial		Other	;C25.0 - Malignant neoplasm: Head of pancreas	Intervention 1: Propranolol 2x20 mg/day, p. o.: 10 days before surgery; Propranolol 2x40 mg/day, p.o.: day of  surgical intervention and 1st day until 7th day after operation; Propranolol 2x20 mg/day, p. o.: 8th until 14th day postoperative.<br>Etodolac 2x400 mg/day p. o., 10 days before surgery until 14th day postoperative Intervention 2: Placebo with similar shape compared to Propranolol 2x1/day, p. o.: 10 days before surgical intervention; 2x2/day p.o.: Day of Operation, and 1st to 7th day postoperative;  <br>2x1/day, p. o.: 8th to 14th day postoperative.<br>Placebo with similar shape compared to Etodolac 2x1/day p. o., 10 days before operation until 14th day postoperative.	Safety endpoints:<br> € Rates of serious adverse events and serious adverse drug re-actions<br> € Mortality at 30 and 90 days postoperatively<br> € Pancreas-associated morbidity (Pancreatic fistula, delayed gas-tric emptying, postoperative pancreatic hemorrhage, biliary leakage, fluid collection/abscess)<br><br>Feasibility endpoints:<br> € Adherence to study medication<br> € Completion of adjuvant chemotherapy	Universit  tsklinikum Heidelberg	All	18 Years - no maximum age	100	Het Anti-Kankerfonds;Klinik f  r Allgemein-, Viszeral-und TransplantationschirurgieUniversit  tsklinikum Heidelberg	Interventional Study	Allocation: Randomized controlled trial;. Masking: Blinded (patient/subject, investigator/therapist, caregiver, assessor). Control: Placebo. Assignment: Parallel. Study design purpose: Treatment;	2018-000415-25;AFmo-385/2018	23/01/2019				29/08/2018					14/11/2022	http://www.drks.de/DRKS00014054		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Germany	GI	Pancreatic Cancer	Etodolac; Propranolol	Safety and/or Dose	Phase 2	DB00749; DB00571	N
CTRI/2021/12/038966	Effect of anaesthetic technique on the recurrence of breast cancer after surgery.		Not Yet Recruiting	Health Condition 1: C509- Malignant neoplasm of breast of unspecified site	Intervention1: Total intravenous anaesthesia combined with fascial plane blocks: TIVA with propofol infusion combined with PEC1 and SAM block   <br>inj fentanyl 1 mcg/kg intravenous.<br>inj propofol 25-100 mcg/kg/min intravenous till end of surgery.<br>PEC1 block USG guided with 10 ml of inj bupivacaine 0.5  in fascial plane<br>SAM block with 20 ml of 0.5  inj bupivacaine in fascial plane<br><br>Control Intervention1: inhalational anaesthesia: inj fentanyl 1-2mcg/kg intravenous<br>Sevoflurane based inhalation anaesthesia (0-2 ) to maintain MAC of 1<br>	1) Recurrence of breast cancer (loco-regional or distant) <br/ ><br>2) Recurrence free survival <br/ ><br>Timepoint: two years <br/ ><br>	nil	-	-	180	Homi Bhabha Cancer Hospital and Research Centre, Punjab	Interventional Study	Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Outcome Assessor Blinded		31/12/2021				28/12/2021					21/02/2022	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=60001		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Breast	Any Breast Cancer	Propofol	DFS/RFS/EFS	Not available/Missing	DB00818	N
CTRI/2018/11/016459	Role of lipid lowering drug in the treatment of rectal cancers		Not Yet Recruiting	Health Condition 1: K628- Other specified diseases of anus and rectum	Intervention1: Rosuvastatin in addition to Neo-adjuvant Chemoradiotherapy: Rosuvastatin is a 3rd generation statin has high potency and efficacy It owes remarkable potency and efficacy due to its fluorinated phenyl group and hydrophilic methane sulphonamide group in addition to the common dihydroxyheptenoic acid side chain. Its unique chemical structure enables multiple and strong binding with HMG-CoA reductase enzyme.<br>In addition :<br>Radiotherapy: 45-50Gy of NACTRT would be given to pelvis for period of 5-6weeks.<br><br>-Concurrent chemotherapy: Tablet Capecitabine 825 mg/m2 given orally twice daily from D1-D35 along with radiotherapy<br><br>Control Intervention1: Neo adjuvant Chemoradiotherapy: Radiotherapy: 45-50Gy of NACTRT would be given to pelvis for period of 5-6weeks.<br><br>-Concurrent chemotherapy: Tablet Capecitabine 825 mg/m2 given orally twice daily from D1-D35 along with radiotherapy<br><br>	To determine the impact of Rosuvastatin in improving pCR in patients with localized rectal cancer undergoing neoadjuvant chemoradiotherapy.Timepoint: Rosuvastatin week 2 and week 4 visit and at week 6	Tata Memorial Hospital	-	-	316	Intramural funding, TMC, Mumbai	Interventional Study	Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Permuted block randomization, fixed  Method of allocation concealment:On-site computer system  Blinding and masking:Open Label		01/12/2018				28/11/2018					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=29100		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	GI	Rectal Cancer	Rosuvastatin	Response rate	Phase 2/3	DB01098	N
CTRI/2020/09/028095	Increasing the local pH during  chemoembolization  for hepatocellular carcinoma		Not Yet Recruiting	Health Condition 1: C220- Liver cell carcinomaHealth Condition 2: C00-D49- Neoplasms	Intervention1: sodium bicarbonate: Before doing standard TACE, In each tumor feeding artery, about 25  ??ml bicarbonate would be injected into tumor feeding artery. Maximum of 3 arteries will be treated per session (i,e maximum dose of 75 ml of 5  sodium bicarbonate will used per session)<br>Intervention2: Standard transarterial chemoembolization with sodium bicarbonate: Before standard TACE, In each tumor feeding artery, about 25  ??ml bicarbonate would be injected into tumor feeding artery. Maximum of 3 arteries will be treated per session (i,e maximum dose of 75 ml of 5  sodium bicarbonate will used per session<br>Intervention3: NA: NA<br>Control Intervention1: Not applicable: Not applicable<br>	-Safety of adding bicarbonate along with TACETimepoint: 1 MONTH, 3 MONTH, 6 MONTH	TATA MEDICAL CENTER	-	-	10	tata medical center	Interventional Study	Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable		29/09/2020				28/09/2020					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46968		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	India	GI	Liver Cancer	Sodium Bicarbonate	Safety and/or Dose	Phase 1	DB01390	N
CTRI/2016/09/007315	The study of oral chemotherapy in locally advanced head and neck cancer post radical chemoradiation		Not Yet Recruiting	Health Condition 1: null- Locally advanced head and neck cancers	Intervention1: Methotrexate and Celecoxib: Tab Methotrexate 15 mg/m2 weekly PO and Capsule Celecoxib 200 mg PO Twice Daily for 18 months<br>Control Intervention1: Observation: Patient will be followed up at regular interval clinically.<br>	Overall SurvivalTimepoint: 3 years	Tata Memorial Hospital	-	-	1038	Tata Memorial Hospital Dr E Borges Marg Parel East	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Stratified randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Open Label		01/11/2016				28/09/2016					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=16278	Adjuvant/Maintenance	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	India	Head and Neck	Any head and neck squamous cell carcinoma	Celecoxib	OS	Phase 3	DB00482	N
JPRN-UMIN000014689	Study about the efficacy of metformin to immune function in cancer patients.		Complete: follow-up continuing	cancer and sarcoma	Administering metformin.	Ability to produce cytokines (IL-2, TNF alpha, IFN gamma) and differentiation (memory, regulatory etc.) in peripheral blood T cells.	Okayama University Hospital	All	20years-old - Not applicable	30	Okayama University Hospital	Interventional Study	Single arm Non-randomized		16/07/2014				28/07/2014					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016406		Any/All Stages	Hospital/University/Research Institute	N	N	N	Japan	Multiple cancer types	Any solid tumours	Metformin	Biomarker	Phase 2	DB00331	N
ACTRN12619000310167	Vitamin C for endometrial cancer		Recruiting	Endometrial Cancer; <br>Endometrial Cancer;Cancer - Womb (Uterine or endometrial cancer)	This study comprises a surgical window-style study design with an intervention administered between diagnosis and planned surgical resection. <br>1. Following diagnosis of endometrial cancer and informed consent, prior to planned elective surgery, tumour tissue will be collected by pipelle biopsy. This biopsy is in addition to standard care, and it will be taken in an outpatient setting. The pipelle biopsy is a commonly performed outpatient procedure and in fact many patients will have experienced this as their diagnostic procedure. The procedure involves insertion of a vaginal speculum and the introduction of a fine plastic tube into the uterus. Material from within the uterine cavity is sucked into the tube by applying negative pressure.  For the purpose of the study the biopsy will be performed by the named clinical investigators who are highly experienced at this procedure, and the patients will have a good understanding of the required procedure. Appropriate oral and local analgesia will be given in consultation with the patient. The procedure will be performed in a safe clinical environment with appropriate analgesia and a nurse assistant. Adverse events associated with the pipelle biopsy will be recorded.<br>2. Patients usually proceed to surgery approximately two  €  four weeks from the initial diagnostic biopsy. Within this time frame, Vitamin C administration will be co-ordinated to start five days before the planned surgical removal of the endometrial tumour. <br>2. Vitamin C will be administered by intravenous infusion daily for four days prior to surgery, beginning with a dose of 25 g, then 1g/kg capped at a maximum of 75 g.  <br>3. Blood samples will be collected at the time of pipelle biopsy, and then daily for four days prior to and after high dose vitamin	1.Measurement of ascorbate levels in endometrial tumour tissue in biopsy samples and post-ascorbate treatment surgical specimens.<br>[Biopsy samples taken at recruitment. Vitamin C infusions given for 4 consecutive days immediately prior to surgery (day 5). Tumour tissue obtained post-surgery.];2.Determination of the composite outcome of the association between ascorbate and the upregulation of the tumour hypoxic pathway, as assessed by the measurement of the HIF-1, VEGF, BNIP3, and CA-IX proteins and tumour ascorbate. [Biopsy samples taken at recruitment. Vitamin C infusions given for 4 consecutive days immediately prior to surgery (day 5). Tumour tissue obtained post-surgery.]	University of Otago	Female	18 Years - 75 Years	21	University of Otago	Interventional Study	Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Efficacy;	Nil known.	22/08/2019				28/02/2019					26/09/2022	https://anzctr.org.au/ACTRN12619000310167.aspx		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	New Zealand	Gynaecological	Endometrial Cancer	Ascorbic acid	Biomarker	Other	DB00126	N
JPRN-UMIN000021231	A search for optimal anesthetic agents for patients with cancer		Complete: follow-up complete	cancer	general anesthesia using propofol and remifentanil for cancer resection<br>general anesthesia using propofol, remifentanil and ketamne for cancer resection<br>general anesthesia using sevoflurane and remifentanil for cancer resection	The cytotoxic activity of natural killer cells	Hirosaki university hopspital	All	18years-old - Not applicable	80	Department of anesthesiology, Hirosaki university hospital	Interventional Study	Parallel Randomized		04/01/2016				28/02/2016					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024492		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Japan	Multiple cancer types	Any solid tumours	Propofol	Biomarker	Not available/Missing	DB00818	N
CTRI/2017/11/010651	standard chemotherapy plus aspirin vs standard chemotherapy alone in locally advanced and metastatic stomach cancer		Closed to Recruitment of Participants	Health Condition 1: null- advanced stomach cancer patients able to take tablets orally with normal organ function and a good performance statusHealth Condition 2: C169- Malignant neoplasm of stomach, unspecified	Intervention1: EOX plus Aspirin: patients of locally advanced and metastatic gastric cancer fulfilling the inclusion criteria<br>Control Intervention1: EOX: patients of locally advanced and metastatic gastric cancer fulfilling the inclusion criteria<br>	response rate PFS OS toxicitiesTimepoint: OS is defined as the time from entry into the clinical trial until death as a result of any cause.PFS is the time from entry into the study until progression or death as a result of any cause.recruitment started from March 2017 and will stop in June 2018.Response assessment will be done every 3 to 4 chemotherapy cycles by imaging and at every cycle clinically. After completion of chemotherapy imaging will be done every 3 months.based on the RECIST 1.1 CR/PR/SD/PD and PFS will be defined.	Jawaharlal Institute of Post graduate Medical education and Research	-	-	110	Jawaharlal Institute of Post graduate Medical Education and Research	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Permuted block randomization, variable  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Outcome Assessor Blinded		01/03/2017				27/11/2017					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=20908		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	India	GI	Gastric Cancer	Acetylsalicylic Acid	Response rate; PFS; OS	Phase 2/3	DB00945	N
CTRI/2013/06/003788	Neo-adjuvant Progesterone and Vitamin D3 in Breast cancer		Completed	Health Condition 1: null- Locally Advanced Breast Cancer and Large Operable Breast Cancer	Intervention1: Vitamin D3: Neo-adjuvant Vitamin D3 will be administered as Inj. Arachitol 300,000 IU/ml intramuscular, before each chemotherapy cycle and surgery date.<br><br>Intervention2: Inj Progestrone 500 mg: Inj.Progesterone used will be administered as single IM depot injection 500mg 5 days prior to each CT cycle and surgery date.<br><br>Control Intervention1: Only neo adjuvant chemotherapy.: The patients in control arm will not received any intervention treatment. i.e  <br>No Inj Progesterone or Vitamin D3, patient received only neo adjuvant chemotherapy followed by surgery.<br><br>	Disease-free survivalTimepoint: 5 years	Tata Memorial Hospital	-	-	120	Tata Memorial Hospital	Interventional Study	Randomized Factorial Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Open Label	TMH/377	19/09/2007				27/06/2013					17/10/2022	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4726		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Breast	Any Breast Cancer	Cholecalciferol	DFS/RFS/EFS	Phase 1	DB00169	N
CTRI/2020/02/023616	To study the combination of oral (Metronomic)chemotherapy along with Intravenous chemotherapy (Paclitaxel) in advanced stage head and neck cancer patients		Not Yet Recruiting	Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx	Intervention1: Paclitaxel and carboplatin with Oral Metronomic Chemotherapy: Patients on arm B will receive initially Paclitaxel (175mg/m2) plus Carboplatin (AUC 5) on day 1 in 3 weekly cycles.  In addition they will receive a fixed dose of  celecoxib 200 mg PO BD, erlotinib 150 mg PO OD and methotrexate 9 mg/m2 weekly.<br>Intervention2: Paclitaxel plus carboplatin followed by maintenance OMCT: Patients on arm C will receive initially Paclitaxel (175mg/m2) plus Carboplatin (AUC 5) on day 1 in 3 weekly cycles for 6 cycles followed by  a fixed dose of  celecoxib 200 mg PO BD, erlotinib 100 mg PO OD and methotrexate 9 mg/m2 weekly. The metronomic will start 2-4 weeks post completion of 6 cycles of Paclitaxel and Carboplatin.<br>Control Intervention1: Paclitaxel plus Carboplatin (Chemotherapy): Patients on arm A will receive Intravenous Paclitaxel (175mg/m2) plus Carboplatin (AUC5) on day 1 in 3 weekly cycles.<br>	Phase 2: Progression Free survival <br/ ><br>Phase 3: Overall SurvivalTimepoint: Phase 2: The response would be monitored in accordance with institutional standards. That is after first 3 cycle and every 2 months therafter. <br/ ><br>Phase 3: After completion of study patients will be followed up every 2 months for overall survival.	Tata Memorial Hospital	-	-	621	Tata Memorial HospitalDr E Borges road,Parel Mumbai 400012	Interventional Study	Randomized, Parallel Group, Multiple Arm Trial<br>  Method of generating randomization sequence:Stratified randomization  Method of allocation concealment:On-site computer system  Blinding and masking:Not Applicable	TMH project Number-3351;Version 2.1 Dated 10 December 2019	01/04/2020				27/02/2020					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=39789		Advanced/Metastatic	Hospital/University/Research Institute	Y	Y	N	India	Head and Neck	Any head and neck cancer	Celecoxib	PFS; OS	Phase 2/3	DB00482	N
NL9017	Blood-borne Assessment of Stromal activation in esophageAL adenocarcinoma to guide tocilizumab Therapy: a randomized phase II proof-of-concept study		Pending	Esophageal adenocarcinoma	tocilizumab	The primary objective of this study is to demonstrate that stroma-targeting by tocilizumab in esophageal adenocarcinoma patients with highly activated stroma increases efficacy of chemoradiotherapy measured by pathological response according to the Mandard criteria. Patients will be grouped for ADAM12, a non-invasive blood-borne marker of stromal activation.	Investigator-initiated, sponsored by Oncode Institute	-	-	48	Oncode Institute	Interventional Study	Randomized  controlled trial, Open (masking not used), N/A , unknown, Parallel	NL9017;METC AMC : METC 2020_187	16/11/2020				27/10/2020					04/03/2023	https://www.onderzoekmetmensen.nl/en/trial/20876		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Netherlands	GI	Esophageal Cancer	Tocilizumab	Other (specify)	Phase 2	DB06273	N
JPRN-UMIN000028405	Phase 1b investigator initiated trial of combination therapy of Metformin and Nivolumab in participants with advanced or recurrent solid cancer.		Complete: follow-up continuing	 lt;Stage 1 gt;  Advanced or recurrent solid cancer   lt;Stage 2 gt;  Advanced or recurrent non-small cell lung cancer, advanced or recurrent thymic epithelial tumor and advanced or recurrent pancreatic cancer	Continue to administer Nivolumab and  Metformin to a patient until the patient correspond to the withdrawal criteria for individual subjects	1) Safety  - Maximum tolerant dose (MTD):from first administration to last administration (stage 1 only)  - Dose limiting toxicity (DLT): for 4 weeks from first administration (stage 1 only)  - Adverse event:from first administration to 30 days after last administration    2) Pharmacokinetics property of metformin: from cycle 1 day8 to a day before cycle 2 day 1	Okayama University Hospital  Center for Innovative Clinical Medicine	All	20years-old - Not applicable	39	Ono Pharmaceutical Co.Ltd.	Interventional Study	Single arm Non-randomized		25/08/2017				27/07/2017					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031915		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Japan	Multiple cancer types	Any solid tumours	Metformin	Safety and/or Dose	Phase 1	DB00331	N
CTRI/2018/06/014620	Safety and effectiveness study of ormeloxifene in breast cancer patients.		Open to Recruitment	Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 2: null- Tamoxifen resistant metastatic/recurrent breast cancer	Intervention1: Ormeloxifene 120 mg per day: Ormeloxifene 120 mg per day in tamoxifen resistant metastatic/recurrent breast cancer patients.<br>	      ?      Overall response rates (ORR) will be calculated as the proportion of patients who achieved a tumor response of partial response (PR) or complete response (CR) as per RECIST 1.1 guidelines. Data will be as number of patients (  of patients) who achieved a tumor response of partial response (PR) or complete response (CR).Timepoint: 60  ?    2 Days, 120  ?    2 Days	HLL Lifecare Limited	-	-	56	HLL Lifecare Limited, (A Government of India Enterprises)Corporate R   D Centre,Akkulum, Sreekariyam, P.OThiruvananthapuram-695017,Kerala, India	Interventional Study	Single Arm Study<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable	ECTS/16/002, Ver 02, 08 Nov 2017, Amendment 001, 12 Oct 2020	16/07/2018				26/06/2018					17/10/2022	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=23948		Advanced/Metastatic; Recurrent/Refractory	Company	N	N	N	India	Breast	Breast - Other	Ormeloxifene	Response rate	Phase 2	DB13310	N
CTRI/2016/04/006872	The study of small dose chemotherapy after surgery not fit for radiotherapy in recurrent head and neck cancers patients.		Not Yet Recruiting	Health Condition 1: null- recurrent head and neck cancers patients post R0 salvage surgical resection who are ineligible for re-irradiation.	Intervention1: Methotrexate and Celecoxib: Oral methotrexate tablet 15mg/m2 will be administered weekly i.e on D1,D8, D15   D22 of every 28 day cycle. Capsule celecoxib will be self administered twice daily in a dose of 200 mg BD continuously from D1-D28.<br>Control Intervention1: Best Supportive Care: Best supportive care will be offered when appropriate and clinically indicated<br>	Overall survivalTimepoint: Overall survival : at 24 months	Tata Memorial Hospital	-	-	400	Tata Memorial HospitalDr E Borges Road Parel Mumbai 400012	Interventional Study	Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label		16/05/2016				26/04/2016					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13989		Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	India	Head and Neck	Any head and neck cancer	Celecoxib	OS	Phase 2/3	DB00482	N
ACTRN12621001458820	Safety and Tolerability of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib		Not yet recruiting	Cancer;Myeloma; <br>Cancer <br>Myeloma;Cancer - Myeloma	All study participants will initially receive 2 cycles of once-weekly intravenous Carfilzomib and oral Dexamethasone as per the standard of care. During the rest period of Cycle 2, disease response assessment will be performed according to the International Myeloma Working Group (IMWG) Criteria for Response Assessment. Each cycle is 28 days.<br>Participants who achieve a very good partial response (VGPR) or above will continue receiving once-weekly Carfilzomib and Dexamethasone (without Hydroxychloroquine), as per the standard of care and at the discretion of the treating physician. Participants who achieve a partial response (PR) or below will undergo additional assessments before beginning treatment with oral Hydroxychloroquine and continued once-weekly Carfilzomib and Dexamethasone. The dose of Hydroxychloroquine that a participant will receive is dependent on the stage of dose-escalation: Level -1, 200 mg every other day; level 1 (starting dose) 200 mg once daily; level 2, 200 mg twice daily; level 3, 200 mg three times daily; level 4, 400 mg twice daily. The duration of combined treatment will be a maximum of 10 cycles. <br><br>Carfilzomib 20 mg/m2 will be given as the starting dose on Cycle 1 Day 1, followed by escalation to 70 mg/m2 for all subsequent doses, if tolerated. Participants will continue to receive Carfilzomib at 70 mg/m2 until treatment discontinuation.<br><br>Strategies to monitor adherence include checking patient records, medication diary and counting hydroxychloroquine tablets at the end of each cycle.	Incidence and severity of adverse events. <br>The tool to measure severity of adverse events is the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0. [Once every cycle till 12 months from the end of treatment. ];Disease response as per the International Myeloma Working Group criteria.[Disease response is measured based on laboratory markers collected just prior to the administration of the next cycle. It is measured every cycle or once a month till 12 months from the end of treatment.];Change in heart function in participants on Hydroxychloroquine and Carfilzomib[ECG is performed at the start of each cycle of combined Hydroxychloroquine and Carfilzomib.<br>Echocardiogram is performed at cycle 2, 4 and 7 in participants on combined Hydroxychloroquine and Carfilzomib.]	South Western Sydney Local Health District	All	19 Years - No limit	36	South Western Sydney Local Health District	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety;		01/06/2022				26/10/2021					05/09/2022	https://anzctr.org.au/ACTRN12621001458820.aspx		Other (specify)	Hospital/University/Research Institute	N	N	N	Australia	Other Haem-onc	Multiple Myeloma	Hydroxychloroquine	Safety and/or Dose; Biomarker	Phase 1	DB01611	N
NTR3632	Development and clinical activity of low dose metronomic chemotherapy with oral paclitaxel.		Recruiting	Cancer, oral, paclitaxel, low dose metronomic, phase 1, kanker, oraal, laaggedoseerd, metronoom, fase 1	Patients with histological or cytological proof of cancer (excluding patients with secondary breast cancer metastasis with only lung metastases and primary brain tumors) for whom no standard treatment options are available, but who might benefit from treatment with paclitaxel and who are in good clinical condition will be eligible. Three patients will be assigned to each dose level. On a predefined day the patient will start receiving oral paclitaxel BID, dosed according to the escalation schedule and 100 mg ritonavir. This regime will be continued until progressive disease or until adverse events, which require dose modifications or discontinuation of therapy, are observed.<br><br /><br /><br>This is a dose escalation study. The starting dose was bi-daily 2.5 mg paclitaxel absolute (as ModraPac001 capsules) and 100 mg ritonavir (as tablets) BID with at least 7, but not more than 12 hours dose interval (intakes around the same time).	To determine the safety and feasibility of LDM bi-daily oral paclitaxel (as ModraPac001 capsules) in combination with boosting agent ritonavir.	The Netherlands Cancer Institute  -  Antoni van Leeuwenhoek Hospital	-	-	40		Interventional Study	N/A: single arm study, N/A , unknown, Parallel	NL3339;NTR3632;NKI-AVL : N10MOP;ISRCTN wordt niet meer aangevraagd.	09/05/2011				26/09/2012					04/03/2023	https://www.onderzoekmetmensen.nl/en/trial/21795		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Netherlands	Leukemia; Lymphoma	Any solid tumours; Any leukemias; Any lymphoma	Ritonavir	Safety and/or Dose; Other (specify)	Phase 1	DB00503	N
ACTRN12617001087347	A clinical trial comparing Simvastatin to placebo, in addition to standard chemotherapy and radiotherapy, in preoperative treatment for patients with rectal cancer.		Recruiting	Rectal Cancer; <br>Rectal Cancer;Cancer - Bowel - Back passage (rectum) or large bowel (colon)	The statin chosen for this trial, simvastatin (SIM), is a well-known and widely available 3-hydroxy-3-methyl-glutaryl-coenzyme (HMG-CoA) reductase inhibitor commonly used in the treatment of hypercholesterolaemia and ischaemic heart disease. Simvastatin or placebo is the trial intervention. <br><br>Simvastatin will be given as a 40 mg capsule taken daily for 90 days, starting 1 week prior to first radiation dose for standard Preoperative chemoradiation (pCRT). <br><br>capsules, Simvastatin will be encapsulated in Swedish orange size DB AA €  capsules, filled with microcrystalline cellulose powder. Patients will be asked to return unused drug and empty drug containers at the Week 13 visit (6 weeks post-pCRT). The number of capsules remaining will be counted by trial research staff and recorded to confirm adherence.	To compare rates of favourable (grades 1-2) MRI-based tumour regression grading (by central review) following preoperative chemoradiation (pCRT)with Simvastatin or placebo, considering MRI-based tumour regression grading in 4 ordered categories: 1, 2, 3, 4-5.[Based on MRI 6 € 8 weeks after preoperative chemoradiation, an analysis of inter-observer agreement on mrTRG between site radiologists and a central<br>radiologist will be repeated on all remaining patients at the conclusion of the trial or prior to any publication of results.]	The Australasian Gastro-Intestinal Trials Group (AGITG)	All	18 Years - No limit	222	Cancer Council NSW;Cancer Australia	Interventional Study	Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Safety/efficacy;	AG0115R/CTC0138	26/04/2018				26/07/2017					18/07/2023	https://anzctr.org.au/ACTRN12617001087347.aspx		Localised/Locoregional	Collaborative Group	Y	N	N	Australia	GI	Rectal Cancer	Simvastatin	Response rate	Phase 2	DB00641	N
CTRI/2012/07/002828	Effect of Celecoxib and Erlotinib in Oral Cancers		Closed to Recruitment of Participants	Health Condition 1: null- Oral cancer	Intervention1: 1.Arm :Celecoxib<br>2.Arm 2:Erlotinib <br>3.Arm 3:Celecoxib and Erlotinib<br>         <br>: 1.Arm 1: Celecoxib 200mg twice daily<br>2.Arm 2:Erlotinib 150mg  alone<br>3.Arm 3:Celcoxib 200mg twice daily+Erlotinib 150mg daily<br><br>Patients in the drug treatment will receive the prescribed drug for 21 days before the tumor being surgically resected.<br><br>Intervention2: Celecoxib: Arm 1: Celecoxib 200mg twice daily. Surgery after 21 days.<br>Intervention3: Erlotinib: Erlotinib 150mg daily for 21 days arm 2<br>Intervention4: Celecoxib 200mg +<br>Erlotinib 150mg: Celecoxib 200 mg twice daily + Erlotinib 150 mg once daily for 21 days. Surgery after completion of 21 days treatment.<br>Control Intervention1: No drugs: Patients will be operated  3 weeks after recruitment<br>Control Intervention2: No drugs: Patients will be operated 21 days after recruitment<br>	oTo study the effect of COX-2 inhibitor Celecoxib and EGFR tyrosine kinase inhibitor Erlotinib alone or in combination on molecular markers of apoptosis and angiogenesis. Markers to be studied include VEGF and p53.Timepoint: Clinical response assessment after 21days of drug treatment. <br/ ><br> <br/ ><br>Marker analysis after recruitment of all (64) patients. <br/ ><br> <br/ ><br>Followup for 36 months. <br/ ><br> <br/ ><br>Survival analysis after 36 months.	Tata Memorial Centre	-	-	64	Tata Memorial Centre	Interventional Study	Randomized, Parallel Group, Multiple Arm Trial   Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label	CT-Drugs/206/2011;TMC IRB project no 830	01/08/2012				25/07/2012					13/11/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4766		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	India	Head and Neck	Oropharyngeal Cancer	Celecoxib	Response rate; Biomarker	Phase 2	DB00482	N
CTRI/2019/02/017815	A study of Metformin plus chemotherapy in Lung cancer		Not Yet Recruiting	Health Condition 1: C34- Malignant neoplasm of bronchus andlung	Intervention1: Metformin: Metformin, orally with food, administered continuously, beginning with chemotherapy. Metformin treatment will follow a dose escalation scheme, starting with a dose of 500 mg twice a day (day 0). At day 8, a metformin dose increase is planned, with the first daily dose of 1000 mg and 500 mg as the second dose. At the start of 2nd cycle metformin will be increased to 1000 mg twice a day<br>Control Intervention1: Not Applicable: Not Applicable<br>	To evaluate if addition of metformin with pemetrexed carboplatin in patients with previously untreated advanced or metastatic NSCLC can increase 6 month PFS rate from 50  to 65 Timepoint: 6 months	Department of Medical Oncology	-	-	100	Department of Medical OncologyAll India Institute of Medical Sciences, New Delhi	Interventional Study	Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable		01/03/2019				25/02/2019					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31537		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	India	Lung	Non-Small Cell Lung Cancer	Metformin	PFS	Phase 2	DB00331	N
NTR1456	Antiviral therapy (cidofovir, an acyclic nucleoside phosphate) in combination with radiotherapy in HPV-positive tumors of the oropharynx		Pending	CarcinomaOropharynxRadiotherapy	Additional adminsitration of cidofovir during the six weeks of radiotherapeutical treatment. Extra biopsy after 96 hours of the first cidofovir administration, if feasible.<br>Monitoring urine and serum for renal, liver function, full blood count weekly and monitoring vital parameters weekly during administration.	1. Primary objective: determining maximum tolerated dose of cidofovir in combination with radiotherapy.	initiator = sponsor	-	-	12	fund = initiator	Interventional Study	N/A , unknown, Other	NL1396;NTR1456;NL19517.068.07;ISRCTN wordt niet meer aangevraagd	03/01/2009				25/09/2008					04/03/2023	https://www.onderzoekmetmensen.nl/en/trial/27994		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Netherlands	Head and Neck	Oropharyngeal Cancer	Cidofovir	Safety and/or Dose	Phase 1	DB00369	N
CTRI/2018/01/011542	Mebendazole in brain tumor		Open to Recruitment	Health Condition 1: C719- Malignant neoplasm of brain, unspecifiedHealth Condition 2: null- Recurrent high grade glioma	Intervention1: Arm C2: Temozolomide + Mebendazole;<br>Temozolomide : 150-200 mg/m2 D1-D5, PO for 28 day cycle. <br>Mebendazole : 100-1600 mg TDS, daily , PO for 28 days. <br>The regimen will continue till progression of disease<br>Control Intervention1: Arm B2: CCNU + Mebendazole;<br>CCNU : 110 mg/m2 D1 PO for 42 day cycle. <br>Mebendazole : 100-1600 mg TDS, daily , PO for 28 days. <br>The regimen will continue till progression of disease<br>	Phase 1 : MTD determination of Mebendazole <br/ ><br>Phase 2 : 9 month overall survival <br/ ><br>   <br/ ><br>Timepoint: 9 Months  <br/ ><br>   <br/ ><br>	Tata Memorial Hospital	-	-	195	Brain Tumor FoundationTata Memorial Hospital,Dr E Borges Road, Parel, Mumbai 400012	Interventional Study	Randomized, Parallel Group, Multiple Arm Trial<br>  Method of generating randomization sequence:Stratified randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Open Label		12/02/2018				24/01/2018					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=21603		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	India	CNS	Glioma	Mebendazole	Safety and/or Dose; OS	Phase 1/2	DB00643	N
NTR988	High dose simvastatin combined with standard chemotherapy in patients with refractory Multiple Myeloma: a phase II study.		Suspended	multiple myeloma	Treatment of relapsed/ refractory multiple myeloma patients with high dose statins, combined with chemotherapy. We treat multiple myeloma patients with 15 mg/kg simvastatin Day 0-7 followed by VAD day 7-11 (Vincristin, adriamycin, dexamethasone)chemotherapy in a scheme as used in HOVON trials (eg HOVON 65). On day 29 a new cycle is started. Patients are treated with 3 cycles. An additional cycle can be given in case of response (MR, PR ,CR).<br>In case of progressive disease during treatment, the therapy is ended.	The primary endpoint is response as defined by the EBMT criteria. This group of extensively pre-treated patients are multiresistent and we defined -based in literature- a respose of 10- 30  as reasonable.	The study is conducted on the department of hematology in het University Medical Center Utrecht. The study is approved by the Medical Ethical Board of this same hospital.	-	-	12	Dutch Cancer SocietyInternational myeloma foundation	Interventional Study	N/A , unknown, Other	NL962;NTR988; : 04/239;ISRCTN85384018	05/03/2005				24/05/2007					04/03/2023	https://www.onderzoekmetmensen.nl/en/trial/20029		Recurrent/Refractory	Collaborative Group	N	N	N	Netherlands	Other Haem-onc	Multiple Myeloma	Simvastatin	Response rate	Phase 2	DB00641	N
PACTR201602001488346	Effect of sodium bicarbonate 8.4  on bronchial carcinoma		Recruiting	<br>Cancer <br>Respiratory <br>Bronchogenic Carcinoma;Cancer;Respiratory;Bronchogenic Carcinoma	;Intra-tumoral injection of sodium bicarbonate 8.4  via fiberoptic bronchoscopy;Inhalation of nebulized sodium bicarbonate 8.4  ;image guided intra-tumoral injection of sodium bicarbonate 8.4 	Cathepsin B level and expression ;histopathological changes;electron microscopic changes;clinical presentation;tumor volume on radiology	Mohammad Khairy El Badrawy	All	18 Year(s) - 70 Year(s)	90	no funding source	Interventional Study	Parallel: different groups receive different interventions at same time during study,Non-randomised		01/02/2016				24/02/2016					29/05/2023	https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1488		Localised/Locoregional	Hospital/University/Research Institute	N	Y	N	Egypt	Lung	Non-Small Cell Lung Cancer; Small Cell Lung Cancer	Sodium Bicarbonate	Response rate; Biomarker	Other	DB01390	N
CTRI/2018/03/012810	Advantages of adding Metformin to Chemotherapy in Breast Cancer Patients		Open to Recruitment	Health Condition 1: null- Carcinoma Breast	Intervention1: Intervention- Metformin with Neoadjuvant Chemotherapy<br>: Intervention-Study group will receive metformin along with neo adjuvant chemotherapy.Participants in Study group will be started with Metformin from day 1 of neo adjuvant chemotherapy up to the 7th cycle of NeoAdjuvant .  Three cycles of FEC and four cycles of Docetaxel will be given as a standard neo adjuvant therapy in this study. 500 mg Metfromin for 2 weeks followed by 500 mg metfromin BD for weeks then 500 mg TDS till last chemotherapy will be added in study group<br>Control Intervention1: METFORMIN: Study Group-Chemotherapy 7 cycles plus Metformin 500 OD for 2 weeks followed by 500 mg for 2 weeks followed by  00 mg TDS till the 7th cycle of Chemotherapy<br><br>control- 7 cycles of chemotherapy alone. 3 cycles of FEC and 4 cycles of Docetaxel<br>Control Intervention2: Neoadjuvant Chemotherapy: Participants will receive only NEoadjuvant Chemotherapy.<br>3 cycles of FEC and 4 cycles of Docetaxel<br>	To assess the effect of adding metformin to neo-adjuvant chemotherapy in Breast Cancer patientsTimepoint: 7 months after starting NACT	JIPMER	-	-	100	Jawaharlal Institute of Post Graduate Medical Education and ResearchDHANVANTRI NAGAR ,PUDUCHERRY 605006INDIA	Interventional Study	Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Permuted block randomization, variable  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Open Label		12/04/2017				23/03/2018					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=23513		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Breast	Any Breast Cancer	Metformin	Response rate	Phase 3/4	DB00331	N
JPRN-jRCTs031190167	Periopertive administration of flurbiprofen axetil for prevention of postoperative recurrence in patients with non-small cell lung cancer		Recruiting	non-small cell lung cancer <br>non-small cell lung cancer;non-small cell lung cancer	arm A: Surgery alone <br><br>arm B: Intravenous drip infusion of 50mg of flurbiprofen axetil given perioperatively	Relapse-free survival (RFS)	Watanabe Katsuya	All	>= 20age old - Not applicable	420		Interventional Study	randomized controlled trial, open(masking not used), active control, parallel assignment, prevention purpose		05/02/2020				23/12/2019					17/10/2023	https://jrct.niph.go.jp/latest-detail/jRCTs031190167		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Japan	Lung	Non-Small Cell Lung Cancer	Flurbiprofen	DFS/RFS/EFS	Phase 2	DB00712	N
CTRI/2015/12/006454	Study of effect of metformin in patients with relapsed epithelial ovarian cancer		Open to Recruitment	Health Condition 1: null- carcinoma ovary	Intervention1: Tab Metformin 500 mg: To assess the response of metformin on CA-125 levels in patients with carcinoma ovary post treatment under followup with rising CA-125 levels.<br>Control Intervention1: NONE: NOT APPLICABLE<br>	Complete response or Partial responseTimepoint: 1 february 2016	Cancer Institute WIA	-	-	25	Cancer Institute (WIA)38, Sardar Patel RoadGuindy, Chennai 600036	Interventional Study	Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable		01/09/2015				22/12/2015					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=9123		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	India	Gynaecological	Ovarian Epithelial Cancer	Metformin	Response rate	Phase 2	DB00331	N
CTRI/2015/09/006204	A study of Oral chemotherapy after completion of radiation  and chemotherapy vs observation in Carcinoma esophagus.		Not Yet Recruiting	Health Condition 1: null- Patients of carcinoma of esophagus	Intervention1: Oral Metronomic: Oral metronomic chemotherapy is the study intervention in this trial. The metronomic chemotherapy consists of oral tablets of methotrexate and celecoxib.<br>Metronomic chemotherapy will be started within 13 weeks of completion of CTRT. <br>Oral methotrexate tablets 15mg/m2 will be self-administered weekly.<br>Capsule celecoxib will be self-administered twice daily in a dose of 200 mg BD continuously.The combination will be continued to a maximum of 12 months; unless prohibitive toxicity or disease progression occurs prior.<br><br>Control Intervention1: Observation: Patients on observation arm will receive standard treatment.<br>	Overall SurvivalTimepoint: At the time of death or at last follow up	Tata Memorial Center	-	-	300	Not applicable yet	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Other  Blinding and masking:Not Applicable		28/09/2015				22/09/2015					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=12600	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Head and Neck	Laryngeal Cancer	Celecoxib	OS	Phase 3	DB00482	N
CTRI/2021/07/035030	Oral chemotherapy for patients with lymphoma who are not fit/unwilling for injectable chemotherapy		Completed	Health Condition 1: C82- Follicular lymphomaHealth Condition 2: C81- Hodgkin lymphomaHealth Condition 3: C88- Malignant immunoproliferative diseases and certain other B-cell lymphomasHealth Condition 4: C84- Mature T/NK-cell lymphomasHealth Condition 5: C83- Non-follicular lymphomaHealth Condition 6: C85- Other specified and unspecified types of non-Hodgkin lymphomaHealth Condition 7: C86- Other specified types of T/NK-celllymphoma	Intervention1: LPEC regimen: An oral combination of Lenalidomide 10mg OD, Prednisolone 20mg OD, Etoposide 50mg OD, and celecoxib 200mg BD for 3 months<br>Control Intervention1: Historical control -PEPC: Patients treated with older oral metronomic protocol at our center( Prednisolone, Etoposide, Procarbazine and cyclophosphamide)<br>	To evaluate effectiveness of a Novel Oral metronomic chemotherapy in  <br/ ><br>relapsed/refractory lymphoma, and in patients who are unfit for full dose treatment at  <br/ ><br>the time of diagnosis. <br/ ><br>This effectiveness will be evaluated by comparing the lymphoma stage via Pet scan or CECT at baseline and after 3 months.Timepoint: At Baseline and 3 months post therapy	Postgraduate Institute of Medical Education and Research	-	-	30	PGIMER, Chandigarh	Interventional Study	Single Arm Study<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable		22/07/2021				22/07/2021					17/10/2022	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=55416		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	India	Lymphoma	Follicular Lymphoma; Hodgkin Lymphoma, Adult	Celecoxib	Other (specify)	Not available/Missing	DB00482	N
NTR7487	Treatment with recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with anaplastic thyroid cancer: a proof of concept study		Pending	anaplastic thyroid carcinoma	Patients will be treated with 600 mg anakinra i.v. daily for the 7 days. Patients will be admitted on our clinical ward as part of standard care to make arrangements for palliative care etc. and to receive anakinra treatment i.v..      <br /><br>To reach the therapeutic level of anakinra quick we will administer higher dosages. The reason it will be given intravenously is to avoid local side effects at the injection site at this high dosage.  <br /><br>After this stage, patients will be treated with 100 mg s.c. daily, through self administration from home.  <br /><br>The treatment will be continued in the context of the study for a total of 6 months.	Primairy endpoints well be:  <br /><br>- Effect of anakinra on health related quality of life (HRQoL), HR QoL defined according to a newly developed HRQoL questionaire specifically for ATC patients.  <br /><br>- Effects on tumor progression/tumor extent, such as TNM classification and tumor size. This will be assessed using radiological examinations using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria .  <br /><br>- Overall Survival (OS): defined as time interval from date of official inclusion to death due to any cause.	Radboud UMC Nijmegen, The Netherlands	-	-	10	Swedish Orphan Biovitrum BVBA (SOBI) provides the study medication.	Interventional Study	N/A: single arm study, Open (masking not used), N/A , unknown, Parallel	NL7272;NTR7487;NL62684.091.17 // 2017-003028-59	24/09/2018				21/09/2018					04/03/2023	https://www.onderzoekmetmensen.nl/en/trial/22269		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Netherlands	Endocrine	Thyroid Cancer	Anakinra	PFS; OS; QoL	Not available/Missing	DB00026	N
IRCT20210819052230N1	Study of the efficacy of memantine in metastatic colon cance		Recruiting	Metastatic colon cancer. <br>Malignant neoplasm of colon	Intervention 1: Intervention group: Standard chemotherapy drugs for colon cancer + memantine                                              Memantine, which is our intervention, will be administered orally at a dose of 20 mg per day. Thus, in the first week, 5 mg daily and then 5 mg per week will be added and eventually continued at a dose of 20 mg per day for three months. Intervention 2: Control group: Standard chemotherapy drugs for colon cancer without prescribing memantine.	Quality of life in patient with colon cancer. Timepoint: Beginning and end of the study (third month). Method of measurement: QLQ-C30 Questionnaire.;The size of tumor in patients with colon cancer. Timepoint: Beginning and end of the study (third month). Method of measurement: CT scan.	Oroumia University of Medical Sciences	All	18 years - no limit	50	Oroumia University of Medical Sciences	Interventional Study	Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In the present study, which will be allocated to 25 people in each group in a block plan, first, because there are two groups A and B, there will be 25 groups of 2, with group A being the intervention group and group B being the control group. After determining the cases, 25 cases will be selected using a random number table, and after determining the order, the list of patients will be randomly divided into two groups, Blinding description: In this study, an epidemiologist colleague will randomly divide patients into two groups, and the physician will prescribe medication for the intervention group. The participants, researcher, and data analyst are blind.		01/10/2022				29/01/2022					02/07/2022	http://en.irct.ir/trial/60821		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Iran	GI	Colon Cancer	Memantine	Response rate; QoL	Phase 2	DB01043	N
IRCT20211213053377N1	The radioprotective effect of metformin against radiotherapy-induced complications		Recruiting	Prostate cancer. <br>Malignant neoplasm of prostate	Intervention 1: Intervention group: Patients will receive oral metformin tablets (Chemi Darou Pharmaceutical Company, Iran) at a single dose of 1000 mg per day before the start of radiotherapy until one month after radiotherapy. Metformin tablets will be taken 2 hours before radiotherapy. Intervention 2: Control group: In the second group, patients will receive a placebo with a similar dose of 1000 mg per day before the start of radiotherapy until one month after radiotherapy. The appearance of a placebo is similar to that of metformin.	The Number of blood cells. Timepoint: Before first session of radiotherapy, once every two weeks during radiation therapy and one months after the end of radiotherapy. Method of measurement: Laboratory measurement of blood cell count.;Genotoxicity. Timepoint: Before first session of radiotherapy, once every two weeks during radiation therapy and one months after the end of radiotherapy. Method of measurement: Laboratory count of micronucleus in peripheral blood lymphocytes.;Urinary complications. Timepoint: Before first session of radiotherapy, once every two weeks during radiation therapy and one months after the end of radiotherapy. Method of measurement: Evaluation of acute urinary complications due to radiation therapy based on physician examination and patient symptoms.;Gastrointestinal complications. Timepoint: Before first session of radiotherapy, once every two weeks during radiation therapy and one months after the end of radiotherapy. Method of measurement: Evaluation of acute gastrointestinal complications due to radiation therapy based on physician examination and patient symptoms.	Ahvaz University of Medical Sciences	Male	18 years - no limit	60	Ahvaz University of Medical Sciences	Interventional Study	Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be assigned into two groups by simple randomization method. Allocation of patients to the study groups will be done by random numbers generation and using computer by excel software. Random numbers will be generated in Excel with RAND function [(=RAND()*(60)] and with this function 60 random numbers will be created in the range of 1 to 60 in a column. Each patient will be assigned a two-digit code from 01 to 60. From the beginning of the first row, move down the column of random numbers and check the first two digits of the random numbers. The first 30 people seen in our code range will be placed in the first group (intervention) and the second 30 people will place in the second group (control). A person from hospital staff, who will not responsible for patient selection, enrollment, or treatment allocation, performs the randomizati		21/01/2022				20/01/2022					05/02/2022	http://en.irct.ir/trial/60641	Primary/Main Curative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Iran	Urological	Prostate Cancer	Metformin	Biomarker	Phase 3	DB00331	N
IRCT20170728035349N2	Evaluation of Metformin impact on the downstaging of rectal cancer patients undergoing  neo-adjuvant chemo-radiotherapy		Recruiting	Rectal Cancer. <br>Malignant carcinoid tumor of the rectum;C7A.026	Intervention 1: Intervention group: 20 patients in the intervention group receive one metformin 500 tablet daily from Tehran Daroo Company at the same time with 28 sessions of chemoradiotherapy. Intervention 2: Control group: One placebo daily with 28 sessions of chemoradiotherapy.	Down Staging in Rectal Cancer Patients in Neo-adjuvant and Metformin Concomitant Recipients. Timepoint: MRI and biopsy of the rectal mucosa to determine the stage of the tumor and compare with similar cases performed at the beginning of the study, Follow-up of patients in both groups at intervals of 1, 3 and 6 months in terms of possible treatment complications, non-recurrent survival, cancer-specific survival and overall survival. Method of measurement: MRI.	Zanjan University of Medical Sciences	All	20 years - 70 years	40	Zanjan University of Medical Sciences	Interventional Study	Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly assigned to two groups: metformin recipients (group M) and placebo recipients (group P). For this purpose, random block methods with size 2 will be used and the random sequence of this allocation will be generated by STATA16 software, Blinding description: Due to the ambiguity of this study (patients and physicians prescribing the drug are not aware of the main drug and placebo), metformin 500 mg and placebo were indefinitely given to the patient at the end of each radiotherapy session and Its consumption is ensured.		29/01/2022				15/01/2022					02/07/2022	http://en.irct.ir/trial/60949	Neo-adjuvant/Window	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Iran	GI	Rectal Cancer	Metformin	Other (specify)	Phase 3	DB00331	N
IRCT20200608047702N1	The effect of finasteride in the prevention of  bladder tumor recurrence		Recruiting	bladder cancer. <br>Malignant neoplasm of bladder, unspecified;C67.9	Intervention 1: Intervention group: Finasteride ( Daru Pakhsh CO. Tehran, Iran) receive 5 mg /day and  complications and response to treatment are evaluated every three months. Intervention 2: Control group: Receive placebo (in the form of finasteride tablets) (Construction of Faculty of Pharmacy, Tabriz University of Medical Sciences)tablet per day for up to one year.	Prevention of recurrence of bladder cancer. Timepoint: before intervention and every 3 months for a period of one year. Method of measurement: cystoscopy pathology report.	Tabriz University of Medical Sciences	All	18 years - 70 years	124	Tabriz University of Medical Sciences	Interventional Study	Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: 124 envelopes are prepared with 62 active and 62 placebo cards and shuffled. Patients are allocated the next study number (1 € 124) in sequence after opening the sealed envelopes to either drug or placebo group, Blinding description: The researcher does not know whether the patient being evaluated belongs to the placebo group or the finasteride group. The patients also do not know if they have used a placebo or finasteride. Drugs and placebos are similar in appearance, such as color, shape, and so on. The patient (placebo or treatment groups) receives the encoded drug.		06/05/2021				25/12/2021					01/11/2022	http://en.irct.ir/trial/48767	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Iran	Urological	Bladder Cancer	Finasteride	Recurrence rate	Phase 3	DB01216	N
IRCT20200409047007N3	The effect of concurrent administration of melatonin and neoadjuvant Chemotherapy on the pathological response in breast cancer patients		Recruiting	Breast Cancer. <br>Malignant neoplasm: Breast, unspecified;C50.9	Intervention 1: Intervention group: Patients are prescribed a 10 mg tablet of melatonin at bedtime during a 5-month course of chemotherapy. Intervention 2: Control group: Patients in the control group are given one placebo tablet (similar to melatonin tablets) each night during a 5-month course of chemotherapy.	Pathological response. Timepoint: surgery after neoadjuvant chemotherapy. Method of measurement: The pathological response after neoadjuvant chemotherapy is assessed according to the Chevallier system as follows:1- Pathological complete response: Disappearance of all the tumor cells in breast and lymph nodes2- Pathological partial response: Presence of invasive carcinoma with stromal alterations3- Pathological no response: little modification in the original tumor appearance.	Mashhad University of Medical Sciences	Female	30 years - 60 years	52	Mashhad University of Medical Sciences	Interventional Study	Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly placed in blocks of 6. In each block, 3 patients receive melatonin and 3 patients receive placebo and patients are placed in blocks in the order of enrollment, Blinding description: Randomization was performed by Dr. Fazelipour and only she knows the type of medicine that is prescribed to each patient. The coded drug packages will be placed in the pharmacy next to the chemotherapy ward and will be delivered to each patient according to the code given to him. Patients, planners, physicians, and those who analyze the data are unaware of the type of medication each patient is receiving.		12/06/2021				12/02/2021					01/11/2022	http://en.irct.ir/trial/59341	Neo-adjuvant/Window	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Iran	Breast	Any Breast Cancer	Melatonin	Response rate	Phase 3	DB01065	N
KCT0006304	An Open Label, Single-Arm, Phase I Exploratory Trial to Assess the Safety and Preliminary Efficacy of mFOLFIRINOX with Hydroxychloroquine and Chlorphenesin carbamate in Patient with in Inoperable Locally Advanced or Metastatic Pancreatic Cancer		Active, not recruiting	;Neoplasms	Drug : This study is a single-arm trial and mFOLFIRINOX therapy, the backbone therapy of this trial, chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily for up to 48 weeks.	AE, Lab Test, Vital sign, 12-lead ECG, Physical examination, ECOG PS	Asan Medical Center	All	19(Year) - 80(Year)	40	CytoGen;ONCOCROSS	Interventional Study	Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable		21/12/2021				30/06/2021					05/02/2023	https://cris.nih.go.kr/cris/search/detailSearchEn.do?seq=24522		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Korea, Republic of	GI	Pancreatic Cancer	Hydroxychloroquine	Biomarker	Phase 1	DB01611	N
ChiCTR2100047864	A clinical study of carrelizumab and apatinib mesylate combined with propranolol in the treatment of advanced cholangiocarcinoma		Pending	Cholangiocarcinoma	Test group:Patients receiving Carrelizumab 200mg QD+ apatinib mesylate tablets 250mgQD+ propranolol 40mg BID for 3 weeks;	objective response rate 1 yeaer after treatment;	Hunan Provincial Tumor Hospital	All	18 -	Test group:30;	Jiangsu Hengrui Pharmaceutical Co. Ltd	Interventional Study	Single arm		30/06/2021				27/06/2021					03/07/2022	http://www.chictr.org.cn/showproj.aspx?proj=129040		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	GI	Cholangiocaricnoma	Propranolol	Response rate	Phase 2	DB00571	N
ChiCTR2100047608	Clarithromycin added to pomadomide-cyclophosphamide-dexamethasone (Cla-PCd)  versus pomadomide cyclophosphamide-dexamethasone (PCd) in relapsed or refractory multiple myeloma: a prospective, multicentre, randomised, controlled clinical trial		Recruiting	Multiple Myeloma	Group 2:pomalidomide combined with cyclophosphamide, clarithromycin, dexamethasone;Group 1:pomalidomide combined with cyclophosphamide and dexamethasone;	Overall response rate;	Shanghai Changzheng Hospital	All	18 - 100	Group 2:68;Group 1:68;	Self-funded	Interventional Study	Parallel		07/01/2021				20/06/2021					21/02/2022	http://www.chictr.org.cn/showproj.aspx?proj=128373		Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	China	Other Haem-onc	Multiple Myeloma	Clarithromycin	Response rate	Phase 4	DB01211	N
ChiCTR2100046201	A prospective, multicenter, randomized, controlled study on whether long-term oral antibiotics can effectively reduce the incidence of postoperative tumor recurrence and metastasis in patients with colorectal cancer		Recruiting	colorectal cancer	experimental group:Metronidazole;control group:placebo;	Incidence of postoperative liver metastasis;	The First Affiliated Hospital of Air Force Medical University	All	-	experimental group:1000;control group:1000;	No	Interventional Study	Parallel		30/07/2021				05/09/2021					21/12/2021	http://www.chictr.org.cn/showproj.aspx?proj=125730		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Colon Cancer; Rectal Cancer	Metronidazole	Recurrence rate	Not available/Missing	DB00916	N
IRCT20200313046756N2	Evaluation of the Effect of deferasirox on the treatment of ??Acute myeloid leukemia		Pending	Acute myeloblastic leukemia. <br>Acute myeloblastic leukemia;C92.0	Intervention 1: Intervention group: receive the standard treatment Cytarabine and idarubicin (7+3) with oral intake of Deferasirox capsule 360 mg daily for 28 days. Intervention 2: Control group: receive the standard treatment Cytarabine and idarubicin (7+3) without Placebo.	The number of white blood cells. Timepoint: on days 14 and 28. Method of measurement: Test for complete blood cell count.;Number of red blood cells. Timepoint: on days 14 and 28. Method of measurement: Test for complete blood cell count.;Platelet numbers. Timepoint: on days 14 and 28. Method of measurement: Test for complete blood cell count.;Percentage of  CD34 + leukemia blasts of bone marrow biopsy specimen. Timepoint: on days 14 and 28. Method of measurement: Flow cytometry with  CD34 monoclonal antibody.	Kerman University of Medical Sciences	All	18 years - 65 years	40	Kerman University of Medical Sciences;Nano Fanavaran Alvand pharmaceutical co.;AryaTinaGene biopharmaceutical co.	Interventional Study	Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: one group receiving standard treatment(without placebo) and the other group receive the standard treatment and interventional drug, Randomization description: Patients divide into two groups n = 20 (including dropouts). Block permuted randomization method uses, based on that, patients organize in a three-level prognosis(A, B, C) in each three-person block of any interventional group. According to the random numbers chart, the researchers consider even numbers for the control group and odd numbers for the intervention group, then put their hand on one of the numbers and move upwards and record the numbers, and assign the patients based on that individual group, Blinding description: People will be kept blind.;Patient: Receives the intervention drug in combination with the daily meals;outcome assessor: The information of each patient is p		23/09/2022				05/08/2021					29/08/2022	http://en.irct.ir/trial/51397		Any/All Stages	Hospital/University/Research Institute	Y	N	N	Iran	Leukemia	Acute Myeloid Leukemia, Adult	Deferoxamine	Other (specify)	Phase 3	DB00746	N
ChiCTR2100044011	Observational clinical study of anlotinib hydrochloride combined with gefitinib in first-line treatment of EGFR-sensitive mutations in advanced NSCLC		Recruiting	Advanced non-squamous non-small cell lung cancer	A+T:A+T;Gefitinib + Anlotinib + Metformin combination therapy:Gefitinib + Anlotinib + Metformin combination therapy;Gefitinib + Anlotinib + Metformin combination therapy (Patients with type 2 diabetes requiring oral metformin):Gefitinib + Anlotinib + Metformin;	DCR;	The First Affiliated Hospital of Xinxiang Medical College	All	18 - 75	A+T:20;Gefitinib + Anlotinib + Metformin combination therapy:20;Gefitinib + Anlotinib + Metformin combination therapy (Patients with type 2 diabetes requiring oral metformin):20;	CSCO-Pilot Tumor Research Fund	Interventional Study	Parallel		03/08/2021				03/06/2021					07/12/2021	http://www.chictr.org.cn/showproj.aspx?proj=56165		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	Y	N	China	Lung	Non-Small Cell Lung Cancer	Metformin	Other (specify)	Other	DB00331	N
ChiCTR2100042869	The Efficacy and Safety of Sirolimus Early Conversion Protocol in Liver Transplant Patients with Hepatocellular Carcinoma: a Single-Arm, Multi-Center, Prospective Study		Recruiting	Hepatocellular carcinoma	experimental group:Sirolimus;	Recurrence-free survival;	Shulan (Hangzhou) hospital	All	18 - 70	experimental group:397;	self-raised	Interventional Study	Single arm		15/02/2021				30/01/2021					30/08/2021	http://www.chictr.org.cn/showproj.aspx?proj=121236		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	GI	Liver Cancer	Sirolimus	DFS/RFS/EFS	Not available/Missing	DB00877	N
ChiCTR1800017822	A Prospective clinical trial of the efficacy and safety of zolledronic acid in the adjuvant treatment of breast malignant phyllodes tumors Adjuvant zoledronic acid in patients with breast malignant phyllodes tumors		Recruiting	breast malignant phyllodes tumor	Case series:receive 4 mg zoledronic acid intravenously once a month, for 2 years;	5 years disease-free survival;lung metastasis;bone metastasis;	Sun Yat-sen Memorial Hospital, Sun Yat-sen University	Female	12 - 70	Case series:28;	Natural Science Foundation of China (81502301)	Treatment Study	Non randomized control		09/01/2018				16/08/2018					24/01/2022	http://www.chictr.org.cn/showproj.aspx?proj=29903		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	Breast	Breast - Other	Zoledronic Acid	DFS/RFS/EFS; Other (specify)	Phase 2	DB00399	N
JPRN-UMIN000013951	Phase II study of concurrent chemotherapy with itraconazole in advanced gynecologic tumors.		Complete: follow-up continuing	Gynecologic cancer	itraconazole with chemotherapy	PFS, Response rate, OS, AEs, QOL, molecular profiling	Department of Obstetrics and Gynecology, Hyogo College of Medicine	Female	20years-old - 75years-old	16	Hyogo College of Medicine	Interventional Study	Single arm Non-randomized		20/05/2014				20/05/2014					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016257		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Japan	Gynaecological	Any gynaecological cancers	Itraconazole	Response rate; PFS	Phase 2	DB01167	N
CTRI/2010/091/000441	Phase III, Multi-centre, Double Blind, Randomized Placebo Controlled Trial of Aspirin for Duke C and High Risk Dukes B Colorectal Cancers		Open to Recruitment	Health Condition 1: null- Dukes C and High Risk Dukes B Colorectal Cancer	Intervention1: Aspirin: 200 mg OD for 3 years<br>Control Intervention1: Placebo: 200 mg OD for 3 years<br>	1. Disease free survival for all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer ptient sub groups)Timepoint: 3 years;Disease free survival for colon cancer (high risk Dukes B and Dukes C colon cancer)Timepoint: 3 years	National Cancer Centre Department of Medical Oncology Singapore	-	-	2660	NIL;NIL	Interventional Study	Randomized, Parallel Group, Placebo Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Participant, Investigator and Outcome Assessor Blinded	ICR02/ASCOLT;NCC IRB Ref No: 07-32-LGI	27/12/2010				17/05/2010					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1629	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Singapore	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	DFS/RFS/EFS	Phase 3	DB00945	N
NTR1250	A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small-cell lung cancer patients with high-risk for recurrence: NVALT 8B		Recruiting	Non-small-cell lung cancer	Within 4-6 weeks after surgery all patients will receive 4 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) on day 1 every 3 weeks. Patients in de nadroparin arm will receive nadroparin s.c. daily for 16 weeks, 2 weeks therapeutic dose en 14 weeks half-therapeutic dose.	The main endpoint is recurrence-free survival.	UMCGHanzeplein 19700 RB  Groningen	-	-	600	Pharmaceutical industryEli Lilly and GlaxoSmithKline'	Interventional Study	Randomized  controlled trial, Open (masking not used), N/A , unknown, Parallel	NL1205;NTR1250; : NVALT 8-B;ISRCTN wordt niet meer aangevraagd	11/01/2007				17/03/2008					04/03/2023	https://www.onderzoekmetmensen.nl/en/trial/24423	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Netherlands	Lung	Non-Small Cell Lung Cancer	Nadroparin	DFS/RFS/EFS	Phase 3	DB08813	N
CTRI/2019/09/021263	Role of affordable oral cancer drugs in advanced mouth cancer - Feasibility study.		Open to Recruitment	Health Condition 1: C06- Malignant neoplasm of other and unspecified parts of mouth	Intervention1: Drugs - Methotrexate and Celecoxib: Methotrexate <br>Dose - 15 mg/m2 of BMI once a week<br>Duration - 8 weeks<br>Route - Oral<br><br>Celecoxib <br>Dose -200 mg twice daily<br>Duration - 8 weeks<br>Route - Oral<br>Control Intervention1: Not Applicable: Not Applicable<br>	To study the feasibility of low cost, oral metronomic therapy in locally advanced borderline oral cancers.Timepoint: 4 weeks and 8 weeks	All India Institute of Medical Sciences Bhubaneswar	-	-	50	Drugs used are standard chemotherapy drugs and will be purchased by patient themselves. The point has been discussed in ethics committee and approved. Rest of the imaging studies and blood investigations are being done by AIIMS, Bhubaneswar free of cost. Address is - Surgical Oncology OPD, Department of Surgical Oncology, AIIMS, Patrapada, Bhubaneswar, Odisha - 751019	Interventional Study	Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable		16/09/2019				16/09/2019					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=36718		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	India	Head and Neck	Oropharyngeal Cancer	Celecoxib	Other (specify)	Not available/Missing	DB00482	N
NTR2655	Potential role of vitamin D treatment in breast cancer.		Pending	Vitamin D, breast cancer, apoptosis, proliferation	Oral administration of colecalciferol 40,000 IU/day, the duration of this therapy will be about 3-8 weeks (time frame between diagnosis of breast cancer and definitive surgery).	To study the influence of vitamin D on immunohistochemical marker Ki 67 (proliferation marker) in breast cancer. This marker will be defined in the biopsy specimen and in the tumour resection specimen. The mean difference between these two marker values will be examined between the intervention and the control group.	none	-	-	110	Fund Coronis, Researchfund of department of gynaecologists Enschede	Interventional Study	Randomized  controlled trial, Double blinded (masking used), Placebo, Parallel	NL2537;NTR2655;NL33552.044.10;ISRCTN wordt niet meer aangevraagd.	02/01/2011				16/12/2010					04/03/2023	https://www.onderzoekmetmensen.nl/en/trial/28013		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Netherlands	Breast	Any Breast Cancer	Cholecalciferol	Biomarker	Not available/Missing	DB00169	N
CTRI/2020/01/022781	Study of a new medicine combination in ovarian cancer which has come back after initial therapy		Completed	Health Condition 1: C569- Malignant neoplasm of unspecifiedovary	Intervention1: Phase 2: Sodium valproate and etoposide each chemo cycle is of 17 days vaproic acid at dose of 60mg/kg/day in 3 divided doses from D1 to D3 followed by oral etoposide from D4-D17 at a dose of 50mg/day. Treatment will be given till disease progression or unacceptable toxicities<br>Control Intervention1: not applicable: single arm study<br>	1. To determine proportion of patients achieving Overall response rate (ORR) with Sodium valproate in addition to oral etoposide in platinum resistant epithelial ovarian cancer (PROC) within 4 months of therapyTimepoint: 4 months	JIPMER	-	-	72	JIPMER, Puducherry	Interventional Study	Single Arm Study  Method of generating randomization sequence:  Method of allocation concealment:  Blinding and masking:		20/01/2020				15/01/2020					29/05/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=35605		Recurrent/Refractory	Local/National government	N	N	N	India	Gynaecological	Ovarian Epithelial Cancer	Valproic Acid	Response rate	Phase 2	DB00313	N
CTRI/2020/01/022784	Preventing Breast Cancer Recurrence after surgery		Completed	Health Condition 1: C509- Malignant neoplasm of breast of unspecified site	Intervention1: Total Intravenous Anaesthesia: Propofol will be used for maintenance of anaesthesia.<br>it will be given at Induction and Maintenance Phase of anaesthesia.<br>total dose given will be 2 mg/kg for induction and 0.1 - 0.2 mg/kg/min for maintence by infusion till the end of surgery.<br>Control Intervention1: Inhalational Anaesthesia: Inhalational Agent (Sevoflurane at 1.3 MAC) with further titration according to Vitals and BIS score will be used.<br><br>	To study perioperative delta change in Vascular Endothelial Growth FactorTimepoint: 24 HOURS BEFORE SURGERY <br/ ><br>24 HOURS AFTER SURGERY	AIIMS Rishikesh	-	-	192	ALL INDIA INSTITUTE OF MEDICAL SCIENCES RISHIKESHPIN: 249203UTTARAKHAND	Interventional Study	Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Investigator Blinded		15/01/2020				15/01/2020					17/10/2022	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=39415		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Breast	Any Breast Cancer	Propofol	Biomarker	Not available/Missing	DB00818	N
JPRN-UMIN000004525	The effect of combination of valproic acid and anti-tumor drug on pancreatic and biliary cancer		Pending	unresectable or reccurrent pancreatic cancer and biliary cancer (20 patients)	To administer valproic acid 15mg/kg twice a day.We estimate the blood concentration of valproic acid once a month. If the patients have the no side effects, we will continue to administer valproic acid. Regarding S-1, we administer this drug twice a day in alternate-day regimen.	tumor marker and tumor size	Department of surgery, Tokushima university hospital	All	Not applicable - Not applicable	20	None	Interventional Study	Single arm Non-randomized		12/01/2010				15/11/2010					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005412		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Japan	GI	Pancreatic Cancer; Cholangiocaricnoma	Valproic Acid	Response rate; Biomarker	Phase 1/2	DB00313	N
ACTRN12614000513617	ASCOLT Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers.		Active, not recruiting	Colorectal Cancer; <br>Colorectal Cancer;Cancer - Bowel - Back passage (rectum) or large bowel (colon)	Eligible participants will be randomised to the study in 1:1 ration to either Aspirin arm: 200 mg Aspirin (oral tablet) once a day for 3 years or Placebo equivalent.<br><br>The study treatment is given as adjuvant therapy <br><br>Drug compliance will be monitored via drug dispensations and drug returns, recorded on drug accountability logs at each study visit.<br><br>Noncompliance is defined as omission of more than 30  of the study period that the patient is on the study.	Disease Free Survival (DFS) among all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer patient sub-groups)<br>[During treatment: prior to each treatment cycle. Patient will have 3 monthly assessments for 3 years (month 3 to month 36) followed by 6 monthly assessments for additional 2 years (month 42 to month 60).]	Australasian Gastro-Intestinal Trial Group (AGITG)	All	18 Years - No limit	460	Cancer Australia;Bowel Cancer Australia	Interventional Study	Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Safety/efficacy;		28/08/2014				15/05/2014					27/02/2023	https://anzctr.org.au/ACTRN12614000513617.aspx	Adjuvant/Maintenance	Localised/Locoregional	Collaborative Group	Y	N	N	Australia	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	DFS/RFS/EFS	Phase 3	DB00945	N
CTRI/2015/01/005405	Study evaluating survival benefit of use of low dose continuous chemotherapy drugs along with surgery and radiation in treatment of advanced stage cancers of the oral cavity		Open to Recruitment	Health Condition 1: null- Operable Oral Cancers Stage III and IV	Intervention1: Metronomic Therapy: Tablet Methotrexate<br>Tablet Celecoxib<br>Intervention2: Metronomic Therapy in addition to standard surgery and adjuvant radiation / chemoradiation: Tablet Methotrexate 15mg/m2 and Tablet Celecoxib 200 mg twice a day given every week for 4 weeks as Neoadjuvant before surgery, for 4 weeks as Intermediate between surgery and radiation therapy and for 12 months after radiation as Maintenance. Total duration of therapy is 14 months.<br>Control Intervention1: Standard Therapy: Surgery followed by Adjuvant Radiation / Chemoradiation<br>	Disease Free SurvivalTimepoint: 3 years	Department of Atomic Energy Clinical Trials Centre	-	-	400	DAECTC	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Open Label		14/08/2013				14/01/2015					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8782	Adjuvant/Maintenance	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Head and Neck	Oropharyngeal Cancer	Celecoxib	DFS/RFS/EFS	Phase 3	DB00482	N
CTRI/2018/07/014865	Sorafenib and supportive medication in advanced Hepatocelluar cancer		Not Yet Recruiting	Health Condition 1: C220- Liver cell carcinoma	Intervention1: Sorafenib, Metformin and Atorvastatin: The 1st leg of the study will recruit 10 patients and they will be started on<br>Sorafenib 400mg BD + Atorvastatin 10mg OD + Metformin 500mg BD<br>Level 2   ?? The 2nd leg of the study will recruit 10 patients and they will be started on<br>Sorafenib 600mg per day + Atorvastatin 10mg OD + Metformin 500mg BD<br>Level 3   ?? The 3rd leg of the study will recruit 10 patients and they will be started on<br>Sorafenib 200mg BD + Atorvastatin 10mg OD + Metformin 500mg BD<br>Level 4   ?? The 4th leg of the study will recruit 10 patients and they will be started on<br>Sorafenib 200mg OD + Atorvastatin 10mg OD + Metformin 500mg BD<br><br>Route of administration :Oral<br>Control Intervention1: NA: NA<br>	1. Safety of combining Sorafenib with Atorvastatin and Metformin <br/ ><br>2. Adverse events of combination SAM <br/ ><br>Timepoint: 30 months	Tata Memorial Hospital	-	-	40	Intramural:Tata Memorial Hospital Dr Ernest Borges Marg Parel Mumbai  Extramural:Educational Grant form DrReddys Pvt limited B/2/337 road no 3 banjara hills hyderbad telegana pin 500034	Interventional Study	Other<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label	Study protocol version 3.0 dated 19/03/2018	27/08/2018				13/07/2018					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=27179		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	India	GI	Liver Cancer	Atorvastatin; Metformin	Safety and/or Dose	Phase 1	DB01076; DB00331	N
NL7726	Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients		Recruiting	metastasized neuroendocrine tumors (NETs)	14 days treatment with valproic acid (30mg/kg body weight/day) and hydralazine (150mg / day)	The primary endpoint will be the percentage of patients that will have an uptake of<br>68Ga-DOTATATE in the tumor equal to or above that of the liver after the 14 days<br>treatment period.	Erasmus MC, Rotterdam, the Netherlands	-	-	10	Erasmus MC	Interventional Study	N/A: single arm study, Open (masking not used), N/A , unknown, Other	NL7726;METC Erasmus MC : MEC-2019-0031	05/01/2019				13/05/2019					04/03/2023	https://www.onderzoekmetmensen.nl/en/trial/23147		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Netherlands	Endocrine	Neuroendocrine Tumours	Hydralazine; Valproic Acid	Biomarker	Not available/Missing	DB01275; DB00313	N
ACTRN12620000156987	Trial of propranolol to assess the spread of melanoma		Recruiting	Melanoma; <br>Melanoma;Cancer - Malignant melanoma	Consenting patients will be awaiting a sentinel node biopsy.<br>They will be randomized 1:1 to receive a daily oral dose of either (1) 40mg twice daily of propranolol  or (2) a placebo.<br>The duration of administration will be from the day of consent until the day of the sentinel node biopsy. This time period is expected to be 2-3 weeks.<br>The drug and the placebo will be in capsule form. The dose will be 40mg twice a day.<br>Participants will be asked to return their capsule bottles in order to monitor adherence.	This is a composite primary outcome. <br>The outcome measure will be signs of activation of genes induced by Sox18/RBPJ activity: IL33 and VCAM reflecting Sox18 re-expression and RBPJ activity. <br>Outcome will be assessed on the sentinel node by gene expresion analysis (RT-PCR) and by immunofluorescence.<br>[3 weeks post commencement of trial drug/placebo]	University of Queensland Diamantina Institute	All	18 Years - No limit	24	NHMRC	Interventional Study	Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;		12/02/2021				13/02/2020					11/08/2021	https://anzctr.org.au/ACTRN12620000156987.aspx		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Australia	Skin	Melanoma	Propranolol	Biomarker	Phase 1	DB00571	N
CTRI/2021/11/038016	An Efficacy and Safety Study of Erdafitinib (JNJ42756493) in Participants with Urothelial Cancer		Closed to Recruitment of Participants	Health Condition 1: N33- Bladder disorders in diseases classified elsewhere	Intervention1: Erdafitinib: 8 mg orally once daily for 28 days on a 28 day cycle.<br><br>Intervention2: Midazolam: DDI substudy will receive pretreatment with single dose of midazolam 2.5mg oral solution on Day -2 and single dose of midazolam on Day 13.<br>Intervention3: Metformin: DDI substudy will receive pretreatment with single dose of metformin 1000mg on Day -1 and single dose of metformin on Day 14.<br>Control Intervention1: NA: NA<br>	Plasma Concentration of Midazolam and its Metabolite (1-OH midazolam)Timepoint: Plasma Concentration of Midazolam and its Metabolite (1-OH midazolam) at Day-2 and Day 15	Janssen Research Development LLC	-	-	22	Janssen Research   Development , LLC	Interventional Study	Single Arm Study   Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label		12/01/2022				12/11/2021					16/10/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=57278		Advanced/Metastatic	Company	N	N	N	India	Urological	Urethral Cancer	Metformin; Midazolam	Safety and/or Dose	Phase 2	DB00331; DB00683	N
CTRI/2019/09/021213	A study to evaluate the role of modified regular interval based combined oral chemotherapy that regresses tumor cell development of various forms which is indicated for the treatment of High-Risk Medulloblastoma (a type of brain tumor)		Open to Recruitment	Health Condition 1: C716- Malignant neoplasm of cerebellum	Intervention1: C.O.M.B.A.T: Combined Oral Metronomic Bio-differentiating Antiangiogenic Treatment<br>Comprising Of Following Drug Regimen: Agent A: Temozolamide<br>60mg/m2/day from week 0 to week 6, to be given orally once a day in<br>empty stomach Agent B: Isotretinoin 100mg/m2/day 2 weeks on and 2<br>weeks, to be given orally in two divided doses to be given post meals<br>preferably with fatty foods like butter, cheese etc. Agent C: Etoposide<br>25mg/m2/day from week 9 to week 12, to be given orally in once a day<br>dose post meals Agent D: Sodium valproate 20mg/kg/day daily for 12<br>weeks all given per orally in two divided doses post meals. Each cycle<br>constitutes 12 weeks and 4 such cycles would be given for a duration of 52<br>weeks without any interruptions.<br>Control Intervention1: Observational<br>Arm: To observe after completion of the conventional therapy on every three<br>months for 30 months and then for 6 months till completion of 5 years<br>	To determine improvement in Event Free SurvivalTimepoint: On monthly follow-up visit till one year and followed by 3 monthly follow-up visit for further 2 years.	TMC Research Administration Council	-	-	128	TMC Research Administration Council, TRAC Office 3rd floor Main building Tata Memorial Hospital Dr Ernest Borges Road Parel. Mumbai. 400012	Interventional Study	Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label		17/09/2019				12/09/2019					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=36714		Localised/Locoregional	Hospital/University/Research Institute	Y	N	Y	India	CNS	Medulloblastoma	Valproic Acid	DFS/RFS/EFS	Phase 2	DB00313	N
JPRN-UMIN000000813	Phase II Study of Amrubicin and Nitroglycerin in Third-Line Chemotherapy in Previously Treated Patients with Non-Small-Cell Lung Cancer		Recruiting	Previously treated non-small-cell lung cancer	Transdermally applied nitroglycerin, 10 mg/day, for consecutive 5 days between before the start of chemotherapy using 36 mg/m2 of amrubicin, D1-3, every 4 weeks and the day 2 of chemotherapy	Progression free survival	Division of Clinical Trial Design and Management, Translational Clinical Center, Kyoto University Hospital	All	40years-old - Not applicable	60	Ministry of Education, Science and Culture (19689018, and 17790524) of the Japanese government	Interventional Study	Single arm Non-randomized		09/01/2007				12/09/2007					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000973		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Japan	Lung	Non-Small Cell Lung Cancer	Nitroglycerin	PFS	Phase 2	DB00727	N
JPRN-UMIN000003905	Phase I/II study of Aurora-A kinase peptide vaccine against hematological malignancies in combination with Pertussis vaccine (Pelita III strain) as an adjuvant.		Recruiting	Conventional therapy-resistant acute or chronic leukemia, elderly patients with hematological malignancies who are not eligible for standard chemotherapy and/or allogeneic or autologous hematopietic stem cell transplantation, relapsed acute or chronic leukemia and advanced phase of myelodysplastic syndrome after allogenic or autologous hematopietic stem cell transplantation, acute leukemia in 1st remission with high risk of relapse.	Cohort1 patients receive 0.5mg of Aurora-A kinase peptide in combination with fixed 5x10e8/100 micro-litter of Pertussis vaccine. <br>Cohort2 patients receive 1.0mg of Aurora-A kinase peptide in combination with fixed 5x10e8/100 micro-litter of Pertussis vaccine. <br>Cohort3 patients receive 2.0mg of Aurora-A kinase peptide in combination with fixed 5x10e8/100 micro-litter of Pertussis vaccine.	Adverse event profile and anti-leukemia effect.	Department of Bioregulatory	All	20years-old - 80years-old	9	Grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan	Interventional Study	Parallel Non-randomized		07/01/2010				12/07/2010					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004697		Any/All Stages	Hospital/University/Research Institute	N	Y	N	Japan	Leukemia; Other Haem-onc	Any leukemias; Myelodysplastic Syndromes	Pertussis vaccine	Safety and/or Dose	Phase 1/2	DB15274	N
JPRN-jRCTs011180011	Neoadjuvant chemoradiotherapy with Metformin for locally advanced pancreatic cancer		Recruiting	pancreatic cancer <br>pancreatic cancer;D010190;pancreatic cancer	Duration: 3 months<br>Dose<br>Neoadjuvantchemoradiation: Gemcitabine(150mg/m2/w)+RT(50.4G/28f)<br>Metformin: from 5days before starting neoadjuvant chemoradiation until surgery. (1500mg/3x);D020360;Neoadjuvant therapies	the ratio of histological remnant cancer cells	Taketomi Akinobu	All	>= 20age old - <= 80age old	40		Interventional Study	single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose	UMIN000017694	28/07/2015				12/03/2019					17/10/2023	https://jrct.niph.go.jp/latest-detail/jRCTs011180011		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Japan	GI	Pancreatic Cancer	Metformin	Biomarker	Phase 2	DB00331	N
CTRI/2019/09/021164	Vitamin D supplementation in Chronic Myeloid Leukemia		Completed	Health Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positive	Intervention1: Vitamin-D3-Cholecalciferol (60,000 I.U.): Vitamin-D3-Cholecalciferol (60,000 I.U.) or placebo will be given once weekly for 8 weeks<br><br>Intervention2: Imatinib 400 mg once daily to continue plus Vitamin D Cholecalciferol 60,000 IU: Drug- Vitamin D Cholecalciferol Dose- 60,000 IU <br>Dosage form- sachet <br>Frequency- once weekly <br>Duration- 8 weeks<br>Control Intervention1: Imatinib 400 mg once daily plus  Placebo: Matching Placebo sachet once weekly for 8 weeks<br>	To compare the early molecular response rates at 3 months of imatinib therapy with   without vitamin D3 supplementation in patients of newly diagnosed CML chronic phase <br/ ><br>Timepoint: Early molecular response at 3 months	Arkapal Bandyopadhyay	-	-	60	Funded by Dr. Arkapal Bandyopadhyay, pursuing DM Clinical Pharmacology at AIIMS Rishikesh	Interventional Study	Randomized, Parallel Group, Placebo Controlled Trial   Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant and Investigator Blinded		15/10/2019				11/09/2019					26/06/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=35430		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Leukemia	Chronic Myelogenous Leukemia	Cholecalciferol	Biomarker	Not available/Missing	DB00169	N
CTRI/2020/06/025818	Effect of Vitamin D and turmeric  in lymphoma patients.		Not Yet Recruiting	Health Condition 1: C833- Diffuse large B-cell lymphoma	Intervention1: Cholecalciferol (Vitamin D capsules) and Curcuma longa (Turmeric capsules): Oral Cholecalciferol 2000 IU once daily and Oral Curcuma longa 550 mg thrice daily with standard R-CHOP therapy for 6 to 8 months<br>Intervention2: Cholecalciferol capsules  as an add-on therapy to R-CHOP: Oral Cholecalciferol 2000 IU once daily  with standard R-CHOP therapy for 6 to 8 months<br>Intervention3: Tab. Curcuma longa as an add on therapy to R-CHOP: Oral Curcuma longa 550 mg thrice daily with standard R-CHOP therapy for 6 to 8 months<br>Control Intervention1: R-CHOP: Standard R-CHOP regimen at an interval of 21 days for 6-8 months<br>	Event Free Survival at the end of two years (EFS24) of diagnosis in patients with DLBCLTimepoint: Two years	JIPMER Intramural fund	-	-	80	JIPMER	Interventional Study	Randomized Factorial Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Open Label		01/07/2020				11/06/2020					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44026		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Lymphoma	Non-Hodgkin Lymphoma, Adult	Cholecalciferol	DFS/RFS/EFS	Not available/Missing	DB00169	N
CTRI/2013/06/003734	Low dose chemotherapy  versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies		Closed to Recruitment of Participants	Health Condition 1: null- Refractory Childhood cancer	Intervention1: Low dose chemotherapy: Etoposide(50 mg/m2/d) Thalidomide   (at 3mg/kg/d)  <br>Celecoxib (100 mg BID for patients  20 kg, 200 mg BID for patients 20  ??50 kg, and 400 mg BID for patients  50 kg)Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d)<br>Total duration of therapy: 6 cycles of 21 days<br>Control Intervention1: Best supportive care: Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration)<br>  ?  Capsules of same size and color as used in metronomic therapy<br>Best supportive care<br>  ?  Management of pain as per WHO standard for pain management<br>Total duration of therapy: 6 cycles of 21 days<br><br><br>	1.To assess the effect of metronomic chemotherapy on PFS.Timepoint: May 2013 to June 2015	Nil	-	-	200	Nil	Interventional Study	Randomized, Parallel Group, Placebo Controlled Trial    Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Pre-numbered or coded identical Containers  Blinding and masking:Participant and Investigator Blinded		30/06/2013				11/06/2013					03/06/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=6693	Palliative	Recurrent/Refractory	Hospital/University/Research Institute	N	N	Y	India	Multiple cancer types	Any solid tumours	Celecoxib	PFS	Phase 3	DB00482	N
RPCEC00000367	Doxycycline for prostate cancer		Recruiting	Prostate cancer;Genital Neoplasms, Male;Urogenital Neoplasms ;Prostatic Diseases;Genital Diseases, Male ;Male Urogenital Diseases;Prostatic Neoplasms	Intervention Experimental Group (group A): You will receive doxycycline 100 mg every 24 hours for 6 months, plus its standard treatment, which consists of bicalutamide 50 mg orally per day, and leuproline 22.5 mg in subcutaneous application every three months. This dose is less than the maximum previously recommended for chronic treatments such as acne conglobata. The commercial presentation for human use is in 100mg pills, so patients in the experimental group will take 1 pill every 24 hours.<br>Control Group Intervention (group B): You will receive your standard treatment as indicated by current clinical practice (bicalutamide 50mg orally per day, and leuproline 22.5mg in subcutaneous application every three months), plus a bottle of placebo pills that your doctor will provide. monthly in his office with the indication to take 1 pill every 24 hours, for 6 months.;Doxycycline ;Leuprolide ;Tablets ;Placebos ;Administration, Oral;Injections, Subcutaneous;Bicalutamida	Complete response (25  reduction in serum specific prostate antigen). Measuring time: 3 and 6 months.	Medical School of the University of Colima, Mexico	Male	18 years - 85 years	40	Mexico Mexican Social Security Institute	Interventional Study	Allocation: Randomized controlled trial. Masking: Double Blind. Control group: Active. Assignment: Parallel. Purpose: Treatment		14/08/2020				11/05/2021					19/12/2023	https://rpcec.sld.cu/en/trials/RPCEC00000367-En		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Mexico	Urological	Prostate Cancer	Doxycycline	Response rate	Phase 2	DB00254	N
ACTRN12622000016730	HER2Pro 1B - Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study		Recruiting	Metastatic HER2-positive breast cancer; <br>Metastatic HER2-positive breast cancer;Cancer - Breast	Overview: <br>Inhibition of dynamin-mediated endocytosis such as with prochlorperazine (PCZ) has been shown to increase the efficacy of trastuzumab and other monoclonal antibodies in preclinical models. Current standard therapy for metastatic HER2-positive breast cancer is paclitaxel in combination with trastuzumab and pertuzumab, followed by continuation of HER2-directed therapy until progression. The addition of PCZ has the potential for enhanced anticancer effect, but this novel combination needs to be assessed for feasibility and safety.<br><br>Interventions:<br>Standard treatment with paclitaxel 80mg/m2 weekly and loading dose trastuzumab 8mg/kg and pertuzumab 840mg. From cycle 2, paclitaxel 80mg/m2 weekly, trastuzumab 6mg/kg and pertuzumab 420mg every 3 weeks in combination with de-escalating doses of PCZ given as 6 weekly treatments.<br><br> € <br><br>Prochlorperazine Administration:<br>Prochlorperazine will be administered as an intravenous infusion at a given dose level over 20 minutes, 60 minutes following the administration of cycle 2 of the standard treatment regimen of pertuzumab, trastuzumab and paclitaxel. The reason for this is that dexamethasone, which may impact ADCC, is not required from cycle 2 of the treatment. <br><br>On completion of the prochlorperazine infusion, the intravenous line will be flushed with 100ml 0.9  normal saline. The standard reconstitution of prochlorperazine is within a solution of the mesylate salt in 5  dextrose. As the dose per infusion varies depending on body size and dose level, the concentration of the infusion will differ: for instance, an expected dose of prochlorperazine would be 50-100mg diluted in 250ml for a 1-2mg/5ml concentration solution running over 20 minutes.<br><br>Prochlorperazine is given over 6 weeks, start	The primary objective is to determine the recommended phase 2 dose (RP2D), defined as the highest dose level achieved with prochlorperazine in combination with pertuzumab, trastuzumab, and paclitaxel where less than 33  patients enrolled have experienced a dose limiting toxicity (DLT).<br><br>Dose limiting toxicity assessed by the occurrence of treatment-emergent adverse events (TEAEs) graded by the Investigator per the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)<br><br>Patients will be assessed for the presence of a DLT during their routine clinical assessments. which includes history, physical examination, and performance status, as well as at the end of their treatment and safety assessment. [Clinical assessments - Participants will be reviewed by their study investigator weekly during the prochlorperazine infusions, then every 3 weeks. Subsequent clinical assessment frequency is at the discretion of the investigator.<br><br>An end of treatment and safety assessment should be performed at 21 days after the last dose of study treatment to identify any adverse events occurring within this time. In the event of unresolved toxicity, participants should continue to be followed.]	University of Queensland	Female	18 Years - No limit	12	NHMRC Ideas Grant	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety;		01/03/2022				11/01/2022					05/08/2023	https://anzctr.org.au/ACTRN12622000016730.aspx		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Australia	Breast	Breast Cancer - HER2+	Prochlorperazine	Safety and/or Dose	Phase 1	DB00433	N
CTRI/2020/06/025790	A new medicine for cancer of the ovary which has returned after initial treatment		Completed	Health Condition 1: C00-D49- Neoplasms	Intervention1: Standard Therapy with Hydroxychloroquine: Standard chemotherapy can be any one of the following three options<br>1. Intravenous Paclitaxel 175 mg per m2 per dose with Intravenous Carboplatin dosed at AUC 5 will be given over 2 hours after paclitaxel infusion once in 3 weeks<br>OR<br>2. Intravenous Paclitaxel 80 mg per m2 per dose with carboplatin AUC 1.5 weekly on days 1, 8 15 of a Q weekly cycle<br>OR<br>3. Gemcitabine intraavenous 1000 mg per m2 on days 1 and 8 and Carboplatin AUC 5 IV on Day 1 of Q 3 weekly cycle<br><br>ALONG WITH <br>Oral Hydroxychloroquine 200 mg BD till completion of last cycle of chemotherapy <br><br>Control Intervention1: Standard Therapy: Standard chemotherapy can be any one of the following three options<br>1. Intravenous Paclitaxel 175 mg per m2 per dose with Intravenous Carboplatin dosed at AUC 5 will be given over 2 hours after paclitaxel infusion once in 3 weeks<br>OR<br>2. Intravenous Paclitaxel 80 mg per m2 per dose with carboplatin AUC 1.5 weekly on days 1, 8 15 of a Q weekly cycle<br>OR<br>3. Gemcitabine intraavenous 1000 mg per m2 on days 1 and 8 and Carboplatin AUC 5 IV on Day 1 of Q 3 weekly cycle<br><br>	Response RatesTimepoint: After 3 cycles of chemotherapy	Jawaharlal Institute of Postgraduate Medical Education and Research	-	-	62	Jawaharlal Institute of Postgraduate Medical Education and Research	Interventional Study	Other   Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Open Label		15/06/2020				10/06/2020					16/10/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43938		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	India	Gynaecological	Ovarian Epithelial Cancer	Hydroxychloroquine	Response rate	Phase 2	DB01611	N
JPRN-UMIN000029402	Pilot clinical study of boron neutron capture therapy on choroidal malignant melanoma		Pending	Treatment-refractory, medium or large-sized primary choroidal malignant melanoma or  choroidal malignant melanoma which recurred after radio-therapy	BNCT for patients with treatment-refractory, medium or large-sized primary choroidal malignant melanoma or choroidal malignant melanoma which recurred after radio-therapy is applied by nuclear reactor. Lithium shield should be used during neutron irradiation to protect elements in orbit from neutron exposure. Neutron irradiation time is decided to apply 1.5 x 10+E12 n/cm2 neutron as flux on retina.	Local control:  Skin lesion of angiosarcoma should be photographed and measured on it, periodically. Major and minor axis should be recorded and judged as CR, PR, SD and PD for the assessment of local control.	Osaka Medical College	All	Not applicable - Not applicable	3	Osaka Medical College	Interventional Study	Single arm Non-randomized		10/10/2017				10/10/2017					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033598		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Japan	Skin	Melanoma	Lithium	Response rate	Phase 1/2	Not found in DrugBank	N
JPRN-UMIN000029403	Pilot clinical study of boron neutron capture therapy on post-radiotherapy, recurrent breast cancer		Pending	Post-radiotherapy, recurrent breast cancer	BNCT for patients with post-radiotherapy, recurrent breast cancer is applied by nuclear reactor. Lithium shield should be used during neutron irradiation to protect elements in orbit from neutron exposure. Neutron irradiation time is decided to apply 1.5 x 10+E12 n/cm2 neutron as flux on skin.	Local control:  The lesions should be measured on MR or CT or directly on the skin periodically. Major and minor axis should be recorded and judged as CR, PR, SD and PD for the assessment of local control, based on RECIST v.1.1..	Osaka Medical College	Female	20years-old - 75years-old	3	Osaka Medical College	Interventional Study	Single arm Non-randomized		10/10/2017				10/10/2017					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033600		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Japan	Breast	Any Breast Cancer	Lithium	Response rate	Phase 1/2	Not found in DrugBank	N
JPRN-UMIN000018388	Prospective Evaluation of the Molecular Effects of Itraconazoleas an anti-cancer agent: A Window of Opportunity Study		Recruiting	solid tumors	Following tumor tissue biopsy and collection of peripheral blood, itraconazole solution 200 mg po BID daily will be taken for 2-4 weeks. Post-treatment biopsy in cohort A and planned surgery in cohort B will be conducted.	Change in Ki-67 proliferative index after 2-4 weeks of oral itraconazole solution 400 mg PO daily.	Hyogo College of Medicine	All	20years-old - Not applicable	20	Hyogo College of Medicine	Interventional Study	Single arm Non-randomized		08/10/2015				10/08/2015					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021292		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Japan	Multiple cancer types	Any solid tumours	Itraconazole	Biomarker	Phase 2	DB01167	N
JPRN-jRCTs011200001	Multicenter Clinical Trial of Neoadjuvant Therapy for Locally Advanced Rectal Cancer by Chemoradiation Combined with Metformin		Not Recruiting	Rectal cancer	Neoadjuvant chemoradiotherapy (capecitabine and 50.4 Gy radiation) with metformin for rectal cancer in patients without diabetes mellitus	Dose-limiting toxicity (Phase I)<br>Pathological complete response rate considering the central pathological diagnosis (Phase II)	Taketomi Akinobu	All	>= 20age old - < 75age old	64		Interventional Study	single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose		05/08/2020				10/07/2020					17/10/2023	https://jrct.niph.go.jp/latest-detail/jRCTs011200001		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Japan	GI	Rectal Cancer	Metformin	Safety and/or Dose; Response rate	Phase 1/2	DB00331	N
CTRI/2020/03/023846	To check safety and efficacy of Naltrexone in advanced esophageal cancer.		Not Yet Recruiting	Health Condition 1: C159- Malignant neoplasm of esophagus, unspecified	Intervention1: Palliative chemotherapy: weekly paclitaxel 80mg/m2<br>Control Intervention1: Palliative chemotherapy and Naltraxone: weekly paclitaxel 80mg/m2 + naltrexone would be 0.1mg/kg body weight to a maximum dose of 5mg/day.<br>	1. Progression Free Survival <br/ ><br>2. Overall Survival <br/ ><br>Timepoint: 1.PFS: At progression <br/ ><br>2. OS: At Death	Tata Memorial Hospital	-	-	492	Tata Memorial Hospital	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Stratified randomization  Method of allocation concealment:On-site computer system  Blinding and masking:Open Label		12/03/2020				09/03/2020					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=41568		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	India	Head and Neck	Laryngeal Cancer	Naltrexone	PFS; OS	Phase 2/3	DB00704	N
CTRI/2018/02/011824	Study of Pantoprazole in a Patients with Head   Neck Cancers		Not Yet Recruiting	Health Condition 1: null- patients who have metastatic, recurrent or locally advanced HNSCC that are unsuitable for loco-regional radical curative intent treatment and are planned for palliative chemotherapy (first-line)	Intervention1: Palliative chemotherapy combined with pantoprazole: Intravenous pantoprazole (at the dose determined from the first phase of the trial) administered 30-60 minutes before chemotherapy, repeated every 21 days; combined with <br>Physician choice of palliative chemotherapy, which can consist of <br>a.Intravenous cisplatin 75 mg/m2every 21 days; or <br>b.OMCT: oral celecoxib 200 mg twice daily and oral methotrexate 15 mg/m2 weekly.<br><br>Control Intervention1: Palliative chemotherapy alone: Physician choice of palliative chemotherapy, which can consist of <br>a.Intravenous cisplatin 75 mg/m2every 21 days; or <br>b.OMCT: oral celecoxib 200 mg twice daily and oral methotrexate 15 mg/m2 weekly.<br><br>	To find out the safe dose of intravenous pantoprazole when combined with intravenous cisplatin chemotherapy or oral metronomic chemotherapy consisting of oral daily celecoxib and weekly oral methotrexate for second phase of the studyTimepoint: At the End of phase I	Tata Memorial Centre	-	-	140	Tata Memorial CentreTRAC DepartmentMB 3rd Floor Tata Memorial  Hospital,Dr E Borges RoadParel Mumbai 400012	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label	249;Version No 4.0 Dated 26 Dec 2017	01/03/2018				09/02/2018					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=22986		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	India	Head and Neck	Any head and neck cancer	Pantoprazole	Safety and/or Dose	Phase 1/2	DB00213	N
NTR1703	A randomized placebo-controlled phase II/III with celecoxib in patients with locally advanced or metastatic non-small cell lung cancer.		Completed	Niet-kleincellig longcarcinoom (NSCLC).	Treatment Group A:<br />  <br>Docetaxel 75 mg/m   plus carboplatin (AUC = 6), on Day 1 every 21 days for 5 cycles.  <br>Placebo 2 x dd 400 mg, starting on Day 1 to a maximum of 3 years.<br /><br>Placebo starts simultaneously with docetaxel/carboplatin chemotherapy.<br><br /><br /><br>Treatment Group B: <br /><br>Docetaxel 75 mg/m   plus carboplatin (AUC = 6),  on Day 1 every 21 days for 5 cycles.  <br>Celecoxib 2 x dd 400 mg, starting on Day 1 to a maximum of 3 years.<br /><br>Celecoxib starts simultaneously with docetaxel/carboplatin chemotherapy.	Phase II:<br /><br>To evaluate the antitumoral efficacy of celecoxib in combination with docetaxel/carboplatin in terms of tumour response (CR, PR versus SD, PD).<br /><br /><br>Phase III:<br /><br>To assess Overall Survival (OS).	University Medical Center MaastrichtDepartment of Pulmonology	-	-	540	KWF kankerbestrijdingAventis Pharma BV, NederlandOrhtobiotec, NederlandPfizer Nederland	Interventional Study	Randomized  controlled trial, Double blinded (masking used), Placebo, Parallel	NL1619;NTR1703;METC UMC Maastricht : 2003/086;ISRCTN wordt niet meer aangevraagd	07/01/2003				03/09/2009					04/03/2023	https://www.onderzoekmetmensen.nl/en/trial/23374		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Netherlands	Lung	Non-Small Cell Lung Cancer	Celecoxib	Response rate; OS	Phase 2/3	DB00482	N
JPRN-C000000142	PhaseII stady of gefitinib and in patients with relapsed advanced non-small cell lung cancer			relapsed advanced non-small cell lung cartinoma	Patients receive oral gefitinib 250mg and meloxicam 10mg once daily	Response rate	Department of Medical Oncology Kinki University School of Medicine	All	20years-old - Not applicable	30	Department of Medical Oncology Kinki University School of Medicine	Interventional Study	Single arm Non-randomized		02/01/2004				08/09/2005					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000204		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Japan	Lung	Non-Small Cell Lung Cancer	Meloxicam	Response rate	Phase 2	DB00814	N
NL7496	Phase II study of oral metformin for intravesical treatment of non- muscle-invasive bladder cancer (TROJAN)		Pending	Non-muscle-invasive bladder cancerNMIBCBladder cancerBlaaskanker, niet-spierinvasief blaascarcinoom	TURB leaving a single marker lesion followed by oral metformin treatment.	Overall response: The primary outcome is the objective response rate (complete responses) after 3 months of treatment with metformin. Evaluable patients are those who have received at least 500 mg metformin twice daily for one week and who undergo a cystoscopy for marker lesion removal.	Amsterdam UMC, AMC	-	-	49	ZonMW project 848082004	Interventional Study	N/A: single arm study, Open (masking not used), N/A , unknown, Other	NL7496;NL62588.018.17	02/12/2019				02/08/2019					04/03/2023	https://www.onderzoekmetmensen.nl/en/trial/25176		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Netherlands	Urological	Bladder Cancer	Metformin	Response rate	Phase 2	DB00331	N
CTRI/2019/11/021924	A trial comparing maintenance with low dose oral methotrexate and propranolol versus observation after standard chemotherapy in patients with relapsed high grade epithelial ovarian cancer.		Open to Recruitment	Health Condition 1: C569- Malignant neoplasm of unspecifiedovary	Intervention1: Oral methotrexate and propranolol: Metronomic maintenance with oral methotrexate and propranolol versus observation after chemotherapy in relapsed platinum sensitive high grade epithelial ovarian cancer<br>Oral administration of the following drugs starting at least 1 month (ie 30days) after the last chemotherapy (to a maximum of 3 months) and continuing till disease progression or toxicity.<br>i.T. MTX 15 mg as a single dose once a week<br>ii.T Propranolol 20 mg BD in first week followed by 40 mg BD  continuously if patient tolerates<br><br>Control Intervention1: Observation: Observation after chemotherapy in relapsed platinum sensitive high grade epithelial ovarian cancer<br>	Progression free survivalTimepoint: Accrual Time- 36 months <br/ ><br>Follow up time       ?    ??24 months <br/ ><br>	Applied for Extramural grant	-	-	150	Institute Tata Memorial Centre,Dr E Borges Marg,Parel,Mumbai 400012, IndiaFunding awaited	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label		01/01/2020				07/11/2019					17/10/2022	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=36645	Adjuvant/Maintenance	Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	India	Gynaecological	Ovarian Epithelial Cancer	Propranolol	PFS	Phase 3	DB00571	N
CTRI/2021/09/036296	Oral Chemotherapy for advanced head and neck cancer.		Not Yet Recruiting	Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx	Intervention1: Triple Metronomic: TAB. Erlotinib 150mg OD<br>Capsule. Celecoxib 200mg BD<br>TAB. Methorexate 9mg/m2 weekly<br>Control Intervention1: Physician Choice Therapy: INJ. methotrexate or<br>INJ. Docetaxel or<br>TAB. Capecitabine<br>	Overall survivalTimepoint: 6 Months	NO	-	-	214	Intramural grantMahamana Pandit Madan Mohan Cancer Centre Sundarpur Varanasi	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Stratified randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label	IEC project No. 11000506	15/09/2021				07/09/2021					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=58988	Palliative	Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	India	Head and Neck	Any head and neck cancer	Celecoxib	OS	Phase 3	DB00482	N
CTRI/2021/05/033482	it is a phase III trial where advanced pancreatic adenocarcinoma  patients will be randomised in 2 arms . 1 arm includes losartan given with folfirinox chemotherapy regime and the other arm includes fofirinox chemotherapy only .		Not Yet Recruiting	Health Condition 1: K868- Other specified diseases of pancreas	Intervention1: LOSARTAN: Arm B   ?? chemotherapy alone Oxaliplatin 65mg/m2 IV over 2 hours Irinotecan 135mg/m2 IV over 90 mins Leucovorin 300mg/m2 IV over 2 hours<br>5 FU - 1800mg/m2 IV over 46 hours continuous infusion<br>Intervention2: LOSARTAN WITH FOLFIRINOX: Tablet Losartan 50 mg PO one tablet daily once at nigh plus Oxaliplatin 65mg/m2 IV over 2 hours<br>Irinotecan 135mg/m2 IV over 90 mins Leucovorin 300mg/m2 IV over 2 hours<br>5 FU - 1800mg/m2 IV over 46 hours continuous infusion<br>Intervention3: ONLY FOLOFIRINOX: Arm B   ?? chemotherapy alone Oxaliplatin 65mg/m2 IV over 2 hours Irinotecan 135mg/m2 IV over 90 mins Leucovorin 300mg/m2 IV over 2 hours<br>5 FU - 1800mg/m2 IV over 46 hours continuous infusion<br>Control Intervention1: not applicable: not applicable<br>	To evaluate whether  the addition of a drug commonly used in control of blood pressure (Losartan) will improve survival when combined with standard chemotherapy in      advanced pancreatic and periampullary cancersTimepoint: 84 months	Tata Memorial Hospital	-	-	264	Intramural tata memorial hospital Dr ernest marg Parel Mumbai 400012	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Not Applicable		25/05/2021				07/05/2021					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=54937	Palliative	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	India	GI	Pancreatic Cancer	Losartan	OS	Phase 3	DB00678	N
CTRI/2012/03/002483	To Evaluate the effect of Metformin versus Placebo as an Add-on Therapy in patients with recurrent epithelial ovarian cancer receiving chemotherapy: A double blind randomized controlled clinical trial.		Closed to Recruitment of Participants	Health Condition 1: null- Recurrent Epithelial Ovarian Cancer	Intervention1: metformin: Dose - 500 mg twice daily orally<br>for one year<br>       <br><br><br>Control Intervention1: placebo(starch powder): Dose - 500 mg twice daily orally for one year<br>	prolonging progression free survivalTimepoint: patients will be followed for 1 year and time to relapse will be noted	Dr Reddys Laboratories Ltd	-	-	100	Dr Reddys Laboratories Ltd.	Interventional Study	Randomized, Parallel Group, Placebo Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Participant and Investigator Blinded		07/03/2012				07/03/2012					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3190	Primary/Main Curative	Recurrent/Refractory	Company	Y	N	N	India	Gynaecological	Ovarian Epithelial Cancer	Metformin	PFS	Phase 3	DB00331	N
ACTRN12621001347853	Clinical study assessing the anti-cancer activity of sulfasalazine in patients with advanced or metastatic pancreatic ductal adenocarcinoma whose cancer has worsened following therapy with current standard of care.		Recruiting	Pancreatic cancer; <br>Pancreatic cancer;Cancer - Pancreatic	Participants will be commenced on treatment with sulfasalazine (500mg oral tablets) at 1.5 g per day in three evenly divided doses. The dose will be incrementally increased to the target dose (4.5 g per day in three evenly divided doses), subject to tolerability. The dose may be further escalated to 6 g per day, in three evenly divided doses, subject to no significant intolerance and study PI approval. <br>Participant acetylator status, which affects how quickly sulfasalazine is processed in the body, is used to inform the dose escalation schedule during the first treatment cycle.  For fast acetylators, the sulfasalazine dose is expected to increase to 3g per day on Day 4, further escalated to the target dose on Day 8 and may be further escalated to 6g per day on Day 15 subject to tolerability and PI approval. For slow acetylators, the dose is expected to increase to 3g per day on Day 8, further escalated to the target dose on Day 15 and may be further escalated to 6g per day on Day 22 subject to tolerability and PI approval.<br>All participants will continue the study treatment until clinical or radiological progression or until treatment discontinuation criteria are met.  Tablet counts will be performed by the study team to assess adherence.  <br>To prevent low levels of folic acid that can occur with sulfasalazine treatment, participants will also take 1mg of oral folic acid tablets daily.	To quantify progression-free survival (PFS) rate at 6 months among patients with pancreatic ductal adenocarcinoma treated with sulfasalazine. Disease progression is assessed by site investigators using Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 criteria using CT scans or clinical criteria based on clinical signs and symptoms.  PFS is assessed by site investigators at study visits/contacts.[ 6 months from start date of study treatment]	Australian Genomic Cancer Medicine Centre Ltd t/a Omico	All	18 Years - No limit	38	Cancer Institute NSW	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;		19/06/2023				07/10/2021					16/10/2023	https://anzctr.org.au/ACTRN12621001347853.aspx		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Australia	GI	Pancreatic Cancer	Sulfasalazine	PFS	Phase 2	DB00795	N
CTRI/2020/11/028953	Assessment of nivolumab and metronomic aspalliative Treatment  in head and neck cancer patients		Not Yet Recruiting	Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynxHealth Condition 2: C00-D49- Neoplasms	Intervention1: Nivolumab Therapy Arm: Nivolumab- Inj Nivolumab 20 mg in 100 ml NS over 60 minutes every 3 weekly will be administered with standard of care chemotherapy.<br>Control Intervention1: Standard of care chemotherapy: Chemotherapy will be administered with tablet erlotinib 150 mg ( fixed dose ) PO OD daily, capsule celecoxib 200 mg ( fixed dose ) PO BD daily and oral weekly methotrexate 9 mg/m2. All chemotherapy medications will be taken 1 hour before breakfast. The methotrexate is available in 2.5 mg tablets. Hence the dose of methotrexate will be rounded of to the nearest lower numerical which is a multiple of 2.5. This could enable delivery of methotrexate without the need for breaking or crushing the tablets. All methotrexate tablets will be taken together. It will be a 21 day cycle<br>	To compare the overall survival.Timepoint: 5 years	Tata Memorial Hospital	-	-	184	Tata Memorial Hospital	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:On-site computer system  Blinding and masking:Not Applicable	900663;Version No 2.0 Dated 26th August 2020	17/11/2020				06/11/2020					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48487		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	India	Head and Neck	Any head and neck squamous cell carcinoma	Celecoxib	OS	Phase 2/3	DB00482	N
TCTR20171106001	Immunomodulatory Effect of Vitamin D in Colon Cancer Patients: a Randomized Clinical Trial		Pending (Not yet recruiting)	Colon cancer stage 1 and 2Male or Female , aged 30 -75 yearsBeing at least 1 month after surgery No previous chemotherapy or radiotherapy <br>Colon cancer<br>Inflammatory markers<br>Immune markers<br>Vitamin D3<br>1 ,25(OH)2D3;Colon cancer<br>Inflammatory markers<br>Immune markers<br>Vitamin D3<br>1 ,25(OH)2D3	Randomized block design by blocking on sex with two arms (vitamin D3 VS non -vitamin D3 supplementations) will be used among 80 patients who meet inclusion and exclusion criteria. Patients in intervention group (40 patients) will receive daily 8 ,000 IU of vitamin D3 supplementation for 3 months. Then , the immunological response and vitamin D status will be observed.,Patients in conventional group (40 patients) will not receive daily 8 ,000 IU of vitamin D3 supplementation for 3 months. They just receive standard treatment care as a conventional therapy. Then , the immunological response and vitamin D status will be observed.;Experimental Dietary Supplement,No Intervention No treatment;Vitamin D receiver group,Conventional group	Immunological markers 3 months Immunological and biochemical tests	Chulabhorn International College of Medicine , Thammasat University	All	30 Years - 75 Years	80	Chulabhorn International College of Medicine , Thammasat University	Interventional Study	Randomized		20/11/2017				06/11/2017					19/12/2023	https://www.thaiclinicaltrials.org/show/TCTR20171106001		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Thailand	GI	Colon Cancer	Calcipotriol; Calcitriol	Biomarker	Phase 2	DB02300; DB00136	N
NTR763	AVOCAT study		Recruiting	Locally advanced or metastatic carcinoma of the prostate.	Group 1 will be hormonally treated with bicalutamide 150 mg/day monotherapy.<br /><br>Group 2 will be hormonally treated with bicalutamide 150 mg/day + 0.5 mg dutasteride/day	PSA progression after 3 years of study treatment	STIWU: Stichting ter bevordering van het Wetenschappelijk Urologisch onderzoek(Foundation for the stimulation of Scientific Urological Research.)	-	-	324	N/A	Interventional Study	Open (masking not used), Active, Parallel	NL752;NTR763; : N/A;ISRCTN47114653	03/01/2006				09/06/2006					04/03/2023	https://www.onderzoekmetmensen.nl/en/trial/26811	Primary/Main Curative	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Netherlands	Urological	Prostate Cancer	Dutasteride	Biomarker	Phase 3	DB01126	N
ISRCTN08912168	A trial of prostate radiotherapy in conjunction with carbogen and nicotinamide		Completed	Prostate cancer <br>Cancer <br>Malignant neoplasm of prostate	The use of carbogen and nicotinamide during radiotherapy.	PSA progression-free survival measured at 5 years	East and North Hertfordshire Hospitals NHS Trust (UK)	Male	-	50	Prostate Cancer Charity (UK)	Interventional Study	Non-randomised interventional trial (Treatment)	2010-021886-63;9930	16/12/2011				06/02/2012					26/09/2022	https://www.isrctn.com/ISRCTN08912168		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United Kingdom	Urological	Prostate Cancer	Nicotinamide	PFS	Phase 2	DB02701	N
CTRI/2012/12/003180	A study to assess safety and effectiveness  of oral medicine   of  valproate in advanced brain tumors		Open to Recruitment	Health Condition 1: null- Recurrent/ Progressive brain Tumors	Intervention1: Valproate/valproic Acid: Valproate is available as 200mg, 300mg and 500mg controlled release tablets which will be used in this study. The total dose will be rounded off to the nearest 100mg.<br>Intervention2: valproate/Valproic acid: Valproate is available as 200mg, 300mg and 500mg controlled release tablets which will be used in this study. The total dose will be rounded off to the nearest 100mg.<br>Intervention3: Valproate/Valproic acid.: Valproate is available as 200mg, 300mg and 500mg controlled release tablets which will be used in this study. The total dose will be rounded off to the nearest 100mg. This drug will be  given orally for  6 months or till progression or unacceptable toxicity.<br>Control Intervention1: Not applicable: Not applicable<br>	To assess  the toxicity of oral valproic acid ( VA) administered at doses required to maintain serum trough VA concentrations of 100 to 150    g/mLTimepoint: Monitoring for toxicity will be done weekly during dose escalation phase and 4 weekly after achieving serum trough concentration of 100-150    g/mL	Tata Memorial Centre	-	-	30	Tata Memorial Centre	Interventional Study	Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label	TMC; IRB Project No : 653	03/10/2011				05/12/2012					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3390		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	India	CNS	Any CNS cancers	Valproic Acid	Safety and/or Dose	Phase 1/2	DB00313	N
CTRI/2020/08/026992	A study  of low intensity chemotherapy in relapsed and refractory lymphoma patients		Open to Recruitment	Health Condition 1: C817- Other Hodgkin lymphomaHealth Condition 2: C858- Other specified types of non-Hodgkin lymphoma	Intervention1: injection paclitaxel and daily oral sodium valproate<br>: Tab Sodium Valproate 60mg/kg/day orally in 3 divided doses 3 days followed by 15 mg/kg/d in two divided doses from 4th day till next cycle <br>Inj Dexamethasone 16mg intravenous , weekly along with Paclitaxel<br>Inj Paclitaxel 80 mg/m2 intravenously once weekly on D4,D11,D18<br>Every 21 days(total of 3 cycles)<br><br>Control Intervention1: nil: nil<br>	To assess the Overall response rates (ORR) of weekly paclitaxel and daily oral sodium valproate in patients of relapsed refractory lymphoma.Timepoint: at  baseline,9 weeks and 6 months	Jawaharlal Institute Post Graduate Medical Education and  Research	-	-	84	Jawaharlal Institute Post Graduate Medical Education and  ResearchDhanwantari NagarPondicherry-605006	Interventional Study	Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label		10/08/2020				05/08/2020					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45791		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	India	Lymphoma	Hodgkin Lymphoma, Adult; Non-Hodgkin Lymphoma, Adult	Valproic Acid	Response rate	Phase 2	DB00313	N
JPRN-UMIN000002577	Effect of Zoledronic acid for Stage D2 hormone-sensitive prostate cancer patients.		Pending	Prostate Cancer	MAB (combination of LHRH agonist and non-steroidal antiandrogen) therapy until PSA refractory <br>MAB therapy with 4mg Zoledronic acid at every 4 weeks	1 PSA nadir rate  2 Time to PSA nadir	Department of Urology, Keio University School of Medicine	Male	Not applicable - 85years-old	96	non	Interventional Study	Parallel Randomized		12/01/2009				05/10/2009					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003142		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Japan	Urological	Prostate Cancer	Zoledronic Acid	Biomarker	Phase 2	DB00399	N
JPRN-jRCTs031180183	Phase 1 study of Disulfiram and Nivolumab for gastric cancer		Complete	Gastric cancer <br>gastric cancer;gastric cancer	Disulfiram (po): 160mg three times daily (480mg/day) or 80mg three times daily (240mg/day) for maximum 6 cycles.<br>Nivolumab (iv): 240mg every 2 weeks for maximum 6 cycles.<br>1 cycle is for 28 days.	Rate of DLT (dose limiting toxicities) expression	Shitara Kohei	All	>= 20age old - Not applicable	16	AMED	Interventional Study	single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose		03/04/2019				05/03/2019					17/10/2023	https://jrct.niph.go.jp/latest-detail/jRCTs031180183		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Japan	GI	Gastric Cancer	Disulfiram	Safety and/or Dose	Phase 1	DB00822	N
JPRN-jRCTs071180031	Newly diagnosed elderly symptomatic multiple myeloma: phase 2 study		Not Recruiting	Multiple myeloma <br>Multiple myeloma;Multiple myeloma	scVRD induction : Four 3-week cycles of scVRD. Cycle 1, subcutaneous bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11, oral Lenalidomide 25 mg on days 1 to 14, and dexamethasone 40 mg/day on days 1, 4, 8, 11. Cycle2-4, subcutaneous bortezomib 1.3 mg/m2 on days 1, 8 and 15, Lenalidomide 25 mg on days 1 to 14, and dexamethasone 40 mg/day on days 1, 8 and 15. <br><br>scBor-plerixafor-G-CSF PBSC mobilization : subcutaneous bortezomib 1.3 mg/m2 on days 1 and 4, and subcutaneous plerixafor 0.24 mg/ kg on day 4 and G-CSF 10ug/kg on day1-5 and PBSCH after day 5. The collection goal is 2.0x10^6 CD34+ cells/kg. <br><br>High dose chemotherapy and PBSCT : subcutaneous bortezomib 1.3mg/m2 on days -4,-1, 3 and 6, L-PAM 70mg/m2 on days -3, and -2, and PBSCT at day 0. <br><br>IRD consolidation : Four 4-week cycles of oral ixazomib 4mg on days 1, 8 and 15, oral lenalidomide 15 mg on days 1 through 21 of each 28-days cycle, and dexamethasone 40 mg/day on days 1, 8 and 15. <br><br>Lenalidomide maintenance : 4-week cycles of oral lenalidomide 10 mg on days 1 through 21 of each 28-days cycle until disease progression or intolerable adverse event.	Complete response (CR) rates after consolidation therapy.	Tanimoto Kazuki	All	>= 66age old - <= 75age old	49	Bristol-Myers Squibb Company;Bristol-Myers Squibb Company	Interventional Study	single arm study, open(masking not used), no treatment control/standard of care control, single assignment, treatment purpose	UMIN000028421	28/11/2017				05/03/2019					17/10/2023	https://jrct.niph.go.jp/latest-detail/jRCTs071180031		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Japan	Other Haem-onc	Multiple Myeloma	Plerixafor	Response rate	Phase 2	DB06809	N
CTRI/2019/09/021060	Effect of addition of zoledronic acid to chemotherapy in improving the response of tumor before surgery, in women with breast cancer (triple negative subtype)		Not Yet Recruiting	Health Condition 1: C50- Malignant neoplasm of breastHealth Condition 2: C50- Malignant neoplasm of breast	Intervention1: Zoledronic acid: Addition of Zoledronic acid to standard of care neoadjuvant chemotherapy<br>Inj. Zoledronic acid 4mg in 100ml saline given intravenously over 30 min - every 21 days<br>Control Intervention1: NIL: NIL<br>	Pathological complete response rate of 42 percentTimepoint: 6 months	Intramural fund of JIPMER	-	-	107	Intra-mural Funding Committee, Jawaharlal institute of postgraduate medical education and research, puducherry	Interventional Study	Single Arm Trial<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable		11/09/2019				04/09/2019					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=35887		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	India	Breast	Breast Cancer - TNBC	Zoledronic Acid	Response rate	Phase 2	DB00399	N
CTRI/2017/08/009265	Role of Nelfinavir during chemoradiation for Cervical Cancer		Open to Recruitment	Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified	Intervention1: Nelfinavir Arm: If patient is randomized to nelfinavir arm then nelfinavir will be started at the dose of 1250 mg bid 5-7 days prior standard treatment which consist of concurrent chemoradiation and brachytherapy.<br>Control Intervention1: Standard Arm: If patient is randomized to standard arm patient will receive concurrent chemoradiation and brachytherapy.<br>	      ?      Improvement in disease free survival at 3 years, by the addition of Nelfinavir to patients with advanced carcinoma of cervix and receiving standard chemoradiation (Cisplatin and Radiotherapy).Timepoint: 3 years	Tata Memorial Centre and Varian International	-	-	348	DAE-CTC, CRS Department, 3rd Floor, Main Building, Tata Memorial Hospital, Parel, Mumbai-400012;Varian Medical Systems Foundation,3100 Hansen Way, M/S E-190 , Palo Alto, CA 94304	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Permuted block randomization, fixed  Method of allocation concealment:On-site computer system  Blinding and masking:Open Label		16/01/2018				04/08/2017					17/10/2022	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=18147	Primary/Main Curative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Gynaecological	Cervical Cancer	Nelfinavir	DFS/RFS/EFS	Phase 3	DB00220	N
JPRN-UMIN000021750	A clinical trial to inspect whether varicella zoster virus vaccine inoculation induces antitumor immunity in patients with adult T-cell leukemia / lymphoma		Complete: follow-up continuing	Adult T-cell leukemia/lymphoma	VZV vaccine<br>Combination chemotherapy including Mogamulizumab	Whether VZV vaccine inoculation can induce anti-HTLV-I specific CTL or not?	Japanese Red Cross Nagasaki Genbaku Hospital	All	20years-old - Not applicable	10	The Research Foundation for Microbial Diseases of Osaka University	Interventional Study	Parallel Non-randomized	jRCTs051180107	25/04/2016				04/04/2016					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025084		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Japan	Leukemia; Lymphoma	Any lymphoma	Varicella vaccine	Safety and/or Dose; Biomarker	Phase 2	Not found in DrugBank	N
ISRCTN13489936	Effect of L-alanyl L-glutamine dipeptide on diarrhea, treatment response, and patients' survival in colon cancer patients receiving chemotherapy		Ongoing	Incidence of diarrhea in colon cancer patients receiving mFOLFOX-6 therapy <br>Signs and Symptoms	<br>                Treatment Plan (Chemotherapy)<br>                All patients will be treated with the standard mFOLFOX-6 consisting of 2-hour intravenous (IV) infusion of oxaliplatin (85 mg/m  ) on day 1, and 2-hour IV drip infusion of calcium folinate (400 mg/m  ) on day 1, followed by IV injection of 5-FU (400 mg/m  ) and continuous infusion of 5-FU (1200 mg/m  ) on days 1-2 (Total 2400 mg/m   over 46-48 hours). The intravenous infusion will be continued every 2 weeks.<br>                Patients will be randomized to receive glutamine dipeptide or not receive glutamine dipeptide (control group). In the glutamine dipeptide group, (N(2)-L-Alanyl-L-Glutamine Dipeptide, (Dipeptiven), by Fresenius Laboratories, Germany) will be given IV  in a dose of 20 gm/100ml on the day 1-2 regimen every 2 weeks.<br><br>                Follow up<br>                The included patients enrolled in both groups will be evaluated at the baseline (prior to chemotherapy) and after two, four, and six cycles of treatment. Treatment response to chemotherapy will be assessed every two cycles according to the Response Evaluation Criteria in Solid Tumors (RECIST). Treatment-related toxicities will be estimated according to standard World Health Organization (WHO) criteria.  Diarrhea will be graded according to the National cancer institute. In case of diarrhea grades I and II, only supportive therapy will be considered. Grade III diarrhea will be managed with supportive therapy, IV fluids and hospitalization. Chemotherapy will be postponed till complete recovery and the dose of chemotherapy will be reduced. Regarding patients with grade IV diarrhea, they will be admitted to the ICU and given IV fluids, supportive care, monitoring of electrolytes and chemotherapy will be stopped until complete recovery with dose re	<br>                At baseline (prior to chemotherapy) and after two, four, and six cycles of treatment:<br>                1. Treatment response to chemotherapy will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST)<br>                2. Diarrhea will be graded according to the National cancer institute.<br>	Taif University	All	-	100	Taif University	Interventional Study	Interventional randomized controlled trial (Treatment)	Nil known;Nil known;34918/3	01/04/2022				04/03/2022					14/03/2022	https://www.isrctn.com/ISRCTN13489936		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Egypt	GI	Colon Cancer	L-Glutamine	Response rate; Other (specify)	Other	DB00130	N
JPRN-UMIN000016438	A feasibility study of the metronomic chemotherapy using oral tegafur-uracil and cyclophosphamide for recurrent gynecological cancers		Recruiting	advance and recurrent gynecological cancer	UFT,cyclophosphamide,celecoxib	Safety  Disease Control Rate	Saitama Medical University International Medical Center	Female	20years-old - Not applicable	30	Saitama Medical University International Medical Center	Interventional Study	Single arm Non-randomized		03/01/2013				04/02/2015					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019089		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Japan	Gynaecological	Endometrial Cancer; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian - Other; Primary Peritoneal Cancer; Fallopian Tube Cancer	Celecoxib	Safety and/or Dose; Other (specify)	Not available/Missing	DB00482	N
CTRI/2020/11/028826	Effects of Anaesthesia On Immune Suppression, Inflammation AND Metastasis Of Breast Cancer.		Closed to Recruitment of Participants	Health Condition 1: C50- Malignant neoplasm of breast	Intervention1: Propofol TIVA: Maintenance of anaesthesia will be done using target controlled infusion of propofol, using Schnieder model for effect site concentration, along with endotracheal intubation and controlled ventilation.<br>Control Intervention1: Volatile Anaesthetic.: Maintenance of anaesthesia will be done using volatile inhaled anaesthetics namely isoflurane, nitrous oxide (1-1.3 MAC) along with endotracheal intubation and controlled ventilation.<br>	Frequency and activity of NK cellsTimepoint: 1. Intra-operatively after 1 hour of incision. <br/ ><br>2. 48 hours post-operatively	Chittaranjan National Cancer Institute	-	-	40	Chittaranjan National Cancer Institute,37, SP Mukherjee Road,Kolkata, 700026	Interventional Study	Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Random Number Table  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant and Outcome Assessor Blinded		18/11/2020				03/11/2020					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48408		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Breast	Any Breast Cancer	Propofol	Biomarker	Not available/Missing	DB00818	N
CTRI/2017/02/007777	Study of chemotherapy treatment after completion of standard treatment		Not Yet Recruiting	Health Condition 1: null- Patients with locally advanced oral cancers post surgery and appropriate adjuvant treatment	Intervention1: In arm B adjuvant metronomic would be administered.: Metronomic chemotherapy is the study intervention in this trial. The metronomic chemotherapy constitutes of methotrexate and celecoxib.<br>Oral methotrexate tablet 15 mg/m2 will be administered weekly ie on D1,D8, D15 and D22 of every 28 day cycle.  <br>Capsule celecoxib would will be self administered twice daily in a dose of 200 mg BID continuously .<br>The combination will be continued to a maximum of Such 18 cycles; unless prohibitive toxicity or   disease progression occurs prior. will be delivered.<br><br>Control Intervention1: In arm Aobservation would be done. The schedule of observation will be in accordance with the institutional follow up protocol  <br>: In arm Aobservation would be done. The schedule of observation will be in accordance with the institutional follow up protocol  is as below<br>First year : Patient would be followed up at 3 monthly intervals. Clinical history and examination would be done. Blood investigations like complete hemogram, renal function tests and TSH would be done. FACT QOL H N would be filled at baseline and at 6 months<br>Second year :  Patient would be followed up at 4 monthly intervals. Clinical history and examination would be done. Blood investigations like complete hemogram, renal function tests and TSH would be done sos. <br>Third year-Fifth year : Patient would be followed up at 6 monthly intervals. Clinical history and examination would be done. Blood investigations like complete hemogram, renal function tests and TSH would be done sos. <br>Post fifth year : Patient would be followed up at 1 year intervals. Clinical history and examination would be done. Blood investigations like complete hemogram, renal function tests and TSH would be done SOS.<br>	1.2 year OS : OS will be defined time in days between date of randomization to date of death. Patients alive at their last follow ups would be censored. The 2 year OS would be estimated by Kaplan meier analysis and would be compared between the 2 arms by the log rank testTimepoint: at two year post treatment	Tata Memorial Hospital	-	-	712	Tata Memorial HospitalDr. E. Borges Road, Parel (east)Mumbai	Interventional Study	Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Stratified randomization  Method of allocation concealment:Other  Blinding and masking:Not Applicable	Protocol No 1708 Version 1.0 dated 16 June 2016	03/02/2017				03/02/2017					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=16667		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	India	Head and Neck	Any head and neck squamous cell carcinoma	Celecoxib	OS	Not available/Missing	DB00482	N
ACTRN12621000223831	Efficacy of assigning treatment for participants with Chronic Myelomonocytic Leukaemia based on their individual molecular results (lenzilumab plus azacitidine versus sodium ascorbate plus azacitidine).		Recruiting	Chronic Myelomonocytic Leukaemia; <br>Chronic Myelomonocytic Leukaemia;Cancer - Leukaemia - Chronic leukaemia	This prospective study will assess whether treatment responses for participants with Chronic Myelomonocytic Leukaemia can be improved by targeting certain mutation sub-groups based on individual molecular profiling. <br><br>As part of the screening process, participants will be required to have a bone marrow aspirate and trephine.  During this procedure, 9 mL of bone marrow aspirate will be collected for central mutation profiling which is a test used to detect certain acquired mutations that can be present in CMML.  The most common genes affected in CMML include TET2 and a group of genes belonging to the RAS pathway (NRAS/KRAS/CBL).  Both TET2 and RAS pathway genes contribute to CMML, but the way in which they work is different.  As a result, we need to tailor our medications specifically to switch them off.  Before participants are enrolled in this research study, we will need to assess whether either of these groups of genes have been affected in their case.  If they are, the participant may be eligible for this study.  Genetic testing is complex and it will take approximately 3 weeks for results to become available.<br><br>Participants with RAS pathway mutations in will receive lenzilumab in combination with azacitidine, while patients with TET2 mutations will receive sodium ascorbate plus azacitidine.      Participants who are found to have both TET2 and RAS pathway mutations (NRAS/KRAS/CBL) will be allocated to the lenzilumab/azacitidine arm of the study. Participants who are negative for both TET2 and NRAS/KRAS/CBL mutations (Variant Allele Frequency [VAF] >= 3 ) at screening will be considered screen failures.  <br><br>Drug schedules:<br>Lenzilumab/Azacitidine Arm (total of 24 Cycles).  Each Cycle is 28 days.<br> € Azacitidine (subcutaneous) 75 mg/m2 on days 1-5,	To assess the frequency of complete response (CR) and partial response (PR) at any point during the first 12 cycles of active therapy according to Savona Criteria. (composite outcome)[ Any point during the first 12 cycles]	South Australian Health   Medical Research Institute Ltd	All	18 Years - No limit	72	Medical Research Future Fund Grant, National Health and Medical Research Council.	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Assignment: Parallel;Type of endpoint: Efficacy;		28/09/2021				03/03/2021					13/11/2023	https://anzctr.org.au/ACTRN12621000223831.aspx		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Australia	Leukemia	Chronic Myelogenous Leukemia	Ascorbic acid	Response rate	Phase 2	DB00126	N
CTRI/2019/01/016837	Comparision of two types of chemotherapy regimen in head and neck cancer		Not Yet Recruiting	Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx	Intervention1: Triple Metronomic: Chemotherapy will be administered with tablet erlotinib 150 mg ( fixed dose ) PO OD daily, capsule celecoxib 200 mg ( fixed dose ) PO  BD daily  and oral weekly methotrexate 9 mg/m2. Schedule will be repeated at 4 weekly intervals. Intervention will be till progression or intolerable side effects.<br>Intervention2: Docetaxel: Docetaxel will be administered (75 mg/m2) on day 1 in 3 weekly cycles.<br>Docetaxel will be administered till progression or intolerable side effects.<br>Control Intervention1: Best Supportive Care: Patient will receive supportive treatment.<br>1.Analgesic for pain<br>2.Antibiotics and dressing for fungating wounds<br>3.Nutritional support :ryle tube insertion, enteral supplementations<br>4.Antitussive for cough<br>5.Physiotherapy and exercises for trismus<br>6.Distress counselling if present by physicians<br>7.Others : symptomatic treated directed towards symptoms<br><br>	Phase II <br/ ><br>1.Disease control rate <br/ ><br>Phase III <br/ ><br>1.Over all survival  <br/ ><br> <br/ ><br> <br/ ><br>Phase III <br/ ><br>1.Over all survival <br/ ><br>Timepoint: Phase II <br/ ><br>1.6 weeks <br/ ><br>Phase III <br/ ><br>1.6 months <br/ ><br>	Tata Memorial Hospital	-	-	455	Tata Memorial Hospital	Interventional Study	Randomized, Parallel Group, Multiple Arm Trial<br>  Method of generating randomization sequence:Adaptive randomization, such as minimization  Method of allocation concealment:On-site computer system  Blinding and masking:Open Label		11/02/2019				02/01/2019					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=28826		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	Y	N	India	Head and Neck	Any head and neck cancer	Celecoxib	OS; DFS/RFS/EFS	Phase 2/3	DB00482	N
JPRN-UMIN000002435	Assessment of a combination therapy with Candesartan and Celecoxib for patients with advanced hepatocellular carcinoma after transhepatic arterial chemoembolization.		Recruiting	unresectable advanced hepatocellular carcinoma	Celecoxib and Candesartan<br>plasebo	Time to progression	Kurume University, School of Medicine,Department of Medicine, Division of Gastroenterology	All	20years-old - Not applicable	80	Kurume University, School of Medicine,Department of Medicine, Division of Gastroenterology	Interventional Study	Parallel Randomized		09/01/2008				02/09/2009					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002980		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Japan	GI	Liver Cancer	Candesartan; Celecoxib	Other (specify)	Phase 2	DB13919; DB00482	N
CTRI/2018/03/012274	A clinical trial to study the effects of two drugs, Curcumin and Metformin in patients with history of head and neck squamous cell cancers		Open to Recruitment	Health Condition 1: null- Patients who have had curative intent treatment for head and neck squamous cell carcinoma	Intervention1: Curcumin Capsule: 1.2 gm once daily oral for 36 months<br>Intervention2: Metformin Tablet: 1 gm once daily oral for 36 months<br>Control Intervention1: Curcumin Placebo: 1.2 gm once daily oral for 36 months<br>Control Intervention2: Metformin Placebo: 1 gm once daily oral for 36 months<br>	To determine the efficacy of curcumin and metformin to reduce the incidence of second primary tumors of aero-digestive tract following curative intent treatment of head and neck squamous cell carcinomasTimepoint: Every 3 months upto the incidence of second primary tumor	National Cancer Grid	-	-	1500	National Cancer Grid (Department of Atomic Energy, Government of India),Room No 1231,12th Floor,Homi Bhabha Block,Tata Memorial Centre,Dr E Borges Road,Parel,Mumbai 400012	Interventional Study	Randomized, Parallel Group, Placebo Controlled Trial<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Not Applicable  Blinding and masking:Double Blind Double Dummy		02/04/2018				01/03/2018					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=21431		Other (specify)	Local/National government	Y	N	N	India	Head and Neck	Any head and neck squamous cell carcinoma	Metformin	Recurrence rate	Phase 2/3	DB00331	N
CTRI/2019/02/017394	Pioglitazone study in Blood cancer		Not Yet Recruiting	Health Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positive	Intervention1: Pioglitazone tablets: Intervention is Tab.Pioglitazone and the comparator agent is Placebo. Both arms will receive Tab.Imatinib at 400 mg od, the standard of care. Pioglitazone will be started at 30 mg od and will be given for 2 months. Subsequently, if tolerated, the dose will be increased to 45 mg od. This will be given for another 10 months, for a total of 12 months.<br>Control Intervention1: Placebo: Comparator agent is Placebo. Both arms will receive Tab.Imatinib at 400 mg od, the standard of care. Pioglitazone will be started at 30 mg od and will be given for 2 months. Subsequently, if tolerated, the dose will be increased to 45 mg od. This will be given for another 10 months, for a total of 12 months.<br>	Proportion of patients achieving Major Molecular Response (MMR) at 12 monthsTimepoint: Proportion of patients achieving Major Molecular Response (MMR) at 12 months	Christian Medical College Vellore	-	-	82	Institution funded study - Academic study	Interventional Study	Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Pre-numbered or coded identical Containers  Blinding and masking:Participant and Investigator Blinded		04/02/2019				01/02/2019					24/11/2021	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30395		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Leukemia	Chronic Myelogenous Leukemia	Pioglitazone	Response rate	Not available/Missing	DB01132	N
TCTR20190701001	Phase II, Multi-Center, Open-Label, Single-Arm Study Evaluating the Efficacy and Safety of Mycophenolate Mofetil in Patients with High-Grade Locally Advanced or Metastatic Osteosarcoma (ESMMO)		Recruiting	High-grade locally advanced or metastatic osteosarcoma <br>Osteosarcoma;Osteosarcoma	Mycophenolate mofetil is normally used for the prophylaxis of organ rejection following transplantation.;Experimental Drug;Mycophenolate mofetil	Progression -free survival at 16 weeks CT/MRI	Faculty of Medicine, Chiang Mai University	All	13 Years - N/A (No limit)	27	National Science and Technology Development Agency (NSTDA)	Interventional Study		ESMMO-2019	01/08/2019				01/07/2019					19/12/2023	https://www.thaiclinicaltrials.org/show/TCTR20190701001		Advanced/Metastatic	Hospital/University/Research Institute	N	N	Y	Thailand	Bone Sarcoma	Osteosarcoma	Mycophenolate	PFS	Phase 2	DB01024	N
JPRN-UMIN000027795	The phaseII study of the efficacy of Abirateron acetate and Dutasteride therapy for castration resistant prostate cancer.		Pending	castration resistant prostate cancer	Patients is treated with abiraterone (1,000 mg daily) and prednisone (5 mg daily) for two 4-week cycles. After this time, dutasteride (0.5 mg daily) is added for 12 weeks. Patients continue on the three-drug regimen until study withdrawal or radiographic disease progression.	the rate of patients with over fifty percent reduction in PSA	Department od Urology, Yamaguchi Graduate School of Medicine	Male	50years-old - 90years-old	20	Grant-in-Aid for Scientific Research	Interventional Study	Single arm Non-randomized		08/01/2017				01/07/2017					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029208		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Japan	Urological	Prostate Cancer	Dutasteride	Biomarker	Phase 2	DB01126	N
JPRN-UMIN000031532	Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE III)		Recruiting	Stage III colorectal cancer	A:Placebo. Patients in this group receive placebo for 3 years with adjuvant chenmotherapy(mFOLFOX6, CAPOX ,or capecitabine). <br>B:Aspirin. Patients in this group receive aspirin, at a dose of 100 mg for 3 years with adjuvant chenmotherapy(mFOLFOX6, CAPOX ,or capecitabine).	Disease-free survival	Japan Clinical Oncology Group (JCOG)	All	20years-old - 80years-old	880	Japan Agency for Medical Research and Development	Interventional Study	Parallel Randomized		30/03/2018				01/03/2018					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035650	Adjuvant/Maintenance	Localised/Locoregional	Collaborative Group	Y	N	N	Japan	GI	Colon Cancer; Rectal Cancer	Acetylsalicylic Acid	DFS/RFS/EFS	Phase 3	DB00945	N
JPRN-UMIN000003261	Randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant   treatment in patients with primary breast cancer		Recruiting	Breast Cancer	FEC100 (500/100/500 mg/m2) every 21 days for 4 cycles followed by weekly Paclitaxel 80 for 12 cycles (or weekly Paclitaxel 80 followed by FEC100).<br>Patients receive zoledronic acid 4mg or an adjusted dose used renal function IV over 15 minutes infusion every 3-4 weeks for 6 months ( 6-7 times infusion).	Pathological complete response rate:pCR	JONIE Study Group	Female	20years-old - 70years-old	180	None	Interventional Study	Parallel Randomized		03/01/2010				01/03/2010					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003949		Localised/Locoregional	Collaborative Group	Y	N	N	Japan	Breast	Any Breast Cancer	Zoledronic Acid	Response rate	Phase 2	DB00399	N
JPRN-jRCTs031200326	A phase I/II study of maintenance therapy with metformin and temozolomide for newly diagnosed glioblastoma patients		Recruiting	Glioblastoma	1) Concomitant phase,<br>metformin (level1 , everyday) 7days<br><br>2) Maintenance phase, metformin and temozolomide<br>temozolomide (150mg/m2, day1-5, every 4 weeks) and metformin (level3 , everyday) 1 cycle<br>temozolomide (150mg/m2, day1-5, every 4 weeks) and metformin (level3 , everyday) 5 cycles<br><br>3) Metformin alone<br>metformin (level3 , everyday) 365days	Phase I:Dose limiting toxicity (DLT) occurrence rate,Phase II:12-month progression-free survival rate	Narita  Yoshitaka	All	>= 20age old - < 75age old	22	Japan Agency for Medical Research and Development	Interventional Study	single arm study, open(masking not used), active control, single assignment, treatment purpose		01/11/2020				01/02/2021					17/10/2023	https://jrct.niph.go.jp/latest-detail/jRCTs031200326		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Japan	CNS	Glioblastoma	Metformin	Safety and/or Dose; PFS	Phase 1/2	DB00331	N
ChiCTR2100049941	Clinical project of new chemotherapy regiments for glioblastoma multiform (GBM)		Pending	glioblastoma multiform	Two groups:TMZ combined with levetiracetam chemotherapy;	patient survival;	the Second Affiliated Hospital of Chongqing Medical University	All	18 - 65	Two groups:142;	Chongqing joint medical scientific research project, the National Nature Science Foundation of People's Republic of China (81401500), Science Foundation of Chongqing (X0231), the High-level Medical Re	Interventional Study	Parallel		30/11/2021				14/08/2021					19/04/2022	http://www.chictr.org.cn/showproj.aspx?proj=131815		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	China	CNS	Glioblastoma	Levetiracetam	OS	Not available/Missing	DB01202	N
ChiCTR2100049694	Effect of Lidocaine on CD4 + / CD8 + T cells and body stress in patients  undergoing gastric cancer surgery		Pending	N/A	Experimental group:Intravenous Lidocaine;Control group:Intravenous physiological saline;	CD4+T cell;CD8+T cell;tumor recurrence rate;	First Affiliated Hospital of Soochow University	All	-	Experimental group:50;Control group:50;	National Natural Science Foundation of China (grant number 81873925), Jiangsu Provincial Medical Youth Talent (grant number QNRC2016741)	Interventional Study	Parallel		08/10/2021				08/08/2021					19/04/2022	http://www.chictr.org.cn/showproj.aspx?proj=131704		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	GI	Gastric Cancer	Lidocaine	Biomarker	Phase 2	DB00281	N
IRCT20210703051770N1	Evaluation and comparison of treatment regimens in patients with acute leukemia.		Recruiting	Acute T cell leukemia. <br>Adult T-cell lymphoma/leukemia (HTLV-1-associated);C91.5	Intervention 1: Intervention group: In the intervention group, the Hyper CVAD drug regimen is performed in alternating cycles A and B. Cycle A: Cyclophosphamide 300 mg / m2 every 12 hours on days 1, 2, and 3. Vincristine 2 mg / m2 on days 4 and 11. Adriamycin (doxorubicin) 50 mg / m2 on day 4 Dexamethasone 40 mg on days 1, 4, 11, 12, 13 and 14. Methotrexate 12.5 mg with dexamethasone 4 mg intrathecally on day 2. Cycle B: Methotrexate 1 g / m2 on day 1. Cytosar 3 g / m2 every 12 hours on days 2 and 3. Intrathecal methotrexate on day 2. Cyclophosphamide (importer of Sina Pishgam Drug New), Wayne Christine (importer of Valian Drug), Adriamycin (Behestan Drug Company), Vial of methotrexate (Kavosh Daro Gostar Co.), Interferon (Aktor and Sinagen Co.). Intervention 2: Control group: Intravenous arsenic 10 mg daily for 5 days a week. Subcutaneous interferon 5 million units per day. Zidovudine 900 mg daily in 3 doses.	Complete Remission. Timepoint: Weekly from before the intervention (beginning of the study) to 60 days after the intervention. Method of measurement: Based on complete response to treatment (Achieving remission or not getting remission) Through chemical tests and CBC.;One-year survival. Timepoint: On a daily basis from before the intervention (beginning of the study) to 60 days after the intervention. Method of measurement: Based on the individuals' survival rate (Calculate the number of days to survive until death) Through the occurrence of death in two groups.	Mashhad University of Medical Sciences	All	18 years - no limit	36	Mashhad University of Medical Sciences	Interventional Study	Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization:  This type of randomization will be done using the site https://www.sealedenvelope.com. In this method, the volume of each block must first be determined. Then, a list of the blocks are prepared and numbers are assigned to each (AABB (1) - ABAB (2) -ABBA (3) -BBAA (4) - BABA (5) - BAAB (6)). In the next step, random numbers from 1 to 6 are selected (e.g. 1 4 5, etc.) and finally, the treatment allocation list is specified based on the previous random numbers (AABB-BBAA-BABA- € ), Blinding description: In this study, participants are blinded to the intervention received based on codes (codes A and B) that people are unaware of the type of intervention received and only researchers are aware of it. Also, the drugs are the same in shape, color and coating to allow blindness at the participant level.		25/03/2022				29/04/2022					05/02/2022	http://en.irct.ir/trial/61873		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Iran	Leukemia	Leukemia - Other	Zidovudine	Response rate	Phase 2	DB00495	N
IRCT20220409054463N1	Metformin as a chemotherapeutic agent		Pending	Endometrial carcinoma. <br>Malignant neoplasm of endometrium;C54.1	Intervention 1: Intervention group: In this study, we intend to refer patients with endometrial cancer who have been referred to Mahdieh / Imam Hossein (AS) Hospital, and are on the list of gynecological surgeries of this hospital, regardless of histological and surgical staging, for at least 4 weeks. Metformin 500 mg tablets are given orally every 8 hours. For each volunteer a form containing basic personal information and demographic information including age, BMI at the time of admission and day of surgery, pregnancy and parity, underlying disease, smoking, menopause, date of first diagnosis And the suggested time for surgery is filled. Patients with the above criteria, after filling out the form related to the initial information, an endometrial sample prepared by pipelle biopsy or curettage will be sent to the pathology department of Imam Hossein Hospital for examination and staining of ki-67 and p-53. And is examined by one pathologist. Patients are given a box of 100 metformin 500 tablets. Explanations about how to take the drug, its side effects, including gastrointestinal symptoms and symptoms of hypoglycemia, etc., and a contact number to communicate with patients participating in the project will be given to the patient by the medical team. All patients will receive treatment according to standard guidelines, and metformin will be discontinued 48 hours before anesthesia to prevent the risk of lactic acidosis. Intervention 2: Control group: In this study, we intend to refer patients with endometrial cancer who have been referred to Mahdieh / Imam Hossein (AS) Hospital, and are on the list of gynecological surgeries of this hospital, regardless of histological and surgical staging, for at least 4 weeks. Metformin 500 mg tablets are given orally every 8 hours. F	Changes in the expression of ki-67 gene in tissue samples of endometrial cancer  after using metformin. Timepoint: Before treatment and on the day of surgery. Method of measurement: Ki-67 tissue staining (IHC).;Determining the effect of metformin use in reducing body mass index. Timepoint: Before treatment and on the day of surgery. Method of measurement: Measuring Body Mass Index (weight over height^2).;Determining the effect of metformin on tumor size reduction. Timepoint: Before treatment and on the day of surgery. Method of measurement: Measurement of mass during diagnosis by ultrasound and by the  surgeon.;Changes in p-53 gene expression in endometrial cancer tissue samples after metformin use. Timepoint: Before treatment and on the day of surgery. Method of measurement: P-53 tissue staining (IHC).	Shahid Beheshti University of Medical Sciences	Female	20 years - no limit	40	Shahid Beheshti University of Medical Sciences	Interventional Study	Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple individual randomization, using the Rand function of Excel software, Blinding description: The study is double-blind, and the patient, caregiver, and researcher do not know which category the patient is in (metformin or placebo).		21/06/2022				27/04/2022					05/02/2022	http://en.irct.ir/trial/63034		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Iran	Gynaecological	Endometrial Cancer	Metformin	Response rate; Biomarker	Phase 1/2	DB00331	N
ChiCTR2100050796	Effects of lidocaine and dexmedetomidine on perioperative tumor metastasis markers and inflammatory markers in patients undergoing thoracoscopic lung cancer resection		Recruiting	lung cancer	Control group:Intravenous pumping 0.9 NS;Lidocaine group:Intravenous pumping lidocaine;Dexmedetomidine group:Intravenous pumping dexmedetomidine;Lidocaine combined with dexmedetomidine group:Intravenous pumping lidocaine and dexmedetomidine;	Myeloperoxidase (MPO), a specific index of neutrophils  extracellular trapping net in serum ;	Affiliated Hospital of Xuzhou Medical University	All	18 - 70	Control group:33;Lidocaine group:33;Dexmedetomidine group:33;Lidocaine combined with dexmedetomidine group:33;	Talent introduction of scientific research start-up funds	Interventional Study	Parallel		21/07/2022				09/04/2021					23/08/2022	http://www.chictr.org.cn/showproj.aspx?proj=133132		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Lung	Any lung cancers	Lidocaine	Biomarker	Phase 2	DB00281	N
CTRI/2022/05/042576	Metformin with  chemotherapy in Triple negative and Her2neu positive breastcancer - a randomisedstudy		Open to Recruitment	Health Condition 1: C509- Malignant neoplasm of breast of unspecified site	Intervention1: Metformin with standard Neo-Adjuvant chemotherapy: Tab Metformin - 850mg PO twice daily for 18-22 weeks<br>Control Intervention1: standard Neo-adjuvant chemotherapy: standard Neo-adjuvant chemotherapy<br>	the pathological complete response rates(ypT0ypN0) in each arm.Timepoint: 18-22 weeks	All India Institute of Medical Sciences	-	-	242	All India Institute of Medical Sciences, New Delhi	Interventional Study	Randomized, Parallel Group Trial   Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label		21/05/2022				17/05/2022					21/08/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=68786		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Breast	Breast Cancer - TNBC; Breast Cancer - HER2+	Metformin	Response rate	Phase 2	DB00331	N
JPRN-jRCTs041220024	A Phase 1 study of Fasudil with MAP targeting cancer stem cell.		Pending	High grade osteosarcoma	fasudil hydrochloride hydrate as an IV infusion;fasudil hydrochloride hydrate	Dose limiting toxicity<br>Maximum tolerated dose	Fujita Nobuyuki	All	>= 14age old - < 65age old	18		Interventional Study	single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose		31/05/2022				31/05/2022					17/10/2023	https://jrct.niph.go.jp/latest-detail/jRCTs041220024		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Japan	Bone Sarcoma	Osteosarcoma	Fasudil	Safety and/or Dose	Phase 1	DB08162	N
ISRCTN73037722	LION: lifting immune checkpoints with NSAIDs		Ongoing	Triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) <br>Cancer <br>Malignant neoplasm of breast, Malignant neoplasm of bronchus and lung, Malignant neoplasm of kidney, except renal pelvis	<br>                Interventions: ALL cohorts<br>                IMP: Celecoxib<br>                Form: Capsule<br>                Dose: 200 mg twice daily for 4 weeks then 100 mg twice daily (continuous until disease progression or stopping immune therapy)<br>                Route: Oral<br><br>                TNBC:<br>                IMP: Atezolizumab<br>                Form: Solution for infusion<br>                Dose: 840 mg on day 1 and day 15 of a 28-day cycle (until disease progression or unacceptable toxicity; patients who are no longer also receiving concurrent Nab-paclitaxel can receive 1680mg d1 of a 28-day cycle)<br>                Route: intravenous (IV)<br><br>                IMP: Nab-paclitaxel<br>                Form: Powder for suspension for infusion<br>                Dose: 100 mg/m   day 1,8,15 of a 28-day cycle (continuous until disease progression)<br>                Route: IV<br><br>                RCC:<br>                IMP: Nivolumab<br>                Form: Concentrate for solution for infusion<br>                Dose: 3 mg/kg every 21 days for the first four cycles and then flat dosed at 480 mg every 28 days (continuous until disease progression)<br>                Route: IV<br><br>                IMP: Ipilimumab<br>                Form: Concentrate for solution for infusion<br>                Dose: 1 mg/kg every 21 days for the first four cycles<br>                Route: IV<br><br>                NSCLC:<br>                IMP: Pembrolizumab<br>                Form: Solution for infusion<br>                Dose: 200 mg every 21 days or 400 mg every 42 days (maximum treatment duration 2 years)<br>                Route: IV<br><br>                Duration of treatment:<br>                All patients will be treated until progressive disease, unacceptable toxicity, end of trial or withdrawal of patient consent. In the case of pembrolizumab patient m	<br>                Best overall response rate (complete response plus partial response) using RECIST criteria and CT scan<br>                during the course of follow-up. For all cohorts a minimum follow-up of 6 months for all patients who do not experience progression prior to 6 months post start of treatment<br>	Christie Hospital NHS Foundation Trust	All	-	89	Jon Moulton Charity Trust, Christie Charity	Interventional Study	Non-randomized study (Treatment)	2021-005109-29;Nil known;CFTSp198, IRAS 1004222	24/04/2023				02/08/2022					13/02/2023	https://www.isrctn.com/ISRCTN73037722		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United Kingdom	Breast; Lung; Urological	Breast Cancer - TNBC; Non-Small Cell Lung Cancer; Renal Cell Carcinoma	Celecoxib	Response rate	Phase 2	DB00482	N
ACTRN12622001201763	Targeting the Renin-Angiotensin System in Glioblastoma (TRAS-GB) Trial		Not yet recruiting	Glioblastoma; <br>Glioblastoma;Cancer - Brain	Study medication is introduced in a step-wise manner, starting 4 weeks after completion of surgery and radiotherapy and the first cycle of chemotherapy (Temozolomide (TMZ)).<br><br>The study treatment consists of six oral medications.  The dosage of the medications is increased over a 4 week period, and the treatment is maintained for the duration of the study.  The total duration of the study is 4 years.<br><br>The dosing regime is as follows;<br>1) Propranolol; week 0 - 40mg twice daily, week 1 - 80mg morning, 40mg evening, continue at this dose for the remainder of the study<br>2) Aliskiren; week 0 - 150mg once daily, continue at this dose for the remainder of the study<br>3) Curcumin with piperine; week 0 - 1000mg twice daily, continue at this dose for the remainder of the study<br>4) Celecoxib; introduced at week 4 - 200mg once daily, continue at this dose for the remainder of the study<br>5) Metformin; week 0 - 250mg once daily, week 1 - 250mg twice daily, week 3 - 500mg morning, 250mg evening, week 4 - 500mg twice daily, continue at this dose for the remainder of the study<br>6) Quinapril; introduced at week 2 - 5mg once daily, week 3 - 10mg once daily, week 4 - 20mg once daily, continue at this dose for the remainder of the study<br><br>Renal function, platelet count, blood pressure and pulse rate are monitored.	Overall median survival from diagnosis[Assessed on an ongoing basis for study duration.  The study is planned for a 4 year duration.]	Gillies McIndoe Research Institute	All	16 Years - 80 Years	75	Gillies McIndoe Research Institute	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Assignment: Single group;Type of endpoint: Efficacy;		01/02/2023				07/09/2022					09/12/2022	https://anzctr.org.au/ACTRN12622001201763.aspx		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	New Zealand	CNS	Glioblastoma	Aliskiren; Celecoxib; Metformin; Propranolol	OS	Phase 2	DB09026; DB00482; DB00331; DB00571	N
ChiCTR2100053537	An exploratory study on the synergistic effect of simultaneous hepatic arterial infusion of sodium bicarbonate injection in the treatment of hepatocellular carcinoma with anti-PD-1 monoclonal antibody		Recruiting	Hepatocellular carcinoma	Treatment group:hepatic artery catheterization and infusion of 5  sodium bicarbonate injection;	Liver-enhanced MRI lesion necrosis;	The Second Affiliated Hospital, Zhejiang University School of Medicine	All	18 -	Treatment group:30;	self-funded	Interventional Study	Single arm		30/11/2021				24/11/2021					10/04/2022	http://www.chictr.org.cn/showproj.aspx?proj=140967		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	GI	Liver Cancer	Sodium Bicarbonate	Other (specify)	Not available/Missing	DB01390	N
CTRI/2022/08/045109	Clinical trial of metformin and valproic acid combination in lung cancer		Not Yet Recruiting	Health Condition 1: C342- Malignant neoplasm of middle lobe,bronchus or lung	Intervention1: T.Metformin 1000 mg BD<br>T.Valproate 20 mg/kg/day<br>for 9 weeks in addition to chemotherapy: Metformin 1000 mg BD and Valprate 20 mg/kg/day adjusted to a target plasma concentration of 50-100 mcg/dL according to previous clinical trials and in vitro studies are given for 9 weeks in ad-dition to chemotherapy<br>Control Intervention1: NIL: NIL<br>	Overall Response Rate by using RECIST 1.1 criteriaTimepoint: 9 weeks	JIPMER Intramural fund	-	-	52	JIPMER Intramural Resarch FundJIPMER,Puducherry 605006	Interventional Study	Single Arm Study<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable	JIP/IEC/2022/58	01/09/2022				31/08/2022					17/10/2022	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=72422		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	India	Lung	Non-Small Cell Lung Cancer	Metformin; Valproic Acid	Response rate	Phase 2	DB00331; DB00313	N
CTRI/2022/08/044794	Metformin as Chemo-sensitizer in Ovarian Malignancies		Not Yet Recruiting	Health Condition 1: C569- Malignant neoplasm of unspecifiedovary	Intervention1: Metformin HCL: Patients will receive Metformin HCL orally 500mg twice daily (BD) and standard chemotherapy regimen for 3-4 cycles in neo-adjuvant settings (Total Duration 3 months)<br>Control Intervention1: Placebo: Patients will receive Placebo orally BD and standard chemotherapy for 3-4 cycles neoadjuvantly. (Total duration 3 months)<br>	Chemotherapy Response Score (CRS) and its correlation with Clinico-radiological response with CECT using RECIST 1.1 Criteria (Response Evaluation Criteria in Solid Tumors)Timepoint: Chemotherapy Response Score (CRS) and its correlation with Clinico-radiological response with CECT using RECIST 1.1 Criteria (Response Evaluation Criteria in Solid Tumors) will be done at 4-6 weeks post completion of neo-adjuvant chemotherapy	Indian Council of Medical Research	-	-	62	Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911Ansari Nagar, New Delhi - 110029, India;JN Medical College, Aligarh Muslim University, Aligarh, U.P-202002	Interventional Study	Randomized, Parallel Group, Placebo Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Case Record Numbers  Blinding and masking:Participant Blinded		01/11/2022				22/08/2022					17/10/2022	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=68406	Neo-adjuvant/Window	Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	India	Gynaecological	Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer	Metformin	Response rate	Phase 3	DB00331	N
CTRI/2022/10/046252	Investigate the effect of Propranolol and Celecoxib combine with Receptor activator of nuclear factor kappa-  ?  ?? ligand (RANKL) blockade therapy during the perioperative period of Osteosarcoma (Bone cancer) patients.		Not Yet Recruiting	Health Condition 1: C419- Malignant neoplasm of bone and articular cartilage, unspecified	Intervention1: Perioperative therapy and Denosumab with OGS-12 protocol chemotherapy: The regimen comprises of oral tablet propranolol 20 mg BD for first 10 days followed by 40<br>mg BD thereafter and Tab Celecoxib 200mg BD and these will be started on Day 8 of last<br>cycle of pre-operative chemotherapy and continued until 24 hours prior to surgery.A single dose of injection Denosumab 120 mg s/c will be administered during the first week<br>of perioperative therapy before surgery. Propranolol and Celecoxib will be restarted once oral<br>feeds have been started post-surgery. Both Propranolol and Celecoxib will be stopped when<br>patient has been started on adjuvant chemotherapy cycles as per the       ?    ?OGS-12      ?    ?   protocol. The<br>expected duration of the use of above drugs in the perioperative period is around 6-8 weeks.Participants randomized to this arm will be treated according to the       ?    ?OGS-12      ?    ?   based<br>chemotherapy alone as described above.<br>Control Intervention1: OGS-12 protocol chemotherapy: It is an in-house standard chemotherapy protocol for high grade osteosarcomas and consists<br>of dose dense, sequential doublets of cisplatinum, adriamycin and ifosfamide in four cycles<br>of neoadjuvant therapy(NACT) and four cycles of (cisplatinum and ifosfamide) as adjuvant<br>chemotherapy (ACT) delivered every 21 days.<br>	2-year Event-free survival (EFS) rate - EFS will be measured from the date of <br/ ><br>randomization to the date of progression or death. <br/ ><br>3-year Overall Survival (OS) rate       ?    ?? OS will be measured from the date of <br/ ><br>randomization to the date of death.Timepoint: Event- free survival (EFS) rate - 2 year <br/ ><br>Overall Survival (OS) rate - 3 year	Tata Memorial Hospital	-	-	86	Nil	Interventional Study	Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Case Record Numbers  Blinding and masking:Open Label		07/11/2022				07/10/2022					17/10/2022	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=73414		Localised/Locoregional	Hospital/University/Research Institute	Y	N	Y	India	Bone Sarcoma	Osteosarcoma	Celecoxib; Propranolol	OS; DFS/RFS/EFS	Phase 2	DB00482; DB00571	N
RBR-76j763k	Vitamin K3 treatment in Stomach Cancer patients in a public hospital		Recruiting	Malignant neoplasm of cardia; Malignant neoplasm of the fundus of the stomach; Malignant neoplasm of the body of the stomach; Malignant neoplasm of the pyloric antrum; Malignant neoplasm of the pylorus; Malignant neoplasm of stomach with invasive lesion	This is a two-arm, double-blind, randomized controlled clinical trial. A total of 160 patients who meet the eligibility criteria will be probabilistically allocated to one or the other intervention group using a table of random numbers. Patients received perioperative chemotherapy, that is, before and after surgery, and will be randomly assigned in a 1:1 ratio to two experimental groups, the first (80 patients regardless of gender) that will receive treatment based on 5-Fluorouracil (5-FU ) and the second (80 patients with the same gender distribution as the first group) who will receive 5-FU and menadione. Both the researchers who will assess the outcomes and the participants will not know to which group each participant belongs. Neoadjuvant treatment (before surgery) consisted of four cycles of two weeks (8 weeks). Patients must be operated on within 28 days of completing the fourth course of treatment. After recovery from the surgical procedure, patients who have not progressed previously will be treated with four additional cycles of adjuvant chemotherapy (after surgery) at the same doses and intervals as neoadjuvant treatment. Thirty days after the end of the last cycle of treatment, an appointment will be held and patients will be referred for routine care. Patients will be followed up for 24 months after resection. The following regimen will be administered to patients in the FLOT group on the first day of the cycle: a) Docetaxel, for two hours of intravenous infusion, at 50 mg/m2; b) Oxaliplatin, for two hours of intravenous infusion, at 85 mg/m2 in 500 ml of 5  glucose; c) Leucovorin, for one hour of intravenous infusion, at 200 mg/m2 in 250 ml of 0.9  sodium chloride; d)5-FU, for 24 hours of intravenous infusion, at 2600 mg/m2. The administration of these four;D02.455.426.559.847.638.721.374.922	A partial or complete response is expected to be found in at least 50  of patients	Hospital Ophir Loyola	-	19Y - 0		Conselho Nacional de Desenvolvimento Cient  fico e Tecnol  gico	Interventional Study			01/02/2022				09/11/2022					29/05/2023	http://ensaiosclinicos.gov.br/rg/RBR-76j763k		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Brazil	GI	Gastric Cancer	Menadione	Response rate	Phase 2	DB00170	N
CTRI/2022/11/046961	A study to compare the effect of  different types of anaesthesia on blood inflammatory markers in gynaecological cancer patients.		Not Yet Recruiting	Health Condition 1: C56- Malignant neoplasm of ovary	Intervention1: TIVA (total intravenous anaesthesia): propofol will be used  for anaesthesia maintenance<br>Control Intervention1: Inhalational anesthesia: inhalation anaesthetic agent for anaesthesia maintenance, with minimal alveolar concentration of 1.<br>	  ??To compare difference in change of post-operative and preoperative NLR (Day 3-preoperative) in both the groups.Timepoint: day 3	All India Institute of Medical Sciences Jodhpur	-	-	82	All India Institute of Medical Sciences, Basni Phase II , Jodhpur, Rajasthan	Interventional Study	Randomized, Parallel Group, Active Controlled Trial  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Not Applicable	AIIMS/IEC/2022/3994	07/11/2022				01/11/2022					21/11/2022	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=67924		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Gynaecological	Any gynaecological cancers	Propofol	Biomarker	Phase 1	DB00818	N
ChiCTR2100054650	A phase II clinical study evaluating the efficacy and safety of Fruquintinib combined with azithromycin liposome in patients with Platinum resistant ovarian cancer		Pending	Ovarian cancer	Experimental group:Fruquintinib combined with azithromycin liposome;	Pathological complete response rate;	Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology	Female	18 - 75	Experimental group:41;	None	Interventional Study	Single arm		23/12/2021				23/12/2021					28/11/2022	http://www.chictr.org.cn/showproj.aspx?proj=144938		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Gynaecological	Ovarian Epithelial Cancer	Azithromycin	Response rate	Phase 4	DB00207	N
CTRI/2023/02/049406	A study comparing two chemotherapy regimens prior to surgery for patients with technically unresectable oral cancers		Open to Recruitment	Health Condition 1: C109- Malignant neoplasm of oropharynx,unspecified	Intervention1: TPF regimen: Inj Docetaxel 75 mg/m2 in 500 ml NS intravenous over 1 hour on Day 1<br>Inj Cisplatin 75 mg/m2 in 500 ml NS over 1 hour on Day 1<br>Inj 5 FU 750 mg/m2 in 500 ml NS over 24 hours<br>Control Intervention1: Paclitaxel carboplatin and oral metronomic chemotherapy: Patients will receive Paclitaxel (80 mg/m2) plus Carboplatin (AUC 1.5) on day 1 in weekly<br>cycles. In addition they will receive a fixed dose of celecoxib 200 mg PO BD, erlotinib 150 mg<br>PO OD and methotrexate 9 mg/m2 weekly. (All chemotherapy medications will be taken 1 hour<br>before breakfast. The methotrexate is in 2.5 mg tablets. Hence the dose of methotrexate will be<br>rounded off to the nearest lower numerical which is a multiple of 2.5. This could enable delivery<br>of methotrexate without the need for breaking or crushing the tablets. All methotrexate tablets<br>will be taken together. It will be a 21 day cycle.)<br>	Overall SurvivalTimepoint: OS will be assessed as time in months from the <br/ ><br>date of randomization to the date of death. Patients <br/ ><br>alive at their last follow-ups will also be censored.	None	-	-	332	Vedant HospitalKasarvadavli, Ghodbunder Road, Pin code: 400 615	Interventional Study	Randomized, Parallel Group Trial  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Centralized  Blinding and masking:Not Applicable		15/02/2023				02/02/2023					29/05/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=78701		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Head and Neck	Other Head and Neck	Celecoxib	OS	Phase 3	DB00482	N
ChiCTR2200057842	Metformin and omeprazole induce enhanced high-dose vitamin C in the treatment of advanced malignant tumors		Recruiting	Advanced malignant tumors	Study Group:Vitamin C injection;Study Group:Omeprazole injection;Study Group:metformin;	Disease control rate;	The First Affiliated Hospital of Sun Yat-Sen University	All	18 -	Study Group:36;Study Group:36;Study Group:36;	National Key Research and Development Program	Interventional Study	Sequential		14/03/2022				19/03/2022					13/11/2023	https://www.chictr.org.cn/showproj.html?proj=160117		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Multiple cancer types	Any solid tumours	Ascorbic acid; Metformin; Omeprazole	Other (specify)	Not available/Missing	DB00126; DB00331; DB00338	N
CTRI/2023/02/049751	A STUDY ON METFORMIN AND CHEMOTHERAPY COMBINATION IN NON-DIABETES MELLITUS PATIENTS FOR BREAST CANCER		Open to Recruitment	Health Condition 1: C509- Malignant neoplasm of breast of unspecified site	Intervention1: METFORMIN AND NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY: 4-8 cycles of neoadjuvant chemotherapy or palliative chemotherapy will be given for all group of patients. Each cycle as a duration of 3 weeks where you have treatment on the 1st and 8th days, but nothing on days 2 to 7 and days 9 to 21.<br>Intervention group will receive metformin 1500 mg per day along with chemotherapy or palliative chemotherapy.<br>Control Intervention1: PLACEBO AND NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY: 4-8 cycles of neoadjuvant chemotherapy or palliative chemotherapy will be given for all group of patients. Each cycle as a duration of 3 weeks where you have treatment on the 1st and 8th days, but nothing on days 2 to 7 and days 9 to 21.<br>Standard group will receive placebo along with chemotherapy or palliative chemotherapy.<br>	Improvement in reduction of tumor size and numbers. <br/ ><br>Reduction in side effects and adverse events of chemo drugs. <br/ ><br>Non chemo drugs also can be used in the treatment of breast cancer. <br/ ><br>Timepoint: baseline  <br/ ><br>3rd month <br/ ><br>6th month	SRM COLLEGE OF PHARMACY	-	-	70	SRM MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTRE,SRM INSTITUTE OF SCIENCE AND TECHNOLOGY,KATTANKULATHUR-603203	Interventional Study	Randomized, Parallel Group, Placebo Controlled Trial    Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant and Investigator Blinded		20/02/2023				15/02/2023					03/06/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=78523		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	India	Breast	Any Breast Cancer	Metformin	Response rate	Not available/Missing	DB00331	N
CTRI/2023/02/049523	Study of Losartan and Standard of care therapy in advanced biliary tract cancer		Not Yet Recruiting	Health Condition 1: C23- Malignant neoplasm of gallbladder	Intervention1: Tab Losartan Drug: Tab Losartan medication given to all gall bladder carcinoma patient as per inclusion criteria<br>Intervention2: no controlled grou[: not applicable<br>Intervention3: tab Losartan: initially started with with 25mg OD dose per oral and gradually increase up to 100 mg depend on patient vitlas for a period of 9 month<br>Control Intervention1: tab losartan: Not applicable<br>Control Intervention2: NIL: NIL<br>	main aim of the study is  repurposing of drug - That is tab losartan will increase the penetration of chemotherapy drugs into the tumors cell effectively - measured by increase the survival of patient for more than 9 month ( normally chemotherapy had survival of 6 month duration) in a sample size of 25 patient and the study will end after 9 months   <br/ ><br>Timepoint: initially at the time of starting chemotherapy then on 3rd month ( after completing 3 cycle chemotherapy ) and 6th month after competing 6th chemotherapy, then onwards    Every 3 months patients will be analyzed  for events <br/ ><br>	INHS ASVINI	-	-	24	Study is conducted in INHS Asvini. Tab losartan will supplied by central drug store  in INHS Asvini for free of cost	Interventional Study	Single Arm Study    Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label		13/02/2023				07/02/2023					03/06/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=77170		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	India	GI	Cholangiocaricnoma	Losartan	OS	Phase 2	DB00678	N
ChiCTR2200061789	Fasudil hydrochloride in the treatment of gene-specific ovarian cancer patients		Pending	Ovary cancer	first group:Fasudil Hydrochloride Injection;second group:Standard chemotherapy agent and placebo;	Number of treatment courses received;Overall survival;progression free survival;objective response rate;complete remission;partial remission;	Tianjin Medical University General Hospital	Female	-	first group:50;second group:50;	Tianjin Medical University General Hospital	Interventional Study	Case-Control study		08/01/2022				07/02/2022					04/03/2023	http://www.chictr.org.cn/showproj.aspx?proj=173662		Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	China	Gynaecological	Ovarian Epithelial Cancer	Fasudil	PFS; OS	Not available/Missing	DB08162	N
ChiCTR2200066615	The effect of intraoperative intravenous lidocaine infusion on short-term recovery and long-term prognosis of patients with lung cancer: a prospective, randomized, controlled clinical trial		Pending	Lung cancer	Lidocaine group:Intraoperative intravenous lidocaine infusion;Control goup:Intraoperative intravenous normal saline infusion;	Overall survival;Disease free survival;	Zhongshan Hospital, Fudan University	All	-	Lidocaine group:386;Control goup:386;	Major clinical research project of Shenkang Hospital Development Center	Interventional Study	Parallel		12/01/2022				12/12/2022					15/05/2023	https://www.chictr.org.cn/showproj.html?proj=186787		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Lung	Any lung cancers	Lidocaine	OS; DFS/RFS/EFS	Not available/Missing	DB00281	N
ChiCTR2200065595	Exploratory Clinical Study on Mifepristone for the Treatment of Recurrent Glioblastoma		Pending	Recurrent Glioblastoma	treatment group:Administration of Mifepristone;	complete blood count;liver function test;kidney function test;endocrine test;contrast-enhanced brain MR;	Huashan Hospital, Fudan University	All	18 -	treatment group:20;	Self Funding	Interventional Study	Single arm		21/11/2022				11/09/2022					15/05/2023	https://www.chictr.org.cn/showproj.html?proj=174280		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	CNS	Glioblastoma	Mifepristone	Biomarker	Not available/Missing	DB00834	N
ChiCTR2300068631	Oral aminophylline combined with sunitinib malate capsule in the treatment of locally advanced unresectable renal clear cell carcinoma or distant metastasis: a prospective, open, single-arm, multicenter exploratory study		Recruiting	locally advanced unresectable renal clear cell carcinoma or distant metastasis	Test group:Aminophylline combined with sunitinib malate capsule was taken orally;	Progression-free survival;	Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	All	18 - 70	Test group:22;	Shanghai Sixth People's Hospital Jieqing Cultivation Fund	Interventional Study	Single arm		03/01/2023				26/02/2023					22/05/2023	https://www.chictr.org.cn/showproj.html?proj=184453		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	China	Urological	Renal Cell Carcinoma	Aminophylline	PFS	Not available/Missing	DB01223	N
ChiCTR2300068563	lidocaine Effects on neutrophil extracellular trapping and angiogenesis biomarkers in postoperative breast cancer patients with different  anesthesia methods		Pending	breast cancer	Sevoflurane anesthesia experimental group:lidocaine;The control group was anesthetized with sevoflurane:saline;Propofol-TIVA anesthesia experimental group:lidocaine ;The control group was anesthetized with propofol-TIVA:saline;	MPO;H3Cit;NE;MMP-9;VEGF-A;	General Hospital of Ningxia Medical University	Female	18 - 70	Sevoflurane anesthesia experimental group:30;The control group was anesthetized with sevoflurane:30;Propofol-TIVA anesthesia experimental group:30;The control group was anesthetized with propofol-TIVA:30;	Department of Science and Technology of Ningxia Hui Autonomous Region	Interventional Study	Parallel		23/02/2023				23/02/2023					22/05/2023	https://www.chictr.org.cn/showproj.html?proj=187911		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Breast	Any Breast Cancer	Lidocaine	Biomarker	Not available/Missing	DB00281	N
CTRI/2023/05/052737	effect of addition of Aspirin in oral cancer survival		Not Yet Recruiting	Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx	Intervention1: Aspirin: Aspirin 150 mg PO daily in addition to standard of care till toxicity or recurrence<br>Control Intervention1: Standard of care: Standard of care as per guidelines based on the TNM stage i.e. Surgery, Surgery with Radiotherapy or palliative chemotherapy of investigators choice<br>	safety and toxicity as per WHO toxicity criteria and adverse event monitoringTimepoint: Every 3 weeks	Banaras Hindu University	-	-	60	Banaras Hindu University, Varanasi, India	Interventional Study	Randomized, Parallel Group, Active Controlled Trial  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Participant Blinded		26/05/2023				17/05/2023					29/05/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=85165		Any/All Stages	Hospital/University/Research Institute	Y	N	N	India	Head and Neck	Any head and neck cancer	Acetylsalicylic Acid	Safety and/or Dose	Phase 2/3	DB00945	N
CTRI/2023/05/053195	Define role of chronomodulation in Gemcitabinne chemotherapy		Not Yet Recruiting	Health Condition 1: C23- Malignant neoplasm of gallbladder	Intervention1: melatonin: In 2 groups of study 2, 20 mg Melatonin will be administered to patients receiving chemotherapy for 14 days starting from chemotherapy cycle 1 day 8.<br>Control Intervention1: none: There is no comparator of melatonin in this study as this is a cross over trial.<br>	To evaluate effect of chrono-modulation on cytidine deaminase enzyme (CDA) activity in metastatic cancer patients on Gemcitabine chemotherapy <br/ ><br>To determine the effect of chrono-modulation on elimination <br/ ><br>kinetics of chrono-modulated Gemcitabine chemotherapy in <br/ ><br>metastatic cancer patients <br/ ><br>To determine the role of melatonin on elimination kinetics of chrono- <br/ ><br>modulated Gemcitabine chemotherapy in metastatic cancer patientsTimepoint: BASELINE CDA, CT1D1, CT2D8, CT2D1, CT2D8 <br/ ><br>	ALL INDIA INSTITUTE OF MEDICAL SCIENCES RISHIKESH	-	-	14	All India Institute of Medical Sciences Rishikesh	Interventional Study	Randomized, Crossover Trial   Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Open Label		10/06/2023				29/05/2023					26/06/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=70292		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	India	GI	Cholangiocaricnoma	Melatonin	Biomarker	Phase 2	DB01065	N
IRCT20230315057722N1	Effect of pentoxifylline in multiple myeloma (MM) patients undergoing autologous hematopoietic stem cell transplantation (ASCT)		Recruiting	Multiple myeloma (MM) patients undergoing autologous hematopoietic stem cell transplantation. <br>Multiple myeloma;C90.0	Intervention 1: Intervention group: Pentoxifylline group: Patients who underwent autologous transplantation receive Pentoxifylline 800 mg/d, orally as 2 divided daily doses, respectively from day +15 through day +98 post-transplant. Intervention 2: Control group: Multiple myeloma patients undergoing autologous transplantation who do not receive any intervention.	Regulatory T cell. Timepoint: Days +14 and +99 post-autologous transplantation. Method of measurement: Number of T regulatory cells (CD4, CD25, FOXP3) in peripheral blood mononuclear cells (PBMC) by using flow cytometry technique.	Shahid Beheshti University of Medical Sciences	All	21 years - 70 years	30	-	Interventional Study	Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: 1. Random sequence generation: Patients were assigned in groups according to the random allocation rule. Based on the size of the research sample, we prepared 30 cards on which the PTXF and control groups were recorded and placed these cards in a lottery container. Then the cards are randomly removed from the container without replacement, and the created sequence is recorded. 2. Allocation concealment: The sequentially numbered, opaque, sealed envelope (SNOSE) method is used to perform randomization. Based on the sample size of the research, several envelopes were prepared with aluminum wrappers, and each of the random sequences created on a card was recorded and the cards were placed in the envelopes of the letter, respectively. To maintain a random sequence, the envelopes were numbered in the same way on the outer surface. Finally, the l		15/05/2023				14/06/2023					26/06/2023	http://en.irct.ir/trial/69164		Other (specify)	Hospital/University/Research Institute	Y	N	N	Israel	Other Haem-onc	Multiple Myeloma	Pentoxifylline	Biomarker	Phase 2	DB00806	N
CTRI/2023/07/055019	EFFECT OF INTRAVENOUS LOCAL ANAESTHETIC AND REGIONAL BLOCK ON LEVELS OF MARKERS OF RECURRENCE IN PATIENTS UNDERGOING SURGERY FOR BREAST CANCER		Not Yet Recruiting	Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 2: O- Medical and Surgical	Intervention1: Intravenous Lidocaine: given in dose of 2mg/kg bolus followed by maintenance 2mg/kg/hr infusion throughout surgery- <br>duration of drug infusion will be total duration of surgery <br>bolus will only be given once at the beginning of surgery<br>Control Intervention1: Erector spinae plane block: 1  lidocaine 2mg/kg bolus through catheter in the erector spinae plane followed by 1  lidocaine 2mg/kg/hr infusion throughout surgery<br>-duration of drug infusion will be throughout total duration of surgery, bolus will only be given once at the time of catheter placement<br>	Comparison of  biomarkers predicting metastasis and recurrence in breast cancer patients undergoing total mastectomy   ?? MMP2 ,MMP9  in patients receiving IV lidocaine and erector spinae blockTimepoint: preoperatively and 36 hours postoperatively samples shall be collected	AIIMS, Rishikesh	-	-	70	Research cell, third floor, AIIMS,Virbhadra marg, Rishikesh-249203	Interventional Study	Randomized, Parallel Group Trial   Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Outcome Assessor Blinded		15/07/2023				10/07/2023					25/07/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=82649		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Breast	Any Breast Cancer	Lidocaine	Biomarker	Phase 2	DB00281	N
ChiCTR2300074309	To explore the safety and efficacy of atorvastatin in combination with chemotherapy versus chemotherapy in patients with extensive small-cell lung cancer resistant to first-line standard therapy: a randomized controlled Phase III trial		Recruiting	small cell lung cancer	group A:Atorvastatin+Irinotecan;group B:Irinotecan;	safety;Overall survival,OS;	The First Affiliated Hospital of Wenzhou Medical University	All	18 - 75	group A:110;group B:110;	Qilu Pharmaceutical Co. LTD	Interventional Study	Parallel		08/10/2023				08/03/2023					08/07/2023	https://www.chictr.org.cn/showproj.html?proj=195072		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	China	Lung	Small Cell Lung Cancer	Atorvastatin	Safety and/or Dose	Phase 3	DB01076	N
IRCT20230627058596N1	Effect of Atorvastatin Usage on Patients with Oral squamous cell carcinoma		Pending	Oral squamous cell carcinoma. <br>Malignant neoplasm of mouth, unspecified;C06.9	Intervention 1: Intervention group: Surgery combined with radiotherapy and Atorvastatin, 40 mg pill, C33H35FN2O5, daily, for 3 months, swallowing with water. Intervention 2: Control group: Surgery combined with radiotherapy.	Superoxide dismutase marker in the saliva. Timepoint: At the beginning of the study and 3 months after taking the drug. Method of measurement: The variable measurement (Superoxide Dismutase marker) in saliva is performed by spectrophotometry method in the laboratory.;Angiogenesis Factors in the Saliva. Timepoint: At the beginning of the study and 3 months after taking the drug. Method of measurement: The measurement of variables (Angiogenesis Factors) in saliva is carried out using the spectrophotometry method in the laboratory.	Karaj University of Medical Sciences	All	no limit - no limit	30	Faculty of Dentistry, Alborz University of Medical Sciences	Interventional Study	Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Other, Purpose: Treatment, Randomization description: Considering the sample size of 15 patients in each group, in order to randomize the samples, we write the words Users of Atorvastatin and Control on two pieces of paper and place them in a container. Then, we randomly select one of the two pieces of paper. The word chosen will determine whether the first patient after surgery is allocated to the Users of Atorvastatin group or the Control group. The second patient will be allocated to the next group (i.e., patients 1, 3, 5, etc., will be in the Users of Atorvastatin group, while patients 2, 4, 6, etc., will be in the Control group). This process will continue until all 15 samples are completed in each group. Additionally, due to the surgeon's lack of preference and choice regarding which patient receives the medication, the drug will be prescribed entirely randomly. Moreover, ne		23/08/2023				08/09/2023					21/08/2023	http://en.irct.ir/trial/70954		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Iran	Head and Neck	Any head and neck squamous cell carcinoma	Atorvastatin	Biomarker	Phase 3	DB01076	N
ChiCTR2300074442	ParecoxibNA can modulate tumor microenvironment and inhibit cell proliferation, metastasis in non-small cell lung cancer		Pending	non-small cell lung cancer	experimental group:experimental group was injected with corresponding amount of parecoxibNA by body weight;control group:experimental group was injected with corresponding amount of saline by body weight;	NRS Score;	He € nan Provincial People's Hospital	All	18 - 70	experimental group:160;control group:160;	Self-funding	Interventional Study	Parallel		09/02/2023				08/07/2023					21/08/2023	https://www.chictr.org.cn/showproj.html?proj=197521		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Lung	Non-Small Cell Lung Cancer	Parecoxib	Biomarker	Not available/Missing	DB08439	N
IRCT20230221057485N1	The effect of adding Desloratadine to neoadjuvant chemotherapy in patients with breast cancer		Recruiting	Breast cancer. <br>Malignant neoplasm of breast	Intervention 1: Intervention group: 52 patients with breast cancer are randomly included in the intervention group. In addition to the neoadjuvant chemotherapy process, desloratadine 5mg (Neotadine   tablets manufactured by Abidi Company, Iran) is prescribed daily (oral) until the patient is re-examined (about 2 months). At the end of 4 chemotherapy courses (every two weeks), breast ultrasound is performed again to evaluate the treatment response. then blood samples (7-10 cc) are taken and the amount of cytokines and gene expression changes in peripheral blood mononuclear cells are measured. Intervention 2: Control group: Control group: 52 patients with breast cancer are randomly included in the control group, this group is subjected to neoadjuvant chemotherapy (anthracyline base drugs) and prescribed until the patient s re-examination (about 2 months).  At the end of 4 courses of chemotherapy (every two weeks), breast ultrasound is performed again to evaluate the treatment response, blood samples of the patients at the beginning and at the end of the study (2 months after the start of the treatment course) were taken in the amount of 7-10 cc and the amount cytokines and gene expression changes are measured in peripheral blood mononuclear cells.	Response rate to treatment based on changes in tumor size and lymph node involvement. Timepoint: At the beginning of the study and 2 months after the start of the first course of chemotherapy. Method of measurement: RECIST criteria.;The serum level of tumor serological markers (CEA, CA15-3). Timepoint: At the beginning of the study and 2 months after the start of the first course of chemotherapy. Method of measurement: ELISA method.	Gorgan University of Medical Sciences	Female	18 years - no limit	104	Gorgan University of Medical Sciences	Interventional Study	Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done in a stratified manner. In this way, 34 people will be selected from among the qualified people in each of the classes. Then, by a simple random method (34 similar cards are prepared and the letter A is written on 17 cards and the letter B is written on the other 17 cards, and then the patients will be randomly assigned to groups.), Blinding description: Participants (patients) who do not know their group type, control or intervention.		08/01/2023				30/07/2023					21/08/2023	http://en.irct.ir/trial/71555		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Iran	Breast	Any Breast Cancer	Desloratadine	Response rate	Phase 2	DB00967	N
KCT0008659	Randomized phase II study of chemoimmunotherapy with or without metformin as a first-line treatment in patients with squamous cell lung carcinoma		Not yet recruiting	;Neoplasms	Drug : This clinical trial will be conducted in patients with advanced squamous epithelial lung cancer to evaluate the effectiveness and safety of standard immuno-chemotherapy and metformin combination therapy.<br><br>Registered study subjects are stratified according to a predetermined stratification factor and randomly assigned to the experimental group and the control group at a ratio of 1:1.<br><br>The study subjects receive pembrolizumab or pembrolizumab and paclitaxel and carboplatin combination therapy depending on the expression of Day 1 and PD-L1 every three weeks. It is stopped when the disease progresses or an unacceptable toxicity or death occurs.<br><br>The experimental group will be continuously administered with Metformin twice a day orally.<br><br>? a method of treatment<br><br><Standard immuno- chemotherapy<br><br>1) PD-L1 expression is 50  or higher<br><br>Injected intravenously with pembrolizumab 200mg on Day 1. It is repeated every three weeks and lasts up to 24 months of total administration period, until the disease progresses, or until unacceptable toxicity or death occurs.<br><br>2) PD-L1 expression below 50 <br><br>Intravenously injected with pembrolizumab 200mg, paclitaxel 175mg/m2, and carboplatin AUC=5 on Day 1. Repeat every three weeks until the fourth. Afterwards, pembrolizumab 200mg was repeated every 3 weeks. The administration period lasts up to 24 months, until the disease progresses, or until unacceptable toxicity or death occurs. When drug-resistant problems are expected, it can proceed to paclitaxel 75mg/m2, carboplatin AUC=3, Day 1, and Day 8.<br><br><Metformin administration group><br><br>From Cycle 1 and Day 1, take 500mg BID every day. Take 1,000mg daily with BID from Cycle2 when there is no drug resistance issue. The administration of Metformin lasts up to 24 months, until the disease progress	6 month progression free survival rate	National Cancer Center	All	19(Year) - No Limit	70	National Cancer Center	Interventional Study	Primary Purpose : Supportive Care, Intervention Model : Parallel, Blinding/Masking : Open, Allocation : RCT		17/07/2023				28/07/2023					21/08/2023	https://cris.nih.go.kr/cris/search/detailSearchEn.do?seq=24933		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Korea, Republic of	Lung	Non-Small Cell Lung Cancer	Metformin	PFS	Phase 2	DB00331	N
JPRN-jRCT2080222349	A Phase 1, Open-Label, Multi-center Study to Assess the Safety and Tolerability of AZD6244 (Selumetinib, ARRY142886) in Combination With Cisplatin/Gemcitabine in Japanese Patients With Inoperable Locally Advanced or Metastatic Biliary Tract Cancer (BTC)			Inoperable Locally Advanced or Metastatic Biliary Tract Cancer	investigational material(s)<br>Generic name etc : Cisplatin, Gemcitabine, Selumetinib(AZD6244)<br>INN of investigational material : <br>Therapeutic category code : 429 Other antitumor agents<br>Dosage and Administration for Investigational material : Cisplatin:day1 and day8 at each cycle, Gemcitabine:day1 and day8 at each cycle, Selumetinib(AZD6244):25mg/day, 50mg/day and 75mg/day		AstraZeneca	All	>= 20age old - Not applicable			Interventional Study	Non-Randomized, Safety Study, Single Group Assignment, Open Label	JapicCTI-132399	24/12/2013				24/12/2013					17/10/2023	https://jrct.niph.go.jp/latest-detail/jRCT2080222349		Advanced/Metastatic; Recurrent/Refractory	Company	N	N	N	Japan	GI	Cholangiocaricnoma	Selumetinib	Safety and/or Dose	Phase 1	DB11689	N
JPRN-jRCTs021230005	A randomized phase 2 study assessing the efficacy and safety of levofloxacin added to the GEM/nabPTX combination therapy in patients with advanced pancreatic cancer(T-CORE2201)		Recruiting	pancretic cancer	Levofloxacin treatment is added to the GEM/nabPTX combination therapy in patients with advanced pancreatic cancer.	Progression free survival	Ishioka Chikashi	All	>= 20age old - < 80age old	140	Tohoku Clinical Oncology Research and Education Society(T-CORE)	Interventional Study	randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose		19/05/2023				19/05/2023					17/10/2023	https://jrct.niph.go.jp/latest-detail/jRCTs021230005		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Japan	GI	Pancreatic Cancer	Levofloxacin	PFS	Phase 2	DB01137	N
NCT05953350	A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i		Recruiting	Inhibition of Autophagy Synergizes Anti-tumor Effect	Drug: 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib; Drug: RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.	The safety dose of the combination of hydroxychloroquine and CDK4/6 inhibitors in patients; the recommended phase II dose; Objective response rate ORR ; Progression-free survival (PFS)	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	All	18 Years and older   (Adult, Older Adult)	29	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SKSKY-2023-488-01	06/12/2023	31/12/2023	31/12/2024			20/07/2023				13/12/2023	https://ClinicalTrials.gov/show/NCT05953350		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	China	Multiple cancer types	Any solid tumours	Hydroxychloroquine	Safety and/or Dose; Response rate; PFS	Phase 1/2	DB01611	N
NCT04539808	NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer		Recruiting	Pancreatic Adenocarcinoma|Stage 0 Pancreatic Cancer AJCC v8|Stage I Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8	Drug: Capecitabine; Drug: Fluorouracil; Drug: Irinotecan Hydrochloride; Drug: Leucovorin Calcium; Drug: Losartan Potassium; Drug: Oxaliplatin; Radiation: Radiation Therapy; Procedure: Resection; Procedure: Diagnostic Imaging; Procedure: Biospecimen Collection	Proportion of participants with R0 resection; Progression-free survival (PFS) NeoOPTIMIZE; PFSNeoOPTIMIZE + pre-operative (preop)-RT; Disease-free survival (DFS) NeoOPTIMIZE; DFSNeoOPTIMIZE + preop-RT; Overall survival (OS) NeoOPTIMIZE; OSNeoOPTIMIZE + preop-RT; Proportion of participants with peri- and post-operative complications; Proportion of participants that die within 30 days of surgery; Incidence of grade >= 3 toxicities	OHSU Knight Cancer Institute; Oregon Health and Science University	All	18 Years and older   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00021614; NCI-2020-06277	27/05/2021	15/04/2024	10/05/2025			09/07/2020				15/11/2023	https://ClinicalTrials.gov/show/NCT04539808		Localised/Locoregional; Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Losartan	Other (specify)	Phase 2	DB00678	N
NCT05564377	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial		Recruiting	Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Malignant Solid Neoplasm|Malignant Female Reproductive System Neoplasm|Metastatic HER2-Negative Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Recurrent Endometrial Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Malignant Female Reproductive System Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Unresectable HER2-Negative Breast Carcinoma|Unresectable Malignant Solid Neoplasm	Drug: Alpelisib; Drug: Binimetinib; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Scan; Procedure: Computed Tomography; Procedure: Echocardiography; Drug: Fluorouracil; Drug: Fulvestrant; Drug: Ipatasertib; Drug: Leucovorin; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Procedure: Mutation Carrier Screening; Drug: Neratinib Maleate; Drug: Nilotinib Hydrochloride Monohydrate; Drug: Olaparib; Drug: Oxaliplatin; Drug: Paclitaxel; Drug: Palbociclib; Biological: Panitumumab; Procedure: Positron Emission Tomography; Drug: Selumetinib Sulfate; Drug: Sotorasib	Accrual of patients to ComboMATCH treatment trials; Assignment of patients to ComboMATCH treatment trials; Enrollment rates to ComboMATCH treatment trials; Rate of positive outcomes within the treatment trial defined cohorts	National Cancer Institute (NCI)	All	Child, Adult, Older Adult	2900	NIH	Interventional Study	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	NCI-2022-06842; EAY191; U10CA180820	04/07/2023	07/01/2030	07/01/2030			10/03/2022				01/09/2024	https://ClinicalTrials.gov/show/NCT05564377		Advanced/Metastatic; Recurrent/Refractory	Local/National government	N	N	N	United States	Multiple cancer types	Any solid tumours	Selumetinib	PFS; Other (specify)	Phase 2	DB11689	N
NCT05091424	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia		Recruiting	Chronic Lymphocytic Leukemia	Drug: Mosunetuzumab; Drug: Tocilizumab; Drug: Venetoclax	Rate of Dose-Limiting Toxicities (DLTs); Objective Response Rate (ORR); Minimal Residual Disease (MRD) Response Rate; Progression-Free Survival (PFS); Overall Survival (OS); Event-Free Survival (EFS); Complete Response (CR) Rate; Duration of Response (DOR); Percentage of Participants with Adverse Events (AEs); Maximum Serum Concentration (Cmax) of Mosunetuzumab SC; Minimum Serum Concentration (Cmin) of Mosunetuzumab SC; Time to Maximum Concentration (Tmax) of Mosunetuzumab SC; Incidence of Anti-Drug Antibodies (ADAs)	Hoffmann-La Roche	All	18 Years and older   (Adult, Older Adult)	137	Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BO43243	03/07/2022	27/05/2027	10/08/2029			25/10/2021				21/12/2023	https://ClinicalTrials.gov/show/NCT05091424		Recurrent/Refractory	Company	N	N	N	Spain	Leukemia	Chronic Lymphocytic Leukemia	Tocilizumab	Safety and/or Dose	Phase 1	DB06273	N
NCT05166577	Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC		Recruiting	Nasopharyngeal Carcinoma|EBV-Related Gastric Carcinoma|EBV-Related Leiomyosarcoma|EBV Related Carcinoma|EBV-Related Sarcoma	Drug: Nanatinostat; Drug: Valganciclovir; Drug: Pembrolizumab	Phase 1b: Incidence of dose-limiting toxicities (DLTs); Phase 2: Overall response rate (ORR); Incidence and severity of adverse events; Duration of response (DOR); Disease control rate (DCR); Progression-free survival (PFS); Overall survival (OS); Pharmacokinetic parameter - time to maximum plasma concentration [tmax]; Pharmacokinetic parameter - maximum plasma concentration [Cmax]; Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC]	Viracta Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	130	Industry	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VT3996-301	10/07/2021	12/01/2024	10/01/2025			22/12/2021				12/11/2023	https://ClinicalTrials.gov/show/NCT05166577		Advanced/Metastatic	Company	N	Y	N	United States	Head and Neck	Nasopharyngeal Cancer	Valganciclovir	Safety and/or Dose; Response rate; PFS; OS; Other (specify)	Phase 1/2	DB01610	N
2020-005088-30	STOP-LEUKEMIA: A pilot study of metformin as a leukemia-preventive drug in patients with CCUS or LR-MDS	STOP-LEUKEMIA	Ongoing	Clonal cytopenia of undetermined significance (CCUS) and lower-risk myelodysplastic syndrome (LR-MDS).		The primary endpoints of WP1 are:  Feasibility A quantitative and qualitative feasibility assessment will be undertaken to inform the decision to proceed with a RCT to assess the effect of this intervention. 1. To estimate recruitment and refusal rates and 12 months follow-up rates. 2. To determine how many participants receive the intervention. 3. To estimate protocol adherence. 4. To explore, qualitatively, the acceptability of interventions and assessments with patients. Safety 1. To describe the type, grade and number of adverse events and serious adverse events in the patients. 2. To assess any suspected unexpected serious adverse reactions. 3. To estimate drop-out rates. 4. To describe any changes in individual medication doses including median maximum tolerated dose.	Kirsten Gr oslash;nb aelig;k	All	Adult 18-64	60	Rigshospitalet	-	Open												https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005088-30/DK		Any/All Stages	Hospital/University/Research Institute	N	N	N	Denmark	Other Haem-onc	Myelodysplastic Syndromes	Metformin	Biomarker	Phase 2	DB00331	N
JPRN-UMIN000001815	Prospective randomized controlled study for preventive effect of menatetrenone against the recurrence of hepatocellular carcinoma after hepatectomy		Complete: follow-up continuing	Hepatocellular carcinoma	The study was designed to test the hypothesis that MNT would reduce the incidence of recurrence of HCC in patients underwent initial hepatectomy.  The patients stated to take 15 mg of menatetrenone, 3 times a day, orally everyday. <br>Control group does not take any drugs.	Disease-free survival period after hepatectomy	Second Department of Surgery  Dokkyo Medical University	All	Not applicable - Not applicable	84	None.	Interventional Study	Parallel Randomized		11/01/2005				30/03/2009					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001929		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Japan	GI	Liver Cancer	Menatetrenone	DFS/RFS/EFS	Phase 2	DB12148	N
JPRN-UMIN000025398	A phase 2 trial of nab-paclitaxel, oxaliplatin, S1 and itraconazole for unresectable pancreatic cancer		Recruiting	Unresectable pancreatic cancer	itraconazole 400 mg po day -2 +3  nabpaclitaxel 125 mg/m2 day 1  gemcitabine 1000 mgm2 day 1  L-OHP 85 mg/m2 day 1    q14d	Response rate, operability	Meiwa Hospital	All	20years-old - 80years-old	28	Meiwa Hospital	Interventional Study	Single arm Non-randomized		06/01/2016				27/12/2016					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029075		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	Japan	GI	Pancreatic Cancer	Itraconazole	Response rate; Other (specify)	Phase 2	DB01167	N
ISRCTN16867955	A randomised phase 3 trial evaluating the role of finasteride in increasing compliance with active surveillance, in men with a new diagnosis of low and intermediate risk prostate cancer, when compared with usual care.		Ongoing	Men with a new diagnosis of low- and intermediate-risk prostate cancer <br>Cancer <br>Malignant neoplasm of prostate	FINESSE is a multicentre, open label, prospective, two-armed randomised controlled CTIMP, to test the superiority of finasteride and active surveillance over- active surveillance alone, in men with newly diagnosed low/intermediate risk localised prostate cancer.  <br><br>We will randomise (1:1), 550 patients to Active Surveillance with or without once daily finasteride, (5mg). Patients will receive finasteride for 2 years and will be followed up for an average of 4 years. Active surveillance will include PSA, re-biopsy and mpMRI as per usual NHS care. The primary outcome is adherence with Active Surveillance in both arms.  <br><br> €  There are no placebo treatments for the following reasons:  The PSA levels in men treated with finasteride will almost halve. Since it is necessary to monitor PSA (for AS) this would unblind both arms unless clinicians and patients were blinded to the PSA results. <br> €  Blinding PSA data would be impractical, since men may actively seek PSA tests outside the study. <br> €  It is ethical that control patients experiencing any side effects, e.g., erectile dysfunction, ejaculatory problems, or a rash, know they are independent of the treatment.  <br> €  Participants unaware they are taking finasteride may opt for radical treatment earlier. This is a pragmatic trial designed to see whether knowing that they are being treated and that the treatment is having a positive impact on PSA levels would reassure men and enable them to continue with active surveillance for longer, rather than seeking radical treatment even though their disease may not have progressed.  <br> €  The prohibitive costs   logistics associated with placebo-controlled trials <br><br>Randomisation:<br>A web-based randomisation system will be designed, using the bespoke KCTU randomisation system. The randomisation syst	Adherence with Active Surveillance at 2 and 5 years after diagnosis. Adherence is defined as the absence of a change in treatment to radical therapy or treatment of advanced disease measured using patient records.	Sheffield Teaching Hospitals NHS Foundation Trust	Male	-	550	Yorkshire Cancer Research	Interventional Study	Interventional randomized controlled trial (Treatment)	2021-004004-17;Nil known;IRAS 1004290, STH21032	15/08/2022				27/08/2021					19/12/2023	https://www.isrctn.com/ISRCTN16867955	Primary/Main Curative	Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United Kingdom	Urological	Prostate Cancer	Finasteride	Other (specify)	Phase 3	DB01216	N
ACTRN12621000784819	A preliminary study of the addition of prazosin to radiotherapy in men with prostate cancer		Recruiting	Prostate Cancer; <br>Prostate Cancer;Cancer - Prostate	This trial will be a feasibility study with dose escalation of the investigational drug (prazosin). The study will follow a standard 3 + 3 model followed by dose expansion. Each participant will remain on the same dose level throughout their treatment. Once dose escalation is complete all new participants will then be enrolled into the dose expansion phase. During the 3 + 3 phase, three participants will be enrolled to each dose level. If there are no dose limiting toxicities (DLT) at the respective dose level the study will proceed to the next level. If one patient develops a DLT then an additional three patients will be enrolled into the dose level, should a second participant develop at DLT at the same level then the previous dose level will be defined as the maximum tolerated dose. It is planned that there will be 6 dose levels, 0.5mg, 1mg, 2mg, 3mg, 4mg and 5mg (all dosed twice daily), however if DLTs occur higher dose levels may not be reached.<br>Participants will commence prazosin one week prior to the commencement of radiotherapy. Prazosin will be provided as 1mg, 2mg and 5mg tablets and dosing will commence one week prior to radiotherapy to enable dose titration and continue until the end of radiotherapy, approximately 4-6 weeks based on prescribed radiotherapy treatment plan. The appropriate tablet strength will be provided to the participant based on their dosing level.<br>Participants will be enrolled into either the 0.5mg, 1mg, 2mg, 3mg, 4mg or 5mg dose levels, dosed twice daily. All patients will be commenced on 0.5mg (half of a 1mg tablet) of prazosin to be taken twice daily one week prior to the commencement of radiotherapy. For subsequent dose levels, the dose will be increased weekly.<br>Compliance will be assessed at weekly review by the returning of	Protocol and treatment schedule compliance as a composite outcome. Compliance feasibility will be defined as = 80  compliance rate to the study protocol/treatment schedule. Treatment compliance will be defined as participants missing < 10  of prazosin doses and being able to complete all radiotherapy fractions. Treatment compliance will be assessed using participant dosing diaries and the return of medication packaging and unused tablets. Assessment compliance will be defined as a completion of = 80  required assessments.[ At the completion of radiotherapy and prazosin treatment.]	GenesisCare	Male	18 Years - No limit	30	GenesisCare Foundation;Griffith University	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;		28/10/2022				22/06/2021					10/03/2023	https://anzctr.org.au/ACTRN12621000784819.aspx		Localised/Locoregional	Other	N	N	N	Australia	Urological	Prostate Cancer	Prazosin	Other (specify)	Phase 1	DB00457	N
JPRN-UMIN000020681	Randomized open-label phase II study of adjuvant chemotherapy of S-1 plus metformin vs. S-1 alone in patients with resected pancreatic cancer		Complete: follow-up continuing	Pancreatic cancer	A:S-1+Metformin  S-1 day1-14 of each 21-day cycle, until progression disease or completion of the planned 6 months   Treatment for diabetes: Metformin 500mg/day day1-21, subsequently 750mg/day for 2 years  <br>B:S-1  S-1 day1-14 of each 21-day cycle, until progression disease or completion of the planned 6 months  Treatment for diabetes: Any diabetic treatment without Metformin for 2 years	2-year survival rate (overall survaival)	National Hospital Organization	All	20years-old - Not applicable	160	National Hospital Organization	Interventional Study	Parallel Randomized		26/01/2018				22/01/2016					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023796		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Japan	GI	Pancreatic Cancer	Metformin	OS	Phase 2	DB00331	N
DRKS00012360	Pharmacokinetic Enhancement of Crizotinib plasmaconcentrations with Cobicistat or Itraconazole in AnaplasticLymphoma Kinase positive advanced Non-Small Cell LungCancer Patients		Recruiting stopped after recruiting started	<br>C34;Malignant neoplasm of bronchus and lung	Group 1: Crizotinib 250 mg BID p.o. + 150 mg Cobicistat QD p.o. for 14 days<br>Group 2: Crizotinib 250 mg BID p.o. + Itraconazole 200 mg QD p.o. for 14 days	Geometric mean ratio (90  confidence interval) of crizotinib AUC0-t and during, cobicistat<br>(itraconazole) treatment.	Ruprecht-Karls University Heidelberg (Medical Faculty)University Hospital Heidelberg represented in law by its commercial directorDipl.-Volksw. Irmtraut G  rkan.	All	18 Years - None	16	Abt. Klinische Pharmakologie und PharmakoepidemiologieMedizinische Klinik	Interventional Study	Allocation: Non-randomized controlled study; Masking: Open (masking not used); Control: Other; Assignment: other; Study design purpose: other	2016-002187-14	13/07/2017				21/04/2017					17/10/2023	http://drks.de/search/en/trial/DRKS00012360		Any/All Stages	Hospital/University/Research Institute	Y	N	N	Germany	Lung	Non-Small Cell Lung Cancer	Itraconazole	Other (specify)	Phase 1	DB01167	N
DRKS00025207	Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy		Recruiting	<br>C71;Malignant neoplasm of brain	Group 1: Meclofenamate, oral administration, duration of treatment: 224 days or until tumor progression (what occurs first). Dosage 100mg - 400mg daily divided into two doses. Application additive to standard temozolomide dosing (TMZ 150-200 mg/m2/d days 1-5/28), 8 four weeks courses).	- Phase I: Incidence of dose-limiting toxicities (DLTs) during the first 8 weeks/56 days of MFA treatment.<br>- Phase II: Progression-free survival (PFS) as measured from the day of randomization until diagnosis of progressive disease determined by MRI (RANO criteria) in the local center. In a sensitivity analysis, the PFS analysis does also include patients from phase I who received MFA at the same dose as applied in phase II (PFS measured from day of trial inclusion)<br>	Medizinische Fakult  t der Universit  t BonnRheinische Friedrich-Wilhelms Universit  t Bonn	All	18 Years - None	72	Bundesministerium f  r Bildung und Forschung Dienstsitz Bonn	Interventional Study	Allocation: N/A: single arm study; Masking: Open (masking not used); Control: uncontrolled; Assignment: single; Study design purpose: treatment	2021-000708-39	11/04/2022				20/07/2021					17/10/2023	http://drks.de/search/en/trial/DRKS00025207		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	Germany	CNS	Glioblastoma	Meclofenamate	Safety and/or Dose; PFS	Phase 1/2	DB00939	N
JPRN-UMIN000003493	Phase II study of neoadjuvant zoledronic acid therapy for early breast cancer patients		Recruiting	early breast cancer	Neoadjuvant  chemotherapy: CEF (EpiADR 100mg/m2 D1, CPA 500mg/m2 D1, 5FU 500mg/m2 D1 per 3 weeks) 4 cycles, then weekly paclitaxel 80mg/m2 for 12 weeks.  zoledronic acid: 4mg + saline 100ml div for 15 minutes, per 3-4 weeks, 6 cycles	Pathological response rate	Division of Medical Oncology and Breast Surgery, Cancer Institute Hospital	Female	20years-old - 70years-old	30	None	Interventional Study	Single arm Non-randomized		04/01/2010				15/04/2010					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004232		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Japan	Breast	Any Breast Cancer	Zoledronic Acid	Response rate	Phase 2	DB00399	N
JPRN-UMIN000004852	The exploratory study for the biological  effects of metformin on endometrial cancer: effect to cell cycle,  MAPK, and AMPK/mTOR signal pathway		Recruiting	endometrial carcinoma	Metformin (an initial dose of 750 mg/day, increased by 750 mg every week up to 1500 or 2250 mg/day) was administered to patients with endometrial cancer prior to surgery.  Endometrial tissue was obtained before and during metformin therapy via endometrial biopsy for diagnosis and hysterectomy, respectively. Patients undergo blood sample collection periodically for biomarker analysis.	To evaluate  the effects of metformin, cell proliferation activity and signal pathway were compared between pre- and post-treatment samples.   1) Cell proliferation was evaluated by immunohistochemistry using antibody of Ki-67 (positive for all cell cycle except for G0) and topoisomerase II A(positive at S/G2/M phase)   2) Findings related to the MAPK, AMPK and mTOR signaling pathways and cell cycle proteins were compared by Western blot analysis.	Graduate School of Medicine, Chiba University	Female	20years-old - 70years-old	30	none	Interventional Study	Single arm Non-randomized		04/01/2010				11/01/2011					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005770		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	Japan	Gynaecological	Endometrial Cancer	Metformin	Biomarker	Not available/Missing	DB00331	N
JPRN-UMIN000020856	Exploratory study on the anti-proliferative effects of metformin on endometrial cancer		Complete: follow-up continuing	Endometrial cancer	1)Patients will receive a daily dose of metformin (initial dose, 500 mg/day; increased weekly up to 2250 mg/day in the absence of any adverse effects).  2)Metformin will be administered in patients who fulfill the eligibility criteria. Metfomin will be administrated in patients until a day prior to the operation.  3)Endometrial biopsy samples will be obtained before metformin administration (as baseline) and during operation.	To evaluate the effect of metformin on H19 expression in endometrial cancer tissue	Ciba University	Female	20years-old - 60years-old	15	the Japan Society for Promotion of Science.	Interventional Study	Single arm Non-randomized		02/04/2016				04/02/2016					17/10/2023	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024069		Any/All Stages	Hospital/University/Research Institute	N	N	N	Japan	Gynaecological	Endometrial Cancer	Metformin	Biomarker	Phase 2	DB00331	N
DRKS00028966	Evaluation of the effect of total intravenous and inhalation anesthesia on tumor growth		Recruiting	<br>C25 <br>C18 <br>C22;Malignant neoplasm of pancreas;Malignant neoplasm of colon;Malignant neoplasm of liver and intrahepatic bile ducts	Group 1: Inhalation anesthesia<br>Patients receive Thiopental for the initiation and sevoflurane as maintanance anesthesia. <br>Both arms contain standard anesthesia protocols - none of them is experimental.<br>Group 2: Injection anesthesia<br>Patients receive propofol anesthesia	The primary study endpoint is the size of subcutaneous metastases in a nude mouse model from single cell suspensions from resected tumor specimen.	Allgemein-, Viszeral- u. Transplantationschirurgie Universit  tsmedizin Mainz	All	18 Years - None	80	Universit  tsmedizin der Johannes Gutenberg-Universit  t Mainz	Interventional Study	Allocation: Randomized controlled study; Masking: Open (masking not used); Control: active; Assignment: parallel; Study design purpose: basic science		02/05/2022				20/05/2022					17/10/2023	http://drks.de/search/en/trial/DRKS00028966		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Germany	GI	Cholangiocaricnoma; Colon Cancer; Liver Cancer; Pancreatic Cancer; Rectal Cancer	Propofol	Other (specify)	Phase 2	DB00818	N
CTRI/2023/01/049248	A study to see the effectives of a parasitic drug called Mebendazole when given with chemotherapy CCNU in patients.		Open to Recruitment	Health Condition 1: C719- Malignant neoplasm of brain, unspecified	Intervention1: CCNU regimen plus Mebendazole: 1. Tablet pantoprazole 40 mg- Early morning empty stomach.<br>2. Mebendazole tablets would be chewed with breakfast (800 mg)- Breakfast for the entire cycle of 42 days.<br>3. Tablet Granisetron 1 mg or ondansetron 8 mg-1    hours post breakfast.<br>4. Capsule CCNU ( 110 mg/m2)- 2 hours post breakfast only on day 1 of the 42 days cycle<br>5. Mebendazole tablets would be chewed with lunch (800 mg)-Lunch for the entire cycle of 42 days.<br>6. Mebendazole tablets would be chewed with dinner (800 mg)-dinner for the entire cycle of 42 days.<br><br><br><br>Control Intervention1: CCNU regimen: CCNU will be given only on day 1 of the 42 days cycle. Rest of the drugs are routinely given as per the standard of care.<br>	To compare the overall survival (OS) between the two arms.Timepoint: OS will be calculated in time in months between the date of randomization to the date of death. Patients alive at their last follow ups will also be censored. <br/ ><br>	Cancer Research and Statistics Foundation CRSF	-	-	182	Cancer Research and Statistics Foundation (CRSF);Krishna Institute of Medical Sciences;Post Graduate Institute of Medical Education   Research;Ramaiah Medical College;Tata Memorial Hospital	Interventional Study	Randomized, Parallel Group Trial   Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Centralized  Blinding and masking:Not Applicable		01/02/2023				27/01/2023					16/10/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=69127	Palliative	Localised/Locoregional; Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	India	CNS	Glioma	Mebendazole	OS	Phase 3	DB00643	N
ISRCTN81939514	Indolent prostate cancer, phytochemicals and probiotics		Ongoing	Indolent prostate cancer <br>Cancer	This is a double-blind, randomised, controlled trial in men who have a diagnosis of indolent prostate cancer managed with surveillance alone. Following written informed consent, patients will be randomised (1:1) to:<br> € Men in one randomised arm (blinded) will receive a phytochemical-rich food supplement (PFS) containing whole dried pomegranate, turmeric, green tea, broccoli, cranberry and ginger plus a probiotic capsule containing a blend of 10 billion colony-forming units (CFU) of 5 lactobacilli plus inulin and low dose cholecalciferol as prebiotics.<br> € Men in the other blinded randomised group will be given the PFS plus placebo <br>Each capsule will be taken twice a day, for 4 months. Participants are asked to stop all other over-the-counter supplements<br>The phytochemical-rich capsule contains dried whole foods which have previously been reported as safe among men with prostate cancer in prospective studies. The ingredients of both supplements have been shown to have a high safety profile. This blend has been used in two previous studies and was safe and well-tolerated.<br><br>Computer generated Block Randomisation will be employed. A spreadsheet will be created; in column 1, sequential participant numbers will be recorded. In column 2, block-generated randomised Arms (A or B), will be recorded. After a participant has consented they will be allocated the next trial number and randomised Arm in strict order. Participants will be given a four-month supply of either A or B plus the whole food supplement.<br><br>Contact will be face-to-face consultations with the medical team at baseline and at trial termination during their routine clinical management for surveillance. Location: Primrose Oncology Research Unit within the Oncology department of Bedford Hospital, Bedfordshire Hospitals	Prostatic specific antigen doubling time (PSAdt) measured using a routine blood test analysis at trial entry baseline and 4 months	Bedford Hospital NHS Trust	Male	-	180	Bedford Hospital Research Fund	Interventional Study	Randomized double-blind controlled study  (Safety, Efficacy)	Nil known;Nil known;IRAS 321309	01/08/2023				19/06/2023					30/10/2023	https://www.isrctn.com/ISRCTN81939514		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United Kingdom	Urological	Prostate Cancer	Cholecalciferol	Biomarker	Other	DB00169	N
NCT06102863	Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia		Recruiting	Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I	Drug: statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);	Pathological cumulative complete response rate;; The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion tissue; Overall complete response rate; Relapse rate; Toxic Side Effect	Peking University People's Hospital	Female	17 Years to 45 Years   (Child, Adult)	38	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20231022	04/01/2023	12/01/2024	02/01/2025			26/10/2023				26/10/2023	https://ClinicalTrials.gov/show/NCT06102863		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Gynaecological	Endometrial Cancer	Atorvastatin; Rosuvastatin	Safety and/or Dose; Response rate; Recurrence rate	Phase 2	DB01076; DB01098	N
NCT06157099	Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA Melanoma		Not yet recruiting	Clinical Stage IIA Cutaneous Melanoma AJCC v8	Drug: Atorvastatin; Drug: Placebo Administration; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Other: Electronic Health Record Review	Recurrence-free survival (RFS); Distant metastasis-free survival (DMFS); Overall survival (OS)	OHSU Knight Cancer Institute; Oregon Health and Science University; Kuni Foundation	All	18 Years and older   (Adult, Older Adult)	150	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	STUDY00025369; NCI-2023-03875	01/01/2024	03/01/2028	03/01/2029			12/05/2023				12/05/2023	https://ClinicalTrials.gov/show/NCT06157099		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Skin	Melanoma	Atorvastatin	OS; DFS/RFS/EFS; Other (specify)	Phase 2	DB01076	N
NCT06148038	CBD for Breast Cancer Primary Tumors		Not yet recruiting	Breast Cancer	Drug: CBD Oral; Other: Control	CBD and cell proliferation; CBD and apoptosis; Number of participants with treatment-related adverse events as assessed by CTCAE 5.0; GAD-7 anxiety level scoring at Pre and post CBD administration	Medical University of South Carolina	All	18 Years and older   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	103565	31/01/2024	30/09/2025	30/09/2026			28/11/2023				12/12/2023	https://ClinicalTrials.gov/show/NCT06148038		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	United States	Breast	Any Breast Cancer	Cannabidiol	Biomarker	Phase 1	DB09061	N
NCT06076837	The Seven Trial: Exploiting the Unfolded Protein Response		Not yet recruiting	Pancreatic Cancer Metastatic|Pancreatic Adenocarcinoma Metastatic	Drug: Botensilimab; Drug: Balstilimab; Drug: Chloroquine Phosphate; Drug: Celecoxib	Maximum Tolerated Dose (MTD); Safety and Tolerability; Complete Response (CR); Overall Response Rate (ORR); Progression free survival (PFS); Overall Survival (OS); Disease Control Rate (CR), Partial Response (PR), and Stable Disease (SD); CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)	HonorHealth Research Institute; Translational Genomics Research Institute; University of Arizona; Agenus Inc.	All	18 Years and older   (Adult, Older Adult)	12	Other; Industry	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HRI-SevenTrial	12/01/2023	06/01/2025	12/01/2025			10/11/2023				10/11/2023	https://ClinicalTrials.gov/show/NCT06076837		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Celecoxib; Chloroquine	Safety and/or Dose; Response rate; OS; Biomarker	Phase 1	DB00482; DB00608	N
NCT06126731	Combination Study of Antibiotics With Enzalutamide (PROMIZE)		Recruiting	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Drug: Enzalutamide 40mg; Drug: Amoxicillin 500mg; Drug: Metronidazole 400mg; Drug: Vancomycin 125mg; Drug: Ciprofloxacin 500g	Confirm the safety and tolerability of the combination of amoxicillin plus metronidazole (2 weeks) followed by ciprofloxacin plus vancomycin (2 weeks) along with enzalutamide in Phase I in mCRPC patients.; Describe the safety profile of the antibiotic combinations along with enzalutamide in Phase I.; Determine the response rate of the antibiotic combinations in patients with mCRPC in Phase II.; To document possible anti-tumour activity in patients in Phase I.; To evaluate progression-free survival (PFS) in mCRPC patients receiving the antibiotic combinations in Phase I.; To evaluate PFS in mCRPC patients receiving the antibiotic combinations along with enzalutamide in Phase II.; To determine the time to PSA progression from the date of antibiotic commencement; To determine the duration of PSA decline as an estimate of the biochemical anti-tumour activity of the combination of amoxicillin plus metronidazole (2-weeks) followed by ciprofloxacin plus vancomycin (2-weeks) along with enzalutamide.; To determine the maximum percentage and absolute PSA decline from baseline; To determine the radiologic PFS (rPFS) of the combination of antibiotics and enzalutamide in Phase II.; To determine the time to radiologic progression to the combination of antibiotics and enzalutamide in Phase II.; To estimate the OS in mCRPC patients receiving the antibiotic combinations along with enzalutamide in Phase II.; To further characterise the safety and tolerability profile of the antibiotic combinations with enzalutamide in Phase II.; To identify biomarkers of response to the antibiotic combinations and of anti-tumour activity in Phase II.; To evaluate the peripheral circulation neutrophil-to-lymphocyte ratio (NLR) as a determinant of response to to treatment in Phase II.	Institute of Cancer Research, United Kingdom; Prostate Cancer Foundation	Male	18 Years and older   (Adult, Older Adult)	39	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCR5461	11/02/2023	30/06/2024	31/07/2025			13/11/2023				13/11/2023	https://ClinicalTrials.gov/show/NCT06126731		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United Kingdom	Urological	Prostate Cancer	Ciprofloxacin; Metronidazole	Safety and/or Dose; Response rate	Phase 1/2	DB00537; DB00916	N
NCT06084780	Intestinal   Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)	TRANSCAPE	Not yet recruiting	Secondary Malignant Neoplasm of Retroperitoneum|Secondary Malignant Neoplasm of Peritoneum|Pseudomyxoma Peritonei	Procedure: Intestinal, Multivisceral or Modified Multivisceral Transplantation; Drug: Alemtuzumab; Drug: Tacrolimus; Drug: Sirolimus	Overall Rate of Survival; Overall Rate of Morbidity; Overall Rate of Mortality	Case Comprehensive Cancer Center	All	18 Years to 75 Years   (Adult, Older Adult)	20	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE7Z23	04/01/2024	31/12/2025	31/12/2025			16/10/2023				16/10/2023	https://ClinicalTrials.gov/show/NCT06084780		Advanced/Metastatic	Hospital/University/Research Institute	N	N	N	United States	Other	Other	Sirolimus	OS; Other (specify)	Phase 2	DB00877	N
NCT06030622	Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer	C3	Recruiting	Pancreatic Cancer Metastatic	Drug: C3 (Metformin, Simvastatin, and Digoxin)	Primary Outcome: Safety and tolerability; Secondary Outcome: Biomarkers	State University of New York - Downstate Medical Center	All	18 Years and older   (Adult, Older Adult)	25	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	1727019-4	12/01/2023	12/01/2024	12/01/2024			09/11/2023				12/04/2023	https://ClinicalTrials.gov/show/NCT06030622		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	GI	Pancreatic Cancer	Digoxin; Metformin; Simvastatin	Safety and/or Dose; Biomarker	Phase 1/2	DB00390; DB00331; DB00641	N
NCT06191133	Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma		Not yet recruiting	Cervical Intraepithelial Neoplasia|Invasive Cervical Cancer	Drug: Fenofibrate; Procedure: Cervical Conization; Procedure: Hysterectomy; Radiation: Chemoradiation	Change in p53 levels; Change in tumor metabolic status; Fenofibrate tolerability	Lindsay Ferguson, MD; Case Comprehensive Cancer Center	Female	18 Years and older   (Adult, Older Adult)	24	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE3822	02/01/2024	31/01/2025	31/05/2025			01/05/2024				01/05/2024	https://ClinicalTrials.gov/show/NCT06191133		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Gynaecological	Cervical Cancer	Fenofibrate	Safety and/or Dose; Biomarker	Phase 1	DB01039	N
NCT06102525	A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma		Not yet recruiting	Glioblastoma	Drug: RZ-001; Combination Product: VGCV	Number of dose limiting toxicities (DLTs); Maximum tolerated dose (MTD) or maximum administered dose (MAD) dose(MAD) and select the recommended Phase 2 dose (RP2D) of RZ-001 in combination with VGCV; Number of participants with treatment-related adverse events as assessed by NCI-CTCAE; Number of participants with significant laboratory abnormalities as assessed by NCI-CTCAE; Overall survival (OS); Change in concentration of serum vascular endothelial growth factor (VEGF); Change in concentration of serum anti-adenovirus antibody; Overall response rate (ORR); Duration of response (DOR); Progression-free survival (PFS) per modified Response Assessment for Neuro-Oncology (mRANO); Neurologic function assessment using the Neurologic Assessment in Neuro-Oncology (NANO) scale ranging from 0 to 3 in each assessment domain	Rznomics, Inc.	All	18 Years and older   (Adult, Older Adult)	43	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RZ-001-201	10/01/2023	03/01/2029	05/01/2029			26/10/2023				26/10/2023	https://ClinicalTrials.gov/show/NCT06102525		Localised/Locoregional	Company	N	N	N	Korea, Republic of	CNS	Glioblastoma	Valganciclovir	Safety and/or Dose; PFS; OS	Phase 1/2	DB01610	N
NCT06150898	Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)	KePreSt	Not yet recruiting	Early-stage Breast Cancer|Estrogen-receptor-positive Breast Cancer	Procedure: Prospective data and sample collection; Drug: Ketorolac 10 Mg Oral Tablet; Drug: Pregabalin 75mg	To detect a reduced increase in systemic inflammation (from baseline to up to 24 hours after surgery) using peri-operative ketorolac; To detect a reduced increase in systemic neurotransmitters (from baseline to up to 24 hours after surgery) using peri-operative pregabalin; Change in biomarkers of metastasis at surgery from baseline; Change in tumoral immune cells recruitment at surgery from baseline; Change in tumoral neurogenesis at surgery from baseline; Change in tumoral neurotransmitters level at surgery from baseline; Change in Peripheral Blood Mononuclear Cells at surgery from baseline; Change in systemic neuro-inflammatory mediators at surgery from baseline; Change in systemic neurotransmitters at surgery from baseline; Change in anxiety level at surgery from baseline; Post-operative pain	Jules Bordet Institute; KU Leuven; University of Milan	Female	18 Years to 70 Years   (Adult, Older Adult)	112	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	IJB-KEPREST-2022	20/02/2024	20/07/2026	12/01/2026			29/11/2023				29/11/2023	https://ClinicalTrials.gov/show/NCT06150898		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	France	Breast	Breast Cancer - ER/HR+	Ketorolac	Biomarker	Phase 2	DB00465	N
NCT06044025	A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy		Not yet recruiting	Castration Sensitive Prostate Cancer	Drug: Metformin; Drug: Turmeric	Assess feasibility of recruitment; Evaluate time to PSA relapse with nutritional intervention on iADT.; Quality of life (QOL) assessed by the Functional Assessment of Cancer Therapy-Prostate (FACT-P), Version 4.; Quality of Life (QOL) assessed by the Aging Male Symptoms Questionnaire (AMS Questionnaire).	University of Arkansas	Male	18 Years to 100 Years   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	274850	02/01/2024	10/01/2025	10/01/2026			21/09/2023				01/05/2024	https://ClinicalTrials.gov/show/NCT06044025		Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Metformin	Safety and/or Dose; QoL; Biomarker; Other (specify)	Phase 1	DB00331	N
NCT06162377	Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A  Window of Opportunity  Pilot Study.		Recruiting	Head and Neck Squamous Cell Carcinoma	Drug: Methylnaltrexone	Safety and adverse events (AEs)	M.D. Anderson Cancer Center	All	18 Years and older   (Adult, Older Adult)	25	Other	Interventional Study	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2022-0729; NCI-2023-10299	01/10/2024	30/06/2024	30/06/2024			12/08/2023				01/12/2024	https://ClinicalTrials.gov/show/NCT06162377		Any/All Stages	Hospital/University/Research Institute	N	N	N	United States	Head and Neck	Oropharyngeal Cancer	Methylnaltrexone	Safety and/or Dose; Biomarker	Phase 4	DB06800	N
NCT06099769	A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer		Recruiting	Metastatic Breast Cancer	Drug: Enzalutamide; Drug: Mifepristone; Drug: TPC	progression-free survival (PFS)	Memorial Sloan Kettering Cancer Center; Astellas Pharma US, Inc.; Breast Cancer Research Foundation; Corcept Therapeutics	All	18 Years and older   (Adult, Older Adult)	201	Other; Industry	Interventional Study	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	22-334	18/10/2023	10/01/2027	10/01/2027			25/10/2023				14/12/2023	https://ClinicalTrials.gov/show/NCT06099769		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	Y	N	United States	Breast	Breast Cancer - TNBC	Mifepristone	PFS	Phase 2	DB00834	N
NCT06049901	Nitazoxanide in Patients With Metastatic Colorectal Cancer		Recruiting	Metastatic Colorectal Cancer	Drug: Nitazoxanide	Investigating the possible efficacy of nitazoxanide through evaluation of its impact on overall response rate (ORR) and disease control rate (DCR).; Evaluating the change in the serum level of Reduced glutathione (GSH); Evaluating the change in the serum level of Superoxide dismutase (SOD); Evaluating the change in the serum level of Nuclear factor-kappa B (NF-kB); Evaluating the change in the serum level of Protein disulfide isomerase (PDI); Evaluating the one-year overall survival (1-year OS); Evaluating the progression free survival (PFS); Evaluating the safety and tolerability of nitazoxanide through investigating Liver function test (ALT (U/mL) and AST (U/mL)).; Evaluating the safety and tolerability of nitazoxanide through investigating Renal function test (SCr (mg/dL), BUN (mg/dL) and eCrCl (mL/min)).; Evaluating the safety and tolerability of nitazoxanide through investigating Hematological parameters (hemoglobin (mg/dL), erythrocytes (cells/ L), leukocytes (cells/ L), platelets (cells/ L) and ANC (cells/ L)).	Tanta University	All	18 Years to 65 Years   (Adult, Older Adult)	60	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Nitazoxanide in mCRC	03/01/2023	03/01/2025	03/01/2026			22/09/2023				22/09/2023	https://ClinicalTrials.gov/show/NCT06049901	Adjuvant/Maintenance	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Egypt	GI	Colon Cancer; Rectal Cancer	Nitazoxanide	Response rate; DFS/RFS/EFS; Biomarker	Phase 3	DB00507	N
NCT06176339	Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients 		Not yet recruiting	Breast Cancer Female	Drug: Pentoxifylline Oral Tablet; Drug: Placebo	Relative reduction in tumor size after neoadjuvant chemotherapy treatment; The number of patients achieving a pathological complete response; The relative change of left ventricular ejection fraction (LVEF); The incidence of grade 2 or more of neurotoxicity according to common terminology criteria for adverse event (NCI-CTCAE) version 5; The relative change of liver function tests; The change in Serum Creatinine concentration	Mansoura University	All	18 Years to 65 Years   (Adult, Older Adult)	70	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	2023-147-1	15/12/2023	30/08/2024	30/09/2024			19/12/2023				19/12/2023	https://ClinicalTrials.gov/show/NCT06176339		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Egypt	Breast	Any Breast Cancer	Pentoxifylline	Safety and/or Dose; Other (specify)	Phase 2	DB00806	N
NCT06115174	Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	CRC - PTX	Not yet recruiting	Metastatic Colorectal Carcinoma	Drug: Pentoxifylline; Radiation: FOLFOX; Radiation: XELOX; Drug: Monoclonal antibodies (target therapy)	Comparison of RECIST between the two groups.; Change in the serum concentration of the measured biological markers.; Difference in progression free survival 'PFS' between the two groups; Difference in overall survival 'OS' between the two groups.	Tanta University	All	18 Years to 75 Years   (Adult, Older Adult)	44	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	Pentoxiphylline in CRC	11/01/2023	11/01/2024	12/01/2024			11/02/2023				11/02/2023	https://ClinicalTrials.gov/show/NCT06115174		Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Egypt	GI	Colon Cancer; Rectal Cancer	Pentoxifylline	Response rate; PFS; OS	Phase 4	DB00806	N
NCT06142318	Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma		Recruiting	Head and Neck Squamous Cell Carcinoma|Radiotherapy|Radiosensitizer|Pirfenidone	Drug: Pirfenidone; Drug: Placebo	Objective response rate (ORR); Overall survival (OS); Incidence of Treatment-Emergent Adverse Events	Nanfang Hospital, Southern Medical University	All	18 Years and older   (Adult, Older Adult)	66	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NFEC-2023-477	15/11/2023	30/01/2025	30/06/2025			21/11/2023				21/11/2023	https://ClinicalTrials.gov/show/NCT06142318		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	China	Head and Neck	Any head and neck squamous cell carcinoma	Pirfenidone	Safety and/or Dose; Response rate; OS	Phase 2	DB04951	N
NCT06145074	Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.	IMPULS	Not yet recruiting	Pancreatic Cancer|Surgery	Drug: Propranolol; Drug: Placebo	Preoperative anxiety; Preoperative anxiety and depression; Preoperative quality of life; Density and subtypes of tumor-infiltrating lymphocytes in the tumor microenvironment.; Desmoplasia in the tumor microenvironment.; Neural markers in the tumor microenvironment.; Adrenergic receptor (ADRB1 ADRB2) expression in the tumor microenvironment.; Spatial distribution of immune cells in the tumor microenvironment.; Immune cells and subtypes in blood samples; Circulating tumor cells before and after intervention in blood samples.; RNA-level gene expression in blood samples.; Heart rate variability in both trial arms; Postoperative complications; Survival 30-days after surgery; Survival 90-days after surgery; Overall survival 1-year after surgery; Overall survival 3-years after surgery; Overall survival 5-years after surgery; Safety of 40 mg propranolol twice daily on blood pressure.; Safety of 40 mg propranolol twice daily on heart rate.	Zealand University Hospital; Rigshospitalet, Denmark	All	18 Years and older   (Adult, Older Adult)	30	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	EU CT 2023-506553-37-00	01/01/2024	31/12/2026	31/12/2035			22/11/2023				22/11/2023	https://ClinicalTrials.gov/show/NCT06145074		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	Denmark	GI	Pancreatic Cancer	Propranolol	OS; Biomarker	Phase 2	DB00571	N
NCT06134388	Sulfasalazine in Patients With Metastatic Colorectal Cancer		Recruiting	Metastatic Colorectal Cancer	Drug: Sulfasalazine	Evaluating the change in the serum level of Ferritin; Evaluating the change in the serum level of Superoxide dismutase (SOD); Evaluating the change in the serum level of Nuclear factor-kappa B (NF-kB); Evaluating the change in the serum level of Bcl-2 associated X protein (Bax); Investigating the possible efficacy of sulfasalazine through evaluation of its impact on overall response rate (ORR).; Investigating the possible efficacy of sulfasalazine through evaluation of its impact on disease control rate (DCR).; Evaluating the progression free survival (PFS); Evaluating the one-year overall survival (1-year OS); Evaluating the safety and tolerability of sulfasalazine through investigating Hematological parameters (hemoglobin (mg/dL), erythrocytes (cells/ L), leukocytes (cells/ L), platelets (cells/ L) and absolute neutrophil count (cells/ L)).; Evaluating the safety and tolerability of sulfasalazine through investigating Liver function test.; Evaluating the safety and tolerability of sulfasalazine through investigating Renal function test (serum creatinine (mg/dL), blood urea nitrogen (mg/dL) and creatinine clearance (mL/min)).	Tanta University	All	18 Years to 65 Years   (Adult, Older Adult)	50	Other	Interventional Study	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sulfasalazine 2023	09/01/2023	09/01/2025	09/01/2026			18/11/2023				18/11/2023	https://ClinicalTrials.gov/show/NCT06134388	Palliative	Advanced/Metastatic	Hospital/University/Research Institute	Y	N	N	Egypt	GI	Colon Cancer; Rectal Cancer	Sulfasalazine	Response rate; PFS; OS; DFS/RFS/EFS; Biomarker	Phase 3	DB00795	N
NCT06168487	Telmisartan in Prostate Cancer		Not yet recruiting	Prostate Cancer	Drug: Telmisartan; Other: Standard of Care Regimen	Tolerability of oral telmisartan; Increase in tumor DNA damage	Tyler J Curiel; Dartmouth-Hitchcock Medical Center	Male	18 Years and older   (Adult, Older Adult)	42	Other	Interventional Study	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY02002057	01/01/2024	01/01/2026	01/01/2027			13/12/2023				13/12/2023	https://ClinicalTrials.gov/show/NCT06168487		Localised/Locoregional	Hospital/University/Research Institute	N	N	N	United States	Urological	Prostate Cancer	Telmisartan	Safety and/or Dose; Biomarker	Phase 1	DB00966	N
CTIS2022-500599-79-00	Treatment with Xeljanz in a population of patients with cutaneous T cell lymphoma		Not Recruiting	Mycosis Fungoides;Therapeutic area: Diseases [C] - Immune System Diseases [C20]-Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutics [E02]-Diseases [C] - Skin and Connective Tissue Diseases [C17]	Product Name: XELJANZ 10 mg film-coated tablets,Product Code: PRD6483620,Pharmaceutical Form: FILM-COATED TABLET,Other descriptive name: ,Strength: Tofacitinib 10mg	Main Objective:Does treatment with Xeljanz decrease disease activity?;Secondary Objective:;Primary end point(s): € To evaluate complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) and the overall response rate to treatment with Xeljanz.	Aarhus University Hospital	Female	18 - 65+	15		Interventional Study	Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Number of treatment arms in the trial: 0		08/07/2022				22/04/2022					18/12/2023	https://euclinicaltrials.eu/app/#/view/2022-500599-79-00?lang=en		Any/All Stages	Hospital/University/Research Institute	N	N	N	Denmark	Lymphoma	Cutaneous T-Cell Lymphoma	Tofacitinib	Response rate	Phase 1	DB08895	N
CTIS2022-500745-24-00	Phase II Dutasteride in combination with CAB vs CAB in SDC (DUCT)		Not Recruiting	Salivary Duct Carcinoma;Therapeutic area: Diseases [C] - Neoplasms [C04]	Product Name: Zoladex-10,8, implantatiestaafje 10,8 mg,Product Code: PRD396274,Pharmaceutical Form: IMPLANT,Other descriptive name: ,Strength: Goserelin Acetate 10.8mg,Product Name: Casodex-50, filmomhulde tabletten 50 mg,Product Code: PRD8720588,Pharmaceutical Form: FILM-COATED TABLET,Other descriptive name: ,Strength: Bicalutamide 50mg,Product Name: Avodart 0,5 mg zachte capsules,Product Code: PRD326105,Pharmaceutical Form: CAPSULE, SOFT,Other descriptive name: ,Strength: Dutasteride 0.5mg	Main Objective:To determine the efficacy of dutasteride in combination with combined androgen blockade therapy in patients with recurrent and/or metastatic salivary duct carcinoma;Secondary Objective:To assess other indicators of therapy efficacy,To assess the safety profile of dutasteride when combined with combined androgen blockade therapy,To assess the quality of life of patients treated with dutasteride in combination to combined androgen blockade therapy,To explore predictive markers of response,To assess the expression of molecular targets and to document the modulation of response in the tumor microenvironment;Primary end point(s):Overall response rate (ORR) defined as proportion of participants who have a confirmed complete response (CR) or partial response (PR) determined by Investigator according to RECIST v1.1,Duration of Response (DoR), defined as the time from first tumor assessment at which the overall response was recorded as PR or CR that is subsequently confirmed until documented progressive disease (PD) determined by Investigator per RECIST v1.1 or death from any cause, whichever occurs first	Stichting Radboud University Medical Center	Female	18 - 65+	98	Radboudumc;ZonMw	Interventional Study	Controlled: yes Randomised: yes Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Number of treatment arms in the trial: 2		11/08/2022				09/06/2022					18/12/2023	https://euclinicaltrials.eu/app/#/view/2022-500745-24-00?lang=en		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	Netherlands	Head and Neck	Salivary Gland Cancer	Dutasteride	Response rate	Phase 2	DB01126	N
ChiCTR2300074976	A single-arm clinical trial to evaluate the efficacy and safety of Simvastatin, Orlistat, and Trimetazidine in combination with second-line treatment drugs for advanced liver cancer		Pending	Liver cancer	Group of liver cancer :Patients with advanced liver cancer received Simvastatin 20mg po qn, Orlistat 120mg po tid, Trimetazidine 20mg po tid combined with second-line treatment drugs for advanced liver cancer;	Objective Response Rate(ORR);	Affiliated Hospital of Qingdao University	All	18 - 99	Group of liver cancer :43;	Self-funding for scientific research	Interventional Study	Single arm		09/01/2023				22/08/2023					26/09/2023	https://www.chictr.org.cn/showproj.html?proj=205420		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	GI	Liver Cancer	Orlistat; Simvastatin	Response rate	Phase 4	DB01083; DB00641	N
ChiCTR2300076126	PET-guided high-dose vitamin C synergised with 131I, 177Lu-DOTA-TATE, 177Lu-PSMA for advanced thyroid cancer, neuroendocrine tumours, and prostate cancer		Pending	advanced thyroid cancer, neuroendocrine tumours, and prostate cancer	Experimental group:1) PET/CT examination: 18F-FDG, 18F-FAA PET/CT imaging <br>2) 131I, 177Lu-DOTA-TATE, 177Lu-PSMA internal irradiation routine treatment<br>3) Intravenous and/or intratumoral vitamin C injections;	Objective Response Rate;	The First Affiliated Hospital of Sun Yat-Sen University	All	18 -	Experimental group:110;	Clinical specialty capacity building support program	Interventional Study	Single arm		27/09/2023				25/09/2023					10/03/2023	https://www.chictr.org.cn/showproj.html?proj=207774		Advanced/Metastatic; Recurrent/Refractory	Hospital/University/Research Institute	N	N	N	China	Endocrine; Urological	Thyroid Cancer; Neuroendocrine Tumours; Prostate Cancer	Ascorbic acid	Response rate	Phase 2	DB00126	N
ACTRN12623001164684	Assessing treatment effectiveness of the 'Repurposing-Drugs-in-Oncology' (ReDO) protocol for cancer: The ReDO cancer treatment study		Not yet recruiting	Cancer; <br>Cancer;Cancer - Any cancer	The REDO Protocol consists of 19 medication (a) and nutrients (b) , introduced one item at the time, each item 3 days apart with side effects monitored over a period of 2 months. The full ReDO protocol (19 items) consists of the following dosages per day administered for 3 months (90 days).<br>All items are administered as oral tablets, with the exception of item 19, which is provided as oil.<br>Order of items in 2 month introduction period / Item / Dosage per day:<br> a) Prescription medication <br>1Dichloroacetate500 mg x2 <br>2Propanolol40mg x 2<br>3Metformin500 mg x 1; 500 mg x 2<br>4Atorvastatin (+ CoQ10)20 mg/ night; 2x 20 mg  <br>7Sodium Phenylbutyrate1-4 g/ night<br>8Dipyridamole2x 100 mg/ day; 2x200 mg<br>9Hydroxychloroquine 200 mg /night<br>10Ivermectin25 mg/night<br>11Melatonin100mg<br>12Doxycycline50 mg x2<br>13Mebendazole / Fenbendazole100 mg x2<br>17Loratadine (Anti-histamine)20 mg x 2<br><br> b) Natural herbal supplements <br>5Genistein100mg x 3<br>6D-Mannose2x 1000 mg<br>14Vitamin A (Retinoic Acid)35,000 IU - 1 week on 1 week off<br>15Berberine2x 500mg<br>16Epigallocatechin Gallate (EGCG) = green tea extract400 mg x2<br>18Hydroxy-citrate (Garcinia cambogia)1000 mg x 2<br>19Nigella Sativa Black Seed Oil5ml x2<br><br>Compliance will be monitored by an online participant diary app.<br>	Circulating Tumour Cell (CTC) count in CTC/ml[blood test using the validated Cytology-based Isolation-by-SizE-of-Tumour (ISET) - CTC system (Rarecells), which consists of two steps, a0 the isolation of cancer cells by  filtration from 10ml of blood, and b) microscopy to count the number of CTC per ml of blood 3 months after implementation of the full ReDO protocol compared to baseline, that is 5 months after 0 months (baseline)];Circulating Tumour Cell (CTC) count in CTC/ml[blood test as above - Isolation of CTC from blood by filtration and analyses by microscopy 6 months after implementation of the full ReDO protocol compared to baseline, that is 8 months after 0 months (baseline)]	Dr Taufiq Binjemain	All	20 Years - No limit	50	Patients at the Willow Vale Clinic	Interventional Study	Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety/efficacy;		30/11/2023				09/11/2023					20/11/2023	https://anzctr.org.au/ACTRN12623001164684.aspx		Any/All Stages	Hospital/University/Research Institute	N	N	N	Australia	Multiple cancer types	Multiple cancer types	Atorvastatin; Chloroquine; Dipyridamole; Doxycycline; Hydroxychloroquine; Ivermectin; Loratadine; Mebendazole; Melatonin; Metformin; Phenylbutyrate	Biomarker	Other	DB01076; DB00608; DB00975; DB00254; DB01611; DB00602; DB00455; DB00643; DB01065; DB00331; DB08909	N
CTRI/2023/11/059909	Utility of Hydroxychloroquine medicine as a supportive treatment for breast cancer patients		Not Yet Recruiting	Health Condition 1: C509- Malignant neoplasm of breast of unspecified site	Intervention1: Hydroxychloroquine (Brand Name-HCQS): Hydroxychloroquine (HCQ)<br>DOSAGE FORM: 200 mg tablet, oral route<br>DOSAGE: 200 mg BID by mouth, for a total daily dose of 400 mg FREQUENCY: HCQ is taken twice daily (morning and night) with food. DURACTION OF HCQ: 2 weeks<br><br>Intervention2: Hydroxychloroquine (Brand Name-HCQS): DOSAGE: 200 mg BID by mouth, for a total daily dose of 400 mg FREQUENCY: HCQ is taken twice daily (morning and night) with food. DURACTION OF HCQ: 2 weeks. Oral route.<br>Intervention3: ARM - A-Hydroxychloroquine (HCQ): ARM A- The patients will be randomized to one of the following arms to receive HCQS and neoadjuvant chemotherapy (NACT).<br>10 patients will be recruited for each arm.<br>Neoadjuvant chemotherapy  €  dose dense AC x 4 cycles followed by 12 weekly paclitaxel. NACT followed by HCQS for 2 weeks followed by surgery. Hydroxychloroquine (HCQ)<br>DOSAGE FORM: 200 mg tablet, oral route<br>DOSAGE: 200 mg BID by mouth, for a total daily dose of 400 mg FREQUENCY: HCQ is taken twice daily (morning and night) with food. DURACTION OF HCQ: 2 weeks<br><br><br>Intervention4: ARM B- Hydroxychloroquine (HCQ): ARM B -The patients will be randomized to one of the following arms to receive HCQS and neoadjuvant chemotherapy (NACT).<br>10 patients will be recruited for each arm.<br>Neoadjuvant chemotherapy  €  dose dense AC x 4 cycles followed by 12 weekly paclitaxel.<br>Surgery  €  BCS/MRM<br>HPE examination to look for T and N pathological response rates. NACT followed by 2 weeks of gap and then surgery<br>Hydroxychloroquine (HCQ)<br>DOSAGE FORM: 200 mg tablet, oral route<br>DOSAGE: 200 mg BID by mouth, for a total daily dose of 400 mg FREQUENCY: HCQ is taken twice daily (morning and night) with food. DURACTION OF HCQ: 2 weeks<br><br><br>Intervention5: ARM C- Hydroxychloroquine (HCQ): ARM C - The patients will be r	1.Demographiccharacteristics,clinicalpresentations, histopathologyreports, diagnostic results, and treatment details. <br/ ><br>2.Genomic and proteomic analysis will be carried out. <br/ ><br>3.Change in Prostate Apoptosis Response-4 (PAR-4) Levels. <br/ ><br>4.PAR-4 levels measured via serum or plasma blood sample. <br/ ><br>Timepoint: 0 weeks, 2 weeks and at the end of treatment	Dr Ananth Pai	-	-	30	No 2 , 1st floor,  Department of Medical Oncology, Shridi Sai baba cancer institute and Research block, Kasturba Medical College and Hospital, Manipal, Udupi	Interventional Study	Cluster Randomized Trial   Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:On-site computer system  Blinding and masking:Open Label		13/01/2024				16/11/2023					19/12/2023	http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=93218		Localised/Locoregional	Hospital/University/Research Institute	Y	N	N	India	Breast	Breast Cancer - TNBC	Hydroxychloroquine	Response rate; Biomarker	Phase 4	DB01611	N
CTIS2023-503938-52-00	Clinical and translational controlled study of Perampanel treatment around Surgery in patients with progressive glioblastoma (PerSurge)		Not Recruiting	Progressive Glioblastoma <br>MedDRA version: 20.0Level: PTClassification code: 10018336Term: GlioblastomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Neoplasms [C04];MedDRA version: 20.0Level: PTClassification code: 10018336Term: GlioblastomaSystem Organ Class: 100000004864	Product Name: F  llstoff DAC in hard gelatine capsules is used as placebo. F  llstoff DAC consists of mannitol 99.5   and<br>colloidal Silicon Dioxide 0.5  .,Product Code: N/A,Pharmaceutical Form: N/A,Other descriptive name: N/A,Strength: N/A,Pharmaceutical form of the placebo: N/A,Product Name: Fycompa 2 mg film-coated tablets,Product Code: PRD4442834,Pharmaceutical Form: FILM-COATED TABLET,Other descriptive name: ,Strength: Perampanel 2mg	Main Objective:The primary aim of the trial is to demonstrate the efficacy of pre-surgical perampanel compared<br>to placebo treatment with respect to<br>A) the shift of mRNA expression patterns to a lower connectivity score in tumour tissue,<br>and<br>B) the presurgical tumour growth rate as assessed by tumour volume [cm  ] per a central blinded<br>independent review committee (BIRC) based on AI-quantified MRI parameters (T2/FLAIRweighted<br>images)<br>in patients with recurrent/progressive glioblastoma willing to adhere to the randomised treatment<br>and who will undergo surgery.;Secondary Objective:kinetics in contrast-enhancing (T1CE images) tumour volume by central AI-based MRI assessment per BIRC [pre-surgical; postsurgical ],kinetics in tumour volume (T2/FLAIR) by central AI-based MRI assessment per the BIRC [postsurgical],health-related quality of life (HRQoL) and symptoms as assessed by the EORTC QLQ-C30 and QLQ-BN20 patient questionnaires,,severity of cognitive impairment as assessed by the mini-mental state examination (MMSE),overall survival (OS),progression-free survival (PFS) (from randomisation until progression according to RANO criteria),epileptic seizure activity,To check for the occurrence of the adverse effects reported in the summary of the medical product characteristics (SmPC) of the drug and to compare between both treatments.;Primary end point(s):A) Connectivity score determined in RNA Seq from tumour tissue (tumour cryosamples),B) Kinetics in T2/FLAIR signal abnormality volume by central AI-based MRI assessment per BIRC [from baseline to pre-surgical resection]	Universitaetsklinikum Heidelberg A  R	Female	18 - 65+	66	BMBF	Interventional Study	Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Number of treatment arms in the trial: 2		30/11/2023				13/09/2023					18/12/2023	https://euclinicaltrials.eu/app/#/view/2023-503938-52-00?lang=en		Localised/Locoregional; Recurrent/Refractory	Hospital/University/Research Institute	Y	N	N	Germany	CNS	Glioblastoma	Perampanel	Response rate; Biomarker	Phase 1	DB08883	N